BACKGROUND OF THE INVENTION The present invention relates to compositions and methods for preventing, treating or diagnosing a number of pathological states such as viral diseases and cancers.

In particular, it provides novel peptides capable of binding selected major histocompatibility complex (MHC) molecules and inducing an immune response.

MHC molecules are classified as either class I or class II molecules. Class II MHC molecules are expressed primarily on cells involved in initiating and sustaining immune responses, such as T lymphocytes, B lymphocytes, macrophages, etc. Class II MHC molecules are recognized by helper T lymphocytes and induce proliferation of helper T lymphocytes and amplification of the immune response to the particular immunogenic peptide that is displayed. Class I MHC molecules are expressed on almost all nucleated cells and are recognized by cytotoxic T lymphocytes (CTLs), which then destroy the antigen-bearing cells. CTLs are particularly important in tumor rejection and in fighting viral infections.

The CTL recognizes the antigen in the form of a peptide fragment bound to the MHC class I molecules rather than the intact foreign antigen itself. The antigen must normally be endogenously synthesized by the cell, and a portion of the protein antigen is degraded into small peptide fragments in the cytoplasm. Some of these small peptides translocate into a pre-Golgi compartment and interact with class I heavy chains to facilitate proper folding and association with the subunit ß2 microglobulin. The peptide-MHC class I complex is then routed to the cell surface for expression and potential recognition by specific CTLs.

A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. et al., Cell 47 : 1071,1986 ; Babbitt, B. P. et al., Nature 317: 359,1985 ; Townsend, A. and Bodmer, H., Annu. Rev. Immunol. 7: 601, 1989 ; Germain, R. N., Annu. Rev. Immunol. 11: 403,1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified (see also, e. g., Southwood, et al., J. Immunol. 160: 3363,1998 ; Rammensee, et al., Immunogenetics 41: 178, 1995; Rammensee et al., SYFPEITHI, access via web at: http ://134. 2.96. 221/scripts. hlaserver. dll/home. htm; Sette, A. and Sidney, J. Curr. Opin.

Immunol. 10: 478, 1998; Engelhard, V. H., Curr. Opin. Immunol. 6: 13,1994 ; Sette, A. and Grey, H. M., Curr. Opin. Immunol. 4: 79,1992 ; Sinigaglia, F. and Hammer, J. Curr.

Biol. 6: 52,1994 ; Ruppert et al., Cell 74: 929-937,1993 ; Kondo et al., J. Immunol.

155: 4307-4312,1995 ; Sidney et al., J. Inamunol. 157: 3480-3490,1996 ; Sidney etal., Human ImnzunoL 45: 79-93,1996 ; Sette, A. and Sidney, J. Immunogenetics 50 : 201-212, 1999).

Furthermore, x-ray crystallographic analysis of HLA-peptide complexes has revealed pockets within the peptide binding cleft of HLA molecules which accommodate, in an allele-specific mode, specific residues of peptide ligands; these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e. g., Madden, D. R. Annu. Rev. Immunol. 13: 587, 1995; Smith, et al., Immunity 4: 203,1996 ; Fremont et al., Immunity 8: 305,1998 ; Stern et al., Structure 2: 245,1994 ; Jones, E. Y. Curr. Opin. Immunol. 9: 75,1997 ; Brown, J. H. et al., Nature 364: 33,1993 ; Guo, H. C. et al., Proc. Natl. Acad Sci. USA 90: 8053,1993 ; Guo, H. C. et al., Nature 360: 364,1992 ; Silver, M. L. et al., Nature 360: 367,1992 ; Matsumura, M. et al., Science 257: 927,1992 ; Madden et al., Cell 70: 1035,1992 ; Fremont, D. H. et al., Science 257: 919,1992 ; Saper, M. A., Bjorkman, P. J. and Wiley, D. C., J. Mol. Biol.

219: 277,1991.).

Peptides of the present invention may also comprise epitopes that bind to HLA class II DR molecules. A greater degree of heterogeneity in both size and binding frame position of the motif, relative to the N and C termini of the peptide, exists for class II peptide ligands. This increased heterogeneity of HLA class II peptide ligands is due to

the structure of the binding groove of the HLA class II molecule which, unlike its class I counterpart, is open at both ends. Crystallographic analysis of HLA class II DRB*0101- peptide complexes showed that the major energy of binding is contributed by peptide residues complexed with complementary pockets on the DRB*0101 molecules. An important anchor residue engages the deepest hydrophobic pocket (see, e. g., Madden, D. R. Ann. Rev. Inzmunol. 13: 587,1995) and is referred to as position 1 (P1). PI may represent the N-terminal residue of a class II binding peptide epitope, but more typically is flanked towards the N-tenninus by one or more residues. Other studies have also pointed to an important role for the peptide residue in the 6th position towards the C- terminus, relative to PI, for binding to various DR molecules.

In the past few years evidence has accumulated to demonstrate that a large fraction of HLA class I and class II molecules can be classified into a relatively few supertypes, each characterized by largely overlapping peptide binding repertoires, and consensus structures of the main peptide binding pockets. Thus, peptides of the present invention are identified by any one of several HLA-specific amino acid motifs, or if the presence of the motif corresponds to the ability to bind several allele-specific HLA molecules, a supermotif. The HLA molecules that bind to peptides that possess a particular amino acid supermotif are collectively referred to as an HLA"supertype." 'Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or class II supermotifs allows identification of regions within a protein that have the potential of binding particular HLA molecules.

Despite the developments in the art, the prior art has yet to provide a useful human epitope-based vaccine or therapeutic agent based on this work. The present invention provides these and other advantages.

SUMMARY OF THE INVENTION The present invention provides compositions comprising immunogenic peptides having allele-specific binding motifs, such as binding motifs for HLA-A2.1 molecules. For HLA class I epitopes, which bind to the appropriate HLA Class I allele, the peptides typically comprise epitopes from 8-11 amino acids in length, often 9 to 10 residues in length, that comprise conserved residues at certain positions such as positions 2 and the C-terminal position. Moreover, the peptides preferably do not comprise

negative binding residues as defined herein at other positions such as, in an HLA-A2.1 motif-bearing epitope, positions 1,3, 6 and/or 7 in the case of peptides 9 amino acids in length and positions 1,3, 4, 5, 7,8 and/or 9 in the case of peptides 10 amino acids in length. For HLA class II epiotpes, the peptides typically comprise a motif of 6 to about 25 amino acids for a class II HLA motif, typically, 9 to 13 amino acids in length, which is recognized by a particular HLA molecule.

Epitopes on a number of immunogenic target proteins, i. e. , target antigens, have been identified. Examples of suitable antigens include tumor-associated antigens such as tyrosinase related proteins 1 and 2 (TRP 1 and TRP), which are frequently associated with melanoma MART1, p53, carcinoembryonic antigen (CEA), Her2/neu, and MAGE, including MAGE1, MAGE2, and MAGE3, which are expressed on a broad range of tumors; prostate cancer-associated antigens such as prostate specific antigen (PSA), human kallikrein (huK2), prostate specific membrane antigen (PSM), and prostatic acid phosphatase (PAP) ; antigens from viruses such as hepatitis B (e. g., HBV core and surface antigens (HBVc, HBVs)) hepatitis C (HCV), Epstein-Barr virus, human immunodeficiency type-1 virus (HIV1), Kapos's sarcoma herpes virus (KSHV), human papilloma virus (HPV), influenza virus, and Lassa virus antigens, Mycobacterium tuberculosis (MT) antigens, trypanosome, e. g., Tyypansoma cruzi (T. cruzi), antigens such as surface antigen (TSA), and malaria antigens.

DEFINITIONS The term"peptide"is used interchangeably with"oligopeptide"in the present specification to designate a series of residues, typically L-amino acids, connected one to the other, typically by peptide bonds between the a-amino and carboxyl groups of adjacent amino acids. The preferred CTL-inducing peptides of the invention are 13 residues or less in length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues.

With regard to a particular amino acid sequence, an"epitope"is a set of amino acid residues which is involved in recognition by a particular immunoglobulin, or in the context of T cells, those residues necessary for recognition by T cell receptor proteins and/or Major Histocompatibility Complex (MHC) receptors. In an immune system setting, in vivo or in vitro, an epitope is the collective features of a molecule, such

as primary, secondary and tertiary peptide structure, and charge, that together form a site recognized by an immunoglobulin, T cell receptor or HLA molecule. Throughout this disclosure epitope and peptide are often used interchangeably.

It is to be appreciated that protein or peptide molecules that comprise an epitope of the invention as well as additional amino acid (s) are still within the bounds of the invention. In certain embodiments, there is a limitation on the length of a peptide of the invention. The embodiment that is length-limited occurs when the protein/peptide comprising an epitope of the invention comprises a region (i. e. , a contiguous series of amino acids) having 100% identity with a native sequence. In order to avoid the definition of epitope from reading, e. g., on whole natural molecules, there is a limitation on the length of any region that has 100% identity with a native peptide sequence. Thus, for a peptide comprising an epitope of the invention and a region with 100% identity with a native peptide sequence, the region with 100% identity to a native sequence generally has a length of : less than or equal to 600 amino acids, often less than or equal to 500 amino acids, often less than or equal to 400 amino acids, often less than or equal to 250 amino acids, often less than or equal to 100 amino acids, , often less than or equal to 85 amino acids, often less than or equal to 75 amino acids, often less than or equal to 65 amino acids, and often less than or equal to 50 amino acids. In certain embodiments, an "epitope"of the invention is comprised by a peptide having a region with less than 51 amino. acids that has 100% identity to a native peptide sequence, in any increment down to 5 amino acids.

Accordingly, peptide or protein sequences longer than 600 amino acids are within the scope of the invention, so long as they do not comprise any contiguous sequence of more than 600 amino acids that have 100% identity with a native peptide sequence. For any peptide that has five contiguous residues or less that correspond to a native sequence, there is no limitation on the maximal length of that peptide in order to fall within the scope of the invention. It is presently preferred that a CTL epitope be less than 600 residues long in any increment down to eight amino acid residues.

An"immunogenic peptide"or"peptide epitope"is a peptide that comprises an allele-specific motif or supermotif such that the peptide will bind an HLA molecule and induce a CTL. Thus, immunogenic peptides of the invention are capable of

binding to an appropriate HLA molecule and thereafter inducing a cytotoxic T cell response to the antigen from which the immunogenic peptide is derived.

The term"derived"when used to discuss an epitope is a synonym for "prepared."A derived epitope can be isolated from a natural source, or it can be synthesized in accordance with standard protocols in the art. Synthetic epitopes can comprise artificial amino acids"amino acid mimetics, "such as D isomers of natural occurring L amino acids or non-natural amino acids such as cyclohexylalanine. A derived/prepared epitope can be an analog of a native epitope.

Immunogenic peptides are conveniently identified using the algorithms of the invention. The algorithms are mathematical procedures that produce a score which enables the selection of immunogenic peptides. Typically one uses the algorithmic score with a"binding threshold"to enable selection of peptides that have a high probability of binding at a certain affinity and will in turn be immunogenic. The algorithm is based upon either the effects on MHC binding of a particular amino acid at a particular position of a peptide or the effects on binding of a particular substitution in a motif containing peptide.

A binding affinity threshold associated with immunogenicity has been determined for HLA Class I. A threshold binding affinity of about 500 nM or less (preferably 50 nM or less) typically determines the capacity of a peptide epitope to elicit a CTL response. A binding affinity threshold of about 1000 nM of less, preferably 100 nM or less, typicallydetermines the capacity of a peptide epitope to elicit an HTL response.

As used herein, "high affinity"with respect to HLA class I molecules is defined as binding with an ICso, or KD value, of 50 nM or less ;"intermediate affinity'is binding with an ICso or KD value of between about 50 and about 500 nM. "High affinity"with respect to binding to HLA class II molecules is defined as binding with an Also or KD value of 100 nM or less;"intermediate affinity"is binding with an IC50 or Ko value of between about 100 and about 1000 nM.

"IC50"is the concentration of peptide in a binding assay at which 50% inhibition of binding of a reference peptide is observed. Given the conditions in which the assays are run (i. e. , limiting HLA proteins and labeled peptide concentrations), these values approximate KD values. Assays for determining binding are described in detail, e. g., in PCT publications WO 94/20127 and WO 94/03205. It should be noted that ICso

values can change, often dramatically, if the assay conditions are varied, and depending on the particular reagents used (e. g. , HLA preparation, etc.). For example, excessive concentrations of HLA molecules will increase the apparent measured IC50 of a given ligand.

Alternatively, binding is expressed relative to a reference peptide.

Although as a particular assay becomes more, or less, sensitive, the ICso's of the peptides tested may change somewhat, the binding relative to the reference peptide will not significantly change. For example, in an assay run under conditions such that the ICso of the reference peptide increases 10-fold, the ICso values of the test peptides will also shift approximately 10-fold. Therefore, to avoid ambiguities, the assessment of whether a peptide is a good, intermediate, weak, or negative binder is generally based on its ICso, relative to the IC50 of a standard peptide.

Binding may also be determined using other assay systems including those using: live cells (e. g. , Ceppellini et al., Nature 339: 392 (1989); Cllristnick et al., Nature 352: 67 (1991); Busch et al., Iiit. Immunol. 2: 443 (1990); Hill et al., J. Immunol. 147: 189 (1991) ; del Guercio et al., J ; Immunol. 154: 685 (1995) ), cell free systems using detergent lysates (e. g., Cerundolo et al., J. Immunol. 21: 2069 (1991) ), immobilized purified MHC (e. g., Hill et al., J. Immunol. 152, 2890 (1994); Marshall et al., J. Immunol. 152: 4946 (1994) ), ELISA systems (e. g., Reay et al., EMBO J. 11: 2829 (1992)), surface plasmon resonance (e. g., Khilko et al., R Biol. Chez. 268: 15425 (1993) ) ; high flux soluble phase assays (Hammer et al., J. Exp. Med. 180: 2353 (1994) ), and measurement of class I MHC stabilization or assembly (e. g. , Ljunggren et al., Nature 346: 476 (1990); Schumacher et al., Cell 62: 563 (1990); Townsend et al., Cell 62: 285 (1990); Parker et al., J. Immunol.

149: 1896 (1992)).

A"conserved residue"is an amino acid which occurs in a significantly higher frequency than would be expected by random distribution at a particular position in a peptide. Typically a conserved residue is one where the MHC structure may provide a contact point with the immunogenic peptide. At least one to three or more, preferably two, conserved residues within a peptide of defined length defines a motif for an immunogenic peptide. These residues are typically in close contact with the peptide binding groove, with their side chains buried in specific pockets of the groove itself.

Typically, an immunogenic peptide will comprise up to three conserved residues, more usually two conserved residues.

As used herein, "negative binding residues"are amino acids which if present at certain positions (for example, positions 1,3 and/or 7 of a 9-mer) will result in a peptide being a nonbinder or poor binder and in turn fail to be immunogenic i. e. induce a CTL response.

The term"motif"refers to the pattern of residues in a peptide of defined length, usually a peptide of from about 8 to about 13 amino acids, often 8 to 11 amino acids, for a class I HLA motif and from about 6 to about 25 amino acids for a class II HLA motif, which is recognized by a particular HLA molecule. Peptide motifs are typically different for each protein encoded by each human HLA allele and differ in the pattern of the primary and secondary anchor residues.

The binding motif for an allele can be defined with increasing degrees of precision. In one case, all of the conserved residues are present in the correct positions in a peptide and there are no negative residues in positions 1,3 and/or 7.

A"supermotif'is a peptide binding specificity shared by HLA molecules encoded by two or more HLA alleles. Preferably, a supermotif-bearing peptide is recognized with high or intermediate affinity (as defined herein) by two or more HLA molecules.

An"HLA supertype or family", as used herein, describes sets of HLA molecules grouped on the basis of shared peptide-binding specificities. HLA class I molecules that share somewhat similar binding affinity for peptides bearing certain amino acid motifs are grouped into HLA supertypes. The terms HLA superfamily, HLA supertype family, HLA family, and HLA xx-like molecules (where xx denotes a particular HLA type), are synonyms.

"Heteroclitic analogs"are defined herein as a peptide with increased potency for a specific T cell, as measured by increased responses to a given dose, or by a requirement of lesser amounts to achieve the same response as a homologous native class I peptide. Advantages of heteroclitic analogs include that the antigens can be more potent, or more economical (since a lower amount is required to achieve the same effect as a homologous class I peptide). In addition, heteroclitic analogs are also useful to overcome antigen-specific T cell unresponsiveness (T cell tolerance).

The phrases"isolated"or"biologically pure"refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. Thus, the peptides of this invention do not contain materials normally associated with their in satu environment, e. g. , MHC I molecules on antigen presenting cells. Even where a protein has been isolated to a homogenous or dominant band, there are trace contaminants in the range of 5-10% of native protein which co-purify with the desired protein. Isolated peptides of this invention do not contain such endogenous co- purified protein.

The term"residue"refers to an amino acid or amino acid mimetic incorporated in an oligopeptide by an amide bond or amide bond mimetic.

"Link"or"join"refers to any method known in the art for functionally connecting peptides, including, without limitation, recombinant fusion, covalent bonding, disulfide bonding, ionic bonding, hydrogen bonding, and electrostatic bonding.

"Pharmaceutically acceptable"refers to a generally non-toxic, inert, and/or physiologically compatible composition.

A'pharmaceutical excipient"comprises a material such as an adjuvant, a carrier, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like.

"Synthetic peptide"refers to a peptide that is not naturally occurring, but is man-made using such methods as chemical synthesis or recombinant DNA technology.

A"non-native"sequence or"construct"refers to a sequence that is not found in nature, i. e. , is"non-naturally occurring". Such sequences include, e. g., peptides that are lipidated or otherwise modified, and polyepitopic compositions that contain epitopes that are not contiguous in a native protein sequence.

As used herein, a"vaccine"is a composition that contains one or more peptides of the invention. There are numerous embodiments of vaccines in accordance with the invention, such as by a cocktail of one or more peptides; one or more epitopes of the invention comprised by a polyepitopic peptide; or nucleic acids that encode such peptides or polypeptides, e. g., a minigene that encodes a polyepitopic peptide. The"one or more peptides"can include any whole unit integer from 1-150, e. g. , at least 2,3, 4,5, 6,7, 8,9, 10,11, 12,13, 14,15, 16,17, 18,19, 20,21, 22,23, 24,25, 26,27, 28, 29,30, 31,32, 33,34, 35,36, 37,38, 39,40, 45,50, 55,60, 65,70, 75,80, 85,90, 95,100, 105,

110,115, 120, 125, 130,135, 140,145, or 150 or more peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class 1-binding peptides of the invention can be admixed with, or linked to, HLA class 11-binding peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. Vaccines can also comprise peptide- pulsed antigen presenting cells, e. g. , dendritic cells.

The nomenclature used to describe peptide compounds follows the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C-terminus) of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxyl-terminal groups, although not specifically shown, are in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by standard three letter or single letter designations. The L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids having D-forms is represented by a lower case single letter or a lower case three letter symbol. Glycine has no asymmetric carbon atom and is simply referred to as"Gly"or G.

DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention relates to the determination of allele-specific peptide motifs for human class I and class II allele subtypes. These motifs are then used to define T cell epitopes from any desired antigen, particularly those associated with human viral diseases, cancers or autoiummune diseases, for which the amino acid sequence of the potential antigen or autoantigen targets is known. The application of supermotifs and motifs and binding analysis to the identification of epitopes is described in WO01/21189 and co-pending U. S. applications numbers 09/239,043, filed 1/27/99 ; 09/350, 401, filed 7/8/99 ; 09/412, 863 filed 10/5/99 ; 09/390,061 filed 9/3/99 ; 09/458,302 filed 12 10/99; 09, 458,297 filed 12 10/99 ; 09/458,298 filed 12/10/99, 09/633,364 filed 8/7/00; 09/458,299 filed 12 10/99 ; and 09/641, 528 filed 8/15/00.

Epitopes on a number of immunogenic target proteins can be identified using the peptides of the invention. Examples of suitable antigens include tumor- associated antigens such as TRP1, p53, CEA, Her2/neu, and MAGE, including MAGE1,

MAGE2, and MAGE3 ; prostate cancer-associated antigens such as prostate specific antigen (PSA), human kallikrein (huK2), prostate specific membrane antigen (PSM), and prostatic acid phosphatase (PAP); antigens from viruses such as hepatitis B (e. g., HBV core and surface antigens (HBVc, HBVs)) hepatitis C, Epstein-Barr virus, human immunodeficiency type-1 virus (HIV1), Kaposi's sarcoma herpes (KSHV), human papilloma virus (HPV), influenza virus, and Lassa virus antigens, Mycobacterium tuberculosis (MT) antigens, trypanosome, e. g., Tiypansoma cruzi (T. cruzi), antigens such as surface antigen (TSA), and malaria antigens. The peptides are thus useful in pharmaceutical compositions for both in vivo and ex vivo therapeutic and diagnostic applications.

Peptides comprising the epitopes from these antigens are synthesized and then tested for their ability to bind to the appropriate MHC molecules in assays using, for example, purified class I molecules and radioiodonated peptides and/or cells expressing empty class I molecules by, for instance, immunofluorescent staining and flow microfluorometry, peptide-dependent class I assembly assays, and inhibition of CTL recognition by peptide competition. Those peptides that bind to the class I molecule are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo CTL responses that can give rise to CTL populations capable of reacting with virally infected target cells or tumor cells as potential therapeutic agents.

The HLA class I antigens are encoded by the HLA-A, B, and C loci.

HLA-A and B antigens are expressed at the cell surface at approximately equal densities, whereas the expression of HLA-C is significantly lower (perhaps as much as 10-fold lower). Each of these loci have a number of alleles. The peptide binding motifs of the invention are relatively specific for each allelic subtype.

For epitope-based vaccines, the peptides of the present invention preferably comprise a supermotif and/or motif recognized by an HLA I or HLA II molecule having a wide distribution in the human population.

Identification of Epitopes The large degree of HLA polymorphism is an important factor to be taken into account with the epitope-based approach to vaccine development. To address this

factor, epitope selection encompassing identification of peptides capable of binding at high or intermediate affinity to multiple HLA molecules is preferably utilized, most preferably these epitopes bind at high or intermediate affinity to two or more allele- specific HLA molecules.

Immunogenic peptides of interest for vaccine compositions preferably include those that have an IC50 or binding affinity value for a class I HLA molecule (s) of 500 nM or better (i. e. , the value is zu 500 nM) or, for class II HLA molecules, 1000 nM or better (i. e. , the value is zu 1000 nM). For example, peptide binding is assessed by testing the capacity of a candidate peptide to bind to a purified HLA molecule in vitro. Peptides exhibiting high or intermediate affinity are then considered for further analysis. Selected peptides are generally tested on other members of the supertype family. In preferred embodiments, peptides that exhibit cross-reactive binding are then used in cellular screening analyses or vaccines.

Peptide Epitope Binding Motifs and Supermotifs Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues required for allele-specific binding to HLA molecules have been identified. The presence of these residues correlates with binding affinity for HLA molecules. The identification of motifs and/or supermotifs that correlate with high and intermediate affinity binding is an important issue with respect to the identification of immunogenic peptide epitopes for the inclusion in a vaccine. Kast et al. (R Immunol. 152: 3904-3912,1994) have shown that motif-bearing peptides account for 90% of the epitopes that bind to allele-specific HLA class I molecules. In this study all possible peptides of 9 amino acids in length and overlapping by eight amino acids (240 peptides), which cover the entire sequence of the E6 and E7 proteins of human papillomavirus type 16, were evaluated for binding to five allele-specific HLA molecules that are expressed at high frequency among different ethnic groups. This unbiased set of peptides allowed an evaluation of the predictive value of HLA class I motifs. From the set of 240 peptides, 22 peptides were identified that bound to an allele-specific HLA molecule with high or intermediate affinity. Of these 22 peptides, 20 (i. e. 91%) were motif-bearing. Thus, this study demonstrates the value of motifs for the identification of peptide epitopes for inclusion in a vaccine: application of

motif-based identification techniques will identify about 90% of the potential epitopes in a target antigen protein sequence.

A relationship between binding affinity for HLA class I molecules and immunogenicity of discrete peptide epitopes on bound antigens was determined by the present inventors. As disclosed in greater detail herein, higher HLA binding affinity is correlated with greater immunogenicity.

Greater immunogenicity can be manifested in several different ways.

Immunogenicity corresponds to whether an immune response is elicited at all, and to the vigor of any particular response, as well as to the extent of a population in which a response is elicited. For example, a peptide might elicit an immune response in a diverse array of the population, yet in no instance produce a vigorous response. In accordance with these principles, close to 90% of high binding peptides have been found to elicit a response and thus be"immunogenic,"as contrasted with about 50% of the peptides that bind with intermediate affinity. (See, e. g. , Schaeffer et al. PNAS (1988)) Moreover, not only did peptides with higher binding affinity have an enhanced probability of generating an immune response, the generated response tended to be more vigorous than the response seen with weaker binding peptides. As a result, less peptide is required to elicit a similar biological effect if a high affinity binding peptide is used rather than a lower affinity one. Thus, in preferred embodiments of the invention, high affinity binding epitopes are used.

The correlation between binding affinity and immunogenicity was analyzed by the present inventors by two different experimental approaches (see, e. g., Sette, et al., J. Immunol. 153: 5586-5592 (1994)). In the first approach, the immunogenicity of potential epitopes ranging in HLA binding affinity over a 10, 000-fold range was analyzed in HLA-A*0201 transgenic mice. In the second approach, the antigenicity of approximately 100 different hepatitis B virus (HBV) -derived potential epitopes, all carrying A*0201 binding motifs, was assessed by using PBL from acute hepatitis patients. Pursuant to these approaches, it was determined that an affinity threshold value of approximately 500 nM (preferably 50 nM or less) determines the capacity of a peptide epitope to elicit a CTL response. These data are true for class I binding affinity measurements for naturally processed peptides and for synthesized T cell epitopes.

An affinity threshold associated with immunogenicity in the context of HLA class II DR molecules has also been delineated (see, e. g., Southwood et al. J.

Immunology 160: 3363-3373, 1998, and W099/61916). In order to define a biologically significant threshold of DR binding affinity, a database of the binding affinities of 32 DR- restricted epitopes for their restricting element (i. e. , the HLA molecule that binds the motif) was compiled. In approximately half of the cases (15 of 32 epitopes), DR restriction was associated with high binding affinities, i. e. binding affinity values of 100 nM or less. In the other half of the cases (16 of 32), DR restriction was associated with intermediate affinity (binding affinity values in the 100-1000 nM range). In only one of 32 cases was DR restriction associated with an IC5o of 1000 nM or greater. Thus, 1000 nM can be defined as an affinity threshold associated with immunogenicity in the context of DR molecules.

Definition of motifs that are predictive of binding to specific class I and class II alleles allows the identification of potential peptide epitopes from an antigenic protein whose amino acid sequence is known. Typically, identification of potential peptide epitopes is initially carried out using a computer to scan the amino acid sequence of a desired antigen for the presence of motifs and/or supermotifs.

HLA Class I Motifs Indicative of CTL Inducing Peptide Epitopes : The primary anchor residues of the HLA class I peptide epitope supermotifs and motifs are delineated below. In some cases, peptide epitopes may be listed in both a motif and a supermotif Table. The relationship of a particular motif and respective supermotif is indicated in the description of the individual motifs.

The HLA-A1 supermotif is characterized by the presence in peptide ligands of a small (T or S) or hydrophobic (L, I, V, or M) primary anchor residue in position 2, and an aromatic (Y, F, or W) primary anchor residue at the C-terminal position of the epitope. The corresponding family of HLA molecules that bind to the Al supermotif (i. e. , the HLA-A1 supertype) is comprised of at least A*0101, A*2601, A*2602, A*2501, and A*3201 (see, e. g., DiBrino, M. et al., J. Immunol. 151: 5930, 1993; DiBrino, M. et al., J ; Immunol 152: 620, 1994; Kondo, A. et al., Imtnunogenetics 45: 249,1997). Other allele-specific HLA molecules predicted to be members of the Al superfamily are shown in Table 1. Peptides binding to each of the individual HLA

proteins can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supennotif.

Primary anchor specificities for allele-specific HLA-A2.1 molecules (see, e. g. , Falk et al., Nature 351: 290-296,1991 ; Hunt et al., Science 255: 1261-1263,1992 ; Parker et al., J ; Immunol. 149: 3580-3587,1992 ; Ruppert et al., Cell 74 : 929-937,1993) and cross-reactive binding among HLA-A2 and-A28 molecules have been described.

(See, e. g., Fruci et al., Human Immunol. 38 : 187-192, 1993; Tanigaki et al., Human Immunol. 39: 155-162,1994 ; Del Guercio et al., J ; Immunol. 154: 685-693,1995 ; Kast et al., J ; Immunol. 152: 3904-3912,1994 for reviews of relevant data. ) These primary anchor residues define the HLA-A2 supermotif ; which presence in peptide ligands corresponds to the ability to bind several different HLA-A2 and-A28 molecules. The HLA-A2 supermotif comprises peptide ligands with L, I, V, M, A, T, or Q as a primary anchor residue at position 2 and L, I, V, M, A, or T as a primary anchor residue at the C- terminal position of the epitope.

The corresponding family of HLA molecules (i. e. , the HLA-A2 supertype that binds these peptides) is comprised of at least: A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*0209, A*0214, A*6802, and A*6901. Other allele- specific HLA molecules predicted to be members of the A2 superfamily are shown in Table 1. As explained in detail below, binding to each of the individual allele-specific HLA molecules can be modulated by substitutions at the primary anchor and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif.

The HLA-A3 supermotif is characterized by the presence in peptide ligands of A, L, I, V, M, S, or, T as a primary anchor at position 2, and a positively charged residue, R or K, at the C-terminal position of the epitope, e. g., in position 9 of 9- mers (see, e. g., Sidney et al., Hum. Immunol. 45: 79,1996). Exemplary members of the corresponding family of HLA molecules (the HLA-A3 supertype) that bind the A3 supermotif include at least A*0301, A*1101, A*3101, A*3301, and A*6801. Other allele-specific HLA molecules predicted to be members of the A3 supertype are shown in Table 1. As explained in detail below, peptide binding to each of the individual allele- specific HLA proteins can be modulated by substitutions of amino acids at the primary

and/or secondary anchor positions of the peptide, preferably choosing respective residues specified for the supermotif.

The HLA-A24 supermotif is characterized by the presence in peptide ligands of an aromatic (F, W, or Y) or hydrophobic aliphatic (L, I, V, M, or T) residue as a primary anchor in position 2, and Y, F, W, L, I, or M as primary anchor at the C- terminal position of the epitope (see, e. g. , Sette and Sidney, Inimunogenetics, in press, 1999). The corresponding family of HLA molecules that bind to the A24 supermotif (i. e., the A24 supertype) includes at least A*2402, A*3001, and A*2301. Other allele-specific HLA molecules predicted to be members of the A24 supertype are shown in Table 1.

Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif.

The HLA-B7 supermotif is characterized by peptides bearing proline in position 2 as a primary anchor, and a hydrophobic or aliphatic amino acid (L, I, V, M, A, F, W, or Y) as the primary anchor at the C-terminal position of the epitope. The corresponding family of HLA molecules that bind the B7 supermotif (i. e. , the HLA-B7 supertype) is comprised of at least twenty six HLA-B proteins including: B*0702, B*0703, B*0704, B*0705, B*1508, B*3501, B*3502, B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*5101, B*5102, B*5103, B*5104, B*5105, B*5301, B*5401, B*5501, B*5502, B*5601, B*5602, B*6701, and B*7801 (see, e. g., Sidney, et al., J ; Immunol. 154: 247,1995 ; Barber, et al., Curr. Biol. 5: 179,1995 ; Hill, et al., Nature 360: 434,1992 ; Rammensee, et al., Immunogenetics 41: 178,1995 for reviews of relevant data). Other allele-specific HLA molecules predicted to be members of the B7 supertype are shown in Table 1. As explained in detail below, peptide binding to each of the individual allele-specific HLA proteins can be modulated by substitutions at the primary and/or secondary anchor positions of the peptide, preferably choosing respective residues specified for the supermotif.

The HLA-B27 supermotif is characterized by the presence in peptide ligands of a positively charged (R, H, or K) residue as a primary anchor at position 2, and a hydrophobic (F, Y, L, W, M, I, A, or V) residue as a primary anchor at the C-terminal position of the epitope (see, e. g., Sidney and Sette, Ininiunogeizetics, in press, 1999).

Exemplary members of the corresponding family of HLA molecules that bind to the B27

supermotif (i. e. , the B27 supertype) include at least B*1401, B*1402, B*1509, B*2702, B*2703, B*2704, B*2705, B*2706, B*3801, B*3901, B*3902, and B*7301. Other allele-specific HLA molecules predicted to be members of the B27 supertype are shown in Table 1. Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif.

The HLA-B44 supermotif is characterized by the presence in peptide ligands of negatively charged (D or E) residues as a primary anchor in position 2, and hydrophobic residues (F, W, Y, L, I, M, V, or A) as a primary anchor at the C-terminal position of the epitope (see, e. g. , Sidney et al., Immunol. Today 17: 261,1996).

Exemplary members of the corresponding family of HLA molecules that bind to the B44 supermotif (i. e. , the B44 supertype) include at least: B*1801, B*1802, B*3701, B*4001, B*4002, B*4006, B*4402, B*4403, and B*4006. Peptide binding to each of the allele- specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions; preferably choosing respective residues specified for the supermotif.

The HLA-B58 supermotif is characterized by the presence in peptide ligands of a small aliphatic residue (A, S, or T) as a primary anchor residue at position 2, and an aromatic or hydrophobic residue (F, W, Y, L, I, V, M, or A) as a primary anchor residue at the C-terminal position of the epitope (see, e. g. , Sidney and Sette, Immuhogenetics, in press, 1999 for reviews of relevant data). Exemplary members of the corresponding family of HLA molecules that bind to the B58 supermotif (i. e. , the B58 supertype) include at least: B*1516, B*1517, B*5701, B*5702, and B*5801. Other allele-specific HLA molecules predicted to be members of the B58 supertype are shown in Table 1. Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif.

The HLA-B62 supermotif is characterized by the presence in peptide ligands of the polar aliphatic residue Q or a hydrophobic aliphatic residue (L, V, M, I, or P) as a primary anchor in position 2, and a hydrophobic residue (F, W, Y, M, I, V, L, or A) as a primary anchor at the C-terminal position of the epitope (see, e. g., Sidney and Sette, Immunogenetics, in press, 1999). Exemplary members of the corresponding family of HLA molecules that bind to the B62 supermotif (i. e., the B62 supertype) include at

least: B*1501, B*1502, B*1513, and B5201. Other allele-specific HLA molecules predicted to be members of the B62 supertype are shown in Table 1. Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif.

Table 1 Allelle-specific HLA-supertype members <BR> <BR> HLA supermotif<BR> verfieda Predictedb A1 A*0101, A*2501, A*2601, A*2602, A*0102, A*2604, A*3601, A*4301, A*3201 A*8001 A2 A*0201, A*0202, A*0203, A*0204, A*0208, A*0210, A*0211, A*0212, A*0205, A*0206, A*0207, A*0209, A*0213 A*0214, A*6802, A*6901 A3 A*0301, A*1101, A*3101, A*3301, A*0302, A*1102, A*2603, A*3302, A*6801 A*3303, A*3401, A*3402, A*6601, A*6602, A*7401 A24 A*2301, A*2402, A*3001 A*2403, A*2404, A*3002, A*3003 B7 B*0702, B*0703, B*0704, B*0705, B*1511, B*4201, B*5901 B*1508, B*3501, B*3502, B*3503, B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*5101, B*5102, B*5103, B*5104, B*5105, B*5301, B*5401, B*5501, B*5502, B*5601, B*5602, B*6701, B*7801 B27 B*1401, B*1402, B*1509, B*2702, B*2701, B*2707, B*2708, B*3802, B*2703, B*2704, B*2705, B*2706, B*3903, B*3904, B*3905, B*4801, B*3801, B*3901, B*3902, B*7301 B*4802, B*1510, B*1518, B*1503 B44 B*1801, B*1802, B*3701, B*4402, B*4101, B*4501, B*4701, B*4901, B*4403, B*4404, B*4001, B*4002, B*5001 B*4006 B58 B*5701, B*5702, B*5801, B*5802, B*1516, B*1517 B62 B*1501, B*1502, B*1513, B*5201 B*1301, B*1302, B*1504, B*1505, B*1506, B*1507, B*1515, B*1520, B*1521, B*1512, B*1514, B*1510 a. Verified alleles include alleles whose specificity has been determined by pool sequencing analysis, peptide binding assays, or by analysis of the sequences of CTL epitopes. b. Predicted alleles are alleles whose specificity is predicted on the basis of B and F pocket structure to overlap with the supertype specificity.

The HLA-A1 motif is characterized by the presence in peptide ligands of T, S, or M as a primary anchor residue at position 2 and the presence of Y as a primary anchor residue at the C-terminal position of the epitope. An alternative allele-specific Al motif is characterized by a primary anchor residue at position 3 rather than position 2.

This motif is characterized by the presence of D, E, A, or S as a primary anchor residue in

position 3, and a Y as a primary anchor residue at the C-terminal position of the epitope (see, e. g. , DiBrino et al., J. Immunol., 152: 620,1994 ; Kondo et al., Immunogenetics 45: 249,1997 ; and Kubo et al., J. Immunol. 152: 3913,1994 for reviews of relevant data).

An HLA-A1 extended motif includes a D residue in position 3 and A, I, L, or F at the C- terminus. Peptide binding to HLA Al can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif. Residues T, S, or M at position 2 and Y at the C-terminal position are a subset of the A1 supermotif primary anchors.

An HLA-A2*0201 motif was characterized by the presence in peptide ligands of L or M as a primary anchor residue in position 2, and L or V as a primary anchor residue at the C-terminal position of a 9-residue peptide (see, e. g. , Falk et al., Nature 351: 290-296,1991) and was further found to comprise an I at position 2 and I or A at the C-terminal position of a nine amino acid peptide (see, e. g., Hunt et al., Science 255: 1261-1263, March 6,1992 ; Parker et al., J : Immunol. 149: 3580-3587, 1992). The A*0201 allele-specific motif has also been defined to additionally comprise V, A, T, or Q as a primary anchor residue at position 2, and M or T as a primary anchor residue at the C-terminal position of the epitope (see, e. g., Kast et al., J ImmunoL 152: 3904-3912, 1994). Thus, the HLA-A*0201 motif comprises peptide ligands with L, I, V, M, A, T, or Q as primary anchor residues at position 2 and L, I, V, M, A, or T as a primary anchor residue at the C-terminal position of the epitope. The preferred and tolerated residues that characterize the primary anchor positions of the HLA-A*0201 motif are identical to the residues describing the A2 supermotif. (For reviews of relevant data, see, e. g., Del Guercio et al., J. Immunol. 154: 685-693,1995 ; Ruppert et al., Cell 74 : 929-937,1993 ; Sidney et al., Immunol. Today 17: 261-266,1996 ; Sette and Sidney, Curr. Opin. in Immunol. 10: 478-482, 1998). Secondary anchor residues that characterize the A*0201 motif have additionally been defined (see, e. g. , Ruppert et al., Cell 74 : 929-937,1993).

Peptide binding to HLA-A*0201 molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif.

The HLA-A3 motif is characterized by the presence in peptide ligands of L, M, V, I, S, A, T, F, C, G, or D as a primary anchor residue at position 2, and the presence of K, Y, R, H, F, or A as a primary anchor residue at the C-terminal position of

the epitope (see, e. g., DiBrino et al., Proc. Natl. Acad. Sci USA 90: 1508, 1993; and Kubo et al., J : Immunol. 152: 3913-3924,1994). Peptide binding to HLA-A3 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif.

The HLA-A11 motif is characterized by the presence in peptide ligands of V, T, M, L, I, S, A, G, N, C, D, or F as a primary anchor residue in position 2, and K, R, Y, or H as a primary anchor residue at the C-terminal position of the epitope (see, e. g., Zhang et al., Proc. Natl. Acad. Sci USA 90: 2217-2221,1993 ; and Kubo et al., J.

Immunol. 152: 3913-3924,1994). Peptide binding to HLA-A11 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif.

The HLA-A24 motif is characterized by the presence in peptide ligands of Y, F, W, or M as a primary anchor residue in position 2, and F, L, I, or W as a primary anchor residue at the C-terminal position of the epitope (see, e. g., Kondo et al., J.

Immunol. 155: 4307-4312,1995 ; and Kubo et al., J ; Immunol. 152: 3913-3924,1994).

Peptide binding to HLA-A24 molecules can be modulated by substitutions at primary and/or secondary anchor positions; preferably choosing respective residues specified for the motif.

Motifs Indicative of Class II HTL Inducing Peptide Epitopes The primary anchor residues of the HLA class II supermotifs and motifs are delineated below.

HLA DR-1-4-7 supermotif Motifs have also been identified for peptides that bind to three common HLA class II allele-specific HLA molecules: HLA DRB1*0401, DRB1*0101, and DRB1 *0701 (see, e. g., the review by Southwood et al. J. Immunology 160: 3363- 3373,1998). Collectively, the common residues from these motifs delineate the HLA DR-1-4-7 supermotif. Peptides that bind to these DR molecules carry a supermotif characterized by a large aromatic or hydrophobic residue (Y, F, W, L, I, V, or M) as a primary anchor residue in position 1, and a small, non-charged residue (S, T, C, A, P, V, I, L, or M) as a primary anchor residue in position 6 of a 9-mer core region. Allele- specific secondary effects and secondary anchors for each of these HLA types have also

been identified (Southwood et al., supra). These are set forth in Table III. Peptide binding to HLA-DRB1*0401, DRB1*0101, and/or DRB1*0701 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supennotif.

Two alternative motifs (i. e. , submotifs) characterize peptide epitopes that bind to HLA-DR3 molecules (see, e. g. , Geluk et al., J. Immunol. 152: 5742,1994). In the first motif (submotif DR3A) a large, hydrophobic residue (L, I, V, M, F, or Y) is present in anchor position 1 of a 9-mer core, and D is present as an anchor at position 4, towards the carboxyl terminus of the epitope. As in other class II motifs, core position 1 may or may not occupy the peptide N-terminal position.

The alternative DR3 submotif provides for lack of the large, hydrophobic residue at anchor position 1, and/or lack of the negatively charged or amide-like anchor residue at position 4, by the presence of a positive charge at position 6 towards the carboxyl terminus of the epitope. Thus, for the alternative allele-specific DR3 motif (submotif DR3B): L, I, V, M, F, Y, A, or Y is present at anchor position 1; D, N, Q, E, S, or T is present at anchor position 4; and K, R, or H is present at anchor position 6.

Peptide binding to HLA-DR3 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif.

Evaluatiotz of motif-beaiyag peptide epitopes Upon identification of motif-bearing sequences, peptides corresponding to the sequences are then synthesized and, typically, evaluated for binding to the corresponding HLA allele. The capacity to bind MHC Class molecules is measured in a variety of different ways. One means is a Class I molecule binding assay as described in the related applications, noted above. Other alternatives described in the literature include inhibition of antigen presentation (Sette, et al., J ; Immunol. 141: 3893 (1991), in vitro assembly assays (Townsend, et al., Cell 62: 285 (1990), and FACS based assays using mutated ells, such as RMA-S (Melief, et al., Eur. J ; Immunol. 21: 2963 (1991)).

Peptides that test positive in the binding assay are assayed for the ability of the peptides to induce specific CTL (or HTL, for class II motif-bearing peptides) responses in vitro. For instance, antigen-presenting cells that have been incubated with a

peptide can be assayed for the ability to induce CTL responses in responder cell populations. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells (Inaba, et al., J ; Exp. Med. 166: 182 (1987) ; Boog, Eur. J. Immu7nol. 18 : 219 (1988)).

Alternatively, mutant mammalian cell lines that are deficient in their ability to load class I molecules with internally processed peptides, such as the mouse cell lines RMA-S (Karre, et al. Nature, 319: 675 (1986); Ljunggren, et al., Emir. J. lininuizol 21: 2963-2970 (1991) ), and the human somatic T cell hybrid, T-2 (Cerundolo, et al., Nature 345: 449-452 (1990) ) and which have been transfected with the appropriate human class I genes are conveniently used, when peptide is added to them, to test for the capacity of the peptide to induce in vitro primary CTL responses. Other eukaryotic cell lines which could be used include various insect cell lines such as mosquito larvae (ATCC cell lines CCL 125,126, 1660,1591, 6585,6586), silkworm (ATTC CRL 8851), armyworm (ATCC CRL 1711), moth (ATCC CCL 80) and Drosophila cell lines such as a Schneider cell line (see Schneider, J. Embryon. Exp. Morphol. 27: 353-365 (1927)).

Peripheral blood lymphocytes are conveniently isolated following simple venipmcture or leukapheresis of normal donors or patients and used as the responder cell sources of CTL precursors. In one embodiment, the appropriate antigen-presenting cells are incubated with 10-100 uM of peptide in serum-free media for 4 hours under appropriate culture conditions. The peptide-loaded antigen-presenting cells are then incubated with the responder cell populations in vitro for 7 to 10 days under optimized culture conditions. Positive CTL activation can be determined by assaying the cultures for the presence of CTLs that kill radiolabeled target cells, both specific peptide-pulsed targets as well as target cells expressing endogenously processed form of the relevant virus or tumor antigen from which the peptide sequence was derived.

Specificity and HLA restriction of the CTL is determined by testing against different peptide target cells expressing appropriate or inappropriate human HLA class 1. The peptides that test positive in the HLA binding assays and give rise to specific CTL responses are referred to herein as immunogenic peptides.

After determining their binding affinity, additional confirmatory work can be performed to select, amongst these vaccine candidates, epitopes with preferred characteristics in terms of population coverage, antigenicity, and immunogenicity.

Thus, various strategies can be utilized to evaluate immunogenicity, including: 1) Evaluation of primary T cell cultures from normal individuals (see, e. g., Wentworth, P. A. et al., Mol. Immunol. 32: 603,1995 ; Celis, E. et al., Proc. Natl. Acad.

Sci. USA 91: 2105,1994 ; Tsai, V. et al., J. Immunol. 158 : 1796,1997 ; Kawashima, 1. et al., Human Immunol. 59: 1, 1998) ; This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting cells in vitro over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, e. g. , a lymphokine- release or a 51 Cr cytotoxicity assay involving peptide sensitized target cells.

2) Immunization of HLA transgenic mice (see, e. g., Wentworth, P. A. et al., J. Immunol. 26: 97,1996 ; Wentworth, P. A. et al., Int. Immunol. 8: 651,1996 ; Alexander, J. et al., J linmuizol. 159: 4753,1997) ; In this method, peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice. Several weeks following immunization, splenocytes are removed and cultured in vitro in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, e. g., a 51 Cr-release assay involving peptide sensitized target cells and target cells expressing endogenously generated antigen.

3) Demonstration of recall T cell responses from patients who have been effectively vaccinated or who have a tumor; (see, e. g., Rehermann, B. et al., J Exp. Med.

181: 1047,1995 ; Doolan, D. L. et al., Immunity 7: 97,1997 ; Bertoni, R. et al., J. Clin.

Invest. 100: 503,1997 ; Threlkeld, S. C. et al., J. Immunol. 159: 1648, 1997; Diepolder, H.

M. et aL, J Virol. 71: 6011,1997 ; Tsangetal., J : Natl. CancerInst. 87 : 982-990,1995 ; Disis et al., J. Immunol. 156: 3151-3158,1996). In applying this strategy, recall responses are detected by culturing PBL from patients with cancer who have generated an immune response"naturally", or from patients who were vaccinated with tumor antigen vaccines.

PBL from subjects are cultured in vitro for 1-2 weeks in the presence of test peptide plus antigen presenting cells (APC) to allow activation of"memory"T cells, as compared to "naive"T cells. At the end of the culture period, T cell activity is detected using assays for T cell activity including 51Cr release involving peptide-sensitized targets, T cell proliferation, or lymphokine release.

Preparation of peptides Peptides that comprise epitopes of the invention can be prepared synthetically, or by recombinant DNA technology or from natural sources such as whole viruses or tumors. Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides can be synthetically conjugated to native fragments or particles The polypeptides or peptides can be a variety of lengths, either in their neutral (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications, subject to the condition that the modification not destroy the biological activity of the polypeptides as herein described.

Often, the peptide will be as small as possible while still maintaining substantially all of the biological activity of the large peptide. In some embodiments, it may be desirable to optimize peptides of the invention to a length of 8, 9,10, or 11 amino acid residues, commensurate in size with endogenously processed viral peptides or tumor cell peptides that are bound to MHC class I molecules on the cell surface.

As the coding sequence for peptides of the length contemplated herein can be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci et al., J. Am. Chem. Soc. 103: 3185 (1981), Alternatively, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1982), which is incorporated herein by reference. For example, a coding sequence encoding a peptide of the invention can be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to transform suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are now available.

Expression constructs, i. e. , minigenes are described in greater detail in the sections below.

Peptides having the desired activity may be modified as necessary to provide certain desired attributes, e. g., improved pharmacological characteristics, while

increasing or at least retaining substantially all of the biological activity of the unmodified peptide to bind the desired MHC molecule and activate the appropriate T cell. For instance, the peptides may be subject to various changes, such as substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, such as improved MHC binding. By conservative substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, e. g. , one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as Gly, Ala; Val, Ile, Leu, Met; Asp, Glu; Asn, Gln ; Ser, Thr; Lys, Arg; and Phe, Tyr. The effect of single amino acid substitutions may also be probed using D-amino acids. Such modifications may be made using well known peptide synthesis procedures, as described in e. g., Merrifield, Science 232: 341-347 (1986), Barany & Merrifield, The Peptides, Gross & Meienhofer, eds.

(N. Y. , Academic Press), pp. 1-284 (1979); and Stewart & Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984), incorporated by reference herein.

The peptides can also be modified by extending or decreasing the compound's amino acid sequence, e. g. , by the addition or deletion of amino acids. The peptides or analogs of the invention can also be modified by altering the order or composition of certain residues, it being readily appreciated that certain amino acid residues essential for biological activity, e. g. , those at critical contact sites or conserved residues, may generally not be altered without an adverse effect on biological activity.

The non-critical amino acids need not be limited to those naturally occurring in proteins, such as L-a-amino acids, or their D-isomers, but may include non-natural amino acids as well as many derivatives of L-a-amino acids.

Typically, a series of peptides with single amino acid substitutions are employed to determine the effect of electrostatic charge, hydrophobicity, etc. on binding.

For instance, a series of positively charged (e. g., Lys or Arg) or negatively charged (e. g., Glu) amino acid substitutions are made along the length of the peptide revealing different patterns of sensitivity towards various MHC molecules and T cell receptors. In addition, multiple substitutions using small, relatively neutral moieties such as Ala, Gly, Pro, or similar residues may be employed. The substitutions may be homo-oligomers or hetero- oligomers. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes

which are sought (e. g., hydrophobicity versus hydrophilicity). Increased binding affinity for an MHC molecule or T cell receptor may also be achieved by such substitutions, compared to the affinity of the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which might disrupt binding.

Amino acid substitutions are typically of single residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final peptide. Substitutional variants are those in which at least one residue of a peptide has been removed and a different residue inserted in its place.

Substantial changes in function (e. g. , affinity for MHC molecules or T cell receptors) are made by selecting substitutions that are less conservative than those in Table 3, i. e. , selecting residues that differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions wleh in general are expected to produce the greatest changes in peptide properties will be those in which (a) hydrophilic residue, e. g. seryl, is substituted for (or by) a hydrophobic residue, e. g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a residue having an electropositive side chain, e. g. , lysl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e. g. glutamyl or aspartyl; or (c) a residue having a bulky side chain, e. g. phenylalanine, is substituted for (or by) one not having a side chain, e. g., glycine.

The peptides may also comprise isosteres of two or more residues in the immunogenic peptide. An isostere as defined here is a sequence of two or more residues that can be substituted for a second sequence because the steric conformation of the first sequence fits a binding site specific for the second sequence. The term specifically includes peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the a-carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks.

See, generally, Spatola, C'laemistfy and Biochenaisty ofAmino Acids, Peptides and Proteins, Vol. VII (Weinstein ed. , 1983).

Modifications of peptides with various amino acid mimetics or unnatural amino acids are particularly useful in increasing the stability of the peptide in vivo.

Stability can be assayed in a number of ways. For instance, peptidases and various biological media, such as human plasma and serum, have been used to test stability. See, e. g., Verhoefetal., Eur. J. DrugMetabPharmacokzn. 11: 291-302 (1986). Half life of the peptides of the present invention is conveniently determined using a 25% human serum (v/v) assay. The protocol is generally as follows. Pooled human serum (Type AB, non-heat inactivated) is delipidated by centrifugation before use. The serum is then diluted to 25% with RPMI tissue culture media and used to test peptide stability. At predetermined time intervals a small amount of reaction solution is removed and added to either 6% aqueous trichloracetic acid or ethanol. The cloudy reaction sample is cooled (4°C) for 15 minutes and then spun to pellet the precipitated serum proteins. The presence of the peptides is then determined by reversed-phase HPLC using stability- specific chromatography conditions.

Another embodiment for generating effective peptide analogs involves the substitution of residues that have an adverse impact on peptide stability or solubility in, e. g., a liquid environment. This substitution may occur at any position of the peptide epitope. For example, a cysteine (C) can be substituted out in favor of a-amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce binding capacity. Substituting a- amino butyric acid for C not only alleviates this problem, but actually improves binding and crossbinding capability in certain instances (see, e. g., the review by Sette et al., In : Persistent Viral Infections, Eds. R. Ahmed and I. Chen, John Wiley & Sons, England, 1999). Substitution of cysteine with a-amino butyric acid may occur at any residue of a peptide epitope, i. e. at either anchor or non-anchor positions.

Modification of binding activity The binding activity, particularly modification of binding affinity or cross- reactivity among HLA supertype family members, of peptides of the invention can also be altered using analoging, which is described in co-pending U. S. application number 09/226,775 filed 1/6/99. In brief, the analoging strategy utilizes the motifs or supermotifs that correlate with binding to certain HLA molecules. Analog peptides can be created by substituting amino acid residues at primary anchor, secondary anchor, or at primary and secondary anchor positions. Generally, analogs are made for peptides that already bear a

motif or supermotif. For a number of the motifs or supermotifs in accordance with the invention, residues are defined which are deleterious to binding to allele-specific HLA molecules or members of HLA supertypes that bind the respective motif or supermotif (see, e. g. , Rupert et al. Cell 74 : 929, 1993 ; Sidney, J. et al., Hu. Immunol. 45: 79,1996 ; and Sidney et al. ; Sidney, et al., J ImmunoL 154: 247,1995). Accordingly, removal of such residues that are detrimental to binding can be performed in accordance with the present invention. For example, in the case of the A3 supertype, when all peptides that have such deleterious residues are removed from the population of peptides used in the analysis, the incidence of cross-reactivity increased from 22% to 37% (see, e. g., Sidney, J. et al., Hu. Immunol. 45: 79,1996).

Thus, one strategy to improve the cross-reactivity of peptides within a given supermotif is simply to delete one or more of the deleterious residues present within a peptide and substitute a small"neutral"residue such as Ala (that may not influence T cell recognition of the peptide). An enhanced likelihood of cross-reactivity is expected if, together with elimination of detrimental residues within a peptide,"preferred"residues associated with high affinity binding to an allele-specific HLA molecule or to multiple HLA molecules within a superfamily are inserted.

To ensure that an analog peptide, when used as a vaccine, actually elicits a CTL response to the native epitope in vivo, the analog peptide may be used to induce T cells in vitro from individuals of the appropriate HLA allele. Thereafter, the immunized cells'capacity to lyse wild type peptide sensitized target cells is evaluated. Alternatively, evaluation of the cells'activity can be evaluated by monitoring IFN release. Each of these cell monitoring strategies evaluate the recognition of the APC by the CTL. It will be desirable to use as antigen presenting cells, typically cells that have been either infected, or transfected with the appropriate genes to establish whether endogenously produced antigen is also recognized by the T cells induced by the analog peptide. It is to be noted that peptide/protein-pulsed dendritic cells can be used to present whole protein antigens for both HLA class I and class II.

Another embodiment of the invention is to create analogs of weak binding peptides, to thereby ensure adequate numbers of cellular binders. Class I binding peptides exhibiting binding affinities of 500-5000 nM, and carrying an acceptable but suboptimal primary anchor residue at one or both positions can be"fixed"by substituting

preferred anchor residues in accordance with the respective supertype. The analog peptides can then be tested for binding and/or cross-binding capacity.

Another embodiment of the invention is to create analogs of peptides that are already cross-reactive binders and are vaccine candidates, but which bind weakly to one or more alleles of a supertype. If the cross-reactive binder carries a suboptimal residue (less preferred or deleterious) at a primary or secondary anchor position, the peptide can be analoged by substituting out a deleterious residue and replacing it with a preferred or less preferred one, or by substituting out a less preferred reside and replacing it with a preferred one. The analog peptide can then be tested for cross-binding capacity.

Heteroclitic analogs Heteroclitic analog peptides of the invention are particularly useful to induce an immune response against antigens to which a patient's immune system has become tolerant. Tolerance refers to a specific immunologic nonresponsiveness induced by prior exposure to an antigen. Thus, tolerance can be overcome in the patient by identifying a particular class I peptide epitope to which a patient is tolerant, modifying the peptide epitope sequence according to the methods of the invention, and inducing an immune response that cross-reacts against the tolerized epitope (antigen). Overcoming tolerance is particularly desirable, for example, when a patient's immune system is tolerant of a viral or tumor-associated antigen, the latter antigens being often over- expressed self-proteins as a consequence of cell transfonnation. Heteroclitic analoging is described in co-pending US provisional application number 60/166,529 filed 11/18/99 and US provisional application for"Heteroclitic Analogs And Related Methods", Tangri et al., inventors, Attorney Docket number 018623-015810US, filed 10/6/00.

Combinations of CTL and HTL epitopes The peptides of the present invention or analogs thereof which have CTL stimulating activity may be modified to provide desired attributes other than improved serum half life. For instance, the ability of the peptides to induce CTL activity can be enhanced by linkage to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Particularly preferred immunogenic peptides/T helper conjugates are linked by a spacer molecule. The spacer is typically comprised of

relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e. g. , Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero-or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues. Alternatively, the CTL peptide may be linked to the T helper peptide without a spacer.

The immunogenic peptide may be linked to the T helper peptide either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated. Exemplary T helper peptides include tetanus toxoid 830-843, influenza 307- 319, malaria circumsporozoite 382-398 and 378-389.

Combination wit/agents to prime tAze immune response In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which assists in priming CTL.

Lipids have been identified as agents capable of assisting the priming CTL in vivo against viral antigens. For example, palmitic acid residues can be attached to the alpha and epsilon amino groups of a Lys residue and then linked, e. g. , via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be injected directly in a micellar form, incorporated into a liposome or emulsified in an adjuvant, e. g. , incomplete Freund's adjuvant. In a preferred embodiment a particularly effective immunogen comprises palmitic acid attached to alpha and epsilon amino groups of Lys, which is attached via linkage, e. g. , Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, E. coli lipoproteins, such as tripalmitoyl-S-glycerylcysteinlyseryl-serine (P3CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide. See, Deres et al., Nature 342: 561-564 (1989), incorporated herein by reference. Peptides of the invention can be coupled to P3CSS, for example, and the lipopeptide administered to an individual to specifically prime a CTL response to the target antigen. Further, as the

induction of neutralizing antibodies can also be primed with P3CSS conjugated to a peptide which displays an appropriate epitope, the two compositions can be combined to more effectively elicit both humoral and cell-mediated responses to infection.

In addition, additional amino acids can be added to the termini of a peptide to provide for ease of linking peptides one to another, for coupling to a carrier support, or larger peptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C-or N-terminus of the peptide or oligopeptide. Modification at the C terminus in some cases may alter binding characteristics of the peptide. In addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by terminal-NH2 acylation, e. g. , by alkanoyl (C1-C20) or thioglycolyl acetylation, terminal-carboxyl amidation, e. g., ammonia, methylamine, etc. In some instances these modifications may provide sites for linking to a support or other molecule.

Vaccine compositions The peptides of the present invention and pharmaceutical and vaccine compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent viral infection and cancer. Examples of diseases which can be treated or prevented using the immunogenic peptides of the invention include prostate cancer, hepatitis B, hepatitis C, HPV infection, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV, malaria, and condlyloma acuminatum.

Vaccines that contain an immunogenically effective amount of one or more peptides as described herein are a further embodiment of the invention. Once appropriately immunogenic epitopes have been defined, they can be delivered by various means, herein referred to as"vaccine"compositions. Such vaccine compositions can include, for example, lipopeptides (e. g., Vitiello, A. et al., J. Clin. Invest. 95: 341,1995), peptide compositions encapsulated in poly (DL-lactide-co-glycolide) ("PLG") microspheres (see, e. g. , Eldridge, et al., Molec. Immunol. 28: 287-294, 1991 : Alonso et al., Vaccine 12: 299-306,1994 ; Jones et al., Vaccine 13: 675-681,1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e. g., Takahashi et al., Nature 344: 873-875, 1990; Hu et al., Clin Exp Immunol. 113: 235-243,

1998), multiple antigen peptide systems (MAPs) (see e. g., Tam, J. P., Proc. Natl. Acad.

Sci. U. S. A. 85: 5409-5413, 1988 ; Tarn, J. P. , J. Immunol. Methods 196: 17-32,1996), viral delivery vectors (Perkus, M. E. et al., In: Concepts in vaccine development, Kaufmann, S H. E., ed. , p. 379, 1996 ; Chakrabarti, S. et al., Nature 320: 535, 1986 ; Hu, S. L. et al., Nature 320: 537,1986 ; Kieny, M.-P. et al., AIDS Bio/Technolgoy 4: 790, 1986 ; Top, F. H. et al., J. Infect. Dis. 124: 148, 1971 ; Chanda, P. K. et al., Virology 175: 535,1990), particles of viral or synthetic origin (e. g., Kofler, N. et al., J-lm7liunol. Metliods. 192: 25, 1996; Eldridge, J. H. et al., Sem. He7natol. 30: 16,1993 ; Falo, L. D. , Jr. et al., Nature Med. 7: 649,1995), adjuvants (Warren, H. S. , Vogel, F. R. , and Chedid, L. A. vInnu. Rev.

Itnmunol. 4: 369,1986 ; Gupta, R. K. et al., Vaccine 11: 293,1993), liposomes (Reddy, R. et al., J. Immunol. 148 : 1585,1992 ; Rock, K. L., bnfnunol. Today 17: 131,1996), or, naked or particle absorbed cDNA (Ulmer, J. B. et al., Science 259: 1745,1993 ; Robinson, H. L. , Hunt, L. A. , and Webster, R. G., Vaccine 11: 957,1993 ; Shiver, J. W. et al., In : Concepts ir oaccine development, Kauftnann, S. H. E. , ed. , p. 423,1996 ; Cease, K. B., and Berzofsky, J. A., Annu. Rev. Immunol. 12: 923,1994 and Eldridge, J. H. et al., Sem.

Hefnatol. 30: 16,1993). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

Vaccine compositions of the invention include nucleic acid-mediated modalities. DNA or RNA encoding one or more of the peptides of the invention can also be administered to a patient. This approach is described, for instance, in Wolff et. al., Science 247: 1465 (1990) as well as U. S. Patent Nos. 5,580, 859; 5,589, 466 ; 5, 804, 566; 5,739, 118; 5,736, 524; 5,679, 647; WO 98/04720 ; and in more detail below. Examples of DNA-based delivery technologies include"naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e. g., U. S. Patent No. 5,922, 687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, for example, as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into an acutely or chronically infected host or into a non-infected host, the recombinant vaccinia virus expresses the

immunogenic peptide, and thereby elicits a host CTL and/or HTL response. Vaccinia vectors and methods useful in immunization protocols are described in, e. g. , U. S. Patent No. 4,722, 848. Another vector is BCG (Bacille Calette Guerin). BCG vectors are described in Stover et al., Nature 351: 456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e. g. adeno and adeno-associated virus vectors, retroviral vectors, salmoflella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein.

Furthermore, vaccines in accordance with the invention can encompass one or more of the peptides of the invention. Accordingly, a peptide can be present in a vaccine individually. Alternatively, the peptide can be individually linked to its own carrier ; alternatively, the peptide can exist as a homopolymer comprising multiple copies of the same peptide, or as a heteropolymer of various peptides. Polymers have the advantage of increased immunological reaction and, where different peptide epitopes are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the pathogenic organism or tumor-related peptide targeted for an immune response. The composition may be a naturally occurring region of an antigen or may be prepared, e. g.,, recombinantly or by chemical synthesis.

Carriers that can be used with vaccines of the invention are well known in the art, and include, e. g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like. The vaccines can contain a physiologically tolerable (i. e., acceptable) diluent such as water, or saline, preferably phosphate buffered saline. The vaccines also typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, CTL responses can be primed by conjugating peptides of the invention to lipids, such as tripalmitoyl-S-glycerylcysteinlyseryl-serine (P3CSS).

Upon immunization with a peptide composition in accordance with the invention, via injection, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal, or other suitable routes, the immune system of the host responds to the vaccine by producing large amounts of CTLs specific for the desired antigen. Consequently, the host

becomes at least partially immune to later infection, or at least partially resistant to developing an ongoing chronic infection, or derives at least some therapeutic benefit when the antigen was tumor-associated.

In certain embodiments, components that induce T cell responses are combined with component that induce antibody responses to the target antigen of interest. combine class I peptide vaccines of the invention with vaccines which induce or facilitate neutralizing antibody responses to the target antigen of interest, particularly to viral envelope antigens. A preferred embodiment of such a composition comprises class I and class II epitopes in accordance with the invention. An alternative embodiment of such a composition comprises a class I epitope in accordance with the invention, along with a pan DR binding molecule, e. g., PADRE (Epimmune, San Diego, CA) (described, for example, in U. S. Patent Number 5,736, 142).

Minige7les A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding multiple epitopes of the invention. To create a DNA sequence encoding the selected CTL epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes are reverse translated. A human codon usage table is used to guide the codon choice for each amino acid. These epitope- encoding DNA sequences are directly adjoined, creating a continuous polypeptide sequence. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequence that could be reverse translated and included in the minigene sequence include: helper T lymphocyte epitopes, a leader (signal) sequence, and an endoplasmic reticulum retention signal. In addition, MHC presentation of CTL epitopes may be improved by including synthetic (e. g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL epitopes.

The minigene sequence is converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) are synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. he ends of the

oligonucleotides are joined using T4 DNA ligase. This synthetic minigene, encoding the CTL epitope polypeptide, can then cloned into a desired expression vector.

Standard regulatory sequences well known to those of skill in the art are included in the vector to ensure expression in the target cells. Several vector elements are required: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an E. coli origin of replication; and an E. coli selectable marker (e. g. ampicillin or kanamycin resistance).

Numerous promoters can be used for this purpose, e. g. , the human cytomegalovirus (hCMV) promoter. See, U. S. Patent Nos. 5, 580, 859 and 5,589, 466 for other suitable promoter sequences.

Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion ofmRNA stabilization sequences can also be considered for increasing minigene expression. It has recently been proposed that immunostimulatory sequences (ISSs or CpGs) play a role in the immunogenicity of DNA vaccines. These sequences could be included in the vector, outside the minigene coding sequence, if found to enhance immunogenicity.

In some embodiments, a bicistronic expression vector, to allow production of the minigene-encoded epitopes and a second protein included to enhance or decrease immunogenicity can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e. g., IL2, IL12, GM-CSF), cytokine-inducing molecules (e. g. LeIF) or costimulatory molecules.

Helper (HTL) epitopes could be joined to intracellular targeting signals and expressed separately from the CTL epitopes. This would allow direction of the HTL epitopes to a cell compartment different than the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the MHC class II pathway, thereby improving CTL induction. In contrast to CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e. g. TGF-ß) may be beneficial in certain diseases.

Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an

appropriate E. coli strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis.

Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.

Therapeutic quantities of plasmid DNA are produced by fermentation in E. coli, followed by purification. Aliquots from the working cell bank are used to inoculate fermentation medium (such as Terrific Broth), and grown to saturation in shaker flasks or a bioreactor according to well known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by Quiagen. If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.

Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). A variety of methods have been described, and new techniques may become available. As noted above, nucleic acids are conveniently formulated with cationic lipids. In addition, glycolipids, fusogenic liposomes, peptides and compounds referred to collectively as protective, interactive, non-condensing (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

Target cell sensitization can be used as a functional assay for expression and MHC class I presentation of minigene-encoded CTL epitopes. The plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for"naked"DNA, whereas cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 labeled and used as target cells for epitope-specific CTL lines. Cytolysis, detected by 5lCr release, indicates production of MHC presentation of minigene-encoded CTL epitopes. lit vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human MHC

molecules are immunized with the DNA product. The dose and route of administration are formulation dependent (e. g. IM for DNA in PBS, IP for lipid-complexed DNA).

Twenty-one days after immunization, splenocytes are harvested and restimulated for 1 week in the presence of peptides encoding each epitope being tested. These effector cells (CTLs) are assayed for cytolysis of peptide-loaded, chromium-51 labeled target cells using standard techniques. Lysis of target cells sensitized by MHC loading of peptides corresponding to minigene-encoded epitopes demonstrates DNA vaccine function for in vivo induction of CTLs.

Ex vivo administration of epitopes An embodiment of a vaccine composition in accordance with the invention comprises ex vivo administration of a cocktail of epitope-bearing peptides to PBMC, or isolated DC therefrom, from the patient's blood. After pulsing the DC with peptides and prior to reinfusion into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs which present the pulsed peptide epitopes in HLA molecules on their surfaces.

Dendritic cells can also be transfected, e. g., with a minigene comprising nucleic acid sequences encoding the epitopes in accordance with the invention, in order to elicit immune responses. Vaccine compositions can be created in vitro, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs in vitro.

Antigenic peptides are used to elicit a CTL response ex vivo, as well. The resulting CTL cells, can be used to treat chronic infections, or tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a therapeutic vaccine peptide or nucleic acid in accordance with the invention. Ex vivo CTL or HTL responses to a particular antigen (infectious or tumor-associated antigen) are induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy their

specific target cell (an infected cell or a tumor cell). Transfected dendritic cells may also be used as antigen presenting cells.

Administration of vaccine compositions For pharmaceutical compositions, the immunogenic peptides of the invention are administered to an individual already suffering from cancer or infected with the virus of interest. Those in the incubation phase or the acute phase of infection can be treated with the immunogenic peptides separately or in conjunction with other treatments, as appropriate. In therapeutic applications, compositions are administered to a patient in an amount sufficient to elicit an effective CTL response to the virus or tumor antigen and to cure or at least partially arrest symptoms and/or complications. An amount adequate to accomplish this'is defined as"therapeutically effective dose. "Amounts effective for this use will depend on, e. g., the peptide composition, the manner of administration, the stage and severity of the di tease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 1. 0 ug to about 50,000 llg of peptide for a 70 kg patient, followed by boosting dosages of from about 1.0 llg to about 10,000 ßg of peptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL activity in the patient's blood. It must be kept in mind that the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life- threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.

For therapeutic use, administration should begin at the first sign of viral infection or the detection or surgical removal of tumors or shortly after diagnosis in the case of acute infection. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In chronic infection, loading doses followed by boosting doses may be required.

Treatment of an infected individual with the compositions of the invention may hasten resolution of the infection in acutely infected individuals. For those

individuals susceptible (or predisposed) to developing chronic infection the compositions are particularly useful in methods for preventing the evolution from acute to chronic infection. Where the susceptible individuals are identified prior to or during infection, for instance, as described herein, the composition can be targeted to them, minimizing need for administration to a larger population.

The peptide compositions can also be used for the treatment of chronic infection and to stimulate the immune system to eliminate virus-infected cells in carriers.

It is important to provide an amount of immuno-potentiating peptide in a formulation and mode of administration sufficient to effectively stimulate a cytotoxic T cell response.

Thus, for treatment of chronic infection, a representative dose is in the range of about 1.0 llg to about 50, 000 ug, preferably about 5 ug to 10,000 pg for a 70 kg patient per dose.

Immunizing doses followed by boosting doses at established intervals, e. g., from one to four weeks, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic infection, administration should continue until at least clinical symptoms or laboratory tests indicate that the viral infection has been eliminated or substantially abated and for a period thereafter.

The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e. g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e. g., water, buffered water, 0.9% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

The concentration of CTL stimulatory peptides of the invention in the pharmaceutical formulations can vary widely, i. e. , from less than about 0. 1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

The peptides of the invention may also be administered via liposomes, which target the peptides to a particular cells tissue, such as lymphoid tissue. Liposomes are also useful in increasing the half-life of the peptides. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to, e. g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes filled with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the selected therapeutic/immunogenic peptide compositions. Liposomes for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e. g. , liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e. g. , Szoka et al., Ann. Rev. Biophys. Bioefzg. 9: 467 (1980), U. S. Patent Nos.

4,235, 871,4, 501,728, 4,837, 028, and 5,019, 369, incorporated herein by reference.

For targeting to the immune cells, a ligand to be incorporated into the liposome can include, e. g. , antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic

composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are 0.01%-20% by weight, preferably 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e. g. , lecithin for intranasal delivery.

Upon immunization with a peptide composition as described herein, via injection, aerosol, oral, transdermal or other route, the immune system of the host responds to the vaccine by producing large amounts of CTLs specific for the desired antigen, and the host becomes at least partially immune to later infection, or resistant to developing chronic infection.

In some instances it may be desirable to combine the peptide vaccines of the invention with vaccines which induce neutralizing antibody responses to the virus of interest, particularly to viral envelope antigens.

Antigenic peptides may be used to elicit CTL ex vivo, as well. The resulting CTL, can be used to treat chronic infections (viral or bacterial) or tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a peptide vaccine approach of therapy. Ex vivo CTL responses to a particular pathogen (infectious agent or tumor antigen) are induced by incubating in tissue culture the patient's CTL precursor cells (CTLp) together with a source of antigen-presenting cells (APC) and the appropriate immunogenic peptide. After an appropriate incubation time (typically 1-4 weeks), in which the CTLp are activated and mature and expand into effector CTL, the cells are infused back into the patient, where they will destroy their specific target cell (an infected cell or a tumor cell). In order to optimize the in vitro

conditions for the generation of specific cytotoxic T cells, the culture of stimulator cells is maintained in an appropriate serum-free medium.

Prior to incubation of the stimulator cells with the cells to be activated, e. g. , precursor CD8+ cells, an amount of antigenic peptide is added to the stimulator cell culture, of sufficient quantity to become loaded onto the human Class I molecules to be expressed on the surface of the stimulator cells. In the present invention, a sufficient amount of peptide is an amount that will allow about 200, and preferably 200 or more, human Class I MHC molecules loaded with peptide to be expressed on the surface of each stimulator cell. Often, the stimulator cells are incubated with >20 llg/ml peptide.

Resting or precursor CD8+ cells are then incubated in culture with the appropriate stimulator cells for a time period sufficient to activate the CD8+ cells.

Preferably, the CD8+ cells are activated in an antigen-specific manner. The ratio of resting or precursor CD8+ (effector) cells to stimulator cells may vary from individual to individual and may further depend upon variables such as the amenability of an individual's lymphocytes to culturing conditions and the nature and severity of the disease condition or other condition for which the within-described treatment modality is used. Preferably, however, the lymphocyte: stimulator cell ratio is in the range of about 30: 1 to 300: 1. The effector/stimulator culture may be maintained for as long a time as is necessary to stimulate a therapeutically useable or effective number of CD8+ cells.

The induction of CTL ih vitro requires the specific recognition of peptides that are bound to allele specific MHC class I molecules on APC. The number of specific MHC/peptide complexes per APC is crucial for the stimulation of CTL, particularly in primary immune responses. While small amounts of peptide/MHC complexes per cell are sufficient to render a cell susceptible to lysis by CTL, or to stimulate a secondary CTL response, the successful activation of a CTL precursor (pCTL) during primary response requires a significantly higher number of MHC/peptide complexes. Peptide loading of empty major histocompatability complex molecules on cells allows the induction of primary cytotoxic T lymphocyte responses. Peptide loading of empty major histocompatability complex molecules on cells enables the induction of primary cytotoxic T lymphocyte responses.

Since mutant cell lines do not exist for every human MHC allele, it is advantageous to use a technique to remove endogenous MHC-associated peptides from

the surface of APC, followed by loading the resulting empty MHC molecules with the immunogenic peptides of interest. The use of non-transformed (non-tumorigenic), non- infected cells, and preferably, autologous cells of patients as APC is desirable for the design of CTL induction protocols directed towards development of ex vivo CTL therapies. This application discloses methods for stripping the endogenous MHC- associated peptides from the surface of APC followed by the loading of desired peptides.

A stable MHC class I molecule is a trimeric complex formed of the following elements: 1) a peptide usually of 8-10 residues, 2) a transmembrane heavy polymorphic protein chain which bears the peptide-binding site, and 3) a non-covalently associated non-polymorphic light chain, ß2 microglobulin. Removing the bound peptides and/or dissociating the (32 microglobulin from the complex renders the MHC class I molecules nonfunctional and unstable, resulting in rapid degradation. All MHC class I molecules isolated from peripheral blood monocytic cells (PBMC) have endogenous peptides bound to them. Therefore, the first step is to remove all endogenous peptides bound to MHC class I molecules on the APC without causing their degradation before exogenous peptides can be added to them.

Two possible ways to free up MHC class I molecules of bound peptides include lowering the culture temperature from 37°C to 26°C overnight to destablize (32microglobulin and stripping the endogenous peptides from the cell using a mild acid treatment. The methods release previously bound peptides into the extracellular environment allowing new exogenous peptides to bind to the empty class I molecules.

The cold-temperature incubation method enables exogenous peptides to bind efficiently to the MHC complex, but requires an overnight incubation at 26°C which may slow the cell's metabolic rate. It is also likely that cells not actively synthesizing MHC molecules (e. g., resting PBMC) would not produce high amounts of empty surface MHC molecules by the cold temperature procedure.

Harsh acid stripping involves extraction of the peptides with trifluoroacetic acid, pH 2, or acid denaturation of the immunoaffinity purified class I-peptide complexes.

These methods are not feasible for CTL induction, since it is important to remove the endogenous peptides while preserving APC viability and an optimal metabolic state which is critical for antigen presentation. Mild acid solutions of pH 3 such as glycine or citrate-phosphate buffers have been used to identify endogenous peptides and to identify

tumor associated T cell epitopes. The treatment is especially effective, in that only the MHC class I molecules are destabilized (and associated peptides released), while other surface antigens remain intact, including MHC class II molecules. Most importantly, treatment of cells with the mild acid solutions do not affect the cell's viability or metabolic state. The mild acid treatment is rapid since the stripping of the endogenous peptides occurs in two minutes at 4°C and the APC is ready to perform its function after the appropriate peptides are loaded. The technique is utilized herein to make peptide- specific APCs for the generation of primary antigen-specific CTL. The resulting APC are efficient in inducing peptide-specific CD8+ CTL.

Activated CD8+ cells may be effectively separated from the stimulator cells using one of a variety of known methods. For example, monoclonal antibodies specific for the stimulator cells, for the peptides loaded onto the stimulator cells, or for the CD8+ cells (or a segment thereof) may be utilized to bind their appropriate complementary ligand. Antibody-tagged molecules may then be extracted from the stimulator-effector cell admixture via appropriate means, e. g. , via well-known immunoprecipitation or immunoassay methods.

Effective, cytotoxic amounts of the activated CD8+ cells can vary between in vitro and in vivo uses, as well as with the amount and type of cells that are the ultimate target of these killer cells. The amount will also vary depending on the condition of the patient and should be determined via consideration of all appropriate factors by the practitioner. Preferably, however, about 1 X 106 to about 1 X 1012, more preferably about 1 X 108 to about 1 X 1011, and even more preferably, about 1 X 109 to about 1 X lOlo activated CD8+ cells are utilized for adult humans, compared to about 5 X 10'-5 X 10' cells used in mice.

Preferably, as discussed above, the activated CD8+ cells are harvested from the cell culture prior to administration of the CD8+ cells to the individual being treated. It is important to note, however, that unlike other present and proposed treatment modalities, the present method uses a cell culture system that is not tumorigenic.

Therefore, if complete separation of stimulator cells and activated CD8+ cells is not achieved, there is no inherent danger known to be associated with the administration of a small number of stimulator cells, whereas administration of mammalian tumor-promoting cells may be extremely hazardous.

Methods of re-introducing cellular components are known in the art and include procedures such as those exemplified in U. S. Patent No. 4,844, 893 to Honsik, et al. and U. S. Patent No. 4,690, 915 to Rosenberg. For example, administration of activated CD8+ cells via intravenous infusion is appropriate.

Use of Peptide Epitopes as Diagnostic Agents for Evaluating Immun. e Responses In one embodiment of the invention, HLA class I and class II binding peptides can be used as reagents to evaluate an immune response. The evaluated immune response can be induced by any immunogen. For example, the immunogen may result in the production of antigen-specific CTLs or HTLs that recognize the peptide epitope (s) employed as the reagent. Thus, a peptide of the invention may or may not be used as the immunogen. Assay systems that can be used for such analyses include tetramer-based protocols, staining for intracellular lymphokines, interferon release assays, or ELISPOT assays.

For example, following exposure to a putative immunogen, a peptide of the invention can be used in a tetramer staining assay to assess peripheral blood mononuclear cells for the presence of any antigen-specific CTLs. The HLA-tetrameric complex is used to directly visualize antigen-specific CTLs and thereby determine the frequency of such antigen-specific CTLs in a sample of peripheral blood mononuclear cells (see, e. g. , Ogg et al., Science 279: 2103-2106,1998 ; and Altman et al., Science 174: 94-96,1996).

A tetramer reagent comprising a peptide of the invention is generated as follows: A peptide that binds to an HLA molecule is refolded in the presence of the corresponding HLA heavy chain and (32-microglobulin to generate a trimolecular complex. The complex is biotinylated at the carboxyl terminal end of the HLA heavy chain, at a site that was previously engineered into the protein. Tetramer formation is then induced by adding streptavidin. When fluorescently labeled streptavidin is used, the tetrameric complex is used to stain antigen-specific cells. The labeled cells are then readily identified, e. g., by flow cytometry. Such procedures are used for diagnostic or prognostic purposes; the cells identified by the procedure can be used for therapeutic purposes.

Peptides of the invention are also used as reagents to evaluate immune recall responses. (see, e. g., Bertoni et al., J. Clin. Invest. 100: 503-513,1997 and Penna et al., J. Exp. Med. 174: 1565-1570, 1991.) For example, a PBMC sample from an individual expressing a disease-associated antigen (e. g. a tumor-associated antigen such as CEA, p53, MAGE2/3, HER2neu, or an organism associated with neoplasia such as HPV or HSV) can be analyzed for the presence of antigen-specific CTLs or HTLs using specific peptides. A blood sample containing mononuclear cells may be evaluated by cultivating the PBMCs and stimulating the cells with a peptide of the invention. After an appropriate cultivation period, the expanded cell population may be analyzed, for example, for CTL or for HTL activity.

Thus, the peptides can be used to evaluate the efficacy of a vaccine.

PBMCs obtained from a patient vaccinated with an immunogen may be analyzed by methods such as those described herein. The patient is HLA typed, and peptide epitopes that are bound by the HLA molecule (s) present in that patient are selected for analysis.

The immunogenicity of the vaccine is indicated by the presence of CTLs and/or HTLs directed to epitopes present in the vaccine. o The peptides of the invention may also be used to make antibodies, using techniques well known in the art (see, e. g. CURRENTPROTOCOLSINIMMUNOLOGY, Wiley/Greene, NY; and Antibodies A Laboratory Manual Harlow, Harlow and Lane, Cold Spring Harbor Laboratory Press, 1989). Such antibodies are useful as reagents to determine the presence of disease-associated antigens or may be used therapetucially.

Antibodies in this category include those that recognize a peptide when bound by an HLA molecule, i. e. , antibodies that bind to a peptide-MHC complex.

Epitopes in accordance with the present invention were successfully used to induce an immune response. Immune responses with these epitopes have been induced by administering the epitopes in various forms. The epitopes have been administered as peptides, as nucleic acids, and as viral vectors comprising nucleic acids that encode the epitope (s) of the invention. Upon administration of peptide-based epitope forms, immune responses have been induced by direct loading of an epitope onto an empty HLA molecule that is expressed on a cell, and via internalization of the epitope and processing via the HLA class I pathway; in either event, the HLA molecule expressing the epitope was then able to interact with and induce a CTL response. Peptides can be delivered

directly or using such agents as liposomes. They can additionally be delivered using ballistic delivery, in which the peptides are typically in a crystalline form. When DNA is used to induce an immune response, it is administered either as naked DNA, generally in a dose range of approximately 1-5 mg, or via the ballistic"gene gun"delivery, typically in a dose range of approximately 10-100 ug. The DNA can be delivered in a variety of conformations, e. g. , linear, circular etc. Various viral vectors have also successfully been used that comprise nucleic acids which encode epitopes in accordance with the invention.

Accordingly compositions in accordance with the invention exist in several forms.

Embodiments of each of these composition forms in accordance with the invention have been successfully used to induce an immune response.

One composition in accordance with the invention comprises a plurality of peptides. This plurality or cocktail of peptides is generally admixed with one or more pharmaceutically acceptable excipients. The peptide cocktail can comprise multiple copies of the same peptide or can comprise a mixture of peptides. The peptides can be analogs of naturally occurring epitopes. The peptides can comprise artificial amino acids and/or chemical modifications such as addition of a surface active molecule, e. g., lipidation; acetylation, glycosylation, biotinylation, phosphorylation etc. The peptides can be CTL or HTL epitopes. In a preferred embodiment the peptide cocktail comprises a plurality of different CTL epitopes and at least one HTL epitope. The HTL epitope can be naturally or non-naturally (e. g., PADRES, Epimmune Inc. , San Diego, CA). The number of distinct epitopes in an embodiment of the invention is generally a whole unit integer from one through one hundred fifty (e. g., 1,2, 3,4, 5,6, 7,8, 9,10, 11,12, 13,14, 15,16, 17,18, 19,20, 21,22, 23,24, 25,26, 27,28, 29,30, 31,32, 33,34, 35,36, 37, 38, 39,40, 41,42, 43,44, 45,46, 47,48, 49,50, 51,52, 53,54, 55,56, 57, 58, 59,60, 61,62, 63,64, 65,66, 67,68, 69,70, 71,72, 73,74, 75,76, 77,78, 79,80, 81,82, 83, 84,85, 86, 87, 88, 89,90, 91,92, 93,94, 95,96, 97,98, 99, or, 100).

An additional embodiment of a composition in accordance with the invention comprises a polypeptide multi-epitope construct, i. e. , a polyepitopic peptide.

Polyepitopic peptides in accordance with the invention are prepared by use of technologies well-known in the art. By use of these known technologies, epitopes in accordance with the invention are connected one to another. The polyepitopic peptides can be linear or non-linear, e. g., multivalent. These polyepitopic constructs can comprise

artificial amino acids, spacing or spacer amino acids, flanking amino acids, or chemical modifications between adjacent epitope units. The polyepitopic construct can be a heteropolymer or a homopolymer. The polyepitopic constructs generally comprise epitopes in a quantity of any whole unit integer between 2-150 (e. g., 2,3, 4,5, 6,7, 8,9, 10,11, 12,13, 14,15, 16,17, 18, 19,20, 21,22, 23,24, 25,26, 27,28, 29,30, 31,32, 33, 34,35, 36,37, 38, 39,40, 41,42, 43,44, 45,46, 47,48, 49,50, 51,52, 53,54, 55,56, 57, 58, 59,60, 61,62, 63,64, 65,66, 67,68, 69,70, 71,72, 73,74, 75,76, 77,78, 79,80, 81, 82, 83, 84,85, 86,87, 88,89, 90,91, 92,93, 94,95, 96,97, 98, 99, or, 100). The polyepitopic construct can comprise CTL and/or HTL epitopes. One or more of the epitopes in the construct can be modified, e. g. , by addition of a surface active material, e. g. a lipid, or chemically modified, e. g. , acetylation, etc. Moreover, bonds in the multiepitopic construct can be other than peptide bonds, e. g., covalent bonds, ester or ether bonds, disulfide bonds, hydrogen bonds, ionic bonds etc.

Alternatively, a composition in accordance with the invention comprises construct which comprises a series, sequence, stretch, etc., of amino acids that have homology to ( i. e. , corresponds to or is contiguous with) to a native sequence. This stretch of amino acids comprises at least one subsequence of amino acids that, if cleaved or isolated from the longer series of amino acids, functions as an HLA class I or HLA class II epitope in accordance with the invention. In this embodiment, the peptide sequence is modified, so as to become a construct as defined herein, by use of any number of techniques known or to be provided in the art. The polyepitopic constructs can contain homology to a native sequence in any whole unit integer increment from 70-100%, e. g. , 70,71, 72,73, 74,75, 76,77, 78,79, 80, 81, 82, 83,84, 85, 86, 87, 88, 89,90, 91,92, 93,94, 95,96, 97,98, 99, or, 100 percent.

A further embodiment of a composition in accordance with the invention is an antigen presenting cell that comprises one or more epitopes in accordance with the invention. The antigen presenting cell can be a"professional"antigen presenting cell, such as a dendritic cell. The antigen presenting cell can comprise the epitope of the invention by any means known or to be determined in the art. Such means include pulsing of dendritic cells with one or more individual epitopes or with one or more peptides that comprise multiple epitopes, by nucleic acid administration such as ballistic

nucleic acid delivery or by other techniques in the art for administration of nucleic acids, including vector-based, e. g. viral vector, delivery of nucleic acids.

Further embodiments of compositions in accordance with the invention comprise nucleic acids that encode one or more peptides of the invention, or nucleic acids which encode a polyepitopic peptide in accordance with the invention. As appreciated by one of ordinary skill in the art, various nucleic acids compositions will encode the same peptide due to the redundancy of the genetic code. Each of these nucleic acid compositions falls within the scope of the present invention. This embodiment of the invention comprises DNA or RNA, and in certain embodiments a combination of DNA and RNA. It is to be appreciated that any composition comprising nucleic acids that will encode a peptide in accordance with the invention or any other peptide based composition in accordance with the invention, falls within the scope of this invention.

It is to be appreciated that peptide-based forms of the invention (as well as the nucleic acids that encode them) can comprise analogs of epitopes of the invention generated using priniciples already known, or to be known, in the art. Principles related to analoging are now known in the art, and are disclosed herein; moreover, analoging principles are disclosed in co-pending application serial number U. S. S. N. 09/226,775 filed 6 January 1999. Generally the compositions of the invention are isolated or purified.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

EXAMPLES The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

Example 1 HLA class I supermotif and motif analysis of antigens of interest was performed as described herein and in the related applications, noted above. Peptides comprising the appropriate HLA I motif or supermotif were then synthesized and assayed for binding activity. A detailed description of the protocol utilized to measure the binding of peptides to Class I and Class II MHC has been published (Sette et al., Mol. Immunol. 31: 813, 1994; Sidney et al. , in Current Protocols in Immunology, Margulies, Ed. , John Wiley & Sons, New York, Section 18.3, 1998).

Since under these conditions [label] < [HLA] and ic5o4HLA], the measured IC50 values are reasonable approximations of the true KD values. To allow comparison of the data obtained in different experiments, a relative binding figure is calculated for each peptide by dividing the IC50 of a positive control for inhibition by the IC50 for each tested peptide (typically unlabeled versions of the radiolabeled probe peptide). For inter-experiment comparisons, relative binding values are compiled. These values can subsequently be converted back into IC50 nM values by dividing the IC50 nM of the positive controls for inhibition by the relative binding of the peptide of interest.

This method of data compilation has proven to be the most accurate and consistent for comparing peptides that have been tested on different days, or with different lots of purified MHC.

HLA class I supermotif and motif-bearing peptides from HIV regulatory proteins, e. g., nef, rev, vif, tat, and vpr, are shown in Tables 2-11. In these tables,"% conserv" refers to percent conservance, which is the degree to which the sequences are conserved in the strains evaluated to identify the sequences. The"A"designation indicates that the peptide is an analog of the native sequence. In the motif column, the designation"i" refers to individual motif and"s"refers to supermotif.

HLA class I supermotif and motif-bearing peptides from other antigens, e. g., cancer antigens such as CEA, p53, Her2/neu, MART1, MAGE2, MAGE3, tyrosinase, flu, gpl00, HBV, HCV, HIV, HPV (including the strain designation), Epstein Barr Virus (EBV), prostate cancer-associated antigens, gliadin, Mycobacterium leprae, Mycobacterium tuberculosis, T. cruzi, Candida antigens, and malaria (Plasmodium falciparuni) antigens are shown in Tables 12-24.

Tables 12 and 13 show peptides bearing an HLA-A1 supermotif and/or motif.

Tables 14-17 shows peptides bearing an HLA-A2 supennotif.

Tables 18 and 19 show peptides bearing an HLA-A3 supermotif and/or motif.

Tables 20 and 21 show peptides bearing an HLA-A24 supermotif and/or motif.

Tables 22 and 23 show peptides bearing an HLA-B7 supermotiff.

Table 24 shows peptides bearing an HLA-B44 supermotif.

Peptide binding data for the designated HLA molecules are provided as IC50 values unless otherwise indicated. The"A"designation indicates that the peptide is an analog of the native sequence.

Example 2 Using the HLA class II supermotif and motifs identified in related applications and as described above, sequences from various pathogens and tumor-related proteins were analyzed for the presence of these motifs. Screening and binding assays was carried out as described in the related applications designated herein.

HLA class II DR supermotif and DR3 motif-bearing peptides from HIV regulatory proteins, e. g., nef, rev, vif, tat, and vpr, are shown in Tables 25 and 31. The term"% conserv"refers to percent conservance, which is the degree to which the sequences are conserved in the strains evaluated to identify the sequences. In Table 31, in the"sequence"column, the core sequence of the motif-bearing peptide is in lower case.

Tables 26-31 shows HLA class II DR supermotif and DR 3 motif bearing peptides and the antigens from which they are derived. The peptide reference number, sequence, antigen protein/position of the sequence in the antigen, and binding data are shown in the tables. Table 27a shows binding data for DRB1*0101, *0301, *0401, *0404, and *0405. Table 27b shows binding data for DRB1*0701, *0802, *0901, *1101, *1201, *1302, *1501, DRB3*0101, DRB4*0101, DRB5*0101, and DQB1*0301. Table 28a and 29a provide the peptide reference number sequence and protein antigen/position of sequence in antigen for the peptides. Binding data are provided in Tables 28b and 29B.

Peptide binding data for the designated HLA molecules are provided as IC50 values unless otherwise indicated. The"A"designation indicates that the peptide is an analog of the native sequence.

TABLE 2 <BR> <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog<BR> <BR> <BR> Consv.

A01i ARELHPEY HIV. nef. 322 38 Aboli ATELHPEY HIV. nef. 322 A 38 AOli ARDLHPEY HIV. nef. 322 A 38 AOli ARELHPEYY HIV. nef. 322 33 AOli ATELHPEYY HIV. nef. 322 A 33 AOli ARDLHPEYY HIV. nef. 322 A 33 A01s DILDLWVY HIV. nef.185 31 AO 1 s DTLDLWVY HIV. nef. 185 A 31 AOls DLWVYHTQGY HIV. nef. 188 33 AOls DTWVYHTQGY HIV. nef. l88 A 33 AO 1 s DLWVYHTQGYF HIV. nef. 188 33 AOls DTWVYHTQGYF HIV. nef. 188 A 33 AOls DLWVYHTQGYY HIV. nef. 188 A 33 AOls EILDLWVY HIV. nef. 185 52 AOls ETLDLWVY HIV. nef. 185 A 52 AO 1 s PLTFGWCF HIV. nef. 219 67 AOls PTTFGWCF HIV. nef. 219 A 67 AOls PLTFGWCY HIV. nef. 219 A 67 AOls QVPLRPMTY HIV. nef. 100 72 AOls QTPLRPMTY HIV. nef. 100 A 72 AOli RQEILDLWVY HIV. nef. 182 50 AOli RTEILDLWVY HIV. nef. l82 A 50 A01i RQDILDLWVY HIV. nef. 182 A 50 AOli RQDILDLWVY HIV. nef. 182 31 AOli RTDILDLWVY HIV. nef. 182 A 31 AOls WSKSSIVGW HIV. nef. 5 31 AOls WTKSSIVGW HIV. nef. 5 A 31 AOls WSKSSIVGY HIV. nef. 5 A 31 AOls WVYHTQGY HIV. nef. 191 33 AOls WTYHTQGY HIV. nef. 191 A 33 AOls WVYHTQGYF HIV. nef. 191 33 AOls WTYHTQGYF HIV. nef. 191 A 33 AOls WVYHTQGYY HIV. nef. 191 A 33 AOli YTPGPGIRY HIV. nef. 207 27 AOli YTDGPGIRY HIV. nef.207 A 27 AOls IIKILYQSNPY HIV. rev. 20 28 AOls ITKILYQSNPY HIV. rev. 20 A 28 AOls-ILYQSNPY HIV. rev. 23 42 AO 1 s ITYQSNPY HIV. rev. 23 A 42 AOls KILYQSNPY HIV. rev. 22 41 A01s KTLYQSNPY HLV. rev. 22 A 41 AOls PVDPNLEPW HIV. tat. 3 31 AO 1 s PTDPNLEPW HIV. tat. 3 A 31 A01s PVDPNLEPY HIV. tat. 3 A 31 TABLE 3 <BR> <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog %<BR> <BR> <BR> Consv.

A02i/s AAEGVGAV HIV. nef. 42 28 A02i/s ALEGVGAV HIV. nef. 42 A 28 A02i/s AITSSNTA HIV. nef. 63 42 A02i/s ALTSSNTA HIV. nef. 63 A 42 A02i/s AITSSNTV HIV. nef. 63 A 42 A02i/s AQEEEEVGFPV HIV. nef. 83 27 A02i/s ALEEEEVGFPV HIV. nef. 83 A 27 A02i/s EAQEEEEV HIV. nef. 82 25 A02i/s ELQEEEEV HIV. nef. 82 A 25 A02i/s EVGFPVRPQV HIV. nef. 91 63 A02i/s ELGFPVRPQV HIV. nef. 91 A 63 A02i/s EILDLWVYHT HIV. nef. 185 34 A02i/s ELLDLWVYHT HIV. nef. 185 A 34 A02i/s EILDLWVYHV HIV. nef. 185 A 34 A02i/s FLKEKGGL HIV. nef. 117 88 A02i/s FLKEKGGV HIV. nef. 117 A 88 A02i/s FLKEKGGLEGL HIV. nef. 117 45 A02i/s FLKEKGGLEGV HIV. nef. 117 A 45 A02i/s FLKEKGGLDGL HIV. nef. 117 41 A02i/s FLKEKGGLDGV HIV. nef. 117 A 41 A02i/s GVGAVSRDL HIV. nef. 45 27 A02i/s GLGAVSRDL HIV. nef. 45 A 27 A02i/s GVGAVSRDV HIV. nef. 45 A 27 A02i/s GAITSSNT HIV. nef. 62 50 A02i/s GLITSSNT HIV. nef. 62 A 50 A02i/s GAITSSNV HIV. nef. 62 A 50 A02i/s GAITSSNTA HIV. nef. 62 42 A02i/s GLITSSNTA HIV. nef. 62 A 42 A02i/s GAITSSNTV HIV. nef. 62 A 42 A02i/s GLIYSKKRQEI HIV. nef. 173 28 A02i/s GLIYSKKRQEV HIV. nef. 173 A 28 A02i/s ILDLWVYHT HIV. nef. 186 53 A02i/s ILDLWVYHV HIV. nef. 186 A 53 A02i/s ILDLWVYNT HIV. nef. 186 30 A02i/s ILDLWVYNV HIV. nef. 186 A 30 A02i/s LIYSKKRQEI HIV. nef. 174 28 A02i/s LLYSKKRQEI HIV. nef. 174 A 28 A02i/s LIYSKKRQEV HIV. nef. 174 A 28 A02i/s LIYSKKRQEIL HIV. nef. 174 28 A02i/s LLYSKKRQEIL HIV. nef. 174 A 28 A02i/s LIYSKKRQEIV HIV. nef. 174 A 28 A02i/s LTFGWCFKL HIV. nef. 221 61 A02i/s LLFGWCFKL HIV. nef. 221 A 61 A02i/s LTFGWCFKV HIV. nef. 221 A 61 A02i/s LTFGWCFKLV HIV. nef. 221 55 A02i/s LLFGWCFKLV HIV. nef. 221 A 55 TABLE 3 <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog Consv.<BR> <BR> <BR> <BR> <P> Consv.

A02i/s NADCAWLEA HIV. nef. 73 27 A02i/s NLDCAWLEA HIV. nef. 73 A 27 A02i/s NADCAWLEV HIV. nef. 73 A 27 A02i/s PAAEGVGA HIV. nef. 41 33 A02i/s PLAEGVGA HIV. nef. 41 A 33 A02i/s PAAEGVGV HIV. nef. 41 A 33 A02i/s PVRPQVPL HIV. nef. 95 75 A02i/s PLRPQVPL HIV. nef. 95 A 75 A02i/s PVRPQVPV HIV. nef. 95 A 75 A02i/s PVRPQVPLRPM HIV. nef. 95 73 A02i/s PLRPQVPLRPM HIV. nef. 95 A 73 A02i/s PVRPQVPLRPV HIV. nef. 95 A 73 A02i/s PQVPLRPM HIV. nef. 99 88 A02i/s PLVPLRPM HIV. nef. 99 A 88 A02i/s PQVPLRPV HIV. nef. 99 A 88 A02i/s PQVPLRPMT HIV. nef. 99 88 A02i/s PLVPLRPMT HIV. nef. 99 A 88 A02i/s PQVPLRPMV HIV. nef. 99 A 88 A02i/s PLRPMTYKGA HIV. nef. 102 39 A02i/s PLRPMTYKGV HIV. nef. 102 A 39 A02i/s PLRPMTYKA HIV. nef. 102 33 A02i/s PLRPMTYKV HIV. nef. 102 A 33 A02i/s PLRPMTYKAA HIV. nef. 102 31 A02i/s PLRPMTYKAV HIV. nef. 102 A 31 A02i/s PLTFGWCFKL HIV. nef. 219 61 A02i/s PLTFGWCFKV HIV. nef. 219 A 61 A02i/s PLTFGWCFKLV HIV. nef. 219 55 A02i/s QAEPAAAGV HIV. nef. 34 33 A02i/s QLEPAAAGV HIV. nef. 34 A 33 A02i/s QAEPAAAGVGA HIV. nef. 34 33 A02i/s QLEPAAAGVGA HIV. nef. 34 A 33 A02i/s QAEPAAAGVGV HIV. nef. 34 A 33 A02i/s QVPLRPMT HIV. nef. 100 89 A02i/s QLPLRPMT HIV. nef. 100 A 89 A02i/s QVPLRPMV HIV. nef. 100 A 89 A02i/s QVPLRPMTYKA HIV. nef. 100 31 A02i/s QLPLRPMTYKA HIV. nef. 100 A 31 A02i/s QVPLRPMTYKV HIV. nef 100 A 31 A02i/s RQEILDLWV HIV. nef. 182 55 A02i/s RLEILDLWV HIV. nef. 182 A 55 A02i/s RQDILDLWV HIV. nef. 182 31 A02i/s RLDILDLWV HIV. nef. 182 A 31 A02i/s WQNYTPGPGT HIV. nef. 204 33 A02i/s WLNYTPGPGT HIV. nef. 204 A 33 A02i/s WQNYTPGPGV HIV. nef. 204 A 33 A02i/s WQNYTPGPGI HIV. nef. 204 29 TABLE 3 <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog %<BR> <BR> <BR> <BR> Consv.

A02i/s WLNYTPGPGI HIV. nef. 204 A 29 A02i/s WQNYTPGPGV HIV. nef. 204 A 29 A02i/s YTPGPGIRYPL HIV. nef. 207 25 A02i/s YLPGPGIRYPL HIV. nef. 207 A 25 A02i/s YTPGPGIRYPV HIV. nef. 207 A 25 A02i/s GTSGTQGV HIV. rev. 94 33 A02i/s GLSGTQGV HIV. rev. 94 A 33 A02i/s LQLPPLERL HIV. rev. 77 56 A02i/s LLLPPLERL HIV. rev. 77 A 56 A02i/s LQLPPLERV HIV. rev. 77 A 56 A02i/s LQLPPLERLT HIV. rev. 77 27 A02i/s LLLPPLERLT HIV. rev. 77 A 27 A02i/s LQLPPLERLV HIV. rev. 77 A 27 A02i/s LQLPPLERLTL HIV. rev. 77 27 A02i/s LLLPPLERLTL HIV. rev. 77 A 27 A02i/s LQLPPLERLTV HIV. rev. 77 A-27 A02i/s PAEPVPLQL. HIV. rev. 71 33 A02i/s PLEPVPLQL HIV. rev. 71 A 33 A02i/s PAEPVPLQV HIV. rev. 71 A 33 A02i/s PVPLQLPPL HIV. rev. 74 55 A02i/s PLPLQLPPL HIV. rev. 74 A 55 A02i/s PVPLQLPPV HIV. rev. 74 A 55 A02i/s PLQLPPLERL HIV. rev. 76 53 A02i/s PLQLPPLERV HIV. rev. 76 A 53 A02i/s QLPPLERLT HIV. rev, 78 28 A02i/s QLPPLERLV HIV. rev. 78 A 28 TABLE 4 <BR> <BR> <BR> <BR> <BR> <BR> <BR> %<BR> <BR> Motif Sequence Source Analog<BR> <BR> <BR> Consv.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>A03i ADCAWLEA HIV. nef. 74 27 A03i AVCAWLEA HIV. nef. 74 A 27 A03i ADCAWLEK HIV. nef. 74 A 27 A03i AFDLSFFLK HIV. nef. lll 28 A03i AVDLSFFLK HIV. nef. lll A 28 A03i AFDLSFFLKEK HIV. nef. lll 27 A03i AVDLSFFLKEK HIV. nef. lll A 27 A03i DLSHFLKEK HIV. nef. 113 42 A03i DVSHFLKEK HIV. nef. 113 A 42 A03i DLSFFLKEK HIV. nef. 113 34 A03i DVSFFLKEK HIV. nef. 113 A 34 A03i EAQEEEEVGF HIV. nef. 82 25 A03i EVQEEEEVGF HIV. nef. 82 A 25 A03i EAQEEEEVGK HIV. nef.82 A 25 A03i EILDLWVYH HIV. nef.185 34 A03i EVLDLWVYH HIV. nef. 185 A 34 A03i EILDLWVYK HIV. nef. 185 A 34 A03s ELHPEYYK HIV. nef. 324 34 A03s EVHPEYYK HIV. nef. 324 A 34 A03i FDLSFFLK HIV. nef. 112 28 A03i FVLSFFLK HIV. nef 112 A 28 A03i FDLSFFLKEK HIV. nef. 112 27 A03i FVLSFFLKEK HIV. nef. 112 A 27 A03i FFPDWQNY HIV. nef. 199 27 A03i FVPDWQNY HIV. nef. 199 A 27 A03i FFPDWQNK HIV. nef. l99 A 27 A03i GFPVRPQVPLR HIV. nef. 93 75 A03i GVPVRPQVPLR HIV. nef. 93 A 75 A03i GFPVRPQVPLK HIV. nef. 93 A 75 A03i GGLEGLIY HIV. nef. 124 30 A03i GVLEGLIY HIV. nef. 124 A 30 A03i GGLEGLIK HIV. nef. 124 A 30 A03i GGLDGLIYSK HIV. nef. 124 25 A03i GVLDGLIYSK HIV. nef. 124 A 25 A03i GLDGLIYSK HIV. nef. 125 25 A03i GVDGLIYSK HIV. nef. 125 A 25 A03i GLIYSKKR HIV. nef. 173 36 A03i GVIYSKKR HIV. nef. 173 A 36 A03i GLIYSKKK HIV. nef. 173 A 36 A03i GFFPDWQNY HIV. nef. 198 27 A03i GVFPDWQNY HIV. nef. 198 A 27 A03i GFFPDWQNK HIV. nef. 198 A 27 A03i HGAITSSNTA HIV. nef. 61 42 A03i HVAITSSNTA HIV. nef. 61 A 42 A03i HGAITSSNTK HIV. nef. 61 A 42 A03i ILDLWVYH HIV. nef. 186 53 TABLE 4 <BR> <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog %<BR> <BR> <BR> Consv.

A03i IVDLWVYH HIV. nef. 186 A 53 A03i ILDLWVYK HIV. nef. 186 A 53 A03i KGGLEGLIY HIV. nef. 122 30 A03i KVGLEGLIY HIV. nef. 122 A 30 A03i KGGLEGLIK HIV. nef. 122 A 30 A03i LSHFLKEK HIV. nef. 114 42 A03i LVHFLKEK HIV. nef. 114 A 42 A03i LSFFLKEK HIV. nef. 114 34 A03i LVFFLKEK HIV. nef. 114 A 34 A03i LDGLIYSK HIV. nef. 171 25 A03i LVGLIYSK HIV. nef. 171 A 25 A03i LDLWVYHTQGY HIV. nef. 187 33 A03i LVLWVYHTQGY HIV. nef. 187 A 33 A03i LDLWVYHTQGK HIV. nef. 187 A 33 A03i LTFGWCFK HIV. nef. 221 61 A03i LLHPICQH HIV. nef. 257 28 A03i LVHPICQH HIV. nef. 257 A 28 A03i LLHPICQK HIV. nef. 257 A 28 A03i LLHPMSQH HIV. nef. 257 27 A03i LVHPMSQH HIV. nef. 257 A 27 A03i LLHPMSQK HIV. nef. 257 A 27 A03i PVRPQVPLR HIV. nef. 95 75 A03i PVRPQVPLK HIV. nef. 95 A 75 A03i PLRPMTYK HIV. nef 102 77 A03i PVRPMTYK HIV. nef. 102 A 77 A03i PLTFGWCFK HIV. nef. 219 61 A03i PVTFGWCFK HIV. nef. 219 A 61 A03i QVPLRPMTYK HIV. nef. 100 72 A03i QDILDLWVY HIV. nef. 184 31 A03i QVILDLWVY HIV. nef. 184 A 31 A03i QDILDLWVK HIV. nef. 184 A 31 A03i QGFFPDWQNY HIV. nef. 196 27 A03i QVFFPDWQNY HIV. nef. 196 A 27 A03i QGFFPDWQNK HIV. nef. 196 A 27 A03i RDLEKHGA HIV. nef. 51 25 A03i RVLEKHGA HIV. nef. 51 A 25 A03i RDLEKHGK HIV. nef. 51 A 25 A03i RFPLTFGWCF HIV. nef. 216 27 A03i RVPLTFGWCF HIV. nef. 216 A 27 A03i RFPLTFGWCK HIV. nef. 216 A 27 A03i RFPLTFGWCFK HIV. nef. 216 27 A03i RVPLTFGWCFK HIV. nef. 216 A 27 A03i YTPGPGTR HIV. nef. 207 33 A03i YTPGPGTK HIV. nef. 207 A 33 A03i YTPGPGIR HIV. nef. 207 31 A03i YTPGPGIK HIV. nef. 207 A 31 TABLE 4 <BR> <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog %<BR> <BR> <BR> Consv.

A03i EGTRQARR HIV. rev. 35 42 A03i EVTRQARR, HIV. rev. 35 A 42 A03i EGTRQARK HIV. rev. 35 A 42 A03i EGTRQARRNR HIV. rev. 35 42 A03i EVTRQARRNR HIV. rev. 35 A 42 A03i EGTRQARRNK HIV. rev. 35 A 42 A03i EGTRQARRNRR HIV. rev. 35 42 A03i EVTRQARRNRR HIV. rev. 35 A 42 A03i EGTRQARRNRK HIV. rev. 35 A 42 A03i GTRQARRNR HIV. rev. 36 53 A03i GTRQARRNK HIV. rev. 36 A 53 A03i GTRQARRNRR HIV. rev. 36 53 A03i GTRQARRNRK HIV. rev. 36 A 53 A03i GTRQARRNRRR HIV. rev. 36 53 A03i GTRQARRNRRK HIV. rev. 36 A 53 A03i GTRQTRKNR HIV. rev. 37 50 A03i GTRQTRKNK HIV. rev. 37 A 50 A03i GTRQTRKNRR HIV. rev. 37 50 A03i GTRQTRKNRK HIV. rev. 37 A 50 A03i GTRQTRKNRRR HIV. rev. 37 50 A03i GTRQTRKNRRK HIV. rev. 37 A 50 A03i PVPLQLPPLER HIV. rev. 74 53 A03i PVPLQLPPLEK HIV. rev. 74 A 53 A03i PLQLPPLER HIV. rev. 76 55 A03i PVQLPPLER HIV. rev. 76 A 55 A03i PLQLPPLEK HIV. rev. 76 A 55 A03i QARRNRRR HIV. rev. 40 59 A03i QVRRNRRR HIV. rev. 40 A 59 A03i QARRNRRK HIV. rev. 40 A 59 A03i QARRNRRRR HIV. rev. 40 59 A03i QVRRNRRRR HIV. rev. 40 A 59 A03i QARRNRRRK HIV. rev. 40 A 59 A03i QARRNRRRRWR HIV. rev. 40 58 A03i QVRRNRRRRWR HIV. rev. 40 A 58 A03i QARRNRRRRWK HIV. rev. 40 A 58 A03i QARKNRRR HIV. rev. 40 27 A03i QVRKNRRR HIV. rev. 40 A 27 A03i QARKNRRK HIV. rev. 40 A 27 A03i QARKNRRRR HIV. rev. 40 25 A03i QVRKNRRRR HIV. rev. 40 A 25 A03i QARKNRRRK HIV. rev. 40 A 25 A03i QARKNRRRRWR HIV. rev. 40 25 A03i QVRKNRRRRWR HIV. rev. 40 A 25 A03i QARKNRRRRWK HIV. rev. 40 A 25 A03i TTRQARRNRRR HIV. rev. 37 50 A03i TTRQARRNRRK HIV. rev. 37 A 50 TABLE 4 <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog %<BR> <BR> Consv.

A03i ACNNCYCK HIV. tat. 24 27 A03i AVNNCYCK HIV. tat. 24 A 27 A03i AGPGGYPRR HIV. tat. 102 50 A03i AVPGGYPRR HIV. tat. 102 A 50 A03i AGPGGYPRK HIV. tat. 102 A 50 A03i AGPGGYPRRK HIV. tat. 102 50 A03i AVPGGYPRRK HIV. tat. 102 A 50 A03i ETGPSGQPCH HIV. tat. 101 50 A03i ETGPSGQPCK HIV. tat. 101 A 50 A03i GGYPRRKGSCH HIV. tat. 105 50 A03i GVYPRRKGSCH HIV. tat. 105 A 50 A03i GGYPRRKGSCK HIV. tat. 105 A 50 A03i ISYGRKKRRQR HIV. tat. 48 61 A03i IVYGRKKRRQR HIV. tat. 48 A 61 A03i ISYGRKKRRQK HIV. tat. 48 A 61 A03i KAGPGGYPRR HIV. tat. 101 50 A03i KVGPGGYPRR HIV. tat. 101 A 50 A03i KAGPGGYPRK HIV. tat. 101 A 50 A03i KAGPGGYPRRK HIV. tat. 101 50 A03i KVGPGGYPRRK HIV. tat. 101 A 50 A03i LGISYGRKKRR HIV. tat. 46 70 A03i LVISYGRKKRR HIV. tat. 46 A 70 A03i LGISYGRKKRK HIV. tat. 46 A 70 A03i PGSQPKTA HIV. tat. 17 41 A03i PVSQPKTA HIV. tat. 17 A 41 A03i PGSQPKTK HIV. tat. 17 A 41 A03i PTGPKESK HIV. tat. 88 31 A03i PTGPKESKK HIV. tat. 88 28 A03i PGGYPRRK HIV. tat. 104 50 A03i PVGYPRRK HIV. tat. 104 A 50 A03s PTGPKESKK HIV. tat. 88 28 A03i RGDPTGPK HIV. tat. 84 25 A03i RVDPTGPK HIV. tat. 84 A 25 A03i TACNNCYCK HIV. tat. 23 27 A03i TVCNNCYCK HIV. tat. 23 A 27 A03i TGPKESKK HIV. tat. 89 30 A03i TVPKESKK HIV. tat. 89 A 30 A03i TGPSGQPCH HIV. tat. 102 50 A03i TVPSGQPCH HIV. tat. 102 A 50 A03i TGPSGQPCK HIV. tat. 102 A 50 A03i VDPNLEPWNH HIV. tat. 4 25 A03i WPNLEPWNH HIV. tat. 4 A 25 A03i VDPNLEPWNK HIV. tat. 4 A 25 A03i YGRKKRRQR HIV. tat. 50 64 A03i YVRKKRRQR HIV. tat. 50 A 64 A03i YGRKKRRQK HIV. tat. 50 A 64 TABLE 4 Motif Sequence Source Analog %<BR> <BR> <BR> Consv.

A03i YGRKKRRQRR HIV. tat. 50 59 A03i YVRKKRRQRR HIV. tat. 50 A 59 A03i YGRKKRRQRK HIV. tat. 50 A 59 A03i YGRKKRRQRRR HIV. tat. 50 34 A03i YVRKKRRQRRR HIV. tat. 50 A 34 A03i YGRKKRRQRRK HIV. tat. 50 A 34 TABLE 5 <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog %<BR> <BR> <BR> <BR> Consv.

A11i QNYTPGPGT HIV.nef.205 31 Alli QVYTPGPGTR HIV. nef. 205 A 31 Alli QNYTPGPGTK HIV. nef. 205 A 31 Alli QNYTPGPGIR HIV. nef. 205 28 Alli QVYTPGPGIR HIV. nef. 205 A 28 Alli QNYTPGPGIK HIV. nef.205 A 28 Alli KNRRRRWR HIV. rev. 43 33 Alli KVRRRRWR HIV. rev. 43 A 33 Al li KNRRRRWK HIV. rev. 43 A 33 alli KNRRRRWRAR HIV. rev. 43 30 Alli KVRRRRWRAR HIV. rev. 43 A 30 A11i KNRRRRWRAK HIV. rev. 43 A 30 Alli RNRRRRWR HIV. rev. 43 63 Alli RVRRRRWR HIV. rev. 43 A 63 Alli RNRRRRWK HIV. rev. 43 A 63 Alli RNRRRRWRAR HIV. rev. 43 36 Alli RVRRRRWRAR HIV. rev. 43 A 36 Alli RNRRRRWRAK HIV. rev. 43 A 36 Alli PNLEPWNH HIV. tat. 9 27 Alli PVLEPWNH HIV. tat. 9 A 27 A11i PNLEPWNK HIV. tat. 9 A 27 TABLE 6 <BR> <BR> <BR> <BR> <BR> <BR> <BR> %<BR> Motif Sequence Source Analog<BR> <BR> <BR> Consv.

A24i AFDLSFFL HIV. nef. all 28 A24i AYDLSFFL HIV. nef. lll A 28 A24i AFDLSFFF HIV. nef. lll A 28 A24i DWQNYTPGPGI HIV. ne£203 28 A24i DYQNYTPGPGI HIV. nef. 203 A 28 A24i DWQNYTPGPGF HIV. nef. 203 A 28 A24i FFLKEKGGL HIV. nef. 116 41 A24i FYLKEKGGL HIV. nef. 116 A 41 A24i FFLKEKGGF HIV. nef. 116 A 41 A24i GFPVRPQVPL HIV. nef. 93 75 A24i GYPVRPQVPL HIV. nef. 93 A 75 A24i GFPVRPQVPF HIV. nef. 93 A 75 A24s GVGAVSQDL HIV. nef. 45 33 A24s GYGAVSQDL HIV. nef. 45 A 33 A24s GVGAVSQDF HIV. nef. 45 A 33 A24i HFLKEKGGL HIV. nef. 116 45 A24i HYLKEKGGL HIV. nef. 116 A 45 A24i HFLKEKGGF HIV. nef. 116 A 45 A24i IYSKKRQEI HIV. nef. 175 29 A24i IYSKKRQEF HIV. nef. 175 A 29 A24i IYSKKRQEIL HIV. nef. 175 29 A24i IYSKKRQEIF HIV. nef. 175 A 29 A24i KWSKSSIVGW HIV. nef. 4 31 A24i KYSKSSIVGW HIV. nef. 4 A 31 A24i KWSKSSIVGF HIV. nef. 4 A 31 A24i LWVYHTQGYF HIV. nef. l90 33 A24i LYVYHTQGYF HIV. nef. 190 A 33 A24s LWVYHTQGY HIV. ne£190 33 A24s LYVYHTQGY HIV. nef. l90 A 33 A24s LWVYHTQGF HIV. nef. 190 A 33 A24i NYTPGPGI HIV. nef. 206 31 A24i NYTPGPGF HIV. nef. 206 A 31 A24s NYTPGPGIRY HIV. nef. 206 27 A24s NYTPGPGIRF HIV. nef. 206 A 27 A24i RYPLTFGW HIV. nef. 216 43 A24i RYPLTFGF HIV. nef. 216 A 43 A24i RYPLTFGWCF HIV. nef. 216 33 A24i RFPLTFGW HIV. nef. 216 32 A24i RYPLTFGW HIV. nef. 216 A 32 A24i RFPLTFGF HIV. nef. 216 A 32 A24i SFFLKEKGGL HIV. nef. 115 34 A24i SYFLKEKGGL HIV. nef. 115 A 34 A24i SFFLKEKGGF HIV. nef. 115 A 34 A24i TFGWCFKL HIV. nef. 222 63 A24i TYGWCFKL HIV. ne£222 A 63 A24i TFGWCFKF HIV. nef. 222 A 63 TABLE 6 <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog %<BR> <BR> <BR> Consv.

A24i VYHTQGYF HIV. nef. 192 33 A24i VYHTQGYFPDW HIV. nef. 192 33 A24i VYHTQGYFPDF HIV. nef. 192 A 33 A24s QLPPLERL HIV. rev. 78 58 A24s QYPPLERL HIV. rev. 78 A 58 A24s QLPPLERF HIV. rev. 78 A 58 A24s QLPPLERLTL HIV. rev. 78 28 A24s QYPPLERLTL HIV. rev. 78 A 28 A24s QLPPLERLTF HIV. rev. 78 A 28 A24i RWRARQRQI HIV. rev. 48 55 A24i RYRARQRQI HIV. rev. 48 A 55 A24i RWRARQRQF HIV. rev. 48 A 55 TABLE 7 <BR> <BR> <BR> <BR> <BR> <BR> <BR> %<BR> <BR> Motif Sequence Source Analog<BR> <BR> <BR> Consv.

B07s APTAAKGV HIV. nef. 34 33 B07s APTAAKGI HIV. nef. 34 A 33 B07s APTAAKGVGA HIV. nef. 34 33 B07s APTAAKGVGI HIV. nef. 34 A 33 B07s APTAAKGVGAV HIV. nef. 34 33 B07s APTAAKGVGAI HIV. nef. 34 A 33 B07s FPVRPQVPL HIV. nef. 94 75 B07s FPVRPQVPI HIV. nef. 94 A 75 B07s FPLTFGWCF HIV. nef. 217 27 B07s FPLTFGWCI HIV. nef. 217 A 27 B07s FPLTFGWCFKL HIV. nef. 217 27 B07s FPLTFGWCFKI HIV. nef. 217 A 27 B07s GPGIRYPL HIV. nef. 210 27 B07s GPGIRYPI HIV. nef. 210 A 27 B07s RPQVPLRPM HIV. nef. 98 73 B07s RPQVPLRPI HIV. nef. 98 A 73 B07s RPQVPLRPMTY HIV. nef. 98 56 B07s RPQVPLRPMTI HIV. nef. 98 A 56 B07s RPMTYKAA HIV. nef. 104 36 B07s RPMTYKAI HIV. nef. 104 A 36 B07s TPGPGIRY HIV. nef. 208 27 B07s TPGPGIRI HIV. nef. 208 A 27 B07s VPLRPMTY HIV. ne£101 73 B07s VPLRPMTI HIV. nef. 101 A 73 B07s VPLRPMTYKGA HIV. nef. 101 37 B07s VPLRPMTYKGI HIV. nef. 101 A 37 B07s VPLRPMTYKA HIV. nef. 101 32 B07s VPLRPMTYKI HIV. nef. 101 A 32 B07s VPLRPMTYKAA HIV. ne£101 30 B07s VPLRPMTYKAI HIV. nef. 101 A 30 B07s YPLTFGWCF HIV. nef. 217 38 B07s YPLTFGWCI HIV. nef. 217 A 38 B07s LPPLERLTL HIV. rev. 79 30 B07s LPPLERLTI HIV. rev. 79 A 30 B07s PPLERLTL HIV. rev. 80 30 B07s PPLERLTI HIV. rev. 80 A 30 B07s RPAEPVPL HIV. rev. 70 31 B07s RPAEPVPI HIV. rev. 70 A 31 B07s RPAEPVPLQL HIV. rev. 70 31 B07s RPAEPVPLQI HIV. rev. 70 A 31 B07s VPLQLPPL HIV. rev. 75 56 B07s VPLQLPPI HIV. rev. 75 A 56 B07s HPGSQPKTA HIV. tat. 16 41 <BR> <BR> _ L A 41 TABLE 8 <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog %<BR> <BR> <BR> <BR> Consv.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>B27s EKGGLEGL HIV. nef. 121 53 B27s EKGGLEGLI HIV. nef. 121 42 B27s EKGGLDGL HIV. nef. 121 41 B27s EKGGLDGLI HIV. nef. 121 36 B27s EKGGLEGLIY HIV. nef. 121 30 B27s GKWSKSSI HIV. nef. 3 28 B27s GKWSKSSIVGW HIV. nef. 3 28 B27s KKRQEILDL HIV. nef. 179 39 B27s KKRQEILDLW HIV. nef 179 39 B27s KRQEILDL HIV. nef. 181 50 B27s KRQEILDLW HIV. nef. 181 50 B27s KRQEILDLWVY HIV. nef. 181 45 B27s KRQDILDL HIV. nef. 181 28 B27s KRQDILDLW HIV. nef. 181 28 B27s KRQDILDLWVY HIV. nef. 181 25 B27s LKEKGGLDGL HIV. nef. 118 42 B27s LKEKGGLDGLI HIV. nef. 118 37 B27s SKSSIVGW HIV. nef. 6 31 B27s SKKRQEIL HIV. nef. 177 39 B27s SKKRQEILDL HIV. nef. 177 39 B27s SKKRQEILDLW HIV. nef.177 39 B27s VRPQVPLRPM HIV. nef.97 73 B27s ARKNRRRRW HIV. rev. 41 28 B27s GRSGDSDEEL HIV. rev. 3 27 B27s GRSGDSDEELL HIV. rev. 3 25 B27s GRPAEPVPL HIV. rev. 69 31 B27s GRPAEPVPLQL HIV. rev. 69 31 B27s IKILYQSNPY HIV. rev. 21 39 B27s RKNRRRRW HIV. rev. 42 33 B27s RRWRARQRQI HIV. rev. 47 53 B27s VRIIKILY HIV. rev. 18 28 B27s TKGLGISY HIV. tat. 43 30 TABLE 9 <BR> <BR> <BR> <BR> <BR> <BR> Motif Sequence Source Analog Consv<BR> <BR> <BR> Consv B44s AEPAAEGV HIV.nef.34 33 B44s AEPAAEGVGA HIV. nef. 34 33 B44s AEPAAEGVGAV HIV. nef. 34 33 B44s DEEVGFPV HIV. nef. 89 50 B44s EEEEVGFPV HIV. nef. 86 27 B44s EEEVGFPV HIV. nef. 87 33 B44s EEVGFPVRPQV HIV. nef. 88 31 B44s EEVGFPVRPQI HIV. nef. 89 50 B44s EEVGFPVRPQV HIV. nef. 90 60 B44s KEKGGLDGL HIV. nef. 120 41 B44s KEKGGLDGLI HIV. nef. l20 37 B44s KEKGGLEGLIY HIV. nef.120 27 B44s QEEEEVGF HIV. nef. 84 27 B44s QEEEEVGFPV HIV. nef. 84 27 B44s QEILDLWV HIV. nef. 184 55 B44s QEILDLWVY HIV. nef 184 50 B44s QDILDLWV HIV. nef. 184 31 B44s QEILDLWV HIV. nef. l84 A 31 B44s TEPAAVGV HIV. nef. 33 33 B44s TEPAAVGVGA HIV. nef. 33 33 B44s TEPAAVGVGAV HIV. ne£33 33 B44s AEPVPLQL HIV. rev. 72 52 B44s EDCGTSGTQGV HIV. rev. 91 30 B44s EECGTSGTQGV HIV. rev. 91 A 30 B44s GDSDEELL-HIV. rev. 6 25 B44s GESDEELL HIV. rev. 6 A 25 B44s VDPNLEPW HIV. tat. 4 34 B44s VEPNLEPW HIV. tat. 4 A 34 Table 10 Sequence Organism Protein Position Length Motif<BR> <BR> <BR> <BR> RTEILDLWVY HIV NEF 182 10 AOli RQDILDLWVY HIV NEF 182 10 AOli RTDILDLWVY HIV NEF 182 10 AOli YTDGPGIRY HIV NEF 207 9 AOli ATELHPEY HIV NEF 322 8 AOli ARDLHPEY HIV NEF 322 8 AOli ATELHPEYY HIV NEF 322 9 AOli ARDLHPEYY HIV NEF 322 9 AOli PTDQGPQREPY HIV VPR 5 11 AOli WTKSSIVGW HIV NEF 5 9 AOls WSKSSIVGY HIV NEF 5 9 AOls QTPLRPMTY HIV NEF 100 9 AOls ETLDLWVY HIV NEF 185 8 AOls DTLDLWVY HIV NEF 185 8 AOls DTWVYHTQGY HIV NEF 188 10 AOls DTWVYHTQGYF HIV NEF 188 11 AOls DLWVYHTQGYY HIV NEF 188 11 AOls WTYHTQGY HIV NEF 191 8 AOls WTYHTQGYF HIV NEF 191 9 AOls WVYHTQGYY HIV NEF 191 9 AOls PTTFGWCF HIV NEF 219 8 AOls PLTFGWCY HIV NEF 219 8 AOls ETLDLWVY HIV NEF 185 8 AOls QTPLRPMTY HIV NEF 100 9 AOls ITKILYQSNPY HIV REV 20 11 A01s KTLYQSNPY HIV REV 22 9 AOls ITYQSNPY HIV REV 23 8 A01s PTDPNLEPW HIV TAT 3 9 A01s PVDPNLEPY HIV TAT 3 9 AOls STVKHHMY HIV VIF 23 8 AOls Table 10 Peptide Sequence Organism Protein/Segment 1st Analog AA Position QLEPAAAGV HIV NEF 34 9 QLEPAAAGVGA HIV NEF 34 11 QAEPAAAGVGV HIV NEF 34 11 PLAEGVGA HIV NEF 41 8 PAAEGVGV HIV NEF 41 8 ALEGVGAV HIV NEF 42 8 GLGAVSRDL HIV NEF 45 9 GVGAVSRDV HIV NEF 45 9 GLITSSNT HIV NEF 62 8 GAITSSNV HIV NEF 62 8 GLITSSNTA HIV NEF 62 9 GAITSSNTV HIV NEF 62 9 ALTSSNTA HIV NEF 63 8 AITSSNTV HIV NEF 63 8 NLDCAWLEA HIV NEF 73 9 NADCAWLEV HIV NEF 73 9 ELQEEEEV HIV NEF 82 8 ALEEEEVGFPV HIV NEF 83 11 ELGFPVRPQV HIV NEF 91 10 PLRPQVPL HIV NEF 95 8 PVRPQVPV HIV NEF 95 8 PLRPQVPLRPM HIV NEF 95 11 PVRPQVPLRPV HIV NEF 95 11 PLVPLRPM HIV NEF 99 8 PQVPLRPV HIV NEF 99 8 PLVPLRPMT HIV NEF 99 9 PQVPLRPMV HIV NEF 99 9 QLPLRPMT HIV NEF. 100 8 QVPLRPMV HIV NEF 100 8 QLPLRPMTYKA HIV NEF 100 11 Peptide Sequence Organism Protein/Segment 1st Analog AA Position QVPLRPMTYKV HIV NEF 100 11 PLRPMTYKGV HIV NEF 102 10 PLPPMTYKV HIV NEF 102 9 PLRPMTYKAV HIV NEF 102 10 FLKEKGGV HIV NEF 117 8 FLKEKGGLEGV HIV NEF 117 11 FLKEKGGLDGV HIV NEF 117 11 C, LIYSKKRQEV HIV NEF 173 11 LLYSKKRQEI HIV NEF 174 10 LIYSKKRQEV HIV NEF 174 10 LLYSKKkQEIL HIV NEF 174 11 LIYSKKRQEIV HIV NEF 174 11 RLEILDLWV HIV NEF 182 9 RLDILDLWV HIV NEF 182 9 ELLDLWVYHT HIV NEF 185 10 EILDLWVYHV HIV NEF 185 10 ILDLWVYHV HIV NEF 186 9 ILDLWVYNV HIV NEF 186 9 WLNYTPGPGT HIV NEF 204 10 WQNYTPGPGV HIV NEF 204 10 WLNYTPGPGI HIV NEF 204 10 WQNYTPGPGV HIV NEF 204 10 YLPGPGIRYPL HIV NEF 207 11 YTPGPGIRYPV HIV NEF 207 11 PLTFGWCFKV HIV NEF 219 10 LLFGWCFKL HIV NEF 221 9 LTFGWCFKV HIV NEF 221 9 LLFGWCFKLV HIV NEF 221 10 PVRPQVPV HIV NEF 95 8 FLKEKGGV HIV NEF 117 8 PQVPLRPV HIV NEF 99 8 Peptide Sequence Organism Protein/Segment Ist Analog AA Position PQVPLRPMV HIV NEF 99 9 QVPLRPMV HIV NEF 100 8 PLRPQVPL HIV NEF 95 8 FVKEKGGL HIV NEF 117 8 PLVPLRPM HIV NEF 99 8 PLVPLRPMT HIV NEF 99 9 QLPLRPMT HIV NEF 100 8 PVVPLRPM HIV NEF 99 8 PVVPLRPMT HIV NEF 99 9 PLEPVPLQL HIV REV 71 9 PAEPVPLQV HIV REV 71 9 PLPLQLPPL HIV REV 74 9 PVPLQLPPV HIV REV 74 9 PLQLPPLERV HIV REV 76 10 LLLPPLERL HIV REV 77 9 LQLPPLERV HIV REV 77 9 LLLPPLERLT HIV REV 77 10 LQLPPLERLV HIV REV 77 10 LLLPPLERLTL HIV REV 77 11 LQLPPLERLTV HIV REV 77 11 QLPPLERLV HIV REV 78 9 GLSGTQGV HIV REV 94 8 WQVDRMRV HIV VIF 11 8 KVGSLQYLAV HIV VIF 146 10 KVGSLQYV HIV VIF 146 8 KVGSLQYLV HIV VIF 146 9 IVWQVDRV HIV VIF 9 8 WLVDRMRI HIV VIF 11 8 KLGSLQYLAL HIV VIF 146 10 KLGSLQYL HIV VIF 146 8 KLGSLQYLA HIV VIF 146 9 Peptide Sequence Organism Protein/Segment 1st Analog AA Position ILWQVDRM HIV VIF 9 8 WVVDRMRI HIV VIF 11 8 Sequence Organism Protein Position Length Motif <BR> <BR> <BR> <BR> <BR> RVLEKHGA HIV NEF 51 8 A03i RDLEKHGK HIV NEF 51 8 A03i HVAITSSNTA HIV NEF 61 10 A03i HGAITSSNTK HIV NEF 61 10 A03i AVCAWLEA HIV NEF 74 8 A03i ADCAWLEK HIV NEF 74 8 A03i EVQEEEEVGF HIV NEF 82 10 A03i EAQEEEEVGK HIV NEF 82 10 A03i GVPVRPQVPLR HIV NEF 93 11 A03i GFPVRPQVPLK HIV NEF 93 11 A03i PVRPQVPLK HIV NEF 95 9 A03i PVRPMTYK HIV NEF 102 8 A03i AVDLSFFLK HIV NEF 111 9 A03i AVDLSFFLKEK HIV NEF 111 11 A03i FVLSFFLK HIV NEF 112 8 A03i FVLSFFLKEK HIV NEF 112 10 A03i DVSHFLKEK HIV NEF 113 9 A03i DVSFFLKEK HIV NEF 113 9 A03i LVHFLKEK HIV NEF 114 8 A03i LVFFLKEK HIV NEF 114 8 A03i KVGLEGLIY HIV NEF 122 9 A03i KGGLEGLIK HIV NEF 122 9 A03i GVLEGLIY HIV NEF 124 8 A03i GGLEGLIK HIV NEF 124 8 A03i GVLDGLIYSK HIV NEF 124 10 A03i GVDGLIYSK HIV NEF 125 9 A03i LVGLIYSK HIV NEF 171 8 A03i GVIYSKKR HIV NEF 173 8 A03i GLIYSKKK HIV NEF 173 8 A03i QVILDLWVY HIV NEF 184 9 A03i QDILDLWVK HIV NEF 184 9 A03i Sequence Organism Protein Position Length Motif <BR> <BR> <BR> <BR> EVLDLWVYH H1V NEF 185 9 A03i EILDLWVYK HIV NEF 185 9 A03i IVDLWVYH HIV NEF 186 8 A03i ILDLWVYK HIV NEF 186 8 A03i LVLWVYHTQGY HIV NEF 187 11 A03i LDLWVYHTQGK HIV NEF 187 11 A03i QVFFPDWQNY HIV NEF 196 10 A03i QGFFPDWQNK HIV NEF 196 10 A03i GVFPDWQNY HIV NEF 198 9 A03i GFFPDWQNK HIV NEF 198 9 A03i FVPDWQNY HIV NEF 199 8 A03i FFPDWQNK HIV NEF 199 8 A03i YTPGPGTK HIV NEF 207 8 A03i YTPGPGIK HIV NEF 207 8 A03i RVPLTFGWCF HIV NEF 216 10 A03i RFPLTFGWCK HIV NEF 216 10 A03i RVPLTFGWCFK HIV NEF 216 11 A03i PVTFGWCFK HIV NEF 219 9 A03i LVHPICQH HIV NEF 257 8 A03i LLHPICQK HIV NEF 257 8 A03i LVHPMSQH HIV NEF 257 8 A03i LLHPMSQK HIV NEF 257 8 A03i PTRPQVPLR HIV NEF 95 9 A03i GTPVRPQVPLR HIV NEF 93 11 A03i PTRPMTYK HIV NEF 102 8 A03i EVTRQARR HIV REV 35 8 A03i EGTRQARK HIV REV 35 8 A03i EVTRQARRNR HIV REV 35 10 A03i EGTRQARRNK HIV REV 35 10 A03i EVTRQARRNRR HIV REV 35 11 A03i EGTRQARRNRK HIV REV 35 11 A03i GTRQARRNK HIV REV 36 9 A03i Sequence Organism Protein Position Length Motif GTRQARRNRK HIV REV 36 10 A03i GTRQARRNRRK HIV REV 36 11 A03i GTRQTRKNK HIV REV 37 9 A03i GTRQTRKNRK HIV REV 37 10 A03i GTRQTRKNRRK HIV REV 37 11 A03i TTRQARRNRRK HIV REV 37 11 A03i QVRRNRRR HIV REV 40 8 A03i QARRNRRK HIV REV 40 8 A03i QVRRNRRRR HIV REV 40 9 A03i QARRNRRRK HIV REV 40 9 A03i QVRRNRRRRWR HIV REV 40 11 A03i QARRNRRRRWK HIV REV 40 11 A03i QVRKNRRR HIV REV 40 8 A03i QARKNRRK HIV REV 40 8 A03i QVRKNRRRR HIV REV 40 9 A03i QARKNRRRK HIV REV 40 9 A03i QVRKNRRRRWR HIV REV 40 11 A03i QARKNRRRRWK HIV REV 40 11 A03i PVPLQLPPLEK HIV REV 74 11 A03i PVQLPPLER HIV REV 76 9 A03i PLQLPPLEK HIV REV 76 9 A03i VVPNLEPWNH HIV TAT 4 10 A03i VDPNLEPWNK HIV TAT 4 10 A03i PVSQPKTA HIV TAT 17 8 A03i PGSQPKTK HIV TAT 17 8 A03i TVCNNCYCK HIV TAT 23 9 A03i AVNNCYCK HIV TAT 24 8 A03i LVISYGRKKRR HIV TAT 46 11 A03i LGISYGRKKRK HIV TAT 46 11 A03i IVYGRKKRRQR HIV TAT 48 11 A03i ISYGRKKRRQK HIV TAT 48 11 A03i YVRKKRRQR HIV TAT 50 9 A03i Sequence Organism Protein Position Length Motif <BR> YGRKKRRQK HIV TAT 50 9 A03i YVRKKRRQRR HIV TAT 50 10 A03i YGRKKRRQRK HIV TAT 50 10 A03i YVRKKRRQRRR HIV TAT 50 11 A03i YGRKKRRQRRK HIV TAT 50 11 A03i RVDPTGPK HIV TAT 84 8 A03i TVPKESKK HIV TAT 89 8 A03i ETGPSGQPCK HIV TAT 101 10 A03i KVGPGGYPRR HIV TAT 101 10 A03i KAGPGGYPRK HIV TAT 101 10 A03i KVGPGGYPRRK HIV TAT 101 11 A03i AVPGGYPRR HIV TAT 102 9 A03i AGPGGYPRK HIV TAT 102 9 A03i TVPSGQPCH HIV TAT 102 9 A03i TGPSGQPCK HIV TAT 102 9 A03i AVPGGYPRRK HIV TAT 102 10 A03i PVGYPRRK HIV TAT 104 8 A03i GVYPRRKGSCH HIV TAT 105 11 A03i GGYPRRKGSCK HIV TAT 105 11 A03i KTLGISYGR HIV TAT 44 9 A03i KTLGISYGRK HIV TAT 44 10 A03i GTGISYGRKKR HIV TAT 45 11 A03i KTLGISYGRKK HIV TAT 44 11 A03i GTGISYGR HIV TAT 45 8 A03i GTGISYGRK HIV TAT 45 9 A03i GTGISYGRKK HIV TAT 45 10 A03i GTSYGRKKR HIV TAT 47 9 A03i LTISYGRKKR HIV TAT 46 10 A03i GTSYGRKK HIV TAT 47 8 A03i ITYGRKKR HIV TAT 48 8 A03i LTISYGRK HIV TAT 46 8 A03i LTISYGRKK HIV TAT 46 9 A03i Sequence Organism Protein Position Length Motif <BR> <BR> <BR> <BR> <BR> KTGSLQYLA HIV VIF 146 9 A03i VTSLQYLA HIV VIF 147 8 A03i KVGSLQYLK HIV VIF 146 9 A03i VGSLQYLK HIV VIF 147 8 A03i ETVRHFPR HIV VPR 29 8 A03i EVHPEYYK HIV NEF 324 8 A03s PTRPQVPLR HIV NEF 95 9 A03s PTRPMTYK HIV NEF 102 8 A03s GTGISYGRKKR HIV TAT 45 11 A03s GTGISYGR HIV TAT 45 8 A03s GTGISYGRK HIV TAT 45 9 A03s GTGISYGRKK HIV TAT 45 10 A03s GTSYGRKKR HIV TAT 47 9 A03s GTSYGRKK HIV TAT 47 8 A03s ITYGRKKR HIV TAT 48 8 A03s ETVRHFPR HIV VPR 29 8 A03s QVYTPGPGTR HIV NEF 205 10 Alli QNYTPGPGTK HIV NEF 205 10 Alli QVYTPGPGIR HIV NEF 205 10 Alli QNYTPGPGIK HIV NEF 205 10 Alli PTRPQVPLR HIV NEF 95 9 Alli GTPVRPQVPLR HIV NEF 93 11 Alli PTRPMTYK HIV NEF 102 8 Alli RVRRRRWR HIV REV 43 8 Al li RNRRRRWK HIV REV 43 8 Alli RVRRRRWRAR HIV REV 43 10 Alli RNRRRRWRAK HIV REV 43 10 Alli KVRRRRWR HIV REV 43 8 Alli KNRRRRWK HIV REV 43 8 Alli KVRRRRWRAR HIV REV 43 10 Al li KNRRRRWRAK HIV REV 43 10 Alli PVLEPWNH HIV TAT 9 8 Alli Sequence Organism Protein Position Length Motif <BR> PNLEPWNK HIV TAT 9 8 Al li KTLGISYGR HIV TAT 44 9 Al li KTLGISYGRK HIV TAT 44 10 Al li GTGISYGRKKR HIV TAT 45 11 Alli KTLGISYGRKK HIV TAT 44 11 Alli GTGISYGR HIV TAT 45 8 Al li GTGISYGRK HIV TAT 45 9 Al li GTGISYGRKK HIV TAT 45 10 Alli GTSYGRKKR HIV TAT 47 9 Alli LTISYGRKKR HIV TAT 46 10 Alli GTSYGRKK HIV TAT 47 8 Alli ITYGRKKR HIV TAT 48 8 Al li LTISYGRK HIV TAT 46 8 Alli LTISYGRKK HIV TAT 46 9 Alli ETVRHFPR HIV VPR 29 8 Alli KYSKSSIVGW HIV NEF 4 10 A24i KWSKSSIVGF HIV NEF 4 10 A24i GYPVRPQVPL HIV NEF 93 10 A24i GFPVRPQVPF HIV NEF 93 10 A24i AYDLSFFL HIV NEF 111 8 A24i AFDLSFFF HIV NEF 111 8 A24i SYFLKEKGGL HIV NEF 115 10 A24i SFFLKEKGGF HIV NEF 115 10 A24i HYLKEKGGL HIV NEF 116 9 A24i HFLKEKGGF HIV NEF 116 9 A24i FYLKEKGGL HIV NEF 116 9 A24i FFLKEKGGF HIV NEF 116 9 A24i IYSKKRQEF HIV NEF 175 9 A24i IYSKKRQEIF HIV'NEF 175 10 A24i LYVYHTQGYF HIV NEF 190 10 A24i VYHTQGYFPDF HIV NEF 192 11 A24i DYQNYTPGPGI HIV NEF 203 11 A24i Sequence Organism Protein Position Length Motif <BR> <BR> <BR> <BR> DWQNYTPGPGF HIV NEF 203 11 A24i NYTPGPGF HIV NEF 206 8 A24i RYPLTFGF HIV NEF 216 8 A24i RYPLTFGW HIV NEF 216 8 A24i RFPLTFGF HIV NEF 216 8 A24i TYGWCFKL HIV NEF 222 8 A24i TFGWCFKF HIV NEF 222 8 A24i GFPVRPQVPF HIV NEF 93 10 A24i GYPVRPQVPL HIV NEF 93 10 A24i RYRARQRQI HIV REV 48 9 A24i RWRARQRQF HIV REV 48 9 A24i VYQVDRMRI HIV VIF 10 9 A24i VWQVDRMRF HIV VIF 10 9 A24i GYGAVSQDL HIV NEF 45 9 A24s GVGAVSQDF HIV NEF 45 9 A24s LYVYHTQGY HIV NEF 190 9 A24s LWVYHTQGF HIV NEF 190 9 A24s NYTPGPGIRF HIV NEF 206 10 A24s PYRPQVPL HIV NEF 95 8 A24s GYPVRPQVPL HIV NEF 93 10 A24s FYKEKGGL HIV NEF 117 8 A24s QYPPLERL HIV REV 78 8 A24s QLPPLERF HIV REV 78 8 A24s QYPPLERLTL HIV REV 78 10 A24s QLPPLERLTF HIV REV 78 10 A24s VWQVDRMRF HIV VIF 10 9 A24s KYGSLQYLAL HIV VIF 146 10 A24s KYGSLQYL HIV VIF 146 8 A24s IYWQVDRM HIV VIF 9 8 A24s IVWQVDRF HIV VIF 9 8 A24s APTAAKGI HIV NEF 34 8 B07s APTAAKGVGI HIV NEF 34 10 B07s Sequence Organism Protein Position Length Motif <BR> <BR> <BR> <BR> APTAAKGVGAI HIV NEF 34 11 B07S FPVRPQVPI HIV NEF 94 9 B07s RPQVPLRPI HIV NEF 98 9 B07s RPQVPLRPMTI HIV NEF 98 11 B07s VPLRPMTI HIV NEF 101 8 B07s VPLRPMTYKGI HIV NEF 101 11 B07s VPLRPMTYKI HIV NEF 101 10 B07s VPLRPMTYKAI HIV NEF 101 11 B07s RPMTYKAI HIV NEF 104 8 B07s TPGPGIRI HIV NEF 208 8 B07s GPGIRYPI HIV NEF 210 8 B07s YPLTFGWCI HIV NEF 217 9 B07s FPLTFGWCI HIV NEF 217 9 B07s FPLTFGWCFKI HIV NEF 217 11 B07s RPQVPLRPMTI HIV NEF 98 11 B07s VPLRPMTI HIV NEF 101 8 B07s RPQVPLRPI HIV NEF 98 9 B07s FPVRPQVPI HIV NEF 94 9 B07s FPVRPQVPI HIV NEF 94 9 B07s RPAEPVPI HIV REV 70 8 B07s RPAEPVPLQI HIV REV 70 10 B07s VPLQLPPI HIV REV 75 8 B07s LPPLERLTI HIV REV 79 9 B07s PPLERLTI HIV REV 80 8 B07s EPVPLQLPPI HIV REV 73 10 B07s VPLQLPPLERI HIV REV 75 11 B07s VPLQLPPI HIV REV 75 8 B07s HPGSQPKTI HIV TAT 16 9 B07s GPQREPYNEI HIV VPR 9 10 B07s QEILDLWV HIV NEF 184 8 B44s GESDEELL HIV REV 6 8 B44s EECGTSGTQGV HIV REV 91 11 B44s VEPNLEPW HIV TAT 4 8 B44s Table 11 Motif Parent source Length Sequence <BR> <BR> <BR> A24i Nef 4 10 KYSKSSIVGW A24i Nef 4 10 KWSKSSIVGF AOls Nef 5 9 WTKSSIVGW AOls Nef 5 9 WSKSSIVGY A02i/s Nef 34 9 QLEPAAAGV A02i/s Nef 34 11 QLEPAAAGVGA A02i/s Nef 34 11 QAEPAAAGVGV B07s Nef 34 8 APTAAKGI B07s Nef 34 10 APTAAKGVGI B07s Nef34 11 APTAAKGVGAI A02i/s Nef 41 8 PLAEGVGA A02i/s Nef41 8 PAAEGVGV A02i/s Nef 42 8 ALEGVGAV A02i/s Nef 45 9 GLGAVSRDL A02i/s Nef45 9 GVGAVSRDV A24s Nef 45 9 GYGAVSQDL A24s Nef 45 9 GVGAVSQDF A03i Nef 51 8 RVLEKHGA A03i Nef 51 8 RDLEKHGK A03i Nef 61 10 HVAITSSNTA A03i Nef 61 10 HGAITSSNTK A02i/s Nef 62 8 GLITSSNT A02i/s Nef 62 8 GAITSSNV A02i/s Nef 62 9 GLITSSNTA A02i/s Nef 62 9 GAITSSNTV A02i/s Nef 63 8 ALTSSNTA A02i/s Nef 63 8 AITSSNTV A02i/s Nef 73 9 NLDCAWLEA A02i/s Nef 73 9 NADCAWLEV A03i Nef 74 8 AVCAWLEA Motif Parent source Length Sequence <BR> <BR> <BR> <BR> A03i Nef 74 8 ADCAWLEK A02i/s Nef 82 8 ELQEEEEV A03i Nef 82 10 EVQEEEEVGF A03i Nef 82 10 EAQEEEEVGK A02i/s Nef 83 11 ALEEEEVGFPV A02i/s Nef91 10 ELGFPVRPQV A03i Nef 93 11 GVPVRPQVPLR A03i Nef 93 11 GFPVRPQVPLK A24i Nef 93 10 GYPVRPQVPL A24i Nef 93 10 GFPVRPQVPF B07s Nef 94 9 FPVRPQVPI A02i/s Nef 95 8 PLRPQVPL A02i/s Nef 95 8 PVRPQVPV A02i/s Nef 95 11 PLRPQVPLRPM A02i/s Nef95 11 PVRPQVPLRPV A03i Nef 95 9 PVRPQVPLK B07s Nef 98 9 RPQVPLRPI B07s Nef98 11 RPQVPLRPMTI A02i/s Nef99 8 PLVPLRPM A02i/s Nef 99 8 PQVPLRPV A02i/s Nef99 9 PLVPLRPMT A02i/s Nef 99 9 PQVPLRPMV A01 s Nef 100 9 QTPLRPMTY A02i/s Nef 100 8 QLPLRPMT A02i/s Nef 100 8 QVPLRPMV A02i/s NeflOO 11 QLPLRPMTYKA A02i/s NeflOO 11 QVPLRPMTYKV B07s Nef 101 8 VPLRPMTI B07s Nef 101 11 VPLRPMTYKGI B07s Nef 101 10 VPLRPMTYKI B07s Nef 101 11 VPLRPMTYKAI A02i/s Nef 102 10 PLRPMTYKGV Motif Parent source Length Sequence <BR> <BR> <BR> <BR> A02i/s Nef 102 9 PLRPMTYKV A02i/s Nef 102 10 PLRPMTYKAV A03i Nef 102 8 PVRPMTYK B07s Nef104 8 RPMTYKAI A03i Nef 111 9 AVDLSFFLK A03i Nef 111 11 AVDLSFFLKEK A24i Nef Ill 8 AYDLSFFL A24i Nef 111 8 AFDLSFFF A03i Nef 112 8 FVLSFFLK A03i Nef 112 10 FVLSFFLKEK A03i Nef 113 9 DVSHFLKEK A03i Nef 113 9 DVSFFLKEK A03i Nef 114 8 LVHFLKEK A03i Nef 114 8 LVFFLKEK A24i Nef 115 10 SYFLKEKGGL A24i Nefll5 10 SFFLKEKGGF A24i Nefll6 9 HYLKEKGGL A24i Nefll6 9 HFLKEKGGF A24i Nefll6 9 FYLKEKGGL A24i Nef 116 9 FFLKEKGGF A02i/s Nefll7 8 FLKEKGGV A02i/s Nefll7 11 FLKEKGGLEGV A02i/s Nef 117 11 FLKEKGGLDGV A03i Nef 122 9 KVGLEGLIY A03i Nef 122 9 KGGLEGLIK A03i Nef 124 8 GVLEGLIY A03i Nef 124 8 GGLEGLIK A03i Nef 124 10 GVLDGLIYSK A03i Nef 125 9 GVDGLIYSK A03i Nef 171 8 LVGLIYSK A02i/s Nef 173 11 GLIYSKKRQEV A03i Nef 173 8 GVIYSKKR Motif Parent source Length Sequence A03i Nef 173 8 GLIYSKKK A02i/s Nef 174 10 LLYSKKRQEI A02i/s Nef 174 10 LIYSKKRQEV A02i/s Nef 174 11 LLYSKKRQEIL A02i/s Nefl74 11 LIYSKKRQEIV A24i Nef 175 9 IYSKKRQEF A24i Nef 175 10 IYSKKRQEIF AOli Nef 182 10 RTEILDLWVY AOli Nef182 10 RQDILDLWVY AOli Nef182 10 RTDILDLWVY A02i/s Nef182 9 RLEILDLWV A02i/s Nef182 9 RLDILDLWV A03i Nef 184 9 QVILDLWVY A03i Nef 184 9 QDILDLWVK B44s Nef 184 8 QEILDLWV AOls Nef 185 8 ETLDLWVY AOls Nef 185 8 DTLDLWVY A02i/s Nef 185 10 ELLDLWVYHT A02i/s Nef 185 10 EILDLWVYHV A03i Nef 185 9 EVLDLWVYH A03i Nef185 9 EILDLWVYK A02i/s Nef 186 9 ILDLWVYHV A02i/s Nef186 9 ILDLWVYNV A03i Nef 186 8 IVDLWVYH A03i Nef 186 8 ILDLWVYK A03i Nef187 11 LVLWVYHTQGY A03i Nef 187 11 LDLWVYHTQGK AOls Nefl88 10 DTWVYHTQGY AOls Nef188 11 DTWVYHTQGYF AOls Nef 188 11 DLWVYHTQGYY A24i Nef 190 10 LYVYHTQGYF A24s Nef 190 9 LYVYHTQGY Motif Parent source Length Sequence <BR> <BR> <BR> A24s Nef 190 9 LWVYHTQGF AOls Nef 191 8 WTYHTQGY A01s Nef191 9 WTYHTQGYF AOls Nef 191 9 WVYHTQGYY A24i Nefl92 11 VYHTQGYFPDF A03i Nef196 10 QVFFPDWQNY A03i Nef196 10 QVFFPDWQNK A03i Nef 198 9 GVFPDWQNY A03i Nef 198 9 GFFPDWQNK A03i Nef 199 8 FVPDWQNY A03i Nef 199 8 FFPDWQNK A24i Nef203 11 DYQNYTPGPGI A24i Nef203 11 DWQNYTPGPGF A02i/s Nef204 10 WLNYTPGPGT A02i/s Nef204 10 WQNYTPGPGV A02i/s Nef204 10 WLNYTPGPGI A02i/s Nef204 10 WQNYTPGPGV Al li Nef 205 10 QVYTPGPGTR Al li Nef 205 10 QNYTPGPGTK Al li Nef205 10 QVYTPGPGIR Al li Nef 205 10 QNYTPGPGIK A24i Nef206 8 NYTPGPGF A24s Nef206 10 NYTPGPGIRF AOli Nef207 9 YTDGPGIRY A02i/s Nef207 11 YLPGPGIRYPL A02i/s Nef207 11 YTPGPGIRYPV A03i Nef207 8 YTPGPGTK A03i Nef207 8 YTPGPGIK B07s Nef 208 8 TPGPGIRI B07s Nef 210 8 GPGIRYPI A03i Nef216 10 RVPLTFGWCF A03i Nef216 10 RFPLTFGWCK Motif Parent source Length Sequence <BR> <BR> <BR> <BR> A03i Nef 216 11 RVPLTFGWCFK A24i Nef216 8 RYPLTFGF A24i Nef216 8 RYPLTFGW A24i Nef216 8 RFPLTFGF B07s Nef217 9 YPLTFGWCI B07s Nef217 9 FPLTFGWCI B07s Nef217 11 FPLTFGWCFKI A01s Nef219 8 PTTFGWCF AOls Nef219 8 PLTFGWCY A02i/s Nef219 10 PLTFGWCFKV A03i Nef219 9 PVTFGWCFK A02i/s Nef221 9 LLFGWCFKL A02i/s Nef221 9 LTFGWCFKV A02i/s Nef221 10 LLFGWCFKLV A24i Nef 222 8 TYGWCFKL A24i Nef 222 8 TFGWCFKF A03i Nef 257 8 LVHPICQH A03i Nef 257 8 LLHPICQK A03i Nef257 8 LVHPMSQH A03i Nef 257 8 LLHPMSQK AOli Nef322 8 ATELHPEY AOli Nef 322 8 ARDLHPEY AOli Nef322 9 ATELHPEYY AOli Nef322 9 ARDLHPEYY A03s Nef324 8 EVHPEYYK AOls Nef 185 8 ETLDLWVY B07s Nef 98 11 RPQVPLRPMTI A01s Nef100 9 QTPLRPMTY B07s Nef 101 8 VPLRPMTI B07s Nef98 9 RPQVPLRPI A02i/s Nef95 8 PVRPQVPV A24s Nef 95 8 PYRPQVPL Motif Parent source Length Sequence <BR> <BR> <BR> <BR> B07s Nef 94 9 FPVRPQVPI B07s Nef 94 9 FPVRPQVPI A03i Nef95 9 PTRPQVPLR A03s Nef95 9 PTRPQVPLR Al li Nef 95 9 PTRPQVPLR A24i Nef#3 10 GFPVRPQVPF A24s Nef93 10 GYPVRPQVPL A03i Nef 93 11 GTPVRPQVPLR Al li Nef 93 11 GTPVRPQVPLR A03i Nef 102 8 PTRPMTYK A03s Nef 102 8 PTRPMTYK Alli Nef 102 8 PTRPMTYK A02i/s Nef 117 8 FLKEKGGV A24s Nef 117 8 FYKEKGGL A02i/s Nef 99 8 PQVPLRPV A02i/s Nef 99 9 PQVPLRPMV A02i/s Nef 100 8 QVPLRPMV A02i/s Nef95 8 PLRPQVPL A24i Nef 93 10 GYPVRPQVPL A02i/s Nef 117 8 FVKEKGGL A02i/s Nef 99 8 PLVPLRPM A02i/s Nef 99 9 PLVPLRPMT A02i/s Nef 100 8 QLPLRPMT A02i/s Nef99 8 PVVPLRPM A02i/s Nef99 9 PVVPLRPMT B44s Rev 6 8 GESDEELL AOls Rev 20 11 ITKILYQSNPY AOls Rev 22 9 KTLYQSNPY AOls Rev 23 8 ITYQSNPY A03i Rev 35 8 EVTRQARR A03i Rev 35 8 EGTRQARK A03i Rev 35 10 EVTRQARRNR Motif Parent source Length Sequence A03i Rev35 10 EGTRQARRNK A03i Rev 35 11 EVTRQARRNRR A03i Rev 35 11 EGTRQARRNRK A03i Rev 36 9 GTRQARRNK A03i Rev 36 10 GTRQARRNRK A03i Rev 36 11 GTRQARRNRRK A03i Rev 37 9 GTRQTRKNK A03i Rev 37 10 GTRQTRKNRK A03i Rev 37 11 GTRQTRKNRRK A03i Rev 37 11 TTRQARRNRRK A03i Rev 40 8 QVRRNRRR A03i Rev 40 8 QARRNRRK A03i Rev 40 9 QVRRNRRRR A03i Rev 40 9 QARRNRRRK A03i Rev 40 11 QVRRNRRRRWR A03i Rev 40 11 QARRNRRRRWK A03i Rev 40 8 QVRKNRRR A03i Rev 40 8 QARKNRRK A03i Rev 40 9 QVRKNRRRR A03i Rev 40 9 QARKNRRRK A03i Rev 40 11 QVRKNRRRRWR A03i Rev 40 11 QARKNRRRRWK Al li Rev 43 8 RVRRRRWR Al li Rev 43 8 RNRRRRWK A11i Rev 43 10 RVRRRRWRAR A11i Rev 43 10 RNRRRRWRAK Al li Rev 43 8 KVRRRRWR Al li Rev 43 8 KNRRRRWK A11i Rev 43 10 KVRRRRWRAR A11i Rev 43 10 KNRRRRWRAK A24i Rev 48 9 RYRARQRQI A24i Rev 48 9 RWRARQRQF Motif Parent source Length Sequence B07s Rev 70 8 RPAEPVPI B07s Rev 70 10 RPAEPVPLQI A02i/s Rev 71 9 PLEPVPLQL A02i/s Rev 71 9 PAEPVPLQV A02i/s Rev 74 9 PLPLQLPPL A02i/s Rev 74 9 PVPLQLPPV A03i Rev 74 11 PVPLQLPPLEK B07s Rev 75 8 VPLQLPPI A02i/s Rev 76 10 PLQLPPLERV A03i Rev 76 9 PVQLPPLER A03i Rev 76 9 PLQLPPLEK A02i/s Rev 77 9 LLLPPLERL A02i/s Rev 77 9 LQLPPLERV A02i/s Rev 77 10 LLLPPLERLT A02i/s Rev 77 10 LQLPPLERLV A02i/s Rev 77 11 LLLPPLERLTL A02i/s Rev 77 11 LQLPPLERLTV A02i/s Rev 78 9 QLPPLERLV A24s Rev 78 8 QYPPLERL A24s Rev 78 8 QLPPLERF A24s Rev 78 10 QYPPLERLTL A24s Rev 78 10 QLPPLERLTF B07s Rev 79 9 LPPLERLTI B07s Rev 80 8 PPLERLTI B44s Rev 91 11 EECGTSGTQGV A02i/s Rev 94 8 GLSGTQGV B07s Rev 73 10 EPVPLQLPPI B07s Rev 75 11 VPLQLPPLERI B07s Rev 75 8 VPLQLPPI AOls Tat 3 9 PTDPNLEPW AOls Tat 3 9 PVDPNLEPY A03i Tat 4 10 VVPNLEPWNH Motif Parent source Length Sequence <BR> <BR> <BR> <BR> A03i Tat 4 10 VDPNLEPWNK B44s Tat 4 8 VEPNLEPW Alli Tat 9 8 PVLEPWNH Al li Tat 9 8 PNLEPWNK B07s Tat 16 9 HPGSQPKTI A03i Tat 17 8 PVSQPKTA A03i Tat 17 8 PGSQPKTK A03i Tat 23 9 TVCNNCYCK A03i Tat 24 8 AVNNCYCK A03i Tat 46 11 LVISYGRKKRR A03i Tat 46 11 LGISYGRKKRK A03i Tat 48 11 IVYGRKKRRQR A03i Tat 48 11 ISYGRKKRRQK A03i Tat 50 9 YVRKKRRQR A03i Tat 50 9 YGRKKRRQK A03i Tat 50 10 YVRKKRRQRR A03i Tat 50 10 YGRKKRRQRK A03i Tat 50 11 YVRKKRRQRRR A03i Tat 50 11 YGRKKRRQRRK A03i Tat 84 8 RVDPTGPK A03i Tat 89 8 TVPKESKK A03i Tat 101 10 ETGPSGQPCK A03i Tat 101 10 KVGPGGYPRR A03i Tat 101 10 KAGPGGYPRK A03i Tat 101 11 KVGPGGYPRRK A03i Tat 102 9 AVPGGYPRR A03i Tat 102 9 AGPGGYPRK A03i Tat 102 9 TVPSGQPCH A03i Tat 102 9 TGPSGQPCK A03i Tat 102 10 AVPGGYPRRK A03i Tat 104 8 PVGYPRRK A03i Tat 105 11 GVYPRRKGSCH Motif Parent source Length Sequence A03i Tat 105 11 GGYPRRKGSCK A03i Tat 44 9 KTLGISYGR Alli Tat 44 9 KTLGISYGR A03i Tat 44 10 KTLGISYGRK Al li Tat 44 10 KTLGISYGRK A03i Tat 45 11 GTGISYGRKKR A03s Tat 45 11 GTGISYGRKKR Al li Tat 45 11 GTGISYGRKKR A03i Tat 44 11 KTLGISYGRKK Alli Tat 44 11 KTLGISYGRKK A03i Tat 45 8 GTGISYGR A03s Tat 45 8 GTGISYGR Alli Tat 45 8 GTGISYGR A03i Tat 45 9 GTGISYGRK A03s Tat 45 9 GTGISYGRK Al li Tat 45 9 GTGISYGRK A03i Tat 45 10 GTGISYGRKK A03s Tat 45 10 GTGISYGRKK Alli Tat 45 10 GTGISYGRKK A03i Tat 47 9 GTSYGRKKR A03s Tat 47 9 GTSYGRKKR Al li Tat 47 9 GTSYGRKKR A03i Tat 46 10 LTISYGRKKR Alli Tat 46 10 LTISYGRKKR A03i Tat 47 8 GTSYGRKK A03s Tat 47 8 GTSYGRKK A11i Tat 47 8 GTSYGRKK A03i Tat 48 8 ITYGRKKR A03s Tat 48 8 ITYGRKKR Alli Tat 48 8 ITYGRKKR A03i Tat 46 8 LTISYGRK A11i Tat 46 8 LTISYGRK Motif Parent source Length Sequence A03i Tat 46 9 LTISYGRKK Al li Tat 46 9 LTISYGRKK AOls Vif23 8 STVKHHMY A02i/s Vif 11 8 WQVDRMRV A24i Vif 10 9 VYQVDRMRI A24s Vif 10 9 VWQVDRMRF A02i/s Vif 146 10 KVGSLQYLAV A24s Vif 146 10 KYGSLQYLAL A02i/s Vif 146 8 KVGSLQYV A24s Vif 146 8 KYGSLQYL A02i/s Vif 146 9 KVGSLQYLV A03i Vif 146 9 KTGSLQYLA A03i Vif 147 8 VTSLQYLA A02i/s Vif 9 8 IVWQVDRV A24s Vif 9 8 IYWQVDRM A02i/s Vif11 8 WLVDRMRI A24i Vif 10 9 VWQVDRMRF A02i/s Vif 146 10 KLGSLQYLAL A02i/s Vif 146 8 KLGSLQYL A02i/s Vif 146 9 KLGSLQYLA A03i Vif 146 9 KVGSLQYLK A03i Vif 147 8 VGSLQYLK A02i/s Vif 9 8 ILWQVDRM A24s Vif 9 8 IVWQVDRF A02i/s Vif 11 8 WVVDRMRI B07s Vpr 9 10 GPQREPYNEI AOli Vpr 5 11 PTDQGPQREPY A03i Vpr 29 8 ETVRHFPR A03s Vpr 29 8 ETVRHFPR Al li Vpr 29 8 ETVRHFPR Table 12<BR> HLA-A1 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0101 A*2902 A*3002<BR> 57.0007 AADNPPAQY .CEA.261 A 9.2<BR> 57.0026 GGDVENPEY .Her2/neu.1188 A 399<BR> 57.0021 VTAGVGSPY .Her2/neu.773 A 269<BR> 1074.17 AC-YTAVVPLVY .Jchain. A 37<BR> 1074.20 AYTAVVPLVY .Jchain. A 455<BR> 1074.19 RYTAVVPLVY .Jchain. A >296.17<BR> 1489.15 LYTCLGLSY .MAGE2.178 4132 18 4101<BR> 1489.16 LVQENYLEY .MAGE2.250 48 13 72<BR> 57.0029 STFSTTINY .MAGE2.69 A 114<BR> 1461.06 MEVDPIGHLY .MAGE3.167 371 333 87<BR> 1489.18 FVQENYLEY .MAGE3.250 26 3.2 99<BR> 26.0224 SAEQSPPPY .MART1.108 269<BR> 57.0128 VGDDCTTIHY .p53.225 A 465<BR> 1044.12 SEVDPIGHLY .PAP.135 A 395<BR> 26.0231 SMHNALHIY .Tyrosinase.361 345<BR> 26.0484 ISSKDLGYDY .Tyrosinase.440 185<BR> 954.06 AADAAAAKAY Artificial sequence PolyA 107<BR> 21.0009 AADAAAAKY Artificial sequence PolyA 20<BR> 954.07 AAEAAAAKY Artificial sequence PolyA 149<BR> 954.04 AAEKAAAAAY Artificial sequence PolyA 236<BR> 954.10 ALAKAAAAAY Artificial sequence PolyA 456<BR> 954.20 ALEKAAAAAY Artificial sequence PolyA 173<BR> 954.19 ALEKAAAAY Artificial sequence PolyA 151<BR> 26.0033 GMQNIYIKY Artificial sequence 294<BR> 26.0034 ITYFKKIYY Artificial sequence 285 Table 12<BR> HLA- A1 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0101 A*2902 A*3002<BR> 962.13 YTAQAAAKF Artificial sequence Poly 127<BR> 1489.10 LHGPTPLLY HCV.II.1623 >34879.01 180 1075<BR> 1489.11 AQPGYPWPLY HCV.II.77 >31382.68 133 3.5<BR> 1489.06 AATLGFGAY HCV.IV.1264 44768 2240 491<BR> 1489.12 TCGFADLMGY HCV.IV.127 2321 350 356<BR> 1489.05 CSFSIFLLA HCV.IV.172 28906 153 11100<BR> 78.0359 RFHNIRGRW HPV.16.E6.131 53191 18 58<BR> 78.0001 IHDIILECVY HPV.16.E6.30 316 8873 8939<BR> 78.0002 YSKISEYRHY HPV.16.E6.77 151 6448 205<BR> 78.0177 EYRHYCYSLY HPV.16.E6.82 2564 2449 120<BR> 78.0006 LQDIEITCVY HPV.18.E6.25 1517 4044 148<BR> 78.0005 RFEDPTRRPY HPV.18.E6.3 19231 17839 145<BR> 78.0361 LFVVYRDSI HPV.18.E6.52 20921 464 100<BR> 78.0363 RFHNIGGRW HPV.31.E6.124 >35714.29 1595 9.5<BR> 78.0009 YSKVSEFRWY HPV.31.E6.70 539 4514 185<BR> 78.0366 RFHNISGRW HPV.33.E6.124 48544 174 37<BR> 78.0364 VYDFAFADL HPV.33.E6.42 19763 163 579<BR> 78.0365 RFLSKISEY HPV.33.E6.68 >35714.29 34623 23<BR> 78.0243 ISEYRHYNY HPV.33.E6.73 25 1329 32<BR> 78.0180 EYRHYNYSVY HPV.33.E6.75 31447 16016 253<BR> 78.0348 LYPEPTDLY HPV.33.E7.15 31 36 71<BR> 78.0244 LKEYVLDLY HPV.33.E7.8 3270 127123 16<BR> 78.0246 ATLERTEVY HPV.45.E6.37 35 11383 175<BR> 78.0368 AFKDLCIVY HPV.45.E6.48 >35714.29 32 0.49<BR> 78.0349 AYAACHKCI HPV.45.E6.61 32895 3300 139 Table 12<BR> HLA- A1 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0101 A*2902 A*3002<BR> 78.0182 FYSRIRELRY HPV.45.E6.71 10-142 20 150<BR> 78.0247 YSRIRELRY HPV.45.E6.72 41 1991 22<BR> 78.0369 VYGETLEKI HPV.45.E6.85 >35714.29 12156 13<BR> 78.0017 ELDPVDLLCY HPV.45.E7.20 26 4291 12746<BR> 78.0371 VYKFLFTDL HPV.52.E6.42 >35714.29 1707 27<BR> 78.0372 LFTDLRIVY HPV.52.F6.46 >35714.29 25003 22<BR> 78.0019 LSKISEYRHY HPV.52.E6.70 14327 55190 186<BR> 78.0248 ISEYRHYQY HPV.52.E6.73 283 >84107.89 3765<BR> 78.0183 EYRHYQYSLY HPV.52.E6.75 2268 2372 130<BR> 78.0249 QAEQATSNY HPV.52.E7.46 74 4203 109<BR> 78.0022 QAEQATSNYY HPV.52.E7.46 101 39409 1436<BR> 78.0023 ATSNYYIVTY HPV.52.E7.50 2209 2117 118<BR> 78.0250 TSNYYIVTY HPV.52.E7.51 >74955.86 3313 76<BR> 78.0376 NFACTELKL HPV.56.E6.47 >35971.22 202 1.0<BR> 1488.11 AVCRVCLLFY HPV.56.E6.64 105<BR> 78.0378 LFYSKVRKY HPV.56.E6.712 1262 12 89<BR> 78.0176 FYSKVRKYRY HPV.56.E6.72 >32894.74 146 326<BR> 1497.15 KYRYYDRYSVY HPV.56.E6.78 17797 2.3<BR> 78.0379 DYSVYGATL HPV.56.E6.83 >35971.22 1460 19<BR> 78.0252 LCDLLIRCY HPV.56.E6.99 656 557 26<BR> 78.0384 RFHNISGRW HPV.58.E6.124 >35971.22 201 35<BR> 78.0253 KTLQRSEVY HPV.58.E6.35 308 6276 566<BR> 78.0381 VYDFVFADL HPV.58.E6.42 >35971.22 27168 27<BR> 78.0027 LSKIEYRHY HPV.58.E6.70 17182 101409 159<BR> 78.0254 ISEYRHYNY HPV.58.E6.73 46 853 81 Table 12<BR> HLA- A1 supertype binding affinity (IC50 nM)<BR> peptide Sequence Source Analog A*0101 A*2902 A*3002<BR> 78.0354 EYRHYNYSL HPV.58.E6.75 54348 268 1473<BR> 78.0185 EYRHYNYSLY HPV.58.E6.75 2405 1774 67<BR> 26.0271 RMAWHAAGTY MT.104 423<BR> 26.0075 VIPEQRPLY MT.1752 331<BR> 26.0283 QWMGLGWKSSY MT.294 340<BR> 26.0037 RTGLYGAQY MT.344 116<BR> 1489.221 ALFQEYQCY Pf.CSP.18 >38534.16 149 1032<BR> 1489.55 YYGKQENWY Pf.CSP.55 373 3155<BR> 1489.61 FYFILVNLLI Pf.LSA1.9 362 8591<BR> 1489.27 FVVPGAATPY Pf.SSP2.520 31338 317 4621 TABLE 13 A*0101 Peptide Seqwuence AA Source Analog (IC50 nM) 57. 0007 AADNPPAQY 9 261 A 46 57.0013 AADNPPAQY 9 CEA. 439 A 46 57.0106 HSDSNPSPQY 10 CEA. 616 A 46 57. 0105. HTASNPSPQY 10 CEA. 616 A 134 57.0014 ITDKNSGLY 9 CEA. 467 A 12 57. 0008 ITDNNSGSY 9 CEA. 289 A 110 57.0103 PTDSPLNTSY 10 CEA. 240 A 292 57.0011 PTDSPSYTY 9 CEA. 418 A 38 57.0104 PTDSPSYTYY 10 CEA. 418 A 2.0 57.0004 QQDTPGPAY 9 CEA. 87 A 57 57.0012 TIDPSYTYY 9 CEA. 419 A 3.5 57.0010 VTDNDVGPY 9 CEA. 383 A 4.5 26.0155 WSQKRSVPY 9 gpl00.143 57.0018 ATCVTACPY 9 Her2/neu. 293 A 57 57.0024 ATPLDSTFY 9 Her2/neu. 997 A 40 57.0113 CTQIAKGMSY 10 Her2/neu. 826 A 20 57.0019 ETDEEITGY 9 Her2/neu. 401 A 18 57.0111 ETMPNPEGRY 10 Her2/neu. 280 A 4.1 57.0114 FTDQSDVWSY 10 Her2/neu. 899 A 0.64 57.0027 FTPAFDNLY 9 Her2/neu. 1213 A 9.1 57.0117 FTPAFDNLYY 10 Her2/neu. 1213 A 0. 82 57.0017 GTDLFEDNY 9 Her2/neu. 104 A 0.91 57.0107 GTDMKLRLPY 10 Her2/neu. 28 A 50 57.0118 GTDTAENPEY 10 Her2/neu. 1239 A 27 57.0016 HTDMLRHLY 9 Her2/neu. 42 A 2.0 57.0023 LTDIDETEY 9 Her2/neu. 869 A 6.5 57.0025 LTDSPQPEY 9 Her2/neu. 1131 A 36 57.0116 MTDLVDAEEY 10 Her2/neu. 1014 A 2.5 57.0115 PADPLDSTFY 10 Her2/neu. 996 A 19 57. 0129 PTDCCHEQCAY 11 Her2/neu. 232 A 18 57.0109 PTDCCHEQCY 10 Her2/neu. 232 A 47 57.0028 SPDFDNLYY 9 Her2/neu. 1214 A 73 57.0112 TLDEITGYLY 10 Her2/neu. 402 A 3.6 57.0022 VMDGVGSPY 9 Her2/neu. 773 A 41 57.0120 ASDFSTTINY 10 MAGE2.68 A 24 57.0123 ASDLPTTMNY 10 MAGE3.68 A 2.6 57.0119 ATSFSTTINY 10 MAGE2.68 A 476 57.0122 ATSLPTTMNY 10 MAGE3.68 A 214 57.0032 GTVVGNWQY 9 MAGE3.137 A 37 57. 0034 ITGGPHISY 9 MAGE3.293 A 36 57.0124 LTDHFVQENY 10 MAGE3.246 A 2.4 57.0121 LTQDLVQENY 10 MAGE2.246 A 64 57.0030 MTDLVQENY 9 MAGE2.247 A 0.79 57.0031 STLPTTMNY 9 MAGE3.69 A 58 57.0003 VTDLGLSY 8 MAGE2. 179 A 2.7 26.0468 LSAEQSPPPY 10 MART1.107 35 TABLE 13 <BR> <BR> <BR> A*0101 Peptide Sequence AA Source Analog (IC50 nom) 57. 0035 GTDCTTIHY 9 p53.226 A 0.85 57.0126 GTDKSVTCTY 10 p53.117 A 43 57.0125 PTQKTYQGSY 10 p53.98 A 37 57.0127 RVDGNLRVEY 10 p53. 196 A 1381.01 PSDKHIKEY9 Pf. CSP. 31027 26.0480 DSDPDSFQDY 10 Tyrosinase. 454 5.5 1074.17 YTAVVPLVY 10 Jchain. A 186 F011. 03 ATDFKFAMY 9 Naturally processed 0.75 F011. 06 DSDGSFFLY 9 Naturally processed 0.65 F020.01 DSGDSFFLY 9 Naturally processed 34 F011. 07 GTDENRLLY 9 Naturally processed 1.3 FO11. 01 IADMGHLKY 9 Naturally processed 3.2 F023.04 YLDDPDLKY 9 Naturally processed 3.2 F011. 02 YTDYGGLIFNSY 12 Naturally processed 2.0 F029.03 YTNPQFNVY 9 Naturally processed 25 F011.04 YTSDYFISY 9 Naturally processed 4.8 F023.02 YTSDYFYSY 9 Naturally processed 0.25 21.0009 AADAAAAKY 9 Artificial sequence Poly A 101 954.05 AADAAAAKY 9 Artificial sequence Poly A 64 962.10 AADAKAAAY 9 Artificial sequence Poly A 95 954.18 ALDKAAAAAY 10 Artificial sequence Poly A 31 954.17 ALDKAAAAY 9 Artificial sequence Poly A 39 962.09 ATDAKAAAY 9 Artificial sequence Poly A 6.9 982.18 ATDKAAAAA 9 Artificial sequence Poly 73 962.08 ATDPKAAAY 9 Artificial sequence Poly A 6.5 954.22 ATEKAAAAAY 10 Artificial sequence Poly A 9.6 954.21 ATEKAAAAY 9 Artificial sequence Poly A 6.2 962.14 YTAQAAAKY 9 Artificial sequence Poly 4.2 1074.02 YTAVVPLVF 9 Artificial sequence A 21 962.11 YTDPKLINY 9 Artificial sequence Poly 8.2 962.12 YTDQAVIKY 9 Artificial sequence Poly 2.8 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 70.0094 FLLAQFTSAI HBV.Pol.503 65 1.9 4.8 148 533<BR> 70.0088 FLPSDYFPSV HBV.Core.18 A 8.5 3.3 3.2 2.2 276<BR> 1369.03 FVLSLGIHV HBV.pol.562 A 45 400 237 1414 133 62<BR> 1369.01 GVLGWSPQV HBV.env.62 A 22 157 393 37 28 9357<BR> 1369.02 HVYSHPHV HBV.pl.1076 A 151 1921 14 11026 1200 122<BR> 1369.26 IVRGTSFVYV HBV.pol.773 a 36765 5298 68 1828 5386 1222<BR> 1369.13 PVLPIFFCV HBV.env.377 A 8.7 3140 13643 43000 22 1814<BR> 924.201 QFLPSDFFPSV HBV.core.27 A 394<BR> 1369.14 VVQAGFFLV HBV.env.177 A 438 78 2484 785 81 624<BR> 1369.15 YVDDVVLGV HBV.pol.538 A 18 14 70 91 16 360<BR> 1489.30 FLLALLSCLT HCV.II.177 90 21 65 488 4235<BR> 1472.05 RVLEDGVNYA HCV.Core.156 3785 24 3292 39 190167<BR> 1327.12 TLWARMILM HCV.II.2871 11 36 118 204 519<BR> 1472.06 VLEDGVNYA HCV.Core.157 2141 53 64 10898 194602<BR> 1489.29 YQATVCASRA HCV.IV.1594 405 13 23 118 4976<BR> 1482.09 ALETSVHEI HPV58.E6.18 1514 248 317 12546 >447213.6<BR> 1491.78 ALETSVHEV HPV.58.E6.18 A 265 114 148 2272 68376<BR> 1481.49 ALETTIHNI HPV33.E6.18 2122 189 894 2265 97129<BR> 1491.36 ALETTIHNV HPV.33.E6.18 A 286 34 272 2070 42534<BR> 1482.04 ALTVTCPLCA HPV56.E7.93 8382 1310 335 157625 >165379.65<BR> 1481.60 AQPATADYYI HPV33.E7.45 17763 224 21164 52372 318546<BR> 1482.20 AQPATANYYI HPV5.E7.46 9604 141 13584 2190 15996<BR> 1090.75 CVYCKQQLL HPV.16.E6.37 38396 425 9535 43026 9097<BR> 14812.10 DLLMGTLGIV HPV16.E7.81 857 70 712 607 12006<BR> 1481.42 ELLMGSFGIV HPV31.E7.81 996 202 26 273 10648 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1481.13 ELTEVFEFA HPV18.E6.40 8079 47 6241 396 51<BR> 1481.76 ELYNLLRCL HPV45.E6.97 11777 1351 425 15935 2191<BR> 1481.86 EVLEIPLIDL HPV56.E6.20 144749 2625 18829 6013 484<BR> 1481.51 EVYDFASFASDL HPV33.E6.41 36182 16188 2710 80 25<BR> 1482.11 EVYDFVFADL HPV5.E6.41 49309 12065 3138 60 9.8<BR> 1481.89 FACTELKLV HPV56.E6.48 4173 3200 38 186 62013<BR> 1481.52 FASFADLTVV HPV33.E6.45 42 16 5.3 22 277<BR> 1481.70 FAFKDLCIV HPV45.E6.47 142 1817 12 62 2618<BR> 1481.14 FAFKDLFVV HPV18.E6.47 20 191 5.8 12 35<BR> 1481.32 FAFTDLTIV HPV31.E6.45 137 75 10 24 179<BR> 1491.61 FLCTELKLV DHPV.56.E6.48 A 247 88 143 D379 50150<BR> 1491.79 FLFADLRIV HPV.58.E6.45 A 32 9.4 5.7 85 4744<BR> 1491.38 FLFADLTVV HPV.33.E6.45 A 12 0.3 2.5 23 327<BR> 1491.48 FLFKDLCIV HPV.45.E6.47 A 12 1.3 5.5 9.3 2446<BR> 1491.14 FLFKDLFVV HPV.18.E6.47 A 6.0 0.9 3.5 8.4 274<BR> 1491.07 FLFRDLCIV HPV.16.E6.52 A 16 3.2 8.2 50 582<BR> 1483.01 FLFTDLRIV HPV.52.E6.45 18 1.7 3.3 34 3803<BR> 1491.29 FLFTDLTIV HPV.31.E6.45 A 17 1.3 3.5 20 1904<BR> 1491.18 FLQLFLNTL HPV.18.E7.86 A 17 1.4 2.5 54 12994<BR> 1481.24 FQQLFLNTL HPV18.E7.86 572 18 11 20 280745<BR> 1491.19 FQQLFLNTV HPV.18.E7.86 A 104 18 2.7 21 23131<BR> 1482.12 FVFADLRIV HPV58.E6.45 98 98 4.0 85 334<BR> 1482.03 GALTVTCPL HPV56.E7.92 1271 1969 7183 140 67111<BR> 1491.72 GALTVTCPV HPV.56.E7.92 A 281 3341 3059 105 8374<BR> 1481.53 GICKICLRFL HPV33.E6.61 733 199 310 2089 11432 Table 14<BR> HLA- A2 supertype binding affinit4y (IC50 nM)<BR> Peptide Sequence source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1491.40 GICKLCLRFV HPV.33.E6.61 A 132 32 28 404 19028<BR> 1491.39 GLCKLCLRFL HPV.33.E6.61 A 127 2.5 18 4135 15406<BR> 1491.08 GLLGIVCPI HPV.16.E7.85 A 13 3.0 14 61 4758<BR> 1491.71 GLLTVTCPL HPV.56.E7.92 1 45 18 256 83 68853<BR> 1481.19 GLYNLLIRCL HPV18.E6.97 1757 18 B6.9 2336 9405<BR> 1491.22 GLYNLLIRCV HPV.18.E6.97 A 167 13 5.3 12231 3203<BR> 1491.09 GTLGIVCPV HPV.16.E7.85 A 20 49 68 33 32<BR> 1481.85 HLSEVLEIPL HPV56.E6.17 1032 3.3 586 2063 486<BR> 1491.59 HLSEVLEIPV HPV.56.E6.17 A 508 15 65 507 176<BR> 1491.49 ILYRDCIAYA HPV.45.E6.54 A 108 1.5 3.3 118 3627<BR> 1483.07 IMCLRFLSKI HPV.52.E6.64 1857 483 239 4398 17904<BR> 1491.89 IMCLRFLSKV HPV.52.E6.64 A 2713 574 81 2357 5259<BR> 1481.63 IQQLLMGTV HPV33.E7.79 6592 17489 36 805 >379509.93<BR> 1481.75 ITNTELYNL HPV45.E6.93 9682 52 3456 2002 6153<BR> 1481.71 IVYRDCIAYA HPV45.E6.54 1162 16 3.9 63 1096<BR> 1491.50 IVYRDCIAYV HPV.45.E6.54 A 697 16 4.3 68 74<BR> 1481.74 KITNTELYNL HPV45.E6.92 3256 18 3310 293 378556<BR> 1491.56 KITNTELYNV HPV.45.E6.92 A 199 109 19 114 80759<BR> 1481.54 KLCLRFLSKI HPV33.E6.64 1588 8581 335 1006 17208<BR> 1491.41 KLCLRFLSKV HPV.33.E6.64 A 1759 594 83 5124 8915<BR> 1481.26 KLHELSSAL HPV31.E6.11 178 1.1 3.8 992 >2234606.8<BR> 1491.24 KLHELSSAV HPV.31.E6.11 A 144 2.5 3.7 1168 47805<BR> 1491.62 KLHTCYLIHV HPV.56.E7.54 A 235 71 94 115 6991<BR> 1491.12 KLPDLCTEV HPV.18/45.E6.13 A 65 2.7 11 101 40670<BR> 1491.05 KLPQLCTEV HPV.16.E6.18 A 93 17 37 92 72458 Table 124<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1481.34 KLTNKGICDL HP31.E6.90 205 440 585 484 >96308.68<BR> 1491.30 KLTNKGICDV HPV.31.E6.90 A 344 25 54 190 >41894<BR> 1491.55 KLTNTELYNL HPV.45.E6.92 A 1412 8.0 34 11272 >41369.22<BR> 1491.20 KLTNTGLYNV HPV.18.E6.92 A 106 2.9 4.7 83 688<BR> 1491.13 KLVLELTEV HPV.18.E6.36 A 88 16 24 226 >52914.06<BR> 1481.97 KQHTCYLIHV HPV56.E7.54 1137 1688 39 79 36431<BR> 1481.12 KTVLELTEV HPV18.E6.36 496 3715 41 96 7576<BR> 1481.88 LIDLRISCV HPV56.E6.26 496 96 44 165 4413<BR> 1491.60 LLDLRLSCV HPV.56.E6.26 A 256 1445 708 139 1905<BR> 1491.45 LLDVSIACV HPV.45.E6.25 A 61 48 387 41 3379<BR> 1482.02 LLMGALTVT HPV56.E7.89 140 52 33 164 139561<BR> 1491.70 LLMGALTVV HPV.56.E7.89 A 40 6.9 18 103 1537<BR> 1481.44 LLMGSFGIV HPV31.E7.82 138 42 3.0 20 64853<BR> 1482.25 LLMGTCTIV HPV58.E7.83 76 3.3 6.0 138 29355<BR> 1481.65 LLMGTVNIV HPV33.E7.82 56 2.4 4.2 128 21582<BR> 1491.53 LLQLFLTL HPV.45.E7.87 A 98 1.5 3.4 181 4252<BR> 1491.63 LLYRDDFPYA HPV.56.E6.55 A 162 3.6 145 25 4031<BR> 1481.67 LQDVSIACV HPV45.E6.25 192 3106 6013 108 199469<BR> 1481.82 LQQLFLSTL HPV45.E7.87 4398 146 81 185 115466<BR> 1491.54 LQQLFLSTV HPV.45.E7.87 A 180 39 5.4 67 24253<BR> 1481.17 LTNTGLYNL HPV18.E6.93 13609 20 4987 1835 1580<BR> 1481.90 LVYRDDFPYA HPV56.E6.55 914 178 628 12 305<BR> 1491.654 LVYRDDFPYV HPV.56.E6.55 A 331 2487 693 53 161<BR> 1481.21 MLCMCCKCEA HPV18.E7.61 1728 178 346 750 3782<BR> 1491.15 MLCMCCKCEV HPV.18.E7.61 A 383 123 235 928 1374 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1483.03 MLLGTLQVV HPV.52 E7.84 36 14 9.9 52 2775<BR> 1481.87 PLIDLRLSCV HPV56.E6.25 569 39 6.0 146 1965<BR> 1482.08 QALETSVHEI HPV58.E6.17 1144 123 346 9600 163332<BR> 1491.77 QALETSVHEV HPV.58.E6.17 A 1785 298 925 7345 6502<BR> 1481.48 QALETTIHNI HPV33.E6.17 4288 181 965 3309 247293<BR> 1491.35 QALETTIHNV HPV.33.E6.17 A 1217 155 475 1509 19421<BR> 1481.83 QLFLSTLSFV HPV45.E7.89 106 3.8 11 75 362<BR> 1491.76 QLLETSVHEI HPV.58.E6.17 A 2427 189 923 1186 39909<BR> 1491.34 QLLETTIHNI HPV.33.E6.17 A 1702 168 474 1128 44525<BR> 1491.86 QLLLGTLQVV HPV.52.E7.83 A 85 26 6.3 137 7677<BR> 1482.01 QLLMGALTV HPV56.E7.88 201 990 149 1360 68105<BR> 1481.99 QLLMGALTVT HPV56.E7.88 1235 238 147 1163 97963<BR> 1491.69 QLLMGALTVV HPV.56.E7.88 A 162 12 4.7 208 1358<BR> 1482.24 QLLMGTCTIV HPV58.E7.82 304 20 41 835 119377<BR> 1481.64 QLLMGTVNIV HPV33.E7.81 502 25 158 3476 99642<BR> 1491.91 QLMLLGTLQV HPV.52.E7.82 A 77 95 68 1298 9110<BR> 1483.04 QMLLGTLQV HPV.52.E7.83 374 186 251 1523 32794<BR> 1483.05 QMLLGTLQVV HPV.52.E7.83 77 12 6.0 120 2977<BR> 1483.09 QQMLLGTLQV HPV.52.E7.82 675 331 344 71 2012<BR> 1481.04 QQYNKPLCDL HPV16.E6.97 25370 12085 52 2166 121435<BR> 1481.23 RAFQQLFLNT HPV18.E7.84 170400 0 4270 114 142375<BR> 1481.06 RLCVQSTHV HPV16.E7.66 1883 250 128 725 25116<BR> 1481.41 RLCVQSTQV HPV31.E7.66 1416 1941 152 2084 78507<BR> 1491.93 RLLHELCEV HPV.52.E6.10 A 25 18 61 93 >63492.06<BR> 1491.65 RLVQQLLMGA HPV.56.E7.84 A 873 1626 9.4 875 >37331.55 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1481.07 RTLEDLLMGT HPV16.E7.77 17556 701 7397 102 >60329.7<BR> 1481.46 RTLHDLCQA HPV33.E6.10 8121 34 678 96 61604<BR> 1482.06 RTLHDLCQA HPV58.E6.10 5274 142 473 73 >447213.6<BR> 1483.11 RTLHELCEV HPV.52.E6.10 82 46 341 7.0 5670<BR> 1481.98 RVVQQLIMGA HPV56.E7.84 1587 7065 372 102 13817<BR> 1491.66 RVVQQLLMGV HPV.56.E7.84 A 254 2412 8.8 69 2336<BR> 1481.27 SALEIPYDEL HPV31.E6.17 11239 2263 111943 306 135671<BR> 1481.68 SIACVYCKA HPV45.E6.29 8938 31 599 8665 2724<BR> 1491.87 SLHEIRLQCV HPV.52.E6.22 A 1003 12 10 7923 11701<BR> 1481.66 SLQDVSIACV HPV45.E6.24 67 22 27 251 82033<BR> 1491.67 SLYGATLESI HPV.56.E6.85 A 451 23 23 401 2114<BR> 1491.16 SLYGDTLEKL HPV.18.E6.84 A 139 2.5 11 275 7640<BR> 1482.15 SLYGDTLEQT HPV58.E6.82 408 9.7 65 1005 261482<BR> 1491.82 SLYGDTLEQV HPV.58.E6.82 A 251 9.2 27 306 257<BR> 1491.51 SLYGETLEKI HPV45.E6.84 A 301 4.0 25 358 3491<BR> 1491.42 SLYGNTLEQT HPV.33.E6.82 A 216 2.5 9.5 513 4712<BR> 1482.10 SVHEIELKCV HPV58.E6.22 12550 1214 1636 871 351<BR> 1483.06 SVHEIRLQCV HPV.52.E6.22 1262 130 262 369 38<BR> 1481.93 SVYGATLESI HPV56.E6.85 813 25 27 110 470<BR> 1491.68 SVYGATLESV HPV.56.E6.85 A 248 12 19 131 35<BR> 1481.16 SVYGDTLEKL HPV18.E6.84 2238 19 82 130 909<BR> 1491.17 SVYGDTLEKV HPV.18.E6.84 A 198 9.6 5.6 130 29<BR> 1481.73 SVYGETLEKI HPV45.E6.84 995 14 23 241 1529<BR> 1491.52 SVYGETLEKV HPV.45.E6.84 A 320 7.8 23 171 30<BR> 1481.55 SVYGNTLEQT HPV33.E6.82 1056 75 32 560 3065 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1491.43 SVYGNTLEQV HPV.33.E6.82 A 157 3.5 12 70 10.2<BR> 1481.33 SVYGTTLEKL HPV31.E6.82 11249 40 932 240 1095<BR> 1481.50 TIHNIELQCV HPV33.E6.22 3411 231 273 301 2630<BR> 1481.62 TIQQLLMGTV HPV33.E7.78 6902 5860 26 7943 3844<BR> 1481.09 TLEDLLMGT HPV16.E7.78 13241 317 1162 2126 >67134.51<BR> 1481.08 TLEDLLMGTL HPV16.E7.78 12724 474 3738 81842 >60329.7<BR> 1491.10 TLGIVCPV HPV.16.E7.86 A 9.0 3.2 7.2 24 165<BR> 1491.06 TLHDHLECV HPV.16.E6.29 A 3.6 0.5 1.9 92 2947<BR> 1481.47 TLHDLCQAL HPV33.E6.11 1404 2.7 40 2182 70390<BR> 1482.07 TLHDLCQAL HPV58.E6.11 1043 8.3 46 11185 130225<BR> 1491.73 TLHDLCQAV HPV.58.E6.11 A 331 13 15 10585 2288<BR> 1491.01 TLHEYMLDV HPV.16.E7.7 A 74 4.4 9.8 78 2424<BR> 1491.37 TLHNIELQCV HPV.33.E6.22 A 206 3.4 7.5 584 2475<BR> 1481.57 TLKEYVLDL HPV33.E7.7 8004 70 12 117530 615105<BR> 1491.11 TLQDIVLHV HPV.18.E7.7 A 20 23 7.0 684 1683<BR> 1481.95 TLQDVVLEL HPV56.E7.7 24 7.8 23 649 13838<BR> 1491.58 TLQDVVLEV HPV.56.E7.7 A 52 73 25 90 2275<BR> 1481.36 TLQDYVLDL HPV31.E7.7 209 32 90 2294 91800<BR> 1491.23 TLQDYVLDV HPV.31.E7.7 A 28 30 6.1 711 6181<BR> 1481.77 TLQEIVLHL HPV45.E7.7 124 20 155 2692 254071<BR> 1491.44 TLQEIVLHV HPV.45.E7.7 A 19 30 5.1 309 2457<BR> 1481.81 TLQQLFLSTL HPV45.E7.86 10329 145 173 1917 295602<BR> 1482.23 TLQQLLMGT HPV58.E7.79 5407 4161 343 19328 355458<BR> 1483.08 TLQQMLLGT HPV.52.E7.80 3994 1876 47 940 66940<BR> 1483.15 TLQQMLLGTL HPV.52.E7.80 11590 1207 82 94848 63961 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1491.90 TLQQMLLGV HPV.52.E7.80 A 42 17 4.6 28 454<BR> 1483.20 TLQVVCPGCA HPV.52.E7.88 173805 8146 446 226554 48401<BR> 1482.17 TLREYILDL HPV58.E7.7 13653 1372 6.2 148231 >389869.03<BR> 1483.19 TLRLCIHSTA HPV.52.E7.66 69139 5407 329 59923 9270<BR> 1481.40 TLRLCVQST HPV31.E7.64 6394 22268 136 28285 4163<BR> 1481.25 TLSFVCPWCA HPV18.E7.93 1611 221 521 27321 13228<BR> 1481.84 TLSFVCPWCA HPV45.E7.94 1499 292 763 3657 7714<BR> 1491.57 TLSFVCPWCV HPV.45.E7.94 A 786 91 370 4357 348<BR> 1491.21 TLSFVCPWCV HPV.18.E7.93 A 368 118 255 7573 2299<BR> 1483.10 VLEESVEHI HPV.52.E6.18 426 22 354 831 >56545.93<BR> 1491.92 VLEESVHEV HPV.52.E6.18 A 236 30 163 1283 198762<BR> 1481.15 VVYRDSIPHA HPV18.E6.54 20174 261 393 702 15021<BR> 1481.91 YAVCRVCLL HPV56.E6.63 9827 27573 937 327 6152<BR> 1482.18 YILDLHPEPT HPV58.E7.11 136 639 28 1236 219394<BR> 1491.75 YILDLHPEPV HPV.58.E7.11 A 91 69 5.8 64 335<BR> 1483.02 YILDLQPET HPV.52.E7.11 449 2778 467 186 67516<BR> 1483.16 YILDLQPETT HPV.52.E7.11 428 1684 336 7730 66404<BR> 1491.94 YILDLQPETV HPV.52.E7.11 A 35 11 10 131 264<BR> 1491.84 YILDLQPEV HPV.52.E7.11 A 145 166 245 78 6387<BR> 1491.80 YLCGTTVRL HPV.58.E7.60 A 246 12 43 1369 2553<BR> 1491.46 YLFAFKDLCI HPV.45.E6.45 A 24 2.2 8.1 81 4067<BR> 1491.74 YLLDLHPEPT HPV.58.E7.11 A 82 15 29 1456 100474<BR> 1491.25 YLLDLQPEA HPV.31.E7.11 A 20 2.2 6.6 136 46519<BR> 1491.27 YLLDLQPEAT HPV.31.E7.11 A 24 16 6.4 975 >57908.91<BR> 1491.02 YLLDLQPET HPV.16.E7.11 A 16 57 78 159 >47202.54 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1491.03 YLLDLQETT HPV.16.E7.11 A 93 18 16 565 39475<BR> 1491.04 YMLDLQPETV HPV.16.E7.11 A 19 1.9 4.5 86 5446<BR> 1202.13 YMLDLQPEV HPV.16.E7.11 A 19 1.6 14 25 18840<BR> 1481.69 YQFAFKDLCI HPV45.E6.45 87 95 23 41 68211<BR> 1491.47 YQFAFKDLCV HPV.45.E6.45 A 15 1.3 4.2 10.0 3698<BR> 1483.18 YQYSLYGKTL HPV.52.E6.79 91919 2095 297 4709 74927<BR> 1482.21 YTCGTTVRL HPV58.E7.60 841 32 950 530 376<BR> 1491.81 YTCGTTVRV HPV.58.E7.60 A 2301 845 353 1061 42<BR> 1481.37 YVLDLQPEA HPV31.E7.11 822 385 3342 92 7409<BR> 1491.28 YVLDLQPEAV HPV.31.E7.11 A 28 26 6.4 115 222<BR> 1491.26 YVLDLQPEV HPV.31.E7.11 A 27 169 430 76 849<BR> 1481.58 YVLDLYPEPT HPV33.E7.11 118 2490 324 332 44993<BR> 1491.33 YVLDLYPPV HPV.33.E7.11 A 25 12 3.4 29 29<BR> 1419.61 ALFPPEGVSV PAP. 15 1.1 18 119 4444<BR> F063.58 ALGIGILTV MART1.27 A 11<BR> 1389.14 ALGTTCYV PSA.143 A 93 6.7 12 288 29169<BR> F188.048 ALLTILGGGL 8.7<BR> F188.039 ALNIWDRFDV 386<BR> F188.010 ALVCNTLWGV 18<BR> F188.033 ALWECGCATL 14<BR> F063.59 AMGIGILTV MART1.27 A 15<BR> 63.0109 DLMLLRLSEPV Kallikrein2.120 A 70 66 31 119 2759<BR> 1485.06 ELCCEHLWQI Gliadin.155 A 1440 25427 5727 133 32<BR> 1485.07 ELCCQHLWEI Gliadin.155 A 1161 1257 1639 147 37<BR> 1485.04 ELIPCMDVV Gliadin.123 A 5190 1491 101 1361 75 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 1485.05 ELIPCMDVVL Gliadin.123 A 4678 1917 15851 2081 329<BR> 1485.08 ELQPFLQPQL Gliadin.57 A 14568 1707 5444 170276 477<BR> F188.052 FILEYQDSL 218<BR> F188.077 FIPLGLFWV 131<BR> F188.030 FLDSGFVGL 21<BR> F188.057 FLIFFEFLL 81<BR> F188.075 FLLGLIFFI 166<BR> F188.011 FLLRGSNNYV 134<BR> F188.024 FLNTPWILGI 186<BR> F188.086 FLPLALLWV 17<BR> F188.009 GIGLDLLPFV 434<BR> F188.001 GLAATHMCV 195<BR> F188.089 GLFERENCV 214<BR> F188.037 GLFGVKGTTV 221<BR> F188.027 GLFLGFSSL 449<BR> 1419.62 GLHGQDLFGV PAP 12 2.3 3.1 18 80000<BR> F188.080 GLIFFIPLGL 111<BR> F188.045 GLLPAVPMFI 29<BR> F188.050 GLLVGLLPAV 19<BR> F188.051 GLPEELPPV 25<BR> F188.091 HLNPLSPNV 113<BR> F188.029 ILALIQTPL 16<BR> F188.083 LIFLPLALL 94<BR> F188.076 LIFNYPGV 146<BR> F188.093 LIYNYPGV 174 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> F188.058 ILQEAEQMV 237<BR> 1485.13 ILQEQLPCM Gliadin.119 A 366 1501 5350 2058 >75515.83<BR> F188.082 ILSDDVIKEV<BR> F188.098 ILVYNYPGV<BR> F188.044 ILYRSTAHL<BR> 1389.06 ILYSAHDTTV PAP.384 A 391 1.1 13 1471 6218<BR> 1418.26 ITYSAHDTTV PAP.284 A 4167 115 238 154 82<BR> 1389.07 IVYSAHDTTV PAP.284 A 7710 91 623 671 745<BR> 1489.31 KILSVFFLAL Pf.EXP1.2 311 18 499 53 1940<BR> F188.100 KLIGANILV 134<BR> F188.094 KLLGANILI 122<BR> F188.085 KLVGWNDISV 46<BR> 1419.58 LLALFPPEGV PAP. 5.0 0.7 1.6 148 163<BR> F188.061 LLFFEEFLLV 209<BR> F188.095 LLIGLIPPL 34<BR> F188.070 LLLDVIPLSL 19<BR> F189.10 LLMWITQCFL NY-ESO-1.158 43<BR> F188.043 LLPAVPMFI 353<BR> 1419.64 LLPPYASCHV PAP. 88 15 16 97 5333<BR> F188.063 LLQAALLQSV 1127<BR> F188.047 LLVGLLPAV 47<BR> 1419.69 LLWQPIPVHV PAP. 25 1.8 18 285 62<BR> F189.08 LMWITQCFL NY-ESO-1.159 78<BR> 1419.59 LVALFPPEGV PAP. 16 17 4.8 463 28<BR> 1389.10 MLLRISEPV PSA.118 A 48 29 48 686 432 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> 7.0045 MPSLTMACM LCMV.NP.175 323<BR> F188.087 NLLVFNYPGI 485<BR> 63.0128 PLVCNGVLQGV Kallikrein2.216 A 92 421 36 210 1633<BR> 1419.17 PLVCNGVLQGV Kallikrein2.216 A 26 126 19 264 4211<BR> 1485.09 QLEPFLQPQL Gliadin.57 A 2741 35 4200 4061 41451<BR> F188.013 QLFSLLKITIV 215<BR> 1485.10 QLQPFLEPQL Gliadin.57 A 2417 103 2899 6540 >74461.3<BR> 1485.11 QLQPFLQPEL Gliadin.57 A 216 20 638 3760 5514<BR> F188.105 RLATLSFSM 35<BR> F188.101 RLFGWGTKAV 136<BR> F188.031 RLIEKQSQV 378<BR> F188.078 RLLEIIWGV 16<BR> F188.007 RLLNLSFFV 25<BR> F188.036 RLNSLPYUI 118<BR> F188.056 RLQEENAQL 252<BR> F188.065 SLADIQAALV 63<BR> F188.067 SLQDAVTNI 194<BR> 1419.52 SLSLGFLFLV PAP. 1.9 3.9 17 42 348<BR> 1419.50 SLSLGFLFV PAP. 77 25 21 93 26667<BR> F188.035 SLSNGVVEL 261<BR> F188.017 SLWGSPSDI 211<BR> F096.13 SVYDFFVWL 36 169 226 10.0 1.2<BR> F001.02 SXPSGGXGV A 234<BR> 1389.03 TLMSAMTNV PAP.112 A 628 14 35 2159 482<BR> F188.020 TLTGLSIPV 23 Table 14<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*6802<BR> F001.01 TXWVDPYEV A 24<BR> 1485.01 VELQSTYQL Gliadin.114 A 929 15 11311 2183 24884<BR> F188.016 VLGQFVFEV 9.7<BR> F188.102 VLIGLILPL 140<BR> F188.069 VLLLDVIPL 29<BR> 1485.02 VLQESTYQL Gliadin.144 A 88 2.3 17 267 16437<BR> 1485.03 VLQQSTYEL Gliadin.144 A 147 8.5 302 356 12794<BR> 63.0105 VLVHPQWVLTV Kallikrein2.53 A 11 1.6 3.0 13 4444<BR> 1419.11 VLVHPQWVLTV Kallikrein2.53 A 11 1.5 16 31 8889<BR> 60.0180 VLVHPQWVV Kallikrein2.53 A 564 65 1982 3199 16000<BR> F188.106 VLWKDGVSFVF 117<BR> F188.025 VMNNVPVML 255<BR> 1418.24 VTAKELKFV PAP.30 A 7143 2688 40 137 26667<BR> F189.09 WITQCFLPV NY-ESO-1.161 173<BR> F188.015 YAFSPMFEV 16<BR> F188.107 YLNDYVLPYA 13<BR> F188.059 YMYGITDSL 112<BR> F188.040 YVFDRILKV 43<BR> F188.108 YLPYASVSI 234 Table 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> F108.09 FVNHRFTVL Clone4.551 373<BR> F108.13 GIRPYEILA Clone4.135 34<BR> F108.15 WVFPESISPV Cloen4.302 120<BR> 36.0132 ALKMTMASV Flu.NS1.76230<BR> 36.0148 ALLKHRFEI Flu.RRP2.70 128<BR> 36.0189 ALLKHRFEII Flu.RRP2.70 226<BR> 36.0149 CLLQSLQQI Flu.RRP2.584 160<BR> 36.0138 FLEESHPGI Flu.RRP1.94 118<BR> 36.0133 FLWHVRKRV Flu.NS1.14 205<BR> 36.0128 GLISLILQI Flu.NRAM.18 38<BR> 36.0139 GMFNMLSTV Flu.RRP1.410 28<BR> 36.0129 GMGWLTIGI Flu.NRAM.172 143<BR> 36.0135 LLLEVEQEI Flu.NS2.105 239<BR> 36.0190 LLMDALKLSI Flu.RRP2.283 38<BR> 36.0158 LMDALKLSI Flu.RRP2.284 41<BR> 36.0185 MLSTVLGVSI Flu.RRP1.414 252<BR> 36.0186 NLYNIRNLHI Flu.RRP1.597 63<BR> 36.0144 RLIDFLKDV Flu.RRP1.162 58<BR> 36.0145 RLNKRSYLI Flu.RRP1.211 90<BR> 36.0167 RMQFSSFTV Flu.RRP3.630 28<BR> 36.0161 SMIEAESSV Flu.RRP2.594 185<BR> 36.0172 WMMAMKYPI Flu.RRP3.49 73<BR> F063.12 ALWGQYWQV gp100.154 A 2.3<BR> F063.08 ATWGQYWQV gp100.154 A 7.7<BR> F063.37 FLDQVPFSV gp100.209 A 2.4<BR> F063.43 FLEPGPVTA gp100.280 A 113<BR> F063.15 FLWGQYWQV gp100.154 A 2.9 Table 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> F063.21 FTDQVPFSV gp100.209 A 61<BR> F063.06 FTWGQYWQV gp100.154 A 1.8<BR> F063.20 IIDQVPFSV gp100.209 A 46<BR> F063.33 ILAQVPFSV gp100.209 A 11<BR> F063.18 ILDQVPFSV gp100.209 A 13<BR> F063.31 ILFQVPFSV gp100.209 A 2.1<BR> F063.34 ILMQVPSFV gp100.209 A 7.6<BR> F063.35 ILSQVPFSV gp100.209 A 20<BR> F063.30 ILWQVPFSV gp100.209 A 1.7<BR> F063.32 ILYQVPFSV gp100.209 A 6.9<BR> F063.19 IMDQVPFSV gp100.209 A 21<BR> F063.27 ITAQVPFSV gp100.209 A 134<BR> F063.25 ITFQVPFSV gp100.209 A 68<BR> F063.28 ITMQVPFSV gp100.209 A 42<BR> F063.24 ITWQVPFSV gp100.209 A 35<BR> F063.26 ITYQVPFSV gp100.209 A 33<BR> F063.04 KIWGQYWQV gp100.154 A 4.9<BR> F063.02 KLWGQYWQV gp100.154 A 2.1<BR> F063.03 KMWGQYWQV gp100.154 A 6.6<BR> F063.11 KTFGQYWQV gp100.154 A 48<BR> F063.10 KTYGQYWQV gp100.154 A 32<BR> F063.13 LLWGQYWQV gp100.154 A 1.6<BR> F063.09 LTWGQYWQV gp100.154 A 3.5<BR> F063.36 WLDQVPFSV gp100.209 A 12<BR> F063.14 WLWGQYWQV gp100.154 A 4.6<BR> F063.05 WTWGQYWQV gp100.154 A 72<BR> F063.50 YLAPGPVTA gp100.280 A 9.4 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> F063.53 YLAPGPVIV gp100.280 A 15<BR> F063.38 YLDQVPFSV gp100.209 A 2.6<BR> F063.42 YLEPGPVTI gp100.280 A 68<BR> F063.41 YLEPGPVTL gp100.280 A 146<BR> F063.40 YLEPGPVTV gp100.280 A 56<BR> F063.47 YLFPGPVTA gp100.280 A 3.7<BR> F063.55 YLFPGPVTV gp100.280 A 5.9<BR> F063.48 YLMPGPVTA gp100.280 A 4.4<BR> F063.51 YLMPGPVTV gp100.280 A 12<BR> F063.49 YLSPGPVTA gp100.280 A 48<BR> F063.52 YLSPGPVTV gp100.280 A 24<BR> F063.16 YLWGQYWQV gp100.154 A 1.7<BR> F063.46 YLWPGPVTA gp100.280 A 3.4<BR> F063.56 YLWPGPVTV gp100.280 A 7.5<BR> F063.45 YLYPGPVTA gp100.280 A 17<BR> F063.54 YLYPGPVTV gp100.280 A 9.1<BR> F063.23 YTDQVPFSV gp100.209 A 94<BR> F063.07 YTWGQYWAV gp100.154 A 3.5<BR> 33.0038 FFPSDYFPSV HBV.core.18 A 1553 1496 739 2171 225 1538<BR> 33.0037 FIPSDYFPSV HBV.core.18 A 29 3 28 4 2 133<BR> 33.0027 FLKSDYFPSV HBV.core.18 A 15 11 1 16 22 3636<BR> 33.0028 FLPKDYFPSV HBV.core.18 A 5.6 5.3 4.8 7.3 3.0 1860<BR> 33.0030 FLPSDKFPSV HBV.core.18 A 9.4 6.26 1.62 11.05 9.58 500<BR> 33.0032 FLPSDYFKSV HBV.core.18 A 20 21 2 58 13 8889<BR> 33.0033 FLPSDYFPKV HBV.core.18 A 36 26 50 24 16 1905<BR> 33.0044 FLPSDYFPSI HBV.core.18 A 25 7 67 18 15 2051<BR> 33.0043 FLPSDYFPSL HBV.core.18 A 31 10 47 14 53 8889 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 33.0048 FLPSDYFPSP HBV.core.18 A 220 10852 2122 11467 314 80000<BR> 33.0049 FLPSDYFPST HBV.core.18 A 166 96 301 155 27 80000<BR> 33.0031 FLPSDYKPSV HBV.core.18 A 555 1254 136 2107 2301 80000<BR> 33.0029 FLPSKYFPSV HBV.core.18 A 8.5 5.74 0.63 7.23 5.63 1038.96<BR> 33.0042 FTPSDYFPSV HBV.core.18 A 423 5.5 419 15 12 73<BR> 1369.32 FVGPLLVLQV HBV.env.171 A 927 51 176 35 21 241<BR> 1369.31 FVLLLCLIFV HBV.env.249 A 1992 306 9032 7246 9027 11364<BR> 1369.03 FVLSLGIHV HBV.pol.562 A 45 400 2837 1414 133 62<BR> 1369.08 FVLSLGIHV HBV.pol.573 A 439 885 18018 14098 487 1303<BR> 33.0036 FVPSDYFPSV HBV.core.18 A 77 2 101 3 4 80<BR> 55.0123 GLSRYVPRL HBV.pol.455 A 94<BR> 1369.01 GVLGWSPQV HBV.env.62 A 22 157 393 37 28 9357<BR> 1369.09 GVLGWSPQV HBV.env.73 A 21 134 637 52 21 9886<BR> 1369.28 GVSPTVWLSV HBV.env.359 A 197 77 4.8 81 55 549<BR> 1369.02 HVYSHPIIV HBV.pol.1076 A 151 1921 14 11026 1200 122<BR> 1369.10 HVYSHPIIV HBV.pol.502 A 255 3562 11 9038 1043 204<BR> 1369.26 IVRGTSFVYV HBV.pol.773 A 36765 5298 68 1828 5386 1222<BR> 1369.34 IVRGTSFVYV HBV.pol.773 A 15661 4367 88 2440 2468 1085<BR> 1369.24 IVSTLPETTV HBV.core.168 A 7447 38 554 403 994 4538<BR> 33.0025 KLPSDYFPSV HBV.core18 A 24 6 14 12 2 40000<BR> 1172.01 KQYLNLYPV HBV.pol.668 85 22 35 28 >30237.16<BR> 1369.23 LVDYQGMLPV HBV.env.271 A 994 1037 510 1118 188 9863<BR> 1369. 30 LVVLQAGFFV HGV.env.175 A 1999 1105 6107 732 191 900<BR> 1369.12 LVWFHISCV HBV.core.129 A 177 272 97 2179 385 467<BR> 1369.07 MVWYWPGSV HBV.env.360 A 169 532 903 416 45 17<BR> 1369.13 PVLPIFFCV HBV.env.377 A 8.7 3140.36 13642.6 43000 21.88 1813.99<BR> 1369.18 PVLPIFFCV HBV.env.388 A 16 3538 23419 43000 17 1621 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 924.20 QFLPSDFFPSV HBV.core.27 A 394<BR> 924.17 RFLPSDFFPSV HBV.core.27 A 481<BR> 1369.14 VVQAGFFLV HBV.env.177 A 438 78 2484 785 81 624<BR> 1369.17 VVQAGFFLY HBV.env.177 A 1708 226 2244 855 28 753<BR> 1369.19 WVLRGTSFV HBV.pol.770 A 500 1023 125 495 86 351<BR> 924.19 YFLPSDFFPSV HBV.core.27 A 151<BR> 1369.15 YVDDVVLGV HBV.pol.538 A 18 14 70 91 16 360<BR> 1369.20 YVDDVVLGV HBV.pol.549 A 16 2 108 112 16 412<BR> 1369.25 YVHTLWKAGV HBV.pol.147 1826 324 62 429. 1081 169<BR> 1369.16 YVVSFGVWV HBV.core.147 A 54 76 33 32 64 8<BR> 35.0083 ALVAYQATV HCV 68 632 4 521 167 1778<BR> 1369.05 AVSTGLIHV HCV.NS1.686 A 2497 891 336 1506 120 4855<BR> 1369.04 IVSPGALVV HCV.NS4.1891 A 19305 3749 184 2115 2990 11495<BR> 13.0060 KLVAYQATV HCV 73 282 6 265 76 8889<BR> 1369.27 RVHGLSAFSV HCV.NS5.2918 A 512 389 398 39 51 684<BR> 35.0071 YFVAYQATV HCV 1071 15739 139 7049 16645 186<BR> 35.0070 YIVAYQATV HCV 58 57 3 41 27 31<BR> 35.0062 YLKAYQATV HCV 32 166 3 83 318 2222<BR> 35.0084 YLQAYQATV HHCV 36 140 4 52 36 80<BR> 35.0086 YLVAAQATV HCV 40 77 4 61 70 174<BR> 35.0064 YLVAKQATV HCV 183 516 5.9 243 208 6154<BR> 35.0087 YLVAYAATV HCV 72 34 3 63 40 276<BR> 35.0065 YLVAYKATV HCV 33 423 7 218 205 808<BR> 35.0089 YLAYQAFV HCV 9.1 19.08 2.65 9.58 22.92 38.1<BR> 35.0067 YLVAYQAKYV HCV 70 104 5 65 144 381<BR> 35.0078 YLVAYQATF HCV 232 6806 53 3457 3322 40000<BR> 35.0077 YLVAYQATI HCV 7 8 305 4 97 166 1270 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 35.0076 YLVAYQATL HCV 17 44 3 26 75 1538<BR> 35.0082 YLVAYQATT HCV 97 3774 2 1475 953 26667<BR> 35.0066 YLVAYQKTV HCV 303 875 5.5 380 310 1127<BR> 35.0088 YLVAYQQTV HCV 40 82 5 41 57 727<BR> 35.0063 YLVKYQATV HCV 45 75 4 50 48 276<BR> 35.0085 YLVQYQATV HCV 15 44 2 35 29 250<BR> 35.0073 YQVATQATV HCV 19 25 4 10 25 3636<BR> 35.0075 YTVAYGATV HCV 29 56 16 31 28 1<BR> 35.0069 YVVAYQATV HCV 60 49 8 27 39 2<BR> 1390.01 ALBRWGLLL Her2/neu.5 A 245 0.6 12 5983 8071<BR> 1382.03 ATBRWGLLV Her2/neu.5 A 14994 240 372 2221 1759<BR> 1382.04 AVBRWGLLV Her2/neu.5 A 9517 249 146 2166 4778<BR> F106.05 CLLTLLGSYI HIV 167<BR> F106.29 FIISLSLLI HIV 76<BR> F106.34 FITVLIFKV HIV 115<BR> F106.14 FLSLQIMDYL HIV 142<BR> F106.19 HFSIAFITV HIV 34<BR> F106.11 IISLSLLIGV HIV 161<BR> 54.0063 ILHEPVHGV HIV.pol.476 A 50<BR> 55.0158 ILKDPVHGV HIV.pol.476 A 355<BR> 55.0170 ILKEFVHGV HIV.pol.476 A 58<BR> 1304.09 ILKEPVMGV HIV.pol.476 A 218<BR> 55.0169 ILKESVHGV HIV.pol.476 A 150<BR> 55.0168 ILKETVHGV HIV.pol.476 A 295<BR> 55.0167 ILKFPVHGV HIV.pol.476 A 136<BR> 55.0166 ILKYPVHGV HIV.pol.476 A 306<BR> 55.0155 ILEPVHGV HIV.pol.476 A 49 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 55.0153 ILVEPVHGV HIV.pol.476 A 459<BR> 1304.07 ILYEPVHGY HIV.pol.476 A 34<BR> 1304.15 IMHEPVHGV HIV.pol.476 A 83<BR> 1304.10 IMKEPVHGV HIV.pol.476 A 280<BR> 1304.17 IMKEPVYGV HIV.pol.476 A 187<BR> 1304.14 IMYEPVIRG HIV.pol.476 A 32<BR> 1304.01 KLTPLCVTV HIV.env.134 A 20<BR> F106.31 KMMHFSIA HIV 251<BR> 1304.02 KMTPLCVTL HIV.env.134 A 20<BR> 1304.03 KMTPLCVTV HIV.env.134 A 9.3<BR> F106.04 LLGSYLELPA HIV 499<BR> F106.16 MLFIISLSL HIV 38<BR> 1304.04 MLKEPVHGV HIV.pol.476 A 110<BR> 1304.11 MMKEPVHGV HIV.pol.476 A 97<BR> F106.10 QIMDYLICL HIV 3.9<BR> F106.03 QLLDFCLSI HIV 0.56<BR> 11.0050 RIHIGPGRA HIV.gp160.311 386<BR> F106.33 RLIKCMNSV HIV 387<BR> F106.12 SLQIMDYLL HIV 67<BR> F106.36 TLGSYIEL HIV 19<BR> F106.26 TLQLLDFCL HIV 17<BR> F106.20 TMLFIISLSL HIV 155<BR> 1304.06 WLKEPVHGV HIV.pol.476 A 350<BR> F106.35 YLLCLLTLL HIV 21<BR> F106.18 YLLPFLSLQI HIV 3.2<BR> 1304.12 YMKEPVHGV HIV.poL.476 A 70<BR> Hafler C LLNGYPVYV HTLV.11 A 23 302 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> F018.03 LLLDVPTAAVQAIP30-P15 41<BR> F018.02 LLLDVPTAAV IP30-P16 8.6<BR> 71.0001 ALGTTAYV Kallikrein2.147 A 479 27 62 37000 6970<BR> 1418.12 ALGTTCYV Kallikrein2.147 A 18 5 16 1028 80000<BR> 71.0002 ALGTTPYV Kallikrein2.147 A 879 1232 273 37000 80000<BR> 71.0003 ALGTTSYV Kallikrein2.147 A 1753 120 96 37000 3508<BR> 71.0004 ALGTTTYV Kallikrein2.147 A 422 72 46 18500 10518<BR> 71.0005 ALGTTVYV Kallikrein2.147 A 59 12 15 16547 >80000<BR> 1418.36 ALPLIQSRIV Kallikrein2.17 A 8333 1870 233 7400 80000<BR> 71.0006 ALSVGATGV Kallikrein2.9 A 774 94 40 3482 11795<BR> 1418.15 ALSVGCTGV Kallikrein2.9 A 24 17 9 264 40000<BR> 71.0007 ALSVGPTGV Kallikrein2.9 A 770 176 119 37000 >80000<BR> 71.0008 ALSVGSTGV Kallikrein2.9 A 2428 72 77 12827 >80000<BR> 71.0009 ALSVGTTGV Kallikrein2.9 A 2250 47 142 12333 >80000<BR> 71.0010 ALSVGVTGV Kallikrein2.9 A 26 14 8 671 >80000<BR> 1418.34 ATSVGCTGAV Kallikrein2.9 A 7143 8600 385 3364 8889<BR> 1418.16 AVPLIQSRV Kallikrein2.17 A 3846 1536 127 2313 73<BR> 1418.33 AVSVGCTGAV Kallikrein2.9 A 2381 2688 189 740 20000<BR> 1418.68 DLCARAYSEKV Kallikrein2.182 A 16667 2263 1282 12333 211<BR> 71.0079 DLLLLRLSEPV Kallikrein2.120 A 1070 528 115 870 10000<BR> 63.0109 DLMLLRLSEPV Kallikrein2.120 A 70 66 31 119 2759<BR> 1418.70 DTCARAYSEKV Kallikrein2.182 A 50000 1792 1786 7400 421<BR> 1418.32 DTVLSIALSV Kallikrein2.3 A 3571 1000 192 712 178<BR> 1418.69 DVCARAYSEKV Kallikrein2.182 A 50000 1593 67 5286 308<BR> 71.0011 FLLAAGLWT Kallikrein2.195 A 17 368 112 302 40000<BR> 71.0012 FLLPAGLWT Kallikrein2.195 A 2.7 375 70 134 >80000<BR> 71.0013 FLLSAGLWT Kallikrein2.195 A 41 374 239 66 32660 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 71.0014 FLLTAGLWT Kallikrein2.195 A 14 193 190 259 40000<BR> 71.0077 FLRPRSLQAV Kallikrein2.165 A 353 30 12 1013 80000<BR> 1419.44 FLRPRSLQBV Kallikrein2. 38 2 6 1850 80000<BR> 1435.02 FLRPRSLQPV Kallikrein2. 4545 113 111 3700 80000<BR> 1435.01 FLRPRSLQSV Kallikrein2. 1389 36 26 5286 80000<BR> 71.0076 FLRPRSLQTV Kallikrein2.165 A 741 112 220 1379 21036<BR> 71.0075 FLRPRSLQVV Kallikrein2.165 A 363 16 19 254 26667<BR> 71.0016 FMLAAGLWV Kallikrein2.195 A 2.2 34 2.8 11 40000<BR> 1418.22 FMLCAGLWV Kallikrein2.195 A 29 12 91 51 80000<BR> 71.0017 FMLPAGLWV Kallikrein2.195 A 7.3 41 8.9 6.3 27734<BR> 71.0018 FMLSAGLWV Kallikrein2.195 A 3.0 15 4.4 10 19230<BR> 71.0019 FMLTAGLWV Kallikrein2.195 A 5.0 47 17 15 26667<BR> 71.0020 FMLVAGLWV Kallikrein2.195 A 13 277 14 25 40000<BR> 71.0022 FTLPAGLWT Kallikrein2.195 A 1469 21500 18257 149 18566<BR> 1418.51 FTRPRSLQCV Kallikrein2.165 A 4169 1000 4 514 5333<BR> 71.0026 FVLAAGLWT Kallikrein2.195 A 1150 1669 1601 166 34943<BR> 71.0027 FVLPAGLWT Kallikrein2.195 A 719 24826 6276 115 46188<BR> 71.0028 FVLSAGLWT Kallikrein2.195 A 1578 13598 8771 304 56569<BR> 1418.50 FVRPRSLQCV Kallikrein2.165 A 1389 269 11 474 8000<BR> 1418.63 GLPTQEPALGV Kallikrein2.140 A 1136 796 91 3700 80000<BR> 67.0063 GTVPLIQSRI Kallikrein2.16 A >61224.1@ 6448 11919 6678 85<BR> 1419.46 HLLSNDMBARA Kallikrein2. A 3571 143 105 2313 80000<BR> 1418.67 HLLSNDMCARV Kallikrein2.177 A 26 1 5 37 860<BR> 1418.20 HLLSNDMCV Kallikrein2.177 A 119 102 278 176 80000<BR> 71.0031 ILLRISEPV Kallikrein2.122 A 112 61 177 244 24228<BR> 71.0080 ILLSVGATGAV Kallikrein2.8 A 2129 1882 187 2383 33193<BR> 1418.57 ILLSVGCTGAV Kallikrein2.8 A 36 33 36308 10000 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 71.0081 ILLSVGPTGAV Kallikrein2.8 A 971 205 85 7400 11795<BR> 71.0082 ILLSVGSTGAV Kallikrein2.8 A 1927 1749 214 15105 >56568.54<BR> 71.0083 ILLSVGTTGAV Kallikrein2.8 A 2221 986 144 5286 >56568.54<BR> 71.0084 ILLSVGVTGAV Kallikrein2.8 A 229 136 22 481 10053<BR> 1418.59 ITLSVGCTGAV Kallikrein2.8 A 294 134 40 206 121<BR> 1418.58 IVLSVGCTGAV Kallikrein2.8 A 1351 705 208 597 2162<BR> 67.0039 KITDVVKVV Kallikrein2.131 A 476 586 84 859 29314<BR> 67.0036 KLTDVVKVL Kallikrein2.131 A 712 15 202439 81679<BR> 67.0037 KVTDVVKVL Kallikrein2.131 A 5158 686 259 2372 3835<BR> 1435.05 KVTEFMLAAGV Kallikrein2. 179 33 13 52 308<BR> 1418.71 KVTEFMLCAGV Kallikrein2.191 A 56 10 26 28 143<BR> 1418.21 KVTEFMLCV Kallikrein2.191 A 53 27 31 34 6667<BR> 1435.07 KVTEFMLPAGV Kallikrein2. 2381 935 137 385 13333<BR> 1435.06 KVTEFMLSAGV Kallikrein2. 1786 430 56 394 3333<BR> 1435.04 KVTEFMLTAGV Kallikrein2. 7143 1536 119 2643 10000<BR> 71.0059 LLLLRLSEPA Kallikrein2.121 A 1130 748 96 1097 11547<BR> 71.0060 LLLLRLSEPV Kallikrein2.121 A 379 361 56 317 26667<BR> 71.0042 LLLRLSEPV Kallikrein2.122 A 35 82 90 179 25746<BR> 1418.13 LLLSIALSV Kallikrein2.4 A 88 179 147 185 80000<BR> 141.44 LLRLSEPAKV Kallikrein2.123 A 2174 518 23 9250 80000<BR> 1418.53 LLSNDMCARV Kallikrein2.178 A 5.3 0.69 4.4 10.3 1702<BR> 1418.43 LMLLRLSEPV Kallikrein2.121 A 114 67 29 25 6154<BR> 71.0062 LTLLRLSEPV Kallikrein2.121 A 1761 6207 860 424 949<BR> 1418.14 LTLSIALSV Kallikrein2.4 A 641 287 313 949 2051<BR> 71.0063 LVANGVLQGV Kallikrein2.121 A 125 25 3 26 12<BR> 1419.47 LVBNGVLQGI Kallikrein2. A 1282 215 9.1 43 118<BR> 1418.72 LVCNGVLQGIV Kallikrein2.217 A 1923 1593 500 370 13333 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 1418.55 LVCNGVLQGV Kallikrein2.217 A 10 3 12 6 3<BR> 1418.60 LVHPQWVLTAV Kallikrein2.54 A 2083 148 370 148 2424<BR> 1418.40 LVHPQWVLTV Kallikrein2.54 A 3571 1049 67 77 13333<BR> 71.0066 LVPNGVLQGV Kallikrein2.217 A 28 15 4 7 20<BR> 71.0067 LVSNGVLQGV Kallikrein2.217 A 133 11 1 23 9<BR> 71.0068 LVTNGVLQGV Kallikrein2.217 A 182 56 2.2 10 17<BR> 71.0069 LVVNGVLQGV Kallikrein2.217 A 55 50 5 40 19<BR> 1418.18 MLLRLSEPV Kallikrein2.122 A 79 31 40 161 1778<BR> 1418.42 NMSLLKHQSV Kallikrein2.102 A 8333 1000 455 18500 40000<BR> 67.0040 PLLGTTCYA Kallikrein2.146A 3541 434 114 6111 46839<BR> 71.0085 PLVANGVLQGV Kallikrein2.216 A 45 683 75 212 2843<BR> 63.0128 PLVCNGVLQGV Kallikrein2.216 A 92 421 36 210 1633<BR> 1419.17 PLVCNGVLQGV Kallikrein2.216 A 26 126 19 264 4211<BR> 71.0086 PLVPNGVLQGV Kallikrein2.216 A 26 93 18 40 17889<BR> 71.0087 PLVSNGVLQGV Kallikrein2.216 A 57 227 76 287 5234<BR> 71.0088 PLVTNGVLQGV Kallikrein2.216 A 138 1267 137 882 11507<BR> 71.0089 PLVVNGVLQGV Kallikrein2.216 A 348 5852 774 683 10000<BR> 67.0042 PTLGTTCYA Kallikrein2.146A 9690 1268 223 54852 9485<BR> 67.0041 PVLGTTCYA Kallikrein2.146A 8211 756 196 6836 10645<BR> 1418.38 QVAVYSHGWV Kallikrein2.39 A 12500 331 714 3083 333<BR> 1418.17 QVWLGRHNV Kallikrein2.72 A 1351 6143 2222 1480 103<BR> 67.0093 SIALSVGCTGV Kallikrein2.7 A 3959 544 136 2137 587<BR> 67.0090 SLALSVGCTGA Kallikrein2.7 A 4789 125 214 3142 5095<BR> 71.0090 SLHLLSNDMAA Kallikrein2.175 A 65 3 89 1165 20435<BR> 1419.45 SLHLLSNDMBA Kallikrein2. 12 1 36 12333 20000<BR> 1418.66 SLHLLSNDMCV Kallikrein2.175 A 8.6 0.7810.2 2312.5 2162.16<BR> 71.0091 SLHLLSNDMPA Kallikrein2.175 A 1687 41 717 37000 >80000 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 71.0092 SLHLLSNDMSA Kallikrein2.175 A 346 4.0 84 9250 >80000<BR> 71.0093 SLHLLSNDMTA Kallikrein2.175 A 93 2 44 26163 80000<BR> 71.0094 SLHLLSNDMVA Kallikrein2.175 A 112 5 74 7126 40000<BR> 71.0070 SLQAVSLHLV Kallikrein2.170 A 142 13 8 219 1404<BR> 1418.52 SLQCVSLHLV Kallikrein2.170 A 13 6 3 5 205<BR> 1418.19 SLQCVSLHV Kallikrein2.170 A 56 165 48 4111 1600<BR> 71.0071 SLQPVSLHLV Kallikrein2.170 A 346 21 35 95 5521<BR> 71.0072 SLQSVSLHLV Kallikrein2.170 A 202 37 73 78 6963<BR> 71.0073 SLQTVSLHLV Kallikrein2.170 A 170 42 11 82 2464<BR> 71.0074 SLQVVSLHLV Kallikrein2.170 A 138 56 11 63 3036<BR> 1418.35 SVGCTGAVPV Kallikrein2.11 A 104 287 154 552 216<BR> 1418.64 TTCYASGWGSV Kallikrein2.150 A 6250 2150 769 2467 500<BR> 1418.56 VLSIALSVGCV Kallikrein2.5 A 1020 1103 83 1947 3333<BR> 63.0105 VLVHPQWVLTV Kallikrein2.53 A 11 2 3 13 4444<BR> 1419.11 VLVHPQWVLTV Kallikrein2.53 A 11 2 16 31 8889<BR> 80.0180 VLVHPQWVV Kallikrein2.53 A 564 65 1982 3199 16000<BR> 1418.54 VTEFMLCAGV Kallikrein2.192 A 625 1483 714 137 131<BR> 1369.36 FVEEQMTWV KSHV.105 A 46 172 552 326 27 6425<BR> 1369.35 LVYHIYSKV KSHV.153 A 319 133 16 1370 328 152<BR> 7.0025 HLNLTMPNA LCMV.GP.83 188<BR> 7.0045 MPSLTMACM LCMV.NP.175 323<BR> 7.0039 SAYLVSIFL LCMV.GP.445 130<BR> 55.0234 YLQLFFGIEV MAGE2.157 A 133 68 511 482 3497<BR> 54.0084 YLQLIFGIEV MAGE2.157 A 259 58 791 462 19372<BR> F063.65 AAFIGILTV MART1.27 A 76<BR> F063.64 AAWIGILTV MART1.72 A 67<BR> F063.66 AAYIGILTV MART1.27 A 102 Table 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> F063.60 AIGIGILTV MART1.27 A 86<BR> F063.74 ALFIGILTV MART1.27 A 2.1<BR> F063.58 ALGIGILTV MART1.27 A 11<BR> F063.73 ALWIGILTV MART1.27 A 5.8<BR> F063.75 ALYIGILTV MART1.27 A 3.9<BR> F063.59 AMGIGILTV MART1.27 A 15<BR> F063.62 FAGIGILTV MART1.27 A 268<BR> F063.71 FLGIGILTV MART1.27 A 1.4<BR> F063.69 KIGIGILTV MART1.27 A 103<BR> F063.67 KLGIGILTV MART1.27 A 20<BR> F063.68 KMGIGILTV MART1.27 A 27<BR> F063.70 WLGIGILTV MART1.27 A 9.8<BR> F063.63 YAGIGILTV MART1.27 A 304<BR> F063.72 YLGIGILTV MART1.27 A 2.5<BR> 3.0188 KTCPVQLWVSA mp53.136 458<BR> 1413.13 LLDRDSFEV mp53.136 A 458<BR> 1413.20 LLGRDSHEV mp53.136 A 8.3<BR> 1413.18 LLGRDSLEV mp53.136 A 177<BR> 1413.19 LLGRDSMEV mp53.136 A 417<BR> 1413.17 LLGRGSFEV mp53.136 A 192<BR> 1413.16 LLGRQSFEV mp53.136 A 76<BR> 1413.14 LLHRDSFEV mp53.136 A 2.8<BR> 1413.12 LLSRDSFEV mp53.136 A 29<BR> F09.702 SIIDPLIYA MSH.291 A 455 5.4 25 17 2.3<BR> F097.01 SVMDPLIYA MSH.291 A 63 6 88 7 8<BR> F097.12 TMLLGVFTV MSH.244 A 3.1<BR> 31.0143 LIANNTRVWV MT.242 239 Table 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 54.0005 CMPPPGTRV P53.149 A 788 1611 100 2303 7851<BR> 1326.04 ELAPPVAPV p53.68 A 60<BR> 1323.28 FLHSGTAKSVV p53.113 A 1222 568 28 9087 11001<BR> 1413.08 GLAPPQQLIRVF P53.187 A 1<BR> 1413.10 GLAPPQSLIRV p53.187 A 3.3<BR> 1413.04 GLVPPAHLIRV P53.187 A 20<BR> 55.0049 SMPPGPRV p53.149 A 641 429 1144 3222 702<BR> 1323.23 YLCNSSCV P53.236 A 14814 31114 138 >21361.96 >35777.09<BR> 63.0040 ALFPPEGVSV PAP.122 A 11 1 3 12 138<BR> 1419.61 ALFPPEGVSV PAP.15 1 18 119 4444<BR> 60.0203 FLFLLFFWV PAP.18 A 42 307 625 308 90<BR> 63.0047 GLHGQDLFGV PAP.196 A 19 4 4 6 976<BR> 1419.62 GLHGQDLFGV PAP. 12 2 3 18 80000<BR> 63.0041 GVSIWNPILV PAP.128 A 250 93 23 451 2286<BR> 60.0207 GVSIWNPIV PAP.128 A 455 269 909 308 80000<BR> 71.0051 ILYSAHDTTV PAP.284 A 991 9.1 100 1871 24228<BR> 1389.06 ILYSAHDTTV PAP.384 A 391 1.1 13 1471 6218<BR> 1418.25 ITLWQPIPV PAP.135 A 33 1720 6 26 32<BR> 71.0052 ITYSAHDTTV PAP.284 A 25000 181 848 1818 733<BR> 1418.26 ITYSAHDTTV PAP.284 A 4167 115 238 154 82<BR> 1389.05 IVLWQPIPV PAP.135 A 391 1865 289 17607 831<BR> 71.0053 IVYSAHCDTTV PAP.284 A 16667 289 7001 1149 1552<BR> 1389.07 IVYSAHDTTV PAP.284 A 7710 91 623 671 745<BR> 63.048 KLRELSELSV PAP.234 A 263 9.2 7.1 49 1818<BR> 63.0046 KLSGLHGQDV PAP.193 A 1064 69 385 1057 26667<BR> 63.0038LLALFPPEGV PAP.120 A 31 0 5 37 160<BR> 1419.58 LLALFPPEGV PAP. 5.0 0.7 1.6 148 163 Table 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 63.0031 LLARAASLSV PAP.7 A 109 10 21 378 727<BR> 60.0201 LLLARAASV PAP.6A 18 215 7 95 20000<BR> 63.0053 LLPPYASCHV PAP.306 A 94 18 15 218 2963<BR> 1419.64 LLPPYASCHV PAP. 88 15 16 97 5333<BR> 63.0044 LLWQPIPVHV PAP.136 A 5.8 2.1 18 116 42<BR> 1419.69 LLWQPIPVHV PAP. 25 23 18 285 62<BR> 1418.23 LTFFWLDRSV PAP.21 A 116 11 10 43 16<BR> 63.0039 LVALFPPEGV PAP.120 A 116 14 12 47 3<BR> 1419.59 LVALFPPEGV PAP. 156 17 5 463 28<BR> 1389.01 LVFFWLDRSV PAP.31 A 1424 259 80 64 82<BR> 63.0042 PLLLWQPIPV PAP.134 A 238 47 19 336 3333<BR> 63.0045 RLHPYKDFIV PAP.180 A 862 24 1887 1609 80000<BR> 63.0033 SLLAKELKFV PAP.29 A 64 6 4 38 6667<BR> 63.0032 SLSLGFLFLV PAP.13 A 33 11 27 40 842<BR> 1419.52 SLSLGFLFVL PAP. 1.9 3.9 17 42 348<BR> 60.0202 SLSLGFLFV PAP.13 A 42 6 5 28 4706<BR> 1419.50 SLSLGFLFV PAP. A 77 25 21 93 26667<BR> 63.0037 TLMSAMTNLV PAP.112 A 63 4 12 43 242<BR> 1389.03 TLMSAMTNV PAP.112 A 628 14 35 2159 482<BR> 1419.56 TLMSAMTNV PAP. 9.6 2.39 3.57 54.41 61.54<BR> 60.0213 TVSGLQMAV PAP.292 A 294 12 122 195 5.7<BR> 63.0034 VLAKELKFVV PAP.30 A 31 12 189 86 2286<BR> 118.24 VTAKELEKFV PAP.30 A 7143 2688 40 137 26667<BR> 1419.53 VTAKELKFV PAP. 6250 1024 53 137 40000<BR> 1419.54 VVAKELKFV PAP. 926 478 22 119 40000<BR> 1369.21 IVSVSSFLFV Pf.CSP.7 A 1066 797 200 993 77 437<BR> F103.01 ALYGALLLA PLP.80 A 7.8 Table 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> F103.05 FLYGAALLA PLP.80 A 3.6<BR> F103.06 FLYGALALA PLP.80 A 2.4<BR> F103.07 FLYGALLAA PLP.80 A 6.4<BR> F103.08 FLYGALRLA PLP.80 A 7.2<BR> F103.09 FLYGALVLA PLP.80 A 41<BR> F103.10 FLYGALYLA PLP.80 A 2.6<BR> F103.04 FLYGGLLLA PLP.80 A 1.1<BR> 1419.34 ALGTTBYA PSA. 50 13 0 18500 80000<BR> 1419.35 ALGTTBYV PSA. 6.7 3.6 2.8 3083 80000<BR> 939.09 ALGTTCYAS PSA. 417 741 667 435 80000<BR> 1389.14 ALGTTCYV PSA.143 A 93 7 12 288 29169<BR> 63.0195 DLMLLRLSEPV PSA.116 A 359 180 183 1746 5000<BR> 63.0186 FLTLSVTWIGV PSA.3 A 5.2 3.5 20 74 114<BR> 60.0216 FLTLSVITWV PSA.3 A 96 9 12 58 13333<BR> 1419.36 FLTPKKKLQBV PSA. 71 3 4 137 80000<BR> 71.0047 FLTPKKLQPV PSA.161 A 5270 204 65 1232 >80000<BR> 71.0048 FLTPKKLQSV PSA.161 A 607 51 52 836 >80000<BR> 71.0049 FLTPPKKLQTV PSA.161 A 876 55 57 1318 >80000<BR> 71.0050 FLTPKKLQVV PSA.161 A 1548 33 48 1230 >80000<BR> 1418.27 FTTPKKLQCV PSA.161 A 5000 1387 15 308 26667<BR> 1389.16 FVTPKKLQCV PSA.11 A 24628 2737 30 7102 >23094.01<BR> 63.0203 HLISNDVCAQV PSA.173 A 2724 84 426 15321 308<BR> 71.0032 KLQADVDLHL PSA.166 A 504 471 818 9553 40000<BR> 71.0054 KLQAVDLHVV PSA.166 A 92 9 32 211 >40000<BR> 1419.37 KLQBVDLHV PSA. 31 36 67 712 80000<BR> 1419.38 KLQBVDLHVUI PSA. 217 27 20 264 80000<BR> 1419.39 KLQBVDLHVV PSA. 38 20 5 86 80000 Table 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 63.0058 KLQCVDLHVV PSA.166 A 13 89 29 528 26667<BR> 71.0055 KLQCVDLHVV PSA.166 A 1023 58 30 130 >80000<BR> 71.0056 KLQCVDLHVV PSA.166 A 526 27 23 446 >80000<BR> 71.0057 KLQCVDLHVV PSA.166 A 233 47 34 171 30526<BR> 71.0036 KLQCVDLHV PSA.166 A 1135 350 554 12333 >80000<BR> 71.0058 KLQCVDLHVV PSA.166 A 49 41 4 92 3943<BR> 71.0037 KLQCVDLHV PSA.187 A 144 136 11 34 7628<BR> 1419.40 KVTKFMLBA PSA. 1786 139 20 58 40000<BR> 1419.41 KVTKFMLBV PSA. 128 226 5 31 6667<BR> 60.0220 KVTKFMLCV PSA.187 A 70 456 80 143 16000<BR> 71.0038 KVTKFMLPV PSA.187 A 33 71 9 15 1827<BR> 71.0039 KVTKFMLSV PSA.187 A 90 180 2 33 1547<BR> 71.0040 KVTKFMLTV PSA.187 A 83 95 9 48 11547<BR> 71.0041 KVTKFMLVV PSA.187 A 223 371 11 67 18267<BR> 1389.12 MLLRISEPAEV PSA.118 A 255 367 130 2627 4095<BR> 1389.10 MLLRLSEPV PSA.118 A 48 29 48 686 432<BR> 1419.43 PLVBNGVLQGV PSA. 14 2689 185 394 6154<BR> 63.0194 SVFHPEDTGQV PSA.75 A 1725 50 57 2064 32<BR> 60.0217 TLSVTWIGV PSA.5 A 27 4 33 777 229<BR> 63.0191 VLVHPQWVLTV PSA.49 A 68 14 36 360 10000<BR> 60.0218 VLVHPQWVV PSA.49 A 267 206 1877 4696 6154<BR> 63.0185 VVFLTLSVTWV PSA.1 A 101 202 78 885 13333<BR> F108.33 FVNHDFTVV pSI2.508 305<BR> F018.29 IAGGVMAVV pSI2.71 204<BR> F108.44 LLGLWGLTGL pSI2.668 1.4<BR> F108.35 LLLLGLWGL pSI2.666 22<BR> F108.31 SVYVDAKLV pSI2.589 117 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Anlag A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> F108.30 VLAKDGTEV pSI2.50 51<BR> 60.0232 ALGLPSIPV PSM.286 A 71 6 13 3147 5477<BR> 63.0063 ALVLAGGFFV PSM.25 A 713 65 798 1404 28522<BR> 1418.30 ATFDIESKV PSM.711 A 238 27 43 82 258<BR> 1389.34 AVFDIESKV PSM.711 A 850 62 41 111 207<BR> 60.0229 ELAHYDVLV PSM.109 A 4412 40 221 111874 86<BR> 63.0068 FLDELKAENV PSM.61 A 419 24 262 4800 43248<BR> 60.0239 GLLGSTEWV PSM.427 A 415 87 138 393 >84187.21<BR> 1389.22 GLPEGDLVYV PSM.168 A 43 2 2 113 1000<BR> 1389.24 GLPSIPVHPV PSM.288 A 77 1 1 315 155<BR> 1418.29 GTPEGDLVYV PSM.168 A 313 134 53 40 571<BR> 1389.23 GVPEGDLVYV PSM.168 A 1401 258 836 214 711<BR> 63.0065 LLGFLFGWFV PSM.34 A 55 9 100 2696 88410<BR> 63.0079 LLQERGVAYV PSM.441 A 535 8 19 616 9038<BR> 71.0043 LLYSLVHNL PSM.469 A 13 1 10 61 376<BR> 71.0044 LTYSLVHNL PSM.469 A 20 2 14 15 2<BR> 63.0064 LVLAGGFFLV PSM.26 A 781 44 151 182 734<BR> 60.0224 LVAGGFFV PSM.26 A 95 81 1031 37 592<BR> 71.0045 LVYSLVHNL PSM.469 A 272 7.4 147 53 18<BR> 63.0085 MLFELANSIV PSM.583 A 42 4 13 440 837<BR> 60.0247 MVFELANSV PSM.583 A 75 7 11 50 2<BR> 63.0060 NVLHETDSAV PSM.3 A 6300 97 583 5087 11149<BR> 60.0244 PLFKYHLTV PSM.568 A 962 119 167 1779 90571<BR> 1389.32 QLMFLERAFV PSM.667 A 553 12 50 739 2<BR> 60.0251 QLYVAAFTV PSM.731 A 2328 122 1233 4039 198<BR> 60.0252 QVYVAAFTV PSM.731 A 9602 6544 7795 733 26<BR> 63.0090 SLFSAVKNFV PSM.631 A 598 8 85 2203 1024 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 60.0242 SLYETYELV PSM.554 A 71 6 17 86 5178<BR> 60.0240 TLRVDCTPV PSM.461 A 5851 598 146 10706 47483<BR> 1389.20 VLAGGFFLV PSM.27 A 28 0 8 57 244<BR> 63.0086 VLPFDCRDYV PSM.592 A 806 76 392 1546 8033<BR> 63.0062 WLCAGALVLV PSM.20 A 4252 74 214 2510 39011<BR> 53.0065 AANPHATFGV T.cruzi.74 15<BR> 53.0083 AASTLLYATV T.cruzi.FL160.377 477<BR> 53.0034 AIVFDHYDV T.cruzi.FL160.108 332<BR> 53.0038 ALKNNGKVV T.cruzi.FL160.230 409<BR> 53.0004 ALSLAAVLY T.cruzi.7 113<BR> 53.0062 ALSLAAVLVV T.cruzi.7 101<BR> 53.0091 AMALIGDSTV T.cruzi.FL160.972 356<BR> 53.0048 FANSKFTLV T.cruzi.FL160.529 377<BR> 53.0087 FANSKFTLVA T.cruzi.FL160.529 214<BR> 53.0011 FLARLHAAA T.cruzi.67 48<BR> 53.0068 GLMNNAFEWI T.cruzi.188 47<BR> 53.0088 IILNGSLLTL T.cruzi.FL160.581 62<BR> 53.0045 KLYCSYEVA T.cruzi.FL160.401 256<BR> 53.0061 LLGLWGTAA T.cruzi.FL160.993 333<BR> 53.0090 LLLEHGQFDL T.cruzi.FL160.961 37<BR> 53.0094 LLLLGLWGTA T.cruzi.FL160.991 245<BR> 53.0021 LLVGYNDSA T.cruzi.287 195<BR> 53.0013 LMNNAFEWI T.cruzi.189 447<BR> 53.0067 LTNLSEQMLV T.cruzi.167 175<BR> 53.0018 MTYTGGVMT T.cruzi.267 356<BR> 53.0089 QMDYSNGLFV T.cruzi.FL160.610 94<BR> 53.0042 RLHLWLSDM T.cruzi.FL160.352 72 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 53.0092 RVFGLLLLGL T.cruzi.FL160.987 62<BR> 53.0026 RVFTSAVLL T.cruzi.FL160.4 11<BR> 53.0010 SVFRENLFL T.cruzi.60 59<BR> 53.0028 VLLLVVVMM T.cruzi.FL160.10 55<BR> 53.0008 VMACLVPAA T.cruzi.16 10<BR> 41.0161 AACDQRVLIV TRP1 44<BR> 41.0173 AVVAALLLVA TRP1 13<BR> 41.0159 DLLPSSGPGT TRP1 420<BR> 41.0188 DLLPSSGPGV TRP1 94<BR> 41.0113 ELPNPNHSM TRP1 44<BR> 41.0156 FLMLFYQVWA TRP1 62<BR> 41.0179 LIFGTASYLI TRP1 160<BR> 41.0064 LLLFQQARA TRP1 211<BR> 41.0182 LLTDHYQRYA TRP1 16<BR> 41.0176 LLVALIFGTA TRP1 91<BR> 41.0069 MAKRTTHPL TRP1 22<BR> 41.0185 PLLLFQQARV TRP1 6.2<BR> 41.0144 PLTNTEMFV TRP1 21<BR> 41.0081 QLERDMQEM TRP1 7.5<BR> 41.0128 QLERDMQEV TRP1 3.3<BR> 41.0089 RLPEPQDVT TRP1 369<BR> 41.0165 SLEEYDTLGT TRP1 13<BR> 41.0076 SVKKTFLGV TRP1 9.2<BR> 41.0074 SVYNYFVWT TRP1 3.5<BR> 41.0087 TLGTLCNST TRP1 283<BR> 41.0095 VLLHTFTDA TRP1 21<BR> F096.41 ALVGLFVLL TRP2.482 28 13544 3208 4447 2731 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> F096.14 FVWLHYYSV TRP2.185 15 13544 974 24 1<BR> F096.18 LIGNESFAL TRP2.234 400 1817 8513 2855 4000<BR> F096.32 NMVPFFPPV TRP2.431 6.1 28 23 7.1 1.1<BR> F096.22 SLDDYNHLV TRP2.288 26 1159 441 735 2582<BR> F096.48 SLHNLVHSFL TRP2.367 277 139 8.4 37000 252<BR> F096.13 SVYDFFVWL TRP2.180 36 169 226 10 1<BR> F096.26 TLDSQVMSL TRP2.360 167 43000 646 1217 >10596.26<BR> F096.50 TLLVVMGTLV TRP2.472 361 10750 363 1818 596<BR> F096.51 TLVALVGLFV TRP2.479 34 21500 35 57 6<BR> F096.30 VLHSFTDAI TRP2.394 424 623 45 9889 1527<BR> F096.38 VMGTLVALV TRP2.476 31 585 6 404 267<BR> F096.16 VTWHRYHLL TRP2.217 164 1087 9410 760 38<BR> F096.37 VVMGTLVAL TRP2.475 67 66 163 51 43<BR> F096.33 YAIDLPVSV TRP2.455 16 46 14 14 1<BR> F096.08 YVITTQHWL TRP2.156 105 41 417 44 1<BR> 980.05 AAAKAAAAV Artificial sequence A 8333 861 68 345 8273 3<BR> 980.13 ACAKAAAAV Artificial sequence A 25000 >8600 640 46237 >1321.43 314<BR> 980.10 AGAKAAAAV Artificial sequence A 25000 4389 418 3202 37000 1960<BR> 953.15 AIAKAAAAAL Artificial sequence A >217.39<BR> 953.23 AIAKAAAAAT Artificial sequence A >217.39<BR> 953.11 AIAKAAAAL Artificial sequence A 50000 281 133 37000 121<BR> 953.19 AIAKAAAAT Artificial sequence A >238.1 43000 2113 >1321.43 2333<BR> 953.03 AIAKAAAAV Artificial sequence A 1786 253 4.9 185 1277 19<BR> 980.17 ALAEAAAAV Artificial sequence A 72<BR> 980.31 ALAKAAAAA Artificial sequence A 1563 21500 59 6604 >1321.43 6532<BR> 980.29 ALAKAAAAI Artificial sequence A 625 377 11 385 13081 433<BR> 953.09 ALAKAAAAL Artificial sequence A 2778 80 4.2 109 15105 320 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Sourc Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 980.30 ALAKAAAAM Artificial sequence A 4545 624 149 797 37000 >3468.44<BR> 953.17 ALAKAAAAT Artificial sequence A 25000 14333 175 9840 >1321.43 14142<BR> 980.28 ALAKAAALV Artificial sequence A 122<BR> 980.26 ALAKAAAQV Artificial sequence A 278<BR> 980.27 ALAKAAATV Artificial sequence A 294<BR> 980.24 ALAKAAYAN Artificial sequence A 64<BR> 980.22 ALAKAIAAV Artificial sequence A 93<BR> 980.19 ALAKKAAAV Artificial sequence A 294<BR> 980.21 ALAKLAAAV Artificial sequence A 114<BR> 980.20 ALAKYAAAV Artificial sequence A 119<BR> 980.18 ALASAAAAV Artificial sequence A 139<BR> 1266.02 ALDKAYVLL Artificial sequence A 59 212<BR> 1266.01 ALDKYTVLL Artificial sequence A 80 648<BR> 980.14 ALFKAAAAV Artificial sequence A 119<BR> 980.15 ALSKAAAAV Artificial sequence A 294<BR> 1037.02 AMAKAAAAA Artificial sequence A 2529 3011 5.9 37000 2818<BR> 953.22 AMAKAAAAAT Artificial sequence A >217.39<BR> 953.10 AMAKAAAAL Artificial sequence A 22 123 4 18500 320<BR> 1037.03 AMAKAAAAM Artificial sequence A 6455 1344 106 >1321.43 7807<BR> 1037.13 AMAKAAAAS Artificial sequence A 25000 >10750 166 >1321.43 >4588.31<BR> 953.18 AMAKAAAAT Artificial sequence A 16667 12413 84 >1321.43 10000<BR> 953.02 AMAKAAAAV Artificial sequence A 273 196 6.7 69 1485 177<BR> 953.02 AMAKAAAAV Artificial sequence A 131<BR> 953.02 AMAKAAAAV Artificial sequence A 167<BR> 980.06 ANAKAAAAV Artificial sequence A 25000 >8600 4454 50000 >1321.43 109<BR> 980.12 APAKAAAAV Artificial sequence A 25000 >8600 15430 >24826.0@ >1321.43 60<BR> 980.04 ASAKAAAAV Artificial sequence A 16667 1109 241 2847 26163 14 TABLE 15<BR> HLA- A2 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source Analog A*0201 A*0202 A*0203 A*0205 A*0206 A*0207 A*6802<BR> 953.16 AVAKAAAAAL Artificial sequence A >217.39<BR> 953.12 AVAKAAAAL Artificial sequence A >238.1 90 241 8273 4.1<BR> 953.20 AVAKAAAT Artificial sequence A 50000 8600 2595 >1321.43 157<BR> 953.04 AVAKAAAAV Artificial sequence A 2362 105 12 30 863 1.2<BR> 953.25 AXAKAAAAL Artificial sequence A 50000 467 3226 37000 11429<BR> 953.25 AXAKAAAAL Artificial sequence A >25000 469 3300 37000 >3468.44<BR> 980.03 FLAKAAAAV Artificial sequence A 114<BR> 1266.07 FLDSDYFPSI Artificial sequence A 196 3240<BR> 1266.06 FLDSDYFPSL Artificial sequence A 321 1571<BR> 1266.05 FLDSDYFPSV Artificial sequence A 11 668<BR> 1266.08 FLDSYIAPL Artificial sequence A 25 60<BR> 980.02 KLAKAAAAV Artificial sequence A 238 Table 16<BR> Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6820 A2 Cross-<BR> reactivity<BR> LQCVSILHLL Kallikrein2 171 9 0.0018 0.010 0.0049 0.17 0.0002 2<BR> ALGTTCYV Kallikrein2 147 A 8 0.28 0.93 0.63 0.0036 0.0001 3<BR> LLLSIALSV Kallikrein2 4 A 9 0.057 0.024 0.068 0.020 0.0001 4<BR> LTLSIALSV Kallikrein2 4 A 9 0.0078 0.015 0.032 0.0039 0.039 2<BR> ALSVGCTGV Kallikrein2 9 A 9 0.21 0.26 1.1 0.014 0.0002 4<BR> AVPLIQSRV Kallikrein2 17 A 9 0.0013 0.0028 0.079 0.0016 0.11 2<BR> QVWLGRHNV Kallikrein2 73 A 9 0.0037 0.0007 0.0045 0.0025 0.078 1<BR> MLLRLSEPV Kallikrein2 122 A 9 0.0063 0.14 0.22 0.023 0.0045 4<BR> SLQCVSLHV Kallikrein2 170 A 9 0.089 0.026 0.21 0.0009 0.0050 3<BR> HLLSNDMCV Kallikrein2 177 A 9 0.042 0.042 0.036 0.021 0.0001 4<BR> KVTEFMLCV Kallikrein2 191 A 9 0.095 0.16 0.32 0.11 0.0012 4<BR> FMLCAGLWV Kallikrein2 195 A 9 0.17 0.37 0.11 0.073 0.0001 4<BR> LTFFWLDRSV PAP 21 A 10 0.043 0.40 1.0 0.086 0.49 5<BR> VTAKELKFV PAP 30 A 9 0.0007 0.0016 0.25 0.027 0.0003 2<BR> ITLWQPIPV PAP 135 A 9 0.15 0.0025 1.6 0.14 0.25 4<BR> ITYSAHDTTV PAP 284 A 10 0.0012 0.0375 0.042 0.024 0.097 4<BR> FTTPKKLQCV PSA 161 A 10 0.O0010 0.0031 0.65 0.012 0.0003 2<BR> GTPEGDLVYV PSM 168 A 10 0.016 0.032 0.19 0.093 0.014 4<BR> ATFDIESKV PSM 711 A 9 0.021 0.16 0.23 0.045 0.031 5<BR> DTVLSIALSV Kallikrein2 3 A 10 0.0014 0.0043 0.052 0.052 0.045 2 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6820 A2 Cross-<BR> reactivity<BR> SVGCTGAVPV Kallikrein2 11 A 10 0.048 0.015 0.065 0.0067 0.037 4<BR> QVAVYSHGWV Kallikrein2 39 a 10 0.0004 0.013 0.014 0.0012 0.024 2<BR> LVHPQWVLTV Kallikrein2 54 a 10 0.0014 0.0041 0.15 0.048 0.006 2<BR> LMLLRLSEPV Kallikrein2 121 A 10 0.044 0.064 0.35 0.15 0.0013 4<BR> FVRPRSLQCV Kallikrein2 165 A 10 0.0036 0.016 0.92 0.0078 0.0010 3<BR> SLQCVSLHLV Kallikrein2 170 A 10 0.39 0.68 3.6 0.71 0.039 5<BR> LLSNDMCARV Kallikrein2 178 A 10 0.94 6.2 2.3 0.36 0.0047 4<BR> VTEFMLCAGV Kallikrein2 192 A 10 0.0080 0.0029 0.014 0.027 0.061 2<BR> LVCNGVLQGV Kallikrein2 217 A 10 0.48 1.5 0.84 0.66 2.3 5<BR> ILLSVGCTGAV Kallikrein2 8 A 11 0.14 0.13 0.28 0.012 0.0008 4<BR> ITLSVGCTGAV Kallikrein2 8 A 11 0.017 0.032 0.25 0.018 0.066 5<BR> LVHPQWVLTAV Kallikrein2 54 A 11 0.0024 0.029 0.027 0.025 0.0033 3<BR> SLHLLSNDMCV Kallikrein2 175 A 11 0.58 5.5 0.98 0.0016 0.0037 3<BR> HLLSNDMCARV Kallikrein2 177 A 11 0.19 3.3 1.9 0.099 0.0093 4<BR> DVCARAYSEKV Kallikrein2 182 A 11 0.0001 0.0027 0.15 0.0007 0.026 2<BR> KVTEFMLCAGV Kallikrein2 191 A 11 0.089 0.45 0.39 0.13 0.056 5<BR> ALGTTCVA Kallikrein2 147 8 0.33 0.23 0.75 0.0066 <0.0001 3<BR> MLLRLSEPA Kallikrein2 122 9 0.026 0.0058 0.069 0.076 0.0003 3<BR> ALSVGCTGAV Kallikrein2 9 10 0.095 0.058 0.57 0.0068 0.0001 3<BR> FLRPRSLQCV Kallikrein2 165 10 0.027 0.89 2.4 0.0003 <0.0001 3<BR> VLVHPQWVLTA Kallikrein2 53 1 1 0.017 0.56 0.099 0.0018 0.0001 3<BR> VLVHPQWVLTV Kallikrein2 53 A 11 0.45 2.8 0.64 0.12 0.009 4 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6820 A2 Cross-<BR> reactivity<BR> SLHLLSNDMCA Kallikrein2 175 11 0.070 0.90 0.4 <0.0001 <0.0001 3<BR> HLLSNDMCARA Kallikrein2 177 11 0.012 0.011 0.040 0.0099 0.0001 4<BR> PLVCNGVLQGI Kallikrein2 216 11 0.0059 0.0089 0.023 0.0023 0.0001 2<BR> PLVCNGVLQGV Kallikrein2 216 A 11 0.19 0.034 0.53 0.014 0.0019 4<BR> PLVBNGVLQGV PSA 212 A 11 0.36 0.016 0.054 0.0094 0.0013 4<BR> FLRPRSLQBV Kallikrein2 165 A 10 0.13 2.5 1.6 0.0020 <0.0001 3<BR> SILHLLSNDMBA Kallikrein2 175 A 11 0.43 3.6 0.28 0.0003 0.0004 3<BR> LLLARAASL PAP 6 9 0.024 0.32 0.35 0.0087 0.0001 4<BR> SLSLGFLFLL PAP 13 10 0.087 0.66 0.0035 0.073 0.0093 3<BR> LLARAASLSL PAP 7 10 0.001 0.82 0.16 0.0004 0.0014 2<BR> SVLAKELEFV PAP 29 10 0.0023 0.0009 0.024 0.012 0.0002 2<BR> LAALFPPEGV PAP 120 10 0.0022 0.023 0.23 0.0012 0.024 3<BR> TLMSAMTNLA PAP 112 10 0.013 1.2 0.27 0.0010 0.0012 3<BR> GLHGQDLFGI PAP 196 10 0.20 4.7 4.0 0.012 <0.0001 4<BR> VVFLTLSVTWI PSA 1 11 0.013 0.027 0.16 0.0013 0.0001 3<BR> ALGTTBYA PSA 143 A 8 0.10 0.34 22 0.0002 <0.0001 3<BR> ALGTTBYV PSA 143 A 8 0.75 1.2 3.6 0.0012 <0.0001 3<BR> FLTPKKLQBV PSA 161 A 10 0.070 1.7 2./4 0.027 <0.0001 4<BR> KLQBVDLHV PSA 166 A 9 0.16 0.12 0.15 0.0052 <0.0001 3<BR> KLQBVDLHVI PSA 166 A 10 0.023 0.16 0.51 0.014 <0.0001 4<BR> KLQBVDLHVV PSA 166 A 10 0.13 0.22 2.0 0.043 <0.0001 4<BR> KVTKFMLBA PSA 187 A 9 0.0028 0.031 0.51 0.064 0.0002 3 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6820 A2 Cross-<BR> reactivity<BR> KVTKFMLBV PSA 187 A 9 0.039 0.019 2.0 0.12 0.0012 4<BR> HLLSNDMBARA Kallikrein2 177 A 11 0.014 0.030 0.095 0.0016 0.0001 2<BR> LVBNGVLQGI Kallikrein2 217 A 10 0.0039 0.020 1.1 0.086 0.068 4<BR> LLLARAASLSL PAP 6 11 0.19 0.018 0.013 0.0010 0.0005 2<BR> LLARAASLSL PAP 7 10 0.0035 0.24 0.13 0.0P002 0.0010 2<BR> SLSLGFLFV PAP 13 A 9 0.065 0.17 0.47 0.040 0.0003 4<BR> SLSGFLFLL PAP 13 10 0.13 0.33 0.025 0.17 0.0009 4<BR> SLSLGFLFLV PAP 13 A 10 2.7 1.1 0.59 0.088 0.023 5<BR> VTAKELKFV PAP 30 A 9 0.0008 0.0042 0.19 0.027 0.0002 2<BR> VVAKELKFV PAP 30 A 9 0.0055 0.0090 0.46 0.031 0.0002 3<BR> FLNESYKHEQV PAP 92 11 0.17 3.0 1.8 0.0097 0.0013 4<BR> TLMSAMTNV PAP 112 A 9 0.52 1.8 2.8 0.068 0.13 5<BR> LAALFPPEGV PAP 120 10 0.0025 0.023 0.60 0.0015 0.035 3<BR> LLALFPPEGV PAP 120 A 10 1.0 5.9 6.2 0.025 0.049 5<BR> LVALFPPEV PAP 120 A 10 0.032 0.25 2.1 0.0080 0.29 5<BR> ALFPPEGVSL PAP 122 10 0.018 0.39 0.075 0.0014 0.0005 3<BR> ALFPPEGVSV PAP 122 A 10 0.33 4.1 0.55 0.031 0.0018 4<BR> GLHGQDLFGV PAP 196 A 10 0.43 1.9 3.2 0.21 <0.0001 4<BR> LLPPYASCHL PAP 306 10 0.0062 0.22 0.062 0.011 0.0002 3<BR> LLPPYASCHV PAP 306 A 10 0.057 0.29 0.63 0.038 0.0015 4<BR> SLQCVSLHLL Kallikrein2 170 10 0.019 0.88 0.14 0.008 30.0016 4<BR> LLWQPIPVHT PAP 136 10 0.0082 0.098 0.;017 0.0003 0.0018 1 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6820 A2 Cross-<BR> reactivity<BR> LLWQPIPVHV PAP 136 A 10 0.20 2.4 0.57 0.013 0.13 5<BR> FLRPRSLQSV Kallikrein2 165 A 10 0.0036 0.12 0.38 0.0007 <0.0001 2<BR> FLRPRSLQPV Kallikrein2 165 A 10 0.0011 0.038 0.090 0.0010 <0.0001 2<BR> KVTEFMLAAGV Kallikrein2 191 A 11 0.028 0.13 0.76 0.071 0.026 5<BR> KVEFMLSAGV Kallikrein2 191 A 11 0.0028 0.010 0.18 0.0094 0.0024 3<BR> KVTEFMLPAGV Kallikrein2 191 A 11 0.0021 0.0046 0.073 0.0096 0.0006 2<BR> ALGTTAYV Kallikrein2 147 A 8 0.010 0.16 0.17 0.0002 0.0013 3<BR> ALGTTSYV Kallikrein2 147 A 8 0.0029 0.027 0.10 0.0001 0.0018 2<BR> ALGTTTVY Kallikrein2 147 A 8 0.00-64 0.044 0.24 0.002 0.0008 2<BR> ALGTTVYV Kallikrein2 147 A 8 0.0857 0.40 0.97 0.0003 0.0001 3<BR> ALSVGATGV Kallikrein2 9 A 9 0.0077 0.055 0.39 0.0012 0.0024 2<BR> ALSVGPTGV Kallikrein2 9 A 9 0.0069 0.029 0.13 0.0001 0.0001 2<BR> ALSVGSTGV Kallikrein2 9 A 9 0.0027 0.076 0.14 0.0003 0.0014 2<BR> FLLAAGLWT Kallikrein2 195 A 9 0.30 0.012 0.092 0.014 0.0002 4<BR> FLLPAGLWT Kallikrein2 195 A 9 2.1 0.024 0.15 0.030 <0.0001 4<BR> FLLSAGLWT Kallikrein2 195 A 9 7.96 0.038 0.0947 0.028 0.00002 4<BR> FLLTAGLWT Kallikrein2 195 A 9 0.53 0.017 0.069 0.022 0.00003 4<BR> ALSVGTTGV Kallikrein2 9 A 9 0.0043 0.11 0.19 0.00002 <0.0001 2<BR> ALSVGVTGV Kallikrein2 9 A 9 0.5 0.38 1.4 0.0061 0.0001 3<BR> FMLAAGLWV Kallikrein2 195 A 9 2.9 0.33 4.8 0.55 0.0002 4<BR> FMLPAGLWV Kallikrein2 195 A 9 0.94 0.12 1.5 0.65 0.0003 4<BR> FMLSAGLWV Kallikrein2 195 A 9 1.2 0.35 2.5 0.42 0.0004 4 Sequence Protein/Segment 1st Position AnalogAA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> FMLTAGLWV Kallikrein2 195 A 9 0.75 0.13 0.59 0.26 0.0003 4<BR> FMLVAGLWV Kallikrein2 195 A 9 0.39 0.021 0.31 0.19 0.0002 4<BR> KLQAVDLHV PSA 166 A 9 0.012 0.015 0.022 0.0014 0.0002 3<BR> KVTKFMLAV PSA 187 A 9 0.042 0.034 1.0 0.12 0.0009 4<BR> KVTKFMLPV PSA 187 A 9 0.17 0.096 2.6 0.39 0.0048 4<BR> KVTKFMLSV PSA 187 A 9 0.047 0.025 2.7 0.11 0.0011 4<BR> KVTKFMLTV PSA 187 A 9 0.056 0.038 1.2 0.081 0.0006 4<BR> KVTKFMLVV PSA 187 A 9 0.029 0.012 0.93 0.061 0.0004 4<BR> FLTPKKLQAV PSA 161 A 10 0.0009 0.0093 0.030 0.0028 <0.0001 2<BR> FLTPKKLQPV PSA 161 A 10 0.0007 0.027 0.83 0.0068 <0.0001 2<BR> FLTPKKLQSV PSA 161 A 10 0.011 0.11 0.14 0.0045 0.0001 3<BR> FLTPKKLQTV PSA 161 A 10 0.0062 0.12 0.19 0.0031 <0.0001 2<BR> FLTPKKLQVV PSA 161 A 10 0.0071 0.11 0.21 0.0033 <0.0001 2<BR> KLQAVDLHVV PSA 166 A 10 0.044 0.51 0.70 0.020 0.0002 4<BR> KLQPVDLHVV PSA 166 A 10 0.0054 0.11 0.36 0.030 <0.0001 3<BR> KLQSVDLHVV PSA 166 A 10 0.017 0.12 0.43 0.011 0.0001 4<BR> KLQTVDLHVV PSA 166A 10 0.018 0.11 0.35 0.022 0.0004 4<BR> KLQVVDLHVV PSA 166A 10 0.077 0.22 2.8 0.0377 0.00034<BR> LVANGVLQGV Kallikrein2 217 A 10 0.040 0.19 4.3 0.15 0.66 5<BR> LVPNGVLQGV Kallikrein2 217 A 100.25 0.35 2.8 0.62 0.41 5<BR> LVSNGVLQGV Kallikrein2 217 A 10 0.045 0.40 8.6 0.13 1.3 5<BR> LVTNGVLQGV Kallikrein2 217 A 10 0.028 0.12 6.6 0.30 0.89 5 Sequence Protein/Segment 1st Position AnalogAA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> LVVNGVLQGV Kallikrein2 217 A 10 0.12 0.087 2.9 0.096 0.46 5<BR> SLQAVSLHLV Kallikrein2 170 A 10 0.019 0.39 1.6 0.021 0.0053 4<BR> SLQPVSLHLV Kallikrein2 170 A 10 0.012 0.16 0.31 0.032 0.0013 4<BR> SLQSVSLHLV Kallikrein2 170 A 10 0.020 0.12 0.18 0.035 0.0022 4<BR> SLQTVSLHLV Kallikrein2 170 A 10 0.023 0.19 0.69 0.037 0.0036 4<BR> SLQVVSLHLV Kallikrein2 170 A 10 0.049 0.15 0.93 0.046 0.0033 4<BR> FLRPRSLQVV Kallikrein2 165 A 10 0.014 0.33 0.40 0.015 0.0003 4<BR> FLRPRSLQTV Kallikrein2 165 A 10 0.0057 0.083 0.067 0.0039 0.0006 2<BR> FLRPRSLQAV Kallikrein2 165 A 10 0.023 0.33 0.63 0.0038 0.0002 3<BR> ILLSVGPTGAV Kallikrein2 8 A 11 0.0056 0.016 0.17 0.0004 0.0008 2<BR> ILLSVGVTGAV Kallikrein2 8 A 11 0.023 0.037 0.33 0.0091 0.0009 4<BR> PLVANGVLQGV Kallikrein2 216 A 11 0.11 0.012 0.13 0.018 0.0028 4<BR> PLVPNGVLQGV Kallikrein2 216 A 11 0.19 0.050 0.55 0.11 0.0006 4<BR> PLVSNGVLQGV Kallikrein2 216 A 11 0.088 0.019 0.13 0.022 0.0019 4<BR> PLVTNGVLQGV Kallikrein2 216 A 11 0.038 0.0046 0.077 0.0090 0.0008 3<BR> SLHLLSNDMAA Kallikrein2 175 A 11 0.11 1.8 0.36 0.0033 0.0004 3<BR> SLHLLSNDMSA Kallikrein2 175 A 11 0.015 1.1 0.22 0.003 0.0001 3<BR> SLHLLSNDMTA Kallikrein2 175 A 11 0.0582.4 0.33 0.0002 0.0001 3<BR> SLHLLSNDMVA Kallikrein2 175 A 11 0.047 0.88 0.30 0.0006 0.00033<BR> ALGTTCYA HuK2 147 8 0.048 0.054 0.27 0.0008 0.012 3<BR> MLLRLSEPA HuK2 122 9 0.053 0.018 0.013 0.0081 0.0016 3<BR> SLQCVSLHL HuK2 170 9 0.01 0.084 0.024 0.0006 0.0031 3 Sequence Protein/Segment 1st Position AnalogAA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> KVTEFMLCA HuK2 191 9 0.0035 0.0092 0.19 0.16 0.0004 3<BR> LLLARAASV PAP 6 A 9 0.28 0.02 1.5 0.039 0.0004 4<BR> SLSLGFLFV PAP 13 A 9 0.12 0.73 2.2 0.13 0.0017 4<BR> FLFLLFFWV PAP 18 A 9 0.12 0.014 0.016 0.012 0.0887 4<BR> GVSIWNPIV PAP 128A 9 0.011 0.016 0.011 0.012 0.0001 3<BR> TVSGLQMAV PAP 292 A 9 0.017 0.35 0.082 0.019 1.4 5<BR> FLTLSVTWV PSA 3 A 9 0.095 0.51 1.2 0.076 0.0006 4<BR> TLSVTWIGV PSA 5 A 9 0.19 0.88 0.25 0.0052 0.035 4<BR> KVTKFMLCV PSA 187 A 9 0.072 0.0083 0.19 0.029 0.0005 3<BR> ALSVGCTGAV HuK2 9 10 0.018 0.26 0.4 0.0051 0.0012 3<BR> QVAVYSHGWA HuK2 39 10 0.0004 0.0097 0.02 0.0005 0.0252 3<BR> LMLLRLSEPA HuK2 121 10 0.025 0.26 0.15 0.004 0.0016 3<BR> FLRPRSLQCV HuK2 165 10 0.041 0.094 1.1 0.0068 0.0036 3<BR> LVCNGVLQGI HuK2 217 10 0.0068 0.096 0.11 0.03 0.016 4<BR> RAAPLLLARA PAP 2 10 0.0026 0.17 0.2 0.16 0.0007 3<BR> LLARAASLSV PAP 7 A 10 0.046 0.44 0.47 0.0098 0.011 4<BR> SLSLGFLFLV PAP 13 A 10 0.15 0.38 0.37 0.093 0.0095 4<BR> SLLAKELKFV PAP 29 A 10 0.078 0.76 2.6 0.098 0.0012 4<BR> VLAKELKFVV PAP 30 A 10 0.16 0.36 0.053 0.043 0.0035 4<BR> TLMSAMTNLY PAP 112 A 10 0.08 1.1 0.83 0.086 0.033 4<BR> LLALFPPEGV PAP 120 A 10 0.16 11 2 0.1 0.05 5<BR> LVALFPPEGV PAP 120 A 10 0.043 0.31 0.86 0.078 2.4 5 Sequence Protein/Segment 1st Position AnalogAA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> ALFPPEGVSV PAP 122 A 10 0.44 8 3.4 0.31 0.058 5<BR> GVSIWNPILV PAP 128 A 10 0.02 0.046 0.43 0.0082 0.0035 4<BR> PLLLWQPIPV PAP 134 A 10 0.021 0.092 0.52 0.011 0.0034 4<BR> LLWQPIPVHV PAP 136 A 10 0.87 2.1 0.57 0.032 0.19 5<BR> GLHGQDLFGV PAP 196 A 10 0.27 1.2 2.6 0.63 0.0082 4<BR> KLRELSELSV PAP 234 A 10 0.019 0.47 1.4 0.075 0.0044 4<BR> EILNHMKRAT PAP 26610 0.0019 0.012 0.064 0.016 0.0028 3<BR> DTTVSGLQMA PAP 290 10 0.005 0.11 0.082 0.012 0.011 3<BR> LLPPYASCHV PAP 306 A 10 0.053 0.24 0.67 0.017 0.0027 4<BR> LTLSVTWIGA PSA 4 10 0.0018 0.045 0.082 0.011 0.0914<BR> KLQCVDLHVV PSA 166 A 10 0.4 0.051 1.1 0.0074 0.0003 4<BR> VLVHPQWVLTA HuK2 53 11 0.012 2.1 0.14 0.019 0.0008 4<BR> VLVHPQWVLTV HuK2 53 A 11 0.68 2.9 3.8 0.34 0.0018 4<BR> LVHPQWVLTAA HuK2 54 11 0.003 0.015 0.49 0.03 0.0034 3<BR> DLMLLRLSEPV HuK2 120 A 11 0.1 0.075 0.35 0.025 0.0029 4<BR> SLHLLSNDMCA HuK2 175 11 0.039 1.9 0.69 0.0005 0.0004 3<BR> HLLSNDMCARA HuK2 177 11 0.029 0.052 0.11 0.0088 0.0004 4<BR> KVTEFMLCAGL HuK2 191 11 0.001 0.028 0.028 0.016 0.0036 3<BR> PLVCNGVLQGV HuK2 216 A 11 0.22 0.017 0.36 0.03 0.0049 4<BR> RAAPLLLARAA PAP 2 11 0.0001 0.18 .14 0.047 0.0037 3<BR> LLLARAASLSL PAP 6 11 0.62 1.4 1.9 0.046 0.056 5<BR> AASLSLGFLFL PAP 11 11 0.022 0.19 0.19 0.039 0.0006 4 Sequence Protein/Segment 1st Position AnalogAA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> FLLFFWLDRSV PAP 20 11 0.37 0.26 3.6 0.013 0.022 5<BR> LLFFWLDRSVL PAP 21 11 0.077 1.5 3.7 0.0045 0.0018 3<BR> VLAKELKFVTL PAP 30 11 0.72 0.53 0.47 0.15 -0.0002 4<BR> FLNESYKHEQV PAP 92 11 0.049 1.9 1.2 0.37 0.001 4<BR> VVFLTLSVTWV PSA 1 A 11 0.056 0.049 0.14 0.011 0.0006 4<BR> FLTLSVTWIGV PSA 3 A 11 0.73 1.4 0.56 0.057 0.07 5<BR> VLVHPQWVLTV PSA 49 A 11 0.1 0.6 0.44 0.019 0.0008 4<BR> SVFHPEDTGQV PSA 75 A 11 0.0038 0.13 0.19 0.0018 0.25 3<BR> DLMLLRLSEPV PSA 116 A 11 0.023 0.017 0.091 0.0022 0.0016 3<BR> HLISNDVCAQV PSA 173 A 11 0.0035 0.6 0.15 0.0028 0.026 3<BR> PLVCNGVLQGV ESA 212 A 11 0.13 0.022 0.4 0.035 0.0075 4<BR> RAAPLLLA PAP 2 8<BR> PLLLARAA PAP 5 8<BR> LLARAASL PAP 7 8<BR> SLGFLFLL PAP 15 8<BR> WLDRSVLA PAP 25 8<BR> LAKELKFV PAP 31 8<BR> ELKFVTLV PAP 34 8<BR> DTFPTDPI PAP 51 8<BR> GMEQHYEL PAP 74 8<BR> STDVDRTL PAP 106 8<BR> RTLMSAMT PAP 111 8 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> LMSAMTNL PAP 113 8<BR> SAMTNLAA PAP 115 8<BR> AMTNLAAL PAP 116 8<BR> ALFPPEGV PAP 122 8<BR> GVSIWNPI PAP 128 8<BR> SIWNPILL PAP 130 8<BR> PILLWQPI PAP 134 8<BR> LLWQPIPV PAP 136 8<BR> PLSEDQLL PAP 147 8<BR> FIATLGKL PAP 187 8<BR> TLGKLSGL PAP 190 8<BR> FTLPSWAT PAP 221 8<BR> WATEDTMT PAP 226 8<BR> TMTKLREL PAP 231 8<BR> KLRELSEL PAP 234 8<BR> ELSELSLL PAP 237 8<BR> SLLSLYGI PAP 242 8<BR> RLQGGVLV PAP 257 8<BR> GLVVNEIL PAP 261 8<BR> ILNHMKRA PAP 267 8<BR> HMKRATQI PAP 270 8<BR> QIPSYKKL PAP 276 8 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> IMYSAHDT PAP 284 8<BR> TTVSGLQM PAP 291 8<BR> TVSGLQMA PAP 292 8<BR> GLQMALDV PAP 295 8<BR> ALDVYNGL PAP 299 8<BR> EMYYRNET PAP 328 8<BR> PLERFAEL PAP 352 8<BR> FAELVGPV PAP 356 8<BR> VIPQDWST PAP 363 8<BR> TTNSHQGT PAP 374 8<BR> LLHETDSA PSM 4 8<BR> ETDSAVAT PSM 7 8<BR> TARRPRWL PSM 14 8<BR> WLCAGALV PSM 20 8<BR> CAGALVLA PSM 22 8<BR> VLAGGFFL PSM 27 8<BR> LAGGFFLL PSM 28 8<BR> FIKSSNEA PSM 42 8<BR> NITPKHNM PSM 51 8<BR> FLYNFTQI PSM 73 8<BR> FTQIPHLA PSM 77 8<BR> QIPHLAGT PSM 79 8 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> GTEQNFQL PSM 85 8<BR> GLDSVELA PSM 104 8<BR> ELAHYDVL PSM 109 8<BR> LAHYDVLL PSM 110 8<BR> LLSYPNKT PSM 116 8<BR> DIVPPFSA PSM 156 8<BR> SAFSPQGM PSM 162 8<BR> GMPEGDLV PSM 168 8<BR> DLVYVNYA PSM 173 8<BR> RTEDFFKL PSM 181 8<BR> KLERDMKI PSM 187 8<BR> KINGSGKI PSM 193 8<BR> VIARYGKV PSM 201 8<BR> KVFRGNKV PSM 207 8<BR> KVKNAQLA PSM 213 8<BR> QLAGAKGV PSM 218 8<BR> LAGAKGVI PSM 219 8<BR> VILYSDPA PSM 225 8<BR> GVQRGNIL PSM 252 8<BR> NILNLNGA PSM 257 8<BR> PLTPGYPA PSM 267 8<BR> YAYRRGIA PSM 277 8 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> GIAEAVGL PSM 282 8<BR> EAVGLPSI PSM 285 8<BR> SLKVPYNV PSM 322 8<BR> HIHSTNEV PSM 345 8<BR> STNEVTRI PSM 348 8<BR> EVTRIYNV PSM 351 8<BR> VTRIYNVI PSM 352 8<BR> RIYNVIGT PSM 354 8<BR> VIGTLRGA PSM 358 8<BR> AVEPDRYV PSM 365 8<BR> GIDPQSGA PSM 385 8<BR> GAAVVHEI PSM 391 8<BR> AAVVHEIV PSM 392 8<BR> EIVRSFGT PSM 397 8<BR> IVRSFGTL PSM 398 8<BR> ILFASWDA PSM 416 8<BR> DAEEFGLL PSM 422 8<BR> LLGSTEWA PSM 428 8<BR> WAEENSRL PSM 434 8<BR> RLLQERGV PSM 440 8<BR> LLQERGVA PSM 441 8<BR> YINADSSI PSM 449 8 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> SIEGNYTL PSM 455 8<BR> YTLRVDCT PSM 460 8<BR> RVDCTPLM PSM 463 8<BR> CTPLMYSL PSM 466 8<BR> GMPRISKL PSM 508 8<BR> SVYETYEL PSM 554 8<BR> PMFKYHLT PSM 568 8<BR> YAQVRGGM PSM 576 8<BR> ELANSIVL PSM 586 8<BR> AVVLRKYA PSM 601 8<BR> YADKIYSI PSM 607 8<BR> SMKHPQEM PSM 615 8<BR> AVKNFTEI PSM 635 8<BR> RMMNDQLM PSM 662 8<BR> QLMFLERA PSM 667 8<BR> EVKRQIYV PSM 727 8<BR> QIYVAAFT PSM 731 8<BR> VAAFTVQA PSM 734 8<BR> AAFTVQAA PSM 735 8<BR> TVQAAAET PSM 738 8<BR> AAETLSEV PSM 742 8<BR> LVHETDSAV PSM 4 A 9 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> ETDSAVATA PSM 7 9<BR> WLCAGALVV PSM 20 A 9<BR> LVLAGGFFV PSM 26 A 9<BR> FIKSSNEAT PSM 42 9<BR> ITPKHNMKA PSM 52 9<BR> KAFLDELKA PSM 59 9<BR> GTEQNFQLA PSM 85 9<BR> ELAHYDVLV PSM 109 A 9<BR> LVYNVYART PSM 174 9<BR> GVILYSDPA PSM 224 9<BR> ALGLPSIPV PSM 286 A 9<BR> DAQKLLEKM PSM 301 9<BR> KVKMHIHST PSM 341 9<BR> HIHSTNEVT PSM 345 9<BR> NVIGTLRGA PSM 357 9<BR> GIDPQSGAA PSM 385 9<BR> TILFASWDA PSM 415 9<BR> GLLGSTEWV PSM 427 A 9<BR> TLRVDCTPV PSM 461 A 9<BR> LASGRARYT PSM 530 9<BR> SLYETYELV PSM 554 A 9<BR> LVEKFYDPM PSM 561 9 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> PLFKYHLTV PSM 568 A 9<BR> PVFKYHLTV PSM 568 A 9<BR> TVAQVRGGM PSM 575 9<BR> MVFELANSV PSM 583 A 9<BR> YAVVLRKYA PSM 600 9<BR> AVKNFTEIA PSM 635 9<BR> EVKROIYVA PSM 727 9<BR> QLYVAAFTV PSM 731 A 9<BR> QVYVAAFTV PSM 731 A 9<BR> YVAAFTVQA PSM 733 9<BR> VAAFTVQAA PSM 734 9<BR> AAFTVQAAA PSM 735 9<BR> PTVQAET PSM 737 9<BR> AAETLSEVA PSM 742 9<BR> NVLHETDSAV PSM 3 A 10<BR> TARRPRWLCA PSM 14 10<BR> WLCAGALVLV PSM 20 A 10<BR> ALVLAGGFFV PSM 25 A 10<BR> LVLAGFFLV PSM 26 A 10<BR> LLGFLFGWFV PSM 34 A 10<BR> ATNITPKHNM PSM 49 10<BR> NITPKHNMKA PSM 51 10 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> FLDELKAENV PSM 61 A 10<BR> NIKKFLYNFT PSM 69 10<BR> FTQIPHLAGT PSM 77 10<BR> DVLISYPNKT PSM 114 10<BR> KVKNAQLAGA PSM 213 10<BR> YAYRRGIAEA PSM 277 10<BR> PVHPIGYYDA PSM 293 10<BR> KLHIHSTNEV PSM 343 A 10<BR> KVHIHSTNEV PSM 343 A 10<BR> VTRIYNVIGT PSM 352 10<BR> RTILFASWDA PSM 414 10<BR> LLQERGVAYV PSM 441 A 10<BR> KVGSGNDFEV PSM 514 A 10<BR> EVFFQRLGIA PSM 522 10<BR> GIASGRARYT PSM 529 10<BR> RARYTKNWET PSM 534 10<BR> LTVAQVRGGM PSM 574 10<BR> MLFELANSIV PSM 583 A 10<BR> VLPFDCRDYV PSM 592 A 10<BR> YADKIYSISM PSM 607 10<BR> SISMKHPQEM PSM 613 10<BR> SVSFDSIFSDA PSM 626 10 Sequence Protein/Segment 1st Positiond Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> SLFSAVKNFV PSM 631 A 10<BR> SAVKNFTEIA PSM 634 10<BR> FLERAFIDPV PSM 670 A 10<BR> YAPSSHNKYA PSM 692 10<BR> EVKRQIYVAA PSM 727 10<BR> YVAAFTVQAA PSM 733 10<BR> VAAFTVQAAA PSM 734 10<BR> AAAETLSEVA PSM 741 10<BR> DVDRTLMSAMT PAP 108 11<BR> RTLMSAMTNLA PAP 111 11<BR> TLMSAMTNLAA PAP 112 11<BR> LMSAMTNLAAL PAP 113 11<BR> NLAALFPPEGV PAP 119 11<BR> AALFPPEGVSI PAP 121 11<BR> ILLWQPIPVHT PAP 135 11<BR> LLWQPIPVHTV PAP 136 11<BR> HTVPLSEDQLL PAP 144 11<BR> TLKSEEFQKRL PAP 171 11<BR> RLHPYKDFIAT PAP 180 11<BR> FATLGKISGL PAP 187 11<BR> KVYDPLYCESV PAP 208 11<BR> PLYCESSVHNFT PAP 212 11 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> SVHNFTLPSWA PAP 217 11<BR> FTLPSWATEDT PAP 221 11<BR> TLPSWATEDTM PAP 222 11<BR> TMTKLRELSEL PAP 231 11<BR> KLRELSELSLL PAP 234 11<BR> GIGIHKQKEKSRL PAP 248 11<BR> RLQGGVLVNEI PAP 257 11<BR> GVLVNEILNHM PAP 261 11<BR> ILNHMKRATQI PAP 267 11<BR> RATQIPSYKKL PAP 273 11<BR> ATQIPSYKKLI PAP 274 11<BR> KLIMYSAHDTT PAP 282 11<BR> LIMYSHDTTV PAP 283 11<BR> DTTVSGLQMAL PAP 290 11<BR> TVSGLQMALDV PAP 292 11<BR> QMALDVYNGLL PAP 297 11<BR> DVYNGLLPPYA PAP 301 11<BR> GLLPPYASCHL PAP 305 11<BR> LLPPYASCHLT PAP 306 11<BR> ELYFEKGEYFV PAP 317 11<BR> ETQHEPYPLML PAP 334 11<BR> MLPGCSPSCPL PAP 343 11 Sequence Protem/Segment 1st Position Analog AA A*0201 A*0202 A*)203 A*02026 A*6802 A2 Cross-<BR> reactivity<BR> VIPQDWSTECM PAP 363 11<BR> NLLHETDSAVA PSM 3 11<BR> LLHETDSAVAT PSM 4 11<BR> AVATARRPRWL PSM 11 11<BR> ATARRPRWLCA PSM 13 11<BR> GALVLAGGFFL PSM 24 11<BR> ALVLAGGFFLL PSM 25 11<BR> LAGGFFLLGFL PSM 28 11<BR> FLLGFLFGWFI PSM 33 11<BR> FIKSSNEATNI PSM 42 11<BR> EATNITPKHNM PSM 48 11<BR> ITPKHNMKAFL PSM 52 11<BR> NMKAFLDELKA PSM 57 11<BR> ELKAENIKKFL PSM 64 11<BR> FLYNFTQIPHL PSM 73 11<BR> HLAGTEQNFQL PSM 82 11<BR> LAGTEQNFQLA PSM 83 11<BR> QIQSQKEFGL PSM 95 11<BR> SVELAHYDVLL PSM 107 11<BR> NVSDIVPPFSA PSM 153 11<BR> DMKINCSGKIV PSM 191 11<BR> KINCSGKIVIA PSM 193 11 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> KVFRGNKVKNA PSM 207 11<BR> NAQLAGAKGVI PSM 216 11<BR> ILYSDPADYFA PSM 226 11<BR> GVKSYPDGWNL PSM 238 11<BR> ILNLNGAGDPL PSM 258 11<BR> LTPGYPANEYA PSM 268 11<BR> PANEYAYRRGI PSM 273 11<BR> YAYRRGLAEAV PSM 277 11<BR> GIEAVGLPSI PSM 282 11<BR> PIGYYDAQKLL PSM 296 11<BR> KVPYNVGPGFT PSM 324 11<BR> PMHIHSTNEVT PSM 343 11<BR> HIHSTNEVTRI PSM 345 11<BR> STNEVTRIYNV PSM 348 11<BR> EVTRIYNVIGT PSM 351 11<BR> VTRIYNVIGTL PSM 352 11<BR> GAVEPDRYVIL PSM 364 11<BR> VILGGHRDSWV PSM 372 11<BR> GIDPQSGAAVV PSM 385 11<BR> VVHEIVRSFGT PSM 394 11<BR> FASWDAEEFGL PSM 418 11<BR> DAEEFGLLGST PSM 422 11 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> STEWAEENSRL PSM 431 11<BR> RLLQERGVAYI PSM 440 11<BR> GVAYINADSSI PSM 446 11<BR> NADSSIEGNYT PSM 451 11<BR> YTLRVDCTPLM PSM 460 11<BR> RVDCTPLMYSL PSM 463 11<BR> PLMYSLVHNLT PSM 468 11<BR> HLTVAQVRGGM PSM 573 11<BR> LTVAQVRGGMV PSM 574 11<BR> QVRGGMVFELA PSM 578 11<BR> GMVFELANSIV PSM 582 11<BR> MVFELANSIVL PSM 583 11<BR> IVLPFDCRDYA PSM 591 11<BR> VLPFDCRDYAV PSM 592 11<BR> AVVLRKYADKI PSM 601 11<BR> SVSFDSLFSAV PSM 626 11<BR> RLQDFDKSNPI PSM 649 11<BR> PIVLRMMNDQL PSM 658 11<BR> IVLRMMNDQLM PSM 659 11<BR> GLPDRPFYRHV PSM 680 11<BR> DIESKVDPSKA PSM 714 11<BR> KVDPSKAWGEV PSM 718 11 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> QIYVAAFTVQA PSM 731 11<BR> YVAAFTQAAA PSM 733 11<BR> AAFTVQAAAET PSM 735 11<BR> QAAAETLSEVA PSM 740 11<BR> PQGFGQLT PAP 64 8<BR> GQLTQLGM PAP 68 8<BR> EQVYIRST PAP 100 8<BR> WQPIPVHT PAP 138 8<BR> FQELESET PAP 164 8<BR> KQKEKSRL PAP 251 8<BR> TQHEPYPL PAP 335 8<BR> HQGTEDST PAP 378 8<BR> SQPWQVLV PSA 31 8<BR> LQCVDLHV PSA 167 8<BR> AQVHPQKV PSA 181 8<BR> PQKVTKFM PSA 185 8<BR> SQWKEFGL PSM 98 8<BR> AQKLLEKM IPSM 302 8<BR> TQKVKMHI PSM 339 8<BR> PQSGAAVV PSM 388 8<BR> AQVRGGMV PSM 577 8<BR> VQAAAETL PSM 739 8 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> WQPIPVHTV PAP 138 9<BR> FQELESETL PAP 164 9<BR> TQIPSYKKL PAP 275 9<BR> TQHEPYPLM PAP 335 9<BR> PQDWSTECMPAP 365 9<BR> SQPWQVLVA PSA 31 9<BR> LQCVDLHVI PSA 167 9<BR> AQVHPQKVT PSA 181 9<BR> PQKVTKFML PSA 185 9<BR> TQIPHLAGT PSM 78 9<BR> PQGMPEGDL PSM 166 9<BR> AQLAGAKGV PSM 217 9<BR> VQRGNILNL PSM 253 9<BR> LQERGVAYI PSM 442 9<BR> PQEMKTYSV PSM 619 9<BR> DQLMFLERA PSM 666 9<BR> RQIYVAAFT PSM 730 9<BR> KLTDVVKVL HuK2 131 9<BR> KVTDVVKVL HuK2 131 9<BR> KTTDVVKVL HuK2 131 9<BR> KITDVVKVV HuK2 131 9<BR> PLLGTTCYA HuK2 146 9 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> PVLGTTCYA HuK2 146 9<BR> PTLGTTCYA HuK2 146 9<BR> PALGTTCYV HuK2 146 9<BR> PQGFGQLTQL PAP 64 10<BR> EQHYELGEYI PAP 76 10<BR> EQVYIRSTDV PAP 100 10<BR> LQGGVLVNEI PAP 258 10<BR> TQIPSYKKLI PAP 275 10<BR> TQHEPYPLML PAP 335 10<BR> PQDWSTECMT PAP 365 10<BR> EQNFQLAKQI PSM 87 10<BR> IQSQWKEFGL PSM 96 10<BR> PQGMPEGDLV PSM 166 10<BR> AQLAGAKGVI PSM 217 10<BR> LQDFDKSNPI PSM 650 10<BR> RQIYVAAFTV PSM 730 10<BR> ILLSVGCTGA HuK2 8 10<BR> IVLSVGCTGA HuK2 8 10<BR> ITLSVGCTGA HuK2 8 10<BR> IALSVGCTGV HuK2 8 10<BR> GLVPLIQSRI HuK2 16 10<BR> GVVPLIQSRI HuK2 16 10 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> GTVPLIQSRI HuK2 16 10<BR> GAVPLIQSRV HuK2 16 10<BR> CLRAYSEKVT HuK2 184 10<BR> CVRAYSEKVT HuK2 184 10<BR> CTRAYSEKVT HuK2 184 10<BR> CARAYSEKVV HuK2 184 10<BR> TQLGMEQHYEL PAP 71 11<BR> WQPIPVHTVPL PAP 138 11<BR> GQDLFGIWSKV PAP 199 11<BR> LQGGVLVNEIL PAP 258 11<BR> TQIPSYKKLIM PAP 275 11<BR> LQMALDVYNGL PAP 296 11<BR> PQDWSTECMTT PAP 365 11<BR> WQVLVASRGRA PSA 34 11<BR> PQWVLTAAHCI PSA 53 11<BR> FQVSHSFPHPL PSA 86 11<BR> PQKVTKFMLCA PSA 185 11<BR> SQWKEFGLDSV PSM 98 11<BR> AQLAGAKGVIL PSM 217 11<BR> TQKVKMHIHST PSM 339 11<BR> PQSGAAVVHEI PSM 388 11<BR> LQERGVAYINA PSM 442 11 Sequence Protein/Segment 1st Position Analog AA A*0201 A*0202 A*0203 A*0206 A*6802 A2 Cross-<BR> reactivity<BR> FQRLGIASGRA PSM 525 11<BR> AQVRGGMVFEL PSM 577 11<BR> LQDFDKSNPIV PSM 650 11<BR> DQLMFLERAFI PSM 666 11<BR> VQAAAETLSEV PSM 739 11<BR> SLALSVGCTGA HuK2 7 11<BR> SVALSVGCTGA HuK2 7 11<BR> STALSVGCTGA HuK2 7 11<BR> SIALSVGCTGV HuK2 7 11 Table 17<BR> Peptide Sequence Organism Protein/Segment 1st Position Analog AA A*0201 Analog type<BR> 1413.08 GLAPPQQLIRV Human p53 187 A 11 0.45 Heteroclitics<BR> 1413.10 GLAPPQSLIRV Human p53 187 A 11 1.5 Heteroclitics<BR> 1413.11 LLGRDSFEV Human mp53 261 A 9 1.6<BR> 1413.12 LLSRDSFEV Human mp53 261 A 9 0.17 Heteroclitics<BR> 1413.13 LLDRDSFEV Human mp53 261 A 9 1.1 Heteroclitics<BR> 1413.14 LLHRDSFEV Human mp53 261 A 9 1.5 Heteroclitics<BR> 1413.15 LLGRNSFEV Human p53 264 A 9 0.035<BR> 1413.16 LLGRQSFEV Human mp53 264 A 9 0.066 Heteroclitics<BR> 1413.17 LLGRGSFEV Human mp53 264 A 9 0.026 Heteroclitics<BR> 1413.18 LLGRDSLEV Human mp53 264 A 9 0.025 Heteroclitics<BR> 1413.19 LLGRDSMEV Human mp53 264 A 9 0.012 Heteroclitics<BR> 1413.20 LLGRDSHEV Human mp53 264 A 9 0.60 Heteroclitics<BR> 54.0078 YLQLVFGIEV Human MAGE2 157 A 10 0.018<BR> 54.0084 YLQLIFGIEV Human MAGE2 157 A 10 0.013 Heteroclitics<BR> 55.0234 YLQLFFGIEV Human MAGE2 157 A 10 0.046 Heteroclitics<BR> 54.0003 SMPPPGTRV Human p53 149 A 9 0.079 Heteroclitics<BR> 54.0005 CMPPPGTRV Human p53 149 A 9 0.182 Heteroclitics<BR> 55.0049 SMPPPGRRV Human p53 149 A 9 0.011 Heteroclitics Peptide Sequence Orgnaism Protein/Segment 1st Position Analog AA A*0201 Analog type<BR> 55.0155 ILLEPVHGV HIV POL 476 A 9 0.0075 Heteroclitics<BR> 54.0063 ILHEPVHGV HIV POL 476 A 9 0.019 Heteroclitics<BR> 55.0123 GLSRYVPRL HIV POL 455 A 9 0.098 Heteroclitics<BR> 54.0042 GLSRYVARL HIV POL 455 A 9 0.057 Heteroclitics<BR> 55.0153 ILVEPVHGV HIV POL 476 A 9 0.0060 Heteroclitics<BR> 55.0185 ILKDPVHGV HIV POL 476 A 9 0.026 Heteroclitics<BR> 55.0159 ILKQPVHGV HIV POL 476 A 9 0.0063 Heteroclitics<BR> 55.0160 ILKNPVHGV HIV POL 476 A 9 0.0055 Heteroclitics<BR> 55.0161 ILKHPVHGV HIV POL 476 A 9 0.0005 Heteroclitics<BR> 55.0162 ILKTPVHGV HIV POL 476 A 9 0.0011 Heteroclitics<BR> 55.0163 ILKRPVHGV HIV POL 476 A 9 0.015 Heteroclitics<BR> 55.0164 ILKVPVHGV HIV POL 476 A 9 0.0048 Heteroclitics<BR> 55.0165 ILKLPVHGV HIV POL 476 A 9 0.010 Heteroclitics<BR> 55.0166 ILKYPVHGV HIV POL 476 A 9 0.032 Heteroclitics<BR> 55.0167 ILKFPVHGV HIV POL 476 A 9 0.077 Heteroclitics<BR> 55.0168 ILKETVHGV HIV POL 476 A 9 0.011 Heteroclitics<BR> 55.0169 ILKESVHGV HIV POL 476 A 9 0.19 Heteroclitics<BR> 55.0170 ILKEFVHGV HIV POL 476 A 9 0.024 Heteroclitics Table 8<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*0301 A*1101 A*3101 A*3301 A*6801<BR> 78.0064 AACHKCIDFY HPV45.E6.63 7769 3564830 10647 4958<BR> 78.0048 AACHKCIDFY HPV18.E6.63 18824 306 20643 >97403.22 31622<BR> 78.0316 AACWRSRRR HPV33.E6.17 13039 9433 407 913 983<BR> 78.0058 AFADLTVVYR HPV33.E6.46 24059 5093 140 249 39<BR> 78.0063 AFKDLCIVYR HPV45.E6.48 13166 3661 26 29 548<BR> 78.0093 AFKDLFVVYR HPV18.E6.48 46161 1035 8.3 14 365<BR> 78.079 AFRDLCIVYR HPV16.E6.53 3106 4377 13 41 600<BR> 78.0052 AFTDLTIVYR HPV31.E6.46 26603 300 810 817 210<BR> 78.0281 AQPATADYY HPV33.E7.45 43 15 10.3 32 23<BR> 78.0294 ATLESITKK HPV56.E6.898 302 160 261 >81119.6 >32130.33<BR> 78.0272 ATLQDIVLH HPV18.E7.6 76 251 >141552.48 >107282.02 3756<BR> 78.0023 ATSNYYIVTY HPV52.E7.50 2437 167 27613 154330 24292<BR> 78.0043 AVCDKCLKFY HPV16.E6.68 561 88 1959 47868 3323<BR> 78.0068 AVCRVCLLFY HPV56.E6.64 77 21 19878 4520 1302<BR> 78.0298 AVCWRPRRR HPV58.E6.137 3.9 13 395 799 23<BR> 78.0284 CIAYAACHK HPV45.E6.59 831 226 8103 17514 1011<BR> 78.0151 CLLFYSKVRK HPV56.E6.69 342 249 3343 9357 405<BR> 78.0061 CVYCKATLER HPV45.E6.32 24489 28088 334 963 4485<BR> 78.0095 DSIPHAACHK HPV18.E6.58 25343 1874 1886 14 69<BR> 78.0049 DSVYGDTLEK HPV18.E6.83 4717 415 51213 116894 408<BR> 78.0297 DTLEQTLKK HPV58.E6.86 446 139 714 5826 2488<BR> 78.0313 EGNPFGICK HPV33.E6.56 406962662 602 585 28<BR> 78.0322 ELQRREVYK HPV52.E6.36 5603 18788 407 17506 25869<BR> 78.0072 ETSVHEIELK HPV58.E6.20 31644 5335 31702 98886 41 Table 18<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*0301 A*1101 A*3101 A*3301 A*6801<BR> 78.0335 FADLRIVYR HPV58.E6.47 5447 20911 86 24176 >30740.14<BR> 78.0115 FAFADLTVVY HPV33.E6.45 18592 5866 23676 26768 402<BR> 78.0103 FAFTDLTIVY HPV31.E6.45 40343 21161 42065 131202 346<BR> 78.0111 FCCQCKSTLR HPV31.E7.57 8975 8510 2056 96 15816<BR> 78.0293 GALESITK HPV56.E6.88 187 300 861 1884 6558<BR> 78.0069 GATLESITKK HPV56.E6.88 1860 283 8619 8728 2487<BR> 78.0046 GIVCPICSQK HPV16.E7.88 2758 117 20749 93473 2714<BR> 78.0055 GTTLEKLTNK HPV31.E6.85 2049 176 3823 42078 16401<BR> 78.0044 GTTLEQQYNK HPV16.E6.92 10850 69 34193 101404 3935<BR> 78.0106 GVCTKCLRFY HPV31.E6.61 1482 244 7528 8360 24818<BR> 78.0326 GVDRPDGQA HPV52.E7.39 214 1290 3356 8720 >30740.14<BR> 78.0273 GVNHQHLPA HPV18.E7.43 816 26 862 1353 203<BR> 78.0100 GVNHQHLPAR HPV18.E7.43 3181 178 62 13039 2897<BR> 78.0134 GVFSHAQLPAR HPV45.E7.44 3689 221 2788 46952 16649<BR> 78.0274 HTMLCMCCK HPV18.E7.59 636 74 6491129386 3658<BR> 78.0265 IILECVYCK HPV16.E6.33 1644 235 5656 8957 1594<BR> 78.0165 ILIRCIICQR HPV58.E6.99 4366 490 379 4273 272<BR> 78.0117 ILIRCIICQR HPV33.E6.99 8550 502 377 2480 537<BR> 78.0311 IVCPNCSTR HPV31.E7.89 18461 >25210.31 350 64095 28178<BR> 78.0278 IVTFCCCK HPV31.E7.54 4511 152 15374 >107282.02 >16962.83<BR> 78.0283 IVYRDCIAY HPV45.E6.54 262 42 598 469 2555<BR> 78.0286 IVYRDNNPY HPV52.E6.52 9024 225 90928 8249 295<BR> 78.0081 KFYSKISEYR HPV16.E6.75 1684 18047 48 79 264<BR> 78.0082 KISEYRHYCY HPV16.E6.79 152 163 4847 2438 2004 Table 18<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*0301 A*1101 A*3101 A*3301 A*6801<BR> 78.0074 KISEYRHYNY HPV58.E6.72 197 1361759 40765 10323<BR> 78.0059 KISEYRHYNY HPV33.E6.72 42 112 1426 35341 25077<BR> 78.0331 KQHTCYLIH HPV56.E7.54 39392 >18660.01 526 521 439<BR> 78.0329 KQLCDLLIR HPV56.E6.97 3513 9972 39 12 58<BR> 78.0156 KQLHCDRKRR HPV56.E6.118 31894 >4691.24 289 71431 >13447.56<BR> 78.0083 KQRFHYNIRGR HPV16.E6.129 2037 11596 178 4441 10279<BR> 78.0288 KTLEERVKK HPV52.E6.86 2694 296 13241 54088 2353<BR> 78.0296 KVCLRLLSK HPV58.E6.64 9470 19 >6985.78 113285 4651<BR> 78.0275 KVSEFRWYR HPV31.E6.72 401 178 65947 >107282.02 43168<BR> 78.0053 KVSEFRWYRY HPV31.E6.72 248 23 11 7073 1908<BR> 78.0155 LCDLLIRCYR HPV56.E6.99 3984 273 856 405 2126<BR> 78.0137 LFTDLRIVYR HPV52.E6.46 57146 >4045.92 430 217 1890<BR> 78.0152 LFYSKVRKYR HPV56.E6.71 6622 6011 8.1 48 1892<BR> 78.0337 LIRCIICQR HPV58.E6.100 198 992 523 117540 >28524.17<BR> 78.0301 LIRCINCQK HPV16.E6.107 2182 216 6859 >74670.44 >34318.65<BR> 78.0317 LIRLRCQK HPV45.E6.102 5501 1647 353 5723 1321<BR> 78.0292 LLFYSKVRK HPV56.E6.70 106 18 3151 70793 33<BR> 78.0045 LLIRCINCQK HPV16.E6.106 296 71 556 5375 32<BR> 78.0108 LLIRCITCQR HPV31E6.99 3319 5272 168 739 30<BR> 78.0066 LLIRCLRCQK HPV45.E6.101 270 226 2496 11367 44<BR> 78.0051 LLIRCLRCQK HPV18.E6.101 437 211 6612 28936 78<BR> 78.0145 LQVVCPGCAR HPV52.E7.89 >55458.03 >1466.98 490 6225 19498<BR> 78.0306 LSFVCPWCA HPV18.E7.94 38337 10864 4289 4603 341<BR> 78.0047 LTEVFEFAFK HPV18E6.41 8672 113 37879 47752 27 Table 18<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*0301 A*1101 A*3101 A*3301 A*6801<BR> 78.0086 MSCCRSSRTR HPV16E6.144 571 829 324 1142 26<BR> 78.0324 NIMGREWTGR HPV52E6.127 38678 1940 41 448 26230<BR> 78.0057 NIVTFCCQCK HPV31.E7.53 3072 1957 6005 10314 199<BR> 78.0065 NSVYYGELTLEK HPV45.E6.83 63 127 5749 8928 289<BR> 78.0280 NTLEQTVKK HPV33E6.86 529 142 743 3428 224<BR> 78.0330 QQARQAKQH HPV56.E7.48 7172 2853 48 36 30<BR> 78.0327 QVVCPGCAR HPV52.E7.90 3819 16820 5080 92 5341<BR> 78.0119 RCAACWRSRR HPV33.E6.135 17390 28729 4862394 6645<BR> 78.0338 RCAVCWRPR HPV58.E6.135 54398 21282 2829 438 1440<BR> 78.0109 RCIACRRRPR HPV31.E6.135 1231 6604 64 438 5855<BR> 78.0097 RFHNIAGHYR HPV18.E6.126 2463 2855 11 99 151<BR> 78.0133 RFHSIAGQYR HPV45.E6.126 4278 3390 24 585 303<BR> 78.0140 RFLSKISEYR HPV52.E6.68 4860 >14665.98 27 749 36<BR> 78.0116 RFLSKISEYR HPV33.E6.68 1640 18468 33 426 172<BR> 78.0107 RFYSKVSEFR HPV31.E6.68 1382 17885 54 204 250<BR> 78.0098 RGQCHSCCNR HPV18.E6.135 22754 1938 192 318 4791<BR> 78.0163 RLLSKISEYR HPV58.E6.68 66 2507 42 1574 240<BR> 78.0320 RLQCVQCKK HPV52E6.27 2200 1289 386 336 993<BR> 78.0062 RTEVYQFAFK HPV45E6.41 285 111 1691 9180 3310<BR> 78.0291 RVCLLFYSK HPV56.E6.67 347 166 >77795.34 >81119.62 2622<BR> 78.0302 SCCRSSRTR HPV16.E6.145 288 230 525 106485 45541<BR> 78.0087 SCCRSSRTRR HPV16.E6.145 16439 21422 401 223 3608<BR> 78.0270 SIPHAACHK HPV18.E6.59 736 268 63 7253 403<BR> 78.0142 SLYGKTLEER HPV52.E6.82 56 1728 435 5499 178 Table 18<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*0301 A*1101 A*3101 A*3301 A*6801<BR> 78.0271 SVYGDTLEK HPV18.E6.84 2575 273 32513 22456 >17538<BR> 78.0285 SVYGETLEK HPV45.E6.84 169 490 795 60127 33480<BR> 78.0276 SYGTTLEK HPV31.E6.82 450 109 1595 1969 439<BR> 78.0076 TAMFQDPQER HPV16.E6.6 40463 2877 11713 8520 16<BR> 78.0303 TGLYNLLIR HPV18.E6.96 2737 2577 197 3780 2592<BR> 78.0333 TSVHEIELK HPV58.E6.21 51582 3692 665 1305 312<BR> 78.0277 TTLEKLTNK HPV31.E6.86 72 14 41179 79901 17<BR> 78.0135 TVESSAEDLR HPV45.E7.76 >58998.41 9973 89136 55083 205<BR> 78.0073 VFADLRIVYR HPV58E6.46 23042 2089 31 52 197<BR> 78.0321 VQCKKELQR HPV52.E6.31 54286 29279 3666049 21290<BR> 78.0295 VQLDIQSTK HPV56.E7.72 153 378 1066 40091 7535<BR> 78.0318 VSHAQLPAR HPV45.E7.45 9181 9024 1784 310 39<BR> 78.0282 VSIACVYCK HPV45.E6.28 19 3.8 8875 33911 15<BR> 78.0071 VVQLDIQSTK HPV56.E7.71 1862 143 35232 83649 3704<BR> 78.0118 WAGRCAACWR HPV33.E6.132 10060 10975 445 49 50<BR> 78.0075 WTGRCAVCWR HPV58.E6.132 4397 4806 358 107 59<BR> 78.0056 WTGRCIACWR HPV31E6.132 2260 1035 179 17 31<BR> 78.0084 WTGRCMSCCR HPV16.E6.139 11458 7557 3126 471 178<BR> 78.0067 WTGRCSECWR HPV52.E6.132 20400 1523 538 69 40<BR> 78.0070 WTGSCLGCWR HPV56.E6.135 25112 1624 208 60 23<BR> 78.0300 YAVCKCLK HPV16.E6.67 56 18 3195 87230 1948<BR> 78.0334 YDFVFADLR HPV58.E6.43 61113 24098 64 153 1332<BR> 78.0054 YSVYGTTLEK HPV31.E6.81 357 100 >100076.57 >36296.57 36 TABLE 19<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 21.0073 GIIHFSFPF 9 Candida.aur.168 18333.3 293.5<BR> 21.0053 LTSQFFLPA 9 Candida.aur.98 6821.9 152.2<BR> 21.0201 STMYLTHHYF 10 Candida.aur.301 >31754.26 36.1<BR> 1371.13 FVSNLATGK 9 CEA.656 A 3315.0 280.2 >17162.33 >48333.33 7.5<BR> 1371.12 HVQVLFIAR 9 CEA.636 A 10357.1 11131.7 1627.8 319.7 479.5<BR> 1371.08 IVPSYTYYK 9 CEA.420 A 17.9 63.3 1550.8 4505.5 21.5<BR> 1371.07 IVPSYTYRYR 9 CEA.420 A 91.4 14.4 49.6 118.7 1.9<BR> 1371.10 RVLTLFNVTK 10 CEA.554 A 20.9 31.2 234.1 42522.0 1738.1<BR> 1371.09 RVLTLFNVTR 10CEA.554 A 298.3 75.1 17.7 7745.4 42.9<BR> 1371.04 RVLTLLSVTK 10 CEA.376 A 38.6 50.1 165.5 >48333.33 4466.8<BR> 1371.03 RVLTLLSVTR 10 CEA.376 A 340.9 248.2 12.4 6127.4 519.5<BR> 1371.02 TVSPLNTSYK 10 CEA.241 A 17.4 11.1 13258.6 30398.3 12.1<BR> 1371.01 TVSPLNTSYR 10 CEA.21 A 365.7 62.4 194.3 646.5 12.4<BR> 1371.06 TVSPYSYTYYK 10 CEA.419 A 53.5 33.6 4172.3 30317.1 9.8<BR> 1371.05 TVSPSYTYYR 10 CEA.419 A 2495.9 3103.6 30.9 270.0 9.0<BR> 1120.17 TYQRTRALK 9 Flu.NP.17 A 32.0 66.5 16000.0<BR> 1.1076 GILYKRETTR 10 HBV.pol.729 >17614.1 >4615.38 2157.6 439.4 80000.0<BR> 1.0973 HLQEDIINR 9 HBV.pol.657 >4032.8 >4670.99 65.0 15.7 1600.0<BR> 1150.34 LAACFARDR 9 HBV.pol.731 >27500 30000.0 4352.9 1435.7 40.0<BR> 1150.32 LAIGHQRMR 9 HBV.pol.708 >27500 30000.0 2964.8 2165.8 66.7<BR> 1150.33 LAIGQSGMR 9 HBV.pol.708 >27500 15000.0 16431.7 7259.1 47.1<BR> 28.0747 LIMPARFYPK 10 HBV.pol.109 2.4 6.1<BR> 38.0397 LVMGHQRMR 9 HBV.pol.697 366.7 498.1<BR> 28.0396 LVNHYFQTR 9 HBV.pol.137 2053.4 363.7<BR> 1.0966 NVNMGLKIR 9 HBV.core.90 >4032.8 >470.99 3728.2 366.9 4705.9<BR> 28.0398 PINRPIDWK 9 HBV.pol.612 102.2 170.3<BR> 1.0984 VLKLKQCFR 9 HBV.pol.1186 15877.1 >5720.78 37.6 668.8 TABLE 19<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 28.0835 VSYVNTNMGLK 11 HBV.core.115 54.0 45.7<BR> 1150.28 WARVHSTTR 9 HBV.pol.244 >27500 >30000 10062.3 248.9 1126.8<BR> 1.0986 YLHLYPVAR 9 HBV.pol.1255 2948.3 8571.4 492.8 471.6<BR> 1371.62 AVPLDSTFYK 10 Her2/neu.997 A 630.7 33.5 1653.8 21481.5 179.0<BR> 1371.61 AVPLDSTFYR 10 Her2/neu.997 A >38890.87 92.0 29950.1 2940.4 54.4<BR> 1371.47 BVNBSQFLK 9 Her2/neu.528 A 35.6 22.1 70.0 4438.9 17.2<BR> 1371.46 BVNBSQFLR 9 Her2/neu.528 A 196.3 80.0 37.7 57.7 9.8<BR> 1371.45 HVVPWDQLFK 10 Her2/neu.478 A 184.2 410.1 >46475.8 38359.8 9.5<BR> 1371.44 HVVPWDQLFR 10 Her2/neu.478 A 7261.7 1434.1 397.5 205.2 3.9<BR> 1371.35 IVKGGVLIQK 10 Her2/neu.148 A 26.5 74.7 470.3 18403.5 21.1<BR> 1371.34 IVKGGVLIQR 10 Her2/neu.148 A 278.9 7349.1 70.7 125.1 32.5<BR> 1371.38 IVWKDIFHK 9 Her2/neu.167 A 23.9 45.8 265.6 970.1 165.8<BR> 1371.39 IVWKDIFHR 9 Her2/neu.167 A 148.4 282.8 6.1 18.6 17.0<BR> 1371.43 IVWLGLRSLK 10 Her2/neu.450 A 4.0 128 293 2283 12<BR> 1371.42 IVWLGLRSLR 10 Her2/neu.450 A 235.3 2195.7 11.6 193.6 7.5<BR> 1371.57 KVTDFGLAK 9 Her2/neu.860 A 27.5 46.2 3495.9 >17985.04 1193.2<BR> 1371.56 YVTDFGLAR 9 Her2/neu.860 A 202.9 82.7 114.3 >17985.04 138.0<BR> 1371.53 LVARNVLVK 9 Her2/neu.846 A 44.3 217.4 8991.0 >17985.04 169.4<BR> 1371.54 LVARNVLVR 9 Her2/neu.846 A 281.2 3117.2 9144.6 20573.1 22.0<BR> 1371.52 LVDHVRENK 9 Her2/neu.806 A 299.4 768.2 >46475.8 >17985.04 3301.1<BR> 1371.55 LVKSPNHVR 9 Her2/neu.852 A 7898.3 12903.2 201.6 107.8 74.9<BR> 1371.60 LVSEFSRMAK 10 Her2/neu.972 A 285.6 78.2 1710.9 5318.2 51.8<BR> 1371.59 MVLESILRK 9 Her2/neu.889 A 62.6 16.4 20930.2 2848.9 290.1<BR> 1371.58 MVLESILRR 9 Her2/neu.889 A 235.7 272.5 208.1 121.5 20.5<BR> 1371.41 TVBAGGBAK 9 Her2/neu.218 A 24.2 29.2 41958.0 34523.8 7.8<BR> 1371.40 TVBAGGBAR 9 Her2/neu.218 A 350.2 114.3 248.3 201.4 7.9<BR> 1371.36 TVLWKDIFHK 10 Her2/neu.166 A 813.7 41.0 9970.4 5896.2 476.3 TABLE 19<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 1371.37 TVLWKDIFHR 10 Her2/neu.166 A 11439.2 298.9 593.0 83.8 44.7<BR> 1371.48 VVFGILIKK 9 Her2/neu.669 A 32.9 19.9 3776.2 10066.0 28.2<BR> 1371.49 VVRENTSPK 9 Her2/neu.754 A 98.1 335.9 753.8 1341.2 5698.0<BR> 1371.50 VVRENTSPR 9 Her2/neu.754 A 335.2 5618.7 374.5 127.2 203.3<BR> 940.08 AC-QVPLRPMTY] 10 HIV.nef.73 A 338.5 731.9<BR> 940.11 AQVPLRPMTYK 11 HIV.nef.73 A 56.6 82.6<BR> 940.10 RQVPLRPMTYK 11 HIV.nef.73 A 10.1 69.9<BR> 31.0116 KTWMDIEGR 9 Lassa.NP.385 8500.8 1131.81 125.7 1902.2 1818.2<BR> 31.0117 MLQKEYMER 9 Lassa.gp.414 >3990.12 1371.2 99.9 195.5 33.3<BR> 1150.47 EMLRKDYIK 9 LCMV.gp.419 >11595.02 20000.0 1477.1 64.5 >40000<BR> 1371.72 AVIETSYVK 9 MAGE2.277 A 410.2 72.8 14064.6>40215.76 30.8<BR> 1371.73 AVIETSYVR 9 MAGE2.277 A 31700.3 172.8129.1 1177.5 18.8<BR> 1371.75 IVYPPLHEK 9 MAGE2.299 A 44.6 108.7 883.6 3025.6 47.5<BR> 1371.74 IVYPPLHER 9 MAGE2.299 A 121.3 391.1 102.1 37.2 17.7<BR> 1371.71 SVFAHPRR 8 MAGE2.237 A 678.3 1573.3 661.1 630.4 152.3<BR> 1371.63 SVFSTTINK 9 MAGE2.69 A 20.8 8.5 3626.3 18804.6 6.0<BR> 1371.64 SVFSTTINR 9 MAGE2.69 A 60.3 6.8 46.7 89.1 6.9<BR> 1371.66 TVINYTLWK 9 MAGE2.73 A 358.9 100.9 9126.4 >17985.04 86.0<BR> 1371.65 TVINYTLWR 9 MAGE2.73 A 300.2 81.0 713.0 333.6 14.4<BR> 1371.68 LVHFLLLKR 9MAGE2/3.116 A 340.4 368.3 246.3 92.2 24.3<BR> 1371.69 YVFPVIFSK 9 MAGE3.138 A 24.8 3.3 2922.5 792.1 1.7<BR> 1371.70 YVFPVIFSR 9 MAGE3.138 A 37.4 2.8 8.4 13.3 0.5<BR> 1371.16 BVYSPALNK 9 p53.124 A 15.8 10.0 448.1 23027.5 801.8<BR> 1371.17 BVYSPALNR 9 p53.124 A 27.8 8.5 34.885.8 11.3<BR> 1371.20 GVRVRAMAIYK 11 p53.154 A 67.2 100.5 431.6 >48333.33 31620.6<BR> 1371.21 GVRVRAMAIYR 11 p53.154 A 2401.3 23166.0 136.6 5237.8 5305.0<BR> 1371.18 KVFBQLAK 8 p53.122 A 652.5 484.7 6529.2 >48333.33 8474.6 TABLE 19<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 1371.15 KVYQGSYGFK 10 p53.101 A 38.5 10.1 139.8 >48333.33 26.7<BR> 1371.14 KVYQGSYGFR 10 p53.101 A 37.9 64.2 74.1 10311.3 33.7<BR> 1371.31 RVBABPGRDRK 11 p53.273 A 324.7 225.2 4670.7 >48333.33 3530.5<BR> 1371.30 RVBABPGRDRR 11 p53.273 A 3195.1 5070.9 183.9 >48333.33 2463.8<BR> 1371.22 RVRAMAIYR 9 p53.156 A 45.4 1691.1 9.1 149.3 427.1<BR> 1371.24 SVBMGGMNK 9 p53.240 A 14.0 17.1 8933.0 >48333.33 38.0<BR> 1371.26 SVBMBBMNR 9 p53.240 A 162.4 96.6 119.3 885.0 11.6<BR> 1371.25 SVBMGGMNRK 10 p53.240 A 102.4 54.5 >17162.33 >48333.33 12.9<BR> 1371.27 SVBMGGMNRR 10 p53.240 A 1030.2 20.2 637.3 1515.0 11.0<BR> 1371.32 SVSRHKKLMFK 11 p53.376 A 34.5 61.9 295.8 18555.5 2531.7<BR> 1371.33 SVSRHKKLMFR 11 p53.376 A 211.9 2976.9 148.7 1571.2 499.8<BR> F029.00 AAMXDTVVFK 10 Naturally processed A 258.8 8.3<BR> F020.06 ASFDKAKLK 9 Naturally processed 43.9 15.8<BR> 1023.01 EVAPPEYHR 9 Naturally processed >27500 60000.0 36000.0 78.4 36.4<BR> 1023.05 EVILIDPFHK 10 Naturally processed >22000 4472.1 >180 11581.5 26.7<BR> F023.05 KVVNPLFEK 9 Naturally processed 162.4 8.4<BR> F020.07 KVVNPLPEK 9 Naturally processed 40.6 13.9<BR> S3R RTQNVLGEK 9 Naturally processed 152.8 32.5<BR> F029.11 RVEQAVESMVK 11 Naturally processed 1226.8 57.2<BR> F020.08 SVLNLVIVK 9 Naturally processed 129.8 7.2<BR> 952.32 AAAAAAAAAK 10 Artificial sequence A 501.6 49.7<BR> 952.42 AAYAAAAAAK 10 Artificial sequence A 26.2 31.3<BR> 952.41 AAYAAAAAK 9 Artificial sequence A 23.6 14.7<BR> 952.43 AAYAAAAAR 9 Artificial sequence A 125.5 124.8<BR> 952.29 AIAAAAAAAK 10 Artificial sequence A 109.6 47.0<BR> 952.34 AIAAAAAAR 9 Artificial sequence A 141.6 107.6<BR> 952.30 ALAAAAAAAK 10 Artificial sequence A 149.8 50.0 TABLE 19<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 952.39 ALAAAAAAAR 10 Artificial sequence A 366.5 2667.3<BR> 4.0105 ALAAAAADK 9 Artificial sequence A 57.7 148.3<BR> 981.31 ALAAAAAEK 9 Artificial sequence A 189.7 42.9<BR> 4.0106 ALAAAAAFK 9 Artificial sequence A 27.9 13.4<BR> 4.0111 ALAAAAANK 9 Artificial sequence A 31.8 17.5<BR> 4.0110 ALAAAAAPK 9 Artificial sequence A 19.3 8.3<BR> 981.30 ALAAAAAQK 9 Artificial sequence A 61.1 37.5<BR> 4.0104 ALAAAAARK 9 Artificial sequence A 21.6 10.5<BR> 4.0108 ALAAAAASK 9 Artificial sequence A 38.6 27.4<BR> 4.0109 ALAAAAATK 9 Artificial sequence A 19.9 23.3<BR> 981.32 ALAAAAAVK 9 Artificial sequence A 131.0 79.0<BR> 4.0107 ALAAAAAYK 9 Artificial sequence A 17.0 10.6<BR> 4.0094 ALAAAADAK 9 Artificial sequence A 169.1 53.4<BR> 4.0095 ALAAAAEAK 9 Artificial sequence A 126.5 65.1<BR> 4.0100 ALAAAAFAK 9 Artificial sequence A 15.2 5.7<BR> 981.27 ALAAAAIAK 9 Artificial sequence A 113.4 20.7<BR> 981.29 ALAAAAKAK 9 Artificial sequence A 100.0 133.3<BR> 4.0096 ALAAAALAK 9 Artificial sequence A 39.1 11.8<BR> 4.0101 ALAAAANAK 9 Artificial sequence A 51.9 22.9<BR> 4.0103 ALAAAAPAK 9 Artificial sequence A 11.7 5.5<BR> 981.28 ALAAAAQAK 9 Artificial sequence A 137.5 74.1<BR> 4.0102 ALAAAASAK 9 Artificial sequence A 27.6 37.5<BR> 4.0099 ALAAAAYAK 9 Artificial sequence A 47.9 10.5<BR> 4.0087 ALAAADAAK 9 Artificial sequence A 195.8 556.6<BR> 981.24 ALAAAIAAK 9 Artificial sequence A 100.0 15.8<BR> 981.25 ALAAAKAAK 9 Artificial sequence A 196.4 600.0<BR> 4.0093 ALAAAMAAK 9 Artificial sequence A 57.3 10.3 TABLE 19<BR> HLA- A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 4.0090 ALAAANAAK 9 Artificial sequence A 35.6 19.3<BR> 4.0092 ALAAAPAAK 9 Artificial sequence A 31.2 29.4<BR> 4.0089 ALAAAQAAK 9 Artificial sequence A 23.8 13.3<BR> 981.26 ALAAASAAK 9 Artificial sequence A 78.6 46.2<BR> 4.0091 ALAAATAAK 9 Artificial sequence A 60.0 17.7<BR> 4.0088 ALAAAYAAK 9 Artificial sequence A 19.5 5.7<BR> 4.0076 ALAADAAAK 9 Artificial sequence A 61.2 113.3<BR> 4.0077 ALAAEAAAK 9 Artificial sequence A 46.9 132.5<BR> 4.0075 ALAAGAAAK 9 Artificial sequence A 18.8 36.5<BR> 1161.16 ALAAGAAAK 9 Artificial sequence A 29.1 32.7 63639.6 >27905.26 2285.7<BR> 4.0085 ALAAHAAAK 9 Artificial sequence A 33.1 33.3<BR> 4.0078 ALAAIAAAK 9 Artificial sequence A 20.4 13.7<BR> 981.22 ALAAKAAAK 9 Artificial sequence A 91.7 111.1<BR> 4.0086 ALAALAAAK 9 Artificial sequence A 38.0 61.6<BR> 4.0082 ALAANAAAK 9 Artificial sequence A 40.1 93.7<BR> 4.0084 ALAAPAAAK 9 Artificial sequence A 13.9 6.9<BR> 4.0081 ALAAQAAAK 9 Artificial sequence A 20.3 50.2<BR> 981.23 ALAASAAAK 9 Artificial sequence A 186.4 33.3<BR> 4.0083 ALAATAAAK 9 Artificial sequence A 38.4 6.8<BR> 981.21 ALAAVAAAK 9 Artificial sequence A 91.7 9.2<BR> 4.0079 ALAAYAAAK 9 Artificial sequence A 9.9 11<BR> 4.0069 ALADAAAAK 9 Artificial sequence A 32.1 13.6<BR> 981.17 ALAEAAAAK 9 Artificial sequence A 423.1 54.6<BR> 4.0070 ALAFAAAAK 9 Artificial sequence A 11.5 17.7<BR> 4.0068 ALAGAAAAK 9 Artificial sequence A 12.7 14.6<BR> 981.19 ALAKAAAAK 9 Artificial sequence A 25.6 82.2<BR> 981.18 ALANAAAAK 9 Artificial sequence A 78.6 4.7 TABLE 19<BR> HLA-A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 4.0072 ALAPAAAAK 9 Artificial sequence A 12.6 7.0<BR> 4.0074 ALAQAAAAK 9 Artificial sequence A 16.0 13.0<BR> 4.0073 ALARAAAAK 9 Artificial sequence A 7.3 14<BR> 4.0071 ALASAAAAK 9 Artificial sequence A 25.1 11.8<BR> 981.20 ALAVAAAAK 9 Artificial sequence A 40.7 18.2<BR> 4.0064 ALDAAAAAK 9 Artificial sequence A 121.0 500.0 >73484.69 >54804.85 80000.0<BR> 981.15 ALFAAAAAK 9 Artificial sequence A 25.0 22.2 2805.0 96666.7 898.9<BR> 4.0066 ALHAAAAAK 9 Artificial sequence A 25.6 284 9091.4 >54804.85 20000.0<BR> 4.0067 ALIAAAAAK 9 Artificial sequence A 36.7 31.0 >25980.76 >54804.85 2352.9<BR> 981.16 ALKAAAAAK 9 Artificial sequence A 122.2 779.2 1450.5 72500.0 80000.0<BR> 4.0065 ALMAAAAAK 9 Artificial sequence A 15.6 6.8 6266.8 >83715.79 824.7<BR> 1012.11 ALNAAAAAK 9 Artificial sequence A 60.7 24.0 4751.7 >17985.04 20000.0<BR> 4.0060 ALNAAAAAK 9 Artificial sequence A 74.0 20.7 10954.5 >54804.85 80000.0<BR> 4.0063 ALPAAAAAK 9 Artificial sequence A 69.9 129.6 90000.0 >54804.85 26666.7<BR> 4.0080 ALQAAAAAK 9 Artificial sequence A 57.0 65 1 51961.5 >54804.85 80000.0<BR> 1012.10 ALQAAAAAK 9 Artificial sequence A 95.7 68.4 25714.3 >17985.04 80000.0<BR> 1012.08 ALRAAAAAK 9 Artificial sequence A 55.0 1474.4 2578.0 96666.7 80000.0<BR> 4.0061 ALSAAAAAK 9 Artificial sequence A 44.1 37.5 51961.5 >54804.85 20000.0<BR> 4.0062 ALTAAAAAK 9 Artificial sequence A 66.3 125.3 >73484.69 >54804.85 20000.0<BR> 981.14 ALYAAAAAK 9 Artificial sequence A 31.4 21.4 3541.0 96666.7 2726.4<BR> 952.40 AMAAAAAAAR 10 Artificial sequence A 482.4 2508.7<BR> 1022.03 AMAAAAAAH 9 Artificial sequence A 279.4 6396.0<BR> 952.36 AMAAAAAAR 9 Artificial sequence A 73.3 288.7<BR> 978.01 ASYAAAAAK 9 Artificial sequence A 28.2 11.5<BR> 955.04 ATAAAAAAAR 10 Artificial sequence A 662.1 280.5<BR> 1022.04 ATAAAAAAH 9 Artificial sequence A 1457.0 218.2<BR> 955.03 ATAAAAAAR 9 Artificial sequence A 55.1 39.3 TABLE 19<BR> HLA-A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 952.28 AVAAAAAAAK 10 Artificial sequence A 456.0 83.0<BR> 952.37 AVAAAAAAAR 10 Artificial sequence A 405.5 193.1<BR> 952.33 AVAAAAAAR 9 Artificial sequence A 102.5 72.8<BR> 952.08 AVAAAAANAK 10 Artificial sequence A 129.6 40.8<BR> 952.05 AVAAAAANK 9 Artificial sequence A 11.0 41.4<BR> 952.07 AVAAAAIAAK 10 Artificial sequence A 26.9 28.3<BR> 952.04 AVAAAAIAK 9 Artificial sequence A 87.6 21.1<BR> 952.06 AVAAALAAAK 10 Artificial sequence A 191.5 36.5<BR> 952.03 AVAAALAAK 9 Artificial sequence A 65.8 31.5<BR> 952.18 AVAKAAAAAK 10 Artificial sequence A 128.3 52.6<BR> 952.15 AVAKAAAAK 9 Artificial sequence A 40.2 88.9<BR> 952.02 AVAPAAAAAK 10 Artificial sequence A 48.5 21.8<BR> 952.01 AVAPAAAAK 9 Artificial sequence A 51.5 9.6<BR> 952.14 AVAPAAAANK 10 Artificial sequence A 44.4 36.4<BR> 952.13 AVAPAAAIAK 10 Artificial sequence A 51.6 11.4<BR> 952.11 AVAPAAANAK 10 Artificial sequence A 107.7 57.2<BR> 952.10 AVAPAAIAAK 10 Artificial sequence A 13.1 20.1<BR> 952.12 AVAPAALAAK 10 Artificial sequence A 82.5 10.8<BR> 952.09 AVAPALAAAK 10 Artificial sequence A 53.3 15.4<BR> 952.20 AVYAAAAAAK 10 Artificial sequence A 55.2 38.7<BR> 952.21 AVYAAAAAAR 10 Artificial sequence A 143.5 76.5<BR> 952.19 AVYAAAAAK 9 Artificial sequence A 42.0 36.3<BR> 952.22 AVYAAAAAR 9 Artificial sequence A 12.7 40.4<BR> 981.03 FLAAAAAAK 9 Artificial sequence A 3.5 79.0 180000.0 72500.0 17.8<BR> 1012.01 ILAAAAAAK 9 Artificial sequence A 33.1 46.3<BR> 1012.02 MLAAAAAAK 9 Artificial sequence A 13.9 15.0<BR> 1012.07 NLAAAAAAK 9 Artificial sequence A 138.3 178.4 TABLE 19<BR> HLA-A3 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog A*0301 A*1101 A*3101 A*3301 A*6801<BR> 1012.04 PLAAAAAAK 9 Artificial sequence A 294.0 8017.8<BR> 1012.06 QLAAAAAAK 9 Artificial sequence A 205.4 107.4<BR> 1012.05 SLAAAAAAK 9 Artificial sequence A 25.2 6.0<BR> 1012.03 TLAAAAAAK 9 Artificial sequence A 20.2 80.9 Table 20<BR> HLA-A24 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*2402 A*2301 A*2902 A*3002<BR> 1489.06 AATLGFGAY HCV..IV.1264 2240 491<BR> 1489.11 AQPGYPWPLY HCV.II.77 133 3.5<BR> 1489.05 CSFSIFLLA HCV..IV.172 153 11100<BR> 1489.1 LHGPTPLLY HCV..II.1623 180 1075<BR> 1489.12 TCGFADLMGY HCV..IV.127 350 356<BR> F185.03 RYLRDQQLL HIV..gp41.583 30<BR> F185.05 RYPLTFGWCF HIV..nef.138 17<BR> 78.0346 AFADLTVVY HPV.33.E6.46 425 71 19408 58420<BR> 78.0368 AFKDLCIVY HPV.45.E6.48 44911 14034 32 0.49<BR> 78.0360 AFKDLFVVY HPV.18.E6.48 419 123 37648 24961<BR> 78.0246 ATLERTEVY HPV.45.E6.37 >141441 >24519.62 11383 175<BR> 78.0023 ATSNYYIVTY HPV.52.E7.50 >65777.37 >22775.44 2117 118<BR> 78.0349 AYAACHKCI HPV.45.E6.61 73 60 3300 139<BR> 78.0358 CYSLYGTTL HPV.16.E6.87 88 133 13882 >21070.15<BR> 78.0379 DYSVYGATL HPV.56.E6.83 33359 2057 1460 19<BR> 78.0177 EYRHYCYSLY HPV.16.E6.82 117278 >18738.91 2449 120<BR> 78.0354 EYRHYNYSL HPV.58.E6.75 41671 23490 268 1473<BR> 78.0185 EYRHYNYSLY HPV.58.E6.75 8139 10625 1774 67<BR> 78.0180 EYRHYNYSVY HPV.33.E6.75 45280 22917 16016 253<BR> 78.0350 EYRHYQYSL HPV.52.E6.75 72 100 58321 1098<BR> 78.0183 EYRHYQYSLY HPV.52.E6.75 8378 1576 2372 130<BR> 78.0176 FYSKVRKYRY HPV.56.E6.72 2309 983 146 326<BR> 78.0172 FYSKVSEFRW HPV.31.E6.69 8.6 8.8 1777 15220<BR> 78.0182 FYSRIRELRY HPV.45.E6.71 356 105 20 150<BR> 78.0243 ISEYRHYNY HPV.33.E6.73 125794 >20304.18 1329 32 Table 20<BR> HLA-A24 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*2402 A*2301 A*2902 A*3002<BR> 78.0254 ISEYRHYNY HPV.58.E6.73 >99979.17 >24899.09 853 81<BR> 1497.13 KFLFTDLRI HPV.52.E6.44 2151 18 2319 1595<BR> 78.0357 KFYSKISEY HPV.16.E6.75 97 95 40636 14219<BR> 1497.15 KYRYYDYSVY HPV.56.E6.78 169334 86607 17797 2.3<BR> 78.0252 LCDLLIRCY HPV.56.E6.99 >113982.57 >25061.21 557 26<BR> 78.0372 LFTDLRIVY HPV.52.E6.46 377 156 25003 22<BR> 78.0361 LFVVYRDSI HPV.18.E6.52 60761 20899 464 100<BR> 78.0378 LFYSKVRKY HPV.56.E6.71 43591 12916 12 89<BR> 78.0244 LKEYVLDLY HPV.33.E7.8 >116712.75 >24519.62 127123 16<BR> 78.0006 LQDIEITCVY HPV.18.E6.25 90823 27246 4044 148<BR> 78.0027 LSKISEYRHY HPV.58.E6.70 >65777.37 >22775.44 101409 159<BR> 78.0019 LSKISEYRHY HPV.52.E6.70 >68154.86 >22775.44 55190 186<BR> 78.0348 LYPEPTDLY HPV.33.E7.15 58956 21752 36 71<BR> 78.0376 NFACTELKL HPV.56.E6.47 48436 18695 202 1.02<BR> 78.0347 NYSVYGNTL HPV.33.E6.80 715 365 >31079.62 36210<BR> 78.0356 PYAVCDKCL HPV.16.E6.66 97 20 44214 5713<BR> 78.0377 PYAVCRVCL HPV.56.E6.62 51 129 40187 2092<BR> 78.1075 PYAVCRVCLL HPV.56.E6.62 133 79 11832 42021<BR> 78.0249 QAEQATSNY HPV.52.E7.46 250000 >20304.18 4203 109<BR> 1497.12 QFAFKDLCI HPV.45.E6.46 20636 370 >30457.25 >27675.94<BR> 78.0005 RFEDPTRRPY HPV.18.E6.3 >66361.54 >22463.51 17839 145<BR> 78.0363 RFHNIGGRW HPV.31.E6.124 71804 27530 1595 9.5<BR> 78.0375 RFHNIMGRW HPV.52.E6.124 469 352 >24155.43 >18916.25<BR> 78.0359 RFHNIRGRW HPV.16.E6.131 53237 11416 18 58<BR> 78.0366 RFHNISGRW HPV.33.E6.124 >76072.88 22871 174 37 Table 20<BR> HLA-A24 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*2402 A*2301 A*2902 A*3002<BR> 78.0384 RFHNISGRW HPV.58.E6.124 209657 28791 201 35<BR> 78.0370 RFHSIAGQY HPV.45.E6.126 52 250 32588 34549<BR> 78.0373 RFLSKISEY HPV.52.E6.68 65 93 32015 14086<BR> 78.0365 RFLSKISEY HPV.33.E6.68 472 121 34623 23<BR> 1497.04 TFCCKCDSTL HPV.16.E7.56 3627 427 >28937.69 22604<BR> 78.0250 TSNYYIVTY HPV.52.E7.51 >113982.57 >25061.21 3313 76<BR> 78.0174 TYCHSCDSTL HPV.52.E7.58 452 122 29791 30747<BR> 78.0353 VFADLRIVY HPV.58.E6.46 499 1336 >35952.44 >19018.22<BR> 78.0171 VFEFAFKDLF HPV.18.E6.44 69 8.9 1090 14434<BR> 78.0340 VYCKTVLEL HPV.18.E6.33 456 348 >31079.62 15605<BR> 78.0364 VYDFAFADL HPV.33.E6.42 >163846.38 >20985.44 163 579<BR> 78.0381 VYDFVFADL HPV.58.E6.42 385 93 27168 27<BR> 78.0369 VYGETLEKI HPV.45.E6.85 430 149 12156 13<BR> 78.0371 VYKFLFTDL HPV.52.E6.42 35396 1536 1707 27<BR> 78.0351 VYNFACTEL HPV.56.E6.45 366 114 >29714.57 12350<BR> 78.0002 YSKISEYRHY HPV.16.E6.77 >66361.54 >22463.51 6448 205<BR> 78.0009 YSKVSEFRWY HPV.31.E6.70 73696 >22249.75 4514 185<BR> 78.0247 YSRIRELRY HPV.45.E6.72 10906 7337 1991 22<BR> 1489.22 ALFQEYQCY Pf..CSP.18 149 1032<BR> 1489.27 FVVPGAATPY Pf..SSP2.520 317 4621<BR> 1489.61 FYFILVNLLI Pf..LSA1.9 20 3.7 362 8591<BR> 1489.55 YYGKQENWY Pf..CSP.55 2883 19195 373 3155<BR> F185.04 AFLPWHRLF Tyrosinase. 20<BR> 1489.18 FVQENYLEY MAGE3.250 3.2 99<BR> 1489.16 LVQENYLEY MAGE2.250 13 72 Table 20<BR> HLA-A24 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source A*2402 A*2301 A*2902 A*3002<BR> 1489.15 LVTCLGLSY MAGE2.178 18 4101<BR> 1461.06 MEVDPIGHLY MAGE3.167 333 87<BR> F185.06 SYLDSGIHF ..B-catenin.29 50 TABLE 21 A*2402 Peptide Sequence AA Source Analog (IC50 nM) 57. 0073 FYNPPTTAKF 10 CEA. 27 A 183 57.0037 IYPNASLLF 9 CEA. 101 A 2.6 57.0039 LYGPDAPTF 9 CEA. 234 A 65 57.0042 LYWVNGQSF 9 CEA. 533 A 16 57.0038 LYWVNNQSF 9 CEA. 177 A 64 57.0078 QYSWLIDGNF 10 CEA. 446 A 63 57.0044 QYSWRINGF 9 CEA. 624 A 108 57.0036 RYCIPWQRF 9 CEA. 10 A 191 57.0072 RYCIPWQRLF 10 CEA. 10 A 59 57. 0079 SYLSGANLNF 10 CEA. 604 A 11 57.0045 TYACFVSNF 9 CEA. 652 A 9.9 57.0075 TYQQSTQELF 10 CEA. 276 A 317 57.0041 TYYRPGVNF 9 CEA. 425 A 54 57.0076 VYAEPPKPFF 10 CEA. 318 A 27 57.0074 VYPELPKPSF 10 CEA. 140 A 114 57. 0077 YYRPGVNLSF 10 CEA. 426 A 12 1081.05 SYVPSAEQI 9 Pf. CSP. 280 69 1120.10 TYQRTRALF 9 Flu. NP. 147 A 1.5 1120.12 TYQRTRALI 9 Flu. NP. 147 A 33 1120.11 TYQRTRALL 9 Flu. NP. 147 A 227 57.0049 AYPDSLPDF 9 Her2/neu. 414 A 43 57.0050 AYSLTLQGF 9 Her2/neu. 440 A 56 57.0048 CYGLGMEHF 9 Her2/neu. 342 A 165 57.0051 EYVNARHCF 9 Her2/neu. 553 A 150 57.0082 GYSYLEDVRF 10 Her2/neu. 832 A 235 57.0053 KYMALESIF 9 Her2/neu. 887 A 20 57.0080 LYISAWPDSF 10 Her2/neu. 410 A 10 57.0052 PYVSRLLGF 9 Her2/neu. 780 A 9.0 57.0059 RYARDPQRF 9 Her2/neu. 978 A 120 57.0046 RYGLLLALF 9 Her2/neu. 8 A 1.5 57.0058 RYRELVSEF 9 Her2/neu. 968 A 37 57.0054 RYTHQSDVF 9 Her2/neu. 898 A 60 57. 0056 SYGVTVWEF 9 Her2/neu. 907 A 28 57.0047 TYLPTNASF 9 Her2/neu. 63 A 46 57.0057 VYMIMVKCF 9 Her2/neu. 951 A 20 57.0055 VYSYGVTVF 9 Her2/neu. 905 A F171.13 NYKRCFPVI 9 Mage4. 143 6.1 57. 0063 EYLQLVFGF 9 MAGE2.156 A 6.5 57.0087 EYLWGPRALF 10 MAGE2.270 A 10 57.0062 IYSKASEYF 9 MAGE2.150 A 15 57.0061 KYVELVHFF 9 MAGE2.112 A 8.0 57.0085 LYILVTCLGF 10 MAGE2.175 A 20 57.0060 MYPDLESEF 9 MAGE2.97 A 51 57.0084 SYSTTINYTF 10 MAGE2.70 A 17 57.0088 SYVKVLHHTF 10 MAGE2.282 A 60 TABLE 21 <BR> <BR> <BR> <BR> <BR> <BR> <BR> A*2402<BR> Peptide Sequence AA Source Analog<BR> <BR> <BR> <BR> (IC50 nom) 57.0064 VYPKTGLLF 9 MAGE2.195 A 6.0 57.0086 VYPKTGLLIF 10 MAGE2.195 A 2.9 57.0068 IYPKAGLLF 9 MAGE3.195 A 9.0 57.0093 IYPKAGLLIF 10 MAGE3.195 A 1.4 57.0067 IYSKASSSF 9 MAGE3.150 A 415 57.0092 LYIFATCLGF 10 MAGE3.175 A 11 57.0066 NYQYFFPVF 9 MAGE3.142 A 3.8 57.0090 NYQYFFPVIF 10 MAGE3.142 A 23 57.0095 SYPPLHEWVF 10 MAGE3.300 A 5.8 57.0065 TYPDLESEF 9 MAGE3. 97 A 220 57.0071 SYGFRLGFF 9 p53.106 A 124 57.0096 TYQGSYGFRF 10 p53.102 A 33 57.0070 TYSDLWKLF 9 p53. 18 A 5. 7 972. 05 SYFPEITHI 9 458 996.01 AWAKAAAAF 9 Artificial sequence Poly 373 F030.01 AYAKAAAAAF 10 Artificial sequence Poly 38 1021.01 AYAKAAAAW 9 Artificial sequence Poly A 140 1079.01 KYNPMKTHI 9 Artificial sequence Consensus 56 1086. 16 KYPDFVDAL 9 Artificial sequence Consensus 62 F020.09 AYVHMVTHF 9 Naturally processed 23 F020.12 KYPENFFLL 9 Naturally processed 5.5 F020.15 YYEEQHPEL 9 Naturally processed 115 Table 22<BR> HLA-B7 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*0702 B*3501 B*5101 B*5301 B*5401<BR> 1259.01 GPRLGVRAT HCV.Core.41 128 >39374.41 >23865.72 >48927.08 64167<BR> 1468.03 IPLVGAPL IHCV.Core.137 25 295 134 7568 598<BR> 1468.01 LPALSTGLI HCV.E2.681 427 25792 2580 1036 5778<BR> 1468.02 LPCSFTTLPA HCV.NS1/E2.680 981 3145 1854 43849 2.2<BR> 78.0396 CPEEKQRHL HPV16.E6.118 10.3 >44991.38 91667 >79732.67 >60017.72<BR> 78.0399 CPEEKQRHL HPV31.E6.111 3.0 >44991.38 1982 >79732.67 15717<BR> 78.0395 DPQERPRKL HPV16.E6.11 92 >44278.57 4010 >7973.67 >60017.72<BR> 78.0397 DPTRRPYKL HPV18.E6.6 111 >44991.38 >35950.78 >79732.67 >69121.86<BR> 78.0191 EPQRHTMLCVM HPV18.E7.55 337 5482 1824 3258 >53217.09<BR> 78.0195 FPYAVCRVAL HPV56.E6.61 148 2253 73 3580 193<BR> 78.0197 GPRETLQEIV HPV45.E7.3 348 >3241.87 >29418.5 >*1260.68 41613<BR> 78.0028 HPEPTDLFCY HPV58.E7.16 >131287.73 3186 18391 346 >62894.33<BR> 78.0190 IPHAACHKCI HPV18.E6.60 246 >34241.87 2070 3661 3002<BR> 78.0398 KPLNPAEKL HPV18.E6.110 20 >44278.57 20215 >79732.67 >60017.72<BR> 78.0392 NPQERPRSL HPV56.E6.7 121 33015 246 34824 65361<BR> 78.0394 NPTLREYIL HPV58.E7.5 21 >44991.38 21839 >79732.67 >58997.31<BR> 78.0189 NPYAVCDKCL HPV16.E6.65 6755 >34241.87 218 115379 97359<BR> 78.0194 NPYGVCIMCL HPV52.E6.58 382 38796 172 11237 30085<BR> 78.0402 RPDGQAPQA HPV33.E7.40 13912 11171 383 5497 >60017.72<BR> 1495.01 RPRKLPQLCT HPV16R.E6.15 38 >48807.02 >20249.86 >73228.35 79388<BR> 78.0393 RPRRRQTQV HPV58.E6.141 275 >44278.57 14963 >79732.67 >58997.31<BR> 78.0192 TPHGVCTKCL HPV31.E6.58 38 >34241.87 14667 44608 7724<BR> 1495.10 TPTLQDYVL HPV31.E7.5 3175 442 42577 34294 41338<BR> 78.0199 YPCCECKFVV HPV56.E7.63 464 21110 174 4882 20<BR> 78.0013 YPEPTDLYCY HPV33.E7.16 >131287.7 3133 16160 74 >62894.33 Table 22<BR> HLA-B7 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*0702 B*3501 B*5101 B*5301 B*5401<BR> 1143.05 LGFVFTLTV 55000 >72000 27500 24013 464<BR> 1125.02 LPFPFTPGF 27500 13 185<BR> 1143.04 TAVPWNASW >1018.52 5445 19445 15 20000 TABLE 23<BR> HLA-B7 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog B*0702 B*3501 B*5101 B*5301 B*5401<BR> 1196.02 OPRAPIRPIPT 11 EBNA.881 109.6 14433.8<BR> 1196.03 RPPIFIRRL 9 EBNA.379 21.2 55000.0<BR> 36.0023 APIMFSNKM 9 Flu.RRP1.340 91.0<BR> 36.0010 APSPYNSPF 9 Flu.NRAM.151 19.9<BR> 36.0072 CPVGEAPSPY 10 Flu.NRAM.146 70.3<BR> 36.0051 DPDEGTAGV 9 Flu.RR[P3.678 119.6<BR> 36.00122 DPGNAEFEDL 10 Flu.VNUC.247 222.0<BR> 36.00119 DPLAIAANII 10 Flu.VMT2.24 86.4<BR> 36.0078 DPNTVSSFQV 10 Flu.NS1.2 10.5<BR> 36.0034 DPSHEGEGI 9 Flu.RRP2.294 10.9<BR> 36.0114 EPFQSLVPKA 10 Flu.RRP23.578 27.1<BR> 36.0094 EPNGYIEGKL 10 Flu.RRP2.237 293.7<BR> 36.0044 FPNEVGARL 9 Flu.RRP3.168 44.2<BR> 36.0107 FPNEVGARIL 10 Flu.RRP3.168 365.2<BR> 36.0019 FPYTGDPPY 9 Flu.RRP1.22 11.3<BR> 36.0029 GPATAQMAL 9 Flu.RRP1.540 45.3<BR> 36.0024 IPAEMLASI 9$RRP1.368 310.7<BR> 36.0088 IPEVCLKWEL 10 Flu.RRP1.606 122.7<BR> 36.0080 IPKQKVAGPL 10 Flu.NS1.106 42.3<BR> 36.0096 IPSIQSRGL 9 Flu.HEMA.338 35.7<BR> 36.0067 KPGDTIIFEA 10 Flu.HEMA.252 35.0<BR> 36.0059 LPFDRTTVM 9 Flu.VNUC.418 49.0<BR> 36.0028 LPSFGVSGI 9 Flu.RRP1.509 36.8<BR> 36.0015 LPSLPGHTA 9 Flu.NS1.163 41.3<BR> 36.0089 MPAHGPAKNM 10 Flu.RRP1.646 266.7<BR> 36.0058 NPAHKSQLV 9 Flu.VNUC.321 2.4<BR> 36.0062 NPECDPLLPV 10 Flu.HEMA.81 213.3 TABLE 23<BR> HLA-B7 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog B*0702 B*3501 B*5101 B*5301 B*5401<BR> 36.0021 NPRMFLAMI 9 Flu.RRP1.314 25.1<BR> 36.0022 QPEWFRNVL 9 Flu.RRP1.329 12.9<BR> 36.0013 RPCFWVELI 9 Flu.NRAM.404 67.3<BR> 36.0025 RPLLIEGTA 9 Flu.RRP1.393 140.0<BR> 36.0060 SPIVPSFDM 9 Flu.VNUC.473 50.0<BR> 36.0103 SPKGVEESSI 10 Flu.RRP2.624 219.0<BR> 36.0037 SPQLEGFSA 9 Flu.RRP2.654 63.1<BR> 36.0068 TPLGAINSSL 10 Flu.HEMA.298 376.8<BR> 36.0079 VPASRYLTDM 10 Flu.NS1.84 42.4<BR> 36.0075 YPDTGKVMCV 10 Flu.NRAM.267 422.7<BR> 36.0039 YITDKRI 9 Flu.RRP3.55 40.2<BR> 36.0041 YPKIYKTYF 9 Flu.RRP3.111 75.0<BR> 36.0005 YPKLKNSYV 9 Flu.HEMA.175 181.5<BR> 1372.03 IPIPSSWAFI 10 HBV.env.324 A 2147.3 767.3 10.7 87.9 1580.2<BR> 1372.01 LPSDFFPSI 9 HGV.core.19 A 7935.3 396.6 2.6 5.5 35.1<BR> 39.0045 APTLWARI 8 HCV.2869 A 452.5 >12000 1142.4 >17897.86 13661.2<BR> 39.0086 FPYLVAYQI 9 HCV.NS3.1588 A 3990.3 101.5 7.5 5.8 1.1<BR> 39.0044 IPLVGAPI 8 HCV.137 A 387.4 >12000 1.6 7282.7 209.3<BR> 39.0156 IPQAVVDMVI 10 HCV.E1.340 A 7439.2 1358.1 68.6 135.9 314.3<BR> 39.0159 LPAILSPGAI 10 HCV.NS4.1888 A 12114.5 >12000 270.5 >17897.86 167.6<BR> 39.0155 LPGCFSIFI 10 HCV.core.168 A 11224.5 19354.8 144.8 313.3 954.2<BR> 39.0043 LPRRGPRI 8 HCV.37 A 49.5 >12000 276.7 >17897.86 3928.6<BR> 39.0158 YPCTVNFTII 10 HCV.NS1/E2.623 A 70887.6 1781.8 44.3 146.2 49.0<BR> 48.0019 FPGGLREI 8 Her/neu.133 A 225.6 >12727.92 3736.2 >19827.67 2062.5<BR> 48.0020 FPGGLREL 8 Her2/neu.133 A 25.7 14814.8 >12963.62 >19827.67 10050.3<BR> 48.0144 FPGGLRELQL 10 Her2/neu.133 A 132.1 >14696.94 >14699.37 2785.2 1625.3<BR> 48.0027 FPKANKEI Her2/neu.760 A 64.5 >12727.92 4913.5 >19827.67 3079.8 TABLE 23<BR> HLA-B7 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog B*0702 B*3501 B*5101 B*5301 B*5401<BR> 45.0128 LPAARPAGATI 11 Her2/neu.1157 A 7.0 >13606.72 27.2 5834.3 5952.4<BR> 45.0030 LPSETDGI 8 Her2/neu.1120 A 530.5 >20784.61 496.4 >13152.19 29850.8<BR> 34.0264 SPGGLRELQI 10 Her2/neu.133 A 90.4 >16099.69 7812.5 >10960.16 3587.6<BR> 45.0124 SPLDSTFYRSI 11 Her2/neu.998 A 242.8 >18000 2121.6 >93000 5527.9<BR> 1146.02 FAVRPQVPL 9 HIV.nef.84 A 1845.7 171.4 526.3 6576.1 4724.6<BR> 1146.07 FLVRPQVPL 9 HIV.nef.84 A 10041.6 >0 55000.0 93000.0 100000.0<BR> 1181.14 FPVRPQVPC 9 HIV.nef.84 A 7145.6 1623.0 55000.0 12427.7 71.4<BR> 1181.12 FPVRPQVPG 9 HIV.nef.84 A 969.3 78.6 55000.0 6711.7 1.9<BR> 1181.11 FPVRPQVPK 9 HIV.nef.84 A 7489.7 7589.5 >152.78 93000.0 5058.0<BR> 1181.09 FPVRPQVPN 9 HIV.nef.84 A 55000.0 3087.0 55000.0 20795.4 6.3<BR> 1181.08 FPVPRPQVPQ 9 HIV.nef.84 A 7367.7 353.0 >152.78 5858.5 2078.9<BR> 1181.15 FPVRPQVPT 9 HIV.nef.84 A 830.2 307.0 18333.3 65760.9 1.9<BR> 1181.07 FPVRPQVPY 9 HIV.nef.84 A 1833.3 65.5 >152.78 140.9 1717.0<BR> 1146.06 FXVRPQVPL 9 HIV.nef.84 A 2690.1 1697.2 278.5 93000.0 5863.7<BR> 1372.05 IPIHYCAPI 9 HIV.env.293 A 338.8 1705.6 38.1 190.6 162.8<BR> 1292.08 IPYNPQSQGI 10 HIV.POL.883 A 1354.8 >34046.7 159.6 56750.6 782.1<BR> 1292.04 LPPLERLTI 9 HIV.REV.77 A 2022.3 >32199.38 16.8 4230.7 20576.1<BR> 39.0047 SPIETVPI 8 HIV.pol.174 A 30386.7 >120000 175.7 >17897.86 >16666.67<BR> 1292.11 TPPLVKLWI 9 HIV.POL.601 A >19445.44 189473.7 10.4 >35150.7 >18898.22<BR> 39.0087 YPLASLRSI 9 HIV.gag.507 A 185.9 11303.0 13.2 1139.9 49.2<BR> 31.0124 IPYCNYSKY 9 Lassa.gp.361 >9166.67 189.1 >8109.31 311.1 25000.0<BR> 31.0188 IPYCNYSKYW 10 Lassa.gp.361 >15877.13 2571.4 >7627.13 262.0 50000.0<BR> 34.0186 EPHISYPPI 9 MAGE2.296 A 253.0 >16099.69 84.6 1135.9 >1639.34<BR> 45.0135 GPRALIETSYI 11 MAGE2.274 A 22.2 >13606.72 852.7 >24855.3 >7715.17<BR> 45.0134 HPRKLLMQDLI 11 MAGE2.241 A 66.1 >41569.22 2211.6 40611.4 6747.6<BR> 1205.09 VPFSIILYIL 9 MAGE2.170 A 43.8 93.9 31.3 2649.6 1672.5<BR> 1205.11 VPISHLYIA 9 MAGE2.170 A 1184.5 2205.2 518.5 93000.0 1.1 TABLE 23<BR> HLA-B7 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog B*0702 B*3501 B*5101 B*5301 B*5401<BR> 45.0139 GPRALVETSYI 11 MAGE3.274 A 11.8 >13606.72 2632.1 >24855.3 >7715.17<BR> 34.0188 YPPLHEWVI 9 MAGE3.301 A 124.0<BR> 45.0140 APRMPEAAPPI 11 p53.63 A 2.3 >13606.72 1917.1 >24855.3 >7715.17<BR> 48.0055 FPALNMF 8 p53.127 A 228.0 3168.8 17027.9 6254.2 3888.0<BR> 48.0234 FPALNKMFCQL 11 p53.127 A 107.5 2714.2 5371.1 8024.2 524.7<BR> 48.0123 FPGTRVRAI 9 p53.152 A 5.2 >15350.45 694.2 24603.2 1723.0<BR> 48.0196 FPPGSTKRAL 10 p53.299 A 7.4 >8485.28 6395.4 >10960.16 >10000<BR> 48.0127 FPQPKKKPI 9 p53.315 A 9.0 >15350.45 >15254.26 >11195.88 16313.2<BR> 48.0128 FPQPKKKPL 9 P53.315 A 2.5 >15350.45 >15254.26 >11195.88 >26726.12<BR> 34.0191 PPGSTKRAI 9 p53.300 A 118.5 >16099.689 >9722.72 >10960.16 >6401.84<BR> 45.0141 VPSQKTYQGSI 11 p53.97 A 246.6 >13606.72 25229.4 >24855.3 >7715.17<BR> 1101.02 IPSLALMLI 9 Pf.SHEBA.7 190.7 2964.1 4714.1<BR> 39.0048 LPYGRTNI P Pf.SSP2.126 A 6857.9 >12000 318.5 45812.8 2308.9<BR> 39.0049 TPFAGEPI 8 Pf.SSP2.524 A 5009.1 >12000 359.7 28792.6 633.8<BR> 1372.04 TPYAGEPAPI 10 PF.SPP2.539 A 227.7 2457.2 14.5 162.2 170.3<BR> F001.11 APRTLVLYL 9 Naturally processed 5.0<BR> F001.10 APRTYVLLL 9 Naturally processed 3.9<BR> F020.14 YAFNMKATV 9 Naturally processed 55000.0 72000.0 12.7<BR> F029.03 YTNPQFNVY 9 Naturally processed >5500 262.1 >16666.67<BR> 980.12 APAKAAAAV 9 Artificial sequence A 8.9 >7200<BR> 953.12 AVAKAAAAL 9 Artificial sequence A 32.6 >12000<BR> 1086.03 FATPNFYTL 9 Artificial sequence A >13750 200.8 35355.3<BR> 1021.04 FPFKYAAAY 9 Artificial sequence A 19445.4 22.6 8.6<BR> 1146.23 FPVTFFFAF 9 Artificial sequence A 1664.4 2.7 2.8 2.1 206.7<BR> 1146.20 FPVTMFFAA 9 Artificial sequence A >1018.52 450.0 1255.9 7508.7 14.2<BR> 1146.13 FPVTMFFAF 9 Artificial sequence A 1467.8 2.1 2.9 1.7 182.3<BR> 1146.17 FPVTMFFAI 9 Artificial sequence A 2961.1 20.7 2.4 4.6 1.2 TABLE 23<BR> HLA-B7 supertype binding affinity (IC50 nM)<BR> Peptide Sequence AA Source Analog B*0702 B*3501 B*5101 B*5301 B*5401<BR> 1146.18 FPVTMFFAV 9 Artificial sequence A 1897.7 5.8 2.1 114.5 0.2<BR> 1146.14 FPVTMFFAW 9 Artificial sequence A 18333.3 5.0 16.8 7.5 226.5<BR> 1146.15 FPVTMFFAY 9 Artificial sequence A 55000.0 3.3 19.3 2.9 148.4<BR> 1125.03 LPFDYTPGF 9 Artificial sequence A 55000.0 19.8 158.0<BR> 1125.06 LPGPYFLQF 9 Artificial sequence A 1672.8 265.1 100000.0 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 69.0007 DEEEAIVAY CMV.E1.379 5.9 >10490.63 >15694.12 6402 1175 12051<BR> 69.0066 DEEEAIVAYT CMV.E1.379 77 >910.43 4304 1909 276 91<BR> 69.0086 DEEEAIVAYTL CMV.E1.379 34 95 103 2747 879 5140<BR> 69.0006 EEAIVAYTTL CMV.E1.381 75 13 24 96 35 213<BR> 69.0008 EEEAIVAYT CMV.E1.380 746 >10490.63 10292 1875 82 94<BR> 69.0065 EEEAIVAYTL CMV.E1.380 75 20 84 532 216 164<BR> 69.0005 SDEEEATVA CMV.E1.378 152 8176 21319 2988 10596 666<BR> 69.0064 SDEEEAIVAY CMV.E1.378 38 3931 >2387.61 558 395 4721<BR> 69.0085 SDEEEAIVAYT CMV.E1.378 175 2462 874 973 616 150<BR> 69.0094 SDEEEAIVAYTL CMV.E1.378 193 23 91 862 726 5939<BR> 69.0009 DEVEFLGHY EBV.BMLF.376 0.8 >10490.63 19784 3158 96 3193<BR> 69.0077 EENLLDFVRF EBV.ENBA6.281 53 12425 5294 59 100 18779<BR> 69.0081 EENLLDFVRM EBV.EBNA6.281 824 5150 3191 369 845 8808<BR> 69.0034 IEDPPFNSL EBV.lmp2.200 13889 428 21900 >9235./11 >7424.95 >10971.25<BR> 69.0052 KEHVIQNAF EBV.EBNA6.335 123 2175 87 6670 1406 12324<BR> 69.0039 SENDRLRLL EBV.BZLF1.209 752 432 77 8303 455 5540<BR> 69.0055 YEITPYKPT EBV.EBNA4.657 6579 2668 130 9667 5432 1442<BR> 69.0054 FEDLRVLSF Flu.NP.338 54 1179 166 730 991 >13709.73<BR> 69.0053 GEISPLPSL Flu.NS1.158 5682 108 124 9347 4158 10242<BR> 1479.45 AEDLNLGNLNV HBV.POL.38 >20833.33 3002 522 5210 2292 239<BR> 1479.04 AELLAACF HBV.POL.717 1.9 390 55 7.1 22 277<BR> 1479.17 AELLAACFA HBV.POL.717 4348 311 21 253 47 8.4<BR> 1479.27 DEAGPLEEEL HBV.POL.16 2242 3117 16606 >36027 14799 219<BR> 1479.35 EDLNLGNLNV HBV.POL.39 9259 >19.75 >27399.83 >12713.88 >36394.05 47430<BR> 1479.07 EEELPRLA HBV.POL.22 >31250 >54.39 >978.7 11201 30535 517 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 1479.16 EELGEEIRL HBV.X.121 41667 275 295 218 251 230<BR> 1479.18 IDWKCVQRI HBV.POL.617 >34482.76 41395 303 >11630.67 >31732.28 4478<BR> 1479.10 LDSWWTSL HBV.ENV.195 >31250 7843 422 >6146.26 37542 38333<BR> 1479.36 LDSWWTSLNF HBV.ENV.195 3559 381 534 3652 10321 14054<BR> 1479.41 LDSWWTSLNFL HBV.ENV.195 28571 4040 242 4148 5013 1567<BR> 1479.05 LDTASALY HBV.NUC.31 198 >43041.42 25994 922 7684 >39859.26<BR> 1479.11 LDVSAAFY HBV.POL.417 387 >46169.74 44544 1534 11913 50317<BR> 1479.21 LDYQGMLPV HBV.ENV.261 24390 >51.1 3.2 >29516.17 >30259.67 >32837.14<BR> 1479.12 LEEELPRL HBV.POL.21 174 27477 223 >6146.26 45455 3287<BR> 1479.22 LEEELPRLA HBV.POL.21 8519 >46371.3 2681 >29516.17 41432 196<BR> 1479.19 RDLLDTASA HBV.NUC.28 38462 40661 206 >11630.67 5077 382<BR> 1479.31 RDLLDTASAL HBV.NUC.28 >30303.03 1526 424 >17359.64 >28814.23 >35815.39<BR> 1479.40 RDLLDTASALY HBV.NUC.28 >27027.03 54528 1891 405 204 32522<BR> 1479.25 RDVLCLRPV HBV.X.13 >34482.76 538 36 >39949.81 624 52946<BR> 1479.01 RETVLEYL HBV.NUC.141 21739 303 30 18054 9268 15626<BR> 1479.15 RETVLEYLV HV.NUC.141 20833 219 59 25309 3910 230<BR> 1479.44 TDNSVVLSRKY HBV.POL.736 >20833.33 269 12127 352 2605 4269<BR> 1479.47 VEELSFLPSDF HBV.NUC.42 134 2956 283 227 333 8264<BR> 1479.03 WEELGEEI HBV.X.120 2000 305 370 9950 19970 30734<BR> 1479.29 WEELGEEIRL HBV.X.120 >30303.03 27 226 2202 412 33947<BR> 64.0143 ADLEVVTSTW HCV.Entire.1656 863 >10429.64 9853 724 221 >12141.28<BR> 64.0060 ADLMGYIPL HCV.Entire.131 >2150.54 778 10 >15730.34 >6343.71 >9931.94<BR> 64.0022 AEAALENL HCV.Entire.749 >2132.2 620 109 20896 390 529<BR> 64.0061. AEAALENLV HCV.Entire.749 >2150.54 130 63 23179 250 40<BR> 64.0029 AETAGARL HCV.Entire.1341 >2132.2 109 132 >12635.38 3704 6484 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 64.0069 AETAGARLV HCV.Entire.1341 >2188.18 7782 809 >15625 5629 116<BR> 64.0145 AETAGARLVV HCV.Entire.1341 >2024.2 4338 244 >1345.22 9910 110<BR> 64.0177 AETAGARLVVL HCV.Entire.1341 >2066.122 59 53 14433 2732 57<BR> 64.0030 CDELAKL HCV.Entire.1405 219 7178 5587 1132 10185 >10913.04<BR> 64.0136 CECYDAGCAW HCV.Entire.1523 802 >10429.64 9798 948 317 16082<BR> 64.0168 CECYDAGCAWY HCV.Entire.1523 93 12623 20016 479 275 8594<BR> 64.0070 CEKMALYDV HCV.Entire.2623 2421 13063 644 8537 9291 109<BR> 64.0146 CEKMALYDVV HCV.Entire.2623 5587 9400 111 9211 10913 92<BR> 64.0063 EDLVNLLPA HCV.Entire.1882 >2188.18 >12687.98 1318 >15625 >6329.11 500<BR> 64.0031 GDLCGSVF HCV.Entire.278 592 >11264.46 81 9818 9338 >10913.04<BR> 64.0187 GEGAVQWMNRL HCV.Entire.1914 >2066.12 402 422 >14613.78 15850 >12443.44<BR> 64.0076 GEIPFYGKA HCV.Entire.1376 >2188.18 1196 68 21807 6440 46<BR> 64.0151 GEIPFYGKAI HCV.Entire.1376 >2227.17 78 51 7761 91 6057<BR> 69.0038 GQIVGGVYL HCV.cAg.27 14286 15 37 681 2357 9032<BR> 64.0181 IEANLLWRQEM HCV.Entire.2236 213 76 69 1246 54647 15152<BR> 1472.01 ELDRDRSEL HCV.NS1/E2.654 >8621.97 129 184 >34204.99 46064 >40390.98<BR> 64.0034 LEVVTSTW HCV.Entire.1658 94 7549 913 742 2927 >01913.04<BR> 64.0074 LEVVTSTWV HCV.Entire.1668 2188 634 144 11345 10496 7890<BR> 64.0147 LEVVTSTWVL HCV.Entire.1658 1006 8.8 8.7 3338 2304 12472<BR> 64.0183 LEVVTSTWVLV HCV.Entire.1658 1101 128 99 4037 1634 874<BR> 64.0024 SELSPLLL HCV.Entire.665 2336 519 110 11094 553 7011<BR> 64.0077 TEAMTRYSA HCV.Entire.2793 1160 9053 145 1686 5832 60<BR> 64.0078 VDFSLDPTF HCV.Entire.1467 2304 >11338.36 145 16241 9565 >11766.22<BR> 64.0188 VDFSLDPTFTI HCV.Entire.1467 >2066.12 >10037./87 68 27778 17350 >12443.44<BR> 64.0040 VDYPYRLW HCV.Entire.614 >2136.75 34027 15625 >11146.5 417 >10913.04 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 64.0018 AEHLKTAV HIV.POL.921 1289 6271 23 1019 1395 1267<BR> 64.0126 AEHLKTAVQM HIV.POL.921 >2096.44 96 78 7384 1008 943<BR> 64.0165 AEHLKTAVQMA HIV.POL.921 >1945.53 8411 982 >8951.41 7514 122<BR> 64.0162 AELELAENREI HIV.POL.488 >1945.53 706 561 7675 90 98<BR> 69.0078 AENLWVTVYY HIV.gP120.1 79 277 89 43 13 275<BR> 64.0048 AETFYVDGA HIV.POL.629 >2136.75 11491 1131 >11146.5 5601 43<BR> 69.0062 AETFYVDGA HIV.RT.592 >9090.91 3350 1406 2587 3493 114<BR> 64.0016 AETGQETA HIV.POL.843 >2257.34 666 546 >11608.62 231 1064<BR> 64.0124 AETGQETAYF HIV.POL.843 >4504.5 6489 1287 7559 387 8634<BR> 64.0045 EEKAFSPEV HIV.GAG.181 2083 14512 112 6869 7597 57<BR> 64.0113 EEKAFSPEVI HIV.GAG.181 >1992.03 14811 4130 8537 7524 253<BR> 64.0115 EEMMTACQGV HIV.GAG.368 >1992.03 9474 6155 5613 2066 125<BR> 64.0053 GDAYFSVPL HIV.POL.301 2899 1430 7.5 16949 >6343.71 >15983.85<BR> 64.0014 GEAMHGQV HIV.POL.799 >2331 836 200 >11844.33 >(259.26 8943<BR> 64.0011 IEAEVIPA HIV.POL.836 41 3166 36 654 8209 389<BR> 64.0001 IEAQQHLL HIV.ENV.645 58 31 28 6034 1252 >12770<BR> 64.0010 IETVPVKL HIV.POL.191 >2013.01 34 79 1275 3205 >12770<BR> 64.0003 KDCTERQA HIV.GAG.457 >2012.07 >1762.29 553 >10401.19 41 42373<BR> 64.0133 KEPPFLWMGY HIV.POL.412 >2024.29 >9386.68 883 3045 10.0 14286<BR> 64.0119 LELANREIL HIV.POL.490 >2096.44 9.3 233 >12567.32 11555 17915<BR> 64.0017 NEQVDKLV HIV.POL.737 233 >3032.82 1297 >11608.62 >6699.15 15318<BR> 64.0009 NETPGIRY HIV.POL.326 19 >1762.29 31250 12080 1911 >12770<BR> 64.0117 NETPGIRYQY HIV.POL.326 58 >12044.75 >11524.1 57 50 11853<BR> 64.0012 QDFWEVQL HIV.POL.274 >2012.07 1080 165 1534 >9369.68 >28690.23<BR> 69.0010 RDYVDRFYK HIV.Gag.292 6250 >10972.49 >2119.25 339 >7635.83 >21942.68 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 64.0406 REPRGSDIA HIV.GAG.250 >2136.75 >12747.77 863 >11146.5 >970.85 402<BR> 64.0002 SELYKYKV HIV.ENV.559 >2012.07 284 135 4192 4808 8845<BR> 64.0044 SELYKYKVV HIV.ENV.559 3436 12904 97 10903 4898 988<BR> 64.0128 TDSQYALGII HIV.POL.689 308 6306 442 783011506 1218<BR> 64.0013 TEEKIKAL HIV.POL.214 1339 356 769 723 >11506.28 >12770<BR> 64.0005 TERQANFL HIV.GAG.460 56 118 14 3319 266 10922<BR> 64.0052 WEFVNTPPL HIV.POL.606 1.9 1.4 5.0 55 305 5848<BR> 64.0121 WEFVNTPPLV HIV.POL.606 272 60 34 8304 9683 7237<BR> 64.0163 WEVQLGIPHPA HIV.POL.277 14 697 73 5872 5972 532<BR> 64.0019 YELHPDKW HIV.POL.421 418 512 504 1547 159 >12767.93<BR> 64.0129 YELHPDKWTV HIV.POL.421 891 123 9.4 4411 11022 7453<BR> 78.0225 AEDLRTLQQL HPV45.E7.81 >24738.53 95 107 3905 297 175<BR> 78.0215 AEPDTSNYVNI HPV31.E7.45 >24738.53 1619 2024 1243 343 1398<BR> 78.0417 AEPQRHTML HPV18.E7.54 5.1 781 22 51 20 21310<BR> 78.0440 AEQATSNYY HPV52.E7.47 12070 326 1486 3006 177 1608<BR> 78.0228 AEQATSNYYI HPV52.E7.47 10638 291 51 92 104 15.3<BR> 78.0210 AERPKLHEL HPV31.E6.6 14213 23648 273 14997 21440 2945<BR> 78.0418 CEARIELVV HPV18.E7.68 0.1 132 1.4 14 16 2162<BR> 78.0446 CECKFVVQL HPV56.E7.66 660 6966 401 303 21 34<BR> 78.0420 DELRLNCVY HPV31.E6.24 >29424.49 >26772.48 29013 9304 25837 47<BR> 78.0217 EEKPRTLHDL HPV33.E6.6 >24738.53 19236 20016 11593 24273 470<BR> 78.0432 EENDEADGV HPV45.E7.37 5530 1429 422 13466 17582 4525<BR> 78.0416 EENDEIDGV HPV18.E7.36 1848 172 674 33228 17141 42422<BR> 78.0434 EESVHEIRL HPV52.E6.20 134 8354 49 1828 18444 44717<BR> 78.0239 FEDPTRRPY HPV18.E6.4 13 592 40 147 205 450 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 78.0206 FEFAFKDLV HPV18.E6.45 2.0 100 2.0 956 174 3006<BR> 78.0419 HELSSALEI HPV31.E6.13 16737 187 256 2022 20691 25882<BR> 78.0232 KEDLRVVQQL HPV56.E7.80 >7860.62 502 44 12913 2608 3447<BR> 78.0435 KELQRREVY HPV52.E6.35 19090 50 44 17557 >32308.25 29973<BR> 78.0442 KELTRAEVY HPV56.E6.38 7699 2122 275 25736 15174 >36998.68<BR> 78.0202 LECVYCKQQL HPV16.E6.35 6984 175 135 11658 1472 41639<BR> 78.0436 LEERVKKPL HPV52.E6.88 24398 3.0 5.4 18172 1347 4031<BR> 78.0226 LEESVHEIRL HPV52.E6.91 12371 123 1679 16032 28988 18357<BR> 78.0230 LEIPLDIRL HPV56.E6.22 4485 42 7.3 8457 206 30242<BR> 78.0211 LEIPYDELRL HPV31.E6.19 11987 1495 303 27643 2325 31587<BR> 78.0421 LEKLTNKGI HPV31.E6.88 37139 5442 291 >20466.26 >33599.1 20543<BR> 78.0208 LELTNTGLY HPV18.E6.90 861 162 6702 622 2639 31186<BR> 78.0444 LELTPQTEI HPV56.E7.13 3998 6461 20 2540 2716 243<BR> 78.0447 LEQTLKKCL HPV58.E6.88 53 1411 16 2674 200 313<BR> 78.0424 LEQTVKKPL HPV33.E6.88 171 1110 164 4453 249 236<BR> 78.0428 LERTEVYQF HPV45.E6.39 3675 15300 7845 1772 222 >35147.94<BR> 78.0443 LESITKKQL HPV56.E6.91 74 122 6.1 242 55 176<BR> 78.0234 LETSVHEIEL HPV58.E6.19 627 25 38 11547 2247 6385<BR> 78.0218 LETTIHNIEL HPV33.E6.19 4384 129 166 19310 1586 5337<BR> 78.0425 NEILIRCII HPV33.E6.97 1830 154 34 2071 209 3646<BR> 78.0448 NEILLRCII HPV58.E6/.97 88 34247 22716 465 1332 >37221.52<BR> 78.0414 NEKRRFHNI HPV18.E6.122 212 150 31 2387 2336 2044<BR> 78.0431 NELDPVDLL HPV45.E7.19 25 384 41 2094 233 451<BR> 78.0423 PEATDLHCY HPV31.E7.17 >2942.49 237 2334 21016 25172 24308<BR> 78.0450 PEPTDLFCY HPV58.E7.17 5453 259 201 1723 3110 37844 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 78.0426 QEKKRHVDL HPV33.E6.113 2.4 8491 37113 337 170 14157<BR> 78.0449 QEKKRHVDL HPV58.E6.113 >8621.97 1051 1869 2361 474 >37221.52<BR> 78.0216 QELLMGSFGI HPV31.E7.80 1699 285 180 204 153 259<BR> 78.0200 QERPRKLPQL HPV16.E6.13 >23870.5 15331 304 39234 28466 2241<BR> 78.0229 QERPRSLHHL HPV56.E6.9 >7860.62 5752 494 6089 13937 2590<BR> 78.0207 RELRHYSDSV HPV18.E6.76 7363 1196 2968524 20650 2086<BR> 78.0221 RELRYYSNSV HPV45.E6.76 >8264.75 895 19 16950 17558 410<BR> 78.0430 RETLQEIVL HPV45.E7.5 2611 2025 55 388 255 32285<BR> 78.0213 SEFRWRYSV HPV31.E6.74 9. 274 2.8 197 21 35<BR> 78.0437 SEITIRCII HPV52.E6.97 3183 456 409 6602 1721 3763<BR> 78.0441 SEVLEIPLI HPV56.E6.19446 28851 6049238 262 32935<BR> 78.0203 SEYRHYCYSL HPV16.E6.81 133 16 13 1498 175 202<BR> 78.0235 SEYRHYNSL HPV58.E6.74 64 9.4 3.6 1124 185 181<BR> 78.0219 SEYRHYNSV HPV33.E6.74 132 1312 17 15814 2842 30<BR> 78.0227 SEYRHQYSL HPV52.DE6.74 97 15 14 228 289 290<BR> 78.0205 TELNTSLQDI HPV18.E6.19 12897 180 1691 5408 112911464<BR> 78.0212 TETEVLDFAF HPV31.E6.38 25 2114 244 192 41 41087<BR> 70.0055 AEDLYGRLEI Pf.LSA1.1649 >1532.81 1095 940 447 366 913<BR> 64.0089 DEFKPIVQY Pf.LSA1.1783 1.2 >11338.36 >14084.51 9.2 324 >13736.27<BR> 70.0030 DEIKYREEV Pf.SSP2.34 250 >2015.33 7984 11200 >7003.42 3856<BR> 70.0057 DELSEDITKY Pf.LSA1.1896 131 >1553.5 >1992.04 5254 5756 >9479.14<BR> 70.0044 DENANANNAV Pf.CSPZ.333 120 >1811.7 2007 >8127.24 >7997.92 1106<BR> 70.0031 DEVDLYLLM Pf.SSP2.45 5.6 1555 603 787 68 >10605.18<BR> 70.0064 EENIGIYKEL Pf.LSA1.1797 >1728.24 1704 1776 31 460 367<BR> 70.0080 EEVCNDEVDL Pf.SSP2.40 2788 434 1870 5723 8026 10252 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 70.0081 GEPAPFDETL Pf.SSP2.531 >10869.57 7.6 13 10558 6848 >8615.59<BR> 70.0050 GEPLIDVHDL Pf.PfEXP-1.44 93<BR> 70.0069 KEGKLIEHII Pf.LSA1.119 2086 631 124 360 3794 11531<BR> 70.0070 KEKEKFIKSL Pf.LSA1.1872 3732 1039 190 7933 >6331.06 >8900.42<BR> 64.0101 KEKFIKSLF Pf.LSA1.1874 >1968.5 7156 65 23810 814 11702<BR> 70.0071 LDEFKPIVQYU Pf.LSA1.1782 2019 96 111 7022 >633.06 >8747.17<BR> 70.0072 LEEKAAKETL Pf.LSA1.149 156 >1491.97 >3937.13 >10838.73 6799 >8747.17<BR> 64.0103 LETVNISDV Pf.LSA1.1744 >1968.5 7497 122 >16055.05 >6892.23 689<BR> 70.0034 NDEVDLYLL Pf.SSP2.44 181 27419 5292 10590 3782 >10343.38<BR> 70.0082 NDEVDLYLLM Pf.SSP2./44 7.3 1141 153 1616 296 16119<BR> 70.0048 NDIEKKICKM Pf.CSPZ.041 1220 1947 937 4833 11254 429<BR> 70.0046 NELNYDNAGI Pf.CSPZ.36 1486 2194 13820 80 58 513<BR> 64.0106 QDEENIGIY Pf.LSA1.1795 23 >12506.23 >11940.49 2088 10358 9016<BR> 70.0083 QDSLKESRKL Pf.SSP2.169 >1357.89 12 5.0 330 386 105<BR> 70.0014 QERLANEEKL Pf.LSA1.1527 814 764 368 2882 766 7733<BR> 70.0015 QERRAKEKL Pf.LSA1.1578 >1901.31 1729 24 4159 4151 11761<BR> 70.0039 RENANQLVV Pf.SSP2.150 244 92 12 564 388 42<BR> 70.0019 SDLEQDRLA Pf.LSA1.1387 235 >2000.2 4867 >20582.18 4864 >10316.53<BR> 70.0024 SEELSEEKI Pf.LSA1.1827 165 89 1486 545 126 4205<BR> 70.0041 SEKEVPSDV Pf.SSP2.371 153 >2015.33 122 8130 >7003.42 777<BR> 70.0025 SENERGYYI Pf.LSA1.1665 97 1983 133 114 74 378<BR> 64.0122 SESNGEPNA Pf.PFEXP1.127 >2247.19 >12506.23 8207 >8805.03 >9632.22 121<BR> 70.0043 WDEWSPCSV Pf.SSP2.247 155 >2015.67 608 15002 6735 >10827.8<BR> 70.0026 YEDEISAEY Pf.LSA1.1760 11 2082 7805 3574 459 >1402.05<BR> 70.0027 YEKTKDNNF Pf.LSA1.1841 2318 >4032.11 152 958 11674 6691 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 64.0086 YENDIEKKI Pf.CSPZ.399 2278 933 133 10938 574 9481<BR> 69.0037 SESPIVVVL Rat.45 144 16 72 1505 619 881<BR> 69.0063 AEEAAGIGI >9090.91 23 565 492 140 67<BR> 69.0084 AEEAAGIGIL 12195 17 36 3085 926 73<BR> 69.0093 AEEAAGIGILT >5780.35 418 524 4732 686 175<BR> 69.0025 AEIGEVIVL 9615 5.6 3.6 92 28 91<BR> 69.0070 AEIGEVIVLW 1026 38 18 369 17 97<BR> 69.0090 AEIGEVIVLWL 10530 13 39 3303 7.5 33.6<BR> 69.0027 AEIPGEIAL 9524 3.3 5.7 1114 150 1086<BR> 69.0075 AEVDKVTGRF 10638 1891 821 416 4152 2005<BR> 69.0051 DEAPAVISY 0.9 2977 17056 508 70 11189<BR> 69.0049 DEFIBVAIY 0.7 14509 1100 2677 14 16200<BR> 69.0050 DENPLVKQY 9.2 989 9799 312 124 >12676.78<BR> 69.0045 DEVGIVTKY 4.6 2597 >15074.52 651 45 >12676.78<BR> 69.0076 DEVPDLERKY 101 4688 86 69 286 >14076.63<BR> 69.0041 EEFQFIKKA 100 12484 37 129 60 73<BR> 69.0022 EEEFYVDLER 12658 5173 14825 10360 367 6137<BR> 69.0058 EEKLIVVAF 1.0 863 184 68 52 806<BR> 69.0059 FEKLLVVLF 4.8 1430 208 44 17 709<BR> 69.0029 FEIPLLDVA 115 704 7.8 3058 11766 61<BR> 69.0048 FEPTVVKKY 1294 >1905.51 882 678 63 >12676.78<BR> 69.0040 GEFGGFGSV 19608 1438 241 4580 1222 7707<BR> 69.0020 GEFIPGNDL 9524 20 146 10874 2299 14142<BR> 69.0018 GEFPGKIFL 8264 30 107 11014 457 >14176.58<BR> 69.0069 GEFPGKIFLY 85 15 14 44 6.4 6986 Table 24<BR> HLA- B44 supertype binding affinity (IC50 nM)<BR> Peptide Sequence Source B*1801 B*4001 B*4002 B*4402 B*4403 B*4501<BR> 69.0089 GEFPGKIFLYA 762 184 16 3793 14 1926<BR> 69.0017 GEFPNKNIL 20833 14 25 5117 872 31325<BR> 69.0068 GEFPNKNILY 428 20 149 458 70 >12241.78<BR> 69.0088 GEFPNKNILYA 7463 457 48 14551 971 2442<BR> 69.0004 GEFSITYK 10870 646 176 4102 782 11469<BR> 69.0002 GEFVDLYV 8696 362 1130 8873 14192 45707<BR> 69.0042 GEHGLIRV >11363.64 39 3.2 3215 174 375<BR> 69.0028 GEILDVFDA 15625 419 15 12689 3939 56<BR> 69.0026 GEVIVLWLW 1230 652 9.0 178 26 5584<BR> 69.0073 HEATLRCWAL 106 16 12 1291 5512 8909<BR> 69.0092 IEVDPDTKEML >9009.01 409 4054 >*202.43 9586 >21808.92<BR> 69.0031 KESTLHLVL 12658 136 119 2251 1895 16607<BR> 69.0091 KEVGVDVALYA 12658 97 56 >8681.62 419 716<BR> 69.0057 MEVDPIGHL 434 24 23 850 188 1105<BR> 69.0079 MEVDPIGHLY 6.4 599 555 6.0 23 256<BR> 69.0033 REIAQDFKT >12658.23 67 119 7115 1408 1562<BR> 69.0072 REIAQDFKTD 13158 45 1497 8272 11532 2012<BR> 69.0003 REIINAV 819 346 14 8136 7702 451<BR> 69.0043 REMIPFADI 8333 4.9 8.5 176 129 8.7<BR> 69.0015 REPVTKAEM >11363.64 167 138 8436 6021 24162<BR> 69.0044 SEIDTVAKY 74 861 5709 367 338 1948<BR> 69.0056 SEIWRDIDF 47 30 44 205 10.1 197<BR> 69.0016 TEFPKERHL 8475 1248 100 10793 599 22219<BR> 69.0019 WEFLQPILL 7.5 0.8 1.0 176 31 5200<BR> 69.0036 YEIHDGMNL 12821 9.3 14 6897 1711 31404 TABLE 25 Sequence Source Motif % Conservation FPDWQNYTPGPGIRY HIV. nef. 200 DRsuper 23 FPDWQNYTPGPGTRF HIV. nef. 200 DRsuper 20 GFPVRPQVPLRPMTY HIV. nef. 93 DRsuper 56 GGKWSKSSIVGWPAI HIV. nef. 2 DRsuper 8 GPGIRYPLTFGWCFK HIV. nef. 210 DRsuper 9 HGAITSSNTAATNAD HIV. nef. 61 DRsuper 16 ILDLWVYHTQGFFPD HIV. nef. 186 DRsuper 20 ILDLWVYHTQGYFPD HIV. nef. 186 DRsuper 33 NNCLLHPMSQHGMDD HIV. nef. 254 DRsuper 9 NNSLLHPICQHGMED HIV. nef. 254 DRsuper 6 RFPLTFGWCFKLVPV HIV. nef. 216 DRsuper 19 RPQVPLRPMTYKGAF HIV. nef. 98 DRsuper 11 RQDILDLWVYHTQGY HIV. nef. 182 DRsuper 14 RQDILDLWVYNTQGY HIV. nef. 182 DRsuper 8 RQEILDLWVYHTQGF HIV. nef. 182 DRsuper 16 RQEILDLWVYHTQGY HIV. nef. 182 DRsuper 19 RYPLTFGWCFKLVPV HIV. nef. 216 DRsuper 24 SRDLEKHGAITSSNT HIV. nef. 50 DRsuper 20 TFGWCFKLVPVDPRE HIV. nef. 222 DRsuper 11 AEPVPLQLPPLERLT HIV. rev. 72 DRsuper 16 IKFLYQSNPPPSPEG HIV. rev. 21 DRsuper 6 LKAVRIIKILYQSNP HIV. rev. 13 DRsuper 9 PVPLQLPPLERLTLD HIV. rev. 74 DRsuper 20 LEPWKHPGSQPKTAC HIV. tat. ll DRsuper 17 LEPWNHPGSQPKTAC HIV. tat. ll DRsuper 17 LEPWNHPGSQPRTPC HIV. tat. ll DRsuper 5 LEPWNHPGSQPTTAC HIV. tat. ll DRsuper 11 NNCYCKKCCFHCQVC HIV. tat. 26 DRsuper 6 QLCFLKKGLGISYGR HIV. tat. 38 DRsuper 5 QVCFITKGLGISYGR HIV. tat. 38 DRsuper 11 QVCFLNKGLGISYGR HIV. tat. 38 DRsuper 6 TNCYCKKCCYHCQVC HIV. tat. 26 DRsuper 3 LDGLIYSKKRQEILD HIV. nef. 171 DR3 17 TABLE 25 LSFFLKEKGGLDGLI HIV. nef. 114 DR3 22 LSHFLKEKGGLEGLI HIV. nef. 114 DR3 23 QDAVSQDLDKCGAAA HIV. nef. 51 DR3 2 TQGFFPDWQNYTPGP HIV. nef. 195 DR3 27 TQGYFPDWQNYTPGP HIV. nef.195 DR3 52 TRQARKNRRRRWRAR HIV. rev. 38 DR3 20 TRQARRNRRRRWRAR HIV. rev. 38 DR3 28 TRQARRNRRRRWRER HIV. rev. 38 DR3 19 KEKVERETETDPAVQ HIV. tat. 95 DR3 2 Table 26<BR> Peptide Sequence AA Source Analog DRB1*0101 DRB5*010 DRB1*1501 DRB1*0301 DRB1*0401<BR> 58.0015 LWWVNNESLPVSPRL 15 CEA.177.A A 310<BR> F168.09 IRNLALQTLPAMCNVY 20 Gliadin.235.<BR> <P>F168.05 VQQQQFLGQQQPFPPQ 20 Gliadin.25.<BR> <P>F168.06 QFLGQQQPFPPQ 20 Gliadin.29.<BR> <P>F116.01 MDIDPYKEFGATVELLSFLPSDFFI 25 HBVcore.1. 1563 957<BR> F164.04 LPETTVVRCRGRSPR 17 HBVcore.143.<BR> <P>F164.12 TNMGLKFRQLLWFHI 25 HBVcore.91.<BR> <P>F164.11 TNVGLKFRQLLWFHI 25 HBVcore.91. 1491 836<BR> RS-21 GP41584-609 26 HIV1gp.. 1250 9100<BR> JR-01 PEFLEQWRRAAVDTYC 15 IEBs2.. 5000<BR> 68.0001 MWDLVLSALSVGCT 15 Kallikrein2.1. 205 11375 10386<BR> 68.0009 NMSLLKHQSLRPDED 15 Kallikrein2.102. 3131<BR> 68.0010 SHDLMLLRLSEPAKI 15 Kallikrein2.118. 56 2031 365 2396 12622<BR> 68.0011 HDLMLLRLSEPAKTT 15 Kallikrein2.119. 16 211 115 1406<BR> 68.0015 PEEFLRPRSLQCVSL 15 Kallikrein2.162. 20012 3193<BR> 68.0016 PRSLQCVSLHLLSND 15 Kallikrein2.1687. 1111 1597<BR> 68.0140 LHLLSNDMCARAYSE 15 Kallikrein2.176. 2104 938<BR> 68.0017 NGVLQGITSWGPEPC 15 KALLIKREIN2.220. 1093 835<BR> 68.0018 KPAVYTKVVHYRKWI 15 Kallikrein2.239. 5000 23 401 8061<BR> 68.0002 DLVLSIALSVGCTGA 15 Kallikrein2.3. 1197 18200<BR> 68.0003 HPQWVLTAAHCLKKN 15 Kallikrein2.56. 22 11 1219 1103 4922<BR> 68.0004 QWVLTAAHCLKKNSQ 15 Kallikrein2.58. 895 382<BR> 68.0005 GQRVPVSHSFPHPLY 15 Kallikrein2.87. 1563 3960<BR> 68.0006 RVPVSHSFPHPLYNM 15 kALLIKREIN2.89. 67 11650 5518<BR> 68.0007 PHPLYNMSLLKHQSL 15 Kallikrein2.97. 1901 3873 4607<BR> 68.0008 HPLYNMSLLKHQSLR 15 Kallikrein2.98. 232 219 472 13007 2807<BR> F118.02 LVIPENAKEKPQEGT 15 M.leprae.28. 1876 827 Table 26<BR> Peptide DRB3*0101 DRB1*1101 DRB1*1201 DRB1*1302 DRB1*0701 DRB1*0802 DRB1*0901 DRB4*0101 DRB1*0404 DQB1*0301<BR> 58.0015<BR> F168.094.9<BR> F168.05 2.2<BR> F168.06 7.8<BR> F116.01 2430 6609<BR> F164.04<BR> F164.12 270 11181 6274<BR> F164.11 5521 1012 150<BR> RS-21 3965 645<BR> JR-01 488<BR> 68.0001 4575 108 3032 1727 158<BR> 68.0009 1288 105<BR> 68.0010 5361 5267 591 1.8 106 1327 112 10.2<BR> 68.0011 488 1147 84 0.8 109 544 43 12<BR> 68.0015 10675 6023 11667 5156 2207 5839 117<BR> 68.0016 11650 11128 3861 3731 2217 6107 544<BR> 68.0140 1989 1152 1876 324<BR> 68.0017 2285 5761<BR> 68.0018 7186 327 1303 1947 2401 53 3677 4581<BR> 68.0002 4915 98 4029 2200 459<BR> 68.0003 8114 981 11450 483 563 1693 822 1106<BR> 68.0004 3402 4813 14395<BR> 68.0005 5507 703 629 102 9860<BR> 68.0006 10397 377 101 97 9213<BR> 68.0007 6455 860 3307 3315 1592 49<BR> 68.0008 248 95 546 1282 382 199 8.4<BR> F118.02 Table 26<BR> Peptide Sequence AA Source ANalog DRB!*0101 DRB5*0101 DRB1*1501 DRB1*0301 DRB1*0401<BR> F006.15 ENPVVHFFKNIVTPR 15 MBP.85. 463 5.2<BR> F006.21 ENPVVAFFKNIVTPR 15 MBP.85.SAAS SAAS 302 2.8<BR> F006.22 ENPVVHAFKNIVTPR 15 MBP.85.SAAS SAAS 910 2.7<BR> F006.24 ENPVVHFFANIVTPR 15 MBP.85.SAAS SAAS 6235 2.9<BR> F006.30 ENPVVHFFKNIVTPA 15 MBP.85.SAAS SAAS 3333 2.5<BR> F006.31 NPVVHFFKNIVT 12 MBP.86. 10000 23<BR> F006.34 NPVVHFFKNIVTPR 14 MBP.86. 1890 3.7<BR> F006.321 HFFKNIVTPRTPPY 14 MBP.90. 377 460<BR> 68.0030 DRTLMSAMTNLAALF 15 PAP.110. 97 871 72<BR> 68.0031 MSAMTNLAALFPPEG 15 PAP.114. 1757 12384 3935<BR> 68.0032 MTNLAALFPPEGVSI 15 PAP.117. 24 10370<BR> 68.0033 PEGVSIWNPILLWQP 15 PAP.126. 111 7.2 10000<BR> 68.0034 GVSIWNPILLWQPIP 15 PAP.128. 44 523 5.0<BR> 68.0022 SLSLGFLFLLFFWLD 15 PAP.13. 11417 11375<BR> 68.0035 WNPILLWQPIPVHTV 15 PAP.132. 208 14 3908<BR> 68.0036 NPILLWQLPIPVHTVP 15 PAP.133. 31 4.6 1160<BR> 68.0037 PILLWQPIPVHTVPL 15 PAP.134. 44 6.9 1451<BR> 68.0038 ILLWQPIPVHTVPLS 15 PAP.135. 45 65 957<BR> 68.0039 WQPIPVHTVPLSEDQ 15 PAP.138. 6386<BR> 68.0147 TVPLSEDQLLYLPFR 15 PAP.145. 4012 332<BR> 68.0040 LSGLHGQDLFGIWSK 15 PAP.194. 148<BR> 68.0023 LLFFWLDRSVLAKEL 15 PAP.21. 2.9 134 34 6.3 15<BR> 68.0041 YDPLYCESVHNFTLP 15 PAP.210. 1597 2136 16625<BR> 68.0042 LPSWATEDTMTKLRE 15 PAP.223. 343 5472<BR> 68.0043 LRELSELSLLSLYGI 15 PAP.235. 655 5185 235 2085<BR> 68.0044 LSELSLLSLYGIHKQ 15 PAP.238. 482 7.3 45 8715<BR> 68.0045 LSLLSLYGIHKQKEK 15 PAP.241. 656 3.4 58 Table 26<BR> Peptide DRB3*0101 DRB1*1101 DRB1*1201 DRB1*1302 DRB1*0701 DRB1*0802 DRB1*0901 DRB4*0101 DRB1*0404 DRB1*0301<BR> F006.15<BR> F006.21<BR> F006.22<BR> F006.24<BR> F006.30<BR> F006.31<BR> F006.34<BR> F006.321<BR> 68.0030 3927 2367 704 114 383 2362 222 57<BR> 68.0031 71258 3873 249 1072<BR> 68.0032 4531 1310 4606<BR> 68.0033 4624 7976 444 107<BR> 68.0034 4428 10287 3902 207 4992 11008 3985 492<BR> 68.0022 3710 1221 639<BR> 68.0035 5694 2259 521 607 81<BR> 68.0036 599 612 250 41 12999 575 67<BR> 68.0037 4041 2370 567 46 168 106<BR> 68.0038 2343 7289 1111 19 13091 131 712<BR> 68.0039 2692 159 1228<BR> 68.0147 4323 14387 5300 11313 872<BR> 68.0040 7891 135<BR> 68.0023 86 154 179 24 135 163 518 7.5<BR> 68.0041 838 643 6901<BR> 68.0042 5973<BR> 68.0043 6958 1169 3218 4010 9368 1614 544<BR> 68.0044 1657 262 1253 1186 1450 79<BR> 68.0045 742 647 1637 4959 772 Table 26<BR> Peptide Sequence AA Source Analog DRB1*0101 DRB5*0101 DRB1*1501 DRB1*0301 DRB1*0401<BR> 68.0046 KSRLQGGVLVNEILN 15 PAP.255. 362<BR> 68.0047 GGVLVNEILNHMKRA 15 PAP.260. 2165 8.7 576 700 2020<BR> 68.0024 DRSVLAKELKFVTLV 15 PAP.27. 705 2217 1359 3203<BR> 68.0048 IPSYKKLIMYSAHDT 15 PAP.277. 9.9 191 17 9728 2871<BR> 68.0049 YKKLIMYSAHDTTVS 15 PAP.280. 17 5482 15 1166<BR> 68.0050 LIMYSAHDTTVSGLQ 15 PAP.283. 4496 184 134<BR> 68.0051 DTTVSGLQMALDVYN 15 PAP.290. 171 10423<BR> 68.0052 ALDVYNGLLPPYASC 15 PAP.299. 18 1091 2731<BR> 68.0019 AAPLLLARAASLSLG 15 PAP.3. 6.8 79 35 783<BR> 68.0053 LDVYNGLLPPYASCH 15 PAP.300. 15 3035 1959<BR> 68.0054 YNGLLPPYASCHLTE 15 PAP.303. 42 252<BR> 68.0153 LTELYFEKGEYFVEM 15 PAP.315. 2249 6655 4043 592<BR> 68.0025 AKELKFVTLVFRRHGD 15 PAP.32. 787 24 1529 4404<BR> 68.0056 FAELVGPVIPWQDWST 15 PAP.356. 12<BR> 68.0156 GPVIPQDWSTECMTT 15 PAP.361.<BR> <P>68.0020 APLLLARAASLSLGF 15 PAP.4. 8.4 114 91 1138<BR> 68.0026 RSPIDTFPTDPIKES 15 PAP.47. 2373<BR> 68.0021 PLLLARAASLSLGFL 15 PAP.5. 10.3 151 118 2932<BR> 68.0028 FGQLTQLGMEQHYEL 15 PAP.67 2259<BR> F025.05 QKGRGYRGQHQAHSLERVCH 20 PLP.121. 9759 495<BR> K-18 SAVPVYIYFNTWTTCQSIAF 20 PLP.171. 20000 92<BR> F025.03 WTTCQWSIAFPSKTSASIGSL 20 PLP.181. 400 277 17308 126<BR> F025.08 AATYNFAVLKLMGRGTKF 18 PLP.260. 18 239 3000<BR> K-09 FLYGALLLAERGFYTTGAVRQ 20 PLP.81. 256 45<BR> 68.0072 SHDLLLRLSEPAEL 15 PSA.114. 532 1099 6215<BR> 68.0073 HDLMLLRLSEPAELT 15 PSA.115. 62 10541 662 2867<BR> 68.0074 TDAVKVMNDLPTQEPA 15 PSA.129.

Table 26<BR> Peptide DRB3*0101 DRB1*1101 DRB1*1201 DRB1*1302 DRB1*0701 DRB1*0802 DRB1*0901 DRB4*0101 DRB1*0404 DQB1*0301<BR> 68.046 9605 318 2838 5516 713<BR> 68.0047 8124 255 6694 49 3239 5.8<BR> 68.0024 301 4410 2016 4719 53<BR> 68.0048 9982 53 669 2122 1946 60 351 12<BR> 68.0049 13224 208 928 37 292 309 107 5.8<BR> 68.0050 6828 1752 731 813 4381<BR> 68.0051 10844 712 3500 2876 961<BR> 68.0052 182 75687 588<BR> 68.0019 10469 100 564 3.2 25 30 64 79<BR> 68.0053 194 9753 404<BR> 68.0054 53009 11667 14027 8022<BR> 68.0153 184 12690 3157 601<BR> 68.0025 8563 123309 693 824 606 1953 2355 51<BR> 68.L0056 12503 983<BR> 68.0156 961<BR> 68.0020 13358 322 225 12 59 76 124 59<BR> 68.0026 6124 469<BR> 68.0021 1255 1511 12 162 37 58 52<BR> 68.0028 653 543<BR> F025.05 17951<BR> K-18<BR> F025.03 505<BR> F025.08 17 1218<BR> K-09<BR> 68.0072 13578 4471 737 5.8 58 3538 64 12<BR> 68.073 5305 2141 520 2.3 152 39124 22 45<BR> 68.0074 747 Table 26<BR> Peptide Sequence AA Source Analog DRB1*0101 DRB5*0101 DRB1*1501 DRB1*0301 DRB1*0401<BR> 68.0077 LHVISNDVCAQVHPQ 15 PSA.172. 789 22750 8318 4443<BR> 68.0078 CAQVHPQKVTKFMLC 15 PSA.180. 10206 1229 809 14434<BR> 68.0079 GGPLVCNGVLQGITS 15 PSDA.210. 3353 13417 383<BR> 68,0080 GPLVCNGVLQGITSW 15 PSA.211. 1724 6537 6310 170<BR> 68.0081 NGVLQGITSWGSEPC 15 PSA.216. 945 11619 258 3149<BR> 68.0082 RPSLYTKVVHYRKWI 125 PSA.235. 6041 13 717 1904<BR> 68.0061 SQPWQVLVASRGRAV 15 PSA.31. 66 84 11259<BR> 68.0062 GRAVCGGVLVHPQWV 15 PSA.42. 386 12888<BR> 68.0063 GVLVHPQWVLTAAHC 15 PSA.48. 87 1062 66 378<BR> 68.0058 TLSVTWIGAAPLILS 15 PSA.5. 3.1 31 97<BR> 68.0064 HPQWVLTAAHCIRNK 15 PSA.52. 13 40 6500 3632 9117<BR> 68.0065 QWVLTAAFHCIRNKSV 15 PSA.54. 50 35 13565<BR> 68.0066 AHCIRNKSVILLGRH 15 PSA.60. 578 3630 88 387<BR> 68.0067 SVILLGRHSKLFHPED 15 PSA.67. 717 16116 106 1400<BR> 68.0068 VILLGRHSLFHPEDT 15 PSDA.68. 273 426 8744<BR> 68.0059 SVTWIGAAPLILSRI 15 PSA.7. 4.1 104 147<BR> 68.0158 HSLFHPEDTGQVFQV 15 PSA.74.<BR> <P>68.0060 VTWIGAAPLLSRIV 15 PSA.8. 8.1 147 552<BR> 68.0069 GQVFQVHSFPHPLY 15 PSA.83. 288 128 2172 46<BR> 68.0070 VFQVSHGSFPHPLYDM 15 PSA.85. 16 897 2396 139<BR> 68.0071 PHPLYDMSLLKNRFL 15 PSA.93. 1315 3104 712<BR> 68.0088 WKEFGLDSVELAHYD 15 PSM.100. 1139 22750 85 540<BR> 68.089 LAHYDVLLSYPNKTH 15 PSM.110. 79 172 82 6285<BR> 68.0165 YISIINEDGNEIFNT 15 PSM.127. 498 2713 397 3511<BR> 68.0166 ISIINEDGNEIFNTS 15 PSM.128. 507 3006 559<BR> 68.0090 GNEIFNTSLFEPPPP 15 PSM.135.<BR> <P>68.0083 PRWLCAGALVLAGGF 15 PSM.18. 46 15167 Table 26<BR> Peptide DRB3*0101 DRB1*1101 DRB1*1201 DRB1*1302 DRB1*0701 DRB1*0802 DRB1*0901 DRB4*0101 DRB1*0404 DQB1*0301<BR> 68.0077 1887 239 1087<BR> 68.0078 2698 2192 8731 604<BR> 68.0079 1828 3745 36 9334 815<BR> 68.0080 11614 915 1876 49 4893 4187 646<BR> 68.0081 8038 9724 2716 775 485 5874 819 4487<BR> 68.0082 2982 350 4160 4183 652 39 5484 4897<BR> 68.0061 135 8775 32 385 386 621 7562<BR> 68.0062 16411 5456 3582 8069 62<BR> 68.0063 263 7488 2427 153 1931 365 6.2<BR> 68.0058 6031 6860 55 642 16 840 5 3506<BR> 68.0064 1324 785 5790 1170 283 1305 107 5518<BR> 68.0065 7342 2169 4171 2062 214 2598 967 3802<BR> 68.0066 4752 93 160 75 2573 104 715 8.7<BR> 68.0067 13045 96 91 96 500 5216 4411<BR> 68.0068 344 56 543 737 10696<BR> 68.0059 13676 2196 512 420 83 139 30 42<BR> 68.0158 553 11503<BR> 68.0060 1779 818 2339 195 731 82 88<BR> 68.0069 1071 103 557 146 27 548 33 416<BR> 68.0070 881 2477 83 51 8751 17<BR> 68.0071 487 11667 10699 12836 7486<BR> 68.0088 829 4935 8413 3511 7052 5925<BR> 68.0089 1406 380 7286 268 3617 415 1009 589<BR> 68.0165 53 346 3705<BR> 68.0166 74 10651 343 5854<BR> 68.0090 2804 10415 835<BR> 68.0083 13149 4596 766 1439 883 Table 26<BR> Peptide Sequence AA Source Analog DRB1*0101 DRB5*0101 DRB1*1501 DRB1*0301 DRB1*0401<BR> 68.0167 EDFFKLERDMKINCS 15 PSM.183. 27120 3494 468 1270<BR> 68.0168 FFKLERDMKINCSGK 15 PSM.185. 4419 3794 73 2719<BR> 68.0096 GKVFRGNKVKNAQLA 15 PSM.206. 612 1385 3373 6115<BR> 68.0097 GNKVKNAQLAGAKGV 15 PSM.211. 677 1218<BR> 68.0170 GVILYSDPADYFAPG 15 PSM.224. 1566 14168 965 17<BR> 68.0100 EYAYRRGIAEAVGLP 15 PSM.276. 5.1 1204 1197<BR> 68.0101 AEAVGLPSIPVHPIG 15 PSM.284. 5.4 56<BR> 68.0102 AVGLPSIPVHPIGYY 15 PSM.286. 3.6 518<BR> 68.0103 IGYYDAQKLLEKMGG 15 PSM.297. 1923 506 1978<BR> 68.0105 TGNFSTQWKVKMHIHS 15 PSM.334. 11180 1927 3745 4688<BR> 68.0084 LGFLFGWFIKSSNEA 15 PSM.35. 10.4 461 355 7524<BR> 68.0107 TRIYNVIGTLRGAVE 15 PSM.353. 14 32 1605 35<BR> 68.0173 GAAVVHEIVRDSFGTL 15 PSM.391. 12409<BR> 68.0176 NSRLLERGVAYINA 15 PSM.438. 614 3473 1229 318<BR> 68.0109 ERGVAYINADSSIEG 15 PSM.444. 2440<BR> 68.0110 GVAYINADSSIEGNY 15 PSM.446. 1054 7610 823<BR> 68.0177 VAYINADSSIEGNYT 15 POSM.447. 4716 531 2311<BR> 68.0111 DSSIEGNYTLRVDCT 15 PSM.453. 16824 1202<BR> 68.0112 NYTLRVDCTPLMYSL 15 PSM.459. 6804 5056 45 56<BR> 68.0113 CTPLMYSLVHNLTKE 15 PSM.466. 93 36 426 19437 1378<BR> 68.0114 DFEVFFQRLGIASGR 15 PSM.520. 143 3559 10249 1245<BR> 68.0115 EVEFQRLGIASGRAR 15 PSM.522. 28 7.9 4556 124<BR> 68.0116 TNKFSGYPLYHSVYE 15 PSM.543. 3402 2942 489<BR> 68.0117 YDPMFKYHLTVAQVR 15 PSM.566. 9.0 62 1348 106<BR> 68.0118 DPMFKYHLTVAQVRG 15 PSM.567. 5.7 11 230 51<BR> 68.0119 MFKYHLTVAQVRGGM 15 PSM.569. 16 5.8 1198 99<BR> 68.0120 KYHLTVAQVRGGMVF 15 PSM.571. 137 86 1222 4532 Table 26<BR> Peptide DRB3*0101 DRB1*1101 DRB1*1201 DRB1*1302 DRB1*0701 DRB1*0802 DRB1*0901 DRB4*0101 DRB1*0404 DQB1*0301<BR> 68.0167 4036 10433 3188 8550 1439 7886<BR> 68.0168 4918 9687 6936 382 8109 98<BR> 68.0096 7591 894 46 2350 4121 7884<BR> 68.0097 7882 1065<BR> 68.0170 14 1078 39 7848 2473 64<BR> 68.0100 8773 2590 12278 5217 70 596 67 6325<BR> 68.0101 700 5456 2015 12394<BR> 68.0102 384 1191 1080 4432 15377 5387<BR> 68.0103 5729 8236 13588<BR> 68.0105 11856 11637 6187 9407 10282 1450 508<BR> 68.0084 681 7303 475 10104 2261 1421 1701 9285<BR> 68.0107 45 502 1460 4806 70 2900 447<BR> 68.0173 788 517 89<BR> 68.0176 3366 12812 620 327 7997 3224 2616 699<BR> 68.0109 6846 3689 87<BR> 68.0110 1420 5493 497 6244 3048 477<BR> 68.0177 471 8247 2147 9745 5467 841<BR> 68.0111 576 8939 7.6 1262<BR> 68.0112 25 7116 594 9.0 6323 404<BR> 68.0113 590 1728 260 140 223 249 58<BR> 68.0114 128 2005 10069 122 2005 4.2<BR> 68.0115 31 2941 5311 6.3 2976 51<BR> 68.0116 4482 614 741 12466<BR> 68.0117 8137 2523 240 1014 158 172 179 553<BR> 68.0118 7297 69 470 699 168 43 258 467<BR> 68.0119 3648 147 482 1615 72 70 266 1062<BR> 68.0120 859 6377 193 228 1519 5860 3446 Table 26<BR> Peptide Sequence AA Source Analog DRB1*0101 DRB5*0101 DRB1*1501 DRB1*0301 DRB1*0401<BR> 68.0121 VAQVRGGMVFELANS 15 PSM.576. 228 117 3725<BR> 68.0122 RGGMVFELANSIVLP 15 PSM.580. 10.3 413 94 1288<BR> 68.0123 GMVFELANSIVLPFD 15 PSM.582. 15 903 83 4604 1295<BR> 68.0124 VFELANSIVLPFDCR 15 PSM.584. 19 10815 477 677 5618<BR> 68.0125 ADKIYSISMKHPQEM 15 PSM.608. 8273<BR> 68.0126 IYSISMKHPQEMKTY 15 PSM.611. 8452 2588 5025<BR> 68.0127 PQEMKTYSVSFDSLF 15 PSM.619. 15143 919<BR> 68.0085 LDELKAENIKKFLYN 15 PSM.62. 1136 150 414 1370<BR> 68.0128 TYSVSFDSLFSAVKN 15 PSM.624. 219 61 3223 110 410<BR> 68.0130 VLRMMNDQLMFLERA 15 PSM.660. 118 85 127 183 162<BR> 68.0131 LRMMNDQLMFLERAF 15 PSM.661. 2704 758 1411 2204<BR> 68.0181 DQLMFLERAFIDPLG 15 PSM.666.<BR> <P>68.0132 YRHVIYAPSSHNKYA 15 PSM.95 54 897 1598<BR> 68.0133 RHVIYAPSSHNKYAG 15 PSM.688. 2174 88 1291 2705<BR> 68.0086 IKKFLYNFTQIPHLA 15 PSM.70. 449 658 305 8080 240<BR> 68.0087 KFLYNFTQIPHLAGT 15 PSM.72. 340 1600 227 13805 1222<BR> 68.0134 RQIYVAAFTVQAAAE 15 PSM.730. 3.7 143 166 6.9<BR> 68.0135 QIYVAAFTVQAAAET 15 PSM.731. 1.6 216 252 9.1<BR> 68.0136 VAAFTVQAAAETLSE 15 PSM.734. 14 378 18200 327<BR> NASE011-30 PATLIKAIDGDTVKLMYKGQ 20 Staph.Nase.11. 278 1517 6429 1667<BR> NASE121-140 HEQHLRKSEAQ2AKKEKLNIW 20 Staph.Nase.121. 4.8<BR> NASE041-60 TPETKHPKKGVEKYGPEASA 20 Staph.Nase.41. 1000 1820 2813<BR> NASE051-70 VEKYGPEASAFTKKMVENAK 20 Staph.Nase.51. 16 7500<BR> NASE061-80 FTKKMVENAKKIEVEFDKGQ 20 Staph.Nase.61. 1000 455 11619 2813<BR> NASE091-110 YIYADGKMVNEALVRQGLAK 20 Staph.Nase.91. 65 1820 2813 Table 26<BR> Peptide DRB3*0101 DRB1*1101 DRB1*1201 DRB1*1302 DRB1*0701 DRB1*0802 DRB1*0901 DRB4*0101 DRB1*0404 DQB1*0301<BR> 68.0121 7605 2802 4449 499 100<BR> 68.0122 132 208 4.4 41 8682 33 411<BR> 68.0123 234 98 12 30 4995 81 4154<BR> 68.0124 128 11765 525 24 39 50 1215<BR> 68.0125 169 9246 4957 4098 1136 3512 3550<BR> 68.0126 213 11436 11573 1357 12293 5356<BR> 68.0127 14565 5347 1192 1981 579<BR> 68.0085 548 324 368 397 7470 1248 12778 788<BR> 68.0128 8546 5981 5277 5888 346 2256 526 10461<BR> 68.0130 98 2353 98 130 1700 10684 88<BR> 68.0131 1570 1833 280 134 2492 4601 50<BR> 68.0181 146 6.6<BR> 68.0132 1462 743 6390 8793 750 528 1117<BR> 68.0133 13363 7082 8750 11667 481 5293<BR> 68.0086 477 137 552 27 29 512 160 96<BR> 68.0087 10211 91 1244 221 30 415 54 256<BR> 68.0134 6807 35 609 524 292 36 91 47<BR> 68.0135 1324 34 934 344 324 102 65 50<BR> 68.0136 2116 2126 4461 446 793 1420 127 464<BR> NASE011-30 2381 6667 8333 3846<BR> NASE121-140 6250<BR> NASE041-60 6667 12500<BR> NASE051-70 2635<BR> NASE061-80 6667 8333<BR> NASE091-110 6667 1563 4167 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> PTS-04 AAWSERAGEAMVLV B.pertussis.247 B.pertussis 625.0 22500.0 500000.0<BR> 582.02 DNVLDHLTGRSC B.pertussis.64 B.pertussis 454.6 90000.0 22500.0 50000.0<BR> PTS-10 NH2-DNVLAHLTGRSCQ- B.pertussis.30 B.pertussis A 122.0<BR> COOH<BR> PTS-17 NH2-DNVLDHLTGRSAQ- B.pertussis.30 B.pertussis A 22.3<BR> COOH<BR> PTS-18 NH2-DNVLDHLTGRSCA- B.pertussis.30 B.pertussis A 714.3<BR> COOH<BR> 541.19 HYTVDKSKPKVYQWRD BeeVenom.109 BeeVenom 1666.7 450000.0 500000.0<BR> 541.15 INTKCYKLEHPVTGCG BeeVenom.85 BeeVenom 227.3 3750.0 500000.0<BR> 541.04 NELGRFKHTDACCRTH BeeVenom.19 BeeVenom 357.1 450000.0 500000.0<BR> 541.11 NNDFYDNSADTISSYF BeeVenom.61 BeeVenom 1666.7 918.4 500000.0<BR> 541.20 SKPKVYQWFDLRKY BeeVenom.115 BeeVenom 1250.0 450000.0 2000.0<BR> 541.13 SSYFVGKMYFNLINTK BeeVenom.73 BeeVenom 714.3 450000.0 500000.0<BR> BMP PDTRPAPGSTAPPAHGVTSAP Breastmucin Breastmucin 50000.0 450000.0 50000.0<BR> DTR-NH2<BR> 1136.18 ALPVFTWLALYFTSAK Candida.aur1768.106 Candida 178.7 1485.2 6675.9<BR> 1136.20 ALYFTSAKIPQEWKPA Candida.aur1768.114 Candida 2886.8 3763.1 47.6<BR> 1136.15 FATSFLIPLTSQFFLP Candida.aur1768.90 Candida 1.8 5683.0 518.5<BR> 1136.52 GLFCRWSYTEIEKIDI Candida.aur1768.338 Candida 15811.4 >9890.71 8079.6 608.0<BR> 1136.53 GLFSRWSYTEIEKIDI Candida.aur1768.338 Candida 25000.0 1288.2 >8101.63<BR> 1136.48 IGGAMLSLTVFEFTKY Candida.aur1768.314 Candida 388.1 >9157.02 10978.9 4976.8<BR> 1136.13 IKLPIILAFATSFLIP Candida.aur1768.82 Candida 5.9 2602.4 16007.8<BR> 1136.43 IMEVLFLSWLFPRFKF Candida.aur1768.274 Candida 208.3 181.5 >25855.73<BR> 1136.67 LTNNDQ2VSGINEEDEE Candida.aur1768.418 Candida >20412.41 >17450.25 >64231.72<BR> 1136.01 MMASSILRSKIIQKPYQ Candida.aur1768.1 Candida 1644.9 9236.6 >13693.06 >8101.63<BR> 1136.41 PSLHSGSSIMEVLFLS Candida.aur1768.266 Candida 735.4 >18541.93 22391.7<BR> 1136.39 SSIIFGAFPSLHSGSS Candida.aur1768.258 Candida 68.2 28.2 82.6 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 1136.10 VSILFFVFVVFPASFF Candida.aur1768.66 Candida 2062.0 >9157.02 637.2 6088.8<BR> 58.0041 IAKITPONNGTYACE CEA.642 CEA A 51.7<BR> 58.0022 IPNITVDNSGSYTCQ CEA.286 CEA A 109.9<BR> 58.0012 IQNIIQDDTGFYTLH CEA.109 CEA A 56.7<BR> 58.0037 LFNVTRDDARAYVCG CEA.558 CEA A 56.8<BR> 58.0017 LFNVTRDDTASYKCE CEA.202 CEA A 56.4<BR> 58.0028 LLSVTRDDVGPYECG CEA.380 CEA A 560.6<BR> 58.0015 LWWVNNESLPVSPRL CEA.177 CEA A 310.4<BR> 58.0027 LWWVNNESLPVSPRL CEA.355 CEA A 229.3<BR> 58.0021 QELFIPDITVNNSGS CEA.282 CEA A 449.8<BR> 58.0032 QELFISDITEKNSGL CEA.460 CEA A 302.3<BR> 58.0009 REIIYPDASLLIQNI CEA.98 CEA A 126.4<BR> 58.0020 SCHAASDPPAQYSWF CEA.258 CEA A 201.5<BR> 58.0023 TITVYADPPKPFITS CEA.315 CEA A 378.0<BR> 58.0005 VLLLVHDLPQHLFGY CEA.51 CEA A 4.9<BR> 58.0042 YACFVSDLATGRNNS CEA.653 CEA A 19.5<BR> CMP PTTTPITTTTTVTPTPTPTGTQT Colonmucin Colonmucin 50000.0 1153.9 333.3<BR> YC-NH2<BR> 722.01 YIAFLKQATAK Cyt.C Cyt.C 104.2 900000.0 7500.0 10000.0<BR> 500.02 FLRRIRPKLK Dynorphin.4 Dynorphin<BR> 199.02 GFLRRIRPKLK Dynorphin.3 Dynorphin<BR> 199.03 LRRIRPKLK Dynorphin.5 Dynorphin<BR> 199.01 YGGFLRRIRPKLK Dynorphin.1 Dynorphin 50000.0 900000.0 450000.0 1923.1<BR> 510.12 DDNGPQDPDNTDDNG EBV.LMP.260 EBV 50000.0 51961.5 22500.0 25000.0<BR> F166.01 FYYTGEHAKAIGN Flu.HA.308 Flu 317.1 >14463.55 >27317.92<BR> 897.07 FPQPQLPYSQPQPFRPQQPY- Gliadin.61 Gliadin 900000.0<BR> NH2 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 897.25 IPPYCTIAPFGIFGIN-NH2 Gliadin.261 Gliadin 900000.0<BR> F168.09 IRNLALQTLPAMCNVY Gliadin.235 Gliadin<BR> 897.04 LGQQQPFPPQQPYPQPQPFP- Gliadin.31 Gliadin 900000.0<BR> NH2<BR> 897.18 LHQQQKQQQQPSSQVSFQQP- Gliadin.181 Gliadin 900000.0<BR> NH2<BR> 897.15 LLQELCCQHLWQIPEQSQCQ- Gliadin.151 Gliadin 900000.0<BR> NH2<BR> 897.13 LQQHNLAHGRSQVLQQSTYQ- Gliadin.131 Gliadin<BR> NH2<BR> F168.04 PQPFRPQQPYPQ Gliadin.71 Gliadin<BR> F168.03 PQPFRPQQPYPQPQPQ Gliadin.71 Gliadin<BR> 897.08 PQPFRPQQPYPQPQPQYSQP- Gliadin.71 Gliadin 900000.0<BR> NH2<BR> 897.09 PQPQPQYSQPQQPISQQQQQ- Gliadin.81 Gliadin 900000.0<BR> NH2<BR> 897.19 PSSQVSFQQPLQQYPLGQGS- Gliadin.191 Gliadin 4691.6<BR> NH2<BR> F168.12 QFEEIRNLALQT Gliadin.231 Gliadin<BR> F168.11 QFEEIRNLALQTLPAM Gliadin.231 Gliadin<BR> 897.23 QFEEIRNLALQTLPAMCNVY- Gliadin.231 Gliadin 900000.0<BR> NH2<BR> F168.06 QFLGQQQPFPPQ Gliadin.29 Gliadin<BR> 897.22 QGSVQPQQLPQFEEIRNLAL- Gliadin.221 Gliadin 900000.0<BR> NH2<BR> 897.02 QNPSQQQPQEQVPLVQQQQF- Gliadin.11 Gliadin 900000.0<BR> NH2<BR> 97.05 QPYPQPQPFPSQQPYLQLQP- Gliadin.41 Gliadin 900000.0<BR> NH2<BR> 897.12 QQLIFCMDVVLQQHNIAHGR- Gliadin.121 Gliadin 9819.8<BR> NH2<BR> F168.08 QVPLVQQQQFLG Gliadin.21 Gliadin TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F168.07 QVPLVQQQQFLGQQQP Gliadin.21 Gliadin<BR> 897.03 QVPLVQQQQFLGQQQPFPPQ- Gliadin.21 Gliadin<BR> NH2<BR> 897.06 SQQPYLQLQPFPQPQLPYSQ- Gliadin.51 Gliadin 900000.0<BR> NH2<BR> F168.05 VQQQQFLGQQQPFPPQ Gliadin.25 Gliadin<BR> 897.01 VRVPVPQLQPQNPSQQQPQE- Gliadin.1 Gliadin 900000.0<BR> NH2<BR> 897.50 YIPPYCTIAPFGIFGIN-NH2 Gliadin.261 Gliadin >45000<BR> 897.44 YPSSQVSFQQPLQQYPLGQGS Gliadin.191 Gliadin 445.5<BR> -NH2<BR> 897.47 YQGSVQPQQLPQFEEIRNLAL- Gliadin.221 Gliadin >30000<BR> NH2<BR> F160.26 EKVPVSEVMGTTLAEMSTPE gp100.377 gp100 10603.5 94.8<BR> AT<BR> F160.02 IYRRRLMKQDFSVPQLPHS gp100.615 gp100 58.6 13.0<BR> F160.07 KRCLLHLAVIGALLAVGATK gp100.6 gp100 >14411.53 408.8<BR> V<BR> F160.03 LCQPVLPSPACQLVLHQILKG gp100.540 gp100 >14411.53 732.0<BR> G<BR> F160.14 MTPAEVSIVVLSGTTAAQVTT gp100.400 gp100 129.3 31.6<BR> T<BR> F160.16 PGPVTAQVVLQAAIPLTSCGS gp100.283 gp100 2519.1 81.1<BR> S<BR> F160.01 VSGLSIGTGRAMLGTHTMEV gp100.167 gp100 10452.1 384.2<BR> TVY<BR> F167.01 VYVWKTTWGQYWQVLGGP gp100.150 gp100 114.9 >14248.07 >3387.8 27886.2<BR> VS<BR> F167.03 WNRQLYPEWTEAQR gp100.44 gp100 7800.3 361.8 145.6 538.4<BR> F115.14 AKRKTVTAMDVVYAL H4.76 H4 1.3<BR> F115.02 KRHRKVLRDNIQGITKPAIRR H4.16 H4 258.0<BR> LAR TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F115.15 KTVTAMDVVYALKRQ H4.79 H4 26.0<BR> F115.10 LRDNIQGITKPAIRR H4.22 H4 16.4<BR> F115.11 NIQGITKPAIRRLAR H4.25 H4 234.7<BR> F115.03 TYTEHAKRKTVTAMDVVYA H4.71 H4 75.9<BR> LKRQG<BR> 590.23 (2)KYVKQNTLKAT(SIC!) HA 307 HA A 15.2 5.9<BR> 752.01 (67) PKYVKQNTLKLAT HA.307 HA 3.9 72.6 25000.0<BR> 594.09 AHAAHAAHAAHAAHAA HA. HA A 263.2 450000.0 500000.0<BR> F049.01 BIOTIN-A2- HA HA 6.5 33.4<BR> PRYVRQNTLRATC<BR> 574.00 CPKYVRSAKLRM HA.302 HA 1666.7 36742.4 450000.0 500000.0<BR> 573.05 GACPKYVKQN HA.304 HA 50000.0 15000.0<BR> 573.04 GACPKYVKQNTL HA.304 HA 50000.0 1153.9<BR> 597.04 GACPKYVKQNTLK HA.304 HA 50000.0 3750.0<BR> 573.03 GACPKYVKQNTLKL HA.304 HA 2500.0 1184.2<BR> 30.1200 HNTNGVTAASSH HA.130 HA 50000.0 450000.0 500000.0<BR> 573.08 KQNTLKLATGMR HA.311 HA 50000.0 15000.0<BR> 711.03 LAQNTLAKQNTLAKQNT HA.307 HA A 50000.0 900000.0 150.0 86.2<BR> 573.09 NTLELATGMR HA.313 HA 50000.0 15000.0<BR> 590.22 P(2)YVKQNTLKAT(SIC!) HA.307 HA A 454.6 20.5<BR> 864.10 PFFVKQNILKLAT HA.307 HA A 7.2 44.6 3571.4<BR> 864.07 PFFVKQNTLKLAT HA.307 HA A 1.4 10.7 344.8<BR> 864.06 PFIVKQNTLKLAT HA.307 HA A 1.0 19.6 79.6<BR> 864.02 PFYVKQNTLKLAT HA.307 HA A 1.6 24.5 12500.0<BR> 864.09 PIFVKQNILKLAT HA.307 HA A 2.9 56.4 3846.2<BR> 864.05 PIFVKQNTLKLAT HA.307 HA A 2.9 32.1 649.4<BR> 864.04 PIIVKQNTLKLAT HA.307 HA A 7.6 68.1 160.3 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 864.01 PIVYKQNTLKLAT HA.307 HA A 3.9 23.8 10000.0<BR> 590.10 PK(1)VKQNTLKAT(SIC!) HA.307 HA A 454.6 2368.4<BR> 590.21 PK(2)VKQNTLKAT(SIC!) HA.307 HA A 454.6 511.4<BR> 772.08 PK(31)VKQNTLKLAT-NH2 HA.307 HA A 5.6 136.4 8333.3<BR> 611.11 PKAVKQNTLKLAT HA.307 HA A 1000.0 15000.0 25000.0<BR> 601.09 PKEVKQNTLKLAT HA.307 HA A 50000.0 4500.0 500000.0<BR> 841.05 PKFQVETTKKLAT HA. HA A 185.2 900000.0 155.7 500000.0<BR> 864.03 PKIVKQNTLKLAT HA.307 HA A 7.3 92.4 130.9<BR> 713.09 PKKVKQNTLKLAT HA.307 HA A 2500.0 9000.0 500000.0<BR> 792.03 PKQVKQNTLKLAT HA.307 HA A 1250.0 9000.0 500000.0<BR> 601.10 PKSVKQNTLKLAT HA.307 HA A 50000.0 57.7 500000.0<BR> 713.14 PKTVKQNTLKLAT HA.307 HA A 2500.0 5625.0 50000.0<BR> 590.09 PKY(1)KQNTLKAT(SIC!) HA.307 HA A 72.5 7.8<BR> 833.08 PKY(41)KQNTLKLAT HA.307 HA A 217.4 436.9 500000.0<BR> 590.08 PKYV(1)QNTLKAT(SIC!) HA.307 HA A 72.5 37.5<BR> 590.19 PKYV(2)QNTLKAT(SIC!) HA.307 HA A 138.9 11.8<BR> 833.07 PKYV(41)QNTLKLAT HA.307 HA A 50000.0 576.9 500000.0<BR> 590.07 PKYVK(1)KTLKAT(SIC!) HA.307 HA A 294.1 225.0<BR> 590.18 PKYVK(2)NTLKAT(SIC!) HA.307 HA A 147.1 463.9<BR> 713.10 PKYVKKNTLKLAT HA.307 HA A 89.3 3000.0 500000.0<BR> 590.06 PKYVKQ(1)TLKAT(SIC!) HA.307 HA A 50.0 6.9<BR> 590.17 PKYVKQ(2)TLKAT(SIC!) HA.307 HA A 116.3 13.6<BR> 833.05 PKYVKQ(41)TLKLAT HA.307 HA A 11.6 61.6 25000.0<BR> 590.05 PKYVKQN(1)LKAT(SIC!) HA.307 HA A 50000.0 450.0<BR> 590.16 PKYVKQN(2)LKAT(SIC!) HA.307 HA A 454.6 2368.4<BR> 772.06 PKYVKQN(24)LKLAT HA.307 HA A 6.8 88.2 25000.0 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 772.01 PKYVKQN(25)LKLAT HA.307 HA A 5.6 1071.4 50000.0<BR> 772.02 PKYVKQN(26)LKLAT HA.307 HA A 166.7 5625.0 500000.0<BR> 772.03 PKYVKQN(27)LKLAT HA.307 HA A 357.1 3000.0 16666.7<BR> 772.04 PKYVKQN(28)LKLAT HA.307 HA A 20.8 2812.5 25000.0<BR> 772.07 PKYVKQN(30)LKLAT HA.307 HA A 625.0 1500.0 25000.0<BR> 601.24 PKYVKQNELKLAT HA.307 HA A 714.3 15000.0 500000.0<BR> 515.09 PKYVKQNHLKLAT HA.307 HA A 96.2 4500.0 500000.0<BR> 864.08 PKYVKQNILKLAT HA.307 HA A 35.5 156.8 5000.0<BR> 713.12 PKYVKQNKLKLAT HA.307 HA A 2500.0 9000.0 500000.0<BR> 863.07 PKYVKQNNLKLAT HA.307 HA A 500.0 3214.3 500000.0<BR> 772.11 PKYVKQNPLKLAT HA.307 HA A 4.2 737.7 50000.0<BR> 713.13 PKYVKQNQLKLAT HA.307 HA A 45.5 5625.0 500000.0<BR> 590.04 PKYVKQNT(1)KAT(SIC!) HA.307 HA A 102.0 281.3<BR> 590.15 PKYVKQNT(2)KAT(SIC!) HA.307 HA A 147.1 264.7<BR> 833.03 PKYVKQNT(41)KLAT HA.307 HA A 714.3 7500.0 500000.0<BR> 601.27 PKYVKQNTKKLAT HA.307 HA A 13.9 2142.9 500000.0<BR> 590.03 PKYVKQNTL(1)AT(SIC!) HA.307 HA A 45.5 6.9<BR> 590.14 PKYVKQNTL(2)AT(SIC!) HA.307 HA A 66.7 11.0<BR> 833.02 PKYVKQNTL(41)LAT HA.307 HA A 56.8 232.0 500000.0<BR> 590.02 PKYVKQNTLK(1)T(SIC!) HA.307 HA A 454.6 2250.0<BR> 590.01 PKYVKQNTLKAT(SIC!) HA.307 HA A 108.7 21.4<BR> 713.06 PKYVKQNTLKEAT HA.307 HA A 2500.0 1097.6 500000.0<BR> 863.08 PKYVKQNTNKLAT HA.307 HA A 70.4 1097.6 500000.0<BR> 713.01 PKYVKQNYLKLAT HA.307 HA A 192.3 9000.0 25000.0<BR> 175.00 RTLYQNVGTYVSVGTSTLNK HA.187 HA 19.2 900000.0 450000.0 25000.0<BR> 597.06 VKQNTLKLATGMR HA.310 HA 50000.0 7500.0 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 841.06 YPKFQVETTKKLAT HA HA A 45.5 111.4 500000.0<BR> 841.04 YPKFVKLNTKKLAT HA HA A 20.8 365.9 5000.0<BR> 771.04 YPKFVKQRTLKLAT HA HA A 3.6 46.9 357.1<BR> 771.02 YPKFVKQRTLKLAT-NH2 HA HA 4.6 37.5 172.4<BR> 771.06 YPKFVKRNTLKLAT HA.307 HA A 14.3 818.2 10000.0<BR> 771.03 YPKYVKQRTLKLAT HA HA A 2.8 51.7 10000.0<BR> 771.01 YPKYVKQRTLKLAT-NH2 HA HA A 5.0 60.0 1724.1<BR> 771.07 YPKYVKRNTLKLAT HA.307 HA A 23.8 1956.5 12500.0<BR> 841.02 YPSFQVQTTLLLAT HA HA A 1.1 2.7 12.2<BR> 27.0278 AAPFTQCGYPALMPL HBV.pol.643 HBV 160.8 >23985.08<BR> F039.09 AILCWGELMTLA HBV.core.58 HBV 6299.4 450000.0 >7462.69<BR> F076.05 ALRQAILCWGELM HBV.core.54 HBV >9183.67 >22727.27<BR> F039.05 ALRQAILCWGELMTLA HBV.core.54 HBV 505.8 24549.5 >7462.69<BR> 799.04 GYRWMCLRRFIIFLFILLLC HBV.env.71 HBV 2500.0 28460.5 424.5 12500.0<BR> F039.02 HHTALRQAILCWGELMTLA HBV.core.51 HBV 1127.1 225000.0 >7462.69<BR> F039.03 HTALRQAILCWGELMTLA HBV.core.52 HBV 512.7 35575.6 >7462.69<BR> F039.10 ILCWGELMTLA HBV.core.59 HBV 50000.0 >818.18 >7462.69<BR> f039.11 LCWGELMTLA HBV.core.60 HBV 50000.0 >900 >7462.69<BR> F164.04 LPETTVVRCRGRSPR HBV.core.143 HBV >1889.82 >504.69 >22680.46<BR> F039.06 LRQAILCWGELMTLA HBV.core.55 HBV 896.6 225000.0 >7462.69<BR> CF-09 LSTLPETTVVRRRGRS HBV.core.140 HBV 50000.0 9000.0 25000.0<BR> F164.14 MDIDPYKEFGASVELLSFL HBV.core.1 HBV 116.9 837.6 27.6<BR> F164.13 MDIDPYKEFGASVELLSFLPSW HBV.core.1 HBV 34.6 2580.9 110.1<BR> DFFP<BR> F164.16 MDIDPYKEFGATVELLSFL HBV.core.1 HBV 1356.7 308.0 108.8<BR> F116.01 MDIDPYKEFGATVELLSFLPS HBV.core.1 HBV 1562.5 957.5<BR> DFFP TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F164.15 MDIDPYKEFGATVELLSFLPS HBV.core.1 HBV 113.8 145.4 17.3<BR> DFFP<BR> F164.17 MDIDPYKEFGATVQLLSFLPS HBV.core.1 HBV 411.6 33.9 10.2<BR> DFFP<BR> F098.11 MGLKFRQLLWF HBV.core.94 HBV 240.6 3620.6 1350.7 206.3<BR> 1297.06 PFLLAQFTSAICSVVRRA HBV.pol.523 HBV<BR> F039.18 PHHTALRQAILCW HBV.core.50 HBV 16666.7 5489.4 >20000<BR> F03.917 PHHTALRQAILCWG HBV.core.50 HBV 2130.1 450000.0 >20000<BR> F039.16 PHHTALRQAILCWGE HBV.core.50 HBV 11180.3 >600 >20000<BR> F039.15 PHHTALRQAILCWGEL HBV.core.50 HBV 2391.8 150000.0 >20000<BR> F039.14 PHHTALRQAILCWGELM HBV.core.50 HBV 389.3 5669.5 >7462.69<BR> F039.13 PHHTALRQAILCWGELMT HBV.core.50 HBV 1725.2 14230.3 >7462.69<BR> F039.12 PHHTALRQAILCWGELMTL HBV.core.50 HBV 145.8 10062.3 >7462.69<BR> 795.01 PLGFFPDHQLDPAFGANSNNP HBV.PreS. HBV 50000.0 9000000.0 6428.6 500000.0<BR> DWDFNP<BR> F039.08 QAILCWGELMTLA HBV.core.57 HBV 1605.7 20539.6 >7462.69<BR> CF-03 RDDLDTASALYRREALESPEH HBV.core.28 HBV 50000.0 7500.0 16666.7<BR> CF-06 RDLVVSYVNTNMGLKFRQLL HBV.core.82 HBV 1000.0 2250.0 2941.2<BR> F039.07 RQAILCWGELMTLA HBV.core.56 HBV 3125.0 225000.0 >7462.69<BR> 801.01 RVRGLYFPAGGSSSGTVN HBV.env.16 HBV 294.1 900000.0 616.4 1666.7<BR> 799.02 SLDSWWTSLNFLGGTTVCLG HBV.env.31 HBV 36.8 15667.0 1956.5 25000.0<BR> F039.04 TALRQAILCWGELMTLA HBV.core.53 HBV 931.5 43301.3 >7462.69<BR> F164.12 TNMGLEKFRQLLWFHI HBV.core.91 HBV >189.82 >7367.12 6273.9<BR> F164.11 TNVGLKFRQLLWFHIHBV.core.91 HBV 1491.4 835.7 149.6<BR> F098.08 TTVVRRRGRSPRRR HBV.core.145 HBV 98039.2 >100623.06 >62500 >66149.51<BR> 800.04 VGAGAFGLGFTPPHGGL HBV.env.47 HBV 5000.0 900000.0 26.5 3333.3<BR> 764.01 VSFGVWIRTPPA HBV.core. HBV 50000.0 900000.0 15000.0 5000.0<BR> 857.01 YPHHTALRQAILCWGELMTL HBV.core.50 HBV 1000.0 633.9 23622.8 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> A<BR> F134.07 GPGEGAVQWMNRLIAFASRG HCV.NS4.291 HCV 8.7 5328.0<BR> Pape22 GRHLIFCHSKRKCDELATKL HCV.NS3.1388HCV >50000 >18750 >62500 >66149.51<BR> F134.06 LLFNILGGWVAAQLARAPGAA HCV.NS4.191 HCV 26.7 >3668.13<BR> 1283.40 PAILSPGALVVGVVCA HCV.NS4.1889 HCV 50.9 63469.7<BR> 221.06 AFVAWRNRCK HEL.107 HEL A<BR> 221.08 AWAAWRNRCK HEL.107 HEL A<BR> 221.10 AWEAWRNRCK HEL.107 HEL A<BR> 221.09 AWLAWRNRCK HEL.107 HEL A<BR> 221.15 AWVAARNRCK HEL.107 HEL A<BR> 221.16 AWVAFRNRCK HEL.107 HEL A<BR> 221.14 AWVAQRNRCK HEL.107 HEL A<BR> 221.19 AWVAWANRCK HEL.107 HEL A<BR> 221.17 AWVAWENRCK HEL.107 HEL A<BR> 221.18 AWVAWKNRCK HEL.107 HEL A<BR> 221.22 AWVAWRARCK HEL.107 HEL A<BR> 221.25 AWVAWRNACK HEL.107 HEL A<BR> 221.23 AWVAWRNECK HEL.107 HEL A<BR> 221.24 AWVAWRNKCK HEL.107 HEL A<BR> 221.32 AWVAWRNRCA HEL.107 HEL A<BR> 539.00 AWVAWRNRCK HEL.107 HEL 5000.0 >45000 3750.0 500000.0<BR> 221.01 AWVAWRNRCK HEL.107 HEL 50000.0 3750.0 500000.0<BR> 221.31 AWVAWRNRCR HEL.107 HEL A<BR> 221.28 AWVAWRNREK HEL.107 HEL A<BR> 221.29 AWVAWRNRKK HEL.107 HEL A<BR> 221.26 AWVAWRNRQK HEL.107 HEL A TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 221.27 AWVAWRNRVK HEL.107 HEL A<BR> 221.20 AWVAWRQRCK HEL.107 HEL A<BR> 221.21 AWVAWRVRCK HEL.107 HEL A<BR> 221.12 AWVEWRNRCK HEL.107 HEL A<BR> 221.11 AWVSWRNRCK HEL.107 HEL A<BR> 221.13 AWVVWRNRCK HEL.107 HEL A<BR> 565.01 EFVAAKAAQK HEL.107 HEL 625.0 900000.0 11250.0 500000.0<BR> 221.02 EWVAWRNRCK HEL.107 HEL A<BR> AP23 LAAAMKRHGLDNYRGYSLG HEL.8 HEL 1250.0 900000.0 22500.0 500000.0<BR> NWV<BR> AP12 RNRCKGTDVQAWIRGCRL HEL.112 HEL 500.0 900000.0 22500.0 1087.0<BR> AP38 SVNCAKKIVSDGNGMN HEL.91 HEL 50000.0 9449.4 11250.0 8333.3<BR> 221.04 SWVAWRNRCK 221.27 AWVAWRNRVK HEL.107 HEL A<BR> 221.03 VWVAWNRNRCK 221.27 AWVAWRNRVK HEL.107 HEL A<BR> 560.02 WRNAKWRNAKWRNAK HEL.112 HEL A 1000.0 900000.0 22500.0 500000.0<BR> AP37 YRGYSLGNWVCAAKFESNFN HEL.20 HEL 555.6 900000.0 22500.0 500000.0<BR> TQ<BR> 58.0052 CWMIDSDCRPRFREL Her2/neu.958 Her2/neu A 5.1<BR> 58.0045 CYGLGMDHLREVRAV Her2/neu.342 Her2/neu A 180.5<BR> 58.0053 FRELVSDFSRMARDP Her2/neu.969 Her2/neu A 121.2<BR> 58.0051 IKWMALDSILRRRFT Her2/neu.886 Her2/neu A 1.7<BR> 58.0046 LALIHHDTHLCFVHT Her2/neu.465 Her2/neu A 17.0<BR> 58.0043 LTYLPTDASLSFLQD Her2/neu.62 Her2/neu A 106.8<BR> 58.0048 QMRILKDTELRKVKV Her2/neu.711 Her2/neu A 335.4<BR> 1385.03 SPYVSRLLGICLT Her2/neu.777 Her2/neu 12.8 >21096.33 >4494.22 172.5<BR> 1385.04 VPIKWMALESILRRRF Her2/neu.884 Her2/neu 12.1 117.7 1154.6 1035.9<BR> 58.0047 WDQLFRDPHQALLHT Her2/neu.482 Her2/neu A 48.8 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F159.13 DRVHPVHAGPIA HIV.gag.245 HIV 7704.2 >7905.69 55555.6 >11109.4<BR> F159.12 DRVHPVHAGPIAPG HIV.gag.245 HIV 229.5 >6830.74 45454.6 >9354.95<BR> F159.11 DRVHPVHAGPIAPGQM HIV.gag.245HIV 801.0 >5929.27 41666.7 >8413.34<BR> F159.10 DRVHPVHAGPIAPGQMRE HIV.gag.245 HIV 332.5 >5303.3 35714.3 >7367.88<BR> F159.09 DRVHPVHAGPIAPGQMREPR HIV.gag.245 HIV 1110.4 >4743.42 31250.0 >6555.62<BR> F170.01 DTEVHNVWATQACVPTDPNP HIV.env6 HIV 753.1 >7694.84 >216.54 3104.3<BR> F169.02 EGLIHSQRRQDILDDL HIV.nef.98 HIV 2648.8 2014.4 >2598.08 >83333.33<BR> F170.06 EPFRDYVDRFYKTLRAEQAS HIV.gag.30 HIV 15.2 1389.5 104.7 3733.3<BR> F170.05 IYKRWIILGLNKIVRMYSPV HIV.gag.27 HIV 1272.4 >15389.68 >435.44 5120.9<BR> F170.02 PKISFEPIPIHYCAPAGFAI HIV.env.20 HIV 228.9 2267.5 163.6 1487.1<BR> F169.01 TAATNAACAWLEA HIV.nef.48 HIV 9806.6 >84868.33 >258.08 83612.0<BR> F170.04 TNNPPIPVGEIYKWRILLGL HIV.gag.26 HIV 13.9 87.8 298.0 155.7<BR> F170.03 VWGIKQLQARVLAVERYLKID HIV.env.54 HIV 2.3 374.3 >435.44 1078.<BR> <P>27.0374 AVQMAVFIHNFKRKG HIV1.pol.917 HIV1 1589.4 1641.6<BR> 27.0299 DQQLLGIWGCSGKLI HIV1.env.755 HIV1 173.7 >22500<BR> 27.0287 DQSLKPCVKLTPLCV HIV1.env.126 HIV1 666.6 >22500<BR> 27.0284 EDIISLWDQSLKPCV HIV1.env.119 HIV1 103.6 >23985.08<BR> 190.20 ERFAVNPGLLETSEGC HIV1.gp.48 HIV1 250.0 900000.0 450000.0 7142.9<BR> 190.15 GARASVLSGGELDKWE HIV1.gp.1 HIV1 833.3 900000.0 450000.0 500000.0<BR> 190.16 GGELDKWEKIRLRPGG HIV1.gp.9 HIV1 2500.0 900000.0 450000.0 500000.0<BR> RS-21 GP41584-609 HIV1.gp HIV1 1250.0<BR> 27.0320 IGGIGGFIKVRQYDQ HIV1.pol.127 HIV1 22026.7 >18766.3<BR> 181.11 ILKALGPAATLEEMMT(200.11 HIV1 HIV1 22.1 900000.0 22500.0 1562.5<BR> )<BR> 200.10 INEEAAEWERVHPVHA HIV1.gp.73 HIV1 625.0 31819.8 450000.0 10000.0<BR> 27.0348 IQKLVGKLNWASQIY HIV1.pol.436 HIV1 191.1 >16112.58<BR> 27.0286 ISLWDQSLKPCVKLT HIV1.env.122 HIV1 1269.7 >22500 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 190.19 IVWASRELERFAVNPG HIV1.gp.33 HIV1 2500.0 1039.23 450000.0 3846.2<BR> 200.17 IYKRWILLGLNKIVRN HIV1.gp.129 HIV1 2500.0 900000.0 450000.0 500000.0<BR> F091.13 KQIINMWQEVGKAMYA HIV1.env.428 HIV1 1813.7 24772 98.1<BR> 200.04 KVVEEKAFSPEVIPMF HIV1.gp.25 HIV1 2500.0 90000.0 450000.0 31250.0<BR> 190.08 LGKIWPSYKGRPGNFL HIV1.gp.57 HIV1 2500.0 31819.8 900.0 151.5<BR> F091.08 LKQIVKKLREQFGNNK HIV1.env.342 HIV1 20412.4 >64951.91 62500.0<BR> 27.0300 LLGIWGCSGKLICTT HIV1.env.758 HIV1 193.7 >23985.08<BR> 27.0302 LSIVNERVRQGYSLLS HIV1.env.877 HIV1 1157.1 293.9<BR> 200.01 PIVQNLQGQMVHQAISHIV1.gp.1 HIV1 625.0 900000l0 450000.0 500000.0<BR> F091.24 PLGVAPTKAKRRRVVQR HIV1.env.671 HIV1 50000.0 >64951.91 12659.2<BR> 190.23 PSLQTGSEELRSLYNT HIV1.gp.65 HIV1 50000.0 12480.8 450000.0 500000.0<BR> F091.16 QARILAVERYLKDQQL HIV1.env.582 HIV1 1740.8 >64951.91 8751.8<BR> 27.0352 QGQWTYQIYQEPFKN HIV1.pol.516 HIV1 4594.9 13146.6<BR> 190.13 QKQEPIDKELYPLTSK HIV1.gp.97 HIV1 1250.0 >30000 450000.0 250.0<BR> 27.0375 QMAVFIHNFKRKGGI HIV1.pol.919 HIV1 10331.1 14711.1<BR> F091.07 RIQRGPGRAFVTIGKL HIV1.env.315 HIV1 14433.8 >64951.91 >91287.09<BR> 190.22 RQILGQLQPSLQTGSE HIV1.gp.57 HIV1 227.3 90000.0 750.0 1000.0<BR> F091.04 SLKPCVKLTPLCVTLN HIV1.env.115 HIV1 319.7 26892. 4247.1<BR> F091.26 SLWDQSLPCVKLTPL HIV1.env.825 HIV1 4902.9 >64951.91 >91287.09<BR> 27.0359 SQIIEQLIKKEKVYL HIV1.pol.701 HIV1 5986.4 >16112.58<BR> F091.22 SQNQQEKNEQELLELD HIV1.env.654 HIV1 50000.0 >64951.91 >91287.09<BR> F091.11 SSGGDOPEIVMHSFNCG HIV1.env.369 HIV1 25000.0 >64951.91 >91287.09<BR> 27.0334 STKWRKLVDFRELNK HIV1.ol.247 HIV1 618.4 1547.7 >16112.58<BR> F091.12 TITLPCRIKQFINMWQE HIV1.env.413 HIV1 50000.0 1636.6 826.7<BR> 27.0292 TVYYGVPVWKEATTT HIV1.env.49 HIV1 3603.9 3900.2<BR> F091.23 VKIEPLGVAPTKAKRR HIV1.env.667 HIV1 1796.1 47434.2 729.3 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 27.0301 VLSIVNRVRQGYSPL HIV1.env.876 HIV1 1624.8 3241.0<BR> 27.0356 VNIVTDSQYALGIIQ HIV1.po.675 HIV1 80.9 4961.6<BR> F091.03 WDQSLKPCVKLTPLCV HIV1.env.112 HIV1 637.1 >64951.91 >91287.09<BR> 27.0335 WRKLVDFRELNKRTQ HIV1.pol.250 HIV1 4543.9 >16122.58<BR> F160.45 STORKUSP45 PHV16.e.7. HPV16 A >25339.89 237.2<BR> 106.00 APYTSTLLPPELSETP HSV.gD.245 HSV 555.6 >450000 450000.0 25000.0<BR> F095.05 FRQLVHFVRDFAQLL HSV HSV<BR> AP30 SLKMADPNRFRGKDLP HSV HSV 1666.7 900000.0 450000.0 25000.0<BR> 605.14 ACRNHVTLSQPKIVK HumanB2-µglobulin.79 HumanB2-µglobulin 500.0 900000.0 5625.0 4166.7<BR> 530.08 GKKIPKVEMSDMSFSK HumanB2-µglobulin.43 HumanB2-µglobulin 50000.0 900000.0 7500.0 8333.3<BR> 605.03 HPAENGKSNFLNCYVS HumanB2-µglobulin.13 HumanB2-µglobulin 833.3 900000.0 1500.0 5555.6<BR> 530.06 HPPHIEIQMLKNGKKI HumanB2-µglobulin.31 HumanB2-µglobulin 100.0 900000.0 450000.0 142.9<BR> 530.01 IQKTPQIQVYSRHPPE HumanB2-µglobulin.1 HumanB2-µglobulin 5000.0 >30000 450000.0 500000.0<BR> 530.07 IQMLKNGKKIPKVEMS HumanB2-µglobulin.37 HumanB2-µglobulin 50000.0 1875.0 450000.0 50000.0<BR> 605.01 IQRTPKIQVYSRHPAE HumanB2-µglobulin.1 HumanB2-µglobulin 1666.7 900000.0 375.0 500000.0<BR> 530.02 IQVYSRHPPENGKPNI HumanB2-µglobulin.7 HumanB2-µglobulin 2500.0 900000.0 535.7 500000.0<BR> 530.04 KPNILNCYVTQFHPPH HumanB2-µglobulin.19 HumanB2-µglobulin 50000.0 >30000 15000.0 147.1<BR> 530.10 SFSKDWSFYILAHTEF HumanB2-µglobulin.55 HumanB2-µglobulin 2500.0 900000.0 343.5 500000.0<BR> 605.10 SFSYDWSFYLLYYTEF HumanB2-µglobulin.55 HumanB2-µglobulin 50000.0 900000.0 833.3 500000.0<BR> 605.11 SFYLLYYTEFTPTEKD HumanB2-µglobulin.61 HumanB2-µglobulin 50000.0 4647.6 957.5 10000.0<BR> 530.14 TETDTYACRVKHDSMA HumanB2-µglobulin.79 HumanB2-µglobulin 50000.0 900000.0 450000.0 500000.0<BR> 530.09 VEMSDMSFSKDWSFYI HumanB2-µglobulin.49 HumanB2-µglobulin 2500.0 0.0 22500.0 500000.0<BR> 544.02 YGSDTITLPCRIKQFINMWQE HumanB2-µglobulin.410 HumanB2-µglobulin 50000.0 900000.0 1607.1 568.2<BR> JR-01 PEFLEQRRAAVDTYC IEBs IEBs2 5000.0 450000.0 500000.0<BR> F073.01 MRGSHHHHHHGSVD-II72-216 Invariantchain Ii 375.0 57.3<BR> 734.01 FVNQHLSGSHLVEALYLVSG- InsulinA InsulinA 38.6 >30000 6495.2 18898.2<BR> CONH2 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 68.0002 DLVLSIALSVGCTGA Kallikrein2.3 Kallikrein2 1196.8 77340.2<BR> 68.0005 GQRVPVSHSFPHPLY Kallikrein2.87 Kallikrein2 1563.3 >142302.49<BR> 68.0011 HDLMLLRLSEPAKIT Kallikrein2.119 Kallikrein2 15.7 1405.6 17231.4<BR> 68.0008 HPLYNMSLLKHQSLR Kallikrein2.98 Kallikrein2 232.1 13006.7 2806.6<BR> 68.0003 HPQWVLTAAHCLKKN Kallikrein2.56 Kallikrein2 22.0 1102.9 4922.1<BR> 68.0018 KPAVYTKVVHYRKWI Kallikrein2.239 Kallikrein2 5000.0 8060.5<BR> 68.0140 LHLLSNDMCARAYSE Kallikrein2.176 Kallikrein2 2103.5 938.1 24058.1<BR> 68.0001 MWDLVLSIALSVGCT Kallikrein2.1 Kallikrein2 205.2 10386.4<BR> 68.0017 NGVLQGITSWGOPEPC Kallikrein2.220 Kallikrein2 1092.9 47434.2<BR> 68.0009 NMSLLKHQSLRPDED Kallikrein2.102 Kallikrein2 3131.1 >183711.73<BR> 68.0015 PEEFLRPRSLQCVSL Kallikrein2.162 Kallikrein2 2001.1 >150000<BR> 68.0007 PHPLYNMSLLKHQSL Kallikrein2.97 Kallikrein2 19078.6 4607.2<BR> 68.0016 PRSLQCVSLHLLSND Kallikrein2.168 Kallikrein2 1111.3 90000.0<BR> 68.0004 QWVLTAAHCLKKNWS Kallikrein2.58 Kallikrein2 895.1 >142302.49<BR> 68.0006 RVPVSHSFPHPLYNM Kallikrein2.89 Kallikrein2 66.7 >90000<BR> 68.0010 SHDLMLLRLSEPAKI Kallikrein2.118 Kallikrein2 55.9 2396.3 12622.4<BR> F090.02 ATGFKQSSKALQRPV Leukemia.15 Leukemia 4921.1 >22786.64<BR> F090.01 IVHSATGFKQSSKALQRPVAS Leukemia.25 Leukemia 1458.6 5844.2<BR> DFEP<BR> F071.29 IKYNGEEYLILSARD M.leprae.79 M.leprae 31980.1<BR> F071.26 IYSKYGGTEIKYNGE M.leprae.70 M.leprae 12519.3<BR> F118.06LVIPENAKEKPQ M.leprae.28 M.leprae<BR> F118.02 LVIPENAKEKPQEGT M.leprae.28 M.leprae<BR> F071.12 LVIPENAKEKPQEGT M.leprae.28 M.leprae >64951.91<BR> F071.30 NGEEYLILSARDVLA M.leprae.82 M.leprae 986.7<BR> F071.11 PSGLVIPENAKEKPQ M.leprae.25 M.leprae >64951.91<BR> F071.22 RIPVDVSEGDIVIYS M.leprae.58 M.leprae 45927.9 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 581.02 RKHRIEDAVRNAKAAVEEGI M.leprae.437 M.leprae 50000.0 871.5 5625.0 12500.0<BR> VAG<BR> F071.24 SEGDIVIYSKYGGTE M.leprae.64 M.leprae >64951.91<BR> 572.03 TLLQAAPALDKY M.leprae.464 M.leprae 135.1 900000.0 450000.0 25000.0<BR> F071.03 VAKVKIKPLEDKILV M.leprae.1 M.leprae 61237.2<BR> F071.04 VKIKPLEDKILVQAG M.leprae.4 M.leprae 44126.1<BR> F071.17 VVAVGPGRWDEDGAK M.leprae.43 M.leprae >64951.91<BR> 581.01 YEKIGAELVKEVAKKTDDVA M.leprae.112 M.leprae 27.8 900000.0 9000.0 500000.0<BR> G<BR> F160.21 EKIWEELSVLEVFEGRED MAGE.219 MAGE 10741.3 320.2<BR> F160.20 ETSYVKNLHHMVKISGG MAGE.280 MAGE >16678.11 958.3<BR> 58.0062 EEKIWEDLSMLEVFE MAGE2.218 MAGE2 A 257.2<BR> 58.0057 FPDLESDFQAAISRK MAGE2.98 MAGE2 A 374.9<BR> 58.0058 LESVLRDCQDFFPVI MAGE2.136 MAGE2 A 384.9<BR> 58.0064 MQDLVQDNYLEYRQV MAGE2.247 MAGE2 A 118.6<BR> 58.0063 PRKLLMEDLVQENYL MAGE2.242 MAGE2 A 6143<BR> 58.0065 QDLVQEDYLEYRQVP MAGE2.248 MAGE2 A 599.8<BR> 58.0059 QLVFGIDVVEVVPIS MAGE2.159 MAGE2 A 770.1<BR> 58.0071 EEKIWEDLSVLEVFE MAGE3.218 MAGE3 A 657.1<BR> 58.0068 LGSVVGDWQYFFPVI MAGE3.136 MAGE3 A 89.9<BR> 58.0074 QHFVQEDYLEYRQVP MAGE3.248 MAGE3 A 138.0<BR> 58.0073 TQHFVQDNYLEYRQV MAGE3.247 MAGE3 A 204.2<BR> F167.06LLKYRAREPVTKAEMLGSVV Mage6.121 Mage6 13.2 465.3 725.5 300.4<BR> GNWQ<BR> F167.08 MVKISGGPRISYPLLHEWALR Mage6.2909 Mage6 319.4 7108.8 >4242.64 14771.1<BR> EGEE<BR> F167.07 QVPGSDPACYEFLWGPRALIE Mage6.260 Mage6 35.3 >11868.85 >2772.68 >20412.41<BR> TSY<BR> F160.27 VGNWQYFFPVIFSKADSDL MAGE6.140 MAGE6 5074.4 566.8 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 520.09 YKLNFYFDLLRAKL Malaria Malaria 1250.0 19655.6 22500.0 500000.0<BR> 520.07 YLDNIKDNVGKMED Malaria Malaria 50000.0 >45000 5000.0 1562.5<BR> F160.15 AAGIGILTVILGVL MART1.27 MART1 >1930.26 92.9<BR> 825.10 AC- MBP.1 MBP 50000.0 900000.0 5000.0 25000.0<BR> ASQKRPSQRHGSKYLATAST<BR> 765.17 AC- MBP.1 MBP 1178.5 >30000 1527.4 25000.0<BR> ASQKRPSQRSKYLATASTMD<BR> F006.16 ANPVVHFFKNIVTPR MBP.85 MBP A<BR> 825.01 ASQKRSQRHGSKYLATAST MBP.1 MBP 50000.0 900000.0 2368.4 50000.0<BR> 765.15 AYDAQGTLSKIFKLGGRDSR MBP.141 MBP 20.5 25980.8 2665.6 303.5<BR> F006.14 DENPVVHFFKN MBP.84 MBP<BR> F006.13 DENPVVHFFKNI MBP.84 MBP<BR> F006.12 DENPVVHFFKNIV MBP.84 MBP<BR> F006.11 DENPVVHFFKNIVT MBP.84 MBP<BR> F006.10 DENPVVHFFKNIVTPR MBP.84 MBP<BR> F006.09 DENPVVHFFKNIVTPRT MBP.4 MBP<BR> F006.01 DENPVVHFFKNIVTPRTPP MBP.84 MBP<BR> F006.0202 DENPVVHFFKNVTPRTPPY MBP.84 MBP<BR> F006.03 DENPVVHFFKNIVTPRTPPY MBP.84 MBP<BR> F006.17 EAPVVHFFKNIVTPR MBP.85 MBP A<BR> F006.18 ENAVVHFFKNIVTPR MBP.85 MBP A<BR> F006.19 ENPAVHFFKNIVTPR MBP.85 MBP A<BR> F038.01 ENPKVHFFKNIVTPR MBP.85 MBP A<BR> F006.20 ENPVAHFFKNIVTPR MBP.85 MBP A<BR> F038.02 ENPVKHFFKNIVTPR MBP.85 MBP A<BR> F006.21 ENPVVAFFKNIVTPR MBP.85 MBP A<BR> F038.03 ENPVVAFFKNIVTPR MBP.85 MBP A TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F038.06 ENPVVDFFKNIVTPR MBP.85 MBP A<BR> F038.05 ENPVVFFFKNIVTPR MBP.85 MBP A<BR> F006.22 ENPVVHAFKNIVTPR MBP.85 MBP A<BR> F038.07 ENPVVHAFKNIVTPR MBP.85 MBP A<BR> F095.08 ENPVVHAFRNIVTPR MBP.85 MBP A<BR> F038.09 ENPVVHDFKNIVTPR MBP.85 MBP A<BR> F006.23 ENPVVHFAKNIVTPR MBP.85 MBP A<BR> F095.06 ENPVVHFARNIVTPR MBP.85 MBP A<BR> F006.24 ENPVVHFFANIVTPR MBP.85 MBP A<BR> F038.14 ENPVVHFFANIVTPR MBP.85 MBP A<BR> Cr-8 ENPVVHFFANIVTPRTP MBP.83 MBP A 8.6<BR> F038.15 ENPVVHFFDNIVTPR MBP.85 MBP A<BR> F038.16 ENPVVHFFHNIVTPR MBP.85 MBP A<BR> F006.25 ENPVVHFFKAIVTPR MBP.85 MBP A<BR> Cr-9 ENPVVHFFKAIVTPRTP MBP.83 MBP A 11.4<BR> F038.19 ENPVVHFFKKIVTPR MBP.85 MBP A<BR> F006.26 ENPVVHFFKNAVTPR MBP.85 MBP A<BR> Cr-10 ENPVVHFFKNAVTPRTP MBP.83 MBP A 10.7<BR> F006.27 ENPVVHFFKNIATPR MBP.85 MBP A<BR> F006.28 ENPVVHFFKNIVAPR MBP.85 MBP A<BR> Cr-11 ENPVVHFFKNIVAPRTP MBP.83 MBP A 13.1<BR> F006.29 ENPVVHFFKNIVTAR MBP.85 MBP A<BR> F006.30 ENPVVHFFKNIVTPA MBP.85 MBP A<BR> F006.36 ENPVVHFFKNIVTPA MBP.85 MBP A<BR> F006.15 ENPVVHFFKNIVTPR MBP.85 MBP A<BR> Cr-7 ENPVVHFFKNIVTPRTP MBP.83 MBP A 10.0 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F006.04 ENPVVHFFKNIVTPRTPPY MBP.85 MBP<BR> F038.20 ENPVVHFFKNKVTPR MBP.85 MBP A<BR> F038.17 ENPVVHFFLNIVTPR MBP.85 MBP A<BR> F038.18 ENPVVHFFRNIVTPR MBP.85 MBP A<BR> F038.13 ENPVVHFKKNIVTPR MBP.85 MBP A<BR> F038.10 ENPVVHHFKNIVTPR MBP.85 MBP A<BR> F095.10 ENPVVHHFRNIVTPR MBP.85 MBP A<BR> F038.11 ENPVVHLFKNIVTPR MBP.85 MBP A<BR> F095.09 ENPVVHLFRNIVTPR MBP.85 MBP A<BR> F038.12 ENPVVHWFKNIVTPR MBP.85 MBP A<BR> F095.12 ENPVVHYFANIVTPR MBP.85 MBP A<BR> F095.11 ENPVVHYFHNIVTPR MBP.85 MBP A<BR> F038.08 ENPVVHYFKNIVTPR MBP.85 MBP A<BR> F095.13 ENPVVHYFLNIVTPR MBP.85 MBP A<BR> F095.07 ENPVVHYFRNIVTPR MBP.85 MBP A<BR> F038.04 ENPVVKFFKNIVTPR MBP.85 MBP A<BR> 613.02 FFKNIVTPFFKNIVTP MBP. MBP A 833.3 5000.0 6250.0<BR> 825.07 FSWGAEGQRPGFGYGGRASD MBP.114 MBP 50000.0 900000.0 2045.5 500000.0<BR> 765.13 GFGYGGRASDYKSAHKGFKG MBP.121 MBP 50000.0 900000.0 15000.0 500000.0<BR> 825.06 GKGRGLSLSRFSWGAEGQRP MBP.104 MBP 833.3 900000.0 725.8 2631.6<BR> 825.04 GSGKDSHHPARTAHYGSLPQ MBP.55 MBP 50000.0 900000.0 45000.0 500000.0<BR> 765.03 HARHGFLPRHRDTGILDSIG MBP.21 MBP 50000.0 >30000 450000.0 500000.0<BR> F006.321 HFFKNIVTPRTPPY MBP.90 MBP<BR> F006.322 HFFKNIVTPRTPPY MBP.90 MBP<BR> 765.16 IFKLGGRDSRSGSPMARR MBP.151 MBP 29.2 900000.0 22500.0 500000.0<BR> 765.06 KRGSGKDSHTRTTHYGSLPQ MBP.51 MBP 500.0 >30000 11250.0 25000.0 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 765.08 KSQHGRTQDENPVVHFFKNI MBP.71 MBP 5000.0 >30000 2500.0 6250.0<BR> F006.31 NPVVHFFKNIVT MBP.86 MBP<BR> F006.37 NPVVHFFKNIVTPA MBP.86 MBP A<BR> F006.34 NPVVHFFKNIVTPR MBP.86 MBP<BR> F006.05 NPVVHFFKNIVTPRTPPY MBP.86 MBP<BR> F006.39 PVVHFFKNIVT MBP.87 MBP<BR> F006.38 PVVHFFKNIVTPA MBP.7 MBP A<BR> F006.35 PVVHFFKNIVTPR MBP.87 MBP<BR> F006.06 PVVHFFKNIVTPRTPPY MBP.87 MBP<BR> 825.11 QKSHGRTQDENPVVHFFKNI MBP.74 MBP 1250.0 900000.0 900.0 1562.5<BR> F121.03 RASDYKSAHKGFKGVDAQGT MBP.131 MBP<BR> F121.02 RASDYKSAHKGLKGHDAQGT MBP.131 MBP A<BR> 825.02 RDTGILDSIGRFFGGDRGAP MBP.33 MBP 50000.0 1822.7 450000.0 500000.0<BR> 765.04 RDTGILDSIGRFFSGDRGAP MBP.31 MBP 50000.0 748.6 45000.0 25000.0<BR> 825.03 RFFGGDRGAPKRGSGKDSHH MBP.43 MBP 50000.0 45000.0 5000.0 500000.0<BR> 765.05 RFFSGDRGAPKRGSGKDSHT MBP.41 MBP 50000.0 7500.0 1046.8 >16666.67<BR> 825.05 RTAHYGSLPQKSHGRTQDEN MBP.65 MBP 50000.0 900000.0 450000.0 500000.0<BR> 825.09 VDAQGTLSKIFKLGGRDSRS MBP.144 MBP 25.4 1383.0 9000.0 314.5<BR> F112.01 VDAQGTLSKIFKLGGRDSRS MBP.144 MBP<BR> F112.04 VDAQGRLSKLFKLGGRDSRS MBP.144 MBP A<BR> F112.03 VDAQGTLSRIFKLGGRDSRS MBP.144 MBP A<BR> F006.08 VHFFKNIVTPRTPPY MBP.89 MBP<BR> 765.10 VTPRTPPPSQGKGRGLSLSR MBP.91 MBP 50000.0 900000.0 5625.0 16666.7<BR> F006.07 VVHFFKNIVTPRTPPY MBP.88 MBP<BR> 765.14 YKSAHKGFKGAYDAQGTLSK MBP.131 MBP 3535.5 >30000 86,8 16666.7<BR> 825.08 YKSAHKGFKGVDAQGTLSKI MBP.134 MBP 70.4 900000.0 5000.0 25000.0 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 9.00 ANERADLIAYLKQATK Moth.CytochromeC.88 Moth 1666.7 >30000 450000.0 8333.3<BR> 847.02 EFVVEFDLPGIKA Mouse.Lysoyzme.38 Mouse 50000.0 1773.3 330.9 500000.0<BR> 593.02 VITAFNEGLK Mouse.Hemoglobin.67 Mouse 50000.0 900000.0 22500.0 500000.0<BR> 847.01 YEFVVFEDLPGIKA Mouse.Lysozyme.38 Mouse 50000.0 40.9 2941.2<BR> 753.03 IAFNSGLEPGVVAEK-NH2 MT.451 MT 50000.0 900000.0 450000.0 500000.0<BR> 753.02 LLPLLEKVIGAGKPL-NH2 MT.231 MT 1666.7 900000.0 22500.0 12500.0<BR> 829.01 YKTIAYDEEARR MT.3 MT 50000.0 142.8 22500.0 500000.0<BR> 831.01 TWQRDGEDQTQDTELVETRP Naturallyprocessed Naturallyprocessed 555.6 592.1 1111.1<BR> AG<BR> F009.04 VDDTLFVRFDSDAASPREEPR Naturallyprocessed Naturallyprocessed 122.3 3194.4<BR> F009.01 VDDTLFVRFDSDATSPRKEPR Naturallyprocessed Naturallyprocessed 37.6 6201.7<BR> F009.06 VDDTQFVRFDSDAASPREEPR Naturallyprocessed Naturallyprocessed 68.1 2094.3<BR> F009.02 VDDTQFVRFDSDAASPRMAP Naturallyprocessed Naturallyprocessed 44.6 1035.6<BR> R<BR> F009.05 VDDTQFVRFDSDAASPRTEPR Naturallyprocessed Naturallyprocessed 93.6 1737.6<BR> 536.00 AHAAHAAHAAHAAHAA Ova Ova A 35.7 900000.0 22500.0 25000.0<BR> N-3 AVHAAHAEINEAGR Ova.326 Ova<BR> 151.00 HIATNAVLFFGR Ova.370 Ova 2500.0 90000.0 450000.0 500000.0<BR> 144.01 ISQAAHAAHAEINE Ova.323 Ova A<BR> 84.04 ISQADHAAHAEINE Ova.323 Ova A<BR> 85.04 ISQAVEAAHAEINE Ova.323 Ova A<BR> 92.06 ISQAVHAAHAEDNE Ova.323 Ova A<BR> 92.05 ISQAVHAAHAEIIE Ova.323 Ova A<BR> 91.02 ISQAVHAAHAQINE Ova.323 Ova A<BR> 90.05 ISQAVHAALAEINE Ova.323 Ova A<BR> 144.08 ISQAVHAANAEINE Ova.323 Ova A<BR> 90.01 ISQAVHAARAEINE Ova.323 Ova A TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 747.01 LKISQAVHAAHAEIN Ova.321 Ova<BR> 705.05 MVYLGAKDSTRTQINKVVRF Ova.40 Ova 384.6 900000.0 11250.0 8333.3<BR> 521.00 NVMEERKIKVYLPRM Ova.271 Ova 1666.7 24053.5 45000.0 25000.0<BR> 560.04 VHAAHAEINVHAAHA Ova.327 Ova A 1250.0 >45000 500.0 7142.9<BR> 560.03 VHAAHAVHAAHAEIN Ova.327 Ova A 41.7 900000.0 22500.0 25000.0<BR> 560.05 VHAAHAVHAAHAVHA Ova.327 Ova A 12.2 900000.0 15000.0 1351.4<BR> 594.03 YTYTVHAAHAYTYT Ova Ova 45.5 5669.5 5625.0 25000.0<BR> 112.06 Y'TY'TVHAAHAY'TY'T Ova Ova 45.5 5625.0 25000.0<BR> 58.0082 LIRVEGDLRVEYLDD p53.194 p53 A 8.7<BR> 58.0081 QHLIRVDGNLRVEYL p53.192 p53 A 64.2<BR> 58.0091 RFEMFRDLNEALELK p53.337 p53 A 876.0<BR> 68.0019 AAPLLLARAASLSLG PAP.3 PAP 6.8 35410.0 782.7<BR> 68.0025 AKELKFVTLVFRHGD PAP.32 PAP 787.4 30000.0 4404.2<BR> 68.0052 ALDVYNGLLPPYASC PAP.299 PAP 18.4 2730.7<BR> 68.0020 APLLLARAASLSLGF PAP.4 PAP 8.4 56250.0 1138.5<BR> 68.0024 DRSVLAKELKFVTLV PAP.27 PAP 704.9 3203.4<BR> 68.0030 DRTLMSAMTNLAALF PAP.110 PAP 97.2 64285.7 71.8<BR> 68.0051 DTTVSGLQMALDVYN PAP.290 PAP 171.2 24885.1<BR> 68.0056 FAELVGPVIPQDWST PAP.356 PAP 12.5 26379.5<BR> 68.0028 FGQLTQLGMEQHYEL PAP.67 PAP 2258.5 18057.9<BR> 68.0047 GGVLVNEILNHMKRA PAP260 PAP 2165.4 699.6 2020.4<BR> 68.0156 GPVIPQDWSTECMTT PAP361 PAP 52098.0<BR> 68.0034 GVSIWNPILLWQPIP PAP.128 PAP 44.2 56250.0 58094.8<BR> 68.0038 ILLWQPIPVHTVPLS PAP.135 PAP 45.1 >67840.05 957.0<BR> 68.0048 IPSYKKLIMYSAHDT PAP.277 PAP 9.9 9727.6 2870.9<BR> 68.0046 KSRLQGGVLVNEILN PAP.255 PAP 361.8 >129903.81 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 68.0053 LDVYNGLLPPYASCH PAP.300 PAP 15.4 1958.8<BR> 68.0050 LIMYSAHDTTVSGLQ PAP.283 PAP 4496.4 134.4<BR> 68.0023 LLFFWLDRSVLAKEL PAP.21 PAP 2.9 6.3 14.8<BR> 68.0042 LPSWATEDTMTKLRE PAP.223 PAP 20274.0 5472.4<BR> 68.0043 LRELSELSLLSLYGI PAP.235 PAP 654.7 2084.6<BR> 68.0044 LSELSLLSLYGIHKQ PAP.238 PAP 482.2 >67840.05 8715.3<BR> 68.0040 LSGLHGQDLFGIWSK PAP.194 PAP 147.7 >129903.81<BR> 68.0045 ISLLSLYGIHKQKEK PAP.241 PAP 656.4 >67840.05 25000.0<BR> 68.0153 LTELYFEKGEYFVEM PAP.315 PAP 2248.9 591.8 45288.4<BR> 68.0031 MSAMTNLAALFPPEG PAP.114 PAP 1756.8 3935.5<BR> 68.0032 MTNLAALFPPEGVSI PAP.117 PAP 24.4 >225000<BR> 68.0036 NPILLWQPIPVHTVP PAP.133 PAP 31.3 >67840.05 1160.3<BR> 68.0033 PEGVSIWNPILLWQP PAP.126 PAP 111.2 10000.0<BR> 68.0037 PILLWQPIPVHTVPL PAP.134 PAP 44.4 >67840.05 1450.7<BR> 68.0021 PLLLARAASLSLGFL PAP.5 PAP 10.3 >67840.05 2932.4<BR> 68.0026 RSPIDTFPTDPIKES PAP.47 PAP >50000 73660.4<BR> 68.0022 SLSLGFLFLLFFWLD PAP.13 PAP 11416.8 26501.2<BR> 68.0147 TVPLSEDQLLYLPFR PAP.145 PAP 4012.0 332.2 60495.7<BR> 68.0035 WNPILLWQPIPVHTV PAP.132 PAP 208.2 >67840.05 3908.3<BR> 68.0039 WQPIPVHTVPLSEDQ PAP.138 PAP 6385.9 >129903.81<BR> 68.0041 YDPLYCESVHNFTLP PAP.210 PAP 1597.4 16625.5 50000.0<BR> 68.0049 YKKLIMYSAHDTTVS PAP.280 PAP 16.8 22677.9 1166.0<BR> 68.0054 YNGLLPPYASCHLTE PAP.303 PAP 41.6 34811.9<BR> 1188.24 AGGIAGGLALLACAG Pf.SSP2.498 Pf 359.7 38031.9 6742.0 >35906.62<BR> 1188.14 ATSVLAGLLGNVSTV Pf.EXP1.77 Pf 19.6 22116.3 943.9 >35906.62<BR> 1188.28 AVPLAMKLIQQLNLN Pf.SSP2.68 Pf 3768.9 22278.3 5750.6 30661.1 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F143.02 EWSPCSVTCGNGIQVRIK Pf.CSP.345 Pf 771.9 >53033.01 60893.1<BR> 27.0396 FLALFFIIFNKESLA Pf.EXP1.8 Pf 719.3 1225.8 4685.8<BR> F143.09 IEQYLKKIKNSISTEWSPCS Pf.CSP.331 Pf 72.7 >53033.01 110.2<BR> 1188.04 IFHINGKIIKNSEKD Pf.LSA1.18 Pf 164.9 7595.4 >60133.78 >59761.43 10302.2<BR> 27.0401 KHILYISFYFILVNL Pf.LSA1.2 Pf 3380.1 892.8 >7615.25<BR> 1188.20 LIDVHDLISDMIKKE Pf.EXP1.47 Pf 401.4 9066.2 1517.0 45454.6 5019.6<BR> F150.02 NAREIIRLHSDASKNKEKAL Pf.SSP2. Pf 98.1 49342.1 2191.4<BR> 27.0414 NHAVPLAMKLIQQLN Pf.SSP2.66 Pf 266.1 3916.3 >7615.25<BR> F107.12 TVLLGGVGLVLYNTE Pf.EXP1.90 Pf 10.3 16198.4 >25333.33<BR> 1188.47 VDLYLLMDCSGSIRR Pf.SSP2.47 Pf 3125.0 3120.9 26688.0 >35906.62<BR> 27.0410 VKNVSQTNFKSLLRN Pf.LSA1.89 Pf 2937.8 1669.1 6441.2 3182.2<BR> 1188.48 VVILTDGIPDSIQDS Pf.SSP2.157 Pf 50000.0 663.6 11707.3 >35906.62<BR> F150.03 YADSAWENVKNVIGPFMKAV Pf.SSP2. Pf 69.7 >51961.52 >4008.92<BR> 191.16 ADLIAY'LKQATAK Piegon.CytochromeC.92 Pigeon 80.7 12500.0<BR> 12.04 DLIAYLKQATAK Piegon.CytochromeC.88 Pigeon A 217.4 4166.7<BR> 12.05 ERADLIAYLKQATAK Piegon.CytochromeC.88 Pigeon A 57.5 1612.9<BR> 12.03 IAYLKQATAK Piegon.CytochromeC.88 Piegon A 1000.0 12500.0<BR> 191.10 KAERADLLAY'LKQATA Piegon.CytochromeC.88 Pigeon 2500.0 12500.0<BR> 199.17 LIAY'LKQATAK Piegon.CytochromeC.94 Pigeon 172.4 4545.5<BR> F025.08 AATYNFAVLKLMGRGTKF PLP.260 PLP >17256.71 3000.0<BR> K-09 FLYGALLLAEGFYTTGAVRQ PLP.81 PLP<BR> F050.02 FLYGALLLAEGFYTTGAVRQ PLP.81 PLP >37242.26 502.9<BR> K-28 FNTWTTCQSIAFPS PLP.278 PLP<BR> K-20 LCADARMYGVLPWNAFPGK PLP.201<BR> V<BR> K-05 LTGTEKLIETYFSKNYQDYE PLP.41 PLP<BR> F025.05 QKGRGYRGQHQAHSLERVCH PLP.121 PLP >15389.68 495.3 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> K-18 SAVPVYIYFNTWTTCQSIAF PLP.171 PLP<BR> F050.05 SAVPVYIYFNTWTTCQSIAF PLP.171 PLP 27272.7 202.7<BR> K-16 TAEFQMTFHLFIAAFVGAAA PLP.231 PLP<BR> F025.03 WTTCQSIAFPSKTSASIGSL PLP.181 PLP 17307.7 126.0<BR> 68.0066 AHCIRNKSVILLGRH PSA.60 PSA 578.1 29704.4 386.8<BR> 68.0078 CAQVHPQKVTKFMLC PSA.180 PSA 10206.2 14433.8<BR> 68.0079 GGPLVCNGVLQGITS PSA.210 PSA 3353.3 382.9<BR> 68.0080 GPLVCNGVLQGITSW PSA.211 PSA 1724.0 169.9<BR> 68.0069 GQVFQVSHSFPHPLY PSA.83 PSA 288.4 45000.0 45.9<BR> 68.0062 GRAVCGGVLVHPQWV PSA.42 PSA 386.5 >129903.81<BR> 68.0063 GVLVHPQWVLTAAHC PSA.48 PSA 87.3 21320.1 378.4<BR> 68.0073 HDLMLLRLSEPAELT PSA.115 PSA 62.1 2867.5 34833.4<BR> 68.0064 HPQWVLTAAHCIRNK PSA.52 PSA 13.1 3631.5 9117.5<BR> 68.0158 HSLFHPEDTGQVFQV PSA.74 PSA 65260.2<BR> 68.0077 LHVISNDVCAQVHPQ PSA.172 PSA 789.0 8318.4 4443.4<BR> 68.0081 NGVLQGITSWGSEPC PSA.216 PSA 944.9 24942.3 3149.4<BR> 68.0071 PHPLYDMSLLKNRFL PSA.93 PSA 1315.5 116928.6<BR> 68.0065 QWVLTAAHCIRNKSV PSA.54 PSA 49.8 109141.0<BR> 68.0082 RPSLYTKVVHYRKWI PSA.235 PSA 6041.0 53785.3 1904.2<BR> 68.0072 SHDLMLLRLSEPAEL PSA.114 PSA 531.8 6214.7 22786.6<BR> 68.0061 SQPWQVLVASRGRAV PSA.31 PSA 66.0 >67840.05 42905.8<BR> 68.0067 SVILLGRHSLFHPED PSA.67 PSA 717.2 1399.7 71151.3<BR> 68.0059 SVTWIGAAPLILSRI PSA.7 PSA 4.1 >67840.05 42905.8<BR> 68.0074 TDAVKVMDLPTQEPA PSA.129 PSA >50000 >225000<BR> 68.0058 TLSVTWIGAAPLILS PSA.5 PSA 3.1 >67840.05 40909.1<BR> 68.0070 VFQVSHSFPHPLYDM PSA.85 PSA 15.5 >63012.6 139.2 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 68.0068 VILLGRHSLFHPEDT PSA.68 PSA 273.0 8743.6 46169.0<BR> 68.0060 VTWIGAAPLILSRIV PSA.8 PSA 8.1 >67840.05 45000.0<BR> 68.0125 ADKIYSISMKHPQEM PSM.608 PSM 22360.7 29867.8<BR> 68.0101 AEAVGLPSIPVHPIG PSM.284 PSM 5.4 55815.6<BR> 68.0102 AVGLPSIPVHPIGYY PSM.286 PSM 3.6 23586.4<BR> 68.0113 CTPLMYSLVHNLTKE PSM.466 PSM 92.9 19437.0 1378.3<BR> 68.0114 DFEVFFQRLGIASGR PSM.520 PSM 143.0 1244.5<BR> 68.0118 DPMFKYHLTVAQVRG PSM.567 PSM 5.7 >63012.6 51.2<BR> 68.0181 DQLMFLERAFIDPLG PSM.666 PSM >14078.28<BR> 68.0111 DSSIEGNYTLRVDCT PSM.453 PSM 16666.7 18898.2<BR> 68.0167 EDFFKLERDMKINCS PSM.183 PSM 2708.9 468.5 1269.5<BR> 68.0109 ERGVAYINADSSIEG PSM.444 PSM 2439.8 38031.9<BR> 68.0115 EVFFQRLGIASGRAR PSM.522 PSM 28.0 >63012.6 123.8<BR> 68.0100 EYAYRRGIAEAVGLP PSM.276 PSM 5.1 1196.9<BR> 68.0168 FFKLKERDMKINCSGK PSM.185 PSM 4419.2 73.0 2719.0<BR> 68.0173 GAAVVHEIVRSFGTL PSM.391 PSM 12409.1<BR> 68.0096 GKVFRGNKVKNAQLA PSM.206 PSM 611.6 6115.2<BR> 68.0123 GMVFELANSIVLPFD PSM.582 PSM 15.0 4603.7 1295.1<BR> 68.0090 GNEIFNTSLFEPPPP PSM.135 PSM 20412.4 >60133.78<BR> 68.0097 GNKVKNAQLAGAKGV PSM.211 PSM 677.0 75000.0<BR> 68.0110 GVAYINADSSIEGNY PSM.446 PSM 1054.1 823.4<BR> 68.0170 GVILYSDPADYFAPG PSM.224 PSM 1565.9 17.1 42232.7<BR> 68.0103 IGYYDAQKLKLEKMGG PSM.297 PSM 1923.1 71151.3<BR> 68.0086 IKKFLYNFTQIPHLA PSM.70 PSM 449.1 8079.6 240.4<BR> 68.0166 ISIINEDGNEIFNTS PSM.128 PSM 506.7 559.2 >51888.14<BR> 68.0126 IYSISMKHPQEMKTY PSM.611 PSM 8451.5 90000.0 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 68.0087 KFLYNFTQIPHLAGT PSM.72 PSM 340.2 13805.4 1221.8<BR> 68.0120 KYHLTVAQVRGGMVF PSM.571 PSM 136.9 33658.1 4531.8<BR> 68.0089 LAHYDVLLSYPNKTH PSM.110 PSM 78.6 37532.6 6284.8<BR> 68.0085 LDELKAENIKKFLYN PSM.62 PSM 1136.4 1369.9 27235.2<BR> 68.0084 LGFLFGWFIKSSNEA PSM.35 PSM 10.4 >63012.6 7524.1<BR> 68.0131 LRMMNDQLMFLERAF PSM.661 PSM 2703.7 2204.1<BR> 68.0119 MFKYHLTVAQVRGGM PSM.569 PSM 15.8 29032.3 98.7<BR> 68.0176 NSRLLQERGVAYINA PSM.438 PSM 613.6 317.8 28624.2<BR> 68.0112 NYTLRVDCTPLMYSL PSM.459 PSM 6804.1 45.1 55.8<BR> 68.0127 PQEMKTYSVSFDSLF PSM.619 PSM 15142.7 17010.0<BR> 68.0083 PRWLCAGALVLAGGF PSM.18 PSM 46.5 >60133.78<BR> 68.0135 QIYVAAFTVQAAAET PSM.731 PSM 1.6 26609.1 9.1<BR> 68.0122 RGGMVFELANSIVLP PSM.580 PSM 10.3 37117.9 1288.1<BR> 68.0133 RHVIYAPSSHNKYAG PSM.688 PSM 2173.9 2705.3<BR> 68.0134 RQIYVAAFTVQAAAE PSM.730 PSM 3.7 28347.3 6.9<BR> 68.0105 TGNFSTQKVKMHIHS PSM.334 PSM 11180.3 4687.8<BR> 68.0116 TNKFSGYPLYHSVYE PSM.543 PSM 3402.1 31053.0<BR> 68.0107 TRIYNVIGTLRGAVE PSM.353 PSM 14.3 33333.3 35.4<BR> 68.0128 TYSVSFDSLFSAVKN PSM.624 PSM 219.1 110.1 410.0<BR> 68.0136 VAAFTVQAAAETLSE PSM.734 PSM 14.5 >63012.6 326.5<BR> 68.0121 VAQVRGGMVFELANS PSM.576 PSM 228.2 3274.7<BR> 68.0177 VAYINADSSIEGNYT PSM.447 PSM 4716.5 530.9 2310.6<BR> 68.0124 VFELANSIVLPFDCR PSM.584 PSM 19.2 667.4 5617.5<BR> 68.0130 VLRMMNDQLMFLERA PSM.660 PSM 117.6 182.7 161.7<BR> 68.0088 WKEFGLDSVELAHYD PSM.100 PSM 1138.8 84.8 540.1<BR> 68.0117 YDPMFKYHLTVAQVR PSM.566 PSM 9.0 >63012.6 106.2 TABLE27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 68.0165 YISIINEDGNEIFNT PSM.127 PSM 497.9 397.1 3510.5<BR> 68.0132 YRHVIYAPSSHNKYA PSM.687 PSM 94.6 >63012.6 1597.6<BR> F112.02 VDAQGTLSRLFKLGGRDSRS Rabbit.144 Rabbit<BR> 938.01 KVNNQVVSLKPEIIVDQEY Rabiesvirus. Rabiesvirus 23.6 7500.0 1752.5<BR> F160.32 STORKUSP32 RAGE. RAGE 392.6 91.5<BR> F160.34 STORKUSP34 RAGE. RAGE >24771.68 721.6<BR> F160.36 STORKUSP36 RAGE. RAGE 658.5 7.5<BR> F160.37 STORKUSP37 RAGE. RAGE 898.3 99.2<BR> F160.39 STORKUSP39 RAGE. RAGE >19733.81 40.3<BR> F047.09 DKLKQQRDTLSTQKET RHD.81 RHD<BR> F047.16 EQKSKQNIGALKQEL RHD. RHD<BR> 938.06 SGGTNYAQKFQGRVTMTRDT Rheumatiodvector Rheumatiodvector 668.2 5625.0 >16666.67<BR> -NH2<BR> 938.08 ELSRLSDDTAVYYCARAPG- Rheumatiodvector Rheumatiodvector 110.1 304.0 10000.0<BR> NH2<BR> 938.09 ELSRLTSDDTAVYYCAIAPG- Rheumatiodvector Rheumatiodvector 130.0 653.6 2344.0<BR> NH2<BR> 938.10 TISCSGSSSNIGSNTVN-NH2 Rheumatiodvector Rheumatiodvector 50000.0 147.1 2646.3<BR> F015.05 APYHFDLSGHA Ryegrass.Lolp1 Ryegrass<BR> 791.08 APYHFDLSGHA Ryegrass.Lolp1.101 Ryegrass 37.5<BR> 791.07 APYHFDLSGHAFGS Ryegrass.Lolp1.101 Ryegrass 10.0<BR> 791.06 APYHFDLSGHAFGSMA Ryegrass.Lolp1.101 Ryegrass 28.1<BR> 791.05 APYHFDLSGHAFGSMAKK Ryegrass.Lolp1.101 Ryegrass 40.9<BR> 620.11 APYHFDLSGHAFGSMAKKGE Ryegrass.Lolp1 Ryegrass 50000.0 25980.8 25.0 500000.0<BR> 620.05 CGYKDVDKAPFNGMTGCGN Ryegrass.Lolp1.41 Ryegrass 50000.0 90.0 3750.0 500000.0<BR> T<BR> 807.03 DLSGHAFGS Ryegrass.Lolp1.106 Ryegrass 450000.0<BR> 595.02 EDVIPEGWKADTSYSAK Ryegrass.Lolp1.80 Ryegrass 50000.0 60.8 500000.0 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 620.14 ELQFRRVKCKYPDDTKPTFH Ryegrass.Lolp1.131 Ryegrass 50000.0 >30000 3750.0 500000.0<BR> 620.13 EQNVRSAGELELQFRRVKCK Ryegrass.Lolp1.121 Ryegrass 50000.0 3750.0 500000.0<BR> 620.20 ESWGAVWRIDTPDKLTGPFT Ryegrass.Lolp1 Ryegrass 2500.0 3128.2 3750.0 333.3<BR> 791.02 FDLSGHAFGSMAKKGE Ryegrass.Lolp1.105 Ryegrass<BR> 620.18 GDVVAVVDIKEKGKDKWIEL Ryegrass.Lolp1 Ryegrass 50000.0 321.6 3750.0 50000.0<BR> K<BR> MA-05 GEKRAYAASDPGRYC Ryegrass.Lolp1 Ryegrass 50000.0 450000.0 500000.0<BR> 620.19 KGKDKWIELKESWGAVWRID Ryegrass.Lolp1.181 Ryegrass 1666.7 >30000 3750.0 8333.3<BR> 791.03 LSGHAFGSMAKKGE Ryegrass.Lolp1.107 Ryegrass 450000.0<BR> 620.23 SEVEDVIPEGWKADTSYSAK Ryegrass.Lolp1.221 Ryegrass 5000.0 725.8 50000.0<BR> MA-06 VAYESSEIASKKAG Ryegrass.Lolp1 Ryegrass 50000.0 714.3 12500.0<BR> 620.16 VEKGSNPNYLAILVKYVDGD Ryegrass.Lolp1.151 Ryegrass 200.0 >30000 3750.0 500000.0<BR> 791.09 YHFDLSGHAFGS Ryegrass.Lolp1.103 Ryegrass 19.6<BR> 791.01 YHFDLSGHAFGSMAKKGE Ryegrass.Lop1.103 Ryegrass 38.1<BR> 620.15 YPDDTKPTFHVEKGSNPNYL Ryegrass.Lolp1.141 Ryegrass 1000.0 >30000 1607.1 500000.0<BR> F165.05 KSDNQIKAVPASQALVA Sm.eggantigen.235 Sm 4.3 86.7 58.0<BR> F165.01 PKSDNQIKAVPAS Sm.eggantigen.234 Sm 4350.5 >504.69 2858.8<BR> F165.03 PKSDNQIKAVPASQA Sm.eggantigen.234 Sm 19.2 326.3 78.1<BR> F165.02 VRPKSDNQIKAVPAS Sm.eggantigen.232 Sm 5154.6 3324.4 375.6<BR> 213.16 FRKDIAAKYKELGY Spermwhale.Myoglobin.138 Spermwhale 1080.2 1000.0<BR> 213.15 LFRKDIAAKYKELGY Spermwhale.Myoglobin.137 Spermwhale 427.2 737.7<BR> 542.00 NKALELFRKDIAA Spermwhale.Myoglobin.132 Spermwhale 3500.2 2250.2<BR> 213.12 NKALELFRKDIAAK Spermwhale.Myoglobin.132 Spermwhale 2547.6 2045.5<BR> 213.11 NKALELFRKDIAAKY Spermwhale.Myoglobin.132 Spermwhale 2593.4 775.9<BR> 13.00 NKALELFRKDIAAKYKELGY Spermwhale.Myoglobin.132 Spermwhlae 37.0 300.0<BR> QG<BR> 213.17 RKDIAAKYKELGY Spermwhale.Myoglobin.139 Spermwhale >6634.89 2250.0 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> NASE061-80 FTKKMVENAKKIEVEFDKGQ Staph..Nase.61 Staph. 1000.0 11619.0 2812.5 500000.0<BR> F015.01 GLAKVAYVYKP Staph..Nase.101 Staph.<BR> <P>NASE121-140 HEQHLRKSEAQAKKEKLNIW Staph..Nase.121 Staph. 50000.0 90000.0 450000.0 1666.7<BR> 191.26 LVRQGLAKVAY Staph..Nase.103 Staph. 166.7 450000.0 500000.0<BR> NASE011-30 PATLIKAIDGDTVKLMYKGQ Staph..Nase.11 Staph. 277.8 6428.6 1666.7 3846.2<BR> NASE031-50 PMTFRLLLVDTPETKHPKKG Staph..Nase.31 Staph. 104.2 45000.0 1216.2 574.7<BR> 191.29 QGLAKVAYVYK Staph..Nase.106 Staph. 50000.0 450000.0 500000.0<BR> 191.28 RQGLAKVAYVY Staph..Nase.105 Staph. 50000.0 450000.0 10000.0<BR> NASE041-60 TPETKHPKKGVEKYGPEASA Staph..Nase.41 Staph. 1000.0 900000.0 2812.5 500000.0<BR> NASE051-70 VEKYGPEASAFTKKMVENAK Staph..Nase.51 Staph. 50000.0 900000.0 7500.0 500000.0<BR> 191.27 VRQGLAKVAYV Staph..Nase.104 Staph. 106.4 450000.0 5000.0<BR> NASE091-110 YIYADGKMVNEALVRQGLAK Staph..Nase.91 Staph. 64.9 2812.5 4166.7<BR> 546.00 FTKKMVENAKKIEVEFDKGQ Staph.nuc..61 Staph.nuc 50000.0 2676.2 22500.0 50000.0<BR> 866.05 HEQHLRKSEAQKKEKLNIW Staph.nuc..121 Staph.nuc 50000.0 6428.6 22500.0 50000.0<BR> 598.00 PATLIKAIDGDTVKLMYKGQ Staph.nuc..11 Staph.nuc 1250.0 63.1 937.5 1388.9<BR> 866.06 QAKKEKLNIWSEDNADSGQ Staph.nuc..131 Staph.nuc 50000.0 >45000 473.7 5000.0<BR> 866.02 VEKYGPEASAFTKKMVENAK Staph.nuc..51 Staph.nuc 5000.0 >45000 9000.0 50000.0<BR> 866.04 YIYADGKMVNEALVRQGLAK Staph.nuc..91 Staph.nuc 119.1 260.9 22500.0 16666.7<BR> 835.03 YGAVDSILGGVATYGAA-NH2 Stp.dt...1 Stp.dt. 59.5 >15000 1216.2 259.1<BR> F178.08 AGTIAALNNSIGVLG Subtilisin.69 Subtilisin 43.1 >25139.39 2234.7 114.4 857.1<BR> F178.10 GSISYPARYANAMAV Subtilisin.157 subtilisin 1389.5 17180.3 11296.9 6016.0 8624.5<BR> F178.06 GTVAALDNSAGVLGV Subtilisin.70 Subtilisin 163.2 2891.9 964.4 10.4 1283.8<BR> F178.05 GTVAALDNSIGVLGV Subtilisin.70 Subtilisin 15.1 236.4 133.3 17.1 757.2<BR> F178.03 GTVAALNNSAGVLGV Subtilisin.70 Subtilisin 19.5 11702.2 598.7 16.3 1304.3<BR> F178.01 GTVAALNNSIGVLGV Subtilisin.70 Subtilisin 6.83999.2 156.0 7.1 186.9<BR> F178.09 IAALNNSIGVLGVAP Subtilisin.72 Subtilisin 6.6 15938.9 283.5 10.0 1610.6 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F178.04 NGIEWAIANNMDVAN Subtilisin.109 Subtilisin 7.7 21675.5 69.1 109.4 15.4<BR> F178.02 NGIEWAIANNMDVIN Subtilisin.109 Subtilisin 8.3 32040.0 77.4 168.4 37.4<BR> F178.11 SYPARYANAMAVGAT Subtilisin.160 Subtilisin 11.0 >25139.39 142.4 60915 1437.1<BR> F178.07 TGSGVKVAVLDTGIS Subtilisin.22 Subtilisin >10270.85 35587.8>28708.41 2709.1 5964.0<BR> 573.13 ANSKFIGITELKK TetTox.834 TetTox 50000.0 11250.0<BR> 573.12 IKANSKFIGITELKK TetTox.832 TetTox 50000.0 11250.0<BR> 597.10 ILMQYIKANS TetTox.287 TetTox 5000.0 1875.0<BR> L-05 QAIKANSKFIGITE TetTox.830 TetTox A 50000.0 450000.0<BR> 650.05 QEIKANSKFIGITE TetTox.830 TetTox A 5000.0 1748.3 11250.0 50000.0<BR> 650.06 QSIKANSKFIGITE TetTox.830 TetTox A 5000.0 4880.9 11250.0 50000.0<BR> 650.21 QYIKANQKFIGITE TetTox.830 TetTox A 5000.0 958.3 11250.050000.0<BR> 650.29 QYIKANSKFKGITE TetTox.830 TetTox A 5000.0 135.4 7500.0 500000.0<BR> 650.14 QYIKKNSKFIGITE TetTox.830 TetTox A 2000.0 36.0 11250.0 500000.0<BR> 650.16 QYIKSNSKFIGITE TetTox.830 TetTox A 2500.0 4330.1 11250.0<BR> 650.13 QYIRANSKFIGITE TetTox.830 TetTox A 100.0 798.0 11250.0 500000.0<BR> 573.14 SKFIGITELKK TetTox.836 TetTox 1250.0 15000.0<BR> 548.02 YNGQIGNDPNRDIL TetTox. TetTox 1666.7<BR> 534.02 DTPYLDITYHFVMQRLPL Torp.Ac..californica.195 Torpedocalifornica 384.6 0.0 900. 500000.0<BR> 1385.07 GELIGILNAAKVPAD TPI.23 TPI 9.0 9674.3 321.8 22.1<BR> F167.11 ALHIYMDGTMSQVQGSA Tyrosinase.365 Tyrosinase 442.3 91.5 17.8 31.8<BR> F167.12 ALHIYMNGTMSQVQGSA Tyrosinase.365 Tyrosinase 526.4 26631.2 3418.4 174.6<BR> F089.22 DQSYLQDSDPDSFQD Tyrosinase.448 Tyrosinase A 923.2<BR> F089.13 DYSFLQDSDPDSFQD Tyrosinase.448 Tyrosinase A >50000 563.6<BR> F089.25 DYSYFQDSDPDSFQD Tyrosinase.448 Tyrosinase A 507.2<BR> 1385.10 DYSYLQDSDPDSFQD Tyrosinase.448 Tyrosinase >9128.71 39391.9 859.9 >27277.24<BR> F089.11 DYSYLQDSVPDSFQD Tyrosinase.448 Tyrosinase A 71428.6 156.0 >62500 >45746.62 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> F089.24 DYSYQQDSDPDSFQD Tyrosinase.448 Tyrosinase A 996.3<BR> 1385.09 FLLHHAFVDSIFEQWLQRHRP Tyrosinase.386 Tyrosinase 10245.9 707.1 >2758.62 11258.7<BR> F089.18 ILLSNAPLGPQFP Tyrosinase.58 Tyrosinase 869.5 32142.9<BR> F089.20 NILLSNAPLGPQFP Tyrosinase.57 Tyrosinase 60.0 338.8<BR> F089.06 QNFLLSNAPLGPQFP Tyrosinase.56 Tyrosinase A 5.1 61.9 3803.0 217.8<BR> F089.28 QNIFLSNAPLGPQFP Tryrosinase.56 Tyrosinase A 321.4<BR> F089.04 QNILLSNAPQGPQFP Tryrosinase.56 Tyrosinase A 297.4 2041.2<BR> F089.33 QNILLSNAQLGPQFP Tryrosinase.56 Tyrosinase A 303.4<BR> F089.34 QNILLSNAVLGPQFP Tryrosinase.56 Tyrosinase A 159.9<BR> F089.03 QNILLSNQPLGPQFP Tryrosinase.56 Tyrosinase A 238.0 7763.2<BR> F089.07 QNILLSNVPLGPQFP Tryrosinase.56 Tyrosinase A 48.2 12.7 32.1 162.0<BR> F089.30 QNILQSNAPLGPQFP Tryrosinase.56 Tyrosinase A 758.6<BR> F089.32 QNILVSNAPLGPQFP Tryrosinase.56 Tyrosinase A 619.9<BR> F089.27 QNIQLSNAPLGPQFP Tryrosinase.56 Tyrosinase A 774.6<BR> F089.29 QNIVLSNAPLGPQFP Tryrosinase.56 Tyrosinase A 99.5<BR> F089.19 QNVLLSNAPLGPQFP Tryrosinase.56 Tyrosinase A 58.9 996.3<BR> F089.15 SYLQDSDPDSFQD Tryrosinase.450 Tyrosinase >50000 346.0<BR> F089.21 SYLQDSVPDSFQD Tryrosinase.450 Tyrosinase A >50000 63.0 166666.7 3084.7<BR> F167.09 WPSVFYNRTCQCSGNF Tryrosinase.80 Tyrosinase 32258.1 >17822.66 >3801.38 36791.8<BR> F167.10 YGQMKNGSTPMFNDINIYDL Tryrosinase.156 Tyrosinase 1123.0 5706.9 1436.3 1086.3<BR> F089.16 YLQDSDPDSFQD Tryrosinase.451 Tyrosinase >50000 567.4<BR> F089.14 YSYLQDSDPDSFQD Tryrosinase.449 Tyrosinase >50000 247.7<BR> 604.01 (AKA)6 Unknown u 625.0 9000.0 500000.0<BR> 848.01 A(56)FAAAA(24)A(56)AA(57)- Unknown u 1.3 1.1 2.8<BR> NH2<BR> 848.03 A(56)FAAAA(24)L(56)AA(57)- Unknown u 6.4 2.5 25.0<BR> NH2 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 848.05 A(56)FAAAATA(56)AA(5)- Unknown u 23.0 12.9 50.0<BR> NH2<BR> 848.07 A(56)FAAAATL(56)AA(57)- UNknown u 2.5 11.3 3.5<BR> NH2<BR> F042.01 A(X)KQNTLKLAT Unknown u A 5.5<BR> 848.02 AAFAAAA(24)A(56)AA(57)- Unknown u 1.1 8.2 38.5<BR> NH2<BR> 848.04 AAFAAAA(24)L(56)AA(57)- Unknown u 2.4 2.0 31.3<BR> NH2<BR> 848.06 AAFAAAATA(56)AA(57)-NH2 Unknown u 2.5 2.7 9.6<BR> 848.08 AAFAAAATL(56)AA(57)-NH2 Unknown u 1.1 4.1 7.9<BR> 603.01 AHAAHAAHAAHAAHAAY Unknown u 20.8 9000.0 2173.9<BR> F182.04 EVIPMFSALSEGA Unknown u 22.0 >5197.13 881.9 87.0 205.5<BR> 520.05 EVWREEAYHAADIKD Unknown u 135.1 30000.0 4090.9 16666.7<BR> 520.06 EVWREEAYHAADIKDY Unknown u 250.0 45000.0 500000.0<BR> 852.04 KYVKQNTLKLAT Unknown u 9.9 34.6 25000.0<BR> 852.05 KYVKQNTLKLAT Unknown u 14.9 30.0 500000.0<BR> F182.09 LNKIVRMYSPTSI Unknown u 10.9 >61289.42 177.9 17.6 14.6<BR> F182.10 NKIVRMYSPTSIL Unknown u 11.0 >51970.13 135.0 40.8 90.8<BR> F042.06 P(X)KQNTLKLAT Unknown u A 1.7<BR> F042.07 P(X)KQNTLKLAT Unknown u A 14.9<BR> F182.03 PEVIPMFSALSEG Unknown u 17.1 >51970.13 123.2 20.8 22.5<BR> F182.01 PIVQNIQGQMVHQ Unknown u 28.0 >59528.21 227735.0 11756.6 4074.0<BR> F042.02 PKFV(X)TLKLAT Unknown u A 6.2<BR> F042.05 PKFVKQNTL(X)T Unknown u A 7.9<BR> F042.03 PKFVQ(X)KLAT Unknown u A 6.9<BR> F182.08 QEQIGWMTNNPPI Unknown u 1765.4 >51970.13 1958.1 240.6 158.5<BR> 832.01 TFGLQLELTEGMRFDKG Unknown u 50000.0 161.0 918.4 16666.7 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 173.00 TYQRTRALVTG Unknown u 2500.0 900000.0 450000.0 500000.0<BR> F182.02 VQNIQGQMVHQAI Unknown u 138.2 >51970.13 1338.7 240.1 2952.5<BR> 835.01 YIDVWLGGLAENFLP-NH2 Unknown u 50000.0 90000.0 15000.0 50000.0<BR> 785.02 YKKSIQFHWKNSNQIKILG Unknown u 217.4 2142.9 1562.5<BR> 843.03 YKLNDRADSRRSL Naturallyprocessed u 50000.0 450000.0 500000.0<BR> F002.02 YKPVSQLRLATPLLLRPL Unknown u 0.3 58.5 851.9 86.9<BR> 835.02 YLDPLIRGLLARPAKLQV- Unknown u 1.5 900000.0 3750.0 44.3<BR> NH2<BR> F002.01 YLPKPPKPVSKLRLATPLLLQ Unknown u 0.8 565.8 1227.5 435.2<BR> ALPL<BR> 824.07 (14)AAAKTAAAFA-NH2 Artificialsequence 1.8 0.9 4.4<BR> 824.08 (15)AAAKTAAAFA-NH2 Artificialsequence 1.4 0.9 3.1<BR> 820.03 (15A)RQTTLKAAA-NH2 Artificialsequence A 4.2 1.8 4.3<BR> 820.05 (15A)RQTTLKAAA-NH2 Artificialsequence A 2500.0 15.3 1851.9<BR> 824.09 (16)AAAKTAAAFA-NH2 Artificialsequence 10.9 1.0 50.3<BR> 820.04 (16A)RQTTLKAAA-NH2 Artificialsequence A 454.6 7.1 37.0<BR> 853.01 (39)AAAATKAA(35)-NH2 Artificialsequence A 250.0 1184.2 25000.0<BR> 853.02 (39)AAAATKAA(36)-NH2 Artificialsequence A 833.3 818.2 50000.0<BR> 853.03 (39)AAAATKAA(37)-NH2 Artificialsequence A 131.6 957.5 25000.0<BR> 824.37 (39)AAAATKAAAA Artificialsequence 156.3 616.4 12500.0<BR> 856.04 (39)AAAKTAAA(35)-NH2 Artificialsequence A 76.9 2.5 294.1<BR> 824.03 (39)-AAAKTAAAFA-NH2 Artificialsequence 5.6 900000.0 1.0 13.2<BR> 824.21 (39)AAAKTAAAF-NH2 Artificialsequence 555.6 25.1 1282.1<BR> 824.26 (39)AAKTAAAFA-NH2 Artificialsequence 714.3 600.0 2083.3<BR> 824.02 (40)-AAAKTAAAFA-NH2 Artificialsequence 52.1 900000.0 11.4 22.7<BR> 717.63 (42)YARFQSQTTLKAKT-NH2 Artificialsequence 21.8 22500.0 7.7 38.5<BR> 787.34 (43)AADFFFFFFFFDA-(NH2) Artificialsequence 50000.0 483.9 500000.0 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 787.43 (43)AAFGIDIFGFKIA-(NH2) Artificialsequence 50000.0 803.6 500000.0<BR> 824.11 (45)AAAKTAAAFA-NH2 Artificialsequence 833.3 23.2 9.1<BR> 824.28 (46)AAAATKAAAA Artificialsequence 17.9 692.3 16666.7<BR> 824.12 (46)AAAKTAAAFA-NH2 Artificialsequence 9.6 0.6 16.7<BR> 824.29 (47)AAAATKAAAA Artificialsequence 263.2 2812.5 33333.3<BR> 824.13 (47)AAAKTAAAFA-NH2 Artificialsequence 83.3 3.8 127.9<BR> 824.14 (48)AAAKTAAAFA-NH2 Artificialsequence 625.0 5.9 20.6<BR> 824.31 (49)AAAATKAAAA Artificialsequence 15.2 36.3 684.9<BR> 862.06 (49)AAAKTAA(64)A-NH2 Artificialsequence 263.2 5.2 505.1<BR> 856.03 (49)AAAKTAAA(35)-NH2 Artificialsequence A 20.4 1.3 33.3<BR> 862.07 (49)AAAKTAAA(64)-NH2 Artificialsequence 9.2 0.9 12.8<BR> 862.01 (49)AAAKTAAAAA-NH2 Artificialsequence 6.2 0.5 5.8<BR> 824.15 (49)AAAKTAAAFA-NH2 Artificialsequence 2.6 0.5 2.0<BR> 824.23 (49)AAKTAAAFA-NH2 Artificialsequence 312.5 5000.0 2173.9<BR> 824.32 (50)AAAATKAAAA Artificialsequence 500.0 5000.0 520.8<BR> 824.16 (5)AAAKTAAAFA-NH2 Artificialsequence 128.2 2.5 1.2<BR> 824.45 (51)AAAATKAAAA Artificialsequence 49.5 175.1 381.7<BR> 824.43 (51)AAAKTAAAFA-NH2 Artificialsequence 13.2 1.7 6.5<BR> 824.44 (52)AAAKTAAAFA-NH2 Artificialsequence 83.3 17.5 43.5<BR> 824.51 (53)AAAATKAAAA Artificialsequence 666.7 2250.0 7142.9<BR> 824.47 (53)AAAKTAAAFA-NH2 Artificialsequence 208.3 5.5 38.5<BR> 824.52 (54)AAAATKAAAA Artificialsequence 454.6 584.4 2000.0<BR> 824.48 (54)AAAKTAAAFA-NH2 Artificialsequence 172.4 5.5 32.7<BR> 824.50 (5@)AAAKTAAAFA-NH2 Artificialsequence 1250.0 149.0 13.3<BR> 601.42 (65)(66)PKFVKQNTLKLAT Artificialsequence 7.4 47.2 400.0<BR> 752.03 (67)AAYAAAAAAKAA-NH2 Artificialsequence A 16.3 102.3 500000.0 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 752.02 (67)FAAAAAAKAA-NH2 Artificialsequence A 7.4 143.8 500000.0<BR> 858.07 (CP)-QSQTTLKAKT-NH2 Artificialsequence 166.7 900000.0 0.8 11.6<BR> 859.03 (CP)YAAFQRQTTLKAAA-NHS Artificialsequence 7.7 900000.0 0.6 1.2<BR> Sandoz374 (NAF)AAAKTAAAFA-NH2 Artificialsequence 20.0 4.5 49.5<BR> 934.15 (X2)KSSQYIKANSKFIGITEAA Artificialsequence A 559.0 3198.0 >50000<BR> AFLPSDFFPSV<BR> 803.11 A(14)AAAKTAAAAA-CONH2 Artificialsequence 1.3 45000.0 1.6 9.4<BR> 838.02 A(14)AAAKTAAAA-NH2 Artificialsequence 61.0 2.7 33.3<BR> 760.73 A(14)AAAKTAAAFA-NH2 Artificialsequence A 50000.0 290.3 25000.0<BR> 838.01 A(14)AAAKTAAA-NH2 Artificialsequence 39.4 2.5 53.8<BR> 838.04 A(14)AAAKTAAA-NH2 Artificialsequence 416.7 25.7 8333.3<BR> 803.10 A(14)AAAKTAA-CONH2 Artificialsequence 50000.0 109.8 500000.0<BR> 838.03 A(14)AAAKTAA-NH2 Artificialsequence 2500.0 5.6 2500.0<BR> 736.21 AA(10)AAAAAAKAAA-NH2 Artificialsequence A 1.9 14.1 25000.0<BR> 736.23 AA(12)AAAAAAKAAA-NH2 Artificialsequence A 4.6 7.5 8333.3<BR> 839.92 AA(14)A(37)ATKAAAA Artificialsequence 625.0 2812.5 1666.7<BR> 828.03 AA(14)AAAA(24)KAAAA-NH2 Artificialsequence A 1.3 10000.0 3.2 24.4<BR> 736.25 AA(14)AAAAAAKAAA-NH2 Artificialsequence A 1.9 4.4 50.5<BR> 828.01 AA(14)AAAAPKAAAA-NH2 Artificialsequence A 0.9 16.7 467.3<BR> 906.30 AA(14)AAAATEKAAA-NH2 Artificialsequence 6.4 6240.4 14.9 20.4<BR> 906.33 AA(14)AAAATFKAAA-NH2 Artificialsequence 1.0 2383.3 1.1 3.3<BR> 906.34 AA(14)AAAATIKAAA-NH2 Artificialsequence 0.5 1505.9 2.3 3.2<BR> 839.17 AA(14)AAAATK(36)AA Artificialsequence 5000.0 750.0 500000.0<BR> 839.31 AA(14)AAAATK(37)AA Artificialsequence 555.6 937.5 4545.5<BR> 839.06 AA(14)AAAATKA(35)A Artificialsequence 1666.7 441.2 500000.0<BR> 839.18 AA(14)AAAATKA(36)A Artificialsequence 217.4 80.9 12500.0<BR> 839.32 AA(14)AAAATKA(37)A Artificialsequence 113.6 30.0 1612.9 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 839.20 AA(14)AAAATKAA(35)-NH2 Artificialsequence 1.8 1.7 41.7<BR> 839.24 AA(14)AAAATKAA(36)-NH2 Artificialsequence 0.8 1.9 45.5<BR> 839.35 AA(14)AAAATKAA(37)-NH2 Artificialsequence 0.7 5.6 25.0<BR> 839.25 AA(14)AAAATKAAAA Artificialsequence 1.1 3.2 29.4<BR> 828.11 AA(14)AAAATKAAAA-NH2 Artificialsequence A 1.5 45000.0 2.8 11.4<BR> 906.29 AA(14)AAAATKKAAA-NH2 Artificialsequence 3.2 >16431.68 4.7 43.1<BR> 906.35 AA(14)AAAATLEAAA-NH2 Artificialsequence 1.7 2675.1 4.0 5.0<BR> 906.38 AA(14)AAAATLFAAA-NH2 Artificialsequence 2.8 >16431.68 3.0 6.8<BR> 760.57 AA(14)AAAATLKAAA-NH2 Artificialsequence A 1.4 1165.6 2.1 3.5<BR> 906.47 AA(14)AAAATLKAEA-NH2 Artificialsequence 3.3 7862.2 2.8 8.2<BR> 906.50 AA(14)AAAATLKAFA-NH2 Artificialsequence 0.5 117.4 1.9 3.3<BR> 906.48 AA(14)AAAATLKAQA-NH2 Artificialsequence 0.5 2433.3 2.3 5.5<BR> 906.49 AA(14)AAAATLKAVA-NH2 Artificialsequence 0.6 503.5 3.2 3.5<BR> 906.41 AA(14)AAAATLKEAA-NH2 Artificialsequence 240.6 4129.5 9.2 229.7<BR> 906.44 AA(14)AAAATLKFAA-NH2 Artificialsequence 2.2 59.6 2.9 37.1<BR> 906.45 AA(14)AAAATLKIAA-NH2 Artificialsequence 1.1 921.1 2.2 21.1<BR> 906.40 AA(14)AAAATLKKAA-NH2 Artificialsequence 79.1 386.4 11.3 29.9<BR> 906.42 AA(14)AAAATLKQAA-NH2 Artificialsequence 11.8 1214.9 5.2 7.3<BR> 906.43 AA(14)AAAATLKVAA-NH2 Artificialsequence 0.5 285.8 1.8 15.7<BR> 906.36 AA(14)AAAATLQAAA-NH2 Artificialsequence 2.6 1019.3 2.9 4.9<BR> 906.39 AA(14)AAAATLRAAA-NH2 Artificialsequence 1.1 790.2 3.9 3.1<BR> 906.31 AA(14)AAAATQKAAA-NH2 Artificialsequence 0.T6 3602.9 4.3 12.4<BR> 906.32 AA(14)AAAATVKAAA-NH2 Artificialsequence 0.3 3834.1 3.5 3.4<BR> 906.24 AA(14)AAAETLKAAA-NH2 Artificialsequence 1.5 1004.8 4.0 4.5<BR> 906.27 AA(14)AAAFTLKAAA-NH2 Artificialsequence 0.5 1252.7 2.4 1.3<BR> 856.02 AA(14)AAAKTAAA(35)-NH2 Artificialsequence A 1.6 2.1 7.8 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 760.50 AA(14)AAAKTAAAAA-NH2 Artificialsequence A 3.1 2345.8 2.8 7.0<BR> 906.23 AA(14)AAAKTLKAAA-NH2 Artificialsequence 0.8 672.5 2.0 4.2<BR> 906.25 AA(14)AAAQTLKAAA-NH2 Artificialsequence 1.6 581.1 2.3 4.5<BR> 906.28 AA(14)AAATTLKAAA-NH2 Artificialsequence 1.8 1058.9 4.5 7.6<BR> 906.26 AA(14)AAAVTLKAAA-NH2 Artificialsequence 1.1 680.7 3.0 2.9<BR> 906.19 AA(14)AAEATLKAAA-NH2 Artificialsequence 3.6 381.9 4.6 7.2<BR> 906.22 AA(14)AAFATLKAAA-NH2 Artificialsequence 1.7 23237.9 2.5 3.0<BR> 906.18 AA(14)AAKATLKAAA-NH2 Artificialsequence 7.0 >900 3.0 29.9<BR> 906.20 AA(14)AAQATLKAAA-NH2 Artificialsequence 1.0 17170.7 2.5 4.8<BR> 906.21 AA(14)AAVATLKAAA-NH2 Artificialsequence 0.7 4305.3 3.0 4.1<BR> 906.14 AA(14)AEAATLKAAA-NH2 Artificialsequence 6.5 3170.1 4.2 15.1<BR> 906.17 AA(14)AFAATLKAAA-NH2 Artificialsequence 1.6 461.8 5.0 5.2<BR> 906.13 AA(14)AKAATLKAAA-NH2 Artificialsequence 2.6 930.8 6.1 5.0<BR> 906.15 AA(14)AQAATLKAAA-NH2 Artificialsequence 2.7 1642.4 4.1 8.5<BR> 906.16 AA(14)AVAATLKAAA-NH2 Artificialsequence 0.7 219.9 5.3 4.3<BR> 906.07 AA(14)EAAATLKAAA-NH2 Artificialsequence 3.0 1373.8 3.3 3.9<BR> 906.10 AA(14)FAAATLKAAA-NH2 Artificialsequence 1.3 783.1 5.0 2.7<BR> 906.11 AA(14)IAAATLKAAA-NH2 Artificialsequence 0.4 70.1 2.9 3.4<BR> 906.06 AA(14)KAAATLKAAA-NH2 Artificialsequence 0.8 597.6 1.7 6.4<BR> 906.12 AA(14)LAAATLKAAA-NH2 Artificialsequence 0.2 266.1 3.7 3.4<BR> 906.08 AA(14)QAAATLKAAA-NH2 Artificialsequence 1.7 653.1 6.8 4.7<BR> 906.09 AA(14)VAAATLKAAA-NH2 Artificialsequence 0.6 107.5 2.7 5.6<BR> 906.56 AA(14)VVAATLKAFA Artificialsequence 0.5 27.2 1.5 4.5<BR> 828.13 AA(15)AAAATKAAAA-NH2 Artificialsequence A 1.5 6.2 152.0<BR> 819.01 AA(15)AAKTAAAFA-NH2 Artificialsequence A 0.4 5.8 3.1<BR> 819.02 AA(15)AAKTGGGFG-NH2 Artificialsequence A 33 2.0 114.4 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 819.04 AA(15)GGKGGGGFG-NH2 Artificialsequence A 18.4 576.9 50000.0<BR> 819.03 AA(15)GGKTAAAFA-NH2 Artificialsequence A 0.4 1.5 50.0<BR> 819.05 AA(15)GGKTGGGFG-NH2 Artificialsequence A 94.3 16.7 5555.6<BR> 736.28 AA(17)AAAAAAKAAA-NH2 Artificialsequence A 23.8 15000.0 500000.0<BR> 736.33 AA(2)AAAAAAKAAA-CONH2 Artificialsequence A 87.7 450000.0 500000.0<BR> 773.08 AA(31)AAAAAAKAAA-NH2 Artificialsequence 6.4 37.5 50000.0<BR> 736.17 AA(6)AAAAAAKAAA-NH2 Artificialsequence A 5.0 409.1 442.5<BR> 736.18 AA(7)AAAAAAKAAA-NH2 Artificialsequence A 1.3 11.3 925.9<BR> 736.19 AA(8)AAAAAAKAAA-NH2 Artificialsequence A 2.4 18.8 649.4<BR> 736.20 AA(9)AAAAAAKAAA-NH2 Artificialsequence A 3.1 23.7 50000.0<BR> 736.34 AA(TIC)AAAAAAKAAA- Artificialsequence A 6.9 3214.3 10000.0<BR> CONH2<BR> 871.14 AAAAKAATLKAAA-NH2 Artificialsequence 5000.0 288.5 463.0<BR> 760.27 AAAFAAAKTAAAFA-NH2 Artificialsequence A 1.4 398.9 1.5 17.9<BR> 730.04 AAAKAAAAAA(10)AA- Artificialsequence A 172.4 1250.0 5000.0<BR> CONH2<BR> 730.02 AAAKAAAAAAFAA-CONH2 Artificialsequence A 714.3 937.5 500000.0<BR> 702.02 AAAKAAAAAAYAA Artificialsequence A 833.3 900000.0 1285.7 50000.0<BR> 702.06 AAAKAAAAAAYAA-COHN2 Artificialsequence A 74.6 900000.0 204.6 500000.0<BR> 789.05 AAAKAAAAAFAAA Artificialsequence 833.3 633.8 5555.6<BR> 730.07 AAAKATAAAA(23)AA- Artificialsequence A 125.0 166.7 25000.0<BR> CONH2<BR> 787.06 AADFGIFIDFIIA-(NH2) Artificialsequence 1000.0 172.4 500000.0<BR> 736.10 AAEAAAAAAKAAA-NH2 Artificialsequence A 1000.0 22500.0 500000.0<BR> 736.07 AAFAAAAAAKAAA-NH2 Artificialsequence A 1.9 15.5 961.5<BR> 761.03 AAFAAAAAARLFA-NH2 Artificialsequence A 1.1 155.2 3846.2<BR> 828.07 AAFAAAAB(24)KAAAA-NH2 Artificialsequence A 13.6 7.6 273.2<BR> 760.71 AAFAAAATAKAAA Artificialsequence A 1.3 45000.0 2.3 11.4 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 760.41 AAFAAAATAKAAA-NH2 Artificialsequence A 1.3 90000.0 1.2 8.1<BR> 760.72 AAFAAAATLKAAA Artificialsequence A 1.9 4803.8 1.4 2.4<BR> 760.43 AAFAAAATLKAAA-NH2 Artificialsequence A 1.5 2686.9 1.4 2.9<BR> 871.12 AAFAAAATLKAKA-NH2 Artificialsequence 2.9 4.0 12.8<BR> 871.11 AAFAAAATLKKAA-NH2 Artificialsequence 500.0 22.5 135.1<BR> 760.37 AAFAAAKTAAAAA-NH2 Artificialsequence A 2.3 15000.0 1.7 9.1<BR> 803.08 AAFAAAKTAAAFA-CONH2 Artificialsequence 1.0 1.7 8.9<BR> 760.15 AAFAAAKTAAAFA-NH2 Artificialsequence A 1.3 1062.6 1.1 6.2<BR> 760.33 AAFAAAKTAAAFA-NH2 Artificialsequence A 2.2 1066.0 1.5 5.8<BR> 760.17 AAFAAAKTAAAFE-NH2 Artificialsequence A 1.2 2.1 7.3<BR> 803.13 AAFAAAKTAAAKA-NH2 Artificialsequence 2.8 6.5 8.2<BR> 760.47 AAFAAAKTLAAAA-NH2 Artificialsequence A 1.9 7252.4 0.9 5.0<BR> 871.10 AAFAAAKTLKAAA-NH2 Artificialsequence 2.0 4.3 7.1<BR> 871.09 AAFAAKATLKAAA-NH2 Artificialsequence 43.1 1.1 73.1<BR> 760.70 AAFAANKNAAFAA-CONH2 Artificialsequence 108.7 62.9 25000.0<BR> 760.68 AAFAAQKQAAFAA-CONH2 Artificialsequence 500.0 6428.6 25000.0<BR> 760.69 AAFAATKTAAFAA-CONH2 Artificialsequence 185.2 29.4 8333.3<BR> 760.64 AAFAKAATAKAAA-CONH2 Artificialsequence A 2.4 45000.0 2.7 14.3<BR> 760.63 AAFAKAATLKAAA-CONH2 Artificialsequence A 3.3 8017.8 4.0 9.1<BR> 871.06 AAFAKAATLKAKA-NH2 Artificialsequence 12.8 3.2 19.2<BR> 871.05 AAFAKAATLKKAA-NH2 Artificialsequence 500.0 20.5 150.2<BR> 871.04 AAFAKAKTLKAAA-NH2 Artificialsequence 8.2 3.6 33.3<BR> 871.03 AAFAKKATLKAAA-NH2 Artificialsequence 312.5 16.7 191.6<BR> 787.05 AAFFGIFKIGKFA-(NH2) Artificialsequence 833.3 1097.6 50000.0<BR> 787.11 AAFGIKIFGFKIA-(NH2) Artificialsequence 50000.0 671.6 50000.0<BR> 871.02 AAFKKAATLKAAA-NH2 Artificialsequence 5.0 2.5 7.5 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 770.04 AAFPPPPTLKAAA-NH2 Artificialsequence 714.3 15000.0<BR> 793.03 AAFVSQTTLKAAA Artificialsequence A 2.3 2.0 5.5<BR> 736.06 AAHAAAAAKAAA-NH2 Artificialsequence A 17. 45000.0 50000.0<BR> 787.03 AAIGFFFFKKGIA-(NH2) Artificialsequence 50000.0 252.8 500000.0<BR> 787.07 AAIGGIFIFKKDA-(NH2) Artificialsequence 50000.0 957.5 500000.0<BR> 736.08 AALAAAAAAKAAA-NH2 Artificialsequence A 1.9 69.2 151.5<BR> 760.09 AALKATAAAAYAA-NH2 Artificialsequence A 500.0 1406.3 500000.0<BR> 736.09 AAWAAAAAAKAAA-NH2 Artificialsequence A 1.7 23.7 8333.3<BR> 758.01 AAYA(4)A(4)AAKAAA Artificialsequence A 38.5 4500.0 50000.0<BR> 758.02 AAYAA(4)A(4)AKAAA Artificialsequence A 5.9 535.7 500000.0<BR> 773.06 AAYAAAA(24)AKAAA-NH2 Artificialsequence 10.2 3.0 128.2<BR> 773.02 AAYAAAA(26)AKAAA-NH2 Artificialsequence 161.3 15.0 500000.0<BR> 773.03 AAYAAAA(27)AKAAA-NH2 Artificialsequence 128.2 321.4 500000.0<BR> 773.04 AAYAAAA(28)AKAAA-NH2 Artificialsequence 5.8 11.8 12500.0<BR> 773.05 AAYAAAA(29)AKAAA-NH2 Artificialsequence 12.8 6.9 25000.0<BR> 773.07 AAYAAAA(30)AKAAA-NH2 Artificialsequence 142.9 2142.9 500000.0<BR> 702.03 AAYAAAAAAKAAA-CONH2 Artificialsequence A 2.6 900000.0 6.8 500000.0<BR> 773.09 AAYAAAAPAKAAA-CONH2 Artificialsequence 1.0 33.8 25000.0<BR> 736.04 AAYAAAATAAAKA-NH2 Artificialsequence A 2.5 2.3 1724.1<BR> 736.03 AAYAAAATAKAAA-NH2 Artificialsequence A 3.9 3.1 2777.8<BR> 736.05 AAYAAAAYAAAKA-NH2 Artificialsequence A 166.7 28.1 50000.0<BR> 736.14 AAYAAJJAAKAAA-NH2 Artificialsequence A 1000.0 3214.3 50000.0<BR> 871.13 AAYAKAATLKAAA-NH2 Artificialsequence 5.5 4.0 213.7<BR> 760.58 AC-AA(14)AAAATLKAAA- Artificialsequence A 2.0 727.8 1.7 2.8<BR> NH2<BR> 760.51 AC-AA(14)AAAKTAAAAA- Artificialsequence A 7.6 4201.7 17.3 29.4<BR> NH2 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 730.13 AC-AAAKAAAAAA(23)AA- Artificialsequence A 1000.0 548.8 1136.4<BR> CONH2<BR> 702.08 AC-AAAKAAAAAAYAA Artificialsequence A 625.0 1956.5<BR> 702.12 AC-AAAKAAAAAAYAA- Artificialsequence A 1000.0 692.3 1666.7<BR> CONH2<BR> 760.42 AC-AAFAAAATAKAAA-NH2 Artificialsequence A 2.5 25980.8 3.5 2.1<BR> 760.44 AC-AAFAAAATLKAAA-NH2 Artificialsequence A 3.5 2358.6 3.3 18.5<BR> 760.38 AC-AAFAAAKTAAAAA-NH2 Artificialsequence A 3.9 1.3 19.9<BR> 760.34 AC-AAFAAAKTAAAFA-NH2 Artificialsequence A 1.7 1530.9 2.5 13.5<BR> 760.48 AC-AAFAAAKTLAAAA-NH2 Artificialsequence A 17.0 16.4 111.1<BR> 760.67 AC-AAFAANKNAAFAA- Artificialsequence 500.0 44.6 25000.0<BR> CONH2<BR> 760.65 AC-AAFAAQKQAAFAA- Artificialsequence 2500.0 5000.0 25000.0<BR> CONH2<BR> 760.66 AC-AAFAATKTAAFAA- Artificialsequence 454.6 38.5 25000.0<BR> CONH2<BR> 806.06 AC-YAA(10)LFLSAARKRA- Artificialsequence A 5.7 300.0 50000.0<BR> NH2<BR> 760.60 AC-YAA(14)AAAATLKAAA- Artificialsequence A 3.1 2253.5 6.4 12.5<BR> NH2<BR> 760.53 AC-YAA(14)AAAKTAAAAA- Artificialsequence A 1.2 18000.0 1.2 20.8<BR> NH2<BR> 760.55 AC-YAAFAAAATAKAAA-NH2 Artificialsequence A 28.9 90000.0 9.6 125.0<BR> 760.46 AC-YAAFAAAATLKAAA-NH2 Artificialsequence A 4.0 12857.1 2.0 9.5<BR> 760.40 AC-YAAFAAAKTAAAAA-NH2 Artificialsequence A 14.3 90000.0 16.7 30.3<BR> 760.36 AC-YAAFAAAKTAAAFA-NH2 Artificialsequence A 6.9 10000.0 6.4 17.9<BR> 760.62 AC-YAAFAAAKTLAAAA-NH2 Artificialsequence A 7.5 18000.0 1.8 4.4<BR> 805.03 AC-YARFLALTTLRARA- Artificialsequence A 1.7 2.3 10.0<BR> CONH2<BR> 906.02 AE(14)AAAATLKAAA-NH2 Artificialsequence 3.7 512.2 4.2 12.0<BR> 760.13 AEFAAAKTLAAFA-NH2 Artificialsequence A 1.7 2.4 5.1 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 906.05 AF(14)AAAATLKAAA-NH2 Artificialsequence 0.9 554.9 1.7 1.8<BR> 851.09 AFAAAKTAA(71) Artificialsequence 1666.7 5.6 657.9<BR> 803.05 AFAAAKTAAAA-CONH2 Artificialsequence 151.5 6.5 2777.8<BR> 803.04 AFAAAKTAAA-NH2 Artificialsequence 5000.0 200.9 50000.0<BR> 760.05 AFLRAAAAAAFAAY-NH2 Artificialsequence A 625.0 1153.9 500000.0<BR> 906.01 AK(14)AAAATLKAAA-NH2 Artificialsequence 1.7 786.0 2.0 5.0<BR> 965.16 AK(14)VAAATLKAAA-NH2 Artificialsequence 4.2 558.2 7.2 71.0<BR> 965.15 AK(14)VAAHTLKAAA-NH2 Artificialsequence 2.1 514.5 3.2 17.4<BR> 965.14 AK(14)VAAKTLKAAA-NH2 Artificialsequence 5.9 296.1 8.5 58.2<BR> 965.08 AK(14)VAANTLKAAA-NH2 Artificialsequence 2.5 105.4 3.0 25.4<BR> 965.08 AK(14)VAANTLKAAA-NH2 Artificialsequence 0.7 484.5 1.3 4.8<BR> 965.10 AK(14)VAAWTLKAAA-NH2 Artificialsequence 2.3 55.0 3.7 14.3 58.8<BR> 965.17 AK(14)VAAWTLKAAA-NH2 Artificialsequence 2.0 678.4 3.8 34.0<BR> 965.09 AK(14)VAAYTLKAAA-NH2 Artificialsequence 1.7 69.4 2.2 12.8<BR> 965.09 AK(14)VAAYTLKAAA-NH2 Artificialsequence 0.6 1129.3 1.1 7.1<BR> 965.07 AK(14)VKAHTLKAAA-NH2 Artificialsequence 1.6 989.1 1.8 10.1<BR> 965.07 AK(14)VKAHTLKAAA-NH2 Artificialsequence 1.3 1458.0 1.4 6.7<BR> 965.01 AK(14)VKANTLKAAA-NH2 Artificialsequence 1.5 83.6 3.1 4.0<BR> 965.01 AK(14)VKANTLKAAA-NH2 Artificialsequence 1.3 925.3 3.5 5.9<BR> 965.02 AK(14)VKAWTLKAAA-NH2 Artificialsequence 0.9 223.0 1.6 4.8<BR> 965.02 AK(14)VKAWTLKAAA-NH2 Artificialsequence 0.7 2574.6 0.8 1.5<BR> 965.03 AK(14)VWANTLKAAA-NH2 Artificialsequence 1.7 107.4 2.2 5.8<BR> 965.03 AK(14)VWANTLKAAA-NH2 Artificialsequence 0.4 275.6 1.0 3.5<BR> 965.04 AK(14)VWAYTLKAAA-NH2 Artificialsequence 0.5 27.8 0.6 2.8<BR> 965.04 AK(14)VWAYTLKAAA-NH2 Artificialsequence 0.3 724.1 1.1 3.6<BR> 965.05 AK(14)VYAWTLKAAA-NH2 Artificialsequence 0.5 58.8 0.3 4.4 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 965.05 AK(14)VYAWTLKAAA-NH2 Artificialsequence 0.8 3368.2 0.8 6.1<BR> 537.00 AKAAKAAKAAKAAKAA Artificialsequence 1250.0 900000.0 22500.0 500000.0<BR> 871.07 AKFAAAATLKAAA-NH2 Artificialsequence 2.9 1.3 10.9<BR> 803.14 AKFAAAKTAAAKA-NH2 Artificialsequence 4.3 4.2 33.3<BR> Sandoz339 AKFAAALTLAAPA-NH2 Artificialsequence 19.2 7.1 6.3<BR> Sandoz338 AKFAAALTLAQAA-NH2 Artificialsequence 238.1 32.1 35.7<BR> 1303.02 AKFIAADTLKAAA Artificialsequence A 991.8<BR> 1303.01 AKFIAAWTLKAAA Artificialsequence A 495.9 5.2<BR> 1024.03 AKFVAAWTLKAAA-NH2 Artificialsequence 1.2 599.2 1.8 8.2 11.5<BR> 1024.06 AKFVAAWTLKAAA-NH2 Artificialsequence 3.9 805.7 5.2 49.1<BR> 1024.04 AKFVAAYTLKAAA-NH2 Artificialsequence 0.9 860.1 4.8 7.0<BR> 1303.04 AKFVADWTLKAAA Artificialsequence A 78.6 38.5 28.8<BR> 1303.03 AKFVIAWTLKAAA Artificialsequence A 1.8 132.9 11.2<BR> 1024.01 AKFVWANTLKAAA-NH2 Artificialsequence 4.0 757.7 1.6 8.1<BR> 1024.02 AKFVYANTLKAAA-NH2 Artificialsequence 3.3 888.1 6.1 12.4<BR> 1303.08 AKIVAAWTLKAAA Artificialsequence A 7.1 409.6 20.3<BR> 1303.06 AKIVADWTLKAAA Artificialsequence A 2506.3 80.0 146.3<BR> 1303.09 AKLVAAWTLKAAA Artificialsequence A 943.5<BR> 1303.10 AKMVAAWTLKAAA Artificialsequence A 17.8 819.1 19.1<BR> 1303.07 AKMVADWTLKAAA Artificialsequence A 3657.6 98.6 143.0<BR> 906.03 AQ(14)AAAATLKAAA-NH2 Artificialsequence 1.7 296.1 2.4 2.1<BR> 965.06 AR(14)VRANTLKAAA-NH2 Artificialsequence 0.8 1715.6 1.4 4.8<BR> 820.07 AR(15A)RQTTOLKAAA-NH2 Artificialsequence A 1.3 3.3 5.1<BR> 788.06 ARFQRQTTLKAAA Artificialsequence A 3.9 6.1 20.0<BR> 781.08 ARFQRQTTLKAAA-NH2 Artificialsequence A 2.4 2.0 7.8<BR> 640.05 ARRLKARRLKAIY Artificialsequence 50.0 900000.0 22500.0 12500.0 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 906.04 AV(14)AAAATLKAAA-NH2 Artificialsequence 0.4 334.5 3.2 3.8<BR> 906.51 AV(14)AVAATLKAFA Artificialsequence 0.5 15.1 1.1 2.5<BR> 906.55 AV(14)VFAATLKAFA Artificialsequence 0.7 196.5 1.8 7.6<BR> 906.52 AV(14)VVAATLKAAA Artificialsequence 0.5 88.5 1.8 3.8<BR> 906.53 AV(14)VVAATLKAFA Artificialsequence 0.4 46.4 1.1 2.2<BR> 640.01 AWRNRAKAWRNRAKAWRN Artificialsequence 1666.7 900000.0 15000.0 500000.0<BR> RAK<BR> 640.03 AWRNRAKAWRNRAKGTD Artificialsequence 1666.7 900000.0 15000.0 500000.0<BR> 758.03 AYAAA(4)A(4)KAAA Artificialsequence A 92.6 264.7 500000.0<BR> S5004 AYZAYAYTLKAAA Artificialsequence 18.8 25.0 32.1<BR> S5003 BOC-AYZAYAYTLKAAA Artificialsequence 72.5 10.2 73.5<BR> S1395 BOCXFAXAXTLKAAA Artificialsequence 20.8 12.5 62.5<BR> 631.02 DDYVKQYTKQYTKQNTLKK Artificialsequence 50000.0 900.0 500000.0<BR> 631.03 DDYVKQYTKQYTKQNTLKK Artificialsequence 238.1 >30000 11250.0 500000.0<BR> 760.08 EFAAATKAAAFAAY-NH2 Artificialsequence A 833.3 2142.9 500000.0<BR> 819.06 GG(15)GGKGGGGFG-NH2 Artificialsequence A 58.8 405.4 3571.4<BR> 736.15 JJYJJAAAAKAAA-NH2 Artificialsequence A 50000.0 22500.0 500000.0<BR> 640.06 KNRAKNRAKNRAKNRAK Artificialsequence 1666.7 900000.0 15000.0 500000.0<BR> 640.07 KRLKRLKRLKRLKRL Artificialsequence 1666.7 314.2 22500.0 6250.0<BR> 965.19 KSSAK(14)VAAWTLKAAA- Artificialsequence 11.3 4.1 41.7 34.8<BR> NH2<BR> 784.08 PKYDKQGGLKIAT Artificialsequence A 151.5 22500.0 500000.0<BR> 784.05 PKYFKQFRLKIAT Artificialsequence A 1000.0 15000.0 25000.0<BR> 784.13 PKYFKQIGLKRAT Artificialsequence A 200.0 633.8 25000.0<BR> 784.04 PKYGKQRFLKIAT Artificialsequence A 5000.0 900.0 10000.0<BR> 784.15 PKYIKQDGLKGAT Artificialsequence A 31.3 11.8 16666.7<BR> 784.09 PKYIKQFFLKRAT Artificialsequence A 50000.0 22500.0 746.3 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 784.01 PKYIKQILLKIAT Artificialsequence A 1250.0 500.0 416.7<BR> 784.10 PKYRKQFILKGAT Artificialsequence A 104.2 23.7 500000.0<BR> 736.01 PNYAAAAAAKAAA-NH2 Artificialsequence A 1.7 25.0 500000.0<BR> 736.31 PNYAAAAAAKAA-CONH2 Artificialsequence A 3.1 30.0 50000.0<BR> 781.07 RFQRQTTLKAAA-NH2 Artificialsequence A 10.9 3.5 9.1<BR> 716.02 TAIKKLTTQRQFRAY Artificialsequence A 1000.0 >45000 2500.0 25000.0<BR> 717.11 TKQKLTTQSQFRAY-NH2 Artificialsequence A 1666.7 900000.0 9000.0 500000.0<BR> S5006 XFAXAXTLKAAA Artificialsequence 50.0 11.8 166.7<BR> Sandoz364 YA(AMK)FAAAAKTAAAFA- Artificialsequence 96.2 6.1 200.0<BR> NH2<BR> Sandoz366 YA(K1)FQ(K1)QTTL(K1)AAA- Artificialsequence 40.3 7.1 35.7<BR> OH<BR> 806.05 YAA(10)LFLSAARKRA-NH2 Artificialsequence A 8.1 36742.4 250.0 500000.0<BR> 828.04 YAA(14)AAAA(24)KAAAA- Artificialsequence A 3.7 900000.0 3.3 24.4<BR> NH2<BR> 828.02 YAA(14)AAAAPKAAAA-NH2 Artificialsequence A 0.8 20.5 675.7<BR> 828.12 YAA(14)AAAATKAAAA-NH2 Artificialsequence A 1.1 45000.0 2.9 6.9<BR> 760.59 YAA(14)AAAATLKAAA-NH2 Artificialsequence A 1.4 353.1 2.0 3.0<BR> 760.52 YAA(14)AAAKTAAAAA-NH2 Artificialsequence A 0.4 1000.8 0.9 1.5<BR> 906.54 YAA(14)AVAATLKAAA Artificialsequence 3.2 3232.9 2.7 7.5<BR> 828.14 YAA(15)AAAATKAAAA-NH2 Artificialsequence A 1.2 3.0 71.0<BR> Sandoz363 YAA(AMF)AAAKTAAAFA- Artificialsequence 172.4 10.7 55.0<BR> NH2<BR> 760.26 YAAAKAAAAAAFAA-NH2 Artificialsequence A 555.6 5625.0 500000.0<BR> Sandoz368 YAAFAAA(DHPS)TAAAFA- Artificialsequence 20.0 0.8 33.3<BR> NH2<BR> Sandoz367 YAAFAAA(K1)TAAAFA-NH2 Artificialsequence 7.0 0.9 10.2<BR> 828.08 YAAFAAAA(24)KAAAA-NH2 Artificialsequence A 12.3 6.3 144.5<BR> 760.25 YAAFAAAAAAKAAA-NH2 Artificialsequence A 4.6 15.5 1388.9 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 761.04 YAAFAAAAAARLFA-NH2 Artificialsequence A 18.5 375.0 16666.7<BR> 761.02 YAAFAAAAAQRLFA-NH2 Artificialsequence A 1.1 52.9 5555.6<BR> 760.54 YAAFAAAATAKAAA-NH2 Artificialsequence A 1.9 15212.8 1.3 7.5<BR> 760.45 YAAFAAAATLKAAA-NH2 Artificialsequence A 0.6 2070.2 1.2 4.9<BR> 760.39 YAAFAAAKTAAAAA-NH2 Artificialsequence A 1.8 8181.8 1.3 3.9<BR> 760.39 YAAFAAAKTAAAAA-NH2 Artificialsequence A 6.5 30000.0 10.2 73.5<BR> 760.39 YAAFAAAKTAAAAA-NH2 Artificialsequence A 1.2 4285.7 1.1 6.4<BR> 760.16 YAAFAAAKTAAAFA-NH2 Artificialsequence A 0.7 0.7 5.0<BR> 760.35 YAAFAAAKTAAAFA-NH2 Artificialsequence A 13.5 2214.3 15.5 53.8<BR> Sandoz362 YAAFAAAKTAAAFA-NH2 Artificialsequence 1.9 4.6 7.0<BR> 760.18 YAAFAAAKTAAAFE-NH2 Artificialsequence A 1.0 1.3 7.7<BR> 760.61 YAAFAAAKTLAAAA-NH2 Artificialsequence A 1.5 4824.5 2.0 5.8<BR> 788.05 YAAFQRQTTLKAAA Artificialsequence A 2.6 1.6 17.9<BR> 788.04 YAAFQSQTTLKAAA Artificialsequence A 1.9 1.9 6.9<BR> 793.02 YAAFVRQTTLKAAA Artificialsequence A 2.6 2.4 7.6<BR> 793.01 YAAFVSQTTLKAAA Artificialsequence A 1.9 1.3 5.1<BR> 760.14 YAEFAAAKTLAAFA-NH2 Artificialsequence A 2.3 2.7 7.9<BR> 781.16 YAK(14)QRQTTLKAAA- Artificialsequence A 5.0 4.7 16.1<BR> CONH2<BR> Sandoz370 YAKFAAAKTAAAA(TR) Artificialsequence 6.4 6.6 19.2<BR> 717.08 YAKFKSTTKKRIKS-NH2 Artificialsequence A 500000.0 900000.0 450000.0 500000.0<BR> 1341.01 YAKFVAAWTLKAAA Artificialsequence A<BR> 717.35 YAR(10)QSQTTLKAKT-NH2 Artificialsequence A 3.9 5.8 80.7<BR> 781.20 YAR(14)QKQTTLKAAA Artificialsequence A 8.9 900000.0 4.0 10.0<BR> 788.01 YAR(14)QRQTTLKAAA Artificialsequence A 31.3 63.4 1041.7<BR> 781.15 YAR(14)QRQTTLKAAA- Artificialsequence A 3.9 2.5 15.6<BR> CONH2 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence Source Ag Analog DRB1 DRB1 DRB1 DRB1 DRB1<BR> *0101 *0301 *0401 *0404 *0405<BR> 782.03 YAR(15)ASQTTLKAKT-NH2 Artificialsequence 1.5 2.6 5.2<BR> 782.07 YAR(15)ASQTTLKAKT-NH2 Artificialsequence 41.7 1.7 29.4<BR> 820.02 YAR(15A)RQTTLKAAA-NH2 Artificialsequence A 1.6 2.0 3.8<BR> 820.11 YAR(15A)RQTTLKAAA-NH2 Artificialsequence A 4.4 3.8 4.3<BR> 820.01 YAR(15A)SQTTLKAKT-NH2 Artificialsequence A 2.4 4.4 5.2<BR> 820.10 YAR(15A)SQTTLKAKT-NH2 Artificialsequence A 10.7 5.1 25.6<BR> 782.04 YAR(16)ASQTTLKAKT-NH2 Artificialsequence 192.3 900000.0 3.5 92.6<BR> 717.34 YAR(9)QSQTTLKAKT-NH2 Artificialsequence A 27.8 4.4 41.7<BR> 717.43 YAREQSQTTLKAKT-NH2 Artificialsequence A 50000.0 750.0 500000.0<BR> 782.06 YARFGGQTTLKAKT Artificialsequence 357.1 6.1 56.2<BR> 805.01 YARFLALTTLRARA-CONH2 Artificialsequence A 1.0 1.6 3.4<BR> 805.02 YARFLALTTLRARA-CONH2 Artificialsequence A 2.0 5.8 12.5<BR> 717.36 YARFQSQT(24)LKAKT-NH2 Artificialsequence A 4.6 5.8 12.8<BR> 717.18 YARFQSQTELKAKT-NH2 Artificialsequence A 714.3 264.7 16666.7<BR> 782.01 YARFQSQTTL(32)AKT-NH2 Artificialsequence 3.6 900000.0 1.7 15.2<BR> 717.24 YARFQSQTTLKEKT-NH2 Artificialsequence A 50000.0 30.0 2083.3<BR> 715.01 YARRLKAIFARRLKA Artificialsequence 38.5 11250.0<BR> 788.03 YASFQSQTTLKAAA Artificialsequence A 3.1 3.1 9.3<BR> 788.02 YASFVSQTTLKAAA Artificialsequence A 1.7 2.9 12.8<BR> 785.01 YKKSIQFHWKNSNQIKILGNQ Artificialsequence 5.7 11078.2 5.6 23.8<BR> GSFLTKGPS<BR> 717.09 YPKFVKQNTLKAAT-NH2 Artificialsequence A 555.6 900000.0 5000.0 16666.7<BR> 806.01 YQFIKANSKFKGKFK-NH2 Artificialsequence A 1666.7 535.7 500000.0<BR> 768.01 YSSFSSSSSSKSSS Artificialsequence A 1000.0 7.9<BR> 768.02 YSSFSSSSSSKSSS-NH2 Artificialsequence A 714.3 900000.0 5.8 192.3<BR> 768.03 YSSFSSSSSSSSSS Artificialsequence A 50000.0 6.9<BR> 768.04 YSSFSSSSSSSSSS-NH2 Artificialsequence A 5000.0 5.8 416.7 TABLE 27a<BR> HLA-DR binding affinity (IC50 nM)<BR> DRB1 DRB1 DRB1 DRB1 DRB1<BR> Peptide Sequence Source AG Analog<BR> *0101 *0301 *0401 *0404 *0405<BR> 564.01 YVKADYVKADYVKADYVK Artificialsequence 1666.7 957.5 500000.0<BR> 718.01 YVKQNTLAFVKQNTLA Artificialsequence A 172.4 239.4 50000.0<BR> 631.01 YVKQYTKQYTKQNTLK Artificialsequence 50000.0 4500.0 500000.0<BR> S1396 ZAAFAAAATLKAAA Artificialsequence 25.0 11.5 54.4<BR> S1399 ZAAFAAAXTAYAYA Artificialsequence 33.3 7.8 122.0<BR> S1400 ZAAFAXAATAYAYA Artificialsequence 18.5 9.0 75.8<BR> S5005 ZAAFAXAATLKAAA Artificialsequence 16.1 7.3 24.6 TABLE 27b<BR> HLA-DR binding affinity (Ic50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> PTS-04 AAWSERAGEAMVLV >25000 10000.0 91000.0 >10000 256.6<BR> 582.02 DNVLDHLTGRSC >25000 10000.0 91000.0 11111.1 >25000<BR> PTS-10 NH2-DNVLAHLTGRSCQ- 91000.0<BR> COOH<BR> PTS-17 NH2-DNVLDHLTGRSAQ- 91000.0<BR> COOH<BR> PTS-18 NH2-DNVLDHLTGRSCA- 91000.0<BR> COOH<BR> 541.19 HYTVDKSKPKVYQWRD 250000.0 1250.0 700.0 2985.4<BR> 541.15 INTKCYKLEHPVTGCG 250000.0 1250.0 1820.0 >7692.31<BR> 541.04 NELGRFKHTDACCRTH 1550.4 266.7 28.4 >9090.91<BR> 541.11 NNDFYDNSADTISSYF 5000.0 1250.0 1820.0 1807.8<BR> 541.20 SKPKVYQWFDLRKY 1666.7 222.2 1011.1 2565.0<BR> 541.13 SSYFVGKMFNLINTK 250000.0 339.0 606.7 >7692.31<BR> BMP PDTRPAPGSTAPPAHGVTSAP >25000 10000.0 91000.0 >245000 10206.2<BR> DTR-NH2<BR> 1136.18 ALPVFTWLALYFTSAK 1181.1 20104.9 48479 11666.7 598.7 2790.5 1182.6<BR> 1136.20 ALYFTSAKIPQEWKPA 381.6 134.6 59.0 >8750 7690.9 >1581.4 8207.6<BR> 1136.15 FATSFLIPLTSQFFLP 41.8 21304.4 95234.8 8750.0 48.0 592.0 42.9<BR> 1136.52 GLFCRWSYTEIEKIDI 555.7 30625.0 2420.8 >6405.13 >2580.87 17500.0 5698.6 791.3 1690.3<BR> 1136.53 GLFSRWSYTEIEKIDI 298.7 11650.2 >9428.09 4341.2 >30333.33 1607.4 >47140.45<BR> 1136.48 IGGAMLSLTVFEFTKY 1946.3 >3357.42 12364.1 >7427.81 123.7 11666.7 15166.7 40312.8 >2439.21<BR> 1136.13 IKLPIILAFATSFLIP 112.4 16257.4 >7767.36 53.4 0.8 1676.4 63.1<BR> 1136.43 IMEVLFLSWLFPRFKF 104.4 >34648.23 9090.9 1144.0 538.1 >16018.68 >47140.45<BR> 1136.67 LTNNDQVSGINEEDEE >33407.66 >34648.23 >6405.13 576.2 >37150.59 >42758.17 >47140.45<BR> 1136.01 MMASSILRSKIIQKPYQ >27777.78 245.3 24607.0 2112.9 >2651.58 >8750 1690.4 >10826.47 85.2 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 1136.41 PSLHSGSSIMEVLFLS 13325.0 >34648.23 >7767.36 >8750 >37150.59 6080.1 >81649.66<BR> 1136.39 SSIIFGAFPSLHSGSS 1228.7 15765.5 1598.0 1909.4 761.0 447.5 470.6<BR> 1136.10 VSILFFVFVVFPASFF 1041.7 13876.0 3413.7 5834.6 >2904.73 4044.6 >9989.28 8004.0 7372.1<BR> 58.0041 IAKITPDNNGTYACF<BR> 58.0022 IPNTVDNSGSYTCQ<BR> 58.0012 IQNIQDDTGFYTLH<BR> 5.0037 LFNVTRDDARAYVCG<BR> 58.0017 LFNVTRDDTASYKCE<BR> 8.0028 LLSVTRDDVGPYECG<BR> 58.0015 LWWVNNESPVSPRL<BR> 58.0027 LWWVNNESLPVSPRL<BR> 58.0021 ELFIPDITVNNSGS<BR> 58.0032 QELFISDITEKNSGL<BR> 58.0009 REIIYPDASLLQNI<BR> 58.0020 SCHAASDPPAQYSWF<BR> 58.0023 TIIVYADPPKPFITS<BR> 85.0005 VLLLVHDLPQHLFGY<BR> 58.0042 YACFVSDLATGRNNS<BR> CMP DPTTTPITTTTVTPTPTPTGTQT >25000 10000.0 91000.0 >25000 >25000<BR> YC-NH2<BR> 722.01 YIAFLKQATSAK >250000 3333.3 91000.0 >50000 >25000<BR> 500.02 FLRRRPKLK 2857.1 11.1<BR> 199.02 GFLRRIRPKLK 625.0 6.1<BR> 199.03 LRRIRPKLK 4000.0 21.7<BR> 199.01 YGGFLRRIRPKLK >25000 274.0 4.1 >16666.67 10206.2<BR> 510.12 DDNGPQDPDNTDDNG 25000.0 10000.0 758.3 >7692.31 >25000 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB4 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F166.01 PYYTGEHAKAIGN >16137.43 >10103.63<BR> 897.07 FPQPQLPYSQPQPFRPQQPY- 250000.0 6666.7 1000000.0 9.7<BR> NH2<BR> 897.25 IPPYCTIAPFGIFGIN-NH2 147.1 200000.0 1000000.0 4833.3<BR> F1368.09 IRNLALQTLPAMCNVY 4.9<BR> 897.04 LGQQQWPFPPQQPYPQPQPFP- 250000.0 20000.0 >33333.33 252.0<BR> NH2<BR> 897.18 LHQQQKQQQPSSQVSFQQP- 25000.0 200000.0 1000000.0 223.1<BR> NH2<BR> 897.15 LLQELCCQHLWQIPEQWSQCQ- 25000.0 200000.0 50000.0 31.4<BR> NH2<BR> 897.13 LQQHNIAHGRSQVLQQSTYQ-<BR> NH2<BR> F168.04 PQPFRPQQPYPQ 2.4<BR> F168.03 PQPFRPQQPYPQPQPQ 3.6<BR> 897.08 PQPFRPQQPYPQPQPQYSQP- 250000.0 2468.3 1000000.0 7.6 25000.0<BR> NH2<BR> 897.09 PQPQPQYSQPQQPISQQQQQ- 250000.0 200000.0 1000000.0 573.3 14433.8<BR> NH2<BR> 897.19 PSSQVSFQQPLQQYPLGQGS-250000.0 11547.0 1000000.0 6.9<BR> NH2<BR> F168.12 QFEEIRNLALQT 84.0<BR> F168.11 QFEEIRNLAQTLPAM 149.9<BR> 897.23 QFEEIRNLALQTLPAMCNVY- 656.5 1230.9 1000000.0 57.7<BR> NH2<BR> F168.06 QFLGQQQPFPPQ 7.8<BR> 897.22 QGSVQPQQLPQFEEIRNLAL-0 158.5 1490.7 1000000.0 873.6<BR> NH2<BR> 897.02 QNPSQQQPQEQVPLVQQQQF- 250000.0 200000.0 1000000.0 213.8<BR> NH2 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 897.05 QPYPQPQPFPSQPYLQLQP- 250000.0 20000.0 1000000.0 23.5<BR> NH2<BR> 897.12 QQLIFCMDVVLQWQHNIAHGR- 8333.3 20000.0 7715.5 40.1 14433.8<BR> NH2<BR> F168.08 QVPLVQQQQFLG 70.3<BR> F168.07 QVPLVQQQQFLGQQQP 0.8<BR> 897.03 QVPLVQQQQFLGQQQPFPPQ- 21.9<BR> NH2<BR> 897.06 SQQPYLQLQPFPQWPQLPYSQ- 3149.7 228.7 1000000.0 49.0<BR> NH2<BR> F168.05 VQQQQFLGQQQPFPPQ 2.2<BR> 897.01 VRVPVPQLQPQNPSQQQPQE- 250000.0 200000.0 1000000.0 7.9<BR> NH2<BR> 897.50 YIPPYCTIAPFGIFGIN-NH2 0.0 >14285.71<BR> 897.44 YPSSQVSFQQPLQQYPLGGGS 250000.0 >11111.11<BR> -NH2<BR> 897.47 YQGSYQPQQLPQFEEIRNLAL- 0.0 >11111.11<BR> NH2<BR> F160.26 EKVPVSEVMGTTLAEMSTPE<BR> AT<BR> F160.02 IYRRRIMKQDFSVPQWLPHS<BR> F160.07 KRCLLHLAVIGALLAVGATK<BR> V<BR> F160.03 LCQPVLPSPACQLVLHQWILKG<BR> G<BR> F160.16 MTPAEVSIVVLSGTTAAQVTT<BR> T<BR> F160.16 PGPVTAQVVLQAAIPLTSCGS<BR> S<BR> F160.01 VSGLSIGTGRAMIGTHTMEV<BR> TVY TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DRB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F167.01 VYVWKTTWGQYWQVLGGP 402.7 123011.2 >14500<BR> VS<BR> F167.03 WNRQWLYPEWTEAQR 162.3 4229.0 21.5<BR> F115.14 AKRKTVTAMDVVYAL<BR> F115.02 KRHRKVLRDNIQGITKPAIRR<BR> LAR<BR> F115.15 KTVTAMDVVYALKRQ<BR> F115.10 LRDDNIQGITKPAIRR<BR> F115.11 NIQGITKPAIRRI.AR<BR> F115.03 TYTEHAKRKTVTAMDVVYA<BR> LKRQG<BR> 590.23 (2)KYVKQNTLKAT(SIC!) 238.1 12.0<BR> @ 752.01 (67PKYVKQNTLKLAT 156.9 210.5 20.7 >50000 >25000<BR> 594.09 AHAAHAAHAAHAAHAA >8838.83 200000.0 91000.0 58.3<BR> F049.01 BIOTIN-A2- 60.2<BR> PRYVRQNTLRATC<BR> 574.00 CPKYVRSAKLRM 36.4 227.3 1300.0 >16666.67 >2500@<BR> 573.06 GACPKYVKQN >250 5000.0 91000.0<BR> 573.04 GACPKYVKQNTL 735.3 5000.0 91000.0<BR> 597.04 GACPKYVKQNTLK 20.8 5000.0 479.0<BR> 573.03 GACPKYVKQNTLKL 25000.0 50000.0 5033.3<BR> 30.1200 HNTNGVTAASSH >2500 10000.0 3033.3 >16666.67 299.8<BR> 573.08 KQNTLKLATGMR 806.5 5000.0 4550.0<BR> 711.03 LAQNTLAKQNTLAKQNT >25000 2857.1 6.1 25000.0 >25000<BR> 573.09 NTLKLATGMR 1315.8 5000.0 1516.7<BR> 590.22 P(2)YVKQNTLKAT(SIC!) 1538.5 94.8<BR> 864.10 PFFVKQNILKLAT TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 864.07 PFFVKQNTLKLAT<BR> 864.06 PFIVKQNTLKLAT<BR> 864.02 PFYVKQNTLKLAT<BR> 864.09 PIFVKQNIKLAT<BR> 864.05 PIFVKQNTLKLAT<BR> 864.04 PIIVKQNTLKIAT<BR> 864.01 PIYVKQNTLKLAT<BR> 590.10 PK(1)VKQNTLKAT(SIC!) 1538.5 606.7<BR> 590.21 PK(2)VKQNTLKAT(SIC!) 1538.5 650.0<BR> 772.08 PK(31)VKQNTLKLAT-NH2<BR> 611.11 PKAVKQNTLKLAST 250000.0 6666.7 505.6<BR> 601.09 PKEVKQNTLKLAT 250000.0 10000.0 91000.0<BR> 841.05 PKFQVETTKKLAT 250000.0 20000.0 650.0 1533.9<BR> 864.03 PKIVKQNTLKLAT<BR> 713.09 PKKVKQWNTLKLAT 250000.0 200000.0 2275.0<BR> 792.03 PKQVKQNTLKLAT 250000.0 20000.0 4550.0 >50000<BR> 601.10 PKSVKQNTLKLAT 250000.0 10000.0 9100.0<BR> 713.14 PKTVKQNTLKLAT 250000.0 200000.0 2275.0<BR> 590.09 PKY(1)KQNTLKAT(SIC!) 256.4 395.7<BR> 833.08 PKY(41)KQNTLKLAT<BR> 590.08 PKYV(1)QNTLKAT(SICI) 181.8 700.0<BR> 590.19 PKYV(2)QNTLKAT(SICI) 1000.0 758.3<BR> 833.07 PKYV(41)QNTLKLAT<BR> 590.07 PKYVK(1)NTLKAT(SIC!) 322.6 45.5<BR> 590.18 PKYVK(2)NTLKAT(SIC!) 1000.0 154.2 TABLE<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 713.10 PKYVKKNTLKLAT 3571.4 107.0 52.9<BR> 590.06 PKYVKQ91)TLKAT9SIC!) 87.0 137.9<BR> 590.17 PKYVKQ(2)TLKAT(SIC!) 219.8 758.3<BR> 833.05 PKYVKQ(41)TLKLAT<BR> 590.05 PKYVKQN(1)LKAT(SIC!) 800.0 182.0<BR> 590.16 PKYVKQN(2)LKAT(SIC!) 1538.5 535.3<BR> 772.06 PKYVKQN(24)LKLAT<BR> 772.01 PKYVKQN(25)LKLAT<BR> 772.02 PKYVKQN(26)LKLAT<BR> 772.03 PKYVKQN(27)LKLAT<BR> 772.04 PKYVKQN(28)LKLAT<BR> 772.07 PKYVKQN(30)LKLAT<BR> 601.24 PKYVKQNELKLAT 446.4 200000.0 3033.3<BR> 515.09 PKYVKQWNHLKLAST 714.3 4000.0 1011.1<BR> 864.08 PKYVKQNILKLAT<BR> 713.12 PKYVKQNKIKLAT 301.2 31.0 1516.7<BR> 863.07 PKYVKQNNLKLAT 431.0 1481.5 1011.1<BR> 772.11 PKYVKQNPLKLAT<BR> 713.18 PKYVKQNQLKLAT 312.5 2857.1 1137.5<BR> 590.04 PKYVKQNT91)KAT(SIC!) 1000.0 395.7<BR> 590.15 PKYVKQNT(2)KAT(SIC!) 1052.6 185.7<BR> 833.03 PKYVKQNT(41)KLAT<BR> 601.27 PKYVKQNTKKLAT 1388.9 16.7 24.4<BR> 590.03 PKYVKQNTL(1)AT(SIC!) 238.1 395.7<BR> 590.14 PKYVKQNTL(20AT(SIC!) 294.1 116.7 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 833.02 PKYVKQNTL(41)LAT<BR> 590.02 PKYVKQNTLK(1)T(SIC!)1538.5 260.0<BR> 590.01 PKYVKQNTLKAT9SSIC!) 219.8 455.0<BR> 713.06 PKYVKQNTLKEAT 862.1 20000.0 1516.7<BR> 863.08 PKYVKQNTNKLAT 25000.0 2000.0 60.7<BR> 713.01 PKYVKQNYLKLAT 80.1 2222.2 700.0 >5000 >25000<BR> 175.00 RTLYQWNVGTYVSVGTSTLNK >12500 1538.5 3033.3 >d111112.11 6455.0<BR> 597.06 VKQNTLKLATGMR >11180.34 769.2 91000.0<BR> 841.06 YPKFQVETTKKLAT<BR> 841.04 YPKFVKLNTKKLAT<BR> 771.04 YPKFVKQWRTLKLAT4 254.9<BR> 771.02 YPKFVKQRTLKLAT-NH2 94.6<BR> 771.06 YPKFVKRNTLKLAT 5000.0<BR> 771.03 YPKYVKQRTLKLAT 134.7<BR> 771.01 YPKYVKQRTLKLAT-NH2 247.5<BR> 771.07 YPKYVKRNTLKLAT 8333.3<BR> 841.02 YPSFQVQTTLLLAT<BR> 27.0278 AAPFTQCGYPALMPL 3186.5 3524.0 267.7 666.1<BR> F039.09 AILCWGELMTLA >1200000 9.5 10000.0<BR> F076.05 ALRQALLCWGELM >28571.43 >377.36<BR> F039.05 ALRQAILCWGELMTLA >100000 11.6 5263.2<BR> 799.04 GYRWMCLRRFIIFLFILLLC 2272.7 4000.0 1820.0 >25000<BR> F039.02 HHTALRQAILCWGELMTLA >66666.67 29.9 3921.6<BR> F039.03 HTALRQAILCWGELMTLA >66666.67 27.0 7407.4<BR> F039.10 LCWGELMTLA >100000 127.7 5882.4 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide SEquence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F039.11 LCWGELMTLA >100000 829.3 >9523.81<BR> F164.04 LPETTVVRCRGRSPR >10640.71 >8750<BR> F039.06 LRQAILCWGELMTLA >100000 9.9 555.6<BR> CF-09 LSTLPETTVVRRRGRS >1923.08 235.3 9100.0 12500.09 >25000<BR> F164.14 MDIDPYKEFGASVELLSFL 566.0 2455.6<BR> F164.13 MDIDPYKEFGASVELLSFLPS 184.3 >8750<BR> DFFP<BR> F164.16 MDIDPYKEFGATVELLSFL 8394.9 4005.4<BR> F116.01 MDIDPYKEFGATVELLSFLPS 6608.8 2429.9<BR> DFFP<BR> F1264,.125 MDIDPYKEFGATVELLSFLPS 1914.3 722.7<BR> DFFP<BR> F1264.17 MDIDP0YKEFGATVQLLSFLPS 777.4 2819.9<BR> DFFP<BR> F098.11 MGLKFRQLLWF 1174.0 255.0 11582.8 13.2 784.3 1795.8 76.1 1483.2<BR> 1297.06 PFLLAQFTSAICSVVRRA 1603.3 2912.2<BR> F039.18 PHHTALRQAILCW >28571.43 207.5 >7407.41<BR> F039.17 PHHTALRQWAILCWG >28571.43 26.5 5128.2<BR> F039.16 PHHTALRQAILCWGE >25000 1685.2 6451.6<BR> F039.15 PHHTALRQAILCWGEL >25000 239.1 >6060.61<BR> F039.14 PHHTALRQAILCWGELM 18181.8 136.8 >5714.29<BR> F039.13 PHHTALRQAILCWGELMT 16666.7 126.1 3389.8<BR> F039.12 PHHTALRQAILCWGELMTL >100000 18.3 5000.0<BR> 795.01 PLGFFPDHQLDPAFGANSNNP 250000.0 200000.0 91000.0 310.6 25000.0<BR> DWDFNP<BR> F039.08 QLILCWGELMTLA >100000 12.1 >120526.32<BR> CF-03 RDLLDTASALYRREAIESPEH 271.7 200000.0 364.0 >33333.33 4225.8<BR> CF-06 RDLVVSYVNINMGLKFRQLL >1470.59 200000.0 3033.3 6250.0 >25000 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F03.907 RQAILCWGELMTLA >100000 8.9 3125.0<BR> 801.01 RVRGLYFPAGGSSSGTVN 8333.3 20000.0 535.3 >25000<BR> 799.02 SLDSWWTSLNFLGGTTVCLG 4166.7 20000.0 91000.0 >25000<BR> F039.04 TALRQAILCWGELMTLA >100000 14.0 >8000<BR> F164.12 TNMGLKFRQLLWFHI 11180.7 269.7<BR> F164.11 TNVGLKFRQLLWFHI 1012.3 5520.5<BR> F098.08 TTVVRRRGRSPRRRR >102062.07 4516.4 >60436.72 2756.5 >6708.41 35000.0 15166.7 530.7<BR> 800.04 VGAGAFGLGFTPPHGGL 250000.0 2000000.0 9100.0 >25000<BR> 764.01 VSFGVWIRTPPA 4724.6 4000.0 19000.0 13609.2 >25000<BR> 857.01 VPHHALRQAILCWGELMTL 35355.3 10767.6 112.2 429.9 5455.5<BR> A<BR> F134.07 GPGEGAVQWMNRLLAFASRG 6305.2 88.3<BR> Papc22 GRHLIFCHSKRKCDELATKL >102062.07>4048.45 >06436.72 17407.8 >608.41 5000.0 827.3 2073.9<BR> F134.06 LLFNLGGWVAAQLAAPGAA 56433.4 7057.2<BR> 1283.40 PAILSPGALVVGVVCA 3429.9<BR> 221.06 AFVAWRNRCK 5.2<BR> 221.08 AWAAWRNRCK 50.6<BR> 221.10 AWEAWRNRCK 60.7<BR> 221.09 AWLAWRNRCK 19.8<BR> 221.15 AWVAARNRCK 2.1<BR> 221.16 AWVAFRNRCK 5.1<BR> 221.14 AWVAQRNRCK 10.1<BR> 221.19 AWVAWARNRCK 26.0<BR> 221.17 AWVAWENRCK 56.9<BR> 221.18 AWVAWKNRCK 11.1<BR> 221.22 AWVAWRARCK 7.6 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 221.25 AWVAWRNACK 13.6<BR> 221.23 AWVAWRNECK 53.5<BR> 221.24 AWVAWRNKCK 36.4<BR> 221.32 AWVAWRNRCA 433.3<BR> 539.00 AWVAWRNRCK >12500 5000.0 20.2 >11111.11<BR> 221.01 AWVAWRNRCK >12500 5000.0 20.2 >11111.11 >25000<BR> 221.31 AWVAWRNRCR 86.7<BR> 221.28 AWVAWRNREK 10.7<BR> 221.29 AWVAWRNRKK 3.3<BR> 221.26 AWARWRNRQK 2.0<BR> 221.27 AWVAWRNRVK 3.4<BR> 221.20 AWVAWRQRCK 606.7<BR> 221.21 AWVAWRVRCK 162.5<BR> 221.12 AWVEWRNRCK 124.7<BR> 221.11 AWVSWRNRCK 36.4<BR> 221.13 AWVVWRNRCK 45.5<BR> 565.01 EFVAAKAAQK >25000 120.0 1.4 >50000 3571.4<BR> 221.02 EWVAWRNRCK 19.0<BR> AP23 LAAAMKRHGLDNYRGYSLG 5000.0 83.3 178.4 >5263.16 >25000<BR> NWV<BR> AP12 NRRCKGTDVQAWIRGCRL 3571.4 2500.0 178.4 >6250 >25000<BR> AP38 SVNCAKKIVSDGNGMN >8333.33 666.7 4550.0 2306.3 >25000<BR> 221.04 SWVAWRNRCK 21.7<BR> 221.03 VWVAWRNRCK 47.9<BR> 60.02 WRNAKWRNAKWRNAK >1200 5000.0 505.6 >14285.71 >25000<BR> AP37 YRGYSLGNWVCAAKFESNFN >6250 5000.0 101Q1.1 >5263.16 25000.0 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> TQ<BR> 58.0052 CWMIDSDCRPRFREL<BR> 58.0045 CYGLGMDHLREVRAV<BR> 58.0053 FRELVSDFRRMARDP<BR> 58.0051 IKWAMALDSILRRRFT<BR> 58.0046 LALIHHDTHLCFVHT<BR> 58.0043 LTYLPTDASLSFLQQD<BR> 48.0048 QMRILKDTELRKVKV<BR> 1385.03 SPYVSRLLGICLT 886.5 4207.3 3414.1 831.4<BR> 1385.04 VPIKWMALESILRRRF 1300.9 2815.12 1430.6 46.9<BR> 58.0047 WDQLFRDPHQALLITT<BR> F159.13 DRVHPVHAGPIA 98.5 >9500.69 >53452.2 528.8 19198.3 >12909.94<BR> F159.12 DRVHPVHAGPIAPG 93.2 >7836.24 >50000 342.3 724.3 11809.5<BR> F159.11 DRVHPVHAGPIAPGQM 265.3 >6971.6 >33333.33 655.6 1102.5 1845.0<BR> F159.10 DRVHPVHAGPIAPGQMRE 399.8 14869.0 >31622.78 591.1 706.9 6288.4<BR> F159.09 DRVHPVHAGPIAPGQMREPR 223.2 >5591.33 >29488.39 1246.7 3572.6 >7905.69<BR> F170.01 DTEVHNVWATQACVPTDPNP >3240.47 >5858.03 >2528.25 >3232.54 >4183.3 5055.6 >3657.23 5493.0 >533.76<BR> F169.02 EGLIHSQRRQDILDL >39528.47 >70725.41 >30316.95 1843.8 837.9 505.6 >77821.01 11901.1 1364.0<BR> F170.06 EPFRDYVDRFYKTLRAEQAS 1761.7 201.7 3463.5 100.7 >7826.2 162.5 >12903.23 2902.6 690.6<BR> F170.05 IYKRWILGINKIVRMYSPV 659.0 151.5 >5056.5 >6428.24 9589.0 10111.1 >12903.23 659.7 >1054.09<BR> F170.02 PKISFFPIPIHYCAPAGFAI 389.3 15312.5 274.0 14285.7 758.2 30.0 >6537.23 78.3 >533.76<BR> F169.01 TAATNAACAWLEA 18351.3 >70725.41 1827.4 >37796.4 974.7 3137.9 >77821.01 59094.5 >6565.32<BR> F170.04 TNNPPIPVGEIYKRWILLGL 912.9 200.8 1616.9 98.6 11.9 20.2 7624.9 442.7 44.7<BR> F170.03 VWGIKQLQARVLAVERYLKD 200.7 7967 2451.5 541.3 134.6 16.9 5951.0 372.8 39.7<BR> 27.0374 AVQMAVFIHNFKRKG 2701.6 73.6 3.5 7.9 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 27.0299 DQQLLGIWGCSGKLI 1437.7 309.0 606.7 2026.7<BR> 27.0287 DQSLKPCVKLTPLCV 2339.9 025.1 5055.6 11063.2<BR> 27.0284 EDIISLWDQSLKPCV >27277.24 >18257.42 5352.9 11985.1<BR> 190.20 ERFAVNPGLLETSEGC >12500 2500.0 1300.0 >33333.33 1976.4<BR> 190.15 CARASVLSGGELDKWE >12500 10000.0 1300.0 >14285.71 315.5<BR> 190.16 GGELDKWEKIRLRPGG >12500 10000.0 252.8 >33333.33 >25000<BR> RS-21 GP41584-609 >1200 645.2 9100.0 3965.3 >25000<BR> 27.0320 IGGIGGFIKVRQYDQ 8059.6 1409.9 45.5 112.2<BR> 181.11 ILKALGPAATLEEMMT(200.11 12500.0 200000.0 9100.0 >50000 25000.0<BR> )<BR> 200.10 INEEAAEWERVHPVHA >12500 10000.0 1300.0 16666.7 >25000<BR> 27.0348 IQKLVGKLNWASQUIY 5936.9 4573.0 6500.0 >7273.93<BR> 27.02I6 ISLWDQSLKPCWVKLT >14153.46 8486.2 313.8 1179.1<BR> 190.19 IVWASRELERFAVNPG >12500 339.0 1300.0 >33333.33 3125.0<BR> 200.17 IYKRWILLGLNKIRVN >12500 10000.0 364.0 >33333.33 >25000<BR> F091.13 KQIINMWQEVGKAMYA 11763.0 22360.7 2527.8 61.1 5661.4<BR> 200.04 KVVEEKAFSPEVIPMF 12500.0 10000.0 606.7 >33333.33 >25000<BR> 190.08 LGKIWPSYKGRPGNFL >12500 277.8 1300.0 20000.0 715.5<BR> F091.08 LKQIVKKLREQFGNNK >45643.55 6900.7 206.8 601.4 492.1<BR> 27.0300 LLGIWGCSGKLICTT 3934.7 >1185.11 1820.0 4279.4<BR> 27.0302 LSIVNRVRQGYSPLS 16606.8 27.8 284.4 668.2<BR> 200.01 PIVQNLQGQMVHQAIS >12500 10000.0 1300.0 >33333.33 >25000<BR> F091.24 PLGVAPTKAKRRVVQR 38575.8 22360.7 19.0 2371.8 57.4<BR> 190.23 PSILQTGSEELRSLYNT >12500 10000.0 758.3 >33333.33 25000.0<BR> F091.16 QARILAVERYLKDQQL 26352.3 66.5 479.0 246.2 1081.5<BR> 27.0352 QGQWTYQIYQEPFKN 9940.4 >30860.67 606.7 1363.5 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 190.13 QKQEPIDKELYPLTSL >12500 10000.0 1300.0 >33333.33 >25000<BR> 27.0375 QMAVFIHNFKRKGGI 7008.2 19.1 7.6 17.4<BR> F091.07 RIQRGPGRAFVTIGKL >45643.55 429.0 1096.4 4207.8 2424.6<BR> 190.22 RQILGQLQPSLQTGSE >123500 10000.0 1300.0 >33333.33 17677.7<BR> F091.04 SLKPCVKLTPLCVTLN 1159.4 449.5 758.3 508.7 1707.5<BR> F091.26 SLWDQSLKPCVKLTPL >45643.55 4255.3 413.6 2774.5 910.0<BR> 27.0359 SQIIEQLIKKEVKVYL >25649.476 428.5 293.6 650.2<BR> F091.22 SQNQQEKNEQELLELD >45643.5 >51639.78 758.3 >64845.97 1666.7<BR> F091.11 SSGGDPEIVMHSFNCG >45643.55 >51639.78 22750.0 503.3 >21821.79<BR> 27.0334 STKWRKLVDFRELNK 2183.7 1753.2 21061.5 124.8 >7407.41 >3818.81 429.6 509.1<BR> F091.12 TITLPCRIKQFINMWQE 24397.5 47140.5 8272.7 730.7 18181.8<BR> 27.0292 TVYYGVPVWKEATTT 1997.6 2275.4 568.8 2098.8<BR> F091.23 VKIEPLGVAPTKAKRR >45643.55 >51639.78 6.1 5913.4 13.3<BR> 27.0301 VLSIVNRVRQGYSPL 2756.6 3.7 5.4 11.9<BR> 27.0356 VNIVTDSQYALGIIQ 2299.5 >25197.63 6500.0 >2773.93<BR> F091.03 WDSQSLKPCVKLTPLCV 3140.7 20203.1 3137.9 4515.3 6896.6<BR> 27.0335 WRKLVDFRELNKRTQ >25649.46 69.0 5352.9 >5939.1<BR> F160.45 STORKUSP45<BR> 106.00 APYTSTLLPPELSETP >1923.08 1818.2 4550.0 >12500 >25000<BR> F095.05 FRQLVHFVRDFAQLL 399.1 869.6<BR> AP30 SLKMADPNRFRGKDLP >25000 1818.2 700.2 >12500 >25000<BR> 605.14 ACRVNHVTLSQPKIVK 312.5 200000.0 1011.1 7216.9<BR> 530.08 GKKIPKVEMSDMSFSK >12500 200000.0 910.0 >7142.86 >25000<BR> 605.03 HPAENGKSNFLNCYVS 2500.0 200000.0 91000.0 >25000<BR> 530.06 HPPHIEIQMLKNGKKI 8333.3 350.9 11.5 >7142.86 >25000 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 530.01 IQKTPQIQVYSRHPPE >12500 833.3 91000.0 >7142.86 >25000<BR> 530.07 IQMLKNGKKIPKVEMS 8333.3 740.7 15.4 >7142.86 >25000<BR> 605.01 IQRTPKIQVYSRHPAE 12500.0 2000.0 1516.7 >25000<BR> 530.02 IQVYSRHPPENGKPNI >1200 20000.0 91000.0 >7142.86 >25000<BR> 530.04 KPNILNCYVTQFHPPH >12500 200000.0 4550.0 >7142.86 >25000<BR> 530.10 SFSKDWSFYILAHTEF 1206.3 2857.1 91000.0 454.3 >25000<BR> 605.10 SFSYDWSFYLLYYTEF 250000.0 200000.0 395.7 >25000<BR> 605.11 SFYLLYYTEFTPTEKD 2777.8 200000.0 91000.0 17677.7<BR> 530.14 TETDTYACRVKHDSMA 925.9 200000.0 91000.0 >7142.86 >25000<BR> 530.09 VEMSDMSFSKDWSFYI 438.6 20000.0 91000.0 322.6 >25000<BR> 544.02 YGSDTTTLPCRIKQFINMWQE 1000.0 909.1 91000.0 >9129.09 >25000<BR> JR-01 PEFLEQRRAAVDTYC 250000.0 47.8 91000.0 >12500<BR> F073.01 MRGSHHHHHHHGSVD-II72-216 147.L3 983.0 63.0 18.4 13.6<BR> 734.01 FVNQHLSGSHLVEALYLVSG- 216.5 200000.0 9100.0 20000.0<BR> CONH2<BR> 6 8.0002 DLVLSIALSVGCTGA 4029.1 >141450.82 2200.2 >115470.05 4914.8 97.5 18200.0 >11629.26 459.5 >100000<BR> 68.0005 GQRVPVSHSFPHPLY 628.7 >141450.82 102.1 >57735.03 5507.3 702.5 3960.3 >11629.26 98605 >100000<BR> 68.0011 HDLMLLRLSEPAKIT 109.3 544.2 3.1 1146.7 84.4 0.8 115.1 488.0 11.6 211.2<BR> 68.0008 HPLYNMSLLKHQSLR 1282.0 381.7 199.2 248.2 95.2 546.3 471.5 >11629.26 8.4 219.0<BR> 68.0003 HPQWVLTAAHCLKKN 563.4 1693.2 822.4 980.8 11450.4 482.8 1219.5 8114.3 1105.8 11.0<BR> 68.0018 KPAVYTKVVHYRKWI 2401.0 53.2 3676.7 327.0 1303.0 1947.L5 401.1 7186.5 4581.2 22.7<BR> 68.0140 LHLLSNDMCARAYSE 27685.5 50230.1 59904.2 26011.5 1152.5 1876.4 >2030.13 1988.8 323.8 28817.3<BR> 68.0001 MWDLVLSIALSVGCT 3031.7 23045.8 1727.3 81096.0 4574.6 107.7 11735.0 15204.5 157.5 70710.7<BR> 68.0017 NGVLQGITSWGPEPC 2285.2 52234.2 50111.5 32444.3 >3132.18 >14288.69 834.9>10217.64 5760.9 >100000<BR> 68.0009 NMSLLKHQSLRPDED 20619.7 26496.2 96824.6 25819.9 1287.6 >20207.26 >23496.1 >11629.26 104.9 >100000<BR> 68.0015 PEEFLRPRSLQCVSL 5155.9 2207.1 5839.1 1065.2 6023.3 11666.7 3193.5 >10463.53 117.0 57537.0 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 68.0007 PHPLYNMSLLKHQSL 2069.06 3315.4 1591.6 6455.0 859.8 3307.2 3873.2 >11629.26 49.4 190.1<BR> 168.0016 PRSLQCVSLHLLSND 2216.7 6106.8 28306.9 1128.3 3861.0 3731.0 1596.7 11649.6 544.1 46415.9<BR> 68.0004 QWVLTAAHCLKKNSQ 3402.1 98000.0 4812.5 14213.4 >10721.94 >24748.74 >30333.33 >11629.26 14395.4 382.2<BR> 68.0006 RVPVSHSFPHPLYNM 101.1 100020.8 96.8 >57735.03 10397.4 376.9 5517.7 >11629.26 9213.5 11649.7<BR> 68.0010 SHDLMLLRLSEPAKI 106.4 1326.9 1115.5 5267.4 591.4 1.8 365.4 5360.8 10.2 2031.1<BR> F090.02 ATGFKQSSKALQRPV 12.0<BR> F090.01 IVHSATGFKQSSKALQRPVAS 16.4<BR> DFEP<BR> F071.29 IKYNGEEYLILSARD 3592.1 322. 1589.2 1443.4<BR> F071.26 IYSKYGGTEIKYNGE >100000 3625.5 >83715.79 457.9<BR> F118.06 LVIPENAKEKPQ 535.3 1217.8<BR> F118.02 LVIPENAKEKPQEGT 827.3 1876.3<BR> F071.12 LVIPENAKEKPQEGT 66666.7 56.9 >71393.06 174.1<BR> F071.30 NGEEYLILSARDVLA 6052.3 5732.5 1691.1 590.5<BR> F071.11 PSGLVIPENAKEKPQ >100000 53.5 >61828.21 138.6<BR> F071.22 RIPVDVSEGDIVIYS >100000 15.3 >61828.21 >51639.78<BR> 581.02 RKHRIEDAVRNAKAAVEEEGI 892.9 200000.0 91000.0 100000.0 3726.8<BR> VAG<BR> F071.24 SEGDIVIYSKYGGTE 3479.5 144.3 >71393.06 40824.8<BR> 572.03 TLLQAAPALDKY 1785.7 10000.0 18200.0 >15429.72 40000.0 >25000<BR> F071.03 VAKVKIKPLEDKILV 4789.8 180.5 5919.6 3722.9<BR> F071.04 VKIKPLEDKILVQAG 2309.4 471.2 483.3 28284.3<BR> F071.17 VVAVGPGRWDEDGAK >100000 650.0 >71393.06 1490.7<BR> 581.01 YEKIGAELVKEVAKKTDDVA 312.5 200000.0 2275.0 >20000 >25000<BR> G<BR> F160.21 EKIWEELSVLEVFFGRED<BR> F160.20 ETSYVKNLHHMVKISGG TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 58.0062 EEKIWEDLSMLEVFE<BR> 58.0057 FPDLESPFQAAISRK<BR> 58.0058 LESVLRDCQDFFPVI<BR> 58.0064 MQDLVQDNYLEYRQV<BR> 58.0063 PRKLLMEDLYQENYL<BR> 58.0065 QDLVQEDYLEYRQVP<BR> 58.0059 QLVFGIDVVEVVPIS<BR> 58.0071 EEKIWEDLSVLEVFE<BR> 58.0068 LGSVVGDWQYFFPVI<BR> 58.0074 QHFVQEDYLEYRQVP<BR> 58.0073 TQHFVQDNYLEYRQV<BR> F167.06 LLKYRAREPVTKAEMLGSVV 974.2 117.0 14.3<BR> GNWQ<BR> F167.08 MVKISGGPRISYPLLHEWALR 161.1 9.9 >11245.72<BR> EGEE<BR> F167.07 QVPGSDPACYEFLWGPRALIE >7816.32 66092.72 27878.8<BR> TSY<BR> F160.27 VGNWQYFFPVIFSKASDSL<BR> 520.09 YKINFYFDLLRAKL 1470.6 1250.0 91000.0 6666.7 >25000<BR> 520.07 YLDNIKDNVGKMED 1470.6 3333.3 91000.0 >13363.62 >1526.32 >25000<BR> F160.15 AAGIGILTVILGVL<BR> 825.10 AC- 362.3 200000.0 91000.0<BR> ASQKRPSQRHGSKYLATAST<BR> AC- 200000.0 3033.3 8165.0<BR> ASQKRPSQRSKYLATASTMD<BR> F006.16 ANPVVHFFKNIVTPR 1.3 315.5<BR> 825.01 ASQKRPSQHRHGSKYLATAST 898.0 200000.0 91000.0<BR> 765.15 AYDAQGTLSKIFKLGGRDSR 2192.7 37.7 45.3 110.0 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F006.14 DENPVVHFFKN 959.2 >6666.67<BR> F006.13 DENPVVHFFKNI 15.7 4472.1<BR> F006.12 DENPVVHFFKNIV 6.5 2020.3<BR> F006.11 DENPVVHFFKNIVT 4.2 691.3<BR> F006.10 DENPVVHFFKNIVTPR 10.7 1529.4<BR> F006.09 DENPVVHFFKNIVTPRT 26.8 2981.4<BR> F006.01 DENPVVHFFKNIVTPRTPP 3.0 54.7<BR> F006.0202 DENPVVHFFKNIVTPRTPPY 12.2 26.3<BR> F006.03 DENPVVHFFKNVTPRTPPY 1.4 19.5<BR> F006.17 EAPVVHFFKNIVTPR 2.8 691.7<BR> F006.18 ENAVVHFFKNIVTPR 4.6 423.9<BR> F006.19 ENPAVHFFKNIVTPR 1.6 678.1<BR> F038.01 ENPKVHFFKNIVTPR 7.3 15.4<BR> F006.20 ENPVAHFFKNIVTPR 156.0 482.8<BR> F038.02 ENPVKHFFKNIVTPR 405.4 869.6<BR> F006.21 ENPVVAFFKNIVTPR 2.8 301.5<BR> F038.03 ENPVVAFFKNIVTPR 5.2 11.1<BR> F038.06 ENPVVDFFKNIVTPR 75.8 166.7<BR> F038.05 ENPVVFFFKNIVTPR 2.1 4.4<BR> F006.22 ENPVVHAFKNIVTPR 2.7 910.0<BR> F038.07 ENPVVHAFKNIVTPR 2.1 4.7<BR> F095.08 ENPVVHAFRNIVTPR 21.9 42.6<BR> F038.09 ENPVVHDFKNIVTPR 451.6 909.1<BR> F006.23 ENPVVHFAKNIVTPR 233.2 6324.6<BR> F095.06 ENPVVHFARNIVTPR 975.1 2020.2 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F006.24 ENPVVHFFANIVTPR 2.9 6235.3<BR> F038.14 ENPVVHFFANIVTPR 3.6 7.7<BR> Cr-8 ENPVVHFFANIVTPRTP 126.4<BR> F038.15 ENPVVHFFDNIVTPR 344.9 740.7<BR> F038.16 ENPVVHFFHNIVTPR 6.4 13.3<BR> F006.25 ENPVVHFFKAIVTPR 4.0 209.7<BR> Cr-9 ENPVVHFFKAIVTPRTP 12.5<BR> F038.19 ENPVVHFFKKIVTPR 650.0 1428.6<BR> F006.26 ENPVVHFFKNAVTPR 2.6 1616.9<BR> Cr-10 ENPVVHFFKNAVTPRTP 82.7 188.9<BR> F006.27 ENPVVHFFKNIATPR 4.1 1020.6<BR> F006.28 ENPVVHFFKNIVAPR 0.6 66.2<BR> Cr-11 ENPVVHFFKNIVAPRTP 16.0 37.0<BR> F006.29 ENPVVHFFKNIVTAR 1.0 495.1<BR> F006.30 ENPVVHFFKNIVTPA 2.5 3333.3<BR> F006.36 ENPVVHFFKNIVTPA 6.9 20000.0<BR> F006.15 ENPVVHFFKNIVTPR 5.2 462.5<BR> Cr-7 ENPVVHFFKNIVTPRTP 43.3<BR> F006.04 ENPVVHFFKNIVTPRTPPY 17.4 573.1<BR> F038.20 ENPVVHFFKNKVTPR 18.5 37.7<BR> F038.17 ENPVVHFFLNIVTPR 3.4 6.3<BR> F038.18 ENPVVHFFRNIVTPR 2.0 4.3<BR> F038.13 ENPVVHFKKNIVTPR 339.1 714.3<BR> F038.10 ENPVVHHFKNIVTPR 7.9 16.7<BR> F095.10 ENPVVHHFRNIVTPR 16.6 33.9 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F038.11 ENPVVHLFKNIVTPR 8.4 16.7<BR> F095.09 ENPVVHLFRNIVTPR 5.5 11.8<BR> F038.12 ENPVVHWFKNIVTPR 19.7 42.6<BR> F095.12 ENPVVHYFANIVTPR 18.3 40.0<BR> F095.11 ENPVVHYFHNIVTPR 14.2 28.2<BR> F038.08 ENPVVHYFKNIVTPR 2.1 4.7<BR> F095.13 ENPVVHYFLNIVTPR 18.1 38.5<BR> F095.07 ENPVVHYFRNIVTPR 49.2 48.8<BR> F038.04 ENPVVKFFKNIVIPR 7.0 15.4<BR> 613.02 FFKNIVTPFFKNIVTP 2272.7<BR> 825.07 FSWGAEGQRPGFGYGGRASD >10206.21 200000.0 91000.0<BR> 765.13 GFGYGGRASDYKSAHKGFKG >10206.21 138.9 61.9<BR> 825.06 GKGRGLSLSRFSWGAEGQRP 4724.6 1666.7 3033.3<BR> 825.04 GSGKDSHHPARTAHYGSLPQ >10206.21 200000.0 91000.0<BR> 765.03 HARHGFLPRHRDTGILDSIG >10206.21 4000.0 91000.0<BR> F006.321 HFFKNIVTPRTPPY 460.2 377.4<BR> F006.322 HFFKNIVTPRTPPY 2144.9 571.7<BR> 765.16 IFKLGGRDSRSGSPMARR >12500 8000.0 1011.1<BR> 765.06 KRGSGKDSHTRTTHYGSLPQ >10206.21 14142.1 479.0 800.0<BR> 765.08 KSQHGRTQDENPVVHFFKNI >10206.21 10000.0 9100.0<BR> F006.31 NPVVHFFKNIVT 23.4 10000.0<BR> F006.37 NPVVHFFKNIVTPA 4.8 13.3<BR> F006.34 NPVVHFFKNIVTPR 3.7 1889.8<BR> F006.05 NPVVHFFKNIVTPRTPPY 7.7 124.0<BR> F006.39 PVVHFFKNIVT 348.0 714.3 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F006.38 PVVHFFKNIVTPA 15.0 20000.0<BR> F006.35 PVVHFFKNIVTPR 18.6 8165.0<BR> F006.06 PVVHFFKNIVTPRTPPY 4.8 45.3<BR> 825.11 QKSHGRTQDENPVVHFFKNI 10000.0 13333.3 1300.0<BR> F121.03 RASDYKSAHKGFKGVDAQGT 449.5<BR> F121.02 RASDYKSAHKGLKGHDAQGT 149.1<BR> 825.02 RDTGILDSIGRFFGGDRGAP >10206.21 169.5 91000.0<BR> 765.04 RDTGILDSIGRFFSGDRGAP 250000.0 265.8 3033.3 5773.5<BR> 825.03 RFFGGDRGAPKRGSGKDSHH >10206.21 200000.0 4550.0<BR> 765.05 RFFSGDRGAPKRGSGKDSHT 250000.0 200000.0 910.0 2000.0<BR> 825.05 RTAHYGSLPQKSHGRTQDEN >10206.21 3333.3 91000.0<BR> 825.09 VDAQGTLSKIFKLGGRDSRS 1170.7 18.2 3033.3 769.2<BR> F112.01 VDAQGTLSKIFKLGGRDSRS 37.7<BR> F112.04 VDAQGTLSKLFKLGGRDSRS 57.1<BR> F112.03 VDAQGTLSRIFKLGGRDSRS 33.9<BR> F006.08 VHFFKNIVTPRTPPY<BR> 765.10 VTPRTPPPSQGKGRGLSLSR >10206.21 10000.0 91000.0<BR> F006.07 VVHFFKNIVTPRTPPY 10.3 46.1<BR> 765.14 YKSAHKGFKGVDAQGTLSKI 250000.0 3333.3 21.7 50.3<BR> 825.08 YKSAHKGFKGVDAQGTLSKI 108.3 2000.0 606.7<BR> 9.00 ANERADLIAYLKQATK >8333.33 1333.3 171.7 >7142.86 >25000<BR> 847.02 EFVVEFDLPGIKA 250000.0 200000.0 91000.0 14285.7 >25000<BR> 593.02 VITAFNEGLK >3125 2222.2 91000.0 >50000 >25000<BR> 847.01 VEFVVEFDLPGIKA 4166.7 20000.0 91000.0<BR> 753.03 IAFNSGLEPGVVAEK-NH2 25000.0 666.7 >15166.67 200000.0 >25000 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 753.02 LLPLLEKVIGAGKPL-NH2 25000.0 6666.7 313.8 >50000 188.0<BR> 829.01 YKTIAYDEEARR 250000.0 200000.0 >18200 >50000 200000.0 >25000<BR> 831.01 TWQRDGEDQTQDTELVETRP<BR> AG<BR> F009.04 VDDTLFVRFDSDAASPREEPR<BR> F009.01 VDDTLFVRFDSDATSPRKEPR<BR> F009.06 VDDTQFVRFDSDAASPREEPR<BR> F009.02 VDDTQFVRFDSDAASPRMAP<BR> R<BR> F009.05 VDDTQFVRFDSDAASPRTEPR<BR> 536.00 AHAAHAAHAAHAAHAA >12500 10000.0 1516.7 >7142.86 33.0<BR> N-3 AVHAAHAEINEAGR 964.4<BR> 151.00 HIATNAVLFFGR >25000 2500.0 91000.0 >16666.67 >25000<BR> 144.01 ISQAAHAAHAEINE 438.6<BR> 84.04 ISQADHAAHAEINE 643.8<BR> 85.04 ISQAVEAAHAEINE 833.8<BR> 92.06 ISQAVHAAHAEDNE 855.0<BR> 92.05 ISQAVHAAHQINE 735.3<BR> 91.02 ISQAVHAAHAQINE 543.5<BR> 90.05 ISQAVHAALAEINE 892.9<BR> 144.08 ISQAVHAARAEINE 836.6<BR> 90.01 ISQAVHAARAEINE 576.6<BR> 747.01 LKISQAVHAAHAEIN 3.5<BR> 705.05 MVYLGAKDSTRTQINKVVRF >6250 5000.0 910.0 >33333.33 >25000<BR> 521.00 NVMEERKIKVYLPRM >25000 2000.0 91000.0 >14285.71 >25000<BR> 560.04 VHAAHAEINVHAAHA >12500 200000.091.000.0 >14285.71 300.3 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 560.03 VHAAHAVIIAAHAEIN >12500 200000.0 91000.0 >14285.71 37.7<BR> 560.05 VHAAHAVHAAHAVHA 324.7 200000.0 758.3 >14285.71 41.6<BR> 594.03 YTYTVHAAHAYTYT 48.1 5000.0 700.0 14285.7<BR> 112.06 Y'TY'TVHAAHAY'TY'T 48.1 5000.0 700.0 >14285.71 328.4<BR> 58.0082 LIRVEGDLRVEYLDD<BR> 58.0081 QHLIRVDGNLRVEYL<BR> 58.0091 RFEMFRDLNEALELK<BR> 68.0019 AAPLLLARAASLSLG 24.8 30.3 64.4 99.8 563.8 3.2 35.0 10469.0 78.8 79.0<BR> 68.0025 AKELKFVTLVFRHGD 605.8 1952.8 2354.9 12309.2 693.3 824.0 1529.5 8563.1 51.4 23.9<BR> 68.0052 ALDVYNGLLPPYASC >28845.61 588.5 86602.5 182.4 7568.1 >24748.74 1090.8 >13968.43 >459.77 115470.1<BR> 68.0020 APLLLARAASLSLGF 58.9 75.9 124.2 322.1 224.7 11.8 91.4 13358.3 58.9 113.9<BR> 68.0024 DRSVLAKELKFVTLV 2016.1 15814.7 4719.3 20965.7 300.7 4409.6 1359.0 >1027.64 53.2 22172<BR> 68.0030 DRTLMSAMTNLAALF 382.6 2361.5 221.6 2366.9 704.3 114.2 870.9 3927.1 57.4 26137.9<BR> 68.0051 DTTVSGLQMALDVYN 14705.9 >110162.86 2875.6 >19640.02 712.5 3500.0 1042.3 10843.6 960.7 >200000<BR> 68.0056 FAELVGPVIPQDWST 24056.3 >110162.86 39471.8 >19640.02 12503.5 >17500 >45500 >13968.43 983.2 >200000<BR> 68.0028 FGQLTQLGMEQIIYEL >51031.04 109567.3 >167705.1 27216.6 652.8 >35000 >18200 >10217.64 543.3 100000.0<BR> 68.0047 GGVLVNEILNHMKRA 29462.8 3238.7 54410.7 254.6 6694.4 48.7 575.6 8124.1 5.8 8.7<BR> 68.0156 GQVIPQDWSTECMTT >8184.79 20296.3 961.1<BR> 68.0034 GVSIWNPILLWQPIP 4992.0 11008.0 3984.9 10286.9 3902.2 207.3 5.0 4427.9 492.0 522.6<BR> 68.0038 ILLWQPIPVHTVPLS 18.8 13091.1 131.0 2343.5 7288.6 1111.3 65.5 >8824.57 712.3 28768.5<BR> 68.0048 IPSYKKLIMYSAHDT 1946.3 60.5 350.5 52.8 669.1 2122.2 17.3 9982.0 12.0 191.1<BR> 68.0046 KSRLQGGVLVNEILN 2837.6 >49000 5516.2 >29814.24 9505.1 318.3 >26269.44 >13968.43 713.0 >100000<BR> 68.0053 LDVYNGLLPPYASCH >28845.61 404.3 31277.2 194.3 9752.9 >24748.74 3035.0 >13968.43 >10496.41 25819.9<BR> 68.0050 LIMYSAHDTTVSGLQ 730.9 24812.1 813.4 >29814.24 >12214.98 1752.2 183.7 6827.8 4381.2 >100000<BR> 68.0023 LLFFWLDRSVLAKEL 135.0 163.2 518.4 154.2 178.6 23.9 33.7 85.8 7.5 134.5 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 68.0042 LPSWATEDTMTKLRE >33407.66 >49000 >108253.18 >28114.42 >8417.51 >24748.74 >31547.94 5972.7 >10717.79 343.5<BR> 68.0043 LRELSELSLISLYGI 4009.8 9367.8 1614.0 6958.4 1169.0 3217.7 234.8 >1368.43 544.0 5184.8<BR> 68.0044 LSELSLLSLYGIHKQ 20906.1 1186.3 1450.2 1657.2 262.1 1253.2 45.0 >10746.91 79.4 7.3<BR> 68.0040 LSGLHGQDLFGIWSK >33407.66 >49000 >108253.18 30151.1 7890.6 >24748.74 32173.4 >8824.57 134.8 81649.7<BR> 68.0045 LSLLSLYGIHKQKEK >33407.66 1636.9 4959.5 742.1 646.5 >247487.74 58.4 >13968.43 771.9 3.4<BR> 68.0153 LTELYFEKGEYFVEM 13061.7 18840.8 26949.3 >18736.1 12690.0 3157.4 4042.7 184.4 600.5 6655.5<BR> 68.0031 MSAMTNLAALFPPEG 36084.4 73870.3 >144439.26 >200000 3873.3 249.5 12383.5 7157.7 1072.0 63245.6<BR> 68.0032 MTNLAALFPPEGVSI >68790.15 39231.4 22821.8 141421.4 4530.8 1309.8 10370.4 >8824.57 4605.8 141421.4<BR> 68.0036 NPILLWQPIPVHTVP 41.4 12998.7 575.3 599.1 612.4 250.0 4.6 >8824.57 67.1 25000.0<BR> 68.0033 PEGVSIWNPILLWQP 15030.0 28577.4 103095.8 30860.7 7975.9 444.3 7.2 4623.6 107.3 22222.2<BR> 68.0037 PILLWQPIPVHTVPL 45.6 21244.2 168.3 4040.6 2370.0 567.3 6.9 >8824.57 106.2 41491.3<BR> 68.0021 PLLLARAASLSLGFL 162.1 36.6 57.9 1254.6 1511.2 12.4 117.7 >8602.89 52.0 150.7<BR> 68.0026 RSPIDTFPTDPIKES >51031.04 >109567.33 6123.7 >200000 >3132.18 >24748.74 2373.5 >10217.64 468.9 28571.4<BR> 68.0022 SLSLGFLFLLFFWLD 22727.3 >58095.92 24620.0 100000.0 1220.9 639.5 11375.0 3710.2 >9602.54 66666.7<BR> 68.0147 TVPLSEDQLLYLPFR 11312.7 42162.0 37369.2 26455.0 14387.2 5300.1 >2030.13 4322.9 872.5 27220.8<BR> 68.0035 WNPILLWQPIPVHTV 520.5 115494.1 607.1 19640.0 5694.0 2259.2 14.0 >8824.57 80.6 100000.0<BR> 68.0039 WQPIPVHTVPLSEDQ 159.4 >49000 17517.8 >28114.42 >1417.51 2692.3 >31547.94 >8824.57 1228.2 >100000<BR> 68.0041 YDPLYCESVHNFTLP 838.4 30867.1 643.1 30151.1 >8417.51 >35000 2136.1 >8824.57 6900.7 28768.5<BR> 68.0049 YKKLIMYSAHDTTVS 291.8 308.8 107.5 207.7 927.6 37.4 14.5 13224.0 5.8 5482.3<BR> 68.0054 YNGLLPPYASCHLTE >54554.47 14026.8 8022.4 5300.4 >12214.98 11666.7 252.1 >13968.43 >10496.41 10000.0<BR> 1188.24 AGGIAGGLALLACAG >72168.78 138871.0 >63245.55 >10864.32 7000.0 >74877.68 >13074.41<BR> 1188.14 ATSVLAGLLGNVSTV >72168.78 95227.4 25000.0 10819.9 18200.0 16307.3 >29814.24<BR> 1188.28 AVPLAMKLIQQLNLN 327.7 1305.2 100000.0 306.2 15166.7 1659.9 >33333.33<BR> F143.02 EWSPCSVTCGNGIQVRIK 1355.0 44208.9 >50000 >225000 1374.0 >64346.72 >66666.67<BR> 27.0396 FLALFFIIFNKESLA 1794.4 23400.9 >2044.59 1004.1 >2412.22 1840.7 4333.3 >6655.58 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F143.09 IEQYLKKIKNSISTEWSPCS 250.4 426.5 1961.0 20044.5 211.1 376.0 2483.4<BR> 1188.04 IFHINGKIIKNSEKD 1685.5 1267.6 9377.5 539.2 3381.2 300.5 420.3 >1147.08 48502.0 349.9<BR> 27.0401 KHILYISFYFILVNL 1533.6 25198.9 9578.0 >2412.22 4333.3 >8908.71<BR> 1188.20 LIDVHDLISDMIKKE 2602.2 5290.8 1734.6 6085.8 >10864.32 9668.5 1491.8 646.8 2679.0<BR> F150.02 NAREIIRLHSDASKNKEKAL >47245.56 24424.4 2064.7 >17500 797.9 2653.1<BR> 27.0414 NHAVPLAMKLIQQLN 4536.7 305.2 5991.9 1174.1 220.8 2010.7 3640.0 8074.6<BR> F107.12 TVLLGGVGLVLYNTE 35816.8 >173241.16 >81649.66 >5590.06 18200.0 >40000<BR> 1188.47 VDLYLLMDCSGSIRR 5597.2 73283.2 >50000 >10864.32 947.9 >52946.51 2522.9<BR> 27.0410 VKNVSQTNFKSLLRN 3469.0 361.1 >20044.59 186.5 >2412.22 1013.5 3198.6 1612.4<BR> 1188.48 VVILTDGIPDSIQDS >72168.78 >141450.82 >50000 >10864.32 15166.7 5138.6 >33333.33<BR> F150.03 YADSAWENVKNVIGPFMKAV 611.0 4751.3 21344.7 >17500 520.8 633.8<BR> 191.16 ADLIAY'LKQATAK 133.3 3033.3<BR> 12.04 DLIAYLKQATAK 95.2 1300.0<BR> 12.05 ERADLIAYLKQATAK 100.0 185.7<BR> 12.03 IAYLKQATAK 1333.3 827.3<BR> 191.10 KAERADLIAY'LKQATA 714.3 165.5<BR> 199.17 LIAY'LKQATAK 181.8 1820.0<BR> F025.08 AATYNFAVLKLMGRGTKF 16.7 239.0 70028.0 1217.9 17.9<BR> K-09 FLYGALLLAEGFYTTGAVRQ 44.6 256.4<BR> F050.22 FLYGALLLAEGFYTTGAVRQ 25197.6 91324.2 1000.6<BR> K-28 FNTWTTCQSIAFPS >9100 99.2<BR> K-20 LCADARMYGVLPWNAFPGK 44.7 5773.5<BR> V<BR> K-05 LTGTEKLIETYFSKNYQDYE 195.8 20000.0<BR> F025.05 QKGRGYRGQHQAHSLERVCH 30151.1 >9100 >25000 17950.6 9759.0<BR> K-18 SAVPVYIYFNTWTTCQSIAF 92.0 20000.0 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F050.05 SAVPVYIYFNTWTTCQSIAF 33333.3 15760.4 72500.0<BR> K-16 TAEFQMTFHLFIAAFVGAAA 548.8 >20000<BR> F025.03 WTTCQSIAFPSKTSASIGSL 40000.0 276.9 37453.2 504.8 400.5<BR> 68.0066 AHCIRNKSVILLGRH 2573.4 104.0 715.1 93.2 159.5 75.1 88.4 4752.4 8.7 3630.5<BR> 68.0078 CAQVHPQKVTKFMLC 32274.9 8730.5 34893.2 18490.0 2697.7 2191.8 808.9 >5543.24 604.1 1229.0<BR> 68.0079 GGPLVCNGVLQGITS >29880.72 9333.8 16308.2 1827.9 3744.7 35.9 30333.3 >3547.48 815.0 13417.3<BR> 60.0080 GPLVCNGVLQGITSW 4893.0 4187.0 32639.6 914.6 1875.7 49.3 6309.7 11614.4 646.0 6537.2<BR> 68.0069 GQVFQVSHSFPHPLY 27.0 548.4 33.2 102.9 557.4 145.7 2172.2 1070.7 415.9 127.6<BR> 68.0062 GRAVCGGVLVHPQWV 3581.7 >110162.86 8068.7 >19640.02 16411.4 5455.9 12888.3 >10756.16 62.1 100000.0<BR> 68.0063 GVLVHPQWVLTAAHC 153.3 1931.0 364.5 262.5 7487.5 2426.8 65.7 >10133.77 6.2 1061.9<BR> 68.0073 HDLMLLRLSEPAELT 152.1 3913.9 22.3 2141.0 520.0 2.3 661.8 5305.0 44.9 10540.9<BR> 68.0064 HPQWVLTAAHCIRNK 282.5 1305.2 106.7 784.7 5790.0 1169.8 6500.0 1324.0 5518.4 40.1<BR> 68.0158 HSLFHPEDTGQVFQV >8184.79 552.6 11502.9<BR> 68.0077 LHVISNDVCAQVHPQ 17451.2 >122500 32670.5 >44721.36 >7118 239.0 22750.0 1886.7 1086.7 >200000<BR> 68.0081 NGVLQGITSWGSEPC 485.4 5874.3 819.3 9724.3 2716.4 775.0 257.6 8037.9 4487.5 11619.1<BR> 68.0071 PHPLYDMSLLKNRFL 10699.0 29812.7 12835.5 >44721.36 486.7 11666.7 711.8 >5543.24 7486.1 3103.9<BR> 68.0065 QWVLTAAHCIRNKSV 213.8 2598.0 966.8 2169.4 4170.5 2062.4 13565.5 7341.6 3801.6 34.7<BR> 68.0082 RPSLYTKVVHYRKWI 652.5 38.7 5483.8 350.4 4160.1 4183.3 717.0 2981.8 4896.6 13.4<BR> 68.0072 SHDLMLLRLSEPAEL 58.1 3537.8 64.4 4470.8 736.7 5.8 1098.5 13577.7 11.6 100000.0<BR> 68.0061 SQPWQVLVASRGRAV 384.7 385.9 621.3 135.2 8775.4 32.1 11258.9 >10756.16 7561.8 83.5<BR> 68.0067 SVILLGRHSLFIIPED 26088.3 500.1 5216.5 96.1 91.2 96.3 105.7 13044.6 4410.6 16116.5<BR> 68.0059 SVTWIGAAPLILSRI 82.9 139.4 30.4 2195.8 511.9 419.8 147.5 13676.2 41.7 104.1<BR> 60.0074 TDAVKVMDLPTQEPA >28306.93 20874.7 >75000 >44721.36 >7118 >35000 >37150.59 >5543.24 747.2 >141421.36<BR> 68.0058 TLSVTWIGAAPLILS 15.7 839.7 5.4 6859.9 55.3 642.2 97.3 6030.6 3506.5 31.2<BR> 68.0070 VFQVSHSFPHPLYDM 50.6 8751.4 17.5 881.2 2477.4 83.2 2395.6 23430.2 >8574.92 897.2 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 68.0068 VILLGRHSLFHPEDT 30624.8 737.2 18519.9 343.6 56.4 543.4 426.4 >10756.16 10695.9 10000.0<BR> 68.0060 VTWIGAAPLILSRIV 195.4 730.7 82.1 1779.4 818.5 2338.5 551.6 >10133.77 88.3 147.1<BR> 68.0125 ADKIYSISMKHPQEM 4098.4 1135.6 3512.2 169.5 9245.9 4957.0 8272.7 >15552.1 3550.1 26726.1<BR> 68.0101 AEAVGLPSIPVHPIG 2015.2 >28290.163 23101.5 >43643.58 699.6 5455.9 55.9 >11642.8 12393. 69336.1<BR> 68.0102 AVGLPSIPVHPIGYY 1079.9 4431.7 15376.7 33333.3 384.3 1190.7 518.4 >11642.8 5386.6 38517.1<BR> 68.0113 CTPLMYSLVHNLTKE 139.7 223.4 249.3 589.5 1727.7 259.8 426.1 18348.6 58.2 35.9<BR> 68.0114 DFEVFFQRLGIASGR 21926.5 122.3 2005.2 128.4 2005.3 10069.0 10248.9 30740.9 4.2 3559.1<BR> 68.0118 DPMFKYHLTVAQVRG 167.6 42.8 257.7 68.6 470.2 699.4 230.0 7297.1 466.8 115<BR> 68.0181 DQLMFLERAFIDPLG 146.3 17114.5 6.6<BR> 68.0111 DSSIEGNYTLRVDCT 14457.9 >163333.33 >100222.97 >40548.01 8939.2 7.6 1202.3 575.7 1261.8 16823.9<BR> 68.0167 EDFFKLERDMKINCS 8549.9 1439.3 >52337.75 10433.3 >1079.89 3188.2 >2432.11 4036.4 7886.1 3494.5<BR> 68.0109 ERGVAYINADSSIEG 34020.7 >163333.33 25515.5 >40548.01 >7055.5 3689.3 30333.3 6846.0 87.4 200000.0<BR> 68.0115 EVFFQRLGIASGRAR 5310.6 6.3 2976.2 30.9 2940.6 17500.0 4555.7 >13118.19 51.2 7.9<BR> 68.0100 EYAYRRGLASGRAR 70.5 596.5 66.6 2589.8 12278.3 5217.5 >45500 8773.5 6324.6 1204.4<BR> 68.0168 FFKLERDMKINCSGK >11622.71 8109.0 >52337.75 9687.3 6935.8 381.7 >2432.11 4917.9 98.4 3795.7<BR> 68.0173 GAAVVHEIVRSFGTL 517.3 788.3 88.7<BR> 68.0096 GKVFRGNKVKNAQLA 2349.8 4120.7 31277.2 894.1 >10595.71 45.8 3372.7 7591.3 7884.3 1385.1<BR> 68.0123 GMVFELANSIVLPFD 29.6 4994.8 81.4 >25819.89 97.5 11.9 82.8 234.0 4154.0 902.6<BR> 68.0090 GNEIFNTSLFEPPPP >29880.72 >126517.46 10414.7 >20380.71 >10595.71 2804.4 >91000 >12809.02 835.0 >115470.05<BR> 68.0097 GNKVKNAQLAGAKGV >72168.78 28904.2 7881.7 >2726.12 >10595.71 >20207.26 >45500 >12103.61 1064.9 1217.9<BR> 68.0110 VAYINADSSIEGNY 6244.5 23359.8 3047.6 >36514.84 5493.2 496.8 7609.8 1420.1 476.5 66666.7<BR> 68.0170 GVILYSDPADYFAPG 7848.0 106290.7 2472.8 >18736.1 1078.3 39.4 964.9 14.2 64.1 14167.9<BR> 68.0103 IGYYDAQKLLEKMGG >72168.78 8235.6 47245.6 >26726.12 >7751.94 5729.1 1978.3 17304.0 13587.6 506.4<BR> 68.0086 IKKFLYNFTQIPHLA 28.8 512.5 159.9 136.8 551.7 27.3 305.2 477.4 96.4 658.5<BR> 68.0166 ISIINEDGNEIFNTS >11622.71 >81666.67 >52337.75 >18736.1 10650.6 343.1 3005.9 73.6 5853.6 >34616.84 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 68.0126 IYSISMKHPQEMKTY 11573.2 1356.9 12292.8 212.9 11435.8 >35000 5024.7 >1552.1 5356.2 2588.2<BR> 68.0087 KFLYNFTQIPHLAGT 29.7 415.0 54.5 90.8 1244.5 220.7 227.1 10211.4 256.3 1600.2<BR> 68.0120 KYHLTVAQVRGGMVF 228.4 1519.1 5860.1 858.6 6376.7 192.9 1221.5 >15552.1 3445.6 86.1<BR> 68.0089 LAHYDVLLSYPNKTH 3617.2 414.9 1009.0 380.1 7286.3 268.2 82.3 1405.7 588.5 172.4<BR> 68.0085 LDELKAENIKKFLYN 7470.2 1248.2 12778.1 324.3 368.1 597.0 413.8 547.8 787.9 149.5<BR> 68.0084 LGFLFGWFIKSSNEA 2261.4 1420.6 1700.6 7303.0 474.6 10103.6 354.8 680.8 9285.1 460.9<BR> 60.0131 LRMMNDQLMFLERAF 17506.9 2492.0 4600.6 1832.9 279.9 1314.0 1411.2 1569.6 49.8 757.8<BR> 68.0119 MFKYHLTVAQVRGGM 72.2 70.4 265.8 147.1 481.6 1615.2 1197.8 3647.9 1061.8 5.8<BR> 68.0176 NSRLLQERGVAYINA 7996.7 3224.4 2616.1 12812.3 619.9 327.5 1229.3 3366.4 698.5 3472.8<BR> 68.0112 NYTLRVDCTPLMYSL 24596.7 6322.7 48412.3 7115.7 593.9 9.0 5055.6 25.4 404.1 66666.7<BR> 68.0127 PQEMKTYSVSFDSLF 1192.4 >82825.12 1980.9 >44721.36 5347.0 24748.7 919.2 14564.5 579.3 100000.0<BR> 68.0083 PRWLCAGALVLAGGF 766.0 26530.7 1438.6 >20380.71 4596.1 20207.3 15166.7 13149.2 883.1 40824.8<BR> 68.0135 QIYVAAFTVQAAAET 323.7 101.7 64.5 33.8 933.7 343.6 251.8 1323.8 50.5 216.1<BR> 68.0122 RGGMVFELANSIVLP 41.5 8682.4 33.1 >25819.89 208.0 4.4 94.2 131.7 411.4 413.4<BR> 68.0133 RHVIYAPSSHNKYAG 31250.0 11666.7 481.2 13363.1 7082.2 8750.0 1290.8 >12475.05 5293.4 87.6<BR> 68.0134 RQIYVAAFTVQAAAE 291.9 36.1 90.9 34.6 609.0 424.4 166.3 6807.4 47.2 142.6<BR> 68.0105 TGNFSTQKVKMHIHS 9407.4 10281.7 1450.5 11856.3 11636.9 6187.2 3744.6 >11642.8 508.5 1926.9<BR> 68.0116 TNKFSGYPLYHSVYE 30853.4 613.6 740.7 33333.3 4482.1 >24748.74 489.3 >15552.1 12465.6 2942.5<BR> 68.0107 TRIYNVIGTLRGAVE 4806.0 70.4 2900.4 45.4 502.4 1459.61605.3 17550.0 447.4 31.6<BR> 68.0128 TYSVSFDSLFSAVKN 345.5 2256.0 526.2 5981.5 5276.7 5888.4 3223.4 8546.3 10461.3 61.1<BR> 68.0136 VAAFTVQAAAETLSE 792.9 1420.0 127.5 2126.2 4460.8 445.9 18200.0 2116.0 464.1 377.7<BR> 68.0121 VAQVRGGMVFELANS 4448.6 >98000 499.1 >44721.36 7605.2 2802.2 116.5 >15552.1 99.9 64366.0<BR> 68.0177 VAYINADSSIEGNYT 9744.9 105831.5 5467.3 >18736.1 8247.2 2147.4 >2432.11 471.3 841.5 >34616.84<BR> 68.0124 VFELANSIVLPFDCR 39.0 36122.8 49.9 11764.7 525.2 23.7 477.2 128.0 1215.0 10814.8<BR> 68.0130 VLRMMNDQLMFLERA 17334.4 1699.9 10683.8 2353.0 98.5 129.8 126.8 97.9 88.1 85.0 TABLE27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 68.0088 WKEFGLDSVELAHYD 3511.0 19970.9 7051.7 4935.0 >10595.71 8413.1 22750.0 829.1 5925.1 89442.7<BR> 68.0117 YDPMFKYHLTVAQVR 158.2 171.9 178.7 252.5 239.7 1014.3 1348.5 8137.L4 552.7 62.4<BR> 68.0165 YISIINEDGNEIFNT 23719.2 >81666.67 83056.5 >18736.1 >10438.01 345.8 2713.2 52.9 3705.3 72992.7<BR> 68.0132 YRHVIYAPSSHNKYA 8792.9 750.0 528.4 1461.8 742.7 6390.1 896.8 61349.7 1117.4 54.1<BR> F112.02 VDAQGTLSRLFKLGGRDSRS 25.3<BR> 938.01 KVNNQVVSLKPEIIVDQEY 2041.2 >1000<BR> F160.32 STORKUSP32<BR> F160.34 STORKUSP34<BR> F160.36 STORKUSP36<BR> F160.37 STORKUSP37<BR> F160.39 STORKUSP39<BR> F047.09 DKLKQQRDTLSTQKET >12578.87 611.4<BR> F047.16 EQKSKQNIGALKQEL >12996.88 110.7<BR> 938.06 SGGTNYAQKFQGRVTMTRDT 8838.8 1571.4<BR> -NH2<BR> 938.08 ELSRLSDDTAVYYCARAPG- 4166.7 40.8<BR> NH2<BR> 938.09 ELSRLTSDDTAVYYCAIAPG- 2311.3 3162.3<BR> NH2<BR> 938.10 TISCSGSSSNIGSNTVN-NH2 17677.7 >6666.67<BR> F015.05 APYHFDLSGHA 208.3<BR> 791.08 APYHFDLSGHAF 603.7<BR> 791.07 APYHFDLSGHAFGS 714.3<BR> 791.06 APYHFDLSGHAFGSMA 54.0<BR> 791.05 APYHFDLSGHAFGSMAKK 101.4<BR> 620.11 APYHFDLSGHAFGSMAKKGE >12500 1000.0 >5051.81 9592.2 172.4 20000.0 90.0<BR> 620.05 CGYKDVDKAPFNGMTGCCN >12500 200000.0 91000.0 >20000 >25000 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> T<BR> 807.03 DLSGHAFGS 928.5<BR> 595.02 EDVIPEGWKADTSYSAK >8333.33<BR> 620.14 ELQFRRVKCKYPDDTKPTFH 8333.3 200000.0 202.2 >25000 >25000<BR> 620.13 EQNVRSAGELELQFRRVKCK 5000.0 2000.0 479.0 >25000 >25000<BR> 620.20 ESWAGVWRIDTPDKLTGPFT >12500 444.4 2268.7 1011.1 18.9 186.0<BR> 791.02 FDLSGHAFGSMAKKGE 143.9<BR> 620.18 GDVVAVVDIKEKGKDKWIEL >12500 200000.0 4550.0 >25000 >25000<BR> K<BR> MA-05 GEKRAYAASDPGRYC 6250.0 2222.2 910.0 408.2 17677.7<BR> 620.19 KGKDKWIELKESWGAVWRID 5000.0 3333.3 3033.3 55.6 295.9<BR> 791.03 LSGHAFGSMAKKGE 443.0<BR> 620.23 SEVEDVIPEGWKADTSYSAK 4166.7 6666.7 91000.0 1041.7 >25000<BR> MA-06 VAYESSEIASKKAG >8333.33 200000.0 15.4 >16666.67 2500.0<BR> 620.16 VEKGSNPNYLAILVKYVDGD 61.0 2000.0 3033. >25000 1560<BR> 791.09 YHFDLSGHAFGS 944.9<BR> 791.01 YHFDLSGHAFGSMAKKGE 171.1<BR> 620.15 YPDDTKPTFHVEKGSNPNYL >12500 200000.0 3033.3 >25000 1178.5<BR> F165.05 KSDNQIKAVPASQALVA 59.0 40.7<BR> F165.01 PKSDNQIKAVPAS 5989.5 >8750<BR> F165.03 PKSDNQIKAVPASQA 1107.8 30.0<BR> F165.02 VRPKSDNQIKAVPAS 1582.1 1197.7<BR> 213.16 FRKDIAAKYKELGY 83.3 3033.3 169.5<BR> 213.15 LFRKDLAAKYKELGY 66.7 1820.0 256.4<BR> 542.00 NKALELFRKDIAA 909.1 91000.0 16666.7<BR> 213.12 NKALELFRKDIAAK 142.9 91000.0 8333.3 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 213.11 NKALELFRKDIAAKY 105.3 91000.0 0.0<BR> 13.00 NKALELFRKDIAAKYKELGY 80.0 650.0 178.6<BR> QG<BR> 213.17 RKDIAAKYKELGY 142.9 91000.0 >20000<BR> NASE061- FTKKMVENAKKIEVEFDKGQ 8333.3 6666.7 455.0 >25000 >25000<BR> 80<BR> F015.01 GLAKVAYVYKP 962.3<BR> NASE121- HEQHLRKSEAQAKKKEKLNIW 6250.0 200000.0 4.8 >5555.56 >25000<BR> 140<BR> 191.26 LVRQGLAKVAY 200000.0 4550.0 533.0<BR> NASE011- PATLIKAIDGDTVKLMYKGQ 8333.3 6666.7 1516.7 2381.0 >25000<BR> 30<BR> NASE031- PMTFRLLLVDTPETKHPKKG >12500 6666.7 1820.0 >5555.56 >25000<BR> 50<BR> 191.29 QGLAKVAYVYK 1333.3 4550.0 75.2<BR> 191.28 ROGLAKVAYVY 200000.0 4550.0 988.2<BR> NASE041- TPETKHPKKGVEKYGPEASA 12500.0 6666.7 1820.0 >11785.5 >25000<BR> 60<BR> NASE051- YEKYGPEASAFTKKMVENAK 12500.0 20000.0 15.6 16666.7 2635.2<BR> 70<BR> 191.27 VRQGLAKVAYV 200000.0 4550.0 637.1<BR> NASE091- YIYADGKMVNEALVRQGLAK 1562.5 6666.7 1820.0 >5555.56 12500.0<BR> 110<BR> 546.00 FTKKMVENAKKIEVEPDKGQ 25000.0 3333.3 116.7 >25000<BR> 66.05 HEQHLRKSEAQAKKEKLNIW 25000.0 200000.0 7.6 16.7<BR> 598.00 PATLIKATDGDTVKLMYKGQ 25000.0 2222.2 568.8 >25000<BR> 866.06 QAKKEKLNIWSEDNADSGQ 25000.0 200000.0 9100.0<BR> 866.02 YEKYGPEASAFTKKMVENAK 25000.0 200000.0 85.9<BR> 866.04 YIYADGKMVNEALVRQGLAK 8333.3 20000.0 3033.3 25000.0 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 835.03 YGAVDSILGGVATYGAA-NH2 250000.0 200000.0 91000.0 26.9<BR> F178.08 AGTIAALNNSIGVLG 4848.3 4873.6 4351.8 6001.8 2069.8 14.9 204.3 3870.9 175.9 99711.3 6099.4<BR> F178.10 GSISYPARYANAMAV 688.0 3679.5 1575.8 22091.7 >7434.33 2701.3 832.5 >4156.45 6815.0 100930.8 6125.0<BR> F178.06 GTVAALDNSAGVLGV 5286.3 36537.9 3850.5 5734.7 1466.7 122.6 983.0 699.9 404.9 19777.6 220.6<BR> F178.05 GTVAALDNSIGVLGV 376.6 22837.4 328.5 9283.1 651.2 26.1 60.4 45.6 48.5 27201.0 1467.1<BR> F178.03 GTVAALNNSAGVLGV 1178.0 12106.6 54.9 3925.6 577.4 3.5 140.2 1788.8 53.5 24476.1 1053.6<BR> F178.01 GTVAALNNSIGVLGV 213.8 2519.7 56.8 3330.3 74.0 1.7 21.0 1468.0 41.7 13528.6 491.9<BR> F178.09 IAALNNSIGVLGVAP 851.3 2926.4 131.1 3058.5 194.5 3.0 273.9 1654.6 6.9 14400.4 4843.7<BR> F178.04 NGIEWAIANNMDVAN 148.6 3188.2 74.7 1742.4 503.0 17.8 214.3 95.9 603.7 1044.3 3305.5<BR> F178.02 NGIEWAIANNMDVIN 109.5 2209.2 45.9 3910.6 932.5 14.0 561.7 116.0 719.2 983.1 2510.3<BR> F178.11 SYPARYANAMAVGAT 129.6 2415.5 196.2 5392.5 >7476.32 465.1 113.4 10999.9 10139.5 2044.3 71.2<BR> F178.07 TGSGVKVAVLDTGIS >184294.24 177601.5 >30905.75 >19820.12 >6676.56 2755.6 >4297.05 1217.5 11.3 >30573.62 2653.0<BR> 573.13 ANSKFIGITELKK 250000.0 10000.0 568.8 >11111.11<BR> 573.13 IKANSKFIGITELKK 2500.0 33.9 178.4 7142.9<BR> 597.10 ILMQYIKANS 12500.0 200000.0 91000.0<BR> L-05 QAIKANSKFIGITE 6666.7 65.0 >3703.7<BR> 650.05 QEIKANSKFIGITE 12500.0 57.1 267.7 >50000 >25000<BR> 650.06 QSIKANSKFIGITE 5000.0 40.0 131.9<BR> 650.21 QYIKANQKFIGITE 1315.8 26.3 20.2 14285.7 >25000<BR> 650.29 QYIKANSKFKGTTE 5000.0 35.1 2.3 >50000 >25000<BR> 650.14 QYIKKNSKFIGITE 531.9 46.5 2600.0 >50000 >25000<BR> 650.16 QYIKSNSKFIGITE 20.8 57.1 32.5<BR> 650.13 QYIRANSKFIGITE 8.9 9.5 18896.5 >25000<BR> 573.14 SKFIGITELKK 781.3 645.2 2275.0 >14285.71<BR> 548.02 YNGQIGNDPNRDIL 0.0 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 534.02 DTPYLDITYHFVMQRLPL 390.6 200000.0 91000.0 800.0 >25000<BR> 1385.07 GELIGILNAAKVPAD 516.9 13.0 >2599.36 931.9<BR> F167.11 ALHIYMDGTMSQVQGSA >10879.85 2933.4 >16680.72<BR> F167.12 ALHIYMNGTMSQVQGSA >9731.24 65.5 >56873.68<BR> F089.22 DQSYLQDSDPDSFQD<BR> F089.13 DYSFLQDSDPDSFQD >66666.67<BR> F089.25 DYSYFQDSDPDSFQD<BR> 1385.10 DYSYLQDSDPDSFQD >11037.77 >10552.9 6582.4 31455.1<BR> F089.11 DYSYLQDSVPDSFQD >102062.07 >48048.45 >7990.27 >66666.67 >6708.41 17500.0 >37150.59 >36514.84<BR> F089.24 DYSYQQDSDPDSFQD<BR> 1385.09 FLLHHAFVDSIFEQWLQRHRP 578.6 >6390.1 >2196.88 21.6<BR> F089.18 ILLSNAPLGQFP >66666.67<BR> F089.20 NILLSNAPLGPQFP 49508.7<BR> F09.06 QNFLLSNAPLGQFP 78.1 169.1 92.0 1677.1 >6708.41 1.6 1184.7 1291.0<BR> F089.28 QNIFLSNAPLGPQFP<BR> F089.04 QNILLSNAPQGPQFP 33256.7<BR> F089.33 QNILLSNQALGPQFP<BR> F089.34 QNILLSNAVLGPQFP<BR> F089.03 QNILLSNQPLGPQFP 6234.6<BR> F089.07 QNILISNVPLGPQFP 869.1 5853.2 1143.8 26263.3 4694.4 3.9 250.2 >36514.84<BR> F089.30 QNILQSNAPLGPQFP<BR> F089.32 QNILVSNAPLGPQFP<BR> F089.27 QNIQLSNAPLGPQFP<BR> F089.29 QNIVLSNAPLGPQFP<BR> F089.19 QVLLSNAPLGPQFP 24784.1 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F089.15 SYLQDSDPDSFQD >6666.67<BR> F089.21 SYLQDSVPDSFQD >102062.07 >48048.45 >60436.72 >66666.67 >6708.41 >17500 >45500 >36514.84<BR> F167.09 WPSVFYNRTCQCSGNF 14367.8 391.8 >17950.55<BR> F167.10 YGQMKNOGSTPMFNDINIYDL 1186.5 172.2 6592.5<BR> F089.16 YLQDSDPDSFQD >66666.67<BR> F089.14 YSYLQDSDPDSFQD >66666.67<BR> 604.01 (AKA)6 >12500<BR> 848.01 A(56)FAAAA(24)A(56)AA(57)- 286.9 2.0 1.4<BR> NH2<BR> 848.03 A(56)FAAAA(24)L56)AA(57)- 174.1 26.6 4.6<BR> NH2<BR> 848.05 A(56)FAAAATA(56)AA(57)- 537.8 79.7 5.1<BR> NH2<BR> 848.07 A(56)FAAAATL(56)AA(57)- 235.3 16.7 5.4<BR> NH2<BR> F042.01 A(X)KQNTLKLAT<BR> 848.02 AAFAAAA(24)A(56)AA(57)- 145.7 36.0 2.5<BR> NH2<BR> 848.04 AAFAAAA(24)L(56)AA(57)- 137.5 14.3 1.6<BR> NH2<BR> 848.06 AAFAAAATA(56)AA(57)-NH2 596.8 18.2 13.3<BR> 848.08 AAFAAAATL(56)AA(57)-NH2 133.4 2.0 4.1<BR> 603.01 AHAAHAAHAAHAAHAAY >12500<BR> F182.04 EVIPMFSALSEGA 15001.0 5769.3 10733.4 52426.9<BR> 520.05 EVWREEAYHAADIKD 25000.0 10000.0 3033.3 >12599.22 >25000<BR> 520.06 EVWREEAYHAADIKDY<BR> 852.04 KYVKQNTLKLAT<BR> 852.05 KYVKQNTLKLAT TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> F182.09 LNKIVRMYSPTSI 1030.8 7820.2 138.9 971.4<BR> F182.10 NKIVRMYSPTSIL 274.9 250.7 306.1<BR> F04.206 P(X)KQNTLKLAT<BR> F042.07 P(X)KONTLKLAT<BR> F182.03 PEVIPMFSALSEG 23900.6 132744.2 3185.4 11281.7<BR> F182.01 PIVQNIQGQMVHQ 15599.3 665242.5 >74649.21 70687.3<BR> F042.02 PKFV(X)TLKLAT<BR> F042.05 PKFVKQNTL(X)T<BR> F042.03 PKFVQ(X)KLAT<BR> F182.08 QEQIGWMTNNPPI 4044.9 313909.2 >74649.21 158188.1<BR> 832.01 TFGLQLELTEGMRFDKG 289.2 20000.1 4550.0<BR> 173.00 TYQRTRALVTG 51.6 4000.0 91000.0 >16666.67 >25000<BR> F182.02 VQNIQGQMVHQAI 22807.6 446065.2 >74649.21 280386.1<BR> 835.01 YIDVWLGGLAENFLP-NH2 2500000.0 200000.0 91000.0 269.9<BR> 785.02 YKKSIQFHWKNSNQIKILG<BR> 843.03 YKLNDRADSRRSL 250000.0 227.3 91000.0<BR> F002.02 YKPVSQLRLATPLLLRPL 14.8 434.8 0. 51.0 21.1<BR> 835.02 YLDPLIGLLARPAKLQV- 250000.0 101.0 216.7 1000000.0 10206.1<BR> NH2<BR> F002.01 YLPKPPKPVSKLRLATPLLLQ 22.8 1451.0 48.2 99.4 93.3<BR> ALPL<BR> 824.07 (14)AAAKTAAAFA-NH2 2551.6 3.2 5.9<BR> 824.08 (15)AAAKTAAAFA-NH2 4419.4 1.3 1.6<BR> 820.03 (15A)RQTTLKAAA-NH2 250000.0 1.8 4.3<BR> 820.05 (15A)RQTTLKAAA-NH2 4550.0<BR> 824.09 (16)AAAKTAAAFA-NH2 25000.0 64.5 325.0 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 820.04 (16A)RQTTLKAAA-NH2 250000.0 76.9 1820.0<BR> 853.01 (39)AAAATKAA(35)-NH2<BR> 853.02 (39)AAAATKAA(36)-NH2<BR> 853.03 (39)AAAATKAA(37)-NH2<BR> 824.37 (39)AAAATKAAAAA<BR> 856.04 (39)AAAKTAAA(35)-NH2<BR> 824.03 (39)-AAAKTAAAFA-NH2 250000.0 65.8 1516.7 1000000.0<BR> 824.21 (39)AAAKTAAAF-NH2<BR> 824.26 (39)AAKTAAAFA-NH2<BR> 824.02 (40)-AAAKTAAAFA-NH2 250000.0 769.2 4550.0 1000000.0<BR> 717.63 (42)YARFQSQITTLKAKT-NII2 7905.7 50.9 137.9 >4347.83 >25000<BR> 787.34 (43)AADFFFFFFFFDA-(NH2)<BR> 787.43 (43)AAFGIDIFGFKIA-(NH2)<BR> 824.11 (45)AAAKTAAAAFA-NH2<BR> 824.28 (46)AAAATKAAAA<BR> 824.12 (46)AAAKTAAAFA-NH2 25000.0 129.0 827.3<BR> 824.29 (47)AAAATKAAAA<BR> 824.13 (47AAAKTAAAFA-NH2 25000.0 1176.5 3033.3<BR> 824.14 (48)AAAKTAAAFA-NH2<BR> 824.31 (49)AAAATKAAAA 8333.3 500.0 1516.7<BR> 862.06 (49)AAAKTAA(64)A-NH2<BR> 856.03 (49)AAAKTAAA(35)-NH2<BR> 862.07 (49)AAAKTAAA(64)-NH2<BR> 862.01 (49)AAAKTAAAAA-NH2<BR> 824.15 (49)AAAKTAAAFA-NH2 8333.3 12.5 30.6 27.2 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 824.23 (49)AAKTAAAFA-NH2<BR> 824.32 (50)AAAATKAAAA<BR> 824.16 (50)AAAKTAAAFA-NH2 >17677.67 1428.6 2275.0<BR> 824.45 (51)AAAATKAAAA 12500.0 869.9 1011.1<BR> 824.43 (51)AAAKTAAAFA-NH2 25000.0 370.4 154.2<BR> 824.44 (52)AAAKTAAAAFA-NH2 12500.0 285.7 910.0<BR> 824.51 (53)AAAATKAAAA<BR> 824.47 (53)AAAAKTAAAAFA-NH2 25000.0 769.2 3033.3<BR> 824.52 (54)AAAATKAAAA<BR> 824.48 (54)AAAKTAAAFA-NH2 25000.0 2000.0 2275.0<BR> 824.50 (55)AAAKTAAAFA-NH2<BR> 601.42 (65)(66)PKFVKQNTLKLAT 129.5 588.2 11.7<BR> 752.03 (67)AAYAAAAAAKAA-NH2 >125000 666.7 43.3 3333.3 357.1<BR> 752.02 (67)FAAAAAAAKAA-NH2 >25000 5000.0 126.4 50000.0 143.5<BR> 858.07 (CP)-QSQTTLKAKT-NH2 250000.0 117.7 1011.1<BR> 859.03 (CP)YAAFQRQTTLKAAA-NH2 250000.0 2.9 123.0 297.7<BR> Sandoz374 (NAF)AAAKTAAAFA-NH2 4000.0<BR> 934.15 (X2)KSSQYIKANSKIGITEAA 1666.7 2390.5 568.5 23678.4 1296.4<BR> AFLPSDFFPSV<BR> 803.11 A(14)AAAKTAAAAA-CONH2 892.9 10.5 22.6 >5000 67.6<BR> 838.02 A(14)AAAKTAAAA-NH2 454.6 108.7 46.0<BR> 760.73 A(14)AAAKTAAAFA-NH2<BR> 838.01 A(14)AAAKTAAA-NH2 96.2 42.7 54.5<BR> 838.04 A(14)AAAKTAAA-NH2<BR> 803.10 A(14)AAAKTAA-CONH2 >8333.3<BR> 838.03 A(14)AAAKTAA-NH2 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 736.21 AA(10)AAAAAAKAAA-NH2 190.8 153.9 13.4 50000.0 82.2<BR> 736.23 AA(12)AAAAAAKAAA-NH2<BR> 839.29 AA(14)A(37)ATKAAAA<BR> 828.03 AA(140AAAA(24)KAAAA-NH2 92.3 6.6 2.6 >4545.45 193.8<BR> 736.25 AA(14)AAAAAAKAAA-NH2 297.6 22.2 13.4<BR> 828.01 AA(14)AAAAPKAAAA-NH2 102.0 8.9 3.2 47.4<BR> 906.30 AA(14)AAAATEKAAA-NH2 773.7 55.4 11.8 756.5 26.2 252.0<BR> 906.33 AA(14)AAAATEKAAA-NH2 44.8 3.3 0.8 4767.4 1.9 31.0<BR> 906.34 AA(14)AAAATIKAAA-NH2 80.9 3.2 1.1 896.2 2.3 69.2<BR> 839.17 AA(14)AAAATK(36)AA<BR> 839.31 AA(14)AAAATK(37)AA<BR> 839.06 AA(14)AAAATKA(35)A<BR> 839.18 AA(14)AAAATKA(36)A<BR> 839.32 AA(14)AAAATKA(37)A<BR> 839.20 AA(14)AAAATKAA(35)-NH2 58.1 16.7 3.5<BR> 839.24 AA(14)AAAATKAA(36)-NH2 2083.3 6.7 1.4<BR> 839.35 AA(14)AAAATKAA(37)-NH2<BR> 839.25 AA(14)AAAATKAAAA 201.6 9.1 1.9<BR> 828.11 AA(14)AAAATKAAAA-NH2 192.3 7.4 7.6 >4545.45 70.0<BR> 906.29 AA(14)AAAATKKAAA-NH2 317.8 7.8 1.3 >19611.69 2.9 471.7<BR> 906.35 AA(14)AAAATLEAAA-NH2 169.6 11.3 7.0 1494.0 17.3 67.8<BR> 906.38 AA(14)AAAATLFAAA-NH2 62.4 19.3 1.8 2719.6 4.1 27.8<BR> 760.57 AA(14)AAAATLKAAA-NH2 171.1 6.9 492.1 2827.2 80.9 4.3 99.2<BR> 906.47 AA(14)AAAATLKAEA-NH2 147.8 26.8 2.4 1792.9 5.7 103.9<BR> 906.50 AA(14)AAAATLKAFA-NH2 79.3 10.1 21.2 459.8 30.1 3.7 35.5 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 906.48 AA(14)AAAATLKAQA-NH2 102.9 20.1 1.0 443.5 2.2 32.7<BR> 906.49 AA(14)AAAATLKAVA-NH2 29.3 4.6 1.0 604.6 2.2 29.5<BR> 906.41 AA(14)AAAATLKEAA-NH2 252.6 295.2 13.0 >19611.69 31.0 449.0<BR> 906.44 AA(14)AAAATLKFAA-NH2 26.2 117.7 3217.3 21.6 845.7 2.3 277.8<BR> 906.45 AA(14)AAAATLKIAA-NH2 28.5 30.6 1.2 54.4 2.6 93.9<BR> 906.40 AA(14)AAAATLKKAA-NH2 625.0 39.3 5253.9 >1754.39 8202.4 0.6 61.0<BR> 906.42 AA(14)AAAATLKQAA-NH2 275.5 29.4 2.7 5661.2 13.4 806.5<BR> 906.43 AA(14)AAAATLKVAA-NH2 49.5 11.9 54.2 85.5 2092.9 2.0 43.4<BR> 906.36 AA(14)AAAATLQAAA-NH2 120.6 17.1 1.6 5423.3 3.8 46.1<BR> 906.39 AA(14)AAAATLRAAA-NH2 97.0 6.9 0.5 5263.2 1.2 48.0<BR> 906.31 AA(14)AAAATQKAAA-NH2 114.9 9.0 0.9 1465.7 1.9 89.0<BR> 906.32 AA(14)AAAATVKAAA-NH2 58.3 4.2 1.3 2917.9 3.0 55.5<BR> 906.24 AA(14)AAAETLKAAA-NH2 423.1 11.4 2.8 343.4 6.3 82.6<BR> 906.27 AA(14)AAAFTLKAAA-NH2 67.6 2.6 1.6 3823.7 3.5 73.7<BR> 856.02 AA(14)AAAKTAAA(35)-NH2<BR> 760.50 AA(14)AAAKTAAAAA-NH2 753.1 6.1 743.0 2416.8 95.3 1250.0 56.5<BR> 906.23 AA(14)AAAKTLKAAA-NH2 29.9 2.2 0.7 4445.6 2.8 52.9<BR> 906.25 AA(14)AAAQTLKAAA-NH2 154.1 3.3 0.8 4545.5 1.8 71.2<BR> 906.28 AA(14)AAATTLKAAA-NH2 75.2 5.3 0.6 2461.8 1.4 50.0<BR> 906.26 AA(14)AAAVTLKAAA-NH2 69.7 4.1 0.7 104.2 1.5 46.6<BR> 906.19 AA(14)AAEATLKAAA-NH2 >1388.89 6.8 6434/.7 315.7 92.4 10.0 1136.4<BR> 906.22 AA(14)AAFATLKAAA-NH2 70.8 4.1 1.5 2858.3 3.7 3125.0<BR> 906.18 AA(14)AAKATLKAAA-NH2 25000.0 1.6 1.6 >19611.69 3.8 581.4<BR> 906.20 AA(14)AAQATLKAAA-NH2 2727.7 4.2 1.5 >19611.69 3.4 1087.0<BR> 906.21 AA(14)AAVATLKAAA-NH2 45.4 2.5 0.7 3261.7 1.6 714.3 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 906.14 AA(14)AEAATLKAAA-NH2 331.1 14.6 15.2 11180.7 24.4 3571.4<BR> 906.17 AA(14)AFAATLKAAA-NH2 33.8 3.3 20.5 1145.9 22.8 1.2 137.8<BR> 906.13 AA(14)AKAATLKAAA-NH2 97.6 3.3 628.0 22361.4 605.4 3.4 >1336.31<BR> 906.15 AA(14)AQAATLKAAA-NH2 104.2 5.7 0.8 21838.8 1.9 581.4<BR> 906.16 AA(14)AVAATLKAAA-NH2 240.2 7.4 75.8 1744.5 13.5 1.3 3571.4<BR> 906.07 AA(14)EAAATLKAAA-NH2 221.8 4.4 7.6 3760.8 18.0 114.5<BR> 906.10 AA(14)FAAATLKAAA-NH2 32.8 4.8 1.8 501.4 4.1 159.8<BR> 906.11 AA(14)IAAATLKAAA-NH2 30.6 4.2 20.5 173.1 42.4 1.4 188.7<BR> 906.06 AA(14)KAAATLKAAA-NH2 53.5 2.8 1.8 318.7 4.3 57.7<BR> 906.12 AA(14)LAAATLKAAA-NH2 47.5 4.8 44.6 305.6 41.7 1.6 97.4<BR> 906.08 AA(14)QAAATLKAAA-NH2 171.9 5.5 1.4 443.0 3.2 123.1<BR> 906.09 AA(14)VAAATLKAAA-NH2 77.2 2.6 14.3 100.0 39.0 1.9 86.0<BR> 906.56 AA(14)VVAATLKAFA 64.6 3.8 6.2 844.8 12.3 8.9<BR> 828.13 AA(15)AAAATKAAAA-NH2 47.5 8.3 0.5<BR> 819.01 AA(15)AAKTAAAFA-NH2 7.8 1.2 0.9<BR> 819.02 AA(15)AAKTGGGFG-NH2 136.1 2.5 1.9<BR> 819.04 AA(15)GGKGGGGFG-NH2<BR> 819.03 AA(15)GGKTAAAFA-NH2 2273.3 2.0 9.1<BR> 819.05 AA(15)GGKTGGGFG-NH2<BR> 736.28 AA(17)AAAAAAKAAA-NH2<BR> 736.33 AA(2)AAAAAAKAAA-CONH2<BR> 773.08 AA(31)AAAAAAKAAA-NH2<BR> 736.17 AA(6)AAAAAAKAAA-NH2<BR> 736.18 AA(7)AAAAAAKAAA-NH2<BR> 736.19 AA(8)AAAAAAKAAA-NH2 TABLE 27b<BR> HAL-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 736.20 AA(9)AAAAAAKAAA-NH2 2083.3 181.8 53.5 50000.0 224.7<BR> 736.34 AA(TIC)AAAAAAKAAA-<BR> CONH2<BR> 871.14 AAAAKAATLKAAA-NH2 493.6<BR> 760.27 AAAFAAAKTAAAFA-NH2 29.4 16.7 6.5 1000000.0 36.1<BR> 730.04 AAAKAAAAAA(10)AA-<BR> CONH2<BR> 730.02 AAAKAAAAAAFAA-CONH2 1785.7 20000.0 1516.7 >50000 >25000<BR> 702.02 AAAKAAAAAAYAA 12500.0 200000.0 1300.0 6250.0 423.7<BR> 702.06 AAAKAAAAAAYAA-COHN2 3125.0 2222.2 364.0 16666.7 25000.0<BR> 789.05 AAAKAAAAAFAAA<BR> 730.07 AAAKATAAAA(23)AA- >6250 1818.2 395.7 >50000 1087.0<BR> CONH2<BR> 787.06 AADFGIFIDFIIA-(NH2)<BR> 736.10 AAEAAAAAAKAAA-NH2<BR> 736.07 AAFAAAAAAKAAA-NH2<BR> 761.03 AAFAAAAAARLFA-NH2<BR> 828.07 AAFAAAAB(24)KAAAA-NH2 1041.7 129.0 5.4 162.3<BR> 760.71 AAFAAAATAKAAA 752.4 22.8 26.0 >4545.45 91.4<BR> 760.41 AAFAAAATAKAAA-NH2 147.1 12.5 13.4 >4545.45 36.6<BR> 760.72 AAFAAAATLKAAA 321.5 13.3 10.7 >4545.45 18.0<BR> 760.43 AAFAAAATLKAAA-NH2 64.1 9.5 8.3 >4545.45 37.9<BR> 871.12 AAFAAAATLKAKA-NH2 44.2<BR> 871.11 AAFAAAATLKKAA-NH2 771.5<BR> 760.37 AAFAAAKTAAAAA-NH2 280.3 5.6 23.2 >4545.45 39.6<BR> 803.08 AAFAAAKTAAAFA-CONH2 35.0<BR> 760.15 AAFAAAKTAAAFA-NH2 67.5 4.6 11.2 20000.0 49.1 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 760.33 AAFAAAKTAAAFA-NH2 98.9 7.7 10.5 >4545.45 47.4<BR> 760.17 AAFAAAKTAAAFE-NH2<BR> 803.13 AAFAAAKTAAAKA-NH2<BR> 760.47 AAFAAAKTLAAAA-NH2 180.7 5.1 14.9 >4545.45 22.7<BR> 871.10 AAFAAAKTLKAAA-NH2 47.6<BR> 871.09 AAFAAKATLKAAA-NH2 1767.8<BR> 760.70 AAFAANKNAAFAA-CONH2 862.1 714.3 182.0<BR> 760.68 AAFAAQKQAAFAA-CONH2 250000.0 1176.5 57.2<BR> 760.69 AAFAATKTAAFAA-CONH2 8.3 222.2 11.5<BR> 760.64 AAFAKAATAKAAA-CONH2 641.0 5.9 36.4 >4545.45 83.0<BR> 760.63 AAFAKAATLKAAA-CONH2 115.2 4.2 10.2 >4545.45 1222.8<BR> 871.06 AAFAKAATLKAKA-NH2 2551.6<BR> 871.05 AAFAKAATLKKAA-NH2 1062.1<BR> 871.04 AAFAKAKTLKAAA-NH2 1511.8<BR> 871.03 AAFAKAKTLKAAA-NH2 >12500<BR> 787.05 AAFFGIFKIGKFA-(NH2)<BR> 787.11 AAFGIKIFGFKIA-(NH2)<BR> 871.02 AAFKKAATLKAAA-NH2 25000.0<BR> 770.04 AAFPPPPTLKAAA-NH2 25000.0<BR> 793.03 AAFVSQTTLKAAA<BR> 736.06 AAHAAAAAAKAAA-NH2<BR> 787.03 AAIGFFFFKKGIA-(NH2)<BR> 787.07 AAIGGIFIFKKDA-(NH2)<BR> 736.08 AALAAAAAAKAAA-NH2 1315.8 2222.2 30.3<BR> 760.09 AALKATAAAAYAA-NH2 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 736.09 AAWAAAAAAKAAA-NH2<BR> 758.01 AAYA(4)A(4)AAKAAA<BR> 758.02 AAYAA(4)A(4)AKAAA<BR> 773.06 AAYAAAA(24)AKAAA-NH2<BR> 773.02 AAYAAAA(26)AKAAA-NH2<BR> 773.03 AAYAAAA927)AKAAA-NH2<BR> 773.04 AAYAAAA(28)AKAAA-NH2<BR> 773.05 AAYAAAA(29)AKAAA-NH2<BR> 773.07 AAYAAAA(30)AKAAA-NH2<BR> 702.03 AAYAAAAAAKAAA-CONH2 129.9 9.1 7.0 3030.3 47.9<BR> 773.09 AAYAAAAPAKAAA-CONH2<BR> 736.04 AAYAAAATAAAKA-NH2<BR> 736.03 AAYAAAATAKAAA-NH2<BR> 736.05 AAYAAAAYAAAKA-NH2<BR> 736.14 AAYAAJJAAKAAA-NH2<BR> 871.13 AAYAKAATLKAAA-NH2<BR> 760.58 AC-AA(14)AAAATLKAAA- 289.0 7.4 3.5 >4545.45 70.7<BR> NH2<BR> 760.51 AC-AA(14)AAAKTAAAAA- 315.5 56.2 91.0 >4545.45 396.5<BR> NH2<BR> 730.13 AC-AAAKAAAAAA(23)AA-<BR> CONH2<BR> 702.08 AC-AAAKAAAAAAYAA<BR> 702.12 AC-AAAKAAAAAAYAA- 2777.8 5000.0 4550.0<BR> CONH2<BR> 760.42 AC-AAFAAAATAKAAA-NH2 533.9 26.2 27.2 >4545.45 50.3<BR> 760.44 AC-AAFAAAATLKAAA-NH2 1075.8 13.3 16.2 >4545.45 68.8 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 760.38 AC-AAFAAAKTAAAAA-NH2 >4347.83<BR> 760.34 AC-AAFAAAKTAAAFA-NH2 203.7 20.0 67.4 >4545.45 472.0<BR> 760.48 AC-AAFAAAKTLAAAA-NH2 5000.0 25.2 202.2<BR> 760.67 AC-AAFAANKNAAFAA- 1190.5 909.1 246.0<BR> CONH2<BR> 760.65 AC-AAFAAQKQAAFAA- 250000.0 1176.5 455.0<BR> CONH2<BR> 760.66 AC-AAFAATKTAAFAA- 50.0 555.6 97.9<BR> CONH2<BR> 806.06 AC-YAA(10)LFLSAARKRA- 1679.2 12.5 0.5<BR> NH2<BR> 760.60 AC-YAA(14)AAAATLKAAA- 705.7 14.3 7.6 >4347.83 85.5<BR> NH2<BR> 760.53 AC-YAA(14)AAAKTAAAAA- 1010.6 11.8 56.5 >4347.83 81.3<BR> NH2<BR> 760.55 AC-YAAFAAAATAKAAA-NH2 25000.0 384.6 84.3 >4347.83 131.0<BR> 760.46 AC-YAAFAAAATLKAAA-NH2 1000.8 20.0 11.6 >4347.83 48.1<BR> 760.40 AC-YAAFAAAKTAAAAA-NH2 1250.0 38.6 93.8 >4347.83 33.5<BR> 760.36 AC-YAAFAAAKTAAAFA-NH2 1828.2 64.9 66.4 >4347.83 63.5<BR> 760.62 AC-YAAFAAAKTLAAAA-NH2 249.6 5.4 17.1 >4347.83 97.3<BR> 805.03 AC-YARFLALTTLRARA- 12500.0<BR> CONH2<BR> 906.02 AE(14)AAAATLKAAA-NH2 181.8 5.8 2.1 2942.5 4.6 50.2<BR> 760.13 AEFAAAKTLAAFA-NH2<BR> 906.05 AF(14)AAAATLKAAA-NH2 35.7 3.4 0.8 1335.1 1.9 39.5<BR> 851.09 AFAAAKTAA(71)<BR> 803.05 AFAAAKTAAAA-CONH2 74.2<BR> 803.04 AFAAAKTAAA-NH2 757.6 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 760.05 AFLRAAAAAAFAAY-NH2<BR> 906.01 AK(14)AAAATLKAAA-NH2 88.9 4.6 1.2 1346.0 2.9 42.3<BR> 965.16 AK(14)VAAATLKAAA-NH2 234.2 23.2 2.8 88.5 10.9<BR> 965.15 AK(14)VAAHTLKAAA-NH2 168.6 30.1 2.5 50.5 4.0<BR> 965.14 AK(14)VAAKTLKAAA-NH2 232.9 34.5 3.6 63.2 8.6<BR> 965.08 AK(14)VAANTLKAAA-NH2 198.9 8.9 1.7 100.1 3.6<BR> 965.08 AK(14)VAANTLKAAA-NH2 146.8 13.7 3.3 5.5<BR> 965.10 AK(14)VAAWTLKAAA-NH2 157.7 97.1 127.6 16.1 >2852.25 220.0 45.1 268.6 104.9 16.9 42.8<BR> 965.17 AK(14)VAAWTLKAAA-NH2 151.3 15.4 2.7 201.1 7.9<BR> 965.09 AK(14)VAAYTLKAAA-NH2 247.5 8.2 3.4 53.3 8.5<BR> 965.09 AK(14)VAAYTLKAAA-NH2 57.8 4.9 2.9 6.7<BR> 965.07 AK(14)VKAHTLKAAA-NH2 174.0 10.5 2.3 5.4<BR> 965.07 AK(14)VKAHTLKAAA-NH2 581.6 5.3 3.0 6.7<BR> 965.01 AK(14)VKANTLKAAA-NH2 492.2 13.2 5.7 13.4<BR> 965.01 AK(14)VKANTLKAAA-NH2 875.4 2.4 4.8 11.3<BR> 965.02 AK(14)VKAWTLKAAA-NH2 93.1 7.3 2.6 5.7<BR> 965.02 AK(14)VKAWTLKAAA-NH2 357.1 1.1 4.1 9.4<BR> 965.03 AK(14)VWANTLKAAA-NH2 206.9 8.8 2.5 261.2 5.8<BR> 965.03 AK(14)VWANTLKAAA-NH2 291.5 3.3 239.8 4134.5 11.0 3227.5<BR> 965.04 AK(14)VWAYTLKAAA-NH2 157.4 3.5 1.2 2.6<BR> 965.04 AK(14)VWAYTLKAAA-NH2 673.0 4.4 4.3 10.1<BR> 965.05 AK(14)VYAWTLKAAA-NH2 885.0 5.7 >20454.55 3.3 7.3<BR> 965.05 AK(14)VYAWTLKAAA-NH2 252.5 7.0 4.1 9.1<BR> 537.00 AKAAKAAKAAKAAKAA 12500.0 363.6 16.6 >7142.86 12500.0<BR> 871.07 AKFAAAATLKAAA-NH2 62.6 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 803.14 AKFAAAKTAAAKA-NH2<BR> Sandoz339 AKFAAALTLAAPA-NH2 >4545.45 84.7<BR> Sandoz338 AKFAAALTLAQAA-NH2 >4545.45 7216.9<BR> 1303.02 AKFIAADTLKAAA<BR> 1303.01 AKFIAAWTLKAAA 3164.2<BR> 1024.03 AKFVAAWTLKAAA-NH2 270.4 12.0 178.4 19.8 5487.8 290.6 29.0 213.9 798.2 16.2 44.5<BR> 1024.06 AKFVAAWTLKAAA-NH2 100.9 9.5 69.9 7.3 572.0 50.4 5362.1 30.4<BR> 1024.04 AKFVAAYTLKAAA-NH2 362.4 15.3 59.0 300.6 1421.8 13.6 30.8<BR> 1303.04 AKFVADWTLKAAA 15212.8 281.4 263.9 >28355.39 248.8 8974.4 >72500 1854.8<BR> 1303.03 AKFVIAWTLKAAA 178.2 20.4 27.8 30000.0 234.1 7.7 10105.7 13.1<BR> 1024.01 AKFVWANTLKAAA-NH2 264.9 15.3 1174.8 415.2 5919.6 47.6 12500.0<BR> 1024.02 AKFVYANTLKAAA-NH2 322.4 33.6 1985.8 6250.0 1764.9 21.7 12500.0<BR> 1303.08 AKIVAAWTLKAAA 302.8 99.2 176.4 1380.3 134.5 76.1 5515.1 190.2<BR> 1303.06 AKIVADWTLKAAA >47245.56 6381.7 5379.4 >28355.39 145.3 653.3 >72500 >66666.67<BR> 1303.09 AKLVAAWTLKAAA<BR> 1303.10 AKMVAAWTLKAAA 396.8 100.0 265.1 90000.0 277.5 160.7 7934.4 178.7<BR> 1303.07 AKMVADWTLKAAA >45950.91 4289.6 5310.6 >28355.39 173.8 4338.5 >72500 61728.4<BR> 906.03 AQ(14)AAAATLKAAA-NH2 53.2 3.7 0.8 1136.4 34.1 92.2<BR> 965.06 AR(14)VRANTLKAAA-NH2 84.0 4.4 2.9 6.6<BR> 820.07 AR(15A)RQTTLKAAA-NH2 1250.0 1.6 0.5<BR> 788.06 ARFQRQTTLKAAA<BR> 781.08 ARFQRQTTLKAAA-NH2<BR> 640.05 ARRLKARRLKAIY >12500 10000.0 650.0 >16666.67 >25000<BR> 906.04 AV(14)AAAATLKAAA-NH2 122.9 3.1 123.8 5564.2 10.8 2.2 69.5<BR> 906.51 AV(14)AVAATLKAFA 77.8 3.6 38.9 411.3 1.3 8.6 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 906.55 AV(14)VFAATLKAFA 91.4 7.0 18.1 3603.7 25.5 16.5<BR> 906.52 AV(14)VVAATLKAAA 135.0 5.4 62.2 221.7 46.6 11.2<BR> 906.53 AV(140VVAATLKAFA 86.2 6.3 26.6 133.2 7.8 14.0<BR> 640.01 AWRNRAKAWRNRAKAWRN >8333.33 714.3 182.0 >10000 1785.7<BR> RAK<BR> 640.03 AWRNRAKAWRNRAKGTD >12500 5000.0 104.6 >12500 2512.6<BR> 758.03 AYAAA(4)A(4)KAAA<BR> S5004 AYZAYAYTLKAAA<BR> S5003 BOC-AYZAYAYTLKAAA<BR> S1395 BOCXFAXAXTLKAAA 3030.3<BR> 631.02 DDYVKQYTKQYTKQNTLKK 12500.0 1111.1 16.0 >11111.11 >25000<BR> 631.03 DDYVKQYTKQYTKQNTLKK >25000 645.2 175.0 >11111.11<BR> 760.08 EFAAATKAAAFAAY-NH2<BR> 819.06 GG(15)GGKGGGGFG-NH2<BR> 736.15 JJYJJAAAAKAAA-NH2 >12500 200000.0 91000.0 >50000 90.7<BR> 640.06 KNRAKNRAKNRAKNRAK >12500 20000.0 197.8 >12500 >25000<BR> 640.07 KRLKRLKRLKRLKRL >12500 87.0 168.5 5882.4 >25000<BR> 965.19 KSSAK(14)VAAWTLKAAA- 514.6 29.3 6.8 10.7 24.8<BR> LHZ<BR> 784.08 PKYDKQGGLKIAT<BR> 784.05 PKYFKQFRLKIAT<BR> 784.13 PKYFKQIGLKRAT<BR> 784.04 PKYGKQRFLKIAT<BR> 784.15 PKYIKQDGLKGAT<BR> 784.09 PKYIKQFFLKRAT<BR> 784.01 PKYIKQIILKIAT TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 784.10 PKYRKQFILKGAT<BR> 736.01 PNYAAAAAAKAAA-NH2 >4166.67<BR> 736.31 PNYAAAAAAKAA-CONH2<BR> 781.07 RFQRQTTLKAAA-NH2<BR> 716.02 TAIKKLTTQRQFRAY >14433.76 200000.0 4550.0 1449.3<BR> 717.11 TKQKLTTQSQFRAY-NH2 >14433.76 200000.0 91000.0 >33333.33<BR> S5006 XFAXAXTLKAAA<BR> Sandoz364 YA(AMK)FAAAKTAAAFA- 4545.5<BR> NH2<BR> Sandoz366 YA(K1)FQ(K1)QTTL(K1)AAA- 4347.8<BR> OH<BR> 806.05 YAA(10)LFLSAARKRA-NH2 2777.8 5.6 2.6 1923.1<BR> 828.04 YAA(14)AAAA(24)KAAAA- 121.4 31.8 3.7 >4347.83 79.4<BR> NH2<BR> 828.02 YAA(14)AAAAPKAAAA-NH2 192.3 10.3 4.7 36.8<BR> 828.12 YAA(14)AAAATKAAAA-NH2 115.7 7.7 5.2 >4347.83 37.1<BR> 760.59 YAA(14)AAAATLKAAA-NH2 256.2 7.1 4.8 >4347.83 30.5<BR> 760.52 YAA(14)AAAKTAAAAA-NH2 406.5 6.9 14.5 2439.0 64.1 20.8<BR> 906.54 YAA(14)AVAATLKAAA 716.3 9.5 10.6 20000.0 48.7 23.5<BR> 828.14 YAA(15)AAAATKAAAA-NH2 75.8 8.3 0.3<BR> Sandoz363 YAA(AMF)AAAKTAAAFA- 4545.5<BR> NH2<BR> 760.26 YAAAKAAAAAAFAA-NH2<BR> Sandoz368 YAAFAAA(DHPS)TAAAFA- 45.2<BR> NH2<BR> Sandoz367 YAAFAAA(K1)TAAAFA-NH2 4000.0 82.8<BR> 828.08 YAAFAAAA(24)KAAAA-NH2 1190.5 129.9 3.3 72.1<BR> 760.25 YAAFAAAAAAKAAA-NH2 266.0 487.8 75.8 1000000.0 409.8 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 CRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 761.04 YAAFAAAAAARLFA-NH2<BR> 761.02 YAAFAAAAAQRLFA-NH2<BR> 760.54 YAAFAAAATAKAAA-NH2 575.1 15.4 14.4 >4347.83 11.9<BR> 760.45 YAAFAAAATLKAAA-NH2 279.7 9.5 4.3 >4347.83 28.3<BR> 760.39 YAAFAAAKTAAAAA-NH2 563.8 12.5 29.2 >4347.83 79.9<BR> 760.39 YAAFAAAKTAAAAA-NH2 1562.5 18.2 91.0<BR> 760.39 YAAFAAAKTAAAAA-NH2 46.3<BR> 760.16 YAAFAAAKTAAAFA-NH2 33.7 2.6 4.3 33333.3 30.0 35.6<BR> 760.35 YAAFAAAKTAAAFA-NH2 1275.8 13.3 46.7 >4347.83 168.1 255.2<BR> Sandoz362 YAAFAAAKTAAAFA-NH2 >4347.83 38.9<BR> 760.18 YAAFAAAKTAAAFE-NH2<BR> 760.61 YAAFAAAKTLAAAA-NH2 134.7 5.0 20.0 >4347.83 37.1<BR> 788.05 YAAFQRQTTLKAAA<BR> 788.04 YAAFOSOTTLKAAA<BR> 793.02 YAAFVRQTTLKAAA<BR> 793.01 YAAFVSQTTLKAAA<BR> 760.14 YAEFAAAKTLAAFA-NH2<BR> 781.16 YAK(14)QRQTTLKAAA- >25000 3.6 31.4 >50000 >25000<BR> CONH2<BR> Sandoz370 YAKFAAAKTAAAA(TR) >4545.45 38.9<BR> 717.08 YAKFKSTTKKRIKS-NH2 785.7 87.0 70.0 >33333.33<BR> 1341.01 YAKFVAAWTLKAAA 2502.4 395.8<BR> 717.35 YAR(10)QSQTTLKAKT-NH2 25000.0 8.0 32.5<BR> 781.20 YAR(14)QKQTTLKAAA >12500 7.1 61.5<BR> 788.01 YAR(14)QRQTTLKAAA<BR> 781.15 YAR(14)QRQTTLKAAA- >25000 2.6 75.8 >50000 >25000 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> CONH2<BR> 782.03 YAR(15)ASQTTLKAKT-NH2 1195.9 3.9 1.7 >25000<BR> 782.07 YAR(15)ASQTTLKAKT-NH2<BR> 820.02 YAR(15A)RQTTLKAAA-NH2 8333.3 1.2 0.4<BR> 820.11 YAR(15A)RQTTLKAAA-NH2 250000.0 1.2 5.4<BR> 820.01 YAR(15A)SQTTLKAKT-NH2 1785.7 2.5 0.7<BR> 820.10 YAR(15A)SQTTLKAKT-NH2 250000.0 4.2 22.8<BR> 782.04 YAR(16)ASQTTLKAKT-NH2 25000.0 800.0 76.5<BR> 717.34 YAR(9)QSQTTLKAKT-NH2 2988.1 47.6 118.2<BR> 717.43 YAREQSQTTLKAKT-NH2 >25000 200000.0 4550.0<BR> 782.06 YARFGGQTTLKAKT<BR> 805.01 YARFLALTTLRARA-CONH2 >25000<BR> 805.02 YARFLALTTLRARA-CONH2 >25000<BR> 717.36 YARFQSQT(24)LKAKT-NH2 >25000 14.3 12.5<BR> 717.18 YARFQSQTELKAKT-NH2 3608.4 4000.0 379.2<BR> 782.01 YARFQSQTTL(32)AKT-NH2 25000.0 57.1 151.7 >4347.83 >25000<BR> 717.24 YARFQSQTTLKEKT-NH2 4166.7 6666.7 193.6<BR> 715.01 YARRLKAIFARRLKA 0.0<BR> 788.03 YASFQSQTTLKAAA<BR> 788.02 YASFVSQTTLKAAA<BR> 785.01 YKKSIQFHWKNSNQIKILGNQ 93.7 170.9 48.4<BR> GSFLTKGPS<BR> 717.09 YPKFVKQNTLKAAT-NH2 >7216.88 1666.7 606.7 >33333.33<BR> 806.11 YQFIKANSKFKGKFK-NH2 5000.0 8.7 2.4<BR> 768.01 YSSFSSSSSSKSSS 2083.3<BR> 768.02 YSSFSSSSSSKSSS-NH2 347.2 20000.0 700.0 1538.5 342.5 TABLE 27b<BR> HLA-DR binding affinity (IC50 nM)<BR> Peptide Sequence DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 DQB1<BR> *0701 *0802 *0901 *1101 *1201 *1302 *1501 *0101 *0101 *0101 *0301<BR> 768.03 YSSFSSSSSSSSSS 2777.8<BR> 768.04 YSSFSSSSSSSSSS-NH2<BR> 564.01 YVKADYVKADYVKADYVK >25000 200000.0 1137.5<BR> 718.01 YVKQNTLAFVKQNTLA 12500.0 200000.0 650.0<BR> 631.01 YVKQYTKQYTKQNTLK 2083.3 689.7 364.0 >14285.71 >25000<BR> S1396 ZAAFAAAATLKAAA<BR> S1399 ZAAFAAAXTAYAYA<BR> S1400 ZAAFAXAATAYAYA<BR> S5005 ZAAFAXAATLKAAA Table 28a Peptide AA Sequence Source 008.00 165 SALLSSDITASVNCAK HEL 81-96 200. 06 16 SALSEGATPQDLNTML HIV gp25 41-56 213. 10 16 NKALELFRKDIAAKYK Sp. W. myo. 132 506. 01 20 NKALELFRKDIAAKYKELGY SW Myo 132-151 506. 03 18 ALELFRKDIAAKYKELGY Sp. W myo. 134 506. 05 16 ELFRKDIAAKYKELGY Sp. W myo. 136 570. 01 16 MAKTIAYDEEARRGLE Heat Shock Prot 705. 06 20 KVYLPRMKMEEKYNLTSVLM Ova 279-298 717. 04 14 YASFVKTTTLRKFT-NH2 DR2 combinatorial 857. 02 20 PHHTALRQAILCWGELMTLA HBV. core. 50 865. 01 15 YKMKMVHAAHAKMKM OVA KM core ext.

F050. 03 20 GFYTTGAVRQIFGDYKTTIC PLP 91-110 F089. 01 15 QNILLSNAPLGPQFP Tyrosinase 56 F098. 03 20 AAYAAQGYKVLVLNPSVAAT HCV. NS3. 1242 F098. 04 20 GYKVLVLNPSVAATLGFGAY HCV NS3 1248 F098. 05 14 GYKVLVLNPSVAAT HCV NS3 1248 F098. 06 19 SYVNTNMGLKFRQLLWFHI HBV Core 87 F098. 10 12 GLKFRQLLWFHI HBV Core 94 F134. 04 20 TLHGPTPLLYRLGAVQNEIT HCV NS4 1-20 F134. 05 20 NFISGIQYLAGLSTLPGNPA HCV. NS4. 151 F134. 08 21 GEGAVQWMNRLIAFASRGNHV HCV. NS4. 293 IA-p5 17 KPVSQMRMATPLLMRPM Mouse. Ii. 85 Tr-28 pl 24 LPKPPKPVSKMRMATPLLMQALPM Human. Ii. 80 27. 0279 15 EYLVSFGVWIRTPPA HBV. nuc. 117 27. 0280 15 GVWIRTPPAYRPPNA HBV. nuc. 123 27. 0281 15 RHYLHTLWKAGILYK HBV. pool. 145 27. 0283 15 VPNLQSLTNLLSSNL HBV POL 409 27. 0288 15 WVTVYYGVPVWKEAT HIVl. env. 47 27. 0293 15 YYGVPVWKEATTTLF HIV1 ENV 51 27. 0294 15 VPVWKEATTTLFCAS HIVl. env. 54 Peptide AA Sequence Source 27. 0295 15 LSGIVQQQNNLLRAI HIV1. env. 711 27. 0296 15 QQHLLQLTVWGIKQL HIV1 ENV 728 27. 0297 15 QHLLQLTVWGIKQLQ HIVl. env. 729 27. 0298 15 LLQLTVWGIKQLQAR HIV1 ENV 731 27. 0304 15 QGQMVHQAISPRTLN HIVE. gag. 171 27. 0307 15 SPEVIPMFSALSEGA HIV1 GAG 197 27. 0310 15 QEQIGWMTNNPPIPV HIV1 GAG 276 27. 0311 15 GEIYKRWIILGLNKI HIVl. gag. 294 27. 0312 15 YKRWIILGLNKIVRM HIV 1 GAG 297 27. 0313 15 KRWIILGLNKIVRMY HIVl. gag. 298 27. 0314 15 WIILGLNKIVRMYSP HIV l. gag. 300 27. 0315 15 VKNWMTETLLVQNAN HIV1 GAG 348 27. 0322 15 GTVLVGPTPVNIIGR HIV1 POL 153 27. 0324 15 PVNIIGRNLLTQIGC HIV1 POL 161 27. 0326 15 GRNLLTQIGCTLNFP HIVl. pol. 166 27. 0328 15 TLNFPISPIETVPVK HIVl POL 176 27. 0329 15 NFPISPIETVPVKLK HIV1. pol. 178 27. 0341 15 FRKYTAFTIPSINNE HIV1.pol. 303 27. 0344 15 SPAIFQSSMTKILEP HIV1.pol. 335 27. 0345 15 PAIFQSSMTKILEPF HIV1 POL 336 27. 0349 15 QKLVGKLNWASQIYA HIV1 POL 437 27. 0350 15 VGKLNWASQIYAGIK HIV1.pol. 440 27. 0351 15 NREILKEPVHGVYYD HIV1.pol.485 27. 0353 15 IPEWEFVNTPPLVKL HIV1 POL 593 27. 0354 15 WEFVNTTPLVKLWYQ HIV1.pol. 596 27. 0360 15 EQLIKKEKVYLAWVP HIV1 POL 705 27. 0361 15 EKVYLAWVPAHKGIG HIV.pol. 711 27. 0364 15 HSNWRAMASDFNLPP HIV1.pol. 758 27. 0370 15 ASGYIEAEVIPAETG HIV1 POL 822 27. 0372 15 AEHLKTAVQMAVFIH HIVl. pol. 911 27. 0373 15 KTAVQMAVFIHNFKR HIV1.pol. 915 Peptide AA Sequence Source 27. 0377 15 QKQITKIQNFRVYYR HIV1.pol. 956 27. 0379 15 KLLWKGEGAVVIQDN HIV1.pol. 982 27. 0381 15 ENRWQVMIVWQVDRM HIV1.vif.2 27. 0382 15 VEAIIRILQQLLFIH HIV1 VPR 57 27. 0384 15 FNVVNSSIGLIMVLS Pf CSP 413 27. 0387 15 MNYYGKQENWYSLKK Pf CSP 53 27. 0388 15 MRKLAILSVSSFLFV Pf. CSP. 2 27. 0390 15 NSSIGLIMVLSFLFL Pf CSP 417 27. 0392 15 SSVFNVVNSSIGLIM Pf. CSP. 410 27. 0393 15 MKLLSVFFLALFFII Pf EXPI 1 27. 0398 15 FILVNLLIFHINGKI Pf LSA1 11 27. 0400 15 HILYISFYFILVNLL Pf LSA1 3 27. 0402 15 LLIFHINGKIIKNSE Pf LSA1 16 27. 0403 15 LVNLLIFHINGKIIK PU LSA 13 27. 0406 15 NLLIFHINGKIIKNS Pf LSA1 15 27. 0408 15 QTNFKSLLRNLGVSE PfLSA1 94 27. 0412 15 AYKFVVPGAATPYAG Pf SSP2 514 27. 0415 15 NVKYLVIVFLIFFDL Pf SSP2 6 27. 0417 15 VKNVIGPFMKAVCVE Pf. SSP2. 223 27. 0418 15 WENVKNVIGPFMKAV Pf SSP2 220 1186. 04 15 CSVVRRAFPHCLAFS HBV. pol. 534 1186. 06 15 FVQWFVGLSPTVWLS HBV ENV 342 1186. 10 15 LAQFTSAICSVVRRA HBV. pol. 526 1186. 15 15 LVPFVQWFVGLSPTV HBV. env. 339 1186. 18 15 NLSWLSLDVSAAFYH HBV POL 422 1186. 25 15 SFGVWIRTPPAYRPP HBV. nué. 121 1186. 26 15 SPFLLAQFTSAICSV HBV. pol. 522 1186. 27 15 SSNLSWLSLDVSAAF HBV POL 420 1188. 01 15 DKELTMSNVKNVSQT PfLSA1 81 1188. 13 15 AGLLGNVSTVLLGGV Pf. EXP1. 82 1188. 16 15 KSKYKLATSVLAGLL Pf. EXP1. 71 Peptide AA Sequence Source 1188. 32 15 GLAYKFVVPGAATPY Pf.SSP2. 512 1188. 34 15 HNWVNHAVPLAMKLI Pf. SSP2. 62 1188. 35 15 IGPFMKAVCVEVEKT Pf SSP2 227 1188. 38 15 KYKIAGGIAGGLALL Pf. SSP2. 494 1188. 45 15 RHNWVNHAVPLAMKL Pf SSP2 61 F091. 15 16 IKQFINMWQEVGKAMY HIV 1. env. 566 F107. 03 15 LQSLTNLLSSNLSWL HBV. pol. 412 F107. 04 15 PFLLAQFTSAICSVV HBV. pol. 523 F107. 09 15 KYKLATSVLAGLLGN Pf EXP 173 F107. 10 15 LAGLLGNVSTVLLGG Pf EXPL 81 F107. 11 15 RHPFKIGSSDPADNA Pf EXP1 107 F107. 14 15 ANQLVVILTDGIPDS PfSSP2153 F107. 17 15 KFVVPGAATPYAGEP Pf SSP2 516 F107. 23 15 VFNVVNSSIGLIMVL Pf CSP 412 35. 0093 15 VGPLTVNEKRRLKLI HBV. pol. 96 35. 0096 15 ESRLVVDFSQFSRGN HBV. pol.387 35. 0100 15 LCQVFADATPTGWGL HBV. pol.683 35. 0106 15 VWVATDALMTGYTG HCV. 1437 35. 0107 15 TVDFSLDPTFTIETT HCV. 1466 35. 0125 15 AETFYVDGAANRETK HIV. pol. 619 35. 0127 15 EVNIVTDSQYALGII HIV. pol. 674 35. 0131 15 WAGIKQEFGIPYNPQ HIV. pol. 874 35. 0133 15 GAVVIQDNSDIKVVP HIV. pol. 989 35. 0135 15 YRKILRQRKIDRLID HIV. vpu. 31 35. 0171 15 PDSIQDSLKESRKLN Pf. SSP2. 165 35. 0172 15 KCNLYADSAWENVKN Pf. SSP2. 211 1280. 02 15 IGTVLVGPTPVNIIG HIV. pool. 152 1280. 03 15 KVYLAWVPAHKGIGG HIV. pol. 712 1280. 04 15 TKELQKQITKIQNFR HIV. pol. 952 1280. 06 15 AGFFLLTRILTIPQS HBV. env. 180 1280. 08 15 GFFLLTRILTIPQSL HBV ENV 181 Peptide AA Sequence Source 1280. 09 15 GTSFVYVPSALNPAD HBV.pol. 774 1280. 12 15 IIFLFILLLCLIFLL HBV ENV 244 1280. 13 15 KFAVPNLQSLTNLLS HBV POL 406 1280. 15 15 LHLYSHPIILGFRKI HBV. pol. 501 1280. 16 15 LLCLIFLLVLLDYQG HBV ENV 251 1280. 21 15 VGLLGFAAPFTQCGY HBV POL 637 1280. 22 15 FYFILVNLLIFHING PULSA19 1280. 23 15 KSLLRNLGVSENIFL Pf. LSA1. 98 1280. 25 15 RGYYIPHQSSLPQDN Pf. LSA1. 1669 1283. 02 15 VYLLPRRGPRLGVRA HCV Core 34 1283. 10 15 GHRMAWDMMMNWSPT HCV El 315 1283. 11 15 CGPVYCFTPSPWVG HCV. NS1/E2. 506 1283. 12 15 VYCFTPSPVVVGTTD HCV NS1/E2 509 1283. 13 15 GNWFGCTWMNSTGFT HCV. NS1/E2. 550 1283. 14 15 FTTLPALSTGLIHLH HCV NS1/E2 684 1283. 16 15 SKGWRLLAPITAYAQ HCV. NS3. 1025 1283. 17 15 DLYLVTRHADVIPVR HCV NS3 1134 1283. 20 15 AQGYKVLVLNPSVAA HCV. NS3. 1251 1283. 21 15 GYKVLVLNPSVAATL HCV. NS3. 1253 1283. 22 15 VLVLNPSVAATLGFG HCV. NS3. 1256 1283. 24 15 GARLVVLATATPPGS HCV NS3 1345 1283. 26 15 DVVVVATDALMTGYT HCV. NS3. 1436 1283. 30 15 FTGLTHIDAHFLSQT HCV. NS3. 1567 1283. 31 15 YLVAYQATVCARAQA HCV. NS3. 1591 1283. 33 15 LEVVTSTWVLVGGVL HCV41658 1283. 34 15 TWVLVGGVLAALAAY HCV NS4 1664 1283. 36 15 AKHMWNFISGIQYLA HCV. NS4. 1767 1283. 37 15 IQYLAGLSTLPGNPA HCV NS4 1777 1283. 44 15 MNRLIAFASRGNHVS HCV. NS4. 1921 1283. 50 15 SYTWTGALITPCAAE HCV. NS5. 2456 1283. 55 15 GSSYGFQYSPGQRVE HCV. NS5. 2641 Peptide AA Sequence Source 1283. 57 15 LELITSCSSNVSVAH HCV. NS5. 2813 1283. 61 15 ASCLRKLGVPPLRVW HCV. NS5. 2939 1298. 02 15 VGNFTGLYSSTVPVF HBV. pol. 53 1298. 03 15 TNFLLSLGIHLNPNK HBV. pol. 568 1298. 04 15 KQCFRKLPVNRPIDW HBV. pol. 615 1298. 06 15 KQAFTFSPTYKAFLC HBV. pol. 661 1298. 07 15 AANWILRGTSFVYVP HBV. pol. 764 1298. 08 15 PDRVHFASPLHVAWR HBV. pol. 824 1298. 10 15 IRPVVSTQLLLNGSL HIV1. env. 333 1298. 11 15 RSELYKYKVVKIEPL HIVE. env. 637 1298. 13 15 DRFYKTLRAEQASQE HIV1 GAG 333 1298. 16 15 KVILVAVHVASGYIE HIV1.pol. 813 F125. 02 17 LVNLLIFHINGKIIKNS Pf. LSA1. 13 F125. 04 16 RHNWVNHAVPLAMKLI Pf.SSP2. 61 -- indicates binding affinity >15, OOOnM.

Table 28b<BR> IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> SALLSSDITASVNCAK >1667 >5000 244 84 >1000 >8333 9592 2<BR> 0<BR> SALSEGATPQDLNTML 417 833 587 -- 323 -- -- 4<BR> NKALELFRKDIAAKYK 1667 233 529 182 261 4<BR> NKALELFRKDIAAKYKELGY >1250 1429 240 306 42 -- 392 4<BR> ALELFRKDIAAKYKELGY 1818 150 237 364 336 4<BR> ELFRKDIAAKYKELGY 1667 297 300 125 470 4<BR> MAKTIAYDEEARRGLE -- >5000 283 -- -- -- 1<BR> KVYLPRMKMEEKYNLTSVLM 1000 3333 335 >11250 1053 714 -- 3<BR> YASFVKTTTLRKFT-NH2 500 3.6 178 12 22 31 -- 6<BR> PHHTALRQAILCWGELMTLA 70 8.3 211 -- 85 263 -- -- 676 196 2701 7<BR> YKMKMVHAAHAKMKM 3.6 8.7 208 92 45 62 6<BR> GFYTTGAVRQIFGDYKTTIC 91 346 -- 7833 48 3<BR> QNILLSNAPLGPQFP 225 1<BR> AAYAAQGYKVLVLNPSVAAT 2.9 48 488 1765 17 1226 105 3239 11 96 61 6528 242 77 10<BR> GYKVLVLNPSVAATLGFGAY 3.6 41 8000 10 1520 241 9613 4.1 23 80 20 8<BR> GYKVLVLNPSVAAT 1.4 38 3704 8 141 74 4585 3.5 125 21 268 9<BR> SYVNTNMGLKFRQLLWFHI 417 123 2899 6618 6441 41 1987 13 833 377 9259 6<BR> GLKFRQLLWFHI 179 34 1053 4091 1027 32 5960 1591 641 123 4688 5 IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> TLHGPTPLLYRLGAVQNEIT 17 1286 690 2273 2<BR> NFISGIQYLAGLSTLPGNPA 10 606 85 74 -- 70 5<BR> GEGAVQWMNRLIAFASRGNHV 3.3 29 182 -- 375 14 -- 26 227 158 8<BR> KPVSQMRMATPLLMRPM 1.2 15 52 49 88 111 25 169 -- 13 9<BR> LPKPPKPVSKMRMATPLLMQA 0.90 14 31 79 141 200 444 392 0.70 40 258 -- 54 8 13<BR> LPM<BR> EYLVSFGVWIRTPPA 8.8 15 435 -- 4091 792 1818 -- 2333 58 6901 87 6<BR> GVWIRTPPAYRPPNA 14 217 2.8 -- 13 67 42 -- >875 114 93 -- 1667 13488 8<BR> 0<BR> RHYLHTLWKAGILYK 17 5.4 35 -- 2250 1462 42 149 745 61 27 11191 174 784 10<BR> VPNLQSLTNLLSSNL 83 3033 -- -- 237 1250 10643 5000 -- 4083 -- 2<BR> WVTVYYGVPVWKEAT 63 2@ 286 -- 2500 4.6 -- -- >875 807 10000 163 6<BR> 0<BR> YYGVPVWKEATTTLF 455 -- 7407 -- 1452 13333 -- >875 109 13243 197 3<BR> 0<BR> VPVWKEATTTLFCAS 192 -- 385 -- 409 422 9524 -- 8750 397 5698 160 6<BR> LSGIVQQQNNLLRAI 54 57 61 10345 300 2000 -- -- 46 -- -- -- 5<BR> QQHLLQLTVWGIKQL 4.5 12 345 -- 1364 141 5556 608 194 64 2333 147 8<BR> QHLLQLTVWGIKQLQ 6.1 21 690 -- 1184 346 2128 1064 350 44 907 -- 375 414 9<BR> LLQLTVWGIKQLQAR 60 2083 2368 267 1389 2<BR> QGQMVHQAISPRTLN 73 65 13 -- 54 400 -- -- 412 455 7313 -- 117 135 9 IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> SPEVIPMFSALSEGA 109 325 5882 -- 281 2667 -- 5000 -- 3769 5769 3<BR> QEQIGWMTNNPPIPV 714 4550 8333 13044 38 -- -- 1.0 1923 -- -- 3<BR> GEIYKRWIILGLNKI 82 138 225 -- 1500 380 213 1656 98 192 63 1205 536 161 10<BR> YKRWILLGLNKIVRM 4.2 5.7 26 273 608 158 65 199 0.90 208 91 121 12<BR> KRWIILGLNKIVRMY 4.2 5.1 24 188 570 404 54 347 0.40 379 49 1808 58 187 13<BR> WIILGLNKIVRMYSP 125 28 182 273 1452 1310 54 1242 1.9 2841 175 -- 7<BR> VKNWMTETLLVQNAN 1515 700 2597 -- 938 -- -- 1094 893 -- -- 3<BR> GTVLVGPTPVNIIGR 758 1492 >14285 -- -- 4651 -- 121 305 -- 4167 3<BR> PVNIIGRNLLTQIGC 848 >14285 10465 202 -- 2<BR> GRNLLTQIGCTLNFP 25 182 >14285 -- 500 >8261 3030 -- 27 4167 -- -- 4<BR> TLNFPISPIETVPVK 263 -- >14285 -- 1286 -- 8054 233 391 -- -- 3<BR> NFPISPIETVPVKLK 104 7000 9091 -- 556 4000 -- 6478 184 167 -- -- 4<BR> FRKYTAFTIPSINNE 185 70 4167 -- 265 136 1818 -- >875 30 803 -- 40 -- 7<BR> 0<BR> SPAIFQSSMTKILEP 357 217 667 -- 3214 109 741 -- 13 68 3267 887 33 14500 9<BR> PAIFQSSMTKILEPF 156 284 1000 -- 7759 59 303 -- 32 34 3500 82 8<BR> QKLVGKLNWASQIYA 128 89 3636 8108 10227 >8261 5714 2709 2.3 510 223 375 6<BR> VGKLNWASQIYAGIK 357 178 13 -- 7258 >8261 4348 1064 2.2 481 5104 68 6<BR> NREILKEPVHGVYYD 17 61 >14285 2500 237 1267 -- 12957 292 7576 -- 3571 4<BR> IPEWEFVNTPPLVKL 4.5 1023 11 3261 68 24 241 5519 152 18 189 29 9<BR> WEFVNTPPLVKLWYQ 7.2 222 2.1 13636 25 20 318 1355 90 15 350 8546 40 527 11 IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> EQLIKKEKVYLAWVP 7.8 114 3390 13636 11 3448 -- >116 -- -- -- 3<BR> 67<BR> EKVYLAWVPAHKGIG 3.6 21 4.9 3226 8.3 27 37 6478 3500 18 31 -- 144 14 10<BR> HSNWRAMASDFNLPP 33 -- 125 -- 9.6 15 95 -- 4375 472 1960 -- 872 951 8<BR> ASGYIEAEVIPAETG 217 -- >9523 -- 196 10000 -- 5833 2083 5052 1563 2<BR> AEHLKTAVQMAVFIH 200 4333 6452 -- 3462 224 -- 7268 66 403 9608 142 5<BR> KTAVQMAVFIHNFKR 161 650 690 -- 818 452 182 -- 125 1786 1441 14688 2586 1000 8<BR> QKQITKIQNFRVYYR 2.9 3.4 80 -- 321 49 53 124 25 25 75 -- 577 611 12<BR> KLLWKGEGAVVIQDN 11 8273 3448 -- 600 1900 3333 -- 78 104 1089 357 5<BR> ENRWQVMIVWQVDRM 2 1542 5556 -- 652 20 6250 -- 1944 208 327 259 6<BR> VEAIIRILQQLLFIH 147 2667 1216 556 1136 2<BR> FNVVNSSIGLIMVLS 66 350 >9523 -- 14063 >1407 -- -- 65 281 -- 469 5<BR> 4<BR> MNYYGKQENWYSLKK 6.4 9100 435 -- 21 292 351 -- 3182 3788 539 -- 6<BR> MRKLAILSVSSFLFV 50 18 1539 -- 5769 1407 541 2483 38 500 -- 682 6<BR> NSSIGLIMVLSFLFL 1250 364 8333 -- 3750 10857 -- 8765 3889 362 -- -- 2<BR> SSVFNVVNSSIGLIM 42 314 2500 -- 450 1652 1177 -- 10 33 891 63 7<BR> MKILSVFFLALFFII 2941 535 >9523 -- 1216 >8261 >2000 -- 1842 694 -- 12500 2<BR> 0<BR> FILVNLLIFHINGKI 1389 700 13333 -- 1406 >8085 2632 -- 1029 521 11667 6818 2<BR> HILYISFYFILVNLL 3125 827 -- -- 1667 >1266 18182 -- 2500 357 -- -- 2 IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> 7<BR> LLIFHINGKIIKNSE 8.8 31 80 682 7500 >1266 56 12957 106 192 350 500 9<BR> 7<BR> LVNLLIFHINGKIIK 78 13 2857 -- 4091 >1266 74 7268 66 208 1690 417 6<BR> 7<BR> NLLIFHINGKIIKNS 3.6 6.1 71 1200 5769 2375 83 6082 19 49 153 278 8<BR> QTNFKSLLRNLGVSE 91 8273 5405 -- 2500 1900 51 -- 47 7813 69 -- 4<BR> AYKFVVPGAATPYAG 14 >1011 323 18750 281 10556 31 2483 21 139 53 577 8<BR> 1<BR> NVKYLVIVFLIFFDL 2000 650 >6897 -- 750 >1266 6667 -- 2188 714 9074 -- 3<BR> 7<BR> VKNVIGPFMKAVCVE 56 212 250 -- -- >1266 476 3239 32 424 2130 -- 862 5859 7<BR> 7<BR> WENVKNVIGPFMKAV 79 54 290 -- -- 8636 -- -- 4375 1563 -- 9375 3<BR> CSVVRRAFPHCLAFS 50 89 260 -- -- >1266 -- -- 65 424 1960 63 1261 6<BR> 7<BR> FVQWFVGLSPTVWLS 11 2600 1250 -- 3462 2778 -- 184 362 2722 1829 -- 3<BR> LAQFTSAICSVVRRA 417 1400 133 -- 3000 1357 2632 -- 3500 893 3267 852 3053 4<BR> LVPFVQWFVGLSPTV 385 13 1429 -- 300 27 53 452 1944 2717 74 1679 30 20 9<BR> NLSWLSLDVSAAFYH 36 -- -- 395 155 6061 14900 106 6098 3267 63 1210 7.4 6<BR> SFGVWIRTPPAYRPP 532 827 47 -- 577 603 769 -- -- 1042 196 -- 938 -- 8 IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> SPFLLAQFTSAICSV 42 455 2353 -- 608 2000 -- -- 65 758 -- 1974 290 6<BR> SSNLSWLSLDVSAAF 36 3033 -- 200 167 4348 8514 35 6410 1065 22 6818 3.2 6<BR> DKELTMSNVKNVSQT 2778 -- -- -- -- 5135 6667 -- 81 610 4455 1015 -- 2<BR> AGLLGNVSTVLLGGV 116 379 -- -- 6923 1056 -- -- 0.80 58 -- 142 -- 5<BR> KSKYKLATSVLAGLL 3.6 1247 24 -- 7.1 47 30 -- 427 13 45 156 28 4143 9<BR> GLAYKFVVPGAATPY 3.1 -- 29 -- 45 1407 11 851 7.1 167 20 47000 125 3053 9<BR> HNWVNHAVPLAMKLI 14 364 143 1304 12 950 2703 497 3.7 66 68 -- 19 3053 10<BR> IGPFMKAVCVEVEKT 694 -- 465 -- -- 4419 -- -- 11667 13158 -- 915 829 4<BR> KYKIAGGIAGGLALL 132 -- 417 12000 3750 -- 87 828 15 3968 31 289 -- 7<BR> RHNWVNHAVPLAMKL 26 260 125 750 9.0 10562532 12417 3.9 57 27 16 1349 9<BR> IKQFINMWQEVGKAMY 128 217 206-- 375 271 4878 -- 1000 -- 350 -- 5769 112 8<BR> LQSLTNLLSSNLSWL 2.0 21 1000 -- 9.4 47 294 397 135 167 557 -- 682 1813 11<BR> PFLLAQFTSAICSVV 28 337 4762 -- 563 317 1667 -- 44 325 845 -- 1271 1349 7<BR> KYKLATSVLAGLLGN 4.2 5056 286 -- 14 317 952 -- 467 39 377 29 9<BR> LAGLLGNVSTVLLGG 119 827 -- 38462 2813 1652 -- -- 5.5 66 -- 136 5<BR> RHPFKIGSSDPADNA 1136 -- -- -- 96 13103 3571 -- 11667 -- 1290 790 2<BR> ANQLVVILTDGIPDS 1316 11375 -- -- 978 6129 -- -- 500 4630 -- 1786 2<BR> KFVVPGAATPYAGEP 217 -- -- 4839 375 5672 20000 3465 76 14706 7656 300 4<BR> VFNVVNSSIGLIMVL 161 4333 -- -- 5696 6786 -- -- 14 139 -- 150 4<BR> VGPLTVNEKRRLKLI 8333 4136 4255 136 >8182 6667 -- 3889 -- 5326 >3615 81691<BR> ESRLVVDFSQFSRGN 7143 1230 -- 115 188 -- -- 875 -- -- 2474 8657 3 IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> LCQVFADATPTGWGL 7143 -- -- 67 489 -- -- 1944 -- -- 1808 1036 2<BR> VVVVATDALMTGYTG 1042 1936 14286 273 >8182 -- -- 1207 625 -- >3615 817 3<BR> TVDFSLDPTFTIETT 5556 -- >1000 150 1957 -- -- 169 8333 >30625 24 3625 3<BR> AETFYVDGAANRETK 2381 -- 4348 769 >8182 -- -- -- -- 14000 1068 -- 1<BR> EVNIVTDSQYALGII -- 2677 -- 732 7627 -- -- 324 -- -- 118 -- 3<BR> WAGIKQEFGIPYNPQ 2778 5056 125 300 >10000 -- 805 285 -- -- >3615 951 5<BR> GAVVIQDNSDIKVVP 1515 325 14286 1000 -- -- -- 78 -- -- >3615 725 4<BR> YRKILRQRKIDRLID 2083 123 488 23 >10000 133 4257 2188 -- 1815 >3615 36 5<BR> PDSIQDSLKESRKLN -- 2275 >11111 357 >10000 -- -- -- -- -- >3615 -- 1<BR> KCNLYADSAWENVKN -- -- -- 857 >10000 -- -- 11667 -- -- -- -- 1<BR> IGTVLVGPTPVNIIG 417 535 -- 56250 12667 -- 88 352 -- 2344 4<BR> KYYLAWVPAHKGIGG 8.3 25 24 -- 141 165 71 12417 2500 179 196 -- 250 290 10<BR> TKELQKQITKIQNFR 704 433 571 833 1900 377 700 4546 1960 -- 6<BR> AGFFLLTRILTIPQS 1.1 217 1053 -- 8.5 253 6 4257 10 8 189 4273 58 699 10<BR> GFFLLTRILTIPQSL 12 607 1818 15 84 9 45 7 31 136 9<BR> GTSFVYVPSALNPAD 14 650 400 -- 118 93 426 -- 35000 93 803 -- 221 -- 9<BR> IIFLFILLLCLIFLL 0<BR> KFAVPNLQSLTNLLS 278 -- -- 346 4651 398 -- -- 3<BR> LHLYSHPIILGFRKI 227 268 500 -- 66 238 488 9613 17500 41667 803 -- 1531 102 8<BR> LLCLIFLLVLLDYQG 0<BR> VGLLGFAAPFTQCGY 106 29 -- -- -- -- 17857 132 3 IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> FYFILVNLLIFHING 0<BR> KSLLRNLGVSENIFL 333 1034 -- 2143 469 6061 6.1 325 -- 47 5<BR> RGYYIPHQSSLPQDN 17 -- 6897 11 136 3125 8750 147 3267 500 5<BR> VYLLPRRGPRLGVRA 357 23 556 -- 1667 -- -- -- 3<BR> GHRMAWDMMMNWSPT 179 6067 4546 281 2532 438 14706 3261 3<BR> CGPVYCFTPSPVVVG 19 3640 -- 173 95 -- -- 93 -- 174 5<BR> VYCFTPSPVVVGTTD 278 -- -- 489 667 3571 -- 338 14000 417 5<BR> GNWFGCTWMNSTGFT 139 284 -- 107 1520 952 -- 1000 14000 2778 5<BR> FTTLPALSTGLIHLH 1.2 2528 12500 6338 1539 -- 625 2419 2<BR> SKGWRLLAPITAYAQ 0.40 125 23 -- 21 252 5 10276 -- 962 54 -- 1191 527 9<BR> DLYLVTRHADVIPVR 617 414 18182 -- 2632 7000 309 1210 3<BR> AQGYKVLVLNPSVAA 6.0 650 -- 10000 7.1 224 74 2980 5.9 833 175 -- 375 276 10<BR> GYKVLVLNPSVAATL 4.5 350-- 3061 4.7567 143 5731 5.1 89 288 -- 54 1933 9<BR> VLVLNPSVAATLGFG 2.8 758 -- 21 10857 1429 11 17 -- 23 6<BR> GARLVVLATATPPGS 167 10111 -- 51 2128 8750 568 11194 3<BR> DVVVVATDALMTGYT 455 827 -- 2500 5278 -- 250 275 -- -- 4<BR> FTGLTHIDAHFLSQT 6.6 15 154 -- 12667 2410 -- 179 980 13393 5<BR> YLVAYQATVCARAQA 6.8 379 571 80 1357 1418 1207 2778 7903 278 5<BR> LEVVTSTWVLVGGVL 417 1167 -- 1607 -- 761 156 6250 3<BR> TWVLVGGVLAALAAY 6.5 8273 -- -- -- -- 439 12931 2<BR> AKHMWNFISGIQYLA 3.3 607 351 11250 633 2632 8750 109 3063 278 6 IC50 nM<BR> Sequence DR1 DR2 DR2w DR3 DR4 DR4 DR5 DR5 DR6 DR7 DR8 DR52a DR9 DR Cross-<BR> w2B1 2B2 w4 w15 w11 w12 w19 w2 w53 reactivity<BR> IQYLAGLSTLPGNPA 1.4 212 2128 12 12 -- 11905 1364 4<BR> MNRLIAFASRGNHVS 66 5 1539 51724 5696585 46 14191 7.3 227 102 -- 313 6374 8<BR> SYTWTGALITPCAAE 192 13000 13333 662 1727 6452 -- 51 3769 1000 4<BR> GSSYGFQYSPGQRVE 11 -- 667 -- 375 745 -- -- 19 156 -- 6620 68 -- 7<BR> LELITSCSSNVSVAH 204 455 -- 517 1086 -- 69 714 -- 2273 5<BR> ASCLRKLGVPPLRVW 5.0 16 217 -- 5625 78 645 157 2500 862 671 -- 8621 5273 8<BR> VGNFTGLYSSTVPVF 2.9 910 12500 3214 224 5714 60 45 11136 242 6<BR> TNFLLSLGIHLNPNK 1.4 222 167 2046 1056 3774 219 114 -- 197 6<BR> KQCFRKLPVNRPIDW 3.3 4136 952 -- 38 45 1539 -- 814 63 845 -- 3000 3053 7<BR> KQAFTFSPTYKAFLC 9.4 38 143 -- 41 173 83 -- 175 76 408 4845 139 322 11<BR> AANWILRGTSFVYVP 54 379 3279 -- 882 1520 1429 805 140 43 196 -- 278 6517 8<BR> PDRVHFASPLHVAWR 98 314 -- -- 7037 -- 184 309 14000 313 5<BR> IRPVVSTQLLLNGSL 568 233 -- 1875 4750 -- 71 74 -- 5769 4<BR> RSELYKYKVVKIEPL 758 284 14286 -- 2000 4762 350 139 446 441 6<BR> DRFYKTLRAEQASQE 94 5688 400 300 465 -- 8929 -- 4<BR> KVILVAVHVASGYIE 7.7 4333 -- 455 2923 2174 714 156 2130 1667 4<BR> LVNLLIFHINGKIIKNS 7.6 17 182 20000 1810 357 11462 200 446 6<BR> RHNWVNHAVPLAMKLI 3.6 260 23 8824 317 1333 438 36 70 7 Table 29a No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 20 FPQPQLPYSQPQPFRPQQPY DR sup Gliadin 61-80 16 IPPYCTIAPFGIFGTN DR sup Gliadin 261-276 20 LGQQQPFPPQQPYPQPQPFP DR sup Gliadin 31-50 20 LHQQQKQQQQPSSQVSFQQP DR sup Gliadin 181-200 20 LLQELCCQHLWQIPEQSQCQ DR sup Gliadin 151-170 20 LQQHNIAHGRSQVLQQSTYQ DR sup Gliadin 131-150 20 PQPFRPQQPYPQPQPQYSQP DR sup Gliadin 71-90 20 PQPQPQYSQPQQPISQQQQQ DR sup Gliadin 81-100 20 PSSQVSFQQPLQQYPLGQGS DR sup Gliadin 191-210 20 QFEEIRNLALQTLPAMCNVY DR sup Gliadin 231-250 20 QGSVQPQQLPQFEEIRNLAL DR sup Gliadin 221-240 20 QNPSQQQPQEQVPLVQQQQF DR sup Gliadin 11-30 20 QPYPQPQPFPSQQPYLQLQP DR sup Gliadin 41-60 20 QQLIFCMDVVLQQHNIAHGR DR sup Gliadin 121-140 20 QVPLVQQQQFLGQQQPFPPQ DR sup Gliadin 21-40 20 SQQPYLQLQPFPQPQLPYSQ DR sup Gliadin 51-70 20 VRVPVPQLQPQNPSQQQPQE DR sup Gliadin 1-20 20 IRNLALQTLPAMCNVY DR sup gliadin 235 12 PQPFRPQQPYPQ DR sup gliadin 71 16 PQPFRPQQPYPQPQPQ DR sup gliadin 71 12 QFEEIRNLALQT DR sup gliadin 231 16 QFEEIRNLALQTLPAM DR sup gliadin 231 20 QFLGQQQPFPPQ DR sup gliadin 29 12 QVPLVQQQQFLG DR sup gliadin 21 16 QVPLVQQQQFLGQQQP DR sup gliadin 21 20 VQQQQFLGQQQPFPPQ DR sup gliadin 25 16 aHAAHAAHAAHAAHAa DR sup d protected AHA reiterative 12 CPKYVRSAKLRM DR sup HA 302-313 (PR8) 12 GACPKYVKQNTL DR sup HA 304-315 13 GACPKYVKQNTLK DR sup HA 304-316 12 KQNTLKLATGMR DR sup HA 311-322 18 LAKQNTLAKQNTLAKQNT DR sup HA 307-319 reiterative 13 PKAVKQNTLKLAT DR sup HA 307-319 analog 13 PKSVKQNTLKLAT DR sup HA 307-319 analog 13 PKYDKQGGLKIAT DR sup HA multivariate 13 PKYFKQFRLKIAT DR sup HA multivariate 13 PKYGKQRFLKIAT DR sup HA multivariate 13 PKYIKQIILKIAT DR sup HA multivariate 13 PKYVKKNTLKLAT DR sup HA 307-319 analog 13 PKYVKQNKLKLAT DR sup HA 307-319 analog 13 PKYVKQNTKKLAT DR sup HA 307-319 analog 13 PKYVKQNTLKEAT DR sup HA 307-319 analog 13 PKYVKQNTLKLAT DR sup HA 307-319 13 PKYVKQNTLKlAT DR sup HA 307-319 analog 13 PKYVKQNTLKlAT DR sup HA 307-319 analog No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 13 PKYVKQNTlKLAT DR sup HA 307-319 analog 13 PKYVKQnTLKLAT DR sup HA 307-319 analog 13 pKYVKQNTLKLAT DR sup HA 307-319 analog 13 PKYVKQNTLKNAT DR sup HA 307-319 analog ; Asn scan 13 PKYVKQNTNKLAT DR sup HA 307-319 analog ; Asn scan 20 RTLYQNVGTYVSVGTSTLNK DR sup HA 187-206 13 VKQNTLKLATGMR DR sup HA 310-322 14 YPKYVKRNTLKLAT DR sup HA 307-319 dbl. substitutions 15 AAPFTQCGYPALMPL DR sup HBV POL 643 95 15 AFSYMDDVVLGAKSV DR sup HBVPOL 546 90 12 AILCWGELMTLA DR sup HBV core 58-69 16 ALRQAILCWGELMTLA DR sup HBV core 54-69 20 ASARFSWLSLLVPFVQWFVG DR sup HBs (ayw) 166-185 15 DWKVCQRRVGLLGFA DR sup HBV POL 629 85 15 GAHLSLRGLPVCAFS DR sup HBV X 50 90 20 GYRWMCLRRFIIFLFILLLC DR sup HBs (ayw) 71-90 19 HHTALRQAILCWGELMTLA DR sup HBV core 51-69 HLSLRGLPVCAFSSA DR sup HBV. X. 52 90 18 HTALRQAILCWGELMTLA DR sup HBV core 52-69 11 ILCWGELMTLA DR sup HBV core 59-69 15 IVGLLGFAAPFTQCG DR sup HBV POL 636 90 LCQVFADATPTGWGL DR sup HBV. POL. 694 95 10 LCWGELMTLA DR sup HBV core 60-69 15 LRQAILCWGELMTLA DR sup HBV core 55-69 20 LSPTVWLSVIWMMWYWGPSL DR sup HBs (ayw) 186-205 16 LSTLPETTVVRRRGRS DR sup Hep. B core 140- 154 19 MDIDPYKEFGASVELLSFL DR sup HBV core 1 25 MDIDPYKEFGASVELLSFLPSDFFP DR sup HBV core 1 19 MDIDPYKEFGATVELLSFL DR sup HBV core 1 20 MDIDPYKEFGATVELLSFLP DR sup Hep. B core 1-20 25 MDIDPYKEFGATVELLSFLPSDFFP DR sup HBV core 1-25 25 MDIDPYKEFGATVELLSFLPSDFFP DR sup HBV core 1 25 MDIDPYKEFGATVQLLSFLPSDFFP DR sup HBV core 1 15 NAPILSTLPETTVVR DR sup HBV NUC 136 95 18 PFLLAQFTSAICSVVRRA DR sup HBV pol 523 95 13 PHHTALRQAILCW DR sup HBV core 50-62 14 PHHTALRQAILCWG DR sup HBV core 50-63 16 PHHTALRQAILCWGEL DR sup HBV core 50-65 17 PHHTALRQAILCWGELM DR sup HBV core 50-66 18 PHHTALRQAILCWGELMT DR sup HBV core 50-67 19 PHHTALRQAILCWGELMTL DR sup HBV core 50-68 20 PHHTALRQAILCWGELMTLA DR sup HBV core 50-69 PLPIHTAELLAACFA DR sup HBV. POL. 722 80 15 PPAYRPPNAPILSTL DR sup HBV NUC 129 95 No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) PQAMQWNSTTFHQTL DR sup HBV. ENV. 114 40 80 13 QAILCWGELMTLA DR sup HBV core 57-69 15 QCGYPALMPLYACIQ DR sup HBV POL 648 95 RDLLDTASALYREAL DR sup HBV. NUC. 28 80 20 RDLLDTASALYRREALESPEH DR sup Hep. B core 28-47 20 RDLVVSYVNTNMGLKFRQLL DR sup Hep. B core 82- 101 15 RFSWLSLLVPFVQWF DR sup HBV ENV 332 100 14 RQAILCWGELMTLA DR sup HBV core 56-69 20 SLDSWWTSLNFLGGTTVCLG DR sup HBs (ayw) 31-50 SVRFSWLSLLVPFVQ DR sup HBV. ENV. 330 80 17 TALRQAILCWGELMTLA DR sup HBV core 53-69 15 TNLLSSNLSWLSLDV DR sup HBV POL 416 90 25 TNMGLKFRQLLWFHI DR sup HBV core 91 25 TNVGLKFRQLLWFHI DR sup HBV core 91 14 TTVVRRRGRSPRRR DR sup HBV Core 146-159 15 VCAFSSAGPCALRFT DR sup HBV X 60 90 20 VSFGVWIRTPPAYRPPNAPI DR sup HBV nuc 120 90 YPALMPLYACIQSKQ DR sup HBV. POL. 648 55 95 AEQFKQKALGLLQTA DR sup HCV. NS4. 1730 86 ANLLWRQEMGGNITR DR sup HCV. NS5. 2238 86 ARLIVFPDLGVRVCE DR sup HCV. NS5. 2610 79 ASQLSAPSLKATCTT DR sup HCV. NS5. 2208 50 79 AVQWMNRLIAFASRG DR sup HCV. NS4. 1917 100 100 DADLIEANLLWRQEM DR sup HCV. NS5. 2232 50 85 EDLVNLLPAILSPGA DR sup HCV. NS4. 1882 79 85 GALVVGVVCAAILRR DR sup HCV. NS4. 1895 79 GCSFSIFLLALLSCL DR sup HCV. Core. 171 86 20 GPGEGAVQWMNRLIAFASRG DR sup HCV NS4 291-310 KPTLHGPTPLLYRLG DR sup HCV. NS4. 1620 79 LAGYGAGVAGALVAF DR sup HCV. NS4. 1857 79 LHGLSAFSLHSYSPG DR sup HCV. NS5. 2919 79 79 20 LLFNILGGWVAAQLAAPGAA DR sup HCV NS4 191-210 LTSMLTDPSHITAET DR sup HCV. NS5. 2176 57 100 20 NFISGIQYLAGLSTLPGNPA DR sup HCV NS4 1772 PAILSPGALVVGVVCA DR sup HCV. NS4. 1889 79 PQTFQVAHLHAPTGS DR sup HCV. NS3. 1225 43 85 PTLWARMILMTHFFS DR sup HCV. NS5. 2870 79 85 RAAVCTRGVAKAVDF DR sup HCV. NS3. 1186 79 TVDFSLDPTFTIETT DR sup HCV. NS3. 1466 79 VVLLFLLLADARVCS DR sup HCV. NS1/E2. 724 29 100 WESVFTGLTHIDAHF DR sup HCV. NS3. 1563 43 92 10 AFVAWRNRCK DR sup HEL 107-116 analogs 10 AWAAWRNRCK DR sup HEL 107-116 analogs 10 AWEAWRNRCK DR sup HEL 107-116 analogs No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 10 AWLAWRNRCK DR sup HEL 107-116 analogs 10 AWVAARNRCK DR sup HEL 107-116 analogs 10 AWVAFRNRCK DR sup HEL 107-116 analogs 10 AWVAQRNRCK DR sup HEL 107-116 analogs 10 AWVAWANRCK DR sup HEL 107-116 analogs 10 AWVAWENRCK DR sup HEL 107-116 analogs 10 AWVAWKNRCK DR sup HEL 107-116 analogs 10 AWVAWRARCK DR sup HEL 107-116 analogs 10 AWVAWRNACK DR sup HEL 107-116 analogs 10 AWVAWRNECK DR sup HEL 107-116 analogs 10 AWVAWRNKCK DR sup HEL 107-116 analogs 10 AWVAWRNRCA DR sup HEL 107-116 analogs 0 AWVAWRNRCK DR sup HEL 107-116 10 AWVAWRNRCK DR sup HEL 107-116 10 AWVAWRNRCR DR sup HEL 107-116 analogs 10 AWVAWRNREK DR sup HEL 107-116 analogs 10 AWVAWRNRKK DR sup HEL 107-116 analogs 10 AWVAWRNRQK DR sup HEL 107-116 analogs 10 AWVAWRNRVK DR sup HEL 107-116 analogs 10 AWVAWRVRCK DR sup HEL 107-116 analogs 10 AWVEWRNRCK DR sup HEL 107-116 analogs 10 AWVSWRNRCK DR sup HEL 107-116 analogs 10 AWWWRNRCK DR sup HEL 107-116 analogs 10 EFVAAKAAQK DR sup Super HEL 107-116 10 EWVAWRNRCK DR sup HEL 107-116 analogs 22 LAAAMKRHGLDNYRGYSLGNWV DR sup HEL 8-29 16 NTDGSTDYGILQINSR DR sup HEL 46-61 No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 18 RNRCKGTDVQAWIRGCRL DR sup HEL 112-129 16 SVNCAKKIVSDGNGMN DR sup HEL91-106 10 SWVAWRNRCK DR sup HEL 107-116 analogs 10 VWVAWRNRCK DR sup HEL 107-116 analogs 15 WRNAKWRNAKWRNAK DR sup HEL 112-116 reit.

22 YRGYSLGNWVCAAKFESNFNTQ DR sup HEL 20-41 13 SPYVSRLLGICLT DR sup Her2/neu. 777 15 ASDFNLPPVVAKEIV DR sup HIV1 POL 765 80 15 AVQMAVFIHNFKRKG DR sup HIV1 POL 917 100 15 DFNLPPVVAKEIVAS DR sup HI1 POL 767 87 15 DQQLLGIWGCSGKLI DR sup HIV1 ENV 755 83 15 DQSLKPCVKLTPLCV DRsup HIV1ENV126 90 12 DRVHPVHAGPIA DR sup HIV gag 245 14 DRVHPVHAGPIAPG DR sup HIV gag 245 16 DRVHPVHAGPIAPGQM DR sup HIV gag 245 18 DRVHPVHAGPIAPGQMRE DR sup HIV gag 245 20 DRVHPVHAGPIAPGQMREPR DR sup HIV gag 245 22 DRVHPVHAGPIAPGQMREPRGS DR sup HIV gag 245 20 DTEVHNVWATQACVPTDPNP DR sup HIV env 6 15 EAIIRILQQLLFIHF DR sup HIV1 VPR 58 82 15 EDIISLWDQSLKPCV DR sup HIV 1 ENV 119 87 15 EKAFSPEVIPMFSAL DR sup HIV1 GAG 193 96 15 EKVYLAWVPAHKGIG DR sup HIV1.pol. 711 74 93 16 ERFAVNPGLLETSEGC DR sup HIV gp17 41-56 16 ERYLKDQQLLGIWGCS DR sup HIV1 ENV 589 15 ESELVSQIIEQLIKK DR sup HIV1 POL 696 80 ETAYFLLKLAGRWPV DR sup HIV. POL. 838 65 15 EVQLGIPHPAGLKKK DR sup HIV1 POL 268 80 15 FWEVQLGIPHPAGLK DR sup HIVI POL 266 100 16 GARASVLSGGELDKWE DR sup HIV gpl7 1-16 15 GCTLNFPISPIETVP DR sup HIV 1 POL 174 100 15 GEIYKRWIILGLNKI DR sup HIV1. gag. 294 45 85 16 GGELDKWEKIRLRPGG DR sup HIV gp 17 9-24 15 HKAIGTVLVGPTPVN DR sup HIV1 POL 149 93 15 IGGIGGFIKVRQYDQ DR sup HIV1 POL 127 93 IIRILQQLLFIHFRI DR sup HIV1. VPR. 60 76 82 15 IISLWDQSLKPCVKL DR sup HIVI ENV 121 85 15 IKVVPRRKAKIIRDY DR sup HIV1 POL 999 80 16 ILKALGPAATLEEMMT (200. 11) DR sup HIV 16 INEEAAEWERVHPVHA DR sup HIV gp25 73-88 15 IQKLVGKLNWASQIY DR sup HIV1 POL 436 100 15 ISLWDQSLKPCVKLT DR sup HI1 ENV 122 83 16 IVWASRELERFAVNPG DR sup HIV gpl7 33-48 20 IYKRWIILGLNKIVRMYSPV DR sup HIV gag 27 16 IYKRWIILGLNKIVRN DR sup HIV gp25 129-144 KARVLAEAMSQVTNS DR sup HIV1.GAG. 394 46 88 No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 15 KDSWTVNDIQKLVGK DR sup HTV1 POL 428 100 16 KQIINMWQEVGKAMYA DRsup HIV1ENV428 15 KRWIILGLNKIVRMY DR sup HIVl. gag. 298 77 88 15 KTILKALGPAATLEE DR sup HIV1 GAG 366 92 16 LGKIWPSYKGRPGNFL DR sup HIV gpl3 57-72 16 LICTTAVPWNASWSNK DR sup HIV1 ENV 607 16 LKQIVKKLREQFGNNK DR sup HI1 ENV 342 15 LLGIWGCSGKLICTT DR sup HIV1 ENV 758 81 15 LSIVNRVRQGYSPLS DR sup HIV1 ENV 877 81 15 NEQVDKLVSAGIRKV DR sup HIV1 POL 727 80 NNLLRAIEAQQHLLQ DR sup HIV1. ENV. 719 61 82 15 PAGLKKKKSVTVLDV DR sup HIV1 POL 276 80 15 PGNFLQSRPEPTAPP DR sup HIV1 GAG 490 80 16 PIVQNLQGQMVHQAIS DR sup HIV gp25 1-16 16 PLGVAPTKAKRRVVQR DR sup HIV ENV 671 16 QARILAVERYLKDQQL DR sup HIV1 ENV 582 15 QGQMVHQAISPRTLN DR sup HIV1. gag. 171 44 85 16 QKQEPIDKELYPLTSL DR sup HIV gp13 97-112 15 QMAVFIHNFKRKGGI DR sup HIV 1 POL 919 100 16 RIQRGPGRAFVTIGKL DR sup HIV 1 ENV 315 16 RQILGQLQPSLQTGSE DR sup HIV gpl7 57-72 16 SLKPCVKLTPLCVTLN DR sup HIV1 ENV 115 16 SLWDQSLKPCVKLTPL DRsup HIV1ENV825 15 SPAIFQSSMTKILEP DR sup HIVl. pol. 335 70 80 15 SPGIWQLDCTHLEGK DR sup HIV1 POL 799 100 15 SQIIEQLIKKEKVYL DR sup HIV1 POL 701 80 16 SSGGDPEIVMHSFNCG DR sup HIV1 ENV 369 13 TAATNAACAWLEA DR sup HIV nef 48 17 TITLPCRIKQFINMWQE DR sup HIV1 ENV 413 15 VDKLVSAGIRKVLFL DR sup HIV1 POL 730 80 15 VIPMFSALSEGATPQ DR sup HIVl GAG 200 88 16 VKIEPLGVAPTKAKRR DR sup HIV1 ENV 667 15 VLSRVNRVRQGYSPL DR sup HRVI ENV 876 81 15 VNIIGRNLLTQIGCT DR sup HIV1 POL 162 87 15 VNIVTDSQYALGHQ DR sup HIVI POL 675 93 15 VTVYYGVPVWKEATT DR sup HIV1 ENV 48 83 20 VWGIKQLQARVLAVERYLKD DR sup HIV env 54 16 WDQSLKPCVKLTPLCV DR sup HIV1 ENV 112 16 WGCSGKLICTTAVPWN DR sup HIV1 ENV 601 15 WRKLVDFRELNKRTQ DR sup HIV1 POL 250 80 20 VYVWKTTWGQYWQVLGGPVS DR sup gp100. 150 17 ALHIYMNGTMSQVQGSA DR sup Tyrosinase. 365 16 WPSVFYNRTCQCSGNF DR sup Tyrosinase. 80 20 YGQMKNGSTPMFNDINIYDL DR sup Tyrosinase. 156 15 DIVIYSKYGGTEIKY DR sup M. Leprae 67-81 15 IKYNGEEYLILSARD DR sup M. Leprae 79-93 15 IYSKYGGTEIKYNGE DR sup M. Leprae 70-84 15 LVIPENAKEKPQEGT DR sup M. Leprae 28-42 No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 15 NGEEYLILSARDVLA DR sup M. Leprae 82-96 15 PSGLVIPENAKEKPQ DR sup M. Leprae 25-39 15 RIPVDVSEGDIVRYS DR sup M. Leprae 58-72 15 SEGDIVIYSKYGGTE DR sup M. Leprae 64-78 15 VAKVKIKPLEDKT-LV DR sup M. Leprae 1-15 15 VKIKPLEDKILVQAG DR sup M. Leprae 4-18 15 LQLVFGIEVVEVVPI DR sup MAGE2. 158 15 PRKLLMQDLVQENYL DR sup MAGE2. 242 15 QDFFPVIFSKASEYL DR sup MAGE2. 144 15 QLVFGIEVVEVVPIS DR sup MAGE2. 159 15 RALIETSYVKVLHHT DR sup MAGE2. 276 15 RKLLMQDLVQENYLE DR sup MAGE2. 243 15 SHLYILVTCLGLSYD DR sup MAGE2. 173 15 YEFLWGPRALIETSY DR sup MAGE2. 269 15 GEALGLVGAQAPATE DR sup MAGE2/3. 20 15 FFPVIFSKASSSLQL DR sup MAGE3. 146 15 FPVIFSKASSSLQLV DR sup MAGE3. 147 15 GIELMEVDPIGHLYI DR sup MAGE3. 163 15 QAALSRKVAELVHFL DR sup MAGE3. 106 15 QYFFPVIFSKASSSL DR sup MAGE3. 144 15 RALVETSYVKVLHHM DR sup MAGE3. 276 15 VDPIGHLYIFATCLG DR sup MAGE3. 169 15 VFGIELMEVDPIGHL DR sup MAGE3. 161 15 VGNWQYFFPVIFSKA DR sup MAGE3. 140 15 YEFLWGPRALVETSY DR sup MAGE3. 269 15 VGNWQYFFPVIFSKA DR sup Mage3/6. 140 25 MVKISGGPRISYPLLHEWALREGEE DR sup Mage6. 290 24 QVPGSDPACYEFLWGPRALIETSY DR sup Mage6. 260 15 ANPVVHFFKNIVTPR DR sup Human MBP 85- 99 (85A) 20 ASQKRPSQRHGSKYLATAST DR sup Human MBP 1-20 20 AYDAQGTLSKIFKLGGRDSR DR sup Mouse MBP 141- 160 11 DENPVVHFFKN DR sup Human MBP 84-94 12 DENPVVHFFKNI DR sup Human MBP 84-95 13 DENPVVHFFKNIV DR sup Human MBP 84-96 14 DENPVVHFFKNIVT DR sup Human MBP 84-97 16 DENPVVHFFKNIVTPR DR sup Human MBP 84-99 17 DENPVVHFFKNfVTPRT DR sup Human MBP 84- 100 19 DENPVVHFFKNIVTPRTPP DR sup Human MBP 84- 102 20 DENPVVHFFKNIVTPRTPPY DR sup Human MBP 84- 102Y 20 DENPVVHFFRNIVTPRTPPY DR sup Human MBP 84- 102Y (99R) 15 EAPVVHFFKN1VTPR DR sup Human MBP 85- 99 (86A) 15 ENAVVHFFKNIVTPR DR sup Human MBP 85- No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 99 (87A) 15 ENPAVHFFKNRVTPR DR sup Human MBP 85- 99 (88A) 15 ENPKVHFFKNRVTPR DR sup Human MBP 85-99 SAAS (88K) 15 ENPVAHFFKNIVTPR DR sup Human MBP 85- 99 (89A) 15 ENPVKHFFKNIVTPR DR sup Human MBP 85-99 SAAS (89K) 15 ENPVVAFFKNIVTPR DR sup Human MBP 85- 99 (90A) 15 ENPVVAFFKNRVTPR DR sup Human MBP 85-99 SAAS (90A) 15 ENPVVDFFKNIVTPR DR sup Human MBP 85-99 SAAS (90D) 15 ENPVVFFFKNRVTPR DR sup Human MBP 85-99 SAAS (90F) 15 ENPVVHAFKNIVTPR DR sup Human MBP 85- 99 (91A) 15 ENPVVHAFKNIVTPR DR sup Human MBP 85-99 SAAS (91A) 15 ENPVVHAFRNIVTPR DR sup MBP85-99 (91A, 93R) 15 ENPVVHDFKNRVTPR DR sup Human MBP 85-99 SAAS (91D) 15 ENPVVHFAKNIVTPR DR sup Human MBP 85- 99 (92A) 15 ENPVVHFARNRVTPR DR sup MBP85-99 (92A, 93R) 15 ENPVVHFFANIVTPR DR sup Human MBP 85- 99 (93A) 15 ENPVVHFFANIVTPR DR sup Human MBP 85-99 SAAS (93A) 17 ENPVVHFFANIVTPRTP DR sup MBP 91K>A analog 15 ENPVVHFFDNRVTPR DR sup Human MBP 85-99 SAAS (93D) 15 ENPVVHFFHNIVTPR DR sup Human MBP 85-99 SAAS (93H) 15 ENPVVHFFKAIVTPR DR sup Human MBP 85- 99 (94A) 17 ENPVVHFFKAIVTPRTP DR sup MBP 92N>A analog 15 ENPVVHFFKKIVTPR DR sup Human MBP 85-99 SAAS (94K) 15 ENPVVHFFKNAVTPR DR sup Human MBP 85- 99 (95A) 17 ENPVVHFFKNAVTPRTP DR sup MBP 93I>A analog 15 ENPVVHFFKNIATPR DR sup Human MBP 85- 99 (96A) No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 15 ENPVVHFFKNIVAPR DR sup Human MBP 85- 99 (97A) 17 ENPVVHFFKNIVAPRTP DR sup MBP 95T>A analog 15 ENPVVHFFKNIVAPR DR sup Human MBP 85- 99 (98A) 15 ENPVVHFFKNIVAPA DR sup Human MBP 85- 99 (99A) 15 ENPVVHFFKNIVTPA DR sup Human MBP 85- 98A 15 ENPVVHFFKNTVTPR DR sup Human MBP 85-99 17 ENPVVHFFKNIVTPRTP DR sup MBP 83 19 ENPVVHFFKNIVTPRTPPY DR sup Human MBP 85- 102Y 15 ENPVVHFFKNIVAPR DR sup Human MBP 85-99 SAAS (95K) 15 ENPVVHFFlNIVTPR DR sup Human MBP 85-99 SAAS (93L) 15 ENPVVHFFRNRVTPR DR sup Human MBP 85-99 SAAS (93R) 15 ENPVVHFKKNIVTPR DR sup Human MBP 85-99 SAAS (92K) 15 ENPVVHHFKNIVTPR DR sup Human MBP 85-99 SAAS (91H) 15 ENPVVHHFRNIVTPR DR sup MBP85-99 (91H, 93R) 15 ENPVVHLFKNIVTPR DR sup Human MBP 85-99 SAAS (91L) 15 ENPWHLFRNIVTPR DR sup MBP85-99 (91L, 93R) 15 ENPVVHWFKNIVTPR DR sup Human MBP 85-99 SAAS (91W) 15 ENPVVHYFANIVTPR DR sup MBP85-99 (91Y, 93A) 15 ENPVVHYFHNIVTPR DR sup MBP85-99 (91Y, 93H) 15 ENPVVHYFKNIVTPR DR sup Human MBP 85-99 SAAS (9 1 Y) 15 ENPWHYFLNIVTPR DR sup MBP85-99 (91Y, 93L) 15 ENPVVHYFRNIVTPR DR sup MBP85-99 (91Y, 93R) 15 ENPVVKFFKNIVTPR DR sup Human MBP 85-99 SAAS (90K) 16 FFKNIVTPFFKNIVTP DR sup MBP reiterative 20 GFGYGGRASDYKSAHKGFKG DR sup Mouse MBP 121- 140/Human 124- 143 14 HFFKNIVTPRTPPY DR sup Human MBP 90- No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 102Y 14 HFFKNIVTPRTPPY DR sup Human MBP 90- 102Y 20 IFKLGGRDSRSGSPMARR DR sup Mouse MBP 151- 168/Human 154- 171 12 NPVVHFFKNIVT DR sup Human MBP 86-97 14 NPVVHFFKNIVTPA DR sup Human MBP 86- 98A 14 NPVVHFFKNIVTPR DR sup Human MBP 86-99 18 NPVVHFFKNIVTPRTPPY DR sup Human MBP 86- 102Y 11 PVVHFFKNIVT DR sup Human MBP 87-97 13 PWHFFKNIVTPA DR sup Human MBP 87- 98A 13 PVVHFFKNIVTPR DR sup Human MBP 87-99 17 PWHFFKNIVTPRTPPY DR sup Human MBP 87- 102Y 20 QKSHGRTQDENPWHFFKNI DR sup Human MBP 74-93 20 RASDYKSAHKGFKGVDAQGT DR sup MBP 131-152 20 RASDYKSAHKGLKGHDAQGT DR sup MBP 131-152 F>L analog 20 RFFSGDRGAPKRGSGKDSHT DR sup Mouse MBP 41-60 20 VDAQGTLSKIFKLGGRDSRS DR sup Hu MBP 144-163 20 VDAQGTLSKLFKLGGRDSRS DR sup MBP 144-163 var./analog 20 VDAQGTLSRIFKLGGRDSRS DR sup MBP 144-163 var./analog 20 VDAQGTLSRLFKLGGRDSRS DR sup Rabbit MBP 144- 163 15 VHFFKNIVTPRTPPY DR sup Human MBP 89- 102Y 16 VVHFFKNIVTPRTPPY DR sup Human MBP 88- 102Y 20 YKSAHKGFKGAYDAQGTLSK DR sup Mouse MBP 131- 150 15 AKSVTCTYSPALNKM DR sup p53. 119 15 APPVAPAPAAPTPAA DR sup p53. 70 15 APSWPLSSSVPSQKT DR sup p53. 88 15 FCQLAKTCPVQLWVD DR sup p53. 134 15 FSDLWKLLPENNVLS DR sup p53. 19 15 GTVRAMAIYKQSQH DR sup p53. 154 15 HYNYMCNSSCMGGMN DR sup p53. 233 15 LGFLHSGTAKSVTCT DR sup p53. 111 15 LSPLPSQAMDDLMLS DR sup p53. 32 15 NNVLSPLPSQAMDDL DR sup p53. 29 15 RLGFLHSGTAKSVTC DR sup p53. 110 15 RNTFRHSVVVPYEPP DR sup p53. 209 15 SWPLSSSVPSQKTYQ DR sup p53. 90 No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 15 SYGFRLGFLHSGTAK DR sup p53. 106 15 WKLLPENNVLSPLPS DR sup p53. 23 15 YNYMCNSSCMGGMNR DR sup p53. 234 14 AKFVAAWTLKAAA DR sup PADRE analog 14 YAKFVAAWTLKAAA DR sup PADRE analog 15 AGGIAGGLALLACAG DRsup PfSSP2498 100 15 ATSVLAGLLGNVSTV DRsup PfEXP177 100 15 AVPLAMKLIQQLNLN DR sup Pf SSP2 68 100 15 FLALFFIIFNKESLA DR sup Pf EXP1 8 100 15 GRDVQNNIVDEIKYR DR sup Pf SSP2 25 90 15 IFHINGKIIKNSEKD DRsup PfLSA118 100 15 KHILYISFYFILVNL DR sup PfLSA12 100 15 KYLVIVFLIFFDLFL DR sup PfSSP28 100 15 LGNVSTVLLGGVGLV DR sup PfEXP1 85 100 15 LIDVHDLISDMIKKE DR sup PfEXPl 47 100 15 LIFFDLFLVNGRDVQ DR sup Pf. TRAP. 15 100 15 LSVFFLALFFIIFNK DR sup Pf EXP1 4 100 20 NAREIIRLHSDASKNKEKAL DR sup Pf. SSP2 15 NDRINRENANQLVVI DR sup PfSSP2145 100 15 NHAVPLAMKLIQQLN DR sup Pf SSP2 66 80 15 SFYFILVNLLIFHIN DR sup Pf LSA1 8 100 15 TVLLGGVGLVLYNTE DR sup Pf EXP1 90 100 15 VFFLALFFIIFNKES DR sup Pf EXP1 6 100 15 VSTVLLGGVGLVLYN DR sup PfEXPl 88 100 15 WILTDGIPDSIQDS DR sup PfSSP2157 100 20 YADSAWENVKNVIGPFMKAV DRsup Pf. SSP2 15 YKFVVPGAATPYAGE DR sup Pf SSP2 515 80 15 DQSYLQDSDPDSFQD DR sup Tyrosinase 448-462 (Q449) 15 DYSFLQDSDPDSFQD DR sup Tyrosinase 448-462 (F451) 15 DYSYFQDSDPDSFQD DR sup Tyrosinase 448-462 (F452) 15 DYSYLQDSDPDSFQD DR sup Tyrosinase. 448 15 DYSYLQDSDPDSFQD DR sup Tyrosinase 448-462 15 DYSYLQDSVPDSFQD DR sup Tyrosinase 448-462 (V456) 15 DYSYQQDSDPDSFQD DR sup Tyrosinase 448-462 (Q452) 14 NILLSNAPLGPQFP DR sup Tyrosinase 57-70 15 QNFLLSNAPLGPQFP DR sup Tyrosinase 56-70 (F58) 15 QNIFLSNAPLGPQFP DR sup Tyrosinase 56-70 (F59) 15 QNILLSNAPLGPQFP DR sup Tyrosinase. 56 15 QNILLSNAQLGPQFP DR sup Tyrosinase 56-70 (Q64) 15 QNILLSNAVLGPQFP DR sup Tyrosinase 56-70 (V64) No. % % amino Sequence Motif Source Conserv Conserv acids (Total) (Core) 15 QNILLSNVPLGPQFP DR sup Tyrosinase 56-70 (V63) 15 QNILQSNAPLGPQFP DR sup Tyrosinase 56-70 (Q60) 15 QNELVSNAPLGPQFP DR sup Tyrosinase 56-70 (V60) 15 QNIQLSNAPLGPQFP DR sup Tyrosinase 56-70 (Q59) 15 QNIVLSNAPLGPQFP DR sup Tyrosinase 56-70 (V59) 15 QNVLLSNAPLGPQFP DR sup Tyrosinase 56-70 (V58) 13 SYLQDSDPDSFQD DR sup Tyrosinase 450-462 13 SYLQDSVPDSFQD DR sup Tyrosinase 450-462 (V456) 12 YLQDSDPDSFQD DR sup Tyrosinase 451-462 14 YSYLQDSDPDSFQD DR sup Tyrosinase 449-462 Table 29b<BR> DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> FPQPQLPYSQP 0.001 0.0001 0.0001 4.6 0<BR> QPFRPQQPY<BR> IPPYCTIAPFGIF 0.0001 0.17 0.0001 0.012 1<BR> GTN<BR> LGQQQPFPPQQ 0.0001 0.0001 0.0001 0.246 0<BR> PYPQPQPFP<BR> LHQQQKQQQQ 0.0001 0.0001 0.0001 0.192 0<BR> PSSQVSFQQP<BR> LLQELCCQHL 0.0001 0.001 0.001 1.3 0<BR> WQIPEQSQCQ<BR> LQQHNIAHGRS<BR> QVLQQSTYQ<BR> PQPFRPQQPYP 0.01 0.0001 0.0001 12.9 0<BR> QPQPQYSQP<BR> PQPQPQYSQPQ 0.0001 0.0001 0.0001 0.074 0<BR> QPISQQQQQ<BR> PSSQVSFQQPL 0.002 0.0001 0.0001 8.5 0<BR> QQYPLGQGS<BR> QFEEIRNLALQ 0.017 0.042 0.0001 1.2 1<BR> TLPAMCNVY<BR> QGSVQPQQLPQ 0.015 0.16 0.0001 0.087 1<BR> FEEIRNLAL<BR> QNPSQQQPQEQ 0.0001 0.0001 0.0001 0.297 0<BR> VPLVQQQQF<BR> QPYPQPQPFPS 0.0001 0.0001 0.0001 1.9 0<BR> QQPYLQLQP<BR> QQLIFCMDVVL 0.001 0.002 0.015 1.5 0<BR> QQHNIAHGR<BR> QVPLVQQQQFL<BR> GQQQPFPPQ<BR> SQQPYLQLQPF 0.102 0.006 0.0001 0.898 0<BR> PQPQLPYSQ DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> VRVPVPQLQPQ 0.0001 0.0001 0.0001 7.4 0<BR> NPSQQQPQE<BR> IRNLALQTLPA 13 0<BR> MCNVY<BR> PQPFRPQQPYP 25 0<BR> Q<BR> PQPFRPQQPYP 16 0<BR> QPQPQ<BR> QFEEIRNLALQ 0.75 0<BR> T<BR> QFEEIRNLALQ 0.39 0<BR> TLPAM<BR> QFLGQQQPFPP 8 0<BR> Q<BR> QVPLVQQQFL 0.86 0<BR> G<BR> QVPLVQQQQFL 86 0<BR> GQQQP<BR> VQQQQFLGQQ 27 0<BR> QPFPPQ<BR> aHAAHAAHAA 0.019 0.0001 0.0001 0.0001 0.0001 0.0001 1<BR> HAAHAa<BR> CPKYVRSAKLR 0.003 0.007 0.0001 0.0001 0.088 0.686 -0.006 1<BR> M<BR> GACPKYVKQN 0.0001 0.0001 0.039 -0.004 0.034 1<BR> TL<BR> GACPKYVKQN 0.0001 -0.019 0.012 -0.004 1.2 1<BR> TLK<BR> KQNTLKLATG 0.0001 0.002 -0.003 -0.004 0.031 1<BR> MR<BR> LAKQNTLAKQ 0.0001 1.5 0.3 0.58 -0.007 0.0001 0.004 1<BR> NTLAKQNT<BR> PKAVKQNTLK 0.005 -0.018 -0.003 0.002 -0.003 0.0001 1<BR> LAT DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> PKSVKQNTLKL 0.0001 0.001 0.78 0.0001 -0.002 0.0001 1<BR> AT<BR> PKYDKQGGLKI 0.033 -0.002 0.0001 1<BR> AT<BR> PKYFKQFRLKI 0.005 0.003 -0.002 1<BR> AT<BR> PKYGKQRFLKI 0.001 0.05 0.005 1<BR> AT<BR> PKYIKQILLKIA 0.004 0.09 0.12 1<BR> T<BR> PKYVKKNTLK 0.056 0.172 0.015 0.0001 0.187 0.007 1<BR> LAT<BR> PKYVKQNKLK -0.002 0.006 -0.005 0.0001 0.646 0.083 1<BR> LAT<BR> PKYVKQNTKK 0.36 0.373 0.021 0.0001 1.2 0.018 1<BR> LAT<BR> PKYVKQNTLK -0.002 0.006 -0.041 0.0001 0.0001 0.029 1<BR> EAT<BR> PKYVKQNTLK 0.45 1<BR> LAT<BR> PKYVKQNTLK1 0.013 0.0001 0.021 0.0001 1<BR> AT<BR> PKYVKQNTLK1 0.14 0.014 1<BR> AT<BR> PKYVKQNTIKL 0.052 0.005 0.028 0.0001 0.003 -0.004 0.0001 1<BR> AT<BR> PKYVKQnTLKL 0.015 0.04 1<BR> AT<BR> pKYVKQNTLKL 0.013 -0.004 1<BR> AT<BR> PKYVKQNTLK 0.0001 0.027 0.031 0.0001 0.01 0.016 0<BR> NAT<BR> PKYVKQNTNK 0.071 0.15 0.041 0.0001 0.01 0.001 1<BR> LAT DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> RTLYQNVGTY 0.26 -0.003 0.0001 -0.002 -0.013 0.0001 -0.009 1<BR> VSVGTSTLNK<BR> VKQNTLKLAT 0.0001 0.0001 -0.006 0.026 0.0001 0<BR> GMR<BR> YPKYVKRNTL 0.21 0.023 0.004 0.003 1<BR> KLAT<BR> AAPFTQCGYPA 0.034 0.034 0.0064 0.008 1 2<BR> LMPL 0.0016<BR> AFSYMDDVVL 0.0027 2.9 0.002 0.0006 - - 1 1<BR> GAKSV 0.0005 0.000 0.0005<BR> AILCWGELMTL 0.0008 1 0.0001 0<BR> A<BR> ALRQAILCWGE 0.013 0.86 0.0019 1<BR> LMTLA<BR> ASARFSWLSLL 0.011 0.001 0.029 0.002 0.0001 0.012 0.009 1<BR> VPFVQWFVG<BR> DWKVCQRIVG 0.012 - 0.003 0.011 0.25 0.0018 0.013 1 1<BR> LLGFA 0.0026<BR> GAHLSLRGLPV 0.78 0.0042 0.0011 0.026 0.0025 0.0077 0.015 1 1<BR> CAFS<BR> GYRWMCLRRF 0.002 0.005 0.106 0.004 0.005 0.011 -0.004 1<BR> HFLFILLLC<BR> HHTALRQAILC 0.008 0.31 0.0002<BR> WGELMTLA<BR> HLSLRGLPVCA 1.3 0.0028 0.013 1 1<BR> FSSA<BR> HTALRQAILCW 0.014 0.38 0.0014 1<BR> GELMTLA<BR> ILCWGELMTLA 0.0001 0.081 0.0001<BR> IVGLLGFAAPF 0.02 - - 0.046 - 0.00009 0.0067 1 1<BR> TQCG 0.0005 0.0007 0.0002<BR> LCQVFADATPT 0.002 0.96 0.011 0.0013 0.33 0.078 1 1<BR> GWGL<BR> LCWGELMTLA 0.0001 0.029 0.0001 0 DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> LR4QAILCWGEL 0.0089 1 0.0002 1<BR> MTLA<BR> LSPTVWLSVIW 0.004 0.003 0.076 0.005 0.004 0.005 -0.004 1<BR> MMWYWGPSL<BR> LSTLPETTVVR 0.0001 0.001 -0.005 0.002 0.085 -0.013 0.008 0<BR> RRGRS<BR> MDIDPYKEFGA 0.044 0.058 1.9 0.0015 0.044 3<BR> SVELLSFL<BR> MDIDPYKEFGA 0.15 0.018 0.46 - 0.15 2<BR> SVELLSFLPSDF 0.0002<BR> FP<BR> MDIDPYKEFGA 0.0037 0.17 0.46 0.0009 0.003 1<BR> TVELLSFL<BR> MDIDPYKEFGA 0.0001 0.0001 0.065 0.275 0.002 -0.017 0.003 1<BR> TVELLSFLP<BR> MDIDPYKEFGA 0.0032 0.047 0.0018 0.004 1<BR> TVELLSFLPSDF<BR> FP<BR> MDIDPYKEFGA 0.045 0.31 3 0.0049 0.013 2<BR> TVELLSFLPSDF<BR> FP<BR> MDIDPYKEFGA 0.013 1.4 4.9 0.0013 0.035 3<BR> TVQLLSFLPSDF<BR> FP<BR> NAPILSTLPETT 0.0009 0.0009 - 0.0054 - 0.0005 0.16 0 0<BR> VVR 0.0007 0.0002<BR> PFLLAQFTSAIC 0.069 0.15 0<BR> SVVRRA<BR> PHHTALRQAIL 0.0003 0.045 0.0094 0<BR> CW<BR> PHHTALRQAIL 0.0024 0.37 0.0001 0<BR> CWG<BR> PHHTALRQAIL 0.0021 0.045 0.0003 0<BR> CWGEL DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> PHHTALRQAIL 0.03 0.067 0.0082 1<BR> CWGELM<BR> PHHTALRQAIL 0.0031 0.0075 0.0055 0<BR> CWGELMT<BR> PHHTALRQAIL 0.039 0.54 0.006 1<BR> CWGELMTL<BR> PHHTALRQAIL 0.0053 1.2 0.001 1<BR> CWGELMTLA<BR> PLPIHTAELLAA 0.0046 0.049 - 1 1<BR> CFA 0.0003<BR> PPAYRPPNAPIL 0.0056 - 0.0038 - 0.0022 0.0024 0.0015 1 1<BR> STL 0.0005 0.0005<BR> PQAMQWNSTT 0.0012 0.03 0.12 1 1<BR> FHQTL<BR> QAILCGELM 0.0039 0.76 0.0026 0<BR> TLA<BR> QCGYPALMPL 0.0062 0.0018 0.0068 0.0023 0.0006 1 1<BR> YACIQ<BR> RDLLDTASALY 0.0001 0.0092 0.077 1 1<BR> REAL<BR> RDLLDTASALY 0.0001 0.025 -0.006 0.003 0.0001 0.092 -0.003 1<BR> RREALESPEH<BR> RDLVVSYVNT 0.005 0.003 0.02 0.017 0.0001 -0.017 0.016 1<BR> NMGLKFRQLL<BR> RFSWLSLLVPF 0.043 0.0009 - 0.0034 0.0002 0.0005 0.0031 1 1<BR> VQWF 0.0007<BR> RQAILCWGEL 0.0016 1.3 0.0002 0<BR> MTLA<BR> SLDSWWTSLNF 0.136 0.0001 0.023 0.002 0.001 0.006 -0.004 1<BR> LGGTTVCLG<BR> SVRFSWLSLLV 0.9 0.0099 0.0037 1 1<BR> PFVQ<BR> TALRQAILCWG 0.0055 0.71 0.0011 1<BR> ELMTLA DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> TNLLSSNLSWL 0.0016 - 0.13 0.023 0.0006 0.0019 0.041 1 1<BR> SLDV 0.0005<BR> TNMGLKFRQL - - 0.0081 0.013 0.0022 0<BR> LWFHI 0.0005 0.0043<BR> TNVGLKFRQLL 0.0034 0.055 0.33 0.0006 0.025 2<BR> WFHI<BR> TTVVRRRGRSP 0.0001 0.0007 0.041 - 0.0001 - 0.0075 -0.005 0.0001 0.0001 0.018 - 0<BR> RRR 0.0004 0.0003 0.0007<BR> VCAFSSAGPCA 0.21 0.26 0.0023 0.0048 0.0003 0.02 0.015 1 2<BR> LRFT<BR> VSFGVWIRTPP -0.012 0.15 0<BR> AYRPPNAPI<BR> YPALMPLYACI 0.24 0.0014 0.0011 1 1<BR> QSKQ<BR> AEQFKQKALG 0.049 0.0006 0.0058 1 1<BR> LLQTA<BR> ANLLWRQEMG 0.7 0.0018 0.0022 1 1<BR> GNITR<BR> ARLIVFPDLGV 0.0053 0.0017 0.0004 1 1<BR> RVCE<BR> ASQLSAPSLKA 0.015 0.0056 0.0006 1 1<BR> TCTT<BR> AVQWMNRLIA 2.2 0.0035 0.0205 1 1<BR> FASRG<BR> DADLIEANLLW 0.0088 -0.001 0.0025 1 1<BR> RQEM<BR> EDLVNLLPAILS 0.37 0.011 0.0015 1 1<BR> PGA<BR> GALVVGVVCA 0.017 0.0067 0.0043 1 1<BR> AILRR<BR> GCSFSIFLLALL 0.006 0.0015 0.003 1 1<BR> SCL<BR> GPGEGAVQWM 0.57 0.0084 0.23 0.004 1<BR> NRLOIAFASRG DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> KPTLHGPTPLL 0.038 0.001 0.0055 1 1<BR> YRLG<BR> LAGYGAGVAG 0.041 - 0.0008 1 1<BR> ALVAF 0.0003<BR> LHGLSAFSLHS 1.6 0.0095 0.007 1 1<BR> YSPG<BR> LLFNILGGWVA 0.19 - 0.0028 0.0004 1<BR> AQLAAPGAA 0.0035<BR> LTSMLTDPSHIT 0.0004 0.074 - 1 1<BR> AET 0.0003<BR> NFISGIQYLAGL 0.18 -0.012 1.6 0<BR> STLPGNPA<BR> PAILSPGALVV 0.11 0.0007 0.0076 1 1<BR> GVVCA<BR> PQTFQVAHLHA 0.24 0.0053 - 1 1<BR> PTGS 0.0003<BR> PTLWARMILM 0.0064 0.02 0.019 1 1<BR> THFFS<BR> RAAVCTRGVA 0.01 0.0077 0.0024 1 1<BR> KAVDF<BR> TVDFSLDPTFTI 0.0001 0.16 0.0005 1 1<BR> ETT<BR> VVLLFLLLADA 0.024 0.012 0.0033 1 1<BR> RVCS<BR> WESVFTGLTHI 0.031 0.0068 0.0005 1 1<BR> DAHF<BR> AFVAWRNRCK 1.75 0<BR> AWAAWRNRC 0.18 0<BR> K<BR> AWEAWRNRCK 0.15 0<BR> AWLAWRNRCK 0.46 0<BR> AWVAARNRCK 4.4 0<BR> AWVAFRNRCK 1.8 0 DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> AWVAQWRNRCK 0.9 0<BR> AWVAWANRC 0.35 0<BR> K<BR> AWVAWENRC 0.16 0<BR> K<BR> AWVAWKNRC 0.82 0<BR> K<BR> AWVAWRARC 1.2 0<BR> K<BR> AWVAWRNAC 0.67 0<BR> K<BR> AWVASWRNEC 0.17 0<BR> K<BR> AWVAWRNKC 0.25 0<BR> K<BR> AWVASWRNRC 0.021 0<BR> A<BR> AWVAWRNRC 0.0001 0.45 0.0001 -0.004 0.0001 -0.009 0<BR> K<BR> AWVASWRNRC 0.0001 0.45 0.012 0.0001 -0.004 0.0001 -0.009 0<BR> K<BR> AWVAWRNRC 0.105 0<BR> R<BR> AWVAWRNRE 0.85 0<BR> K<BR> AWVAWRNRK 2.8 0<BR> K<BR> AWVAWRNRQ 4.6 0<BR> K<BR> AWVAWRNRV 2.7 0<BR> K<BR> AWVAWRVRC 0.056 0<BR> K<BR> AWVEWRNRCK 0.073 0 DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 Dr8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> AWVSWRNRCK 0.25 0<BR> AWVVWRNRC 0.2 0<BR> K<BR> EFVAAKAAQK 0.008 6.7 0.004 0.0001 -0.016 0.0001 -0.002 1<BR> EWVAWRNRCK 0.48 0<BR> LAAAMKRHGL -0.004 0.051 -0.002 0.0001 0.24 0.005 -0.019 0<BR> DNYRGYSLGN<BR> WV<BR> NTDGSTDYGIL 0.007 -0.003 0.01 0.013 -0.007 -0.003 -0.014 1<BR> QINSR<BR> RNRCKGTDVQ 0.01 0.051 -0.002 0.046 -0.008 0.007 -0.016 1<BR> AWIRGCRL<BR> SVNCAKKIVSD 0.0001 -0.002 0.04 0.006 0.03 -0.003 0.044 0<BR> GNGMN<BR> SWVAWRNRCK 0.42 0<BR> VWVAWRNRC 0.19 0<BR> K<BR> WRNAKWRNA 0.005 0.018 -0.002 0.0001 0.004 0.0001 -0.007 1<BR> KWRNAK<BR> YRGYSLGNWV 0.009 0.009 -0.002 0.0001 0.004 -0.004 -0.019 1<BR> CAAKFESNFNT<BR> Q<BR> SPYVSRLLGICL 0.41 - 0.32 0.0008 0.022 0.014 0.098 1<BR> T 0.0035<BR> ASDFNLPPVVA 0.0026 - - - 0.084 1 1<BR> KEIV 0.0021 0.0028 0.0006<BR> AVQWMAVFIHNF 0.0032 2.6 0.032 0.3 0.0096 0 1<BR> KRKG<BR> DFNLPPVVAKE 0.0042 - - 0.0036 0.053 1 1<BR> IVAS 0.0021 0.0024<BR> DQQLLGIWGCS 0.029 0.015 - 0.0073 0.018 1 1<BR> GKLI 0.0016 DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> DQSLKPCVKLT 0.0076 0.0018 - 0.005 0.011 1 1<BR> PLCV 0.0016<BR> DRVHPVHAGPI 0.0006 0.0005 - - - - 0.0066 0.27 - 1<BR> A 0.0005 0.0027 0.0009 0.0001 0.0014<BR> DRVHPVHAGPI 0.023 0.013 0.0019 - - - 0.01 0.28 - 2<BR> APG 0.0031 0.0011 0.0001 0.0017<BR> DRVHPVHAGPI 0.0066 0.0083 0.011 - - - 0.0055 0.14 - 2<BR> APGQM 0.0036 0.0012 0.0002 0.0019<BR> DRVHPVHAGPI 0.012 0.013 0.0051 -0.004 - - 0.0059 0.064 0.0034 2<BR> APGQMRE 0.0014 0.0002<BR> DRVHPVHAGP1 0.0045 0.0026 - - - - 0.0029 0.12 - 1<BR> APGQMREPR 0.0008 0.0045 0.0016 0.0002 0.0024<BR> DRVHPVHAGPI 0.021 0.0053 0.0014 - - - 0.0055 0.24 - 2<BR> APGQMREPRGS 0.0049 0.0017 0.0002 0.0027<BR> DTEVHNVWAT 0.0073 - 0.0027 0.016 - 0.0006 0.0065 0.0007 - - 0.011 1<BR> QACVPTDPNP 0.0018 0.0006 0.0027 0.0005<BR> EAIIRILQQLLFI 0.047 0.033 0.016 0.023 1 1<BR> HF 0.0021<BR> EDIISLWDQSL 0.052 0.0017 - -0.001 - 1 1<BR> KPCV 0.0016 0.0007<BR> EKAFSPEVIPMF 0.0086 0.0015 0.034 -0.001 0.0023 1 1<BR> SAL<BR> EKVYLAWVPA 0.0052 3.5 0<BR> HKGIG<BR> ERFAVNPGLLE 0.02 -0.007 0.0001 0.007 0.008 0.0001 -0.003 1<BR> TSEGC<BR> ERYLKDQQLL 0.0018 - 0.089 - 0.L004 - 0.18 1 1<BR> GIWCS 0.0004 0.0005 0.0005<BR> ESELVSQIEQLI 0.0059 0.021 0.0095 0.0009 0.004 1 1<BR> KK<BR> ETAYFLLKLAG 0.061 0.021 0.0041 1 1<BR> RWPV<BR> EVQLGIPHPAG 0.002 0.13 - - - 0 1<BR> LKKK 0.0026 0.0007 0.0005 DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w125 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> FWEVQLGIPHP 0.024 - 0.0033 - 0.0024 1 1<BR> AGLK 0.00124 0.0006<BR> GARASVLSGGE 0.006 -0.007 0.0001 0.0001 -0.002 0.0001 -0.007 1<BR> LDKWE<BR> GCTLNFPISPIE 0.0014 - - - 0.038 1 1<BR> TVP 0.0014 0.0026 0.0006<BR> GEIYKRWILLGL 0.066 0.16 0<BR> NKI<BR> GGELDKWEKIR -0.002 0.036 0.0001 0.001 -0.002 0.0001 -0.003 0<BR> LRPGG<BR> HKAIGTVLVGP 0.0072 - - -0.001 0.0016 1 1<BR> TPVN 0.0013 0.0022<BR> IGGIGGFIKVRQ 0.0002 0.2 - 0.015 0.0031 0 1<BR> YDQ 0.0023<BR> IIRILQQLLFIHF 0.0054 0.02 0.0084 1 1<BR> RI<BR> IISLWDQSLKPC 0.0057 0.0061 0.0096 0.0059 0.0012 1 1<BR> VKL<BR> IKVVPRRKAKII 0.0003 0.007 - 2.5 0.003 0 1<BR> RDY 0.0024<BR> ILKALGPAATL 0.226 0.0001 0.002 0.032 0.0001 0.001 0.0001 1<BR> EEMMT(2009.11)<BR> INEEAAEWERV 0.008 -0.007 0.0001 0.005 0.002 0.0001 0.006 1<BR> HPVHA<BR> IQWKLVGKLNW 0.026 - - 0.0044 0.0043 1 1<BR> AWQTY 0.0014 0.0026<BR> ISLWDQSLKPC 0.004 0.029 - 0.0024 0.0012 0 1<BR> VKLT 0.0016<BR> IVWASRELERF 0.002 -0.007 0.0001 0.013 0.059 0.0001 -0.003 0<BR> AVNPG<BR> IYKRWIILLN 0.0044 - 0.0067 0.01 0.0022 0.0004 0.041 0.32 0.0073 0.05 0.185 1<BR> KIVRMYSPV 0.0009<BR> IYKRWIILGLN -0.002 0.025 0.0001 0.0001 -0.002 0.0001 -0.003 0<BR> KIVRN DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a Dr9 w53 react. (4/7) (7/10)<BR> KARVLAEAMS 0.008 0.012 0.0025 1 1<BR> QVTNS<BR> KDSWTVNDIQW 0.0027 - - 0.12 - 0 0<BR> KLVGK 0.00124 0.0026 0.0005<BR> KQWIINMWQEV 0.003 0.0036 0.021 0.51 0.0009 0.0027 0.96 0 0<BR> GKAMUYA<BR> KRWILLGLNKI 0.18 0.4 0<BR> VRMY<BR> KTILKALGPAA 0.076 0.01 - -0.001 0.0006 12 1<BR> TLEE 0.0023<BR> LGKIWPSYKGR -0.002 -0.007 0.005 0.33 0.072 0.0001 0.005 0<BR> PGNFL<BR> LICTTAVPWNA 0.0036 0.0004 0.0012 0.0011 - 0.052 0.0013 1 1<BR> SWSNK 0.0003<BR> LKQIVKKLREQ 0.0003 0.044 - 0.0008 0.0051 - 0.11 0 1<BR> FGNNK 0.0006 0.0005<BR> LLGIWGCSGKL 0.028 0.005 - 0.0014 0.0064 1 1<BR> ICTT 0.0016<BR> ISIVNRVRQGY 0.0045 0.032 0.018 0.72 0.0015 0 1<BR> SPLS<BR> NEQVDKLVSA 0.0024 0.59 - - 0.0028 0 1<BR> GIRKV 0.0026 0.0006<BR> NNLLRAIEAQQ 0.028 0.015 0.015 1 1<BR> HLLQ<BR> PAGLKKKKSVT 0.006 - - - 0.01P4 1 1<BR> VLDV 0.0014 0.0026 0.0006<BR> PGNFLQSRPEP 0.097 0.017 0.019 0.0015 0.013 1 1<BR> TAPP<BR> PIVQNLQGQM 0.008 -0.007 0.0001 0.0001 -0.002 0.0001 -0.003 1<BR> VHQAIS<BR> PLGVAPTKAKR 0.0001 0.48 - 0.004 0.0017 0.0007 0.025 0 1<BR> LRVQR 0.0006<BR> QARILAVERYL 0.0056 0.019 - 0.0058 0.033 0.001 0.26 1 1<BR> KDQQL 0.0006 DR147 Cross- Cross<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react4. (4/7) (7/10)<BR> QGQMVHQWAISP - 1.2 0<BR> RTLN 0.0047<BR> QKQEPIDKELY 0.04 -0.007 0.0001 0.2 -0.002 0.0001 -0.003 1<BR> PLTSL<BR> QMAVFIHNFKR 0.0005 1.2 0.0031 1.1 0.0037 0 1<BR> KGGI<BR> RIQRGPGRAFV 0.0004 0.0083 - - 0.085 - 0.015 0 0<BR> TIGKL 0.0006 0.0005 0.0005<BR> RQILGQWLQPSL 0.022 -0.007 0.006 0.05 -0.002 0.0001 -0.003 1<BR> QTGSE<BR> SLKPCVKLTPL 0.018 0.012 0.003 0.013 0.047 0.023 0.12 1 1<BR> CTLN<BR> SLWDQSLKPCV 0.0011 0.022 - - 0.0047 - 0.016 0 0<BR> KLTPL 0.0006 0.0005 0.0005<BR> SPAIFQSSMTKI 1 0.0025 0<BR> LEP<BR> SPGIWQLDCTH 0.0013 - 0.099 - - 1 1<BR> LEGK 0.0021 0.0006 0.0009<BR> SQIIEQLIKKEK 0.0006 0.031 - 0.052 - 0 1<BR> VYL 0.0026 0.0005<BR> SSGGDPEIVMH 0.0001 - - - - - 0.12 0 0<BR> SFNCG 0.0004 0.0006 0.0005 0.0003 0.0005<BR> TAATNAACAW 0.0005 - -0.015 0.0006 - 0.0036 0.0015 - - 0.046 0.0012 0<BR> LEA 0.0029 0.0004 0.0006 0.0011<BR> TITLPCRIKQFI 0.0002 0.0011 0.03 0.061 0.0005 0.0011 0.08 0 0<BR> NMWQE<BR> VDKLVSAGIRK 0.0039 0.15 - 0.0045 0.012 0 1<BR> VLFL 0.0026<BR> VIPMFALSEG 0.008 5- 0.L0058 -0.001 - 1 1<BR> ATPQ 0.0014 0.0007<BR> VKIEPLGVAPT 0.0028 1.5 0.001 0.074- - 0.01 0 1<BR> KAKRR 0.0003 0.0005<BR> VLSIVNRVRQG 0.0031 1.7 0.026 5.9 0.0092 0 1<BR> YSPL DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 dw4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> VNIIGRNLLTQI 0.0027 - 0.062 0.0067 0.0012 1 1<BR> GCT 0.0014<BR> VNIVTDSQYAL 0.062 - 0.0091 - 0.018 1 1<BR> GIIQ 0.0014 0.0007<BR> VTVYGVPVW 0.0087 0.027 0.0071 0.0021 0.016 1 2<BR> KEATT<BR> VWGIKQLQAR 2.2 0.54 0.013 0.047 0.041 0.026 0.13 0.064 0.018 0.034 0.239 2<BR> VLAVERYLKD<BR> WDQSLKPCVK 0.0083 0.0029 - - 0.0011 0.0081 0.013 1 1<BR> LTPLCV 0.0006 0.0005<BR> WGCSGKLICTT 0.0001 - 0.0033 - - 0.031 -0.001 1 1<BR> AVPWN 0.0004 0.0005 0.0003<BR> WRKLVDFREL 0.0011 0.0017 - 0.29 - 0 0<BR> NKRTQ 0.0026 0.0005<BR> VYVWKTIWG 0.044 - 0.0018 0.0003 0.0623 - 2<BR> QYWQVLGGPV 0.0063 0.0016<BR> S<BR> ALHIYMNGTM 0.014 0.026 0.29 0.056 -0.001 - 1<BR> SQVQGSA 0.008<BR> WPSVFYNRTC 0.P002 - 0.0014 0.009 0.0017 - 0<BR> QCSGNF 0.0048 0.0012<BR> YGQMKNGSTP 0,.005 0.032 0.052 0.021 0.021 0.0092 1<BR> MFNDINIYDL<BR> DIVIYSKYGGT 0.01 0.0031 - - - 0<BR> EIKY 0.0006 0.0002 0.0006<BR> IKYNGEEYLILS 0.031 0.014 0.0016 0.0056 0.037 0<BR> ARD<BR> IYSKYGGTEIK 0.0026 0.045 0.0036 - - 0<BR> YNGE 0.0002 0.0008<BR> LVIPENAKEKP 0.0001 0.16 - 0.0003 - 0<BR> QEGT 0.0006 0.0006<BR> NGEEYLILSAR 0.0017 0.034 0.049 0.0037 0.039 1<BR> DVLA DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> PSGLVIPENAK 0.0001 0.17 - - - 0<BR> EKPQ 0.0006 0.0002 0.0008<BR> RIPVDVSEGDIV 0.64 - 0.001 - - 0<BR> IYS 0.0003 0.0002 0.0008<BR> SEGDIVIYSKY 0.064 0.0006 - 0.0058 - 0<BR> GGTE 0.0006 0.0006<BR> VAKVKIKPLED 0.055 0.0057 0.0008 0.006 0.011 0<BR> KILV<BR> VKIKPLEDKILV 0.023 0.0008 0.0025 0.0088 0.14 0<BR> QAG<BR> LQLVFGIEVVE 0.1 0.033 0.27 2<BR> VVPI<BR> PRKLLMQDLV 0.0009 0.16 - 1<BR> QENYL 0.0019<BR> QDFFPVIFSKAS 0.011 - 0.27 2<BR> EYL 0.0019<BR> QLVFGIEVVEV 0.017 0.018 0.283 2<BR> VPIS<BR> RALIETSYVKV 0.022 0.075 0.13 3<BR> LHHT<BR> RKLLMQDLVQ - 0.14 - 1<BR> ENYLE 0.0003 0.0019<BR> SHLYILVT LG 0.015 0.022 0.0036 1<BR> LSYD<BR> YEFLWGPRALI 1.8 0.0059 0.011 1<BR> ETSY<BR> GEALGLVGAQ 0.082 - - 1<BR> ASPATE 0.0019 0.0019<BR> FFPVIFSKASSS 0.048 0.12 0.63 3<BR> LQL<BR> FPVIFSKASSSL 0.026 0.049 0.21 3<BR> QLV<BR> GIELMEVDPIG 0.0094 0.028 0.0049 1<BR> HLYI DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> QAALSRKVAEL 0.03 - 0.0046 1<BR> VHFL 0.0019<BR> QYFFPVIFSKAS 0.099 0.18 0.22 3<BR> SSL<BR> RALVETSYVKV 0.021 0.38 0.23 3<BR> LHHM<BR> VDPIGHLYIFAT 0.0093 0.0043 0.0073 1<BR> CLG<BR> VFGIELMEVDPI 0.0039 0.057 - 1<BR> GHL 0.0019<BR> VGNWQYFFPVI 0.14 2.1 0.26 3<BR> FSKA<BR> YEFLWGPRAL 3.7 0.0051 0.0061 1<BR> VETSY<BR> VGNWQYFFPVI 0.014 0.034 0.028 0.0002 0.0076 - 1<BR> FSKA 0.0012<BR> MVKISGGPRIS 0.018 - 0.0034 0.35 0.29 - 2<BR> YPLLHEWALRE 0.0075 0.0019<BR> GEE<BR> QVPGSDPACYE 0.15 - - - - 0.0021 1<BR> FLWGPRALIET 0.0075 0.0005 0.0003 0.0011<BR> SY<BR> ANPVVHFFKNI 7.2 0.07 0<BR> VTPR<BR> ASQKRPSQRHG 0.0001 0.0001 0.019 0.001 0.0001 0.028 1<BR> SKYLATAST<BR> AYDAQGTLSKI 0.172 0.201 0.017 0.212 0.535 0.012 1<BR> FKLGGRDSR<BR> DENPVVHFFKN 0.012 0<BR> DENPVVHFFKN 0.55 0.005 0<BR> I<BR> DENPVVHFFKN 1.4 0.011 0<BR> IV DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> DENPVVHFFKN 2.5 0.029 0<BR> IVT<BR> DENPVVHFFKN 0.86 0.014 0<BR> IVTPR<BR> DENPVVHFFKN 0.69 0.007 0<BR> IVTPRT<BR> DENPVVHFFKN 2.8 0.42 0<BR> IVTPRTPP<BR> DENPVVHFFKN 0.76 0<BR> IVTPRTPPY<BR> DENPVVHFFRN 6.6 1.1 0<BR> IVTPRTPPY<BR> EAPVVHFFKNI 3.3 0.032 0<BR> VTPR<BR> ENAVVHFFKNI 2 0.048 0<BR> VTPR<BR> ENPAVHFFKNI 5.7 0.053 0<BR> VTPR<BR> ENPKVHFFKNI 1.3 0<BR> VTPR<BR> ENPVAHFFKNI 0.065 0.042 0<BR> VTPR<BR> ENPVKHFFKNI 0.023 0<BR> VTPR<BR> ENPVVAFFKNI 3.3 0.068 0<BR> VTPR<BR> ENPVVAFFKNI 1.8 0<BR> VTPR<BR> ENPVVDFFKNI 0.12 0<BR> VTPR<BR> ENPVVFFFKNI 4.5 0<BR> VTPR<BR> ENPVVHAFKNI 4 0.022 0<BR> VTPR DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> ENPVVHAFKNI 4.3 0<BR> VTPR<BR> ENPVVHAFRNI 0.47 0<BR> VTPR<BR> ENPVVHDFKNI 0.022 0<BR> VTPR<BR> ENPVVHFAKNI 0.056 0.002 0<BR> VTPR<BR> ENPVVHFARNI 0.0099 0<BR> VTPR<BR> ENPVVHFFANI 3.6 0.005 0<BR> VTPR<BR> ENPVVHFFANI 2.6 0<BR> VTPR<BR> ENPVVHFANI 0.072 5.8 0<BR> VTPR<BR> ENPVVHFFDNI 0.027 0<BR> VTPR<BR> ENPVVHFFHNI 1.5<BR> VTPR<BR> ENPVVHFFKAI 2.6 .1 0<BR> VTPR<BR> ENPVVHFFKAI 0.73 4.4 0<BR> VTPRTP<BR> ENPVVHFKKI 0.014 0<BR> VTPR<BR> ENPVVHFFKNA 3.8 0.013 0<BR> VTPR<BR> ENPVVHFFKNA 0.11 4.8 0<BR> VTPR<BR> ENPVVHFFKNI 2.3 0.022 0<BR> ATPR<BR> ENPVVHFKNI 13 0.31 0<BR> VTPR DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> ENPVVHFFKNI 0.57 3.9 0<BR> VTPRTP<BR> ENPVVHFFKNI 9.5 0.046 0<BR> VTAR<BR> ENPVVHFFKNI 4.3 0.007 0<BR> VTPA<BR> ENPVVHFFKNI 1.4 0.001 0<BR> VTPA<BR> ENPVVHFFKNI 2.2 0.045 0<BR> VTPR<BR> ENPVVHFFKNI 0.21 5 0<BR> VTPRTP<BR> ENPVVHFFKNI 1.1 0.036 0<BR> VTPRTPPY<BR> ENPVVHFFKNK 0.53 0<BR> VTPR<BR> ENPVVHFFLNI 3.2 0<BR> VTPR<BR> ENPVVHFFRNI 4.7 0<BR> VTPR<BR> ENPVVHFKKNI 0.028 0<BR> VTPR<BR> ENPVVHHFKNI 1.2 0<BR> VTPR<BR> ENPVVHHFRNI 0.59 0<BR> VTPR<BR> ENPVVHLFKNI 1.2 0<BR> VTPR<BR> ENPVVHLFRNI 1.7 0<BR> VTPR<BR> ENPVVHWFKNI 0.47 0<BR> VTPR<BR> ENPVVHYFANI 0.5 0<BR> VTPR DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> ENPVVHYFHNI 0.71 0<BR> VTPR<BR> ENPVVHYFKNI 4.3 0<BR> VTPR<BR> ENPVVHYFLNI 0.52 0<BR> VTPR<BR> ENPVVHYFRNI 0.41 0<BR> VTPR<BR> ENPVVHFFKNI 1.3 0<BR> VTPR<BR> FFKNIVTPFFKN 0.006 0.009 0.008 0.011 1<BR> IVTP<BR> GFGYGGRASD 0.0001 0.14 0.003 0.0001 0.144 0.001 0<BR> YKSAHKGFKG<BR> HFFKNIVTPRTP 0.02 0.056 0<BR> PY<BR> HFFKNIVTPRTP 0.005 .038 0<BR> PY<BR> IFKLGGRDSRS 0.171 0.009 0.002 0.001 0.0025 0.001 1<BR> GSPMARR<BR> NPVVHFFKNIV 0.39 0.002 0<BR> T<BR> NPVVHFFKNIV 1.5 0.001 0<BR> TPA<BR> NPVVHFFKNIV 2.6 0.011 0<BR> TPR<BR> NPVVHFFKNIV 1.3 0.17 0<BR> TPRTPPY<BR> PVVHFFKNIVT 0.028 0.001 0<BR> PVVHFFKNIVT 0.91 0.001 0<BR> PA<BR> PVVHFFKNIVT 0.54 0.003 0<BR> PR DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> PVVHFFKNIVT 3.8 0.48 0<BR> PRTPPY<BR> QKSHGRTQDE 0.004 0.007 0.05 0.032 0.0015 0.003 1<BR> NPVVHFFKNI<BR> RASDYKASHK 0.053 0<BR> GFKGVDAQGT<BR> RASDYKSAHK 0.099 0<BR> GLKGHDAQGT<BR> RFFSGDRGAPK 0.001 0.01 0.158 0.0001 0.0001 00001 1<BR> RGSGKDSHT<BR> VDAQGTLSKIF 0.53 0<BR> KLGGRDSRS<BR> VDAQGTLSKLF 0.35 0<BR> KLGGRDSRS<BR> VDAQGTLSRIF 0.59 0<BR> KLGGRDSRS<BR> VDAQGTLSRLF 079 0<BR> KLGGRDSRS<BR> VHFFKNIVTPR 0.27 0.46 0<BR> TPPY<BR> VVHFFKNIVTP 1.4 0.47 0<BR> RTPPY<BR> YKSAHKGFKG 0.002 0.419 0.53 20.02 0.007 0.0001 1<BR> AYDAQGTLSK<BR> AKSVTCTYSPA 0.002 0.013 0.17 1<BR> LNKM<BR> APPVAPAPAAP 0.014 - - 1<BR> TPAA 0.0019 0.0019<BR> APSWPLSSSVP 0.001 0.046 0.017 1<BR> SQKT<BR> FCQLAKTCPVQ 0.14 0.045 0.42 3<BR> LWVD<BR> FSDLWKLLPEN 1.8 0.22 0.0051 2<BR> NVLS DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> GTRVRAMAIY 0.15 0.49 0.87 3<BR> KQSQH<BR> HYNYMCNSSC 0.066 0.041 0.0099 1<BR> MGGMN<BR> LGFLHSGTAKS 0.46 0.57 0.19 3<BR> VTCT<BR> LSPLPSQAMDD 0.011 0.0079 - 1<BR> LMLS 0.0019<BR> NNVLSPLPSQA 0.037 0.002 0.016 1<BR> MDDL<BR> RLGFLHSGTAK 0.028 0.057 0.01 2<BR> SVTC<BR> RNTFRHSVVVP 0.031 0.072 0.27 3<BR> YEPP<BR> SWPLSSSVPSQ 0.0015 0.049 0.013 1<BR> KTYQ<BR> SYGFRLGFLHS 0.14 0.24 0.079 3<BR> GTAK<BR> WKLLPENNVLS 0.071 0.41 - 2<BR> PLPS<BR> YNYMCNSSCM 0.041 - - 1<BR> GGMNR 0.0019 0.0018<BR> AKFVAAWTLK 0.27 0.21 0<BR> AAA<BR> YAKFVAAWTL 0.044 0.15 0<BR> KAAA<BR> AGGIAGGLALL 0.016 0.0013 0.0014 0.008 - - 0.0007 - 0.0004 - 1 1<BR> ACAG 0.0014 0.0002 0.0003 0.0005<BR> ATSVLAGLLGN 0.26 - 0.0021 0.054 - 0.0008 0.0043 - 0.005 0.0039 1 1<BR> VSTV 0.0005 0.0014 0.0003<BR> AVPLAMKLIQQ 0.0015 - 0.0023 0.0097 0.0013 0.0002 0.13 0.077 0.04 0.035 1 1<BR> LNLN 0.0006<BR> FLALFFIIFNKE 0.0081 - 0.043 0.0082 0.022 0.0002 0.0021 0.014 0.0021 -0001 1 1<BR> SLA 0.0021 DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> GRDVQNNIVDE 0.0001 0.0001 - - - - - 0.0001 0.081 - - - 0.085 0 1<BR> IKYR 0.0006 0.0006 0.0005 0.0014 0.0004 0.0003 0.0003 0.0005<BR> IFHINGKIIKNSE 0.032 0.022 0.066 - - 0.0038 0.038 0.019 0.012 0.016 0.04 -0.04 0.0093 0.002 1 4 5<BR> KD 0.0007 0.0005<BR> KHILYISFYFIL 0.0016 - 0.051 -0.003 0.023 0.0009 0.016 0.0019 1 1<BR> VNL 0.0021<BR> KYLVIVFLIFFD 0.0012 0.0057 -0.002 0.068 -0.003 - 0.0021 0.0034 0.013 0.0065 - 1 1<BR> LFL 0.0009 0.0018<BR> LGNVSTVLLGG0.014 0.001 - 0.0016 - - - 0.0005 0.0006 - - - - 1 1<BR> VGLV 0.0005 0.0005 0.0014 0.0002 0.0003 0.0003 0.0005 0.0005<BR> LIDVHDLISDMI 0.013 0.0061 0.031 0.0011 0.0076 0.0037 0.0001 0.0004 0.01 0.0096 0.043 0.094 1 1<BR> KKE<BR> LIFFDLFLVNGR 0.0042 0.0036 0.047 1 1<BR> DVQ<BR> LSVFFLALFFIIF 0.0015 0.016 - 0.0095 - 0.0015 0.0006 0.0006 0.009 0.0028 - 0 1<BR> NK 0.0021 0.0047 0.0018<BR> NAREIIRLHSDA 0.051 0.013 0.0078 0.024 0.01 - - 0.002<BR> SKNKEKAL 0.0001 0.0004 1<BR> NDRINRENANQ 0.077 0.0015 0.0011 0.002 0.001 - 0.0001 - - 0.0096 1 1<BR> LVVI 0.0004 0.0003 0.0003<BR> NHAVPLAMKLI 0.02 0.0025 0.0091 -0.003 0.019 0.24 0.0019 0.0056 0.17 0.013 1 1<BR> QQLN<BR> SFYFILVNLLIF 0.0009 0.01 -0.002 0.025 0.0038 - 0.0009 0.0004 0.0084 - - 0 1<BR> HIN 0.0005 0.0007 0.0018<BR> TVLLGGVGLVL 0.49 - 0.0032 - - 0.0004 0.0007 - 1 1<BR> YNTE 0.0005 0.0009 0.0002 0.0002<BR> YFFLALFFIIFN 0.0006 0.018 - 0.0047 0.01 - 0.0002 - 0.0056 - - 0 1<BR> KES 0.0021 0.0005 0.0002 0.0007 0.0018<BR> VSTVLLGGVGL 0.8 0.008 0.0005 0.0067 - 0.0003 0.0011 0.0002 0.002 - 0.012 1 1<BR> VLYN 0.0009 0.0002<BR> VVILTDGIPDSI 0.0001 - 0.12 0.0045 - - 0.0001 - - 0.0114 1 1<BR> QDS 0.0006 0.0014 0.0004 0.0003 0.0003<BR> YADSAWENVK 0.055 0.018 0.036 - 0.0009 - 0.031 0.01 2<BR> NVIGPFMKAV 0.0045 0.0001 DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> YKFVVPGAATP 0.1 10.0008 0.0053 0.0057 - 0.0036 0.0001 0.017 0.016 0.0026 0.02 1 1<BR> YAGE 0.0014<BR> DQSYLQDSDPD 0.049 1<BR> SFQD<BR> DYSFLQDSDPD 0.08 1<BR> SFQD<BR> DYSYFQDSDPD 0.089 1<BR> SFQD<BR> DYSYLQDSDPD - 0.053 - - - 0.029 0.0016 1<BR> SFQD 0.0001 0.0004 0.0001 0.0009<BR> DYSYLQDSDPD 0.046 1<BR> SFQD<BR> DYSYLQDSVPD 0.29 1<BR> SFQD<BR> DYSYQQQDSDP 0.046 1<BR> DSFQD<BR> NILLSNAPLGP 0.14 1<BR> QFP<BR> QNFLLSNAPLG 0.82 1<BR> PQFP<BR> QNIFLSNAPLGP 0.14 1<BR> QFP<BR> QNILLSNAPLG 0.22 0.04 0.37 0.66 0.085 - 0.13 2<BR> PQFP 0.0024<BR> QNILLSNAQLG 0.16 1<BR> PQFP<BR> QNILLSNAVLG 0.29 1<BR> PQFP<BR> QNILLSNVPLG 3.7 1<BR> PQFP<BR> QNILQSNAPLG 0.06 1<BR> PQFP<BR> QNILVSNAPLG 0.074 1<BR> PQFP DR147 Cross- Cross-<BR> DR2 DR2 DR4 DR4 DR4 DR5 DR5 DR6 DR8 DR Cross- react. react<BR> Sequence DR1 w21 w22 w4 w14 w15 w11 w12 w19 DR7 w2 DR52a DR9 w53 react. (4/7) (7/10)<BR> QNIQLSNAPLG 0.06 1<BR> PQFP<BR> QNIVLSNAPLG 0.48 1<BR> PQFP<BR> QNVLLSNAPLG 0.047 1<BR> PQFP<BR> SYLQDSDPDSF 0.14 1<BR> QD<BR> SYLQDSVPDSF 0.72 1<BR> QD<BR> YLQDSDPDSFQ 0.08 1<BR> D<BR> YSYLQDSDPDS 0.19 1<BR> FQD Table 30<BR> Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy % % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> 68.0001 MWDLVLSIALSVGCT Human Kallikrein2 1 DR super 0.025 0.000 0.0022 0.0055 0.0003 0.033 0.0083 0.0038 0.036 2<BR> 68.0002 DLVLSIALSVGCTGA Human Kallikrein2 3 DR super 0.0046 0.0005 0.0002 0.0007 0.0004 0.043 0.0082 0.0003 0.030 1<BR> 68.0003 HPQWVLTAAHCLKKN Human Kallikrein2 56 DR super 0.44 0.0077 1.9 0.011 0.017 0.0073 0.093 0.058 0.10 6<BR> 68.0004 QWVLTAAHCLKKNSQ Human Kallikrein2 58 DR super 0.093 <0.0002 0.052 0.0005 0.0016 <0.0001 0.0098 0.0005 0.016 2<BR> 68.0005 GQRVPVSHSFPHPLY Human Kallikrein2 87 DR super 0.027 0.0019 <0.0001 0.0006 <0.0001 0.0054 0.0900.0002 0.84 3<BR> 68.0006 RVPVSHSFPHPLYNM Human Kallikrein2 89 DR super 0.075 0.0019 0.0024 0.0002 <0.0001 0.011 0.26 0.0005 0.97 4<BR> 68.0008 HPLYNMSLLKHQSLR Human Kallikrein2 908 DR super 0.0460.022 0.095 0.017 0.085 0.0075 0.026 0.13 0.34 8<BR> 68.0010 SHDLMLLRLSEPAKI Human Kallikrein2 118 DR super 0.074 0.033 0.0098 0.0038 0.0048 2.0 0.18 0.041 0.89 5<BR> 68.0011 DHLMLLRLSEPAKIT Human Kallikrein2 119 DR super 0.37 0.16 0.072 0.0040 0.013 4.3 0.13 0.10 1.9 7<BR> 68.0017 NGVLQGITSWGPEPC Human Kallikrein2 220 DR super 0.0024 0.011 0.0002 0.0012 0.0019 <0.0001 0.012 0.0022 0.0012 1<BR> 68.0018 KPAVYTKVVHYRKWI Human Kallikrein2 239 DR super 0.0008 0.023 0.69 0.0063 0.063 0.0037 0.027 1.1 0.024 6<BR> 68.0019 AALLLARAASLSLG Human PAP 3 DR super 0.74 0.28 0.21 0.0630.21 1.2 0.17 1.3 1.69<BR> 68.0020 APLLLARAASLSLGF Human PAP 4 DR super 0.52 0.12 0.1 0.034 0.048 0.87 0.22 0.85 0.55 8<BR> 68.0021 PLLLARAASLSLGFL Human PAP 5 DR super 0.46 0.084 0.14 0.020 0.034 0.29 0.17 1.1 1.4 8<BR> 68.0022 SLSLGFLFLLFFWLD Human PAP 13 DR super 0.0005 0.0007 0.0005 0.0020 0.0021 0.0069 0.0011 <0.0004 0.0055 1<BR> 68.0023 LLFFWLDRSVLAKEL Human PAP 21 DR super/ 1.0 0.7 0.22 3.6 0.1 0.15 0.20 0.44 0.17 9<BR> DR3<BR> 68.0024 DRSVLAKELKFVTLV Human PAP 27 DR super 0.0087 0.016 0.017 0.013 0.0036 0.0008 0.014 0.0063 0.014 2<BR> 68.0025 AKELKFVTLVFRHGD Human PAP 32 DR super 0.0049 0.0051 0.66 0.0083 0.0048 0.0033 0.046 0.024 0.024 2<BR> 68.0030 DRTLMSAMTNLAALF Human PAP 110 DR super 0.046 0.014 0.0009 0.87 0.0062 0.041 0.047 0.022 0.26 6<BR> 68.0031 MSAMTNLAALFPPEG Human PAP 114 DR super 0.0028 0.0007 0.0003 0.0139 <0.0001 0.016 0.0003 0.0007 <0.0004 1<BR> 68.0032 MTNLAALFPPEGVSI Human PAP 117 DR super 0.17 0.0009 0.0002 <0.0002 0.0001 0.0028 <0.0002 0.0019 0.0045 1<BR> 68.0033 PEGVSIWNPILLWQP Human PAP 126 DR super 0.048 18 0.0016 0.0003 0.0005 0.0082 0.00260.0038 0.0007 3<BR> 68.0034 GVSIWNPILLWQPIP Human PAP 128 DR super 0.10 2.4 0.029 0.0019 0.0014 0.019 0.0052 0.0049 0.019 4<BR> 68.0035 WNPILLWQPIPVHTV Human PAP 132 DR super 0.029 0.57 0.0002 0.012 0.0015 0.0017 0.070 0.0005 0.10 4 Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy % % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> 68.0036 NPILLWQPIPVHTVP Human PAP 133 DR super 0.16 2.6 0.0007 0.039 0.026 0.014 0.61 0.0078 0.17 6<BR> 68.0037 PILLWQPIPVHTVPL Human PAP 134 DR super 0.1361 1.127 0.0311 0.0064 3<BR> 68.0038 ILLWQPIPVHTVPLS Human PAP 135 DR super 0.1175 0.17560.0518 0.0033 3<BR> 68.0039 WQPIPVHTVPLSEDQ Human PAP 138 DR super 0.0009 <0.0002 <0.0003 0.0013 0<BR> 68.0040 LSGLHGQDLFGIWSK Human PAP 194 DR super 0.0253 0.0003 <0.0003 0.0002 1<BR> 68.0041 YDPLYCESVHNFTLPHuman PAP 210 DR super/ 0.0042 0.0044 0.0009 <0.0001 0<BR> DR3<BR> 68.0042 LPSWATEDTMTKLRE Human PAP 223 DR super 0.0003 <0.0002 .0084 0.0002 0<BR> 68.0043 LRELSELSLLSLYGI Human PAP 235 DR super 0.0077 0.0456 0.0393 0.0011 2<BR> 68.0044 LSELSLLSLYGIHKQ Human PAP 238 DR super 0.0172 0.18060.0053 0.0023 2<BR> 68.0045 LSLLSLYGIHKQKEK Human PAP 241 DR super 0.0083 0.1789 0.0018 0.0001 2<BR> 68.0046 KSRLQGGVLVNEILN Human PAP 255 DR super 0.0156 0.0002 <0.0003 0.0094 2<BR> 68.0047 GGVLVNEILNHMKRA Human PAP 260 DR super/ 0.0042 0.0217 0.0237 0.1210 2<BR> DR3<BR> 68.0048 IPSYKKLIMYSAHDT Human PAP 277 DR super 0.638 0.4477 0.0181 0.0042 3<BR> 68.0049 YKKLMYSAHDTTVS Human PAP 280 DR super 0.2156 0.9144 0.0443 0.1011 3<BR> 68.0050 LIMYSADHTTVSGLQ Human PAP 283 DR super 0.0014 0.0507 0.3934 0.002 2<BR> 68.0051 DTTVSGLQMALDVYN Human PAP 290 DR super 0.0623 0.0072 0.0003 0.0009 1<BR> 68.0052 ALDVYNGLLPPYASC Human PAP 299 DR super 0.3874 0.0070 0.0166 0.0003 1<BR> 68.0053 LDVYNGLLPPYASCH Human PAP 300 DR super 0.6779 0.0026 0.0236 0.0002 1<BR> 68.0054 YNGLLPPYASCHLTE Human PAP 303 DR super 0.1217 0.0319 0.0031 0.0003 2<BR> 68.005 PYPLMLPGCSPSCPL Human PAP 339 DR super 0.0007 0.0012 0.0005 0.0003 0<BR> 68.0056 FAELVGPVIPQDWST Human PAP 356 DR super 0.5207 <0.0002 0.0003 <0.0001 1<BR> 68.0057 PQDWSTECMTTNSHQ Human PAP 365 DR super <0.0001 <0.0002 0.0049 0.0002 0<BR> 68.0058 TLSVTWIGAAPLILS Human PAP 5 DR super 2.9004 0.1003 0.0012 0.0083 3<BR> 68.0059 SVTWIGAAPLILSRI Human PAP 7 DR super 1.4446 0.783 0.0044 0.0083 3<BR> 68.0060 VTWIGAAPLILSRIV Human PAP 8 DR super 0.8231 0.0198 0.0009 0.0025 2 Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy% % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> 68.0061 SQPWQVLVASRGRAV Human PSA 31 DR super 0.0870 0.0008 0.0023 0.1456 2<BR> 68.0062 GRAVCGGVLVHPQWV Human PSA 42 DR super 0.0130 0.0008 <0.0003 0.0007 1<BR> 68.0063 GVLVHPQWVLTAAHC Human PSA 48 DR super 0.0719 0.1391 0.1412 0.0019 3<BR> 68.0064 HPQWVLTAAHCIRNK Human PSA 52 DR super 0.2853 0.0015 0.0014 0.0034 1<BR> 68.0065 QWVLTAAHCIRNKSV Human PSA 54 DR super 0.1376 0.0007 0.0009 0.0013 1<BR> 68.0066 AHCIRNKSVILLGRH Human PSA 60 DR super 0.0087 0.2285 0.0555 0.0377 4<BR> 68.0067 SVILLGRHSLFHPED Human PSA 67 DR super 0.0147 0.1045 0.0006 0.0276 3<BR> 68.0068 VILLGRHSLFHPEDT Human PSA 68 DR super 0.0298 0.0223 0.0012 0.0054 3<BR> 68.0069 GOVFOVSHSFPHPLY Human PSA 83 DR super 0.0238 0.0051 1.1475 0.0322 3<BR> 68.0070 VFQVSHSFPHPLYDM Human PSA 85 DR super 0.3534 0.0033 0.3255 0.0473 3<BR> 68.0071 PHPLYDMSLLKNRFL Human PSA 93 DR super 0.0048 0.0132 0.0007 0.0005 1<BR> 68.0072 SHDLMLLRLSEPAEL Human PSA 114 DR super 0.0181 0.0232 0.0014 0.6572 3<BR> 68.0073 HDLMLLRLSEPAELT Human PSA 115 DR super 0.0807 0.0294 0.0014 2.0129 3<BR> 68.0074 TDAVKVMDLPTQEPA Human PSA 129 DR super 0.0002 <0.0002 <0.0001 0.0001 0<BR> 68.0075 AVKVMDLPTQEPALG Human PSA 131 DR super 0.0002 <0.0002 <0.0001 <0.0001 0<BR> 68.0076 VMDLPTQEPALGTTC Human PSA 134 DR super <0.0001 0.0002 <0.0001 <0.0001 0<BR> 68.0077 LHVISNDVCAQVHPQ Human PSA 172 DR super/ 0.0076 0.0004 0.0175 0.0194 2<BR> DR3<BR> 68.0078 CAQVHPQKVTKFMLC Human PSA 180 DR super 0.0011 0.0121 0.0009 0.0024 1<BR> 68.0079 GGPLVCNGVLQGITS Human PSA 210 DR super 0.0023 0.0003 0.1185 0.0785 2<BR> 68.0080 GPLVCNGVLQGITSW Human PSA 211 DR super 0.0050 0.0012 0.2750 0.0826 3<BR> 68.0081 NGVLQGITSWGSEPC Human PSA 216 DR super 0.0055 0.0356 0.0376 0.0055 3<BR> 68.0082 RPSLYTKVVHYKKWI Human PSA 235 DR super 0.0012 0.0128 0.0353 0.0008 1<BR> 68.0083 PRWLCAGALVLAGGT Human PSM 18 DR super 0.1374 0.0006 <0.0004 0.0002 1<BR> 68.0084 LGFLFGWFIKSSNEA Human PSM 35 DR super 0.6071 0.0220 0.0047 0.0005 2<BR> 68.0085 LDELKAENIKKFLYN Human PSM 62 DR super/ 0.0066 0.0222 0.0049 0.0064 3<BR> DR3 Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy% % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> 68.0086 IKKFLYNFTQIPHLA Human PSM 70 DR super 0.0177 0.0396 0.2948 0.1991 4<BR> 68.0087 KFLYNFTQIPHLAGT Human PSM 72 DR super 0.0257 0.0437 0.0456 0.0171 4<BR> 68.0088 WKEFGLDSVELAHYD Human PSM 100 DR super/ 0.0054 0.0004 0.0842 0.0004 2<BR> DR3<BR> 68.0089 LAHYDVLLSYPNKTH Human PSM 110 DR super 0.1256 0.11610.0077 0.0181 3<BR> 68.0090 GNEIFNTSLFEPPPP Human PSM 135 DR super 0.0004 <0.0001 <0.0004 0.0013 0<BR> 68.0091 NTSLFEPPPPGYENV Human PSM 140 DR super <0.0001 <0.0001 0.0008 <0.0001 0<BR> 68.0092 YENVSDIVPPFSAFS Human PSM 151 DR super 0.0002 <0.0001 <0.0004 <0.0001 0<BR> 68.0093 VSDIVPPFSAFSPQG Human PSM 154 DR super <0.0001 0.0031 <0.0003 <0.0001 0<BR> 68.0094 VPPFSAFSPQGMPEG Human PSM 158 DR super 0.0011 <0.0002 0.0008 <0.0001 0<BR> 68.0095 FSAFSPQGMPEGDLV Human PSM 161 DR super 0.0005 <0.0002 0.0008 <0.0001 0<BR> 68.0096 GKVFRGNKVKNAQLA Human PSM 206 DR super 0.0083 0.0022 0.0076 0.0567 2<BR> 68.0097 GNKVKNAQLAGAKGV Human PSM 211 DR super 0.0034 0.0003 0.0006 0.0001 0<BR> 68.0098 PADYFAPGVKSYPDG Human PSM 231 DR super 0.0011 0.0065 0.0013 <0.0001 0<BR> 68.0099 GWNLPGGGVQRGNIL Human PSM 245 DR super 0.0008 <0.0002 <0.0003 0.0002 0<BR> 68.0100 EVAYRRGLAEAVGLP Human PSM 276 DR super 0.9961 <0.0002 0.0381 0.0022 1<BR> 68.0101 AEAVGLPSIPVHPIG Human PSM 284 DR super 0.8834 0.1429 0.0009 0.0007 2<BR> 68.0102 AVGLPSIPVHPIGYY Human PSM 286 DR super 1.0857 0.0176 0.0021 0.0030 2<BR> 68.0103 IGYYDAQKLLEKMGG Human PSM 297 DR super 0.0029 0.0055 0.0007 0.0009 0<BR> 68.0104 GPGFTGNFSTQKVKM Human PSM 330 DR super 0.0007 <0.0002 0.0010 0.0003 0<BR> 68.0105 TGNPSTQKVKMHIHS Human PSM 334 DR super 0.0004 0.0024 0.0096 0.0009 0<BR> 68.0106 KVKMHIHSTNEVTRI Human PSM 341 DR super <0.0001 <0.0002 <0.0003 0.0001 0<BR> 68.0107 TRIYNVIGTLRGAVE Human PSM 353 DR super 0.3949 0.0057 1.4548 0.0026 2<BR> 68.0108 AEEFGLLGSTEWAES Human PSM 423 DR super 0.0043 <0.0001 0.0026 <0.0001 0<BR> 68.0109 ERGVAYINADSSIFG Human PSM 444 DR super 0.0015 0.0003 0.0016 0.0010 0<BR> 68.0110 GVAYINADSSIEGNY Human PSM 446 DR super 0.0101 0.0014 0.0547 0.0076 3 Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy% % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> 68.0111 DSSIEGNYTLRVDCT Human PSM 453 DR super 0.0005 0.0077 0.0024 0.4910 1<BR> 68.0112 NYTLRVDCTPLMYSL Human PSM 459 DR super/ 0.0024 0.0020 0.8167 0.3464 2<BR> DR3<BR> 68.0113 CTPLMYSLVHNLTKE Human PSM 466 DR super 0.0450 0.0217 0.0326 0.0151 3<BR> 68.0114 DFEVFFQRLGIASGR Human PSM 520 DR super 0.0465 0.0010 0.0372 0.0004 1<BR> 68.0115 EVFFQRLGIASGRAR Human PSM 522 DR super 0.2315 0.0029 0.3827 0.0002 2<BR> 68.0116 TNKFSGYPLYHSVYE Human PSM 543 DR super 0.0026 0.0186 0.0015 0.0001 1<BR> 68.0117 YDPMFKYHLTVAQVR Human PSM 566 DR super 1.0795 0.0081 0.4387 0.0044 3<BR> 68.0118 DPMFKYHLTVAQVRG Human PSM 567 DR super 0.9479 0.0424 0.9194 0.0080 4<BR> 68.0119 MFKYHLTVAQVRGGM Human PSM 569 DR super 0.6395 0.0062 0.4702 0.0025 2<BR> 68.0120 KYHLTVAQVRGGMVF Human PSM 571 DR super 0.0646 0.0081 0.0100 0.0188 2<BR> 68.0121 VAQVRGGMVFELANS Human PSM 576 DR super 0.0478 0.0804 0.0130 0.0009 2<BR> 68.0122 RGGMVFELANSIVLP Human PSM 580 DR super/ 0.6223 0.0981 0.0350 1.6407 3<BR> DR3<BR> 68.0123 GMVFELANSIVLPFD Human PSM 582 DR super 0.7165 0.0976 0.0347 0.2378 3<BR> 68.0124 VFELANSIVLPFDCR Human PSM 584 DR super 0.3050 0.0197 0.0081 0.1282 3<BR> 68.0125 ADKIYSISMKHPQEM Human PSM 608 DR super 0.0003 0.0009 0.0015 0.0008 0<BR> 68.0126 IYSISMKHPQEMKTY Human PSM 611 DR super 0.0014 0.0018 0.0005 <0.0001 0<BR> 68.0127 PQEMKTYSVSFDSLF Human PSM 619 DR super 0.0004 0.0101 0.0048 0.0002 1<BR> 68.0128 TYSVSFDSLFSAVKN Human PSM 624 DR super/ 0.0354 0.0031 0.1139 0.0006 2<BR> DR3<BR> 68.0129 VKNFTEIASKFSERL Human PSM 636 DR super 0.0036 0.0014 0.0050 <0.0001 0<BR> 68.0130 VLRMMNDQLMFLERA Human PSM 660 DR super/ 0.0878 0.0677 0.2804 0.0239 4<BR> DR3<BR> 68.0131 LRMMNDQLMFLERAF Human PSM 661 DR super 0.0037 0.0057 0.0208 0.0027 0<BR> 68.0132 YRHVIYAPSSHNKYA Human PSM 687 DR super 0.0404 0.0110 0.0287 0.0007 2<BR> 68.0133 RHVIYAPSSHNKYAG Human PSM 688 DR super 0.0051 0.0069 0.0195 0.0004 1<BR> 68.0134 DQIYVAAFTVQAAAE Human PSM 730 DR super 2.6553 0.0471 5.6034 0.0151 4<BR> 68.0135 QIYVAAFTVQAAAET Human PSM 731 DR super 4.8432 0.0387 8.9131 0.0080 4 Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy% % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> 68.0136 VAAFTVQAAAETLSE Human PSM 734 DR super 0.4271 0.0005 0.1482 0.0092 3<BR> GGKWSKSSIVGWPAI HIV NEF 2 8 31 DRsuper<BR> SRDLEKHGAITSSNT HIV NEF 50 20 30 DRsuper<BR> HGAITSSNTAATNAD HIV NEF 61 16 20 DRsuper<BR> GFPVRPQVPLRPMTY HIV NEF 93 56 75 DRsuper<BR> RPQVPLRPMTYKGAF HIV NEF 98 11 73 DRsuper<BR> RQDILDLWVYHTQGY HIV NEF 182 14 53 DRsuper<BR> RQEILDLWVYHTQGF HIV NEF 182 16 53 DRsuper<BR> RQEILDLWVYHTQGY HIV NEF 182 19 53 DRsuper<BR> RQDILDLWVYNTQGY HIV NEF 182 8 30 DRsuper<BR> ILDLWVYHTQGYFPD HIV NEF 186 33 33 DRsuper<BR> ILDLWVYHTQGFFPD HIV NEF 186 20 20 DRsuper<BR> FPDWQNYTPGPGIRY HIV NEF 200 21 83 DRsuper<BR> FPDWQNYTPGPGTRF HIV NEF 200 20 83 DRsuper<BR> GPGIRYPLTFGWCFK HIV NEF 210 9 20 DRsuper<BR> RPFPLTFGWCFKLVP HIV NEF 216 19 61 DRsuper<BR> RYPLTFGWCFKLVPV HIV NEF 216 24 61 DRsuper<BR> TFGWCFKLVPVDPRE HIV NEF 222 11 41 DRsuper<BR> NNCLLHPMSQHGMDD HIV NEF 254 9 27 DRsuper<BR> NNSLLHPICQHGMED HIV NEF 254 6 253 DRsuper<BR> LKAVRIIKILYQSNP HIV NEF 13 9 25 DRsuper<BR> IKFLYQSNPPPSPEG HIV NEF 21 6 28 DRsuper<BR> AEPVPLQLPPLERLT HIV NEF 72 16 56 DRsuper<BR> PVPLQLPPLERLTLD HIV NEF 74 20 56 DRsuper<BR> LEPWNHPGSQPKTAC HIV TAT 11 17 23 DRsuper Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy% % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> LEPWKHPGSQPKTAC HIV TAT 11 17 20 DRsuper<BR> LEPWNHPGSQPTTAC HIV TAT 11 11 16 DRsuper<BR> LEPWNHPGSQPRTPC HIV TAT 72 16 56 DRsuper<BR> NNCYCKKCCFHCQVC HIV TAT 26 6 17 DRsuper<BR> TNCYCKKCCYHCQVC HIV TAT 26 3 17 DRsuper<BR> QVCFLNKGLGISYGR HIV TAT 38 6 22 DRsuper<BR> QVCFITKGLGISYGR HIV TAT 38 11 14 DRsuper<BR> QLCFLKKGLGISYGR HIV TAT 38 5 116 DRsuper<BR> 68.0023 LLFFWLDRSVLAKEL Human PAP 21 DR3a/ 1.9 0.27 0.22 3.6 0.15 0.15 0.20 0.44 0.17 9<BR> DR super<BR> 68.0027 IDTFPTDPIKESSWP Human PAP 50 DR3a/<BR> DR super<BR> 68.0041 YDPLYCESVHNFTLP Human PAP 210 DR3a/ 0.0042 0.0044 0.0009 <0.0001 0<BR> DR super<BR> 68.0047 GGVLVNEILNHMKRA Human PAP 260 DR3a/ 0.0042 0.0217 0.0237 0.1210 2<BR> DR super<BR> 68.0077 LHVISNDVCAQVHPQ Human PSA 172 DR3a/ 0.0076 0.0004 0.0175 0.0194 2<BR> DR super<BR> 68.0085 LDELKAENIKKFLYN Human PSM 62 DR3a/ 0.0066 0.0222 0.0049 0.0064 3<BR> DR super<BR> 68.0088 WKEFGLDSVELAHYD Human PSM 100 DR3a/ 0.0054 0.0004 0.0842 0.0004 2<BR> DR super<BR> 68.0112 NYTLRVDCTPLMYSL Human PSM 459 DR3a/ 0.0024 0.0020 0.8167 0.3464 2<BR> DR super<BR> 68.0122 RGGMVFELANSIVLP Human PSM 580 DR3a/ 0.6223 0.0981 0.0350 1.6407 3<BR> DR super<BR> 68.0128 TYSVSFDSLFSAVKN Human PSM 624 DR3a/ 0.0354 0.0031 0.1139 0.0006 2<BR> DR super<BR> 68.0130 VLRMMNDQLMFLERA Human PSM 660 DR3a/ 0.0878 0.0677 0.2804 0.0239 4<BR> DR super<BR> 68.0137 HNLFEPEDTGQRVPV Human Kallikrein2 78 DR3a<BR> 68.0138 HQSLRPDEDSSHDLM Human Kallikrein2 108 DR3a<BR> 68.0139 WGSIEPEEFLRPRSL Human Kallikrein2 157 DR3a<BR> 68.0140 LHLLSNDMCARAYSE Human Kallikrein2 176 DR3a Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy% % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> 68.0141 RSVLAKELKFVTLVF Human PAP 28 DR3b<BR> 68.0142 LTQLGMEQHYELGEY Human PAP 70 DR3b<BR> 68.0143 YRKFLNESYKHEQVY Human PAP 89 DR3a<BR> 68.0144 RKFLNESYKHEQVYI Human PAP 90 DR3b<BR> 68.0145 NESYKHEQVYIRSTD Human PAP 94 DR3a<BR> 68.0146 AALFPPEVSIWNPIY Human PAP 121 DR3a<BR> 68.0147 TVPLSEDQLLYLPFR Human PAP 145 DR3a<BR> 68.0148 FQELESETLKSEFFQ Human PAP 164 DR3a<BR> 68.0149 SETLKSEEFQKRLHP Human PAP 169 DR3a<BR> 68.0150 DPLYCESVHNFTLPS Human PAP 211 DR3b<BR> 68.0151 KKLIMYSAHDTTVSG Human PAP 281 DR3b<BR> 68.0152 GLQMALDVYNGLLPP Human PAP 295 DR3a<BR> 68.0153 LTELYFEKGEYFVEM Human PAP 315 DR3a<BR> 68.0154 AALFPPEVSIWNPIY Human PAP 322 DR3a<BR> 68.0155 EMYYRNETQHEPYPL Human PAP 328 DR3a<BR> 68.0156 GPVIPQDWSTECMTT Human PAP 361 DR3a<BR> 68.0157 TECMTINSHQGTEDS Human PAP 370 DR3b<BR> 68.0158 HSLFHPEDTGQVFQV Human PSA 74 DR3a<BR> 68.0159 WGSIEPEEFLTPKKL Human PSA 153 DR3a<BR> 68.0160 SNDVCAQVHPQKVTK Human PSA 176 DR3a<BR> 68.0161 MWNLLHETDSAVATA Human PSM 1 DR3a<BR> 68.0162 TDSAVATARRPRWLC Human PSM 8 DR3b<BR> 68.0163 MKAFLDELKAENIKK Human PSM 58 DR3b<BR> 68.0164 AKQIQSQWKEFGLDS Human PSM 93 DR3b<BR> 68.0165 FISIINEDGNEIFNT Human PSM 127 DR3a Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy% % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> 68.0166 ISIINEDGNEIFNTS Human PSM 128 DR3a<BR> 68.0167 EDFFKLERDMKINCS Human PSM 183 DR3a<BR> 68.0168 FFKLERDMKINCSGK Human PSM 185 DR3b<BR> 68.0169 DMKINCSGKIVIARY Human PSM 191 DR3b<BR> 68.0170 GVILYSDPADYFAPG Human PSM 224 DR3a<BR> 68.0171 IYNYIGTLRGAVEPD Human PSM 355 DR3b<BR> 68.0172 RGAVEPDRYVILGGH Human PSM 363 DR3a<BR> 68.0173 GAAVVHEIVRSFGTL Human PSM 391 DR3a<BR> 68.0174 FGTLKKEGWRPRRTI Human PSM 402 DR3a<BR> 68.0175 TEWAEENSRLLQERG Human PSM 432 DR3b<BR> 68.0176 NSRLLQERGVAYINA Human PSM 438 DR3a<BR> 68.0177 VAYINADSSIEGNYT Human PSM 447 DR3a<BR> 68.0178 VHNLTKELKSPDEGF Human PSM 474 DR3b<BR> 68.0179 SIVLPFDCRDYAVVL Human PSM 590 DR3b<BR> 68.0180 DKIYSISMKHPQEMK Human PSM 609 DR3b<BR> 68.0181 DQLMFLERAFIDPLG Human PSM 666 DR3a<BR> 68.0182 HVIYAPSSHNKYAGE Human PSM 689 DR3b<BR> 68.0183 HNKYAGESFPGIYDA Human PSM 697 DR3a<BR> 68.0184 DALFDIESKVDPSKA Human PSM 710 DR3b<BR> 68.0185 PSKAWGEVKRQIYVA Human PSM 721 DR3b<BR> QDAVSQDLDKCGAAA HIV NEF 51 2 100 DR3a<BR> LSHFLKEKGGLEGLI HIV NEF 114 23 47 DR3a<BR> LSHFLKEKGGLDGLI HIV NEF 114 22 41 DR3a<BR> TQGYFPDWQNYTPGP HIV NEF 195 52 56 DR3a<BR> TQGFFPDWQNYTPGP HIV NEF 195 27 27 DR3a Core<BR> Total Conser-<BR> Protein/ 1st Conser- vancy DRB1 DRB1 DRB5 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Degen-<BR> Peptide. Sequence Organism Segment Position vancy% % Motif *0101 *1501 *0101 *0401 *1101 *1302 *0701 *0802 *0901 eracy<BR> LDGLIYSKKRQEILD HIV NEF 171 17 28 DR3b<BR> TRQARRNRRRRWRAR HIV REV 38 28 61 DR3b<BR> TRQARRNRRRRWRER HIV NEV 38 19 61 DR3b<BR> TRQARKNRRRRWRAR HIV NEV 38 20 28 DR3b<BR> KEKVERETETDPAVQ IV TAT 95 2 17 DR3a Table 31 Class II motif bearing peptides for HIV regulatory proteins core core HLA protein % cons. # aa position sequence position 9 sequence conservation DR3a NEF 2 15 51 QDAvsqdldkgegAAA 54 VSQDLDKCG 100 DRsuper NEF 23 15 200 FPDwqnytpgpgIRY 204 WQNYTPGPG 83 DRsuper NEF 20 15 200 FPDwqnytpgpgTRF 204 WQNYTPGPG 83 DRsuper NEF 56 15 93 GFPvrpqvplrpMTY 97 VRPQVPLRP 75 DRsuper NEF 11 15 98 RPQvplrpmtykGAF 101 VPLRPMTYK 73 DRsuper NEF 19 15 216 RFPltfgwcflkVPV 221 LTFGWCFKL 61 DRsuper NEF 24 15 216 RYPltfgwcfklVPV 221 LTFGWCFKL 61 DR3a NEF 52 15 195 TQGyfpdwqnytPGP 199 YFPDWQNYT 56 DRsuper NEF 14 15 182 RQDildlwvyhtQGY 186 ILDLWVYHT 53 DRsuper NEF 16 15 182 RQEildlwvyhtQGF 186 ILDLWVYHT 53 DRsuper NEF 19 15 182 RQEildlwvyhtQGY 186 ILDLWVYHT 53 DR3a NEF 23 15 114 LSHflkekggleGLI 117 FLKEKGGLE 47 DR3a NEF 22 15 114 LSFflkekggldGLI 117 FLKEKGGLD 41 DRsuper NEF 11 15 222 TFGwefklvpvdPRE 225 WCFKLVPVD 41 DRsuper NEF 33 15 186 ILDlwvyhtqgyFPD 190 LWVYHTQGY 33 DRsuper NEF 8 15 2 GGKwskssivgwPAI 5 WSKSSIVGW 31 DRsuper NEF 8 15 182 RQDildlwvyntQGY 186 ILDLWVYNT 30 DR3b NEF 17 15 171 LDGliyskkrqeILD 174 LIYSKKRQE 28 DR3a NEF 27 15 195 TQGffpdwqnytPGP 199 FFPDWQNYT 27 DRsuper NEF 9 15 254 NNCllhpmsqhg MDD 257 LLHPMSQHG 27 DRsuper NEF 6 15 254 NNSllhpicqhgMED 257 LLHPICQHG 25 DRsuper NEF 9 15 210 GPGirypltfgwCFK 214 IRYPLTFGW 20 DRsuper NEF 16 15 61 HGAitssntaatNAD 64 ITSSNTAAT 20 DRsuper NEF 20 15 50 SRDIekhgaitsSNT 58 LEKHGAITS 20 DRsuper NEF 20 15 186 ILDlwvyhtqgfFPD 190 LWVYHTQGF 20 DR3b REV 28 15 38 TRQarrnrrrrwRAR 41 ARRNRRRRW 61 DR3b REV 19 15 38 TRQarrnrrrrwRER 41 ARRNRRRRW 61 DRsuper REV 20 15 74 PVPlqlpplerlTLD 77 LQLPPLERL 56 DRsuper REV 16 15 72 AEPvplqlppleRLT 75 VPLQLPPLE 56 DR3b REV 20 15 38 TRQarknrrrwRAR 41 ARKNRRRRW 28 DRsuper REV 6 15 21 IKFlyqsnpppsPEG 24 LYQSNPPPS 28 DRsuper REV 9 15 13 LKAvriikilyqSNP 18 VRIIKILYQ 25 DRsuper TAT 17 15 11 LEPwnhpgsqpkTAC 14 WNHPGSQPK 23 DRsuper TAT 6 15 38 QVCflnkglgisYGR 41 FLNKGLGIS 22 DRsuper TAT 17 15 11 LEPwkhpgsqpkTAC 14 WKHPGSQPK 20 DR3a TAT 2 15 95 KEKveretetdpAVQ 98 VERETETDP 17 DRsuper TAT 6 15 26 NNCyckkccfhcQVC 29 YCKKCCFHC 17 DRsuper TAT 3 15 26 TNCyckkccyhcQVC 29 YCKKCCYHC 17 DRsuper TAT 11 15 11 LEPwnhpgsqptTAC 14 WNHPGSQPT 16 DRsuper TAT 11 15 38 QVCfitkglgisYGR 41 FITKGLGIS 14 DRsuper TAT 5 15 11 LEPwnhpgsqprTPC 14 WNHPGSQPR 13 DRsuper TAT 5 15 38 QLCflkkglgisYGR 41 FLKKGLGIS 11